

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 12, 2005, 10:48:15 ; Search time 1 Seconds
(without alignments)
1.148 Million cell updates/sec

Title: US-09-745-763-35
Perfect score: 1851
Sequence: 1 GGCTAGCCGCGAGCTTAGT.....CTGAAAAA.....1851

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 0.5

Searched: 19 seqs, 310 residues

Total number of hits satisfying chosen parameters: 38

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 19 summaries

Database : rst35.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	18.8	1.0	22	1	CA587453
C 2	17	0.9	22	1	CR786821
C 3	16.4	0.9	18	1	AJ725584
C 4	16	0.9	16	1	CR786853
C 5	16	0.9	18	1	CR786637
C 6	15.4	0.8	20	1	AZ352278
C 7	15	0.8	16	1	CR786609
C 8	14.8	0.8	19	1	AJ650841
C 9	13.4	0.7	15	1	CF291030
C 10	13.4	0.7	15	1	CR789161
C 11	13.4	0.7	16	1	AJ569544
C 12	13.4	0.7	16	1	AJ592205
C 13	12.8	0.7	16	1	RA937877
C 14	12.4	0.7	14	1	CF301021
C 15	12	0.6	12	1	AJ739036
C 16	11.8	0.6	15	1	BM658732
C 17	11.4	0.6	13	1	AJ655484
C 18	11.4	0.6	13	1	CF291168
C 19	11.4	0.6	14	1	AJ600105

ALIGNMENTS

RESULT 1
CA587453/c CA587453 22 bp mRNA linear EST 12-JAN-2004
LOCUS LBE12P58 cDNA from mouse aorta Mus musculus cdna, mRNA sequence.
DEFINITION CA587453
ACCESSION CA587453
VERSION CA587453.1 GI:40792715
KEYWORDS EST.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus

REFERENCE
AUTHORS Borang, S., Andersson, T., Thelin, A., Odeberg, J. and Lundberg, J.
TITLE Vascular gene expression in atherosclerotic plaque prone regions analysed by representational difference analysis
JOURNAL Unpublished (2002)
COMMENT Contact: Andersson Tove
Department of Biotechnology
KTH
Teknikringen 34, plan 6, 100 44 Stockholm, Sweden
Tel: +46 8 790 71 29
Fax: +46 8 245452
Email: tovebiochem.kth.se
Representations (amplified cDNA) from plaque prone regions
Seq primer: CTA TGA CCA TGA TTA CGC CAA G.
Location/Qualifiers
1. 22

FEATURES
source

/organism="Mus musculus"
/mol_type="mRNA"
/strain="ApoE-/- and LDLR-/- on C57BL/6x 129 background"
/db_xref="taxon:10090"
/sex="male"
/dev_stage="8 weeks old"
/clone_lib="cDNA from mouse aorta"
/notes="Organ: aorta; Site 1: DpnII; Site 2: DpnII; CDNA was prepared from whole aorta divided in atherosclerotic plaque prone regions (aortic arch and abdominal aorta proximal part) and less plaque prone regions (descending thoracic aorta and abdominal aorta distal part). CDNA was fragmented with DpnII, linker ligated and amplified to generated starting material for representational difference analysis (RDA). The two cDNA pools were subjected to iterative RDA subtraction and amplification to enrich for gene fragments differentially expressed at early stages of atherosclerosis."

Query Match 1.0%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 1.3;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 900 TCCTTCAACTCTGACGAGAGA 921
Db 22 TCCTTCAACTCTGACGAGAGA 1

RESULT 2

CR786821 22 bp mRNA linear EST 01-OCT-2004
DEFINITION DKFZp468F2431 r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
LOCUS DKFZp468F2431-5', mRNA sequence.
ACCESSION CR786821
VERSION CR786821.1 GI:53705818
KEYWORDS EST.
SOURCE Pongo pygmaeus (orangutan)
ORGANISM Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pongo.
REFERENCE 1 (bases 1 to 22)
AUTHORS Koehrer, K., Beyer, A., Mewes, H.W., Weil, B., Amid, C., Osanger, A., Fobo, G., Han, M. and Wiemann, S.
TITLE Pongo pygmaeus mRNA (Koehrer, K., Beyer, A., Mewes, H.W., et al.)
JOURNAL Unpublished (2004)
COMMENT Contact: MIPS

MIPS
Ingolstaedter Landstr. 1, D-85764 Neuherberg, Germany
This is the 5' sequence of the clone insert. Clone from S. Wiemann,
Molecular Genome Analysis, German Cancer Research Center (DKFZ);
Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
Germany. Please contact RZPD for ordering:
http://www.rzpd.de/cgi-bin/products/ci.cgi?CloneID=DKFZp468F2431
Further information about the clone and the sequencing project is
available at http://mips.gsf.de/projects/cdna/.

```

FEATURES
source
    Location/Qualifiers
    1..22
    /organism="Pongo pygmaeus"
    /mol_type="mRNA"
    /db_xref="taxon:9600"
    /clone="DKFZp468F2431"
    /tissue_type="heart"
    /dev_stage="adult"
    /lab_host="DH10B"
    /notes="vector: pSport1_Sfi; Site_1: SfiI; Site_2: SfiIb"

Query Match
Best Local Similarity 0.9%; Score 17; DB 1; Length 22;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1834 GAAAAAAAAAAAAAAAAA 1850
Db 6 GAAAAAAAAAAAAAAAAA 22

RESULT 3
AJ725584
LOCUS
DEFINITION AJ725584 riken1 Gallus gallus cDNA clone 2c16r4, mRNA sequence.
ACCESSION AJ725584
VERSION AJ725584.1 GI:53890998
KEYWORDS EST.
SOURCE Gallus gallus (chicken)
ORGANISM Gallus gallus
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
REFERENCE 1 (bases 1 to 18)
AUTHORS Caldwell,R.B., Kierzek,A.M., Arakawa,H., Bezzubov,Y., Zaim,J.,
Fiedler,P., Kutter,S., Blagodatski,A., Kostovska,D., Koter,M.,
Plachy,J., Carninci,P., Hayashizaki,Y. and Buerstedde,J.M.
TITLE Full-length cDNAs from bursal lymphocytes to facilitate gene
function analysis
JOURNAL Unpublished (2004)
COMMENT Contact: Caldwell RB
GSF - Forschungszentrum, Institut fuer Molekulare Strahlenbiologie
Ingolstaedter Landstr. 1, D-85764 Neuherberg, GERMANY.

FEATURES
source
    Location/Qualifiers
    1..18
    /organism="Gallus gallus"
    /mol_type="mRNA"
    /db_xref="taxon:9031"
    /clone="2c16r4"
    /cell_type="bursal lymphocyte"
    /dev_stage="2-3 weeks old"
    /clone_lib="riken1"
    /notes="CB inbred strain"

Query Match
Best Local Similarity 0.9%; Score 16.4; DB 1; Length 18;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1833 TGAATAAAAAAAAAAAAAA 1850
Db 1 TCAAAAAAAAAAAAAAAAAA 18

RESULT 4
CR786853
LOCUS
DEFINITION DKFZp468E2231 r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
ACCESSION CR786853
VERSION CR786853.1 GI:53705850
KEYWORDS EST.
SOURCE Pongo pygmaeus (orangutan)
ORGANISM Pongo pygmaeus

Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
REFERENCE 1 (bases 1 to 16)
AUTHORS Koehrer,K., Beyer,A., Mewes,H.W., Weil,B., Amid,C., Osanger,A.,
Fobo,G., Han,M. and Wiemann,S.
Pongo pygmaeus mRNA (Koehrer,K., Beyer,A., Mewes,H.W., et al.)
Unpublished (2004)
Contact: MIPS
MIPS Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
This is the 5' sequence of the clone insert. Clone from S. Wiemann,
Molecular Genome Analysis, German Cancer Research Center (DKFZ);
Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
Germany. Please contact RZPD for ordering:
http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468E2231
Further information about the clone and the sequencing project is
available at http://mips.gsf.de/projects/cdna/.

FEATURES
source
    Location/Qualifiers
    1..18
    /organism="Pongo pygmaeus"
    /mol_type="mRNA"
    /db_xref="taxon:9600"
    /clone="DKFZp468E2231"
    /tissue_type="heart"
    /dev_stage="adult"
    /lab_host="DH10B"
    /notes="vector: pSport1_Sfi; Site_1: SfiI; Site_2: SfiIb"

Query Match
Best Local Similarity 0.9%; Score 16; DB 1; Length 16;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1850
Db 1 AAAAAAAAAAAAAAAAAA 16

RESULT 5
CR786637
LOCUS
DEFINITION DKFZp468J2331 r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
ACCESSION CR786637
VERSION CR786637.1 GI:53705634
KEYWORDS EST.
SOURCE Pongo pygmaeus (orangutan)
ORGANISM Pongo pygmaeus
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
REFERENCE 1 (bases 1 to 18)
AUTHORS Koehrer,K., Beyer,A., Mewes,H.W., Weil,B., Amid,C., Osanger,A.,
Fobo,G., Han,M. and Wiemann,S.
Pongo pygmaeus mRNA (Koehrer,K., Beyer,A., Mewes,H.W., et al.)
Unpublished (2004)
Contact: MIPS
MIPS Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
This is the 5' sequence of the clone insert. Clone from S. Wiemann,
Molecular Genome Analysis, German Cancer Research Center (DKFZ);
Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
Germany. Please contact RZPD for ordering:
http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468J2331
Further information about the clone and the sequencing project is
available at http://mips.gsf.de/projects/cdna/.

FEATURES
source
    Location/Qualifiers
    1..18
    /organism="Pongo pygmaeus"
    /mol_type="mRNA"
    /db_xref="taxon:9600"
    /clone="DKFZp468J2331"
    /tissue_type="heart"
    /dev_stage="adult"

```



```

/lab_host="DH10B"
/clone_lib="468 (synonym: phrt1)"
/notes="vector: pSport1_Sfi; Site_1: SfiI; Site_2: SfiIb"

Query Match      0.8%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1850
Db 1 AAAAAAAAAAAAAAAAAA 16

RESULT 6
AZ352278/c
LOCUS      AZ352278          20 bp    DNA        linear      GSS 29-SEP-2000
DEFINITION 1M0090K08R Mouse 10kb plasmid UGCM library Mus musculus genomic
clone UGCM1M0090K08 R, genomic survey sequence.
ACCESSION  AZ352278
VERSION     AZ352278.1  GI:10431515
KEYWORDS   GSS.
SOURCE     Mus musculus (house mouse)
ORGANISM   Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 20)
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausen,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0090 row: K column: 08
Seq primer: CACACAGGAACACGCTATGACC
Class: plasmid ends
High quality sequence stop: 20.

FEATURES             Location/Qualifiers
     source            1..20
     -organism="Mus musculus"
     -mol_type="genomic DNA"
     -strain="C57BL/6J"
     -db_xref="taxon:10090"
     -clone="UGCM1M0090K08"
     -Sex="Male"
     -lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
     -clone_lib="Mouse 10kb plasmid UGCM library"
     -notes="vector: pWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 [gi|4732114|gb|AF129072.1], a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into

```

```

chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

Query Match      0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.5; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1;

Qy 1128 TTCAGTATTATCAGTT 1144
Db 17 TTCATTATTATCAGTT 1

RESULT 7
CR786609
LOCUS      CR786609          16 bp    mRNA        linear      EST 01-OCT-2004
DEFINITION DKFZp468C2031_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
DKFZp468C2031_5', mRNA sequence.
ACCESSION  CR786609
VERSION     CR786609.1  GI:53705606
KEYWORDS   EST.
SOURCE     Pongo pygmaeus (orangutan)
ORGANISM   Pongo pygmaeus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pongo.
1 (bases 1 to 16)
Koehler,K., Beyer,A., Mewes,H.W., Weil,B., Amid,C., Osanger,A.,
Fobo,G., Han,M. and Wiemann,S.
Pongo pygmaeus mRNA (Koehler,K., Beyer,A., Mewes,H.W., et al.)
Unpublished (2004)
Contact: MIPS
MIPS
Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
This is the 5' sequence of the clone insert. Clone from S. Wiemann,
Molecular Genome Analysis, German Cancer Research Center (DKFZ);
Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
Germany. Please contact RZPD for ordering:
http://www.rzpd.de/cgi-bin/products/cl.cgi?cloneID=DKFZp468C2031
Further information about the clone and the sequencing project is
available at http://mips.gsf.de/projects/cdna/.

FEATURES             Location/Qualifiers
     source            1..16
     -organism="Pongo pygmaeus"
     -mol_type="mRNA"
     -db_xref="taxon:9600"
     -clone="DKFZp468C2031"
     -tissue_type="heart"
     -dev_stage="adult"
     -lab_host="DH10B"
     -clone_lib="468 (synonym: phrt1)"
     -notes="Vector: pSport1_Sfi; Site_1: SfiI; Site_2: SfiIb"

Query Match      0.8%; Score 15; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 3.4; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1849
Db 2 AAAAAAAAAAAAAAAAAA 16

RESULT 8
AJ650841
LOCUS      AJ650841          19 bp    mRNA        linear      EST 07-JUL-2004
DEFINITION AJ650841 CSEQRAN19 Sus scrofa cDNA clone C0003276_H22, mRNA
sequence.
ACCESSION  AJ650841
VERSION     AJ650841.1  GI:49327686
KEYWORDS   EST.
SOURCE     Sus scrofa (pig)
ORGANISM   Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
1 (bases 1 to 19)

```

AUTHORS Anderson, S.I., Finlayson, H.A. and Archibald, A.L.
TITLE Development of cDNA and EST resources for studying reproduction and embryo development in pigs and cattle
JOURNAL Unpublished (2004)
COMMENT Contact: Anderson SI
 Genomics and Bioinformatics
 Roslin Institute
 Roslin, Midlothian, EH25 9PS, UNITED KINGDOM

Single pass sequencing. Bases called and trimmed with phred v0.020425.c. Vector identified by cross_match with the -mnscore 20 and -mismatch 12 options. Vector: pBlueScriptII(KS) R. Site1: EcoRI R. Site2: NotI 5' Seq Primer M13F Normalised library constructed from pooled ovaries. Clones available from UK Centre for Functional Genomics in Farm Animals, Roslin Institute, Roslin, Midlothian, UK, EH25 9PS, www.ark-genomics.org.

FEATURES

source

1. .19
 /organism="Sus scrofa"
 /mol_type="mRNA"
 /db_xref="taxon:9823"
 /clone="C0003276_H22"
 /tissue_type="ovary"
 /clone_lib="CSEQUAN19"
 /notes="Vector: pBlueScriptII(KS+); Site 1: EcoRI; Site 2: NotI; Single pass sequencing; Normalised library constructed from pooled ovaries"

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 5.1;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1259 GGTATGAGCCTCTGCA 1276

DB 2 GGTTTTGAGCCTACTGCA 19

RESULT 9

LOCUS

CF291030 15 bp mRNA linear EST 14-AUG-2003
 14ROOT--01-E19.g1 Rice root plasmid cDNA library (14ROOT) Oryza sativa (japonica cultivar-group) cDNA clone 14ROOT--01-E19, mRNA sequence.

ACCESSION

CF291030.1 GI:33660063

VERSION

EST.

SOURCE

Oryza sativa (japonica cultivar-group)
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae; Oryza.

REFERENCE

1 (bases 1 to 15)

AUTHORS

Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,

Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.

TITLE

Large-scale Sequencing Analysis of Rice ESTs

JOURNAL

Unpublished (2003)

COMMENT

Contact: Nahm B.H.
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
 Yongin, Kyeonggi, Korea
 Tel: 82 31 330 6193
 Fax: 82 31 321 6355
 Email: bnahm@ggbio.com, bnahm@bio.myongji.ac.kr.

FEATURES

source

1. .15
 /organism="Oryza sativa (japonica cultivar-group)"
 /mol_type="mRNA"
 /cultivar="Nackdong"
 /db_xref="taxon:39947"
 /clone="14ROOT--01-E19"
 /tissue_type="root"
 /dev_stage="14 days after germination"
 /lab_host="E.coli DH10B"
 /clone_lib="Rice root plasmid cDNA library (14ROOT)"

/note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.7;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849

DB 1 AAAAAAAAAAAAAA 15

RESULT 10

LOCUS

CR789161 15 bp mRNA linear EST 01-OCT-2004
 DKFZp468J1632.r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone DKFZp468J1632.5', mRNA sequence.

ACCESSION

CR789161

VERSION

EST.

SOURCE

Pongo pygmaeus (orangutan)

ORGANISM

Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pongo.
 1 (bases 1 to 15)

REFERENCE

AUTHORS

Ansorge, W., Krieger, S., Regiert, T., Rittmueller, C., Schwager, B.,

Mewes, H.W., Weil, B., Amid, C., Osanger, A., Pobo, G., Han, M. and

Wiemann, S.

TITLE

JOURNAL

COMMENT

Pongo pygmaeus mRNA (Ansorge, W., Krieger, S., Regiert, T., et al.)
 Unpublished (2004)
 Contact: MIPS
 MIPS
 Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
 This is the 5' sequence of the clone insert. Clone from S. Wiemann,
 Molecular Genome Analysis, German Cancer Research Center (DKFZ);
 Email s.wiemann@dkfz-heidelberg.de; rlin, Germany. Please contact
 RZPD for ordering;
<http://www.rzpd.de/cgi-bin/products/cl.cgi?cloneID=DKFZp468J1632>
 Further information about the clone and the sequencing project is
 available at <http://mips.gsf.de/projects/cdna/>.

FEATURES

source

1. .15
 /organism="Pongo pygmaeus"
 /mol_type="mRNA"
 /db_xref="taxon:9600"
 /clone="DKFZp468J1632"
 /tissue_type="heart"
 /dev_stage="adult"
 /lab_host="DH10B"
 /clone_lib="468 (synonym: phrt1)"
 /note="Vector: pSPort1_Sfi; Site_1: SfiI; Site_2: SfiIb"

Query Match 0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 5.7;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849

DB 1 AAAAAAAAAAAAAA 15

RESULT 11

LOCUS

AI569544 16 bp mRNA linear EST 12-MAY-1999
 to28d10.x1 NCI CGAP Ut4 Homo sapiens cDNA clone IMAGE:2180371.3,
 similar to TR:Q18444 Q18444 COSMID C34D4.; contains MSRL.b2 MSRL
 repetitive element ;, mRNA sequence.

ACCESSION

AI569544

VERSION

EST.

SOURCE

Homo sapiens (human)

ORGANISM

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 16)
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality
Insert Length: 1683 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 1
POLYA=No.

FEATURES
source
1..16
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:2180371"
/tissue_type="serous papillary carcinoma, high grade, 2 pooled tumors"
/lab_host="DH10B"
/clone_lib="NCI CGAP Ut4"
/note="Organ: uterus; Vector: pCMV-SPORT6; Site 1: SalI; Site 2: NotI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 1.48 kb. Life Technologies catalog #: 11542-016"

Query Match 0.7%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 6.5;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1705 CCCCTCCCTCCACC 1719
Db 1 CCCCTCCCTCCACC 15

RESULT 12
AJ592205/c
LOCUS
DEFINITION
368G08, genomic survey sequence.
AJ592205 16 bp DNA linear GSS 15-JAN-2004
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
AJ592205
AJ592205.1 GI:37941829
GSS; left border; T-DNA flanking sequence.
Arabidopsis thaliana (thale cress)
ORGANISM
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
AUTHORS
Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G., Lepiniec, L., Caboche, M. and Lecharry, A.
T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites
EMBO Rep. 3 (12), 1152-1157 (2002)
JOURNAL
MEDLINE
PUBMED
22363535
12446565
REFERENCE
2 (bases 1 to 16)
AUTHORS
Balzergue, S.
Direct Submission
Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue

Gaston Cremieux, 91057 Evry cedex, FRANCE
PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.inbio.gen.fr>).
Location/Qualifiers
1..16
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassillewskija"
/db_xref="taxon:3702"
/clone="368G08"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
1..16
/note="T-DNA flanking sequence left border"

Query Match 0.7%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 6.5;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 79 AAAACCACTGGAAA 93
Db 15 AAAACCAACCGAAA 1

RESULT 13
AA937877/c
LOCUS
DEFINITION
AA937877 16 bp mRNA linear EST 30-APR-1998
Similar to TR:Q35989 Q35989 CYTOCHROME C OXIDASE SUBUNIT 1; mRNA sequence.
AA937877
AA937877.1 GI:3095988
EST.
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 16)
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: W. Douglas Figg, Ph.D., Paul H. Duray, M.D., Rodrigo F. Chuqui, M.D., Michael R. Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: David B. Krizman, Ph.D.
cDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality
Seq primer: -40ml3 fwd. ET from Amersham
High quality sequence stop: 1.
Location/Qualifiers
1..16
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:1253890"
/sex="male"
/tissue_type="metastatic prostate bone lesion"

```

/lab_host="DH10B"
/clone_lib="NCI_CGAP_Pr12"
/note="Vector: pAMP10; mRNA made from metastatic prostate
lesion of the bone, cDNA made by oligo-dT priming.
Non-directionally cloned. Size-selected on agarose gel,
average insert size 600 bp. Library made by D. Krizman,
NIH."

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 8.2;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1850
Db 16 AAAAAATAAAAAACAA 1

RESULT 14
CF301021      14 bp mRNA linear EST 15-AUG-2003
LOCUS 7LEAF--05-L10.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
DEFINITION sativa (japonica cultivar-group) cDNA clone 7LEAF--05-L10, mRNA
sequence.
ACCESSION CF301021
VERSION CF301021.1 GI:33672782
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.
1 (bases 1 to 14)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source
1..14
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--05-L10"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match      0.7%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 7.5;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1848
Db 1 AAAAAATAAAAAAA 14

RESULT 15
AJ739036
LOCUS AJ739036 riken1 Gallus gallus cDNA clone 16p11r3, mRNA sequence.
DEFINITION AJ739036
ACCESSION AJ739036
VERSION AJ739036.1 GI:53904414

```

```

KEYWORDS EST.
SOURCE Gallus gallus (chicken)
ORGANISM Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
1 (bases 1 to 12)
Caldwell,R.B., Kierzek,A.M., Arakawa,H., Bezubov,Y., Zaim,J.,
Fiedler,P., Kutter,S., Blagodatski,A., Kostovska,D., Kotet,M.,
Plachy,J., Carninci,P., Hayashizaki,Y. and Buerstedde,J.M.
Full-length cDNAs from bursal lymphocytes to facilitate gene
function analysis
Unpublished (2004)
Contact: Caldwell RB
GSF - Forschungszentrum, Institut fuer Molekulare Strahlenbiologie
Ingolstaedter Landstr. 1, D-85764 Neuherberg, GERMANY.

FEATURES
source
1..12
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
/clone="16p11r3"
/cell_type="bursal lymphocyte"
/dev_stage="2-3 weeks old"
/clone_lib="riken1"
/note="CB inbred strain"

Query Match      0.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.5;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1846
Db 1 AAAAAAAAAAAAAA 12

RESULT 16
BM658732/c
LOCUS LZV602768445.R1 CSEQFXL37 pig adrenal Sus scrofa cDNA, mRNA
DEFINITION sequence.
ACCESSION BM658732
VERSION BM658732.1 GI:18959003
KEYWORDS EST.
SOURCE Sus scrofa (pig)
ORGANISM Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
1 (bases 1 to 15)
Adelson,D.L. and Gill,C.A.
Porcine ESTs
Unpublished (2002)
Contact: David L. Adelson
Animal Breeding and Genetics
Texas A&M University
Animal Science Dept., TAMU-2471, College Station, TX 77843-2471,
USA
Tel: 9798452616
Fax: 9798456970
Email: david.adelson@tamu.edu.

FEATURES
source
1..15
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone_lib="CSEQFXL37 pig adrenal"
/note="Organ: adrenal gland; Vector: pBluescript SK+;
Site 1: NotI; Site 2: EcoRI; sequence 5' of the insert
(5'-NNN...NNNinsert)
GGCAATGGAGCTCCACCGCGGTGGCGCGCGGCTCGAG. Sequence 3' of
the inserts (AAGAATTCGATATCAAGCTATCGATACCGTGCACCTCGAG.
non-normalized library, sequenced 3' with M13R primer."

```

Query Match	0.6%; Score 11.8; DB 1; Length 15;
Best Local Similarity	86.7%; Pred. No. 11;
Matches	13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	1835 AAAAAAAAAAAAAAAAAA 1849
Db	15 AAAAAAAAAAGAAAAA 1
RESULT 17	
LOCUS	AJ655484
DEFINITION	AJ655484 KN277 Sus scrofa cDNA clone C0005190_D17, mRNA sequence.
ACCESSION	AJ655484
VERSION	AJ655484.1 GI:493339516
KEYWORDS	EST.
SOURCE	Sus scrofa (pig)
ORGANISM	Sus scrofa
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
AUTHORS	1 (bases 1 to 13) Anderson, S.I., Finlayson, H.A. and Archibald, A.L.
TITLE	Development of cDNA and EST resources for studying reproduction and embryo development in pigs and cattle
JOURNAL	unpublished (2004)
COMMENT	Contact: Anderson SI Genomics and Bioinformatics Roslin Institute Roslin, Midlothian, EH25 9PS, UNITED KINGDOM Single pass sequencing. Bases called and trimmed with phred v0.020425.c. Vector identified by cross match with the -minscore.20 and -minmatch.12 options. Vector:pBlueScriptII(SK+) R. Site1: EcoRI R. Site2: NotI 5' Seq Primer M13P Normalised library constructed from pooled early embryos, from 8- cell stage to blastocysts. Clones available from UK Centre for Functional Genomics in Farm Animals, Roslin Institute, Roslin, Midlothian, UK, EH25 9PS, www.arkgenomics.org.
FEATURES	Location/Qualifiers 1..13 /organism="Sus scrofa" /mol_type="mRNA" /db_xref="taxon:9823" /clone="C0005190_D17" /tissue_type="embryo" /clone_lib="KN277" /notes="Vector: pBlueScriptII(SK+); Site 1: EcoRI; Site 2: NotI; Single pass sequencing. Normalised library constructed from pooled early embryos, from 8-cell stage to blastocysts."
Query Match	0.6%; Score 11.4; DB 1; Length 13;
Best Local Similarity	92.3%; Pred. No. 9.6;
Matches	12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	790 CAGCCTGTATTAC 802
Db	1 CAGCCTGTATTCC 13
RESULT 18	
LOCUS	CF291168
DEFINITION	CF291168 14ROOT--01-H20.g1 Rice root plasmid cDNA library (14ROOT) Oryza sativa (japonica cultivar-group) cDNA clone 14ROOT--01-H20, mRNA sequence.
ACCESSION	CF291168
VERSION	CF291168.1 GI:33660201
KEYWORDS	EST.
SOURCE	Oryza sativa (japonica cultivar-group)
ORGANISM	Oryza sativa (japonica cultivar-group) Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzoideae; Oryza.

```

FEATURES             http://genoplate-info.infobiogen.fr).
  source              Location/Qualifiers
    1..14
      /organism="Arabidopsis thaliana"
      /mol_type="genomic DNA"
      /cultivar="Wassillewskija"
      /db_xref="taxon:3702"
      /clone="500809"
      /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
  misc_feature        1..14
      /note="T-DNA flanking sequence
      right border"

Query Match          0.6%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 11;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 476 AATTCATAAGATA 488
    |||||
Db 13 AATTCATAAATA 1

```

Search completed: July 12, 2005, 10:48:16
 Job time : 1 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 12, 2005, 10:44:49 ; Search time 10 Seconds
(without alignments)
3.652 Million cell updates/sec

Title: US-09-745-763-35

Perfect score: 1851

Sequence: 1 GGCTAGGCCGCGAGCTTAGT.....CTGAAAAAAAAAAAAAAAAA 1851

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 504 seqs, 9864 residues

Total number of hits satisfying chosen parameters: 1008

Minimum DB seq length: 0

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 504 summaries

Database : rnpb35.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	28	1.5	29	1	US-09-745-763-54
C 2	25	1.4	25	1	US-10-719-900-327131
C 3	25	1.4	25	1	US-10-956-157-44562
4	25	1.4	25	1	US-10-956-157-44563
5	25	1.4	25	1	US-10-956-157-44564
6	25	1.4	25	1	US-10-956-157-44565
7	25	1.4	25	1	US-10-956-157-44566
8	25	1.4	25	1	US-10-956-157-44567
9	25	1.4	25	1	US-10-956-157-44568
10	25	1.4	25	1	US-10-956-157-44569
11	25	1.4	25	1	US-10-956-157-44570
12	25	1.4	25	1	US-10-956-157-44571
13	25	1.4	25	1	US-10-956-157-44572
14	25	1.4	25	1	US-10-956-157-44573
15	25	1.4	25	1	US-10-956-157-44574
16	25	1.4	25	1	US-10-956-157-44575
17	25	1.4	25	1	US-10-956-157-44576
18	25	1.4	25	1	US-10-956-157-44577
19	25	1.4	25	1	US-10-956-157-44578
20	25	1.4	25	1	US-10-956-157-44579
21	25	1.4	25	1	US-10-956-157-44580
22	25	1.4	25	1	US-10-956-157-44581
23	25	1.4	25	1	US-10-956-157-44582
24	25	1.4	25	1	US-10-956-157-44583
25	25	1.4	25	1	US-10-956-157-44584
26	25	1.4	25	1	US-10-956-157-44585
27	25	1.4	25	1	US-10-956-157-124005
28	25	1.4	25	1	US-10-956-157-124207
29	25	1.4	25	1	US-10-956-157-127217
30	25	1.4	25	1	US-10-956-157-129079
31	25	1.4	25	1	US-10-956-157-136211
32	25	1.4	25	1	US-10-956-157-137039
33	25	1.4	25	1	US-10-956-157-152266

Sequence 161580,
Sequence 162447,
Sequence 169555,
Sequence 178856,
Sequence 182012,
Sequence 182211,
Sequence 186267,
Sequence 187410,
Sequence 189946,
Sequence 193114,
Sequence 198539,
Sequence 218907,
Sequence 218550,
Sequence 225436,
Sequence 241762,
Sequence 251130,
Sequence 256776,
Sequence 260715,
Sequence 260866,
Sequence 261245,
Sequence 290004,
Sequence 295664,
Sequence 296148,
Sequence 297155,
Sequence 302256,
Sequence 312448,
Sequence 312779,
Sequence 315180,
Sequence 325522,
Sequence 103390,
Sequence 127130,
Sequence 129011,
Sequence 181479,
Sequence 212376,
Sequence 103389,
Sequence 209370,
Sequence 456064,
Sequence 917234,
Sequence 623295,
Sequence 585846,
Sequence 623294,
Sequence 664932,
Sequence 752325,
Sequence 764443,
Sequence 917233,
Sequence 298572,
Sequence 298573,
Sequence 36103, A
Sequence 917267,
Sequence 456190,
Sequence 607010,
Sequence 970578,
Sequence 127295,
Sequence 443028,
Sequence 732505,
Sequence 36101, A
Sequence 33, Appl
Sequence 7, Appl
Sequence 34, Appl
Sequence 28, Appl
Sequence 29727, A
Sequence 29728, A
Sequence 3, Appl
Sequence 32, Appl
Sequence 45, Appl
Sequence 21, Appl
Sequence 23, Appl
Sequence 913, App
Sequence 939, App
Sequence 150, App

c 107	17	0.9	18	1	US-10-674-159A-112	Sequence 112, App	c 180	16.4	0.9	20	1	US-10-289-762-3072	Sequence 3072, Ap
c 108	17	0.9	18	1	US-10-776-917-141	Sequence 141, App	181	16.4	0.9	20	1	US-10-831-901A-26525	Sequence 26525, A
c 109	17	0.9	18	1	US-10-766-946-9	Sequence 9, Appl	182	16.4	0.9	20	1	US-10-831-901A-26526	Sequence 26526, A
c 110	17	0.9	18	1	US-10-638-141-10	Sequence 10, Appl	183	16.4	0.9	20	1	US-10-831-901A-26527	Sequence 26527, A
c 111	17	0.9	18	1	US-10-776-934-741	Sequence 741, App	c 184	16.4	0.9	20	1	US-10-831-901A-29726	Sequence 29726, A
c 112	17	0.9	18	1	US-10-601-140A-24	Sequence 24, Appl	185	16.2	0.9	21	1	US-09-828-034-10	Sequence 10, Appl
c 113	17	0.9	18	1	US-10-884-617-2	Sequence 2, Appl	186	16.2	0.9	21	1	US-09-765-111A-32	Sequence 32, Appl
c 114	17	0.9	18	1	US-10-669-962-27	Sequence 27, Appl	187	16.2	0.9	21	1	US-10-072-012-1128	Sequence 1128, Ap
c 115	17	0.9	18	1	US-10-669-962-29	Sequence 29, Appl	c 188	16.2	0.9	21	1	US-10-792-280-220	Sequence 220, App
c 116	17	0.9	18	1	US-10-503-120-1	Sequence 1, Appl	189	16.2	0.9	21	1	US-10-751-736-7618	Sequence 7618, Ap
c 117	17	0.9	18	1	US-10-503-120-8	Sequence 8, Appl	190	16.2	0.9	21	1	US-10-751-736-7619	Sequence 7619, Ap
c 118	17	0.9	18	1	US-10-503-120-9	Sequence 9, Appl	c 191	16.2	0.9	21	1	US-10-751-736-17864	Sequence 17864, A
c 119	17	0.9	18	1	US-10-503-120-10	Sequence 10, Appl	192	16.2	0.9	21	1	US-10-751-736-23615	Sequence 23615, A
c 120	17	0.9	18	1	US-10-503-120-21	Sequence 21, Appl	193	16.2	0.9	21	1	US-10-847-918-9328	Sequence 9328, Ap
c 121	17	0.9	18	1	US-11-024-428-7	Sequence 7, Appl	c 194	16.2	0.9	21	1	US-10-847-918-9330	Sequence 9330, Ap
c 122	17	0.9	19	1	US-10-760-940-1	Sequence 1, Appl	195	16.2	0.9	21	1	US-10-847-918-9570	Sequence 9570, Ap
c 123	17	0.9	19	1	US-10-913-246-22	Sequence 22, Appl	196	16.2	0.9	21	1	US-10-847-918-12368	Sequence 12368, A
c 124	17	0.9	19	1	US-10-913-246-24	Sequence 24, Appl	c 197	16.2	0.9	21	1	US-10-847-918-12887	Sequence 12887, A
c 125	17	0.9	19	1	US-10-934-890-22	Sequence 22, Appl	198	16.2	0.9	21	1	US-10-847-918-13478	Sequence 13478, A
c 126	17	0.9	19	1	US-10-934-890-24	Sequence 24, Appl	c 199	16	0.9	16	1	US-10-755-118-94	Sequence 94, Appl
c 127	17	0.9	19	1	US-10-700-884-23	Sequence 23, Appl	c 200	16	0.9	17	1	US-10-608-863-4	Sequence 4, Appl
c 128	17	0.9	19	1	US-10-800-487-162	Sequence 162, App	c 201	16	0.9	18	1	US-10-872-984-6	Sequence 6, Appl
c 129	17	0.9	19	1	US-10-800-487-328	Sequence 328, App	202	16	0.9	21	1	US-10-751-736-19139	Sequence 19139, A
c 130	17	0.9	19	1	US-10-940-360-1	Sequence 1, Appl	203	15.8	0.9	19	1	US-10-871-222-150	Sequence 150, App
c 131	17	0.9	20	1	US-09-976-900A-55	Sequence 55, Appl	c 204	15.8	0.9	19	1	US-10-871-222-300	Sequence 300, App
c 132	17	0.9	20	1	US-10-661-415-12	Sequence 12, Appl	205	15.8	0.9	19	1	US-10-840-731-34	Sequence 34, Appl
c 133	17	0.9	20	1	US-10-661-415-15	Sequence 15, Appl	c 206	15.8	0.9	19	1	US-10-840-731-129	Sequence 129, App
c 134	17	0.9	20	1	US-10-831-778-226	Sequence 226, App	207	15.8	0.9	20	1	US-09-987-025-8	Sequence 8, Appl
c 135	17	0.9	20	1	US-10-831-778-556	Sequence 556, App	c 208	15.8	0.9	20	1	US-10-108-164-125	Sequence 125, App
c 136	17	0.9	20	1	US-10-831-778-560	Sequence 560, App	209	15.8	0.9	20	1	US-10-139-604-2	Sequence 2, Appl
c 137	17	0.9	20	1	US-10-728-078-14	Sequence 14, Appl	210	15.8	0.9	20	1	US-10-261-706-4	Sequence 4, Appl
c 138	17	0.9	20	1	US-10-728-078-23	Sequence 23, Appl	c 211	15.8	0.9	20	1	US-10-289-762-6169	Sequence 6169, Ap
c 139	17	0.9	20	1	US-10-601-140A-1	Sequence 1, Appl	212	15.8	0.9	20	1	US-10-831-901A-8646	Sequence 8646, Ap
c 140	17	0.9	20	1	US-10-601-140A-2	Sequence 2, Appl	213	15.8	0.9	20	1	US-10-831-901A-8647	Sequence 8647, Ap
c 141	17	0.9	20	1	US-10-601-140A-3	Sequence 3, Appl	214	15.8	0.9	20	1	US-10-699-362A-4	Sequence 4, Appl
c 142	17	0.9	20	1	US-10-601-140A-4	Sequence 4, Appl	215	15.8	0.9	20	1	US-10-966-829-8	Sequence 8, Appl
c 143	17	0.9	20	1	US-10-601-140A-6	Sequence 6, Appl	c 216	15.8	0.9	20	1	US-10-792-280-376	Sequence 376, App
c 144	17	0.9	20	1	US-10-601-140A-7	Sequence 7, Appl	217	15.8	0.9	21	1	US-10-751-736-23903	Sequence 23903, A
c 145	17	0.9	20	1	US-10-601-140A-8	Sequence 8, Appl	c 218	15.8	0.9	21	1	US-10-751-736-29406	Sequence 29406, A
c 146	17	0.9	20	1	US-10-601-140A-9	Sequence 9, Appl	219	15.8	0.9	21	1	US-10-831-819-12	Sequence 12, Appl
c 147	17	0.9	20	1	US-10-601-140A-10	Sequence 10, Appl	c 220	15.8	0.9	21	1	US-10-479-472A-7	Sequence 7, Appl
c 148	17	0.9	20	1	US-10-601-140A-23	Sequence 23, Appl	221	15.4	0.8	17	1	US-09-877-478-266	Sequence 266, App
c 149	17	0.9	20	1	US-10-601-140A-34	Sequence 34, Appl	c 222	15.4	0.8	17	1	US-10-342-903-266	Sequence 266, App
c 150	17	0.9	20	1	US-10-601-140A-40	Sequence 40, Appl	c 223	15.4	0.8	17	1	US-10-669-841-266	Sequence 266, App
c 151	17	0.9	20	1	US-10-601-140A-44	Sequence 44, Appl	c 224	15.4	0.8	18	1	US-09-969-373-3693	Sequence 3693, Ap
c 152	17	0.9	20	1	US-10-876-086-49	Sequence 49, Appl	c 225	15.4	0.8	18	1	US-10-436-231-2	Sequence 1, Appl
c 153	17	0.9	20	1	US-10-620-642-32	Sequence 32, Appl	226	15.4	0.8	18	1	US-10-436-231-1	Sequence 6, Appl
c 154	17	0.9	20	1	US-10-831-901A-29729	Sequence 29729, A	c 227	15.4	0.8	19	1	US-09-916-136A-6	Sequence 6, Appl
c 155	17	0.9	20	1	US-10-831-901A-29730	Sequence 29730, A	228	15.4	0.8	19	1	US-10-444-925-420	Sequence 420, App
c 156	17	0.9	20	1	US-10-831-901A-29731	Sequence 29731, A	229	15.4	0.8	19	1	US-10-871-222-404	Sequence 404, App
c 157	17	0.9	20	1	US-10-831-901A-29732	Sequence 29732, A	c 230	15.4	0.8	19	1	US-10-871-222-508	Sequence 508, App
c 158	17	0.9	20	1	US-10-831-901A-29733	Sequence 29733, A	231	15.4	0.8	19	1	US-10-881-118-121	Sequence 121, App
c 159	17	0.9	20	1	US-10-831-901A-29734	Sequence 29734, A	c 232	15.4	0.8	19	1	US-10-881-118-284	Sequence 284, App
c 160	17	0.9	20	1	US-10-831-901A-29735	Sequence 29735, A	c 233	15.4	0.8	19	1	US-10-840-731-32	Sequence 32, Appl
c 161	17	0.9	20	1	US-10-831-901A-29736	Sequence 29736, A	234	15.4	0.8	19	1	US-10-840-731-33	Sequence 33, Appl
c 162	17	0.9	20	1	US-10-789-831-22	Sequence 22, Appl	c 235	15.4	0.8	19	1	US-10-840-731-127	Sequence 127, App
c 163	17	0.9	20	1	US-10-789-831-23	Sequence 23, Appl	c 236	15.4	0.8	19	1	US-10-840-731-128	Sequence 128, App
c 164	17	0.9	20	1	US-10-789-831-24	Sequence 24, Appl	c 237	15.4	0.8	19	1	US-10-863-973-389	Sequence 389, App
c 165	17	0.9	21	1	US-10-831-778-912	Sequence 912, App	c 238	15.4	0.8	19	1	US-10-863-973-589	Sequence 589, App
c 166	17	0.9	21	1	US-10-751-736-19135	Sequence 19135, A	c 239	15.4	0.8	20	1	US-09-242-772-55	Sequence 55, Appl
c 167	17	0.9	21	1	US-10-751-736-19136	Sequence 19136, A	c 240	15.4	0.8	20	1	US-10-058-422-14	Sequence 14, Appl
c 168	17	0.9	21	1	US-10-751-736-19138	Sequence 19138, A	241	15.4	0.8	20	1	US-10-289-762-6103	Sequence 6103, Ap
c 169	17	0.9	21	1	US-10-913-246-23	Sequence 23, Appl	242	15.4	0.8	20	1	US-10-766-185-47	Sequence 47, Appl
c 170	17	0.9	21	1	US-10-934-890-23	Sequence 23, Appl	243	15.4	0.8	20	1	US-10-380-049-11	Sequence 11, Appl
c 171	17	0.9	21	1	US-10-830-287A-7	Sequence 7, Appl	244	15.4	0.8	20	1	US-10-831-901A-26524	Sequence 26524, A
c 172	17	0.9	21	1	US-10-601-140A-43	Sequence 43, Appl	245	15.4	0.8	20	1	US-10-831-901A-26528	Sequence 26528, A
c 173	16.8	0.9	21	1	US-09-263-981-4	Sequence 4, Appl	c 246	15.4	0.8	20	1	US-10-831-901A-29725	Sequence 29725, A
c 174	16.8	0.9	21	1	US-10-843-938-4	Sequence 4, Appl	c 247	15.4	0.8	20	1	US-10-317-869A-54	Sequence 54, Appl
c 175	16.8	0.9	21	1	US-10-751-736-25521	Sequence 25521, A	c 248	15.4	0.8	20	1	US-10-317-869A-103	Sequence 103, App
c 176	16.8	0.9	22	1	US-10-027-632-52359	Sequence 52359, A	c 249	15.2	0.8	17	1	US-10-872-645-29	Sequence 29, Appl
c 177	16.8	0.9	22	1	US-10-027-632-52359	Sequence 52359, A	c 250	15.2	0.8	20	1	US-09-768-917-9	Sequence 9, Appl
c 178	16.4	0.9	18	1	US-10-349-143-4101	Sequence 4101, Ap	c 251	15.2	0.8	20	1	US-09-888-326-410	Sequence 410, App
c 179	16.4	0.9	18	1	US-10-872-984-5	Sequence 5, Appl	c 252	15.2	0.8	20	1	US-09-802-640-74	Sequence 74, Appl

C 253	15.2	0.8	20	1	US-09-776-479-243	Sequence 243, App	C 326	15	0.8	17	1	US-10-724-270-1285	Sequence 1285, Ap
C 254	15.2	0.8	20	1	US-09-776-479-243	Sequence 243, App	C 327	15	0.8	20	1	US-10-644-052A-376	Sequence 376, App
C 255	15.2	0.8	20	1	US-09-932-419-5	Sequence 5, Appli	C 328	15	0.8	20	1	US-10-644-052A-377	Sequence 377, App
C 256	15.2	0.8	20	1	US-09-915-814-184	Sequence 184, App	C 329	14.8	0.8	18	1	US-10-479-472A-8	Sequence 8, Appli
C 257	15.2	0.8	20	1	US-09-965-101-57	Sequence 57, Appli	C 330	14.8	0.8	18	1	US-10-479-472A-9	Sequence 9, Appli
C 258	15.2	0.8	20	1	US-10-112-663-235	Sequence 235, App	C 331	14.8	0.8	18	1	US-10-349-143-6888	Sequence 6888, Ap
C 259	15.2	0.8	20	1	US-10-017-995-243	Sequence 243, App	C 332	14.8	0.8	19	1	US-10-349-143-7139	Sequence 7139, Ap
C 260	15.2	0.8	20	1	US-10-067-076-10	Sequence 10, Appl	C 333	14.8	0.8	19	1	US-10-830-569-307	Sequence 307, App
C 261	15.2	0.8	20	1	US-10-314-578-243	Sequence 243, App	C 334	14.8	0.8	19	1	US-10-830-569-614	Sequence 614, App
C 262	15.2	0.8	20	1	US-10-403-902A-74	Sequence 74, Appl	C 335	14.8	0.8	19	1	US-10-840-731-35	Sequence 35, Appli
C 263	15.2	0.8	20	1	US-10-175-499-39	Sequence 39, Appl	C 336	14.8	0.8	19	1	US-10-840-731-130	Sequence 130, App
C 264	15.2	0.8	20	1	US-10-289-762-4294	Sequence 4294, Ap	C 337	14.8	0.8	19	1	US-10-863-973-694	Sequence 694, App
C 265	15.2	0.8	20	1	US-10-210-556-35	Sequence 35, Appl	C 338	14.8	0.8	19	1	US-10-863-973-765	Sequence 765, App
C 266	15.2	0.8	20	1	US-10-210-556-158	Sequence 158, App	C 339	14.4	0.8	16	1	US-10-164-915-3	Sequence 3, Appli
C 267	15.2	0.8	20	1	US-10-280-183A-69	Sequence 69, Appl	C 340	14.4	0.8	17	1	US-09-866-108-8364	Sequence 8364, Ap
C 268	15.2	0.8	20	1	US-10-303-326-30	Sequence 30, Appl	C 341	14.4	0.8	17	1	US-09-866-108-8365	Sequence 8365, Ap
C 269	15.2	0.8	20	1	US-10-303-326-60	Sequence 60, Appl	C 342	14.4	0.8	17	1	US-09-866-108-10030	Sequence 10030, A
C 270	15.2	0.8	20	1	US-10-304-125-30	Sequence 30, Appl	C 343	14.4	0.8	17	1	US-09-866-108-10031	Sequence 10031, A
C 271	15.2	0.8	20	1	US-10-304-125-100	Sequence 100, App	C 344	14.4	0.8	17	1	US-09-927-046-1622	Sequence 1622, Ap
C 272	15.2	0.8	20	1	US-10-688-706-2869	Sequence 2869, Ap	C 345	14.4	0.8	17	1	US-09-877-478-265	Sequence 265, App
C 273	15.2	0.8	20	1	US-10-304-019-23	Sequence 23, Appl	C 346	14.4	0.8	17	1	US-09-877-478-267	Sequence 267, App
C 274	15.2	0.8	20	1	US-10-304-019-94	Sequence 94, Appl	C 347	14.4	0.8	17	1	US-09-848-754A-2911	Sequence 2911, Ap
C 275	15.2	0.8	20	1	US-10-318-819A-64	Sequence 64, Appl	C 348	14.4	0.8	17	1	US-09-848-754A-3506	Sequence 3506, Ap
C 276	15.2	0.8	20	1	US-10-318-819A-120	Sequence 120, App	C 349	14.4	0.8	17	1	US-09-780-164-1033	Sequence 1033, Ap
C 277	15.2	0.8	20	1	US-10-712-795-261	Sequence 261, App	C 350	14.4	0.8	17	1	US-09-740-332-1266	Sequence 1266, Ap
C 278	15.2	0.8	20	1	US-10-712-795-627	Sequence 627, App	C 351	14.4	0.8	17	1	US-09-740-332-1414	Sequence 1414, Ap
C 279	15.2	0.8	20	1	US-10-712-795-835	Sequence 835, App	C 352	14.4	0.8	17	1	US-09-740-332-3289	Sequence 3289, Ap
C 280	15.2	0.8	20	1	US-10-712-795-880	Sequence 880, App	C 353	14.4	0.8	17	1	US-09-817-879-1266	Sequence 1266, Ap
C 281	15.2	0.8	20	1	US-10-831-778-243	Sequence 243, App	C 354	14.4	0.8	17	1	US-09-817-879-1414	Sequence 1414, Ap
C 282	15.2	0.8	20	1	US-10-920-612-261	Sequence 261, App	C 355	14.4	0.8	17	1	US-09-817-879-3289	Sequence 3289, Ap
C 283	15.2	0.8	20	1	US-10-920-612-627	Sequence 627, App	C 356	14.4	0.8	17	1	US-10-238-700-1286	Sequence 1286, Ap
C 284	15.2	0.8	20	1	US-10-920-612-835	Sequence 835, App	C 357	14.4	0.8	17	1	US-10-342-902-265	Sequence 265, App
C 285	15.2	0.8	20	1	US-10-920-612-880	Sequence 880, App	C 358	14.4	0.8	17	1	US-10-342-902-267	Sequence 267, App
C 286	15.2	0.8	20	1	US-10-838-659-57	Sequence 57, Appl	C 359	14.4	0.8	17	1	US-10-138-674-4471	Sequence 4471, Ap
C 287	15.2	0.8	20	1	US-10-831-901A-22	Sequence 22, Appl	C 360	14.4	0.8	17	1	US-10-138-674-7673	Sequence 7673, Ap
C 288	15.2	0.8	20	1	US-10-831-901A-1686	Sequence 1686, Ap	C 361	14.4	0.8	17	1	US-10-138-674-7675	Sequence 7675, Ap
C 289	15.2	0.8	20	1	US-10-831-901A-1687	Sequence 1687, Ap	C 362	14.4	0.8	17	1	US-10-287-949A-4471	Sequence 4471, Ap
C 290	15.2	0.8	20	1	US-10-831-901A-8645	Sequence 8645, Ap	C 363	14.4	0.8	17	1	US-10-287-949A-7673	Sequence 7673, Ap
C 291	15.2	0.8	20	1	US-10-831-901A-8648	Sequence 8648, Ap	C 364	14.4	0.8	17	1	US-10-287-949A-8905	Sequence 8905, Ap
C 292	15.2	0.8	20	1	US-10-831-901A-11564	Sequence 11564, A	C 365	14.4	0.8	17	1	US-10-669-841-265	Sequence 265, App
C 293	15.2	0.8	20	1	US-10-831-901A-11564	Sequence 11564, A	C 366	14.4	0.8	17	1	US-10-669-841-267	Sequence 267, App
C 294	15.2	0.8	20	1	US-10-831-901A-11565	Sequence 11565, A	C 367	14.4	0.8	17	1	US-10-669-841-3859	Sequence 3859, Ap
C 295	15.2	0.8	20	1	US-10-831-901A-21448	Sequence 21448, A	C 368	14.4	0.8	17	1	US-10-669-841-4007	Sequence 4007, Ap
C 296	15.2	0.8	20	1	US-10-831-901A-23367	Sequence 23367, A	C 369	14.4	0.8	17	1	US-10-669-841-5882	Sequence 5882, Ap
C 297	15.2	0.8	20	1	US-10-831-901A-25435	Sequence 25435, A	C 370	14.4	0.8	17	1	US-10-723-361-8364	Sequence 8364, Ap
C 298	15.2	0.8	20	1	US-10-831-901A-25436	Sequence 25436, A	C 371	14.4	0.8	17	1	US-10-723-361-8365	Sequence 8365, Ap
C 299	15.2	0.8	20	1	US-10-663-451-166	Sequence 166, App	C 372	14.4	0.8	17	1	US-10-723-361-10030	Sequence 10030, A
C 300	15	0.8	15	1	US-10-182-049-151	Sequence 151, App	C 373	14.4	0.8	17	1	US-10-723-361-10031	Sequence 10031, A
C 301	15	0.8	15	1	US-10-830-484-4	Sequence 4, Appli	C 374	14.4	0.8	17	1	US-10-712-633-729	Sequence 729, App
C 302	15	0.8	15	1	US-10-755-118-3	Sequence 3, Appli	C 375	14.4	0.8	17	1	US-10-712-633-4103	Sequence 4103, Ap
C 303	15	0.8	15	1	US-10-755-118-4	Sequence 4, Appli	C 376	14.4	0.8	17	1	US-10-724-270-1286	Sequence 1286, Ap
C 304	15	0.8	15	1	US-10-755-118-31	Sequence 31, Appl	C 377	14.4	0.8	18	1	US-09-263-959-1276	Sequence 1276, Ap
C 305	15	0.8	15	1	US-10-755-118-32	Sequence 32, Appl	C 378	14.4	0.8	18	1	US-09-955-529-189	Sequence 189, App
C 306	15	0.8	15	1	US-10-755-118-36	Sequence 36, Appl	C 379	14.4	0.8	18	1	US-09-955-529-189	Sequence 189, App
C 307	15	0.8	15	1	US-10-755-118-38	Sequence 38, Appl	C 380	14.4	0.8	18	1	US-10-214-670-29	Sequence 29, Appl
C 308	15	0.8	15	1	US-10-755-118-39	Sequence 39, Appl	C 381	14.4	0.8	18	1	US-10-277-216-327	Sequence 327, App
C 309	15	0.8	15	1	US-10-755-118-40	Sequence 40, Appl	C 382	14.4	0.8	18	1	US-10-126-022-327	Sequence 327, App
C 310	15	0.8	15	1	US-10-755-118-43	Sequence 43, Appl	C 383	14.4	0.8	18	1	US-10-416-708A-8	Sequence 8, Appli
C 311	15	0.8	15	1	US-10-755-118-44	Sequence 44, Appl	C 384	14.4	0.8	19	1	US-10-604-944-221	Sequence 221, App
C 312	15	0.8	15	1	US-10-755-118-45	Sequence 45, Appl	C 385	14.4	0.8	19	1	US-10-840-731-31	Sequence 31, Appl
C 313	15	0.8	15	1	US-10-755-118-48	Sequence 48, Appl	C 386	14.4	0.8	19	1	US-10-840-731-126	Sequence 126, App
C 314	15	0.8	15	1	US-10-755-118-49	Sequence 49, Appl	C 387	14.2	0.8	17	1	US-10-671-034-5	Sequence 5, Appli
C 315	15	0.8	15	1	US-10-770-989-9	Sequence 9, Appli	C 388	14.2	0.8	14	1	US-10-830-484-3	Sequence 3, Appli
C 316	15	0.8	15	1	US-10-833-502-9	Sequence 9, Appli	C 389	14	0.8	14	1	US-10-764-393-11	Sequence 11, Appl
C 317	15	0.8	15	1	US-10-939-214-54	Sequence 54, Appl	C 390	14	0.8	14	1	US-10-764-389-11	Sequence 11, Appl
C 318	15	0.8	15	1	US-10-939-214-55	Sequence 55, Appl	C 391	14	0.8	14	1	US-10-855-595-21	Sequence 21, Appl
C 319	15	0.8	15	1	US-10-601-140A-5	Sequence 5, Appli	C 392	14	0.8	14	1	US-10-763-076-11	Sequence 11, Appl
C 320	15	0.8	15	1	US-10-601-140A-16	Sequence 16, Appl	C 393	14	0.8	14	1	US-10-855-532-21	Sequence 21, Appl
C 321	15	0.8	15	1	US-10-601-140A-19	Sequence 19, Appl	C 394	14	0.8	14	1	US-10-764-388-11	Sequence 11, Appl
C 322	15	0.8	15	1	US-10-239-919A-4	Sequence 4, Appli	C 395	14	0.8	14	1	US-10-096-076-11	Sequence 11, Appl
C 323	15	0.8	17	1	US-10-938-661A-22	Sequence 22, Appl	C 396	14	0.8	17	1	US-09-866-108-2590	Sequence 2590, Ap
C 324	15	0.8	17	1	US-10-238-700-1285	Sequence 1285, Ap	C 397	14	0.8	17	1	US-09-866-108-2591	Sequence 2591, Ap
C 325	15	0.8	17	1	US-10-608-863-3	Sequence 3, Appli	C 398	14	0.8	17	1	US-09-866-108-2592	Sequence 2592, Ap
C 326	15	0.8	17	1	US-10-608-863-5	Sequence 5, Appli	C 399	14	0.8	17	1	US-09-866-108-2593	Sequence 2593, Ap

TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 498-8284
TELEFAX: (617) 876-5851
INFORMATION FOR SEQ ID NO: 54:
SEQUENCE CHARACTERISTICS:
LENGTH: 29 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "oligonucleotide"
SEQUENCE DESCRIPTION: SEQ ID NO: 54:
US-09-745-763-54

Query Match 1.5%; Score 28; DB 1; Length 29;
Best Local Similarity 96.6%; Pred. No. 14;
Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 295 GATTGGCACTTCTGGTTGATCACTGTGGA 323
DB 29 GATTGGCACTTCTGGTTGATCACTGTGGA 1

RESULT 2
US-10-719-900-527131/c
; Sequence 527131, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Yue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 527131
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-527131

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1426 TGGATCCAAAGCAGATGAATGTGC 1450
DB 25 TGGATCCAAAGCAGATGAATGTGC 1

RESULT 3
US-10-956-157-44562
; Sequence 44562, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44562
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44562

Query Match 1.4%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 618 AACCAACCTTACATCAACTACTCAA 642
DB 1 AACCAACCTTACATCAACTACTCAA 25

RESULT 4
US-10-956-157-44563
; Sequence 44563, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44563
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44563

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1125 GCCTTCCAGTATTATCAGTTACACA 1149
DB 1 GCCTTCCAGTATTATCAGTTACACA 25

RESULT 5
US-10-956-157-44564
; Sequence 44564, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44564
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44564

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1124 TGCCTTCCAGTATTATCAGTTACAC 1148
DB 1 TGCCTTCCAGTATTATCAGTTACAC 25

RESULT 6
US-10-956-157-44565
; Sequence 44565, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William

```
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44565
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44565

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1123 GTGCTTCCAGTATTATCAGTTACA 1147
Db      1 GTGCTTCCAGTATTATCAGTTACA 25

RESULT 7
US-10-956-157-44566
; Sequence 44566, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44566
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44566

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      617 TAACCAACCTTACATCAACTACTCA 641
Db      1 TAACCAACCTTACATCAACTACTCA 25

RESULT 8
US-10-956-157-44567
; Sequence 44567, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44567
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44567

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      619 ACCAACCTTACATCAACTACTCAAG 643
Db      1 ACCAACCTTACATCAACTACTCAAG 25

RESULT 11
US-10-956-157-44570
; Sequence 44570, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

```
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1129 TCAGTATTATCAGTTACACAAGGT 1153
Db      1 TCAGTATTATCAGTTACACAAGGT 25

RESULT 9
US-10-956-157-44568
; Sequence 44568, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44568
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44568

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1122 GTGCTTCCAGTATTATCAGTTAC 1146
Db      1 GTGCTTCCAGTATTATCAGTTAC 25

RESULT 10
US-10-956-157-44569
; Sequence 44569, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44569
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44569

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      619 ACCAACCTTACATCAACTACTCAAG 643
Db      1 ACCAACCTTACATCAACTACTCAAG 25

RESULT 11
US-10-956-157-44570
; Sequence 44570, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44570
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44570

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 892 ATACTGATTCCTTCAACACTGAGC 916
Db 1 ATACTGATTCCTTCAACACTGAGC 25

RESULT 12

US-10-956-157-44571
; Sequence 44571, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44571
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44571

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 616 ATAAACCAACCTTACATCAACTACTC 640
Db 1 ATAAACCAACCTTACATCAACTACTC 25

RESULT 13

US-10-956-157-44572
; Sequence 44572, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44572
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44572

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1128 TTCCAGTATTATCAGTTACACAAGG 1152
Db 1 TTCCAGTATTATCAGTTACACAAGG 25

RESULT 14

US-10-956-157-44573
; Sequence 44573, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44573
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44573

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1126 CTTCCAGTATTATCAGTTACACAA 1150
Db 1 CTTCCAGTATTATCAGTTACACAA 25

RESULT 15

US-10-956-157-44574
; Sequence 44574, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44574
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44574

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 890 AGATACCTGATTCCTTCAACACTGTA 914
Db 1 AGATACCTGATTCCTTCAACACTGTA 25

RESULT 16

US-10-956-157-44575
; Sequence 44575, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44575
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44575

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 891 GATACTGATTCCTTCAACACTGTAG 915
Db 1 GATACTGATTCCTTCAACACTGTAG 25
|||||

RESULT 17

US-10-956-157-44576
; Sequence 44576, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44576
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44576

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 889 CAGATAGTATTCCTTCAACACTGT 913
Db 1 CAGATAGTATTCCTTCAACACTGT 25
|||||

RESULT 18

US-10-956-157-44577
; Sequence 44577, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44577
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44577

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 625 CTTACATCAACTACTCAAGGACGGT 649
Db 1 CTTACATCAACTACTCAAGGACGGT 25
|||||

RESULT 19

US-10-956-157-44578
; Sequence 44578, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44578
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44578

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1130 CCAGTATTATCAGTTACACAAGSTA 1154
Db 1 CCAGTATTATCAGTTACACAAGSTA 25
|||||

RESULT 20

US-10-956-157-44579
; Sequence 44579, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44579
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44579

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 893 TACTGATTCCTTCAACACTGTAGCA 917
Db 1 TACTGATTCCTTCAACACTGTAGCA 25
|||||

RESULT 21

US-10-956-157-44580
; Sequence 44580, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; SOFTWARE: PatentIn version 3.2

; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44580
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44580

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 626 TTACATCAACTACTCAAGGACGGTG 650
|||||
Db 1 TTACATCAACTACTCAAGGACGGTG 25

RESULT 22

US-10-956-157-44581
; Sequence 44581, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44581
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44581

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 888 CCAGATACTGATTCCTTCAACACTG 912
|||||
Db 1 CCAGATACTGATTCCTTCAACACTG 25

RESULT 23

US-10-956-157-44582
; Sequence 44582, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44582
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44582

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 732 ATCTACAGTCCTCACAGGTATTC 756

Db 1 ATCTACAGTCCTCACAGGTATTC 25
|||||

RESULT 24

US-10-956-157-44583
; Sequence 44583, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44583
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44583

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 898 ATTCCTTCAACACTGTAGCAGAGAT 922
|||||
Db 1 ATTCCTTCAACACTGTAGCAGAGAT 25

RESULT 25

US-10-956-157-44584
; Sequence 44584, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44584
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44584

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 731 CATCTACAGTCCTCACAGGTATT 755
|||||
Db 1 CATCTACAGTCCTCACAGGTATT 25

RESULT 26

US-10-956-157-44585
; Sequence 44585, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44585
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44585

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1712 CTCGCCACCATAGATCAACATAT 1736
|||||
DB 1 CTCGCCACCATAGATCAACATAT 25

RESULT 27

US-10-956-157-124005
; Sequence 124005, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 124005

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-124005

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1610 ATTCACTTCAAAGCACACTCTAT 1634
|||||
DB 1 ATTCACTTCAAAGCACACTCTAT 25

RESULT 28

US-10-956-157-124207
; Sequence 124207, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 124207

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-124207

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1744 ATTACAGTGGGGCATTTCTTTATA 1768
|||||

Db 1 ATTACAGTGGGGCATTTCTTTATA 25

RESULT 29

US-10-956-157-127217
; Sequence 127217, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 127217

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-127217

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1594 ATAACAATTTCAATTCATCTT 1618
|||||

Db 1 ATAACAATTTCAATTCATCTT 25

RESULT 30

US-10-956-157-129079
; Sequence 129079, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 129079

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-129079

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1614 ATCTTCAAAGCACACTCTATTCA 1638
|||||

Db 1 ATCTTCAAAGCACACTCTATTCA 25

RESULT 31

US-10-956-157-136211
; Sequence 136211, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 136211
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-136211

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1740 AGGGATTACAGTGGGGGCAATTCCT 1764
|||||
Db 1 AGGGATTACAGTGGGGGCAATTCCT 25

RESULT 32
US-10-956-157-137039
; Sequence 137039, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 137039
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-137039

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AGTGGGGGCATTCCTTTATATACCC 1773
|||||
Db 1 AGTGGGGGCATTCCTTTATATACCC 25

RESULT 33
US-10-956-157-152266
; Sequence 152266, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 152266
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-152266

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1747 ACATGGGGGCATTCCTTTATATCA 1771
|||||
Db 1 ACATGGGGGCATTCCTTTATATCA 25

RESULT 34

US-10-956-157-161580
; Sequence 161580, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 161580
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-161580

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1529 AAGAAACGTTTTCATGCTTCTGGCC 1553
|||||
Db 1 AAGAAACGTTTTCATGCTTCTGGCC 25

RESULT 35

US-10-956-157-162447
; Sequence 162447, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 162447
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-162447

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1621 AAGCACAACTCTATTTTCATGCTTTC 1645
|||||
Db 1 AAGCACAACTCTATTTTCATGCTTTC 25

RESULT 36

US-10-956-157-168555
; Sequence 168555, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 168555
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-168555

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1608 CAATTTCATCTTCAAGCACAACTCT 1632
Db 1 CAATTCATCTTCAAGCACAACTCT 25

RESULT 37
US-10-956-157-178856
; Sequence 178856, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 178856
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-178856

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1637 CATGCTTTCGTATTATCTTTCTT 1661
Db 1 CATGCTTTCGTATTATCTTTCTT 25

RESULT 38
US-10-956-157-182012
; Sequence 182012, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 182012
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-182012

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1616 CTTCAAAGCACAACTCTATTTCATG 1640
Db 1 CTTCAAAGCACAACTCTATTTCATG 25

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 168555
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-182211
; Sequence 182211, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 182211
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-182211

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1655 CTTTCTTGATACCTTCCAAATTCCTC 1679
Db 1 CTTTCTTGATACCTTCCAAATTCCTC 25

RESULT 40
US-10-956-157-186267
; Sequence 186267, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186267
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-186267

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1712 CTCCCACCACATAGATCAACATAT 1736
Db 1 CTCCCACCACATAGATCAACATAT 25

RESULT 41
US-10-956-157-187410
; Sequence 187410, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
```

; SEQ ID NO 187410
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-187410

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTGGAAACTCTCTTC 1591
|||||
Db 1 CTGCAACTTTGGAAACTCTCTTC 25

RESULT 42

US-10-956-157-189946
; Sequence 189946, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 189946
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-189946

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1561 CTGGGCTGCAACTTTGGAAACTC 1585
|||||
Db 1 CTGGGCTGCAACTTTGGAAACTC 25

RESULT 43

US-10-956-157-193114
; Sequence 193114, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193114
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-193114

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1714 CCCACCACATAGATCAACATATGG 1738
|||||
Db 1 CCCACCACATAGATCAACATATGG 25

RESULT 44

US-10-956-157-198539
; Sequence 198539, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 198539
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-198539

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1711 CCTCCACCATAGATCAACATA 1735
|||||
Db 1 CCTCCACCATAGATCAACATA 25

RESULT 45

US-10-956-157-216907
; Sequence 216907, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216907
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-216907

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1569 GCAACTTTGGAAACTCTCTTCAC 1593
|||||
Db 1 GCAACTTTGGAAACTCTCTTCAC 25

RESULT 46

US-10-956-157-218550
; Sequence 218550, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 218550


```
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-260715

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1563 GGGTCTGCAACTTTGGAAACTCCT 1587
      |||||
Db 1 GGGTCTGCAACTTTGGAAACTCCT 25

RESULT 52
US-10-956-157-260866
; Sequence 260866, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 260866
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-260866

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1741 GGGATTACAGTGGGGGCATTTCTTT 1765
      |||||
Db 1 GGGATTACAGTGGGGGCATTTCTTT 25

RESULT 53
US-10-956-157-261245
; Sequence 261245, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 261245
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-261245

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1564 GGTCTGCAACTTTGGAAACTCCTC 1588
      |||||
Db 1 GGTCTGCAACTTTGGAAACTCCTC 25

RESULT 54
US-10-956-157-290004
```

```
; Sequence 290004, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 290004
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-290004

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1559 TCCTGGGTCTGCAACTTTGGAAAC 1583
      |||||
Db 1 TCCTGGGTCTGCAACTTTGGAAAC 25

RESULT 55
US-10-956-157-295664
; Sequence 295664, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 295664
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-295664

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1658 TCTTGATACTTCCAAATTCCTGA 1682
      |||||
Db 1 TCTTGATACTTCCAAATTCCTGA 25

RESULT 56
US-10-956-157-296148
; Sequence 296148, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 296148
; LENGTH: 25
; TYPE: DNA
```

; ORGANISM: Probe Sequence
US-10-956-157-296148

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels

Qy 1612 TCATCTTCAAAGCACAACTCTATTT 1636
|||
Db 1 TCATCTTCAAAGCACAACTCTATTT 25

RESULT 57

US-10-956-157-297155
; Sequence 297155, Application US/10956157
; Publication No. US20050118625A1

; GENERAL INFORMATION:

APPLICANT: Wveth

APPLICANT: Mounts, William

TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION
 ;
 TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

FILE OF INVENTOR: ROYAL OSCAR HANSEN
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157

: CURRENT FILING DATE: 2004-10-04

: NUMBER OF SEO ID NOS: 319805

: SOFTWARE: PatentIn version 3.2

: SEO TD NO 297155

: LENGTH: 25

TYPE: DNA

TYPE: DNA
ORGANISM: Probe sequence

ORGANISM: FLODE
IIS-10-956-157-297155

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels

Qy 1618 TCAAAGCACAACTCTATTTCATGCT 1642
|||
Db 1 TCAAAGCACAACTCTATTTCATGCT 25

RESULT 58

US-10-956-157-302256
; Sequence 302256, Application US/10956157
; Publication No. US20050118625A1

GENERAL INFORMATION:

: APPLICANT: Wveth

APPLICANT: Mounts. William

TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION

FILE OF INVENTION HUMAN OSTEOCALCIN
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956.157

CURRENT FILING DATE: 2004-10-04

: NUMBER OF SEQ TD NOS: 319805

: SOFTWARE: Patent In version 3 2
; NUMBER OF SEQ ID NOS: 313803

: CEO TD NO 303256
 : BOFWK. FACEM

;	SEQ	ID	NO	30
:	LENGTH:			25

LENGTH: 2.0
TYPE: DNA

TYPE: DNA
CPCNTSM: Probe sequence

ORGANISM: Probe
; IIS-10-956-157-302256

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels

Qy 1746 TACAGTGGGGGCATTTCTTTATATC 1770
|||
Db 1 TACAGTGGGGGCATTTCTTTATATC 25

RESULT 59

US-10-956-157-312448
; Sequence 312448, Application US/10956157


```
Query Match      1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 39;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 CTCTGGCCAGGAATCCTGGGTCTG 1569
      |||||
Db 1 CTCTGGCCAGGATCCTGGGTCTG 25

RESULT 67
US-10-956-157-212376
; Sequence 212376, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; NUMBER OF SEQ ID NOS: 2004-10-04
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 212376
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-212376

Query Match      1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 39;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1544 GCTTCTGGCCAGGAATCCTGGGTCT 1568
      |||||
Db 1 GCTTCTGGCCAGGATCCTGGGTCT 25

RESULT 68
US-10-719-900-103389/c
; Sequence 103389, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 103389
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-103389

Query Match      1.2%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 62;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1399 ACTCCACGGAGACACCATGACTGT 1423
      |||||
Db 25 ATTCCACGGAGTCACCATGACTGT 1

RESULT 69
US-10-719-900-209370
; Sequence 209370, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 209370
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-209370

Query Match      1.2%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 62;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1381 AGTATTTCTTCTCCATCATCTCCA 1405
      |||||
Db 1 AGTATTTCTTTTCCATCATCTCCA 25

RESULT 70
US-10-719-900-456064/c
; Sequence 456064, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 456064
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-456064

Query Match      1.2%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 62;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1489 ACATGGAAGAAATGCTGCTAGTGC 1513
      |||||
Db 25 ACATGATGAAATGCTGCCAGTGC 1

RESULT 71
US-10-719-900-623295
; Sequence 623295, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 623295
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-623295
```


Query Match 1.2%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 62;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1463 GCGCTGTGTTCTTATGTTGCA 1487
|||||
Db 1 GCGCTGTGCTTAATGTTGCA 25
|||||

RESULT 72
US-10-719-900-917234
; Sequence 917234, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 917234
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-917234

Query Match 1.2%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 62;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1324 TCACTTTTGATCCAACTGAGT 1348
|||||
Db 1 TTACTTCTGATCCAACTGAGT 25
|||||

RESULT 73
US-10-719-900-106985
; Sequence 106985, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 106985
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-106985

Query Match 1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 1438 AGATGAATGTGCTGCTGCTTTG 1462
|||||
Db 1 ACATGGATGTGCTGATGCTTTG 25
|||||

RESULT 74
US-10-719-900-209369
; Sequence 209369, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 209369
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-209369

Query Match 1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 1381 AGTATTTCTTCTCCATCATCTCCA 1405
|||||
Db 1 AGTATTTCTTCTCCATCATCTCCA 25
|||||

RESULT 75
US-10-719-900-456065/c
; Sequence 456065, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 456065
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-456065

Query Match 1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 1489 ACATGGAAGAAATGCTCCCTAGGTC 1513
|||||
Db 25 ACATGGATGAAAGCTGCCAGGTC 1
|||||

RESULT 76
US-10-719-900-585846
; Sequence 585846, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 585846
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-585846

Query Match 1.1%; Score 20.2; DB 1; Length 25;

Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1324 TCAACTTTTGGATCAAGCTGGAGT 1348
Db 1 TTAACCTTCTGGAACCAAGCTGGAGT 25

RESULT 82

US-10-719-900-298572
; Sequence 298572, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 298572
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-298572

Query Match 1.1%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 1.1e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1236 AAGCCAGGGCCATCATGAGGA 1258
Db 2 AAGCCAGGGCCATCATGAGGA 24

RESULT 83

US-10-719-900-298573
; Sequence 298573, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 298573
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-298573

Query Match 1.1%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 1.1e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1236 AAGCCAGGGCCATCATGAGGA 1258
Db 2 AAGCCAGGGCCATCATGAGGA 24

RESULT 84

US-10-809-189-36103/c
; Sequence 36103, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart

; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 36103
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-36103

Query Match 1.1%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 1.1e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 961 GTGGACATCTGGACAGCTGGGAT 983
Db 25 GTGGACATCTGGTCAGCTGGGAT 3

RESULT 85

US-10-719-900-917267/c
; Sequence 917267, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 917267
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-917267

Query Match 1.0%; Score 19.4; DB 1; Length 25;
Best Local Similarity 95.2%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1457 TGTTCGGCTGTTGTTCTTA 1477
Db 22 TGTTCGGCTGTTGTTCTTA 2

RESULT 86

US-10-719-900-456190/c
; Sequence 456190, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 456190
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus

US-10-719-900-456190

Query Match 1.0%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1275 CAGCCCTCAATATCACTCAGGTC 1298

Db 24 CAGCCACTCAATATGACACAGGTC 1

RESULT 87

US-10-719-900-607010/c
Sequence 607010, Application US/10719900
Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 607010

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-607010

Query Match 1.0%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1538 TTTGATGCTTCTGCGCAGGAATCC 1561

Db 24 TTTGATGCTTCTGCGCAGGAATCC 1

RESULT 88

US-10-719-900-970578/c
Sequence 970578, Application US/10719900
Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 970578

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-970578

Query Match 1.0%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 559 CCTCTTTCGATGAATCCAGAGAA 582

Db 25 CCTCGTTCGATGAGCTCCAGAGAA 2

RESULT 89

US-10-809-189-127295
Sequence 127295, Application US/10809189
Publication No. US20050048531A1

; GENERAL INFORMATION:

; APPLICANT: Michael Mitmann

; APPLICANT: David Mack

; APPLICANT: David Lockhart

; APPLICANT: Affymetrix, Inc.

; TITLE OF INVENTION: Methods of Genetic Analysis

; FILE REFERENCE: 3101.1

; CURRENT APPLICATION NUMBER: US/10/809,189

; CURRENT FILING DATE: 2004-03-25

; PRIOR APPLICATION NUMBER: US/09/396,196

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: 60/100,678

; PRIOR FILING DATE: 1998-09-17

; NUMBER OF SEQ ID NOS: 127806

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 127295

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-809-189-127295

Query Match 1.0%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 138 CTTTATCCCTGCTCTCGGAAA 161

Db 1 CTTTATCCCTGCTCTCGGAAA 24

RESULT 90

US-10-719-900-443028/c

; Sequence 443028, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 443028

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-443028

Query Match 1.0%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 833 GGCTTCTCATGGGATCAAAATT 854

Db 23 GGCTTCTCATGGGATCAAAATT 2

RESULT 91

US-10-719-900-732505

; Sequence 732505, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

```
; SEQ ID NO 732505
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-732505

Query Match      1.0%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1128 TTCCAGTATTATCAGTTACACA 1149
Db 2 TTGCAGCATTATCAGTTACACA 23

RESULT 92
US-10-809-189-36101/c
; Sequence 36101, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 36101
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-36101

Query Match      1.0%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 962 TGGACATCTGGACAGCTGGGAT 983
Db 25 TGGACATCTGGCTGAGCTGGGAT 4

RESULT 93
US-10-620-642-33/c
; Sequence 33, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Kristina M.
; APPLICANT: Bosselman, Robert A.
; APPLICANT: Suggs, Sidney V.
; APPLICANT: Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESS: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-620-642-33

Query Match      1.0%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1832 CTGAAAAA1851
Db 20 CTA1851

RESULT 94
US-10-872-984-7/c
; Sequence 7, Application US/10872984
; Publication No. US2004026588A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/10/872,984
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US/09/994,311
; PRIOR FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-7

Query Match      1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1833 TGAAGAAAAAAGAAAAA 1850
Db 18 TGAAGAAAAAAGAAAAA 1

RESULT 95
US-10-669-962-28/c
; Sequence 28, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
; APPLICANT: Bruggiera, Filippa
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US/09/142,108C
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: PN8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
US-10-669-962-28

Query Match      1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAGAAAAAAGAAAA 1851
Db 18 GAAAAAAGAAAAAAGAAAA 1

RESULT 96
US-10-620-642-34/c
; Sequence 34, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; APPLICANT: Bosseilman, Robert A.
; APPLICANT: Suggs, Sidney V.
; APPLICANT: Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
```

```
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/10/620,642
; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-10-620-642-34

Query Match      1.0%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 11e-02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAGAAAAAAGAAAA 1851
Db 19 GAAAAAAGAAAAAAGAAAA 2

RESULT 97
US-10-831-901A-29727/c
; Sequence 29727, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (SIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
```

;; PRIOR APPLICATION NUMBER: 60/466,426
;; PRIOR FILING DATE: 2003-04-28
;; PRIOR APPLICATION NUMBER: 60/468,562
;; PRIOR FILING DATE: 2003-05-06
;; PRIOR APPLICATION NUMBER: 60/467,770
;; PRIOR FILING DATE: 2003-04-30
;; PRIOR APPLICATION NUMBER: 60/468,627
;; PRIOR FILING DATE: 2003-05-06
;; PRIOR APPLICATION NUMBER: 60/477,637
;; PRIOR FILING DATE: 2003-06-10
;; PRIOR APPLICATION NUMBER: 60/483,579
;; PRIOR FILING DATE: 2003-06-27
;; NUMBER OF SEQ ID NOS: 3063
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 29727
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Antisense compound
US-10-831-901A-29727

Query Match 0.9%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1833 TGAAGAAAAA 1851
Db 19 TGACAAAAA 1

RESULT 98
US-10-831-901A-29728/c
;; Sequence 29728, Application US/10831901A
;; Publication No. US20050100885A1
;; GENERAL INFORMATION:
;; APPLICANT: Crooke, Stanley T.
;; APPLICANT: Ecker, David J.
;; APPLICANT: Sampath, Rangarajan
;; APPLICANT: Freier, Susan M.
;; APPLICANT: Massire, Christian
;; APPLICANT: Hofstadler, Steven A.
;; APPLICANT: Lowery, Kristin Sannes
;; APPLICANT: Swayze, Eric
;; APPLICANT: Baker, Brenda F.
;; APPLICANT: Bennett, C. Frank
;; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
;; FILE REFERENCE: ISIS0083-100 (BIOL000808)
;; CURRENT APPLICATION NUMBER: US/10/831,901A
;; CURRENT FILING DATE: 2004-04-26
;; PRIOR APPLICATION NUMBER: 60/466,426
;; PRIOR FILING DATE: 2003-04-28
;; PRIOR APPLICATION NUMBER: 60/468,562
;; PRIOR FILING DATE: 2003-05-06
;; PRIOR APPLICATION NUMBER: 60/467,770
;; PRIOR FILING DATE: 2003-04-30
;; PRIOR APPLICATION NUMBER: 60/468,627
;; PRIOR FILING DATE: 2003-05-06
;; PRIOR APPLICATION NUMBER: 60/477,637
;; PRIOR FILING DATE: 2003-06-10
;; PRIOR APPLICATION NUMBER: 60/483,579
;; PRIOR FILING DATE: 2003-06-27
;; NUMBER OF SEQ ID NOS: 3063
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 29728
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Antisense compound
US-10-831-901A-29728

Query Match 0.9%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.3e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1833 TGAAGAAAAA 1851
Db 20 TGACAAAAA 2

RESULT 99
US-10-664-000-3/c
;; Sequence 3, Application US/10664000
;; Publication No. US20040248144A1
;; GENERAL INFORMATION:
;; APPLICANT: Mir, Kalim
;; TITLE OF INVENTION: Arrays and Methods of Use
;; FILE REFERENCE: 8654/2182
;; CURRENT APPLICATION NUMBER: US/10/664,000
;; CURRENT FILING DATE: 2003-09-16
;; PRIOR APPLICATION NUMBER: PCT/GB02/01245
;; PRIOR FILING DATE: 2002-03-18
;; PRIOR APPLICATION NUMBER: GB0106635.6
;; PRIOR FILING DATE: 2001-03-16
;; PRIOR APPLICATION NUMBER: GB0118879.6
;; PRIOR FILING DATE: 2001-08-02
;; NUMBER OF SEQ ID NOS: 3
;; SOFTWARE: PatentIn version 3.2
;; SEQ ID NO 3
;; LENGTH: 22
;; TYPE: DNA
;; ORGANISM: Artificial
;; FEATURE:
;; OTHER INFORMATION: Anchored capture oligonucleotide
;; NAME/KEY: misc feature
;; LOCATION: (22)..(22)
;; OTHER INFORMATION: n is a, c, g, or t
US-10-664-000-3

Query Match 0.9%; Score 17.2; DB 1; Length 22;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAA 1851
Db 21 BAAAAA 4

RESULT 100
US-10-601-140A-32/c
;; Sequence 32, Application US/10601140A
;; Publication No. US20050053942A1
;; GENERAL INFORMATION:
;; APPLICANT: KAUPPINEN, SAKARI
;; APPLICANT: JACOBSEN, NANA
;; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;; FILE REFERENCE: 57764(71994)
;; CURRENT APPLICATION NUMBER: US/10/601,140A
;; CURRENT FILING DATE: 2003-06-20
;; PRIOR APPLICATION NUMBER: US 60/390,928
;; PRIOR FILING DATE: 2002-06-24
;; NUMBER OF SEQ ID NOS: 45
;; SOFTWARE: PatentIn Ver. 3.2
;; SEQ ID NO 32
;; LENGTH: 22
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;; OTHER INFORMATION: oligonucleotide
;; NAME/KEY: modified_base

```
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (22)
; OTHER INFORMATION: a, t, c or g
US-10-601-140A-32
```

```
Query Match 0.9%; Score 17.2; DB 1; Length 22;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1834 GAAAAAAAAAAAAAAAAA 1851
Db 21 BAAAAAAAAAAAAAAAAA 4
```

```
RESULT 101
US-10-601-140A-45/c
; Sequence 45, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764 (71994)
; CURRENT APPLICATION NUMBER: US/10/601.140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 45
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (22)
; OTHER INFORMATION: a, t, c or g
US-10-601-140A-45
```

```
Query Match 0.9%; Score 17.2; DB 1; Length 22;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1834 GAAAAAAAAAAAAAAAAA 1851
Db 21 BAAAAAAAAAAAAAAAAA 4
```

```
RESULT 102
US-10-849-072-21
; Sequence 21, Application US/10849072
; Publication No. US20040214221A1
; GENERAL INFORMATION:
; APPLICANT: Roche Diagnostics GmbH
; TITLE OF INVENTION: High density labeling of DNA with modified or
; TITLE OF INVENTION: "chromophore" carrying nucleotides and DNA polymerases
; TITLE OF INVENTION: used
; FILE REFERENCE: 4780/00/WO
; CURRENT APPLICATION NUMBER: US/10/849,072
; CURRENT FILING DATE: 2004-05-19
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: second
; OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-21
```

```
Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 1 AAAAAAAAAAAAAAAAAA 17
```

```
RESULT 103
US-10-849-072-23/c
; Sequence 23, Application US/10849072
; Publication No. US20040214221A1
; GENERAL INFORMATION:
; APPLICANT: Roche Diagnostics GmbH
; TITLE OF INVENTION: High density labeling of DNA with modified or
; TITLE OF INVENTION: "chromophore" carrying nucleotides and DNA polymerases
; TITLE OF INVENTION: used
; FILE REFERENCE: 4780/00/WO
; CURRENT APPLICATION NUMBER: US/10/849,072
; CURRENT FILING DATE: 2004-05-19
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```


; OTHER INFORMATION: Description of Artificial Sequence: second
; OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-23

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 104

US-10-831-778-913/c
; Sequence 913, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 913
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-913

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 105

US-10-831-778-939/c
; Sequence 939, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 939
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-939

Query Match 0.9%; Score 17; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 106

US-10-776-933-150/c
; Sequence 150, Application US/10776933
; Publication No. US20040241717A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, BO
; APPLICANT: TRUE, CHARLOTTE ALBAEK
; APPLICANT: WESTERGAARD, MAJKEN
; APPLICANT: PETERSEN, KANILLE DUMONG
; APPLICANT: WISENBACH, MARGIT
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN
; FILE REFERENCE: 58614(71432)
; CURRENT APPLICATION NUMBER: US/10/776,933
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: 60/446,374
; PRIOR FILING DATE: 2003-02-10
; NUMBER OF SEQ ID NOS: 150
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 150
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: poly-T oligonucleotide
; FEATURE:
; OTHER INFORMATION: This sequence may encompass 12-18 nucleotides
; OTHER INFORMATION: according to the specification as filed
US-10-776-933-150

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 107

US-10-674-159A-112/c
; Sequence 112, Application US/10674159A
; Publication No. US20040242518A1
; GENERAL INFORMATION:
; APPLICANT: Chen, Jianzhu
; APPLICANT: Ge, Qing
; APPLICANT: Eisen, Herman
; TITLE OF INVENTION: Influenza Therapeutic
; FILE REFERENCE: 0492611-0506
; CURRENT APPLICATION NUMBER: US/10/674,159A
; CURRENT FILING DATE: 2003-09-29
; NUMBER OF SEQ ID NOS: 271
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 112
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: mRNA
US-10-674-159A-112

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Publication No. US20050014712A1
GENERAL INFORMATION:
APPLICANT: HANSEN, BO
APPLICANT: THURIE, CHARLOTTE ALBAEK
APPLICANT: WESTERGAARD, MAJKEN
APPLICANT: PETERSEN, KAMILLE DUMONG
APPLICANT: WISENBACH, MARGIT
TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
FILE REFERENCE: 58610(71432)
CURRENT APPLICATION NUMBER: US/10/776,934
CURRENT FILING DATE: 2004-02-10
PRIOR APPLICATION NUMBER: 60/446,372
PRIOR FILING DATE: 2003-02-10
PRIOR APPLICATION NUMBER: 60/523,591
PRIOR FILING DATE: 2003-11-19
NUMBER OF SEQ ID NOS: 741
SOFTWARE: PatentIn version 3.2
SEQ ID NO 741
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: poly-T oligonucleotide
FEATURE:
OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according to the
US-10-776-934-741

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 112
US-10-601-140A-24/c
Sequence 24, Application US/10601140A
Publication No. US20050053942A1
GENERAL INFORMATION:
APPLICANT: KAUPPINEN, SAKARI
APPLICANT: JACOBSEN, NANA
TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
FILE REFERENCE: 57764(71994)
CURRENT APPLICATION NUMBER: US/10/601,140A
CURRENT FILING DATE: 2003-06-20
PRIOR APPLICATION NUMBER: US 60/390,928
PRIOR FILING DATE: 2002-06-24
NUMBER OF SEQ ID NOS: 45
SOFTWARE: PatentIn Ver. 3.2
SEQ ID NO 24
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
NAME/KEY: misc feature
LOCATION: (1)..(18)
OTHER INFORMATION: this sequence may encompass 12-18 nucleotides
US-10-601-140A-24

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 113
US-10-884-617-2/c
Sequence 2, Application US/10884617
Publication No. US20050054730A1
GENERAL INFORMATION:
APPLICANT: Fu, Jin
APPLICANT: Gaetani, Silvana
APPLICANT: Picomelli, Daniele
TITLE OF INVENTION: Compounds, Compositions and Treatments of
FILE REFERENCE: 02307E-133310US
CURRENT APPLICATION NUMBER: US/10/884,617
CURRENT FILING DATE: 2004-07-01
PRIOR APPLICATION NUMBER: US 60/279,542
PRIOR FILING DATE: 2001-03-27
PRIOR APPLICATION NUMBER: US 60/336,289
PRIOR FILING DATE: 2001-10-31
PRIOR APPLICATION NUMBER: US 10/112,509
PRIOR FILING DATE: 2002-03-27
PRIOR APPLICATION NUMBER: US 60/485,062
PRIOR FILING DATE: 2003-07-02
NUMBER OF SEQ ID NOS: 23
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 2
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:Oligo(dt)-12-18
OTHER INFORMATION: primer for reverse transcription of total RNA
NAME/KEY: modified base
LOCATION: (13)..(18)
OTHER INFORMATION: t at positions 13-18 may be present or absent
US-10-884-617-2

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 114
US-10-669-962-27/c
Sequence 27, Application US/10669962
Publication No. US20050081264A1
GENERAL INFORMATION:
APPLICANT: Brugliera, Filippa
APPLICANT: Holton, Timothy A.
APPLICANT: Michael, Michael Z.
TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
FILE REFERENCE: 11658
CURRENT APPLICATION NUMBER: US/10/669,962
CURRENT FILING DATE: 2003-09-24
PRIOR APPLICATION NUMBER: US/09/142,108C
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: PN8386
PRIOR FILING DATE: 1996-03-01
NUMBER OF SEQ ID NOS: 45
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 27
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-27

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851

Db 17 AAAAAAAAAAAAAAAAAA 1

RESULT 115
US-10-669-962-29/c
; Sequence 29, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
; APPLICANT: Brugliera, Filippa
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US/09/142,108C
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: P8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-29

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851

Db 17 AAAAAAAAAAAAAAAAAA 1

RESULT 116
US-10-503-120-1/c
; Sequence 1, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-503-120-1

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851

Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 117
US-10-503-120-8/c
; Sequence 8, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(17)
; OTHER INFORMATION: Residues 1, 3, 5, 7, 9, 11, 13, 15 and 17 are 2'-O-methyl-D-uridi
US-10-503-120-8

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851

Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 118
US-10-503-120-9/c
; Sequence 9, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: Residues 1-3, 7-9, and 13-15 are 2'-O-methyl-D-uridine
US-10-503-120-9

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851

Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 119
US-10-503-120-10/c
; Sequence 10, Application US/10503120
; Publication No. US2005014235A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(18)
; OTHER INFORMATION: Residues 1-6 and 13-18 are 2'-O-methyl-D-uridine
US-10-503-120-10

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
|||||
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 120
US-10-503-120-21
; Sequence 21, Application US/10503120
; Publication No. US2005014235A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Target RNA oligonucleotide
US-10-503-120-21

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
|||||
Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 121
US-11-024-428-7/c
; Sequence 7, Application US/11024428
; Publication No. US20050106676A1
; GENERAL INFORMATION:

; APPLICANT: NAGAI, HIROSHI
; APPLICANT: KURODA, KYOKO
; APPLICANT: NAKAJIMA, TERUMI
; TITLE OF INVENTION: NOVEL PROTEINS HAVING HEMOLYTIC ACTIVITY AND GENES
; TITLE OF INVENTION: ENCODING THE PROTEIN
; FILE REFERENCE: 037181.50611US
; CURRENT APPLICATION NUMBER: US/11/024,428
; CURRENT FILING DATE: 2004-12-30
; PRIOR APPLICATION NUMBER: US/09/979,275
; PRIOR FILING DATE: 2003-05-27
; PRIOR APPLICATION NUMBER: PCT/JPO1/02209
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: JP 2000-78967
; PRIOR FILING DATE: 2000-03-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides
US-11-024-428-7

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
|||||
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 122
US-10-760-940-1/c
; Sequence 1, Application US/10760940
; Publication No. US20040219577A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Capaldi, Daniel C.
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas L.
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS
; FILE REFERENCE: ISIS-5422
; CURRENT APPLICATION NUMBER: US/10/760,940
; CURRENT FILING DATE: 2004-01-20
; PRIOR APPLICATION NUMBER: US 10/232,881
; PRIOR FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US 09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: US 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-760-940-1

Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
|||||
Db 18 AAAAAAAAAAAAAAAAAA 2

```
Db      19 AAAAAAAAAAAAAAAAAA 3

RESULT 123
US-10-913-246-22
; Sequence 22, Application US/10913246
; Publication No. US2005003441A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/913,246
; CURRENT FILING DATE: 2004-08-05
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-913-246-22

Query Match      0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1835 AAAAAAAAAAAAAAAAAA 1851
      |||||
Db      2 AAAAAAAAAAAAAAAAAA 18

RESULT 124
US-10-913-246-24
; Sequence 24, Application US/10913246
; Publication No. US2005003441A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/913,246
; CURRENT FILING DATE: 2004-08-05
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-913-246-24

Query Match      0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1835 AAAAAAAAAAAAAAAAAA 1851
      |||||
Db      1 AAAAAAAAAAAAAAAAAA 17

RESULT 125
US-10-934-890-22
; Sequence 22, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-934-890-22

Query Match      0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1835 AAAAAAAAAAAAAAAAAA 1851
      |||||
Db      2 AAAAAAAAAAAAAAAAAA 18

RESULT 126
US-10-934-890-24
; Sequence 24, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-934-890-24

Query Match      0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1835 AAAAAAAAAAAAAAAAAA 1851
      |||||
Db      1 AAAAAAAAAAAAAAAAAA 17
```

```
RESULT 127
US-10-700-884-23/c
; Sequence 23, Application US/10700884
; Publication No. US20050118605A9
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F.
; APPLICANT: Eldrup, Anne B.
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bhat, Balkrishen
; APPLICANT: Griffey, Richard
; APPLICANT: Swayze, Eric E.
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Prakash, Thazha P.
; APPLICANT: Rajeev, Kallanthottathil G.
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE
; FILE REFERENCE: ISIS-5317
; CURRENT APPLICATION NUMBER: US/10/700,884
; PRIOR FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: US 10/635,380
; PRIOR FILING DATE: 2003-08-06
; PRIOR APPLICATION NUMBER: US 60/423,760
; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 10/078,949
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/479,783
; PRIOR FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 08/870,608
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: US 08/659,440
; PRIOR FILING DATE: 1996-06-06
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (167)..(19)
; OTHER INFORMATION: 2'-O-[(methoxy)ethyl]-2-thio-5-methyluridine
US-10-700-884-23

Query Match          0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 128
US-10-800-487-162/c
; Sequence 162, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 328
; LENGTH: 19
```

```
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 162
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-800-487-162

Query Match          0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1834 GAAAAAAAAAAAAAAAAA 1850
Db 19 GAAAAAAAAAAAAAAAAA 3

RESULT 129
US-10-800-487-328
; Sequence 328, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 328
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-800-487-328

Query Match          0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1834 GAAAAA-AAAAAAAAA 1850
Db 1 GAAAAA-AAAAAAAAA 17

RESULT 130
US-10-940-360-1/c
; Sequence 1, Application US/10940360
; Publication No. US20050137391A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthia
; APPLICANT: Capaldi, Daniel
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric Compounds
; FILE REFERENCE: ISIS3380
; CURRENT APPLICATION NUMBER: US/10/940,360
; CURRENT FILING DATE: 2004-09-14
; PRIOR APPLICATION NUMBER: US/09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Novel Sequence
US-10-940-360-1

Query Match          0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAA-AAAAAAAAA 1851
Db 19 AAAAAA-AAAAAAAAA 3

RESULT 131
US-09-976-900A-55
; Sequence 55, Application US/09976900A
; Publication No. US20040219520A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Eighanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-123
; CURRENT APPLICATION NUMBER: US/09/976,900A
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
```

```
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
; OTHER INFORMATION: synthetic sequence
US-09-976-900A-55

Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAA-AAAAAAAAA 1851
Db 1 AAAAAA-AAAAAAAAA 17

RESULT 132
US-10-661-415-12
; Sequence 12, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-415-12

Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAA-AAAAAAAAA 1851
Db 1 AAAAAA-AAAAAAAAA 17

RESULT 133
US-10-661-415-15/c
; Sequence 15, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
```


; FILE REFERENCE: 029849/0205
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-661-415-15

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAAAAAA 4

RESULT 134

US-10-831-778-226/c
; Sequence 226, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 226
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-226

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAAAAAA 4

RESULT 135

US-10-831-778-556/c
; Sequence 556, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy

; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 556
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-556

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAAAAAA 4

RESULT 136

US-10-831-778-560
; Sequence 560, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 560
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-560

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 137

US-10-728-078-14
; Sequence 14, Application US/10728078
; Publication No. US20050038229A1
; GENERAL INFORMATION:
; APPLICANT: Lipovsek, Dasa
; APPLICANT: Wagner, Richard W
; APPLICANT: Kuimelis, Robert G
; TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
; TITLE OF INVENTION: AND OTHER BINDING PROTEINS
; FILE REFERENCE: 50036/021004
; CURRENT APPLICATION NUMBER: US/10/728,078
; CURRENT FILING DATE: 2003-12-03
; PRIOR APPLICATION NUMBER: US/09/688,566
; PRIOR FILING DATE: 2000-10-16

```
; PRIOR APPLICATION NUMBER: US 60/111,737
; PRIOR FILING DATE: 1998-12-10
; PRIOR APPLICATION NUMBER: US 09/456,693
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: US 09/515,260
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 202
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Puromycin linker oligonucleotide
US-10-728-078-14
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1835 AAAAAAAAAAAAAAAAAA 1851
    |||||
Db 1 AAAAAAAAAAAAAAAAAA 17
```

```
RESULT 138
US-10-728-078-23/c
; Sequence 23, Application US/10728078
; Publication No. US20050038229A1
; GENERAL INFORMATION:
; APPLICANT: Lipovsek, Dasa
; APPLICANT: Wagner, Richard W
; APPLICANT: Kuimelis, Robert G
; TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
; TITLE OF INVENTION: AND OTHER BINDING PROTEINS
; FILE REFERENCE: 50036/021004
; CURRENT APPLICATION NUMBER: US/10/728,078
; CURRENT FILING DATE: 2003-12-03
; PRIOR APPLICATION NUMBER: US/09/688,566
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: US 60/111,737
; PRIOR FILING DATE: 1998-12-10
; PRIOR APPLICATION NUMBER: US 09/456,693
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: US 09/515,260
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 202
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-728-078-23
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1835 AAAAAAAAAAAAAAAAAA 1851
    |||||
Db 20 AAAAAAAAAAAAAAAAAA 4
```

```
RESULT 139
US-10-601-140A-1/c
; Sequence 1, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
```

```
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-1
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1835 AAAAAAAAAAAAAAAAAA 1851
    |||||
Db 20 AAAAAAAAAAAAAAAAAA 4
```

```
RESULT 140
US-10-601-140A-2/c
; Sequence 2, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
```

```
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-2
```

```
Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAAAAAA 4
```

RESULT 141

```
US-10-601-140A-3/c
; Sequence 3, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; ORGANISM: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 3
; TYPE: DNA
; LENGTH: 20
; FEATURE:
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-601-140A-3
```

```
Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAAAAAA 4
```

RESULT 142

```
US-10-601-140A-4/c
; Sequence 4, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; ORGANISM: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
```

```
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (16)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-4
```

```
Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAAAAAA 4
```

RESULT 143

```
US-10-601-140A-6/c
; Sequence 6, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; ORGANISM: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 6
; TYPE: DNA
; LENGTH: 20
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
```

```
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-6
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAA 4
```

RESULT 144

```
US-10-601-140A-7/c
; Sequence 7, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (14)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-7
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAA 4
```

RESULT 145

```
US-10-601-140A-8/c
; Sequence 8, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-8
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAA 4
```

RESULT 146

```
US-10-601-140A-9/c
; Sequence 9, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (3)..(4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
```

; LOCATION: (8)..(9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)..(14)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (18)..(19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-9

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
|||||

Db 20 AAAAAAAAAAAAAAAAAA 4

RESULT 147

US-10-601-140A-10/c
; Sequence 10, Application US/10601140A
; Publication No. US20050053942A1

; GENERAL INFORMATION:

; APPLICANT: KAUPPINEN, SAKARI

; APPLICANT: JACOBSEN, NANA

; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A

; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE

; FILE REFERENCE: 57764(71994)

; CURRENT APPLICATION NUMBER: US/10/601,140A

; CURRENT FILING DATE: 2003-06-20

; PRIOR APPLICATION NUMBER: US 60/390,928

; PRIOR FILING DATE: 2002-06-24

; NUMBER OF SEQ ID NOS: 45

; SOFTWARE: PatentIn Ver. 3.2

; SEQ ID NO 10

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: oligonucleotide

; FEATURE:

; NAME/KEY: modified_base

; LOCATION: (3)..(5)

; OTHER INFORMATION: LNA monomer

; FEATURE:

; NAME/KEY: modified_base

; LOCATION: (10)..(12)

; OTHER INFORMATION: LNA monomer

; FEATURE:

; NAME/KEY: modified_base

; LOCATION: (17)..(19)

; OTHER INFORMATION: LNA monomer

US-10-601-140A-10

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
|||||

Db 20 AAAAAAAAAAAAAAAAAA 4

RESULT 148

US-10-601-140A-23/c

; Sequence 23, Application US/10601140A

; Publication No. US20050053942A1

; GENERAL INFORMATION:

; APPLICANT: KAUPPINEN, SAKARI

; APPLICANT: JACOBSEN, NANA

; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A

; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE

; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide capture probe
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-23

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
|||||

Db 20 AAAAAAAAAAAAAAAAAA 4

RESULT 149

US-10-601-140A-34

; Sequence 34, Application US/10601140A

; Publication No. US20050053942A1

; GENERAL INFORMATION:

; APPLICANT: KAUPPINEN, SAKARI

; APPLICANT: JACOBSEN, NANA

; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A

; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE

<pre>; FILE REFERENCE: 57764(71994) ; CURRENT APPLICATION NUMBER: US/10/601,140A ; CURRENT FILING DATE: 2003-06-20 ; PRIOR APPLICATION NUMBER: US 60/390,928 ; PRIOR FILING DATE: 2002-06-24 ; NUMBER OF SEQ ID NOS: 45 ; SOFTWARE: PatentIn Ver. 3.2 ; SEQ ID NO 34 ; LENGTH: 20 ; TYPE: DNA ; ORGANISM: Artificial Sequence ; FEATURE: ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic ; OTHER INFORMATION: oligonucleotide linker US-10-601-140A-34</pre>	<pre>Query Match 0.9%; Score 17; DB 1; Length 20; Best Local Similarity 100.0%; Pred. No. 1.5e+02; Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;</pre>
<pre>QY 1835 AAAAAAAAAAAAAAAA 1851 Db 1 AAAAAAAAAAAAAAAA 17 RESULT 150 US-10-601-140A-40/c ; Sequence 40, Application US/10601140A ; Publication No. US20050053942A1 ; GENERAL INFORMATION: ; APPLICANT: KAUPPINEN, SAKARI ; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A ; FILE REFERENCE: 57764(71994) ; CURRENT APPLICATION NUMBER: US/10/601,140A ; CURRENT FILING DATE: 2003-06-20 ; PRIOR APPLICATION NUMBER: US 60/390,928 ; PRIOR FILING DATE: 2002-06-24 ; NUMBER OF SEQ ID NOS: 45 ; SOFTWARE: PatentIn Ver. 3.2 ; SEQ ID NO 40 ; LENGTH: 20 ; TYPE: DNA ; ORGANISM: Artificial Sequence ; FEATURE: ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic ; OTHER INFORMATION: oligonucleotide US-10-601-140A-40</pre>	<pre>Query Match 0.9%; Score 17; DB 1; Length 20; Best Local Similarity 100.0%; Pred. No. 1.5e+02; Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;</pre>
<pre>QY 1835 AAAAAAAAAAAAAAAA 1851 Db 1 AAAAAAAAAAAAAAAA 17 RESULT 151 US-10-601-140A-44/c ; Sequence 44, Application US/10601140A ; Publication No. US20050053942A1 ; GENERAL INFORMATION: ; APPLICANT: KAUPPINEN, SAKARI ; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A ; FILE REFERENCE: 57764(71994) ; CURRENT APPLICATION NUMBER: US/10/601,140A ; CURRENT FILING DATE: 2003-06-20 ; PRIOR APPLICATION NUMBER: US 60/390,928 ; PRIOR FILING DATE: 2002-06-24</pre>	<pre>Query Match 0.9%; Score 17; DB 1; Length 20; Best Local Similarity 100.0%; Pred. No. 1.5e+02; Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;</pre>

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/620,642
FILING DATE: 16-Jul-2003
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/10/175,608
FILING DATE: 16-Oct-2002
APPLICATION NUMBER: 09/635,249
FILING DATE: 07-AUG-2000
APPLICATION NUMBER: 09/486,546
FILING DATE: 24-MAY-1995
APPLICATION NUMBER: 08/172,329
FILING DATE: 21-DEC-1993
APPLICATION NUMBER: 07/982,255
FILING DATE: 25-NOV-1992
APPLICATION NUMBER: 07/684,535
FILING DATE: 10-APR-1991
APPLICATION NUMBER: 09/589,701
FILING DATE: 10-OCT-1991
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/35199
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-10-620-642-32

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 154
US-10-831-901A-29729/c
Sequence 29729, Application US/10831901A
Publication No. US20050100885A1
GENERAL INFORMATION:
APPLICANT: Crooke, Stanley T.
APPLICANT: Ecker, David J.
APPLICANT: Sampath, Rangarajan
APPLICANT: Freier, Susan M.
APPLICANT: Massire, Christian A.
APPLICANT: Hofstadler, Steven A.
APPLICANT: Lowery, Kristin Sannes
APPLICANT: Swayze, Eric
APPLICANT: Baker, Brenda F.
APPLICANT: Bennett, C. Frank
TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
FILE REFERENCE: ISIS0083-100 (BIOL00008US)

CURRENT APPLICATION NUMBER: US/10/831,901A
CURRENT FILING DATE: 2004-04-26
PRIOR APPLICATION NUMBER: 60/466,426
PRIOR FILING DATE: 2003-04-28
PRIOR APPLICATION NUMBER: 60/468,562
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/467,770
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: 60/468,627
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/477,637
PRIOR FILING DATE: 2003-06-10
PRIOR APPLICATION NUMBER: 60/483,579
PRIOR FILING DATE: 2003-06-27
NUMBER OF SEQ ID NOS: 30063
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 29729
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense compound
US-10-831-901A-29729

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 17 AAAAAAAAAAAAAAAAAA 1

RESULT 155
US-10-831-901A-29730/c
Sequence 29730, Application US/10831901A
Publication No. US20050100885A1
GENERAL INFORMATION:
APPLICANT: Crooke, Stanley T.
APPLICANT: Ecker, David J.
APPLICANT: Sampath, Rangarajan
APPLICANT: Freier, Susan M.
APPLICANT: Massire, Christian A.
APPLICANT: Hofstadler, Steven A.
APPLICANT: Lowery, Kristin Sannes
APPLICANT: Swayze, Eric
APPLICANT: Baker, Brenda F.
APPLICANT: Bennett, C. Frank
TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
FILE REFERENCE: ISIS0083-100 (BIOL00008US)
CURRENT APPLICATION NUMBER: US/10/831,901A
CURRENT FILING DATE: 2004-04-26
PRIOR APPLICATION NUMBER: 60/466,426
PRIOR FILING DATE: 2003-04-28
PRIOR APPLICATION NUMBER: 60/468,562
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/467,770
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: 60/468,627
PRIOR FILING DATE: 2003-05-06
PRIOR APPLICATION NUMBER: 60/477,637
PRIOR FILING DATE: 2003-06-10
PRIOR APPLICATION NUMBER: 60/483,579
PRIOR FILING DATE: 2003-06-27
NUMBER OF SEQ ID NOS: 30063
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 29730
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense compound

US-10-831-901A-29730

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
DB 18 AAAAAAAAAAAAAAAAAA 2

RESULT 156

US-10-831-901A-29731/c
; Sequence 29731, Application US/10831901A

; Publication No. US20050100885A1

; GENERAL INFORMATION:

; APPLICANT: Crooke, Stanley T.

; APPLICANT: Ecker, David J.

; APPLICANT: Sampath, Rangarajan

; APPLICANT: Freier, Susan M.

; APPLICANT: Massire, Christian

; APPLICANT: Hofstadler, Steven A.

; APPLICANT: Lowery, Kristin Sannes

; APPLICANT: Swayze, Eric

; APPLICANT: Baker, Brenda F.

; APPLICANT: Bennett, C. Frank

; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe

; FILE REFERENCE: ISIS0083-100 (BIOL00008US)

; CURRENT APPLICATION NUMBER: US/10/831,901A

; CURRENT FILING DATE: 2004-04-26

; PRIOR APPLICATION NUMBER: 60/466,426

; PRIOR FILING DATE: 2003-04-28

; PRIOR APPLICATION NUMBER: 60/468,562

; PRIOR FILING DATE: 2003-05-06

; PRIOR APPLICATION NUMBER: 60/467,770

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: 60/468,627

; PRIOR FILING DATE: 2003-05-06

; PRIOR APPLICATION NUMBER: 60/477,637

; PRIOR FILING DATE: 2003-06-10

; PRIOR APPLICATION NUMBER: 60/483,579

; PRIOR FILING DATE: 2003-06-27

; NUMBER OF SEQ ID NOS: 30063

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 29731

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense compound

US-10-831-901A-29731

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
DB 19 AAAAAAAAAAAAAAAAAA 3

RESULT 157

US-10-831-901A-29732/c

; Sequence 29732, Application US/10831901A

; Publication No. US20050100885A1

; GENERAL INFORMATION:

; APPLICANT: Crooke, Stanley T.

; APPLICANT: Ecker, David J.

; APPLICANT: Sampath, Rangarajan

; APPLICANT: Freier, Susan M.

; APPLICANT: Massire, Christian

; APPLICANT: Hofstadler, Steven A.

; APPLICANT: Lowery, Kristin Sannes

; APPLICANT: Swayze, Eric

; APPLICANT: Baker, Brenda F.

; APPLICANT: Bennett, C. Frank

; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe

; FILE REFERENCE: ISIS0083-100 (BIOL00008US)

; CURRENT APPLICATION NUMBER: US/10/831,901A

; CURRENT FILING DATE: 2004-04-26

; PRIOR APPLICATION NUMBER: 60/466,426

; PRIOR FILING DATE: 2003-04-28

; PRIOR APPLICATION NUMBER: 60/468,562

; PRIOR FILING DATE: 2003-05-06

; PRIOR APPLICATION NUMBER: 60/467,770

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: 60/468,627

; PRIOR FILING DATE: 2003-05-06

; PRIOR APPLICATION NUMBER: 60/477,637

; PRIOR FILING DATE: 2003-06-10

; PRIOR APPLICATION NUMBER: 60/483,579

; PRIOR FILING DATE: 2003-06-27

; NUMBER OF SEQ ID NOS: 30063

; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 29732

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense compound

US-10-831-901A-29732

Query Match 0.9%; Score 17; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.5e+02;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
DB 20 AAAAAAAAAAAAAAAAAA 4

RESULT 158

US-10-831-901A-29733/c

; Sequence 29733, Application US/10831901A

; Publication No. US20050100885A1

; GENERAL INFORMATION:

; APPLICANT: Crooke, Stanley T.

; APPLICANT: Ecker, David J.

; APPLICANT: Sampath, Rangarajan

; APPLICANT: Freier, Susan M.

; APPLICANT: Massire, Christian

; APPLICANT: Hofstadler, Steven A.

; APPLICANT: Lowery, Kristin Sannes

; APPLICANT: Swayze, Eric

; APPLICANT: Baker, Brenda F.

; APPLICANT: Bennett, C. Frank

; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe

; FILE REFERENCE: ISIS0083-100 (BIOL00008US)

; CURRENT APPLICATION NUMBER: US/10/831,901A

; CURRENT FILING DATE: 2004-04-26

; PRIOR APPLICATION NUMBER: 60/466,426

; PRIOR FILING DATE: 2003-04-28

; PRIOR APPLICATION NUMBER: 60/468,562

; PRIOR FILING DATE: 2003-05-06

; PRIOR APPLICATION NUMBER: 60/467,770

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: 60/468,627

; PRIOR FILING DATE: 2003-05-06

; PRIOR APPLICATION NUMBER: 60/477,637

; PRIOR FILING DATE: 2003-06-10

; PRIOR APPLICATION NUMBER: 60/483,579

; PRIOR FILING DATE: 2003-06-27

; NUMBER OF SEQ ID NOS: 30063


```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29733
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29733
```

```
Query Match          0.9%  Score 17;  DB 1;  Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAAAAAA 1851
    |||||
Db 20 AAAAAAAAAAAAAAAAAA 4
```

RESULT 159

```
US-10-831-901A-29734/c
; Sequence 29734, Application US/10831901A
; Publication No. US20050100885A1
```

GENERAL INFORMATION:

```
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
```

```
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE OF INVENTION: Acute Respiratory Syndrome (SARS)
```

```
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
```

```
; CURRENT FILING DATE: 2004-04-26
```

```
; PRIOR APPLICATION NUMBER: 60/466,426
```

```
; PRIOR FILING DATE: 2003-04-28
```

```
; PRIOR APPLICATION NUMBER: 60/468,562
```

```
; PRIOR FILING DATE: 2003-05-06
```

```
; PRIOR APPLICATION NUMBER: 60/467,770
```

```
; PRIOR FILING DATE: 2003-04-30
```

```
; PRIOR APPLICATION NUMBER: 60/468,627
```

```
; PRIOR FILING DATE: 2003-05-06
```

```
; PRIOR APPLICATION NUMBER: 60/477,637
```

```
; PRIOR FILING DATE: 2003-06-10
```

```
; PRIOR APPLICATION NUMBER: 60/483,579
```

```
; PRIOR FILING DATE: 2003-06-27
```

```
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 29734
```

```
; LENGTH: 20
```

```
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
```

```
; OTHER INFORMATION: Antisense compound
```

```
US-10-831-901A-29734
```

```
Query Match          0.9%  Score 17;  DB 1;  Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAAAAAA 1851
    |||||
Db 20 AAAAAAAAAAAAAAAAAA 4
```

RESULT 160

```
US-10-831-901A-29735/c
; Sequence 29735, Application US/10831901A
; Publication No. US20050100885A1
```

GENERAL INFORMATION:

```
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
```

```
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE OF INVENTION: Acute Respiratory Syndrome (SARS)
```

```
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)
```

```
; CURRENT APPLICATION NUMBER: US/10/831,901A
```

```
; CURRENT FILING DATE: 2004-04-26
```

```
; PRIOR APPLICATION NUMBER: 60/466,426
```

```
; PRIOR FILING DATE: 2003-04-28
```

```
; PRIOR APPLICATION NUMBER: 60/468,562
```

```
; PRIOR FILING DATE: 2003-05-06
```

```
; PRIOR APPLICATION NUMBER: 60/467,770
```

```
; PRIOR FILING DATE: 2003-04-30
```

```
; PRIOR APPLICATION NUMBER: 60/468,627
```

```
; PRIOR FILING DATE: 2003-05-06
```

```
; PRIOR APPLICATION NUMBER: 60/477,637
```

```
; PRIOR FILING DATE: 2003-06-10
```

```
; PRIOR APPLICATION NUMBER: 60/483,579
```

```
; PRIOR FILING DATE: 2003-06-27
```

```
; NUMBER OF SEQ ID NOS: 30063
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 29735
```

```
; LENGTH: 20
```

```
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
```

```
; OTHER INFORMATION: Antisense compound
```

```
US-10-831-901A-29735
```

Query Match

```
Best Local Similarity 0.9%  Score 17;  DB 1;  Length 20;
```

```
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAAAAAA 1851
    |||||
Db 20 AAAAAAAAAAAAAAAAAA 4
```

RESULT 161

```
US-10-831-901A-29736/c
; Sequence 29736, Application US/10831901A
; Publication No. US20050100885A1
```

GENERAL INFORMATION:

```
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
```

```
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE OF INVENTION: Acute Respiratory Syndrome (SARS)
```

```
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)
```

```
; CURRENT APPLICATION NUMBER: US/10/831,901A
```

```
; CURRENT FILING DATE: 2004-04-26
```

```
; PRIOR APPLICATION NUMBER: 60/466,426
```

```
; PRIOR FILING DATE: 2003-04-28
```

```
; PRIOR APPLICATION NUMBER: 60/468,562
```

```
; PRIOR FILING DATE: 2003-05-06
```

```
; PRIOR APPLICATION NUMBER: 60/467,770
```

```
; PRIOR FILING DATE: 2003-04-30
```

; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29736
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29736

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
| | | | | | | | | | | | | | | | | |
Db 20 AAAAAAAAAAAAAAAAAA 4

RESULT 162
US-10-789-831-22
; Sequence 22, Application US/10789831
; Publication No. US20050130174A1
; GENERAL INFORMATION:
; APPLICANT: Bao, Yijia P.
; TITLE OF INVENTION: LABEL-FREE GENE EXPRESSION PROFILING WITH UNIVERSAL NANOPARTICLE
; FILE REFERENCE: 03-214-A
; CURRENT APPLICATION NUMBER: US/10/789,831
; PRIOR FILING DATE: 2004-02-27
; PRIOR APPLICATION NUMBER: US 60/450,268
; PRIOR FILING DATE: 2003-02-27
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: detection probe
; NAME/KEY: unsure
; LOCATION: (1)-(1)
; OTHER INFORMATION: a comprises an epiandrosterone disulfide group
US-10-789-831-22

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
| | | | | | | | | | | | | | | | | |
Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 163
US-10-789-831-23/c
; Sequence 23, Application US/10789831
; Publication No. US20050130174A1
; GENERAL INFORMATION:
; APPLICANT: Bao, Yijia P.
; APPLICANT: Muller, Uwe R.
; TITLE OF INVENTION: LABEL-FREE GENE EXPRESSION PROFILING WITH UNIVERSAL NANOPARTICLE
; FILE REFERENCE: 03-214-A
; CURRENT APPLICATION NUMBER: US/10/789,831

; CURRENT FILING DATE: 2004-02-27
; PRIOR APPLICATION NUMBER: US 60/450,268
; PRIOR FILING DATE: 2003-02-27
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: detection probe
; NAME/KEY: unsure
; LOCATION: (1)-(1)
; OTHER INFORMATION: t comprises an epiandrosterone disulfide group
US-10-789-831-23

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
| | | | | | | | | | | | | | | | | |
Db 20 AAAAAAAAAAAAAAAAAA 4

RESULT 164
US-10-789-831-24
; Sequence 24, Application US/10789831
; Publication No. US20050130174A1
; GENERAL INFORMATION:
; APPLICANT: Bao, Yijia P.
; APPLICANT: Muller, Uwe R.
; TITLE OF INVENTION: LABEL-FREE GENE EXPRESSION PROFILING WITH UNIVERSAL NANOPARTICLE
; FILE REFERENCE: 03-214-A
; CURRENT APPLICATION NUMBER: US/10/789,831
; CURRENT FILING DATE: 2004-02-27
; PRIOR APPLICATION NUMBER: US 60/450,268
; PRIOR FILING DATE: 2003-02-27
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: detection probe
US-10-789-831-24

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
| | | | | | | | | | | | | | | | | |
Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 165
US-10-831-778-912/c
; Sequence 912, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991

; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 912
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-912

Query Match 0.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 21 AAAAAAAAAAAAAAAAAA 5

RESULT 166

US-10-751-736-19135
; Sequence 19135, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751.736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19135
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-19135

Query Match 0.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1444 ATGTTGCTGCTGCTGTT 1460
Db 4 ATGTTGCTGCTGCTGTT 20

RESULT 167

US-10-751-736-19136
; Sequence 19136, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751.736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19136
; LENGTH: 21

; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-19136

Query Match 0.9%; Score 17; DB 1; Length 21;
Best Local Similarity 52.9%; Pred. No. 1.7e+02;
Matches 9; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 1444 ATGTTGCTGCTGCTGTT 1460
Db 2 AUGUUGCUGCUGUGUU 18

RESULT 168

US-10-751-736-19138
; Sequence 19138, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751.736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19138
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-19138

Query Match 0.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1444 ATGTTGCTGCTGCTGTT 1460
Db 2 ATGTTGCTGCTGCTGTT 18

RESULT 169

US-10-913-246-23
; Sequence 23, Application US/10913246
; Publication No. US20050003441A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 49262000500
; CURRENT APPLICATION NUMBER: US/10/913.246
; CURRENT FILING DATE: 2004-08-05
; PRIOR APPLICATION NUMBER: US/10/100.321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G

US-10-913-246-23

Query Match 0.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
|||||
DB 2 AAAAAAAAAAAAAAAAAA 18

RESULT 170

US-10-934-890-23
; Sequence 23, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: AMPLIFICATION OF RNA SEQUENCES
; FILE REFERENCE: 49269200500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-934-890-23

Query Match 0.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
|||||
DB 2 AAAAAAAAAAAAAAAAAA 18

RESULT 171

US-10-830-287A-7/c
; Sequence 7, Application US/10830287A
; Publication No. US20050038238A1
; GENERAL INFORMATION:
; APPLICANT: Kriesel, John D.
; APPLICANT: Jones, Brandt B.
; APPLICANT: Grissom, Charles B.
; APPLICANT: Herpin, Geoff
; APPLICANT: Glazer, Peter M.
; TITLE OF INVENTION: OLIGONUCLEOTIDE COMPLEXES FOR USE AS ANTI-VIRAL THERAPEUTICS
; FILE REFERENCE: 007180-19
; CURRENT APPLICATION NUMBER: US/10/830,287A
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,270
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Variola virus
US-10-830-287A-7

Query Match 0.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
|||||
DB 21 AAAAAAAAAAAAAAAAAA 5

RESULT 172

US-10-601-140A-43
; Sequence 43, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 43
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-601-140A-43

Query Match 0.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
|||||
DB 1 AAAAAAAAAAAAAAAAAA 17

RESULT 173

US-09-263-981-4/c
; Sequence 4, Application US/09263981
; Patent No. US20020155437A1
; GENERAL INFORMATION:
; APPLICANT: Fisher, Paul B.
; TITLE OF INVENTION: Use of Prostate Tumor Inducing Gene for Detection of
; FILE REFERENCE: Cancer Cells
; FILE REFERENCE: 51950-A-PCT-US/JML
; CURRENT APPLICATION NUMBER: US/09/263,981
; CURRENT FILING DATE: 1999-03-05
; PRIOR APPLICATION NUMBER: PCT/US97/15645
; PRIOR FILING DATE: 1997-09-05
; PRIOR APPLICATION NUMBER: 08/708,208
; PRIOR FILING DATE: 1996-09-06
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-263-981-4

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1441 TGAATGTTGCTGCTGTT 1460
|||||

Db 20 TGAATGTTGCTGCTGCTGTT 1

RESULT 174
US-10-843-938-4/c
; Sequence 4, Application US/10843938
; Publication No. US20040203063A1
; GENERAL INFORMATION:
; APPLICANT: Fisher, Paul B.
; TITLE OF INVENTION: USE OF PROSTATE TUMOR INDUCING GENE FOR
; FILE REFERENCE: A34609-A-PCT-USA-A (070050.2578)
; CURRENT APPLICATION NUMBER: US/10/843,938
; CURRENT FILING DATE: 2004-05-12
; PRIOR APPLICATION NUMBER: 09/263,981
; PRIOR FILING DATE: 1999-03-05
; PRIOR APPLICATION NUMBER: PCT/US97/15645
; PRIOR FILING DATE: 1997-09-05
; PRIOR APPLICATION NUMBER: 08/708,208
; PRIOR FILING DATE: 1996-09-06
; PRIOR APPLICATION NUMBER: 08/371,377
; PRIOR FILING DATE: 1995-01-11
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-843-938-4

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1441 TGAATGTTGCTGCTGCTGTT 1460

Db 20 TGAATGTTGCTGCTGCTGTT 1

RESULT 175
US-10-751-736-25521
; Sequence 25521, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25521
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-25521

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 123 TTCGTGGTGTTCACCTTTT 142

Db 1 UUCGGUGAGUUCACCGUU 20

RESULT 176
US-10-027-632-52359
; Sequence 52359, Application US/10027632
; Publication No. US20020198371A1
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 52359
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-52359

Query Match 0.9%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 789 ACAGCCTGTATTACGGTGA 808

Db 1 ACAACCTGTATTACGGTGA 20

RESULT 177
US-10-027-632-52359
; Sequence 52359, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 52359
; LENGTH: 22
; TYPE: DNA

```
; ORGANISM: Human
US-10-027-632-52359

Query Match          0.9%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 789 ACAGCCTGTATTACGGTGA 808
Db 1 ACAACCTGTATTACGGTGAA 20

RESULT 178
US-10-349-143-4101/c
; Sequence 4101, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020C01
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4101
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-13272 for SEQ 167,
US-10-349-143-4101

Query Match          0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 730 CCATCTACAGTCTCTACA 747
Db 18 CCATCTACATCTCTACA 1

RESULT 179
US-10-872-984-5/c
; Sequence 5, Application US/10872984
; Publication No. US20040265888A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/10/872,984
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US/09/994,311
; PRIOR FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
```

```
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-5

Query Match          0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1834 GAAAAAAAAAAAAAAAAA 1851
Db 18 GCAAAAAAAAAAAAAAAAA 1

RESULT 180
US-10-289-762-3072/c
; Sequence 3072, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffois, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3072
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-3072

Query Match          0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1612 TCATCTTCAAGCACCAAC 1629
Db 19 TCATCTTCAAGCACGCAC 2

RESULT 181
US-10-831-901A-26525
; Sequence 26525, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
```

;; PRIOR FILING DATE: 2003-06-10
;; PRIOR APPLICATION NUMBER: 60/483,579
;; PRIOR FILING DATE: 2003-06-27
;; NUMBER OF SEQ ID NOS: 30063
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 26525
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Antisense compound
US-10-831-901A-26525

Query Match 0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 366 ATTATGTACCAAAACCTG 383
|||||

Db 1 ATTATGTACCAAAACCTG 18

RESULT 182
US-10-831-901A-26526
; Sequence 26526, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26526
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound

US-10-831-901A-26526

Query Match 0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 366 ATTATGTACCAAAACCTG 383
|||||

Db 2 ATTATGTACCAAAACCTG 19

RESULT 183
US-10-831-901A-26527
; Sequence 26527, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26527
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound

US-10-831-901A-26527

Query Match 0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 366 ATTATGTACCAAAACCTG 383
|||||

Db 3 ATTATGTACCAAAACCTG 20

RESULT 184
US-10-831-901A-29726/c
; Sequence 29726, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28


```
Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 451 AATCAGCTGTGATGCTGGAGC 471
Db 21 AATCATAAAGTGATGCTGGAGC 1

RESULT 192
US-10-751-736-23615/c
; Sequence 23615, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 23615
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-23615

Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 207 AAAGAGAAATAGCCAGCTCT 227
Db 21 AAAGAGAAAGAGCCAGCTGT 1

RESULT 193
US-10-847-918-9328
; Sequence 9328, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 9328
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-847-918-9328

Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 AAAGGAATCATCTCCCTCC 1711
Db 1 AAAGGAGTCATTCTCTACTCC 21

RESULT 194
US-10-847-918-9330/c
; Sequence 9330, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 9330
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-847-918-9330

Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 AAAGGAATCATCTCCCTCC 1711
Db 21 AAAGGAGTCATTCTCTACTCC 1

RESULT 195
US-10-847-918-9570/c
; Sequence 9570, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 9570
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-847-918-9570

Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1690 AAAAGGAATCATCTCCCTCC 1710
Db 21 AAAAGGAGTCATTCTCTACTC 1

RESULT 196
US-10-847-918-12368/c
; Sequence 12368, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
```

```
RESULT 194
US-10-847-918-9330/c
; Sequence 9330, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 9330
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-847-918-9330

Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 AAAGGAATCATCTCCCTCC 1711
Db 21 AAAGGAGTCATTCTCTACTCC 1

RESULT 195
US-10-847-918-9570/c
; Sequence 9570, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 9570
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-847-918-9570

Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1690 AAAAGGAATCATCTCCCTCC 1710
Db 21 AAAAGGAGTCATTCTCTACTC 1

RESULT 196
US-10-847-918-12368/c
; Sequence 12368, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
```

; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; PRIOR FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12368
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI-sense strand
US-10-847-918-12368

Query Match 0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1599 AATTCATCCCAATTCATCTTC 1619
Db 21 AATTCCTCCATTCACCTTC 1

RESULT 197
US-10-847-918-12887/c
; Sequence 12887, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12887
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI-sense strand
US-10-847-918-12887

Query Match 0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 240 AAAGCAATCATCAACCTAGCT 260
Db 21 AAAGCAATGGTCAACCTGGCT 1

RESULT 198
US-10-847-918-13478/c
; Sequence 13478, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)

; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13478
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI-sense strand
US-10-847-918-13478

Query Match 0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 240 AAAGCAATCATCAACCTAGCT 260
Db 21 AAAGCAATGGTCAACCTGGCT 1

RESULT 199
US-10-755-118-94/c
; Sequence 94, Application US/10755118
; Publication No. US20050009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 94
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-755-118-94

Query Match 0.9%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1850
Db 16 AAAAAAAAAAAAAA 1

RESULT 200
US-10-608-863-4/c
; Sequence 4, Application US/10608863
; Publication No. US20040214192A1
; GENERAL INFORMATION:
; APPLICANT: Hashida, Ryoichi
; APPLICANT: Kagaya, Shinji
; APPLICANT: Yayoi, Yoshihiro

```
; APPLICANT: Sugita, Yuji
; APPLICANT: Saito, Hirohisa
; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREA
; TITLE OF INVENTION: ALLERGIC DISEASES
; FILE REFERENCE: 3462.1003-000
; CURRENT APPLICATION NUMBER: US/10/608,863
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: JP 2002-188490
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Artificially
; OTHER INFORMATION: Synthesized Primer Sequence
US-10-608-863-4

Query Match          0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1834 GAAAAAAAAAAAAAAAAA 1849
Db 17 GAAAAAAAAAAAAAAAAA 2

RESULT 201
US-10-872-984-6/c
; Sequence 6, Application US/10872984
; Publication No. US20040265889A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/10/872,984
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US/09/994,311
; PRIOR FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-6

Query Match          0.9%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1850
Db 16 AAAAAAAAAAAAAAAAAA 1

RESULT 202
US-10-751-736-19139
; Sequence 19139, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```

```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19139
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
; ORGANISM: RNAi
US-10-751-736-19139

Query Match          0.9%; Score 16; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 2.2e+02;
Matches 8; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGTGCTGCTGCTT 1460
Db 1 UGUUGCUGCUGCUGU 16

RESULT 203
US-10-871-222-150
; Sequence 150, Application US/10871222
; Publication No. US20050119212A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids
; TITLE OF INVENTION: Synthase Ligand (FASL) Gene Expression Using Short Interfering
; TITLE OF INVENTION: Nucleic Acid (SINA)
; FILE REFERENCE: 400/164 (MHB04-487)
; CURRENT APPLICATION NUMBER: US/10/871,222
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 706
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 150
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/sina sense r
US-10-871-222-150

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.9e+02;
```

Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1833 TGAAGAAAAA 1851
:|||||||

Db 1 UGUUAAAAA 19

RESULT 204
US-10-871-222-300/c
; Sequence 300, Application US/10871222
; Publication No. US20050119212A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haeberli, Peter
; TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids
; TITLE OF INVENTION: Synthese Ligand (FASL) Gene Expression Using Short Interfering
; TITLE OF INVENTION: Nucleic Acid (siNA)
; FILE REFERENCE: 400/164 (MBHB04-487)
; CURRENT APPLICATION NUMBER: US/10/871,222
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 706
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 300
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-871-222-300

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1833 TGAAGAAAAA 1851
:|||||||

Db 19 TGGTAAAAA 1

RESULT 205
US-10-840-731-34
; Sequence 34, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/155 (MBHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731

; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 34
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-840-731-34

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 47.4%; Pred. No. 1.9e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 1813 AATAATTTTGGAGATCT 1831
:|||||||

Db 1 AUAUUUUUGAGGAUGU 19

RESULT 206
US-10-840-731-129/c
; Sequence 129, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/155 (MBHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346

```
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 129
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-840-731-129

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1813 ATAAATTTTGGAGATCT 1831
Db 19 ATAAATTTTGGAGGATGT 1

RESULT 207
US-09-987-025-8
; Sequence 8, Application US/09987025
; Patent No. US20020108148A1
; GENERAL INFORMATION:
; APPLICANT: Boronati, Albert
; APPLICANT: Campos, Narcisco
; APPLICANT: Kishore, Ganesh M.
; TITLE OF INVENTION: Nucleic Acid Sequences Involved in
; FILE REFERENCE: 17142/02/US
; CURRENT APPLICATION NUMBER: US/09/987,025
; CURRENT FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: 09/549,787
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/129,899
; PRIOR FILING DATE: 1999-04-15
; PRIOR APPLICATION NUMBER: 60/146,461
; PRIOR FILING DATE: 1999-07-30
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-09-987-025-8

Query Match          0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1244 GGCATCATCGAGGAGGTT 1262
Db 1 GGCATGCTGGAGGAGTT 19

RESULT 208
US-10-108-164-125
; Sequence 125, Application US/10108164
; Publication No. US20030104356A1
; GENERAL INFORMATION:
; APPLICANT: Berger, Shelley L.
; APPLICANT: Fraser, Nigel W.
; APPLICANT: Tal-Singer, Ruth
; APPLICANT: Leary, Jeffrey J.
; TITLE OF INVENTION: Compounds And Methods For Treating And
; FILE REFERENCE: P50682C1
; CURRENT APPLICATION NUMBER: US/10/108,164
; CURRENT FILING DATE: 2002-03-26
```

```
; PRIOR APPLICATION NUMBER: 09/424,348
; PRIOR FILING DATE: 1999-07-01
; PRIOR APPLICATION NUMBER: PCT/US98/13733
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/051,633
; PRIOR FILING DATE: 1997-07-03
; PRIOR APPLICATION NUMBER: 60/054,515
; PRIOR FILING DATE: 1997-08-01
; PRIOR APPLICATION NUMBER: 60/080,352
; PRIOR FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 145
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-108-164-125

Query Match          0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 590 AGAAGCAAGGAGGAGATT 608
Db 2 AAAAGCAAGGAGGAGATT 20

RESULT 209
US-10-139-604-2
; Sequence 2, Application US/10139604
; Publication No. US20030124551A1
; GENERAL INFORMATION:
; APPLICANT: METRIS THERAPEUTICS LIMITED
; APPLICANT: LNIENICEK, Mirna
; APPLICANT: PAPPA, Helen
; TITLE OF INVENTION: AGENTS IMPLICATED IN ENDOMETRIOSIS
; FILE REFERENCE: 1396-1-006
; CURRENT APPLICATION NUMBER: US/10/139,604
; CURRENT FILING DATE: 2002-08-23
; PRIOR APPLICATION NUMBER: GB 9926081.2
; PRIOR FILING DATE: 1999-11-03
; PRIOR APPLICATION NUMBER: GB 9926074.7
; PRIOR FILING DATE: 1999-11-03
; PRIOR APPLICATION NUMBER: GB 9926079.6
; PRIOR FILING DATE: 1999-11-03
; PRIOR APPLICATION NUMBER: GB 9926076.2
; PRIOR FILING DATE: 1999-11-03
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: SeqWin99, version 1.02
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 5' RT-PCR primer for Elongation factor-1
US-10-139-604-2

Query Match          0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1441 TGAATGTTGCTGCTGCTGT 1459
Db 2 TGATTTGTTGCTGCTGCTGT 20

RESULT 210
US-10-261-706-4
; Sequence 4, Application US/10261706
; Publication No. US20040001830A1
; GENERAL INFORMATION:
; APPLICANT: Freskgaard, Per-Ola
; APPLICANT: Clausen, Jes T
```

```
; APPLICANT: Sorensen, Brit B
; APPLICANT: Kjaake, Marianne
; TITLE OF INVENTION: Human Tissue Factor Antibodies
; FILE REFERENCE: 6264.200-US
; CURRENT APPLICATION NUMBER: US/10/261,706
; CURRENT FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: Danish Application PA 2001 01437
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 60/329,775
; PRIOR FILING DATE: 2001-10-16
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-706-4

Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1172 TCTGCTGAGCTGCTGAC 1190
      |||||
Db 2 TCTGCTGAGCTGCTGAC 20

RESULT 211
US-10-289-762-6169/c
; Sequence 6169, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6169
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-6169

Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1440 ATGAATGTTGCTGCTGCTG 1458
      |||||
Db 19 ATGATTGTTGCTGCTGCCG 1

RESULT 212
US-10-831-901A-8646
; Sequence 8646, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8647
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
```

```
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8646
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-8646

Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 815 AGAATGATGTCAGAGATG 833
      |||||
Db 1 AGAATGATGTCAGAGTG 19

RESULT 213
US-10-831-901A-8647
; Sequence 8647, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8647
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
```

```
US-10-831-901A-8647
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-966-829-8
Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      815 AGAAATGATGTCAGGAATG 833
Db      2 AGAAATGATGTCAGGATG 20

RESULT 214
US-10-699-362A-4
; Sequence 4, Application US/10699362A
; Publication No. US20050106139A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk A/S
; APPLICANT: Svendsen, Ivan
; APPLICANT: Kjaergaard, Kristian
; APPLICANT: Zahn, Stefan
; TITLE OF INVENTION: Humanized Tissue Factor Antibodies
; FILE REFERENCE: 6600.200-US
; CURRENT APPLICATION NUMBER: US/10/699,362A
; CURRENT FILING DATE: 2003-10-31
; PRIOR APPLICATION NUMBER: Danish Application No. 2002 01661
; PRIOR FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US Application No. 60/427,157
; PRIOR FILING DATE: 2002-11-18
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-699-362A-4
Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1172 TCTGGTGATGAGTCTGCAC 1190
Db      2 TCTGGTGATGACAGCTGCAC 20

RESULT 215
US-10-966-829-8
; Sequence 8, Application US/10966829
; Publication No. US20050120406A1
; GENERAL INFORMATION:
; APPLICANT: Boronot, Albert
; APPLICANT: Campos, Narciso
; APPLICANT: Kishore, Ganesh M.
; TITLE OF INVENTION: Nucleic Acid Sequences Involved in
; FILE REFERENCE: 17142/02/US
; CURRENT APPLICATION NUMBER: US/10/966,829
; CURRENT FILING DATE: 2004-10-15
; PRIOR APPLICATION NUMBER: US/09/987,025
; PRIOR FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: 09/549,787
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/129,899
; PRIOR FILING DATE: 1999-04-15
; PRIOR APPLICATION NUMBER: 60/146,461
; PRIOR FILING DATE: 1999-07-30
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA

US-10-831-901A-8647
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-966-829-8
Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1244 GGCCATCATGAGGAGGTT 1262
Db      1 GGCCATGCTGGAGAGGTT 19

RESULT 216
US-10-792-280-376/c
; Sequence 376, Application US/10792280
; Publication No. US20040234517A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Bowman, Michael
; APPLICANT: Follettie, Maximillian
; APPLICANT: Chen, Heng
; APPLICANT: Williams, Cara
; APPLICANT: Ellis, Debra
; APPLICANT: Winkler, Aaron
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING ASTHMA OR
; FILE REFERENCE: AM101023-2
; CURRENT APPLICATION NUMBER: US/10/792,280
; CURRENT FILING DATE: 2004-03-04
; NUMBER OF SEQ ID NOS: 1535
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 376
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-792-280-376
Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1164 AACTACAGTCTGGTGATGG 1182
Db      21 AACTCCAGCTGGTGATGG 3

RESULT 217
US-10-751-736-23903/c
; Sequence 23903, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23903
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-23903
```


Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 211 AAGAAATAGCCAGCTGTGG 229
||||| ||||||| |||
DB 21 AAGAAGAGCCAGCTGTGG 3

RESULT 218
US-10-751-736-29406/c
; Sequence 29406, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29406
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-29406

Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 801 ACGGTGAAGATGCAGAA 819
||||| ||||||| |||
DB 19 ACGGTGAAGATGAAGAA 1

RESULT 219
US-10-831-819-12/c
; Sequence 12, Application US/10831819
; Publication No. US20050112613A1
; GENERAL INFORMATION:
; APPLICANT: KRAHE, RALF
; APPLICANT: ZHANG, SHANXIANG
; TITLE OF INVENTION: METHODS AND REAGENTS FOR PREDICTING THE LIKELIHOOD OF
; FILE REFERENCE: 18525/04053
; CURRENT APPLICATION NUMBER: US/10/831,819
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/320,146
; PRIOR FILING DATE: 2003-04-25
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Probe
US-10-831-819-12

Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCCTCGTCGCCGCG 46
||||| ||| |||||||

DB 19 GCCGCCGCGCGCGCGCG 1

RESULT 220
US-10-479-472A-7
; Sequence 7, Application US/10479472A
; Publication No. US20050118581A1
; GENERAL INFORMATION:
; APPLICANT: DEL-FAVERO, JURGEN PETER LODE
; APPLICANT: VAN BROECKHOVEN, CHRISTINE
; TITLE OF INVENTION: NOVEL BRAIN EXPRESSED GENE AND PROTEIN ASSOCIATED WITH
; TITLE OF INVENTION: BIPOLAR DISORDER
; FILE REFERENCE: JAB-1711
; CURRENT APPLICATION NUMBER: US/10/479,472A
; CURRENT FILING DATE: 2003-12-01
; PRIOR APPLICATION NUMBER: PCT/EP02/06316
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: EP 01202214.1
; PRIOR FILING DATE: 2001-06-11
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Illustrative
; OTHER INFORMATION: oligonucleotide
US-10-479-472A-7

Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCCTCGTCGCCGCG 46
||||| ||| |||||||
DB 3 GCCGCCGCGCGCGCGCG 21

RESULT 221
US-09-877-478-266/c
; Sequence 266, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MHB00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 266
; LENGTH: 17

```

; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-266

Query Match          0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 529 AAGGCATTACAGCAGAA 545
Db 17 AAGGCATTAAAGCAGAA 1

RESULT 222
US-10-342-902-266/c
; Sequence 266, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBHB00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-266

Query Match          0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 529 AAGGCATTACAGCAGAA 545
Db 17 AAGGCATTAAAGCAGAA 1

RESULT 223
US-10-669-841-266/c
; Sequence 266, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPN

```

```

; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 266
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-266

Query Match          0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 529 AAGGCATTACAGCAGAA 545
Db 17 AAGGCATTAAAGCAGAA 1

RESULT 224
US-09-969-373-3693/c
; Sequence 3693 Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Eifert, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3693
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-3693

Query Match          0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 465 CTGGAGCCGAAGATTCA 481
Db 18 CTGGAGCCGAAGATTCA 2

```



```
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 706
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 404
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-871-222-404

Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 3 AAAAAAAAAAAAAAAAAA 19

RESULT 230
US-10-871-222-508/c
; Sequence 508, Application US/10871222
; Publication No. US20050119212A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acid
; TITLE OF INVENTION: Synthase Ligand (FASL) Gene Expression Using Short Interfering
; TITLE OF INVENTION: Nucleic Acid (SINA)
; FILE REFERENCE: 400/164 (MBHB04-487)
; CURRENT APPLICATION NUMBER: US/10/871,222
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 706
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 404
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-871-222-404
```

```
; NUMBER OF SEQ ID NOS: 706
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 508
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-871-222-508

Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 17 AAAAAAAAAAAAAAAAAA 1

RESULT 231
US-10-881-118-121
; Sequence 121, Application US/10881118
; Publication No. US20050130181A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Mediated Inhibition of Wingless Gene Expression Using Short
; TITLE OF INVENTION: Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400-197 (MBHB04-546)
; CURRENT APPLICATION NUMBER: US/10/881,118
; CURRENT FILING DATE: 2004-06-30
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 452
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 121
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-881-118-121

Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.8%; Pred. No. 2.1e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 11 CGAGCTTAGTCTCTGGGA 27
Db 3 CAAGCUUAGUCCUGGA 19

RESULT 232
US-10-881-118-284/c
```

```
; Sequence 284, Application US/10881118
; Publication No. US20050130181A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Inc.
; TITLE OF INVENTION: RNA Mediated Inhibition of Wingless Gene Expression Using Short
; FILE REFERENCE: 400-197 (MEHB04-546)
; CURRENT APPLICATION NUMBER: US/10/881,118
; PRIOR FILING DATE: 2004-06-30
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 452
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 284
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-881-118-284

Query Match 0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 11 CGAGCTTAGTCTGGGA 27
Db 17 CAAGCTTAGTCTGGGA 1

RESULT 233
US-10-840-731-32
; Sequence 32, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Inc.
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MEHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 33
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
```

```
; Sequence 284, Application US/10881118
; Publication No. US20050130181A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Inc.
; TITLE OF INVENTION: RNA Mediated Inhibition of Wingless Gene Expression Using Short
; FILE REFERENCE: 400-197 (MEHB04-546)
; CURRENT APPLICATION NUMBER: US/10/881,118
; PRIOR FILING DATE: 2004-06-30
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 32
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-840-731-32

Query Match 0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 2.1e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy 1813 ATAAATTTTTCGAAGAT 1829
Db 3 AUAUUUUUGGAGAU 19

RESULT 234
US-10-840-731-33
; Sequence 33, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Inc.
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MEHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 33
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-840-731-33
```

```
Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.94; Pred. No. 2.1e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1813 ATAAATTTTGGAGAT 1829
    :|||:|||||:|
    2 AUAUUUUUGGAGAU 18

RESULT 235
US-10-840-731-127/c
; Sequence 127, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MBHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; PRIOR FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 127
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-840-731-127

Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.94; Pred. No. 2.1e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1813 ATAAATTTTGGAGAT 1829
    :|||:|||||:|
    2 AUAUUUUUGGAGAU 18

RESULT 236
US-10-840-731-128/c
; Sequence 128, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MBHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; PRIOR FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 127
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-840-731-127

Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.94; Pred. No. 2.1e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1813 ATAAATTTTGGAGAT 1829
    :|||:|||||:|
    2 AUAUUUUUGGAGAT 18

RESULT 237
US-10-863-973-389/c
; Sequence 389, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Polisky, Barry
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```
FILE REFERENCE: 400/155 (MBHB04-410)
CURRENT APPLICATION NUMBER: US/10/840,731
CURRENT FILING DATE: 2004-05-06
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: US 10/652,791
PRIOR FILING DATE: 2003-08-29
PRIOR APPLICATION NUMBER: US 10/422,704
PRIOR FILING DATE: 2003-04-24
PRIOR APPLICATION NUMBER: US 10/417,012
PRIOR FILING DATE: 2003-04-16
PRIOR APPLICATION NUMBER: US 10/427,160
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 296
SOFTWARE: PatentIn version 3.3
SEQ ID NO 128
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-840-731-128

Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1813 ATAAATTTTGGAGAT 1829
    :|||:|||||:|
    18 ATAAATTTTGGAGAT 2

Db

RESULT 237
US-10-863-973-389/c
; Sequence 389, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Polisky, Barry
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1832
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 389
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense x
US-10-863-973-389

Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      689 GGGGGCTTTGGCATCTC 705
Db      19  GGGGGCTTTGGCATGTC 3

RESULT 238
US-10-863-973-589
; Sequence 589, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: Polisky, Barry
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBH803-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1832
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 589
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-863-973-589

Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
```

```
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy      689 GGGGGCTTTGGCATCTC 705
Db      1  GGGGGCTTUGGCAUGUC 17

RESULT 239
US-09-242-772-55/c
; Sequence 55, Application US/09242772
; Publication No. US20020009720A1
; GENERAL INFORMATION:
; APPLICANT: Vlaams Interuniversitair Instituut voor Biotechnologie
; TITLE OF INVENTION: PLAG gene family and tumorigenesis
; FILE REFERENCE: VIB-011-US
; CURRENT APPLICATION NUMBER: US/09/242,772
; CURRENT FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: EP 96202229.6
; PRIOR FILING DATE: 1996-08-22
; PRIOR APPLICATION NUMBER: EP 97200130.9
; PRIOR FILING DATE: 1997-01-17
; PRIOR APPLICATION NUMBER: PCT/EP97/04759
; PRIOR FILING DATE: 1997-08-22
; NUMBER OF SEQ ID NOS: 139
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
; NAME/KEY: misc feature
; OTHER INFORMATION: sense primer EM156
US-09-242-772-55

Query Match      0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1441 TGAATGTTGCTGCTGCT 1457
Db      20  TGACTGTTGCTGCTGCT 4

RESULT 240
US-10-058-422-14/c
; Sequence 14, Application US/10058422
; Publication No. US20030108881A1
; GENERAL INFORMATION:
; APPLICANT: Hyeoung Lee, Hye Eun Bang, Sang-Nae Cho, Gill-Han BAI,
; APPLICANT: Sang-Jae Kim
; TITLE OF INVENTION: A method for identifying Micobacteria tuberculosis and
; TITLE OF INVENTION: non-tuberculosis Micobacteria, together with detecting resistance
; TITLE OF INVENTION: to an antituberculosis drug of Micobacteria obtained by mutation
; FILE REFERENCE: 0217-0008
; CURRENT APPLICATION NUMBER: US/10/058,422
; CURRENT FILING DATE: 2002-01-30
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: Kopatentin 1.71
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligomer probe for M. abscesus
US-10-058-422-14

Query Match      0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 126 GGTGGTGTTCACCTTTT 142
Db 17 GGTGGTGTTCACCTTTT 1

RESULT 241
US-10-289-762-6103
; Sequence 6103, Application US/10289762
; Publication No. US2004006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6103
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-6103

Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 150 TGCTCTGGGAAGCTAT 166
Db 2 TGCTCTGGGAAGCTAT 18

RESULT 242
US-10-766-185-47
; Sequence 47, Application US/10766185
; Publication No. US20040152655A1
; GENERAL INFORMATION:
; APPLICANT: Yoon, Heejeong
; APPLICANT: Ahn, Chang Ho
; APPLICANT: Lee, Young Bok
; APPLICANT: Mao, Lingjun
; APPLICANT: Jiang, Xiaoming
; TITLE OF INVENTION: Antisense oligonucleotides that inhibit expression of HIF-1
; FILE REFERENCE: RX 7034
; CURRENT APPLICATION NUMBER: US/10/766,185
; CURRENT FILING DATE: 2004-01-28
; NUMBER OF SEQ ID NOS: 130
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-10-766-185-47

Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1134 TATTATCAGTTACACAA 1150
Db 4 TAATATCAGTTACACAA 20

RESULT 243
US-10-380-049-11
; Sequence 11, Application US/10380049
; Publication No. US20050013804A1
; GENERAL INFORMATION:
; APPLICANT: KATO Yukio
; TITLE OF INVENTION: Method for culturing bone marrow mesenchymal stem cells
```

```
; FILE REFERENCE: FP1021
; CURRENT APPLICATION NUMBER: US/10/380,049
; CURRENT FILING DATE: 2003-03-11
; PRIOR APPLICATION NUMBER: JP2000-276971
; PRIOR FILING DATE: 2000-09-12
; NUMBER OF SEQ ID NOS: 14
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-380-049-11

Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1403 CCACGGAGACACCATGA 1419
Db 1 CCACGGAGACACCATGA 17

RESULT 244
US-10-831-901A-26524
; Sequence 26524, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian A.
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,527
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26524
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-26524

Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 367 TTATGTACCAAAACCTG 383
Db 1 TTATGTACCAAAACCTG 17
```



```
RESULT 245
US-10-831-901A-26528
; Sequence 26528, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26528
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-26528

Query Match          0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 366 ATTATGTACCAAAACCT 382
Db 4 ATTATGTACAAAAACCT 20

RESULT 246
US-10-831-901A-29725/c
; Sequence 29725, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
```

```
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29725
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29725

Query Match          0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1833 TGAAGAGATCAGCTGTGTA 462
Db 17 TGACAAAAAAGAAAAA 1

RESULT 247
US-10-317-869A-54
; Sequence 54, Application US/10317869A
; Publication No. US20050101000A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF PHOSPHODIESTERASE 4B EXPRESSION
; FILE REFERENCE: RTS-0429
; CURRENT APPLICATION NUMBER: US/10/317,869A
; CURRENT FILING DATE: 2002-12-11
; NUMBER OF SEQ ID NOS: 113
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-317-869A-54

Query Match          0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 446 AGAAGATCAGCTGTGTA 462
Db 3 AGAAGATCATCTGTGA 19

RESULT 248
US-10-317-869A-103/c
; Sequence 103, Application US/10317869A
; Publication No. US20050101000A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF PHOSPHODIESTERASE 4B EXPRESSION
; FILE REFERENCE: RTS-0429
; CURRENT APPLICATION NUMBER: US/10/317,869A
; CURRENT FILING DATE: 2002-12-11
; NUMBER OF SEQ ID NOS: 113
; SEQ ID NO 103
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-317-869A-103

Query Match      0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 446 AGAAGATCAGCTGTGA 452
Db 18 AGAAGATCATCTGTGA 2

RESULT 249
US-10-872-645-29/c
; Sequence 29, Application US/10872645
; Publication No. US20050100887A1
; GENERAL INFORMATION:
; APPLICANT: AXIMA Pharmaceuticals AG
; APPLICANT: Salasidis, Konstadinos
; APPLICANT: Schubart, Daniel
; APPLICANT: Laasidis, Konstadinos
; APPLICANT: Muellner, Stefan
; APPLICANT: Kraetzer, Friedrich
; APPLICANT: Obert, Sabine
; TITLE OF INVENTION: Targets for Hepatitis C Virus Infections
; FILE REFERENCE: AXM-014.1 US
; CURRENT APPLICATION NUMBER: US/10/872,645
; PRIOR FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: PCT/EP02/14578
; PRIOR FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: US 60/341,757
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 29
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: v = a or g or c
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: n=a or g or t or c
US-10-872-645-29

Query Match      0.8%; Score 15.2; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1834 GAAAAAAGAAAAA 1849
Db 16 BAAAAAAGAAAAA 1

RESULT 250
US-09-768-917-9
; Sequence 9, Application US/09768917
; Patent No. US20020034494A1
; GENERAL INFORMATION:
; APPLICANT: Vicari, Alain P.
; APPLICANT: Caux, Christophe
; APPLICANT: LaFace, Drake
; TITLE OF INVENTION: Chemokines as Adjuvants of Immune Response
; FILE REFERENCE: SF0896K US
; CURRENT APPLICATION NUMBER: US/09/768,917
; CURRENT FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: EP 0 974 357

; PRIOR FILING DATE: 1998-07-16
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-768-917-9

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1083 CGGCTGGTCTCTGGACTGC 1102
Db 1 CTGCTGGTCTCTGGACTTC 20

RESULT 251
US-09-888-326-410/c
; Sequence 410, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Hartmann, Gunther
; TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
; FILE REFERENCE: C1039/7052 (AWS)
; CURRENT APPLICATION NUMBER: US/09/888,326
; CURRENT FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: US 60/213,346
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 848
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 410
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (0)..(0)
; OTHER INFORMATION: phosphodiester backbone
US-09-888-326-410

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CGGCTCTCGTCCGCCGCTC 48
Db 20 CCGCCGCCGCCGCCGCC 1

RESULT 252
US-09-802-640-74
; Sequence 74, Application US/09802640
; Publication No. US20030036057A1
; GENERAL INFORMATION:
; APPLICANT: Braun, Andreas
; APPLICANT: Kley, Patrick
; TITLE OF INVENTION: GENES AND POLYMORPHISMS ASSOCIATED WITH
; FILE REFERENCE: 24736-2048
; CURRENT APPLICATION NUMBER: US/09/802,640
; CURRENT FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 74
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Artificial sequence
US-09-802-640-74

Query Match
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1265 GAGCCTGCTGCAGCCCTCA 1284
Db 1 GTGACTTCTGCAGCCCTCA 20

RESULT 253
US-09-776-479-243/c
; Sequence 243, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; PRIOR FILING DATE: 2001-02-02
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 243
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-243

Query Match
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 29 CCGCCTCGTCGCGCGCGTC 48
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 254
US-09-776-479-243/c
; Sequence 243, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 243
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-243

Query Match
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 29 CCGCCTCGTCGCGCGCGTC 48
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 255
US-09-932-419-5/c
; Sequence 5, Application US/09932419
; Publication No. US20030096238A1
; GENERAL INFORMATION:
; APPLICANT: Salceda, Susana
; APPLICANT: Cafferkey, Robert
; TITLE OF INVENTION: COMPOSITIONS AND METHODS RELATING TO GYNECOLOGIC CANCER
; FILE REFERENCE: DEX-0216
; CURRENT APPLICATION NUMBER: US/09/932,419
; PRIOR FILING DATE: 2001-08-16
; PRIOR APPLICATION NUMBER: 60/225,857
; PRIOR FILING DATE: 2000-08-17
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-932-419-5

Query Match
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1445 TGTTCGTGCTGCTGTTTGGG 1464
Db 20 TCTTGATGCTGCTGTTTCGG 1

RESULT 256
US-09-915-814-184
; Sequence 184, Application US/09915814
; Publication No. US20030096771A1
; GENERAL INFORMATION:
; APPLICANT: Madeline M. Butler
; APPLICANT: Andrew T. Watt
; APPLICANT: Susan M. Freier
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF HORMONE-SENSITIVE LIPASE EXPRESSION
; FILE REFERENCE: ISPH-0587
; CURRENT APPLICATION NUMBER: US/09/915,814
; PRIOR FILING DATE: 2001-07-26
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 184
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-915-814-184

Query Match
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 524 TCCAGAGGCATTACAGCAG 543
Db 1 TCCAGAGGCTTCCAGAG 20

RESULT 257
```

```
US-09-965-101-57/c
; Sequence 57, Application US/09965101
; Publication No. US20040186067A1
; GENERAL INFORMATION:
; APPLICANT: Davis, Heather L.
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schorr, Joachim
; APPLICANT: Wu, Tong
; TITLE OF INVENTION: Vectors and Methods for Immunization or
; TITLE OF INVENTION: Therapeutic Protocols
; FILE REFERENCE: C1039/7057 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/965,101
; CURRENT FILING DATE: 2001-09-26
; PRIOR APPLICATION NUMBER: US 03/082,649
; PRIOR FILING DATE: 1998-05-20
; PRIOR APPLICATION NUMBER: US 60/047,233
; PRIOR FILING DATE: 1997-05-20
; PRIOR APPLICATION NUMBER: US 60/047,209
; PRIOR FILING DATE: 1997-05-20
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
US-09-965-101-57

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCCTCCGTCGCGCGGTC 48
Db 20 CCGCGCGCGCGCGCGGCC 1

RESULT 258
US-10-112-653-235/c
; Sequence 235, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Berg, Daniel J.
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
; TITLE OF INVENTION: TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
; FILE REFERENCE: C01039/70060 (AWS)
; CURRENT APPLICATION NUMBER: US/10/112,653
; CURRENT FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: US 60/279,642
; PRIOR FILING DATE: 2001-03-29
; NUMBER OF SEQ ID NOS: 1040
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 235
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-235

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCCTCCGTCGCGCGGTC 48
Db 20 CCGCGCGCGCGCGCGGCC 1

RESULT 259
US-10-017-995-243/c
; Sequence 243, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
; FILE REFERENCE: C1037/7025 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/017,995
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US 60/255,534
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 243
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-017-995-243

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCCTCCGTCGCGCGGTC 48
Db 20 CCGCGCGCGCGCGCGGCC 1

RESULT 260
US-10-067-076-10
; Sequence 10, Application US/10067076
; Publication No. US20030104404A1
; GENERAL INFORMATION:
; APPLICANT: Wise, Carol A.
; TITLE OF INVENTION: Genetic Markers for Autoimmune Disorder
; FILE REFERENCE: TEX871/4-006US/36000
; CURRENT APPLICATION NUMBER: US/10/067,076
; CURRENT FILING DATE: 2002-02-04
; PRIOR APPLICATION NUMBER: 60/287,893
; PRIOR FILING DATE: 2001-05-01
; PRIOR APPLICATION NUMBER: 09/710,693
; PRIOR FILING DATE: 2000-11-08
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Human Nucleic Acid
US-10-067-076-10

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 989 GCAGGTGTCATGATGATG 1008
Db 1 GCAGGTGTCATGATGATG 20

RESULT 261
US-10-314-578-243/c
; Sequence 243, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schetter, Christian
; APPLICANT: Vollmer, Jorg
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
```

; PRIOR FILING DATE: 1999-09-25
; PRIOR APPLICATION NUMBER: US 60/156,135
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 60/227,436
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 1145
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 243
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-243

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 29 CCGCCTCGTGGCGCGCGTC 48
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 262
US-10-403-902A-74
; Sequence 74, Application US/10403902A
; Publication No. US20030224418A1
; GENERAL INFORMATION:
; APPLICANT: Braun, Andreas
; APPLICANT: Bansal, Aruna
; APPLICANT: Kleyn, Patrick
; TITLE OF INVENTION: GENES AND POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: CARDIOVASCULAR DISEASE AND THEIR USE
; FILE REFERENCE: 24736-2048B
; CURRENT APPLICATION NUMBER: US/10/403,902A
; CURRENT FILING DATE: 2003-07-21
; PRIOR APPLICATION NUMBER: 09/802,640
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
US-10-403-902A-74

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1265 GAGCCTGCTGCAGCGCCCTCA 1284
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GTGACTTCTGCAGCGCCCTCA 20

RESULT 263
US-10-175-499-39/c
; Sequence 39, Application US/10175499
; Publication No. US2003023977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Susan J. Myers
; TITLE OF INVENTION: ANTISENSE MODULATION OF SPLICING FACTOR R/S-RICH 10 EXPRESSION
; FILE REFERENCE: HTS-0018
; CURRENT APPLICATION NUMBER: US/10/175,499
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 62
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-175-499-39

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1411 ACACCATGACTGTCATGGAT 1430
| | | | | | | | | | | | | | | | | | | | | |
Db 20 ACACATACCTGTCATGGAT 1

RESULT 264
US-10-289-762-4294
; Sequence 4294, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Grifflais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4294
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-4294

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1428 GATCCAAAGCAGATGAATGT 1447
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GCTCCGAACCAAGATGAATGT 20

RESULT 265
US-10-210-556-35/c
; Sequence 35, Application US/10210556
; Publication No. US20040023904A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowbert
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTPRA EXPRESSION
; FILE REFERENCE: PTS-0015
; CURRENT APPLICATION NUMBER: US/10/210,556
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 227
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-556-35

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 888 CCAGATACGATTCCTTCAA 907
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CCAGATTCGATTACATCAA 1

RESULT 266
US-10-210-556-158

```
; Sequence 158, Application US/10210556
; Publication No. US20040023904A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTBRA EXPRESSION
; FILE REFERENCE: PTS-0015
; CURRENT APPLICATION NUMBER: US/10/210,556
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 227
; SEQ ID NO 158
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-210-556-158

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      888 CCAGTACTGATTCCTTCAA 907
Db      1 CCAGATTCGATTACATCAA 20

RESULT 267
US-10-280-183A-69/c
; Sequence 69, Application US/10280183A
; Publication No. US20040081964A1
; GENERAL INFORMATION:
; APPLICANT: Pfizer Inc.
; APPLICANT: Bachmanov, Alexander A
; APPLICANT: Beauchamp, Gary K.
; APPLICANT: Chatterjee, Anubindo
; APPLICANT: De Jong, Pieter J.
; APPLICANT: Li, Shanru
; APPLICANT: Li, Xia
; APPLICANT: Ohmen, Jeffrey D
; APPLICANT: Reed, Danielle R.
; APPLICANT: Ross, David
; APPLICANT: Tordoff, Michael G
; TITLE OF INVENTION: GENE AND SEQUENCE VARIATION ASSOCIATED WITH SENSING
; FILE REFERENCE: PC18106A
; CURRENT APPLICATION NUMBER: US/10/280,183A
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 60/200,794
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 652
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mouse
US-10-280-183A-69

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      685 AGGTGGGGGCTTTGGCATCT 704
Db      20 AGGTGAGGGTTTGGCTTCT 1

RESULT 268
US-10-303-326-30/c
; Sequence 30, Application US/10303326
; Publication No. US20040101849A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
```

```
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF SELENOPROTEIN W EXPRESSION
; FILE REFERENCE: HTS-0033
; CURRENT APPLICATION NUMBER: US/10/303,326
; CURRENT FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-303-326-30

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      37 GTGCGCGCGTCAGAGCCGC 56
Db      20 GTGCGCGCCATCAAGCCGC 1

RESULT 269
US-10-303-326-60
; Sequence 60, Application US/10303326
; Publication No. US20040101849A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF SELENOPROTEIN W EXPRESSION
; FILE REFERENCE: HTS-0033
; CURRENT APPLICATION NUMBER: US/10/303,326
; CURRENT FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-303-326-60

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      37 GTGCGCGCGTCAGAGCCGC 56
Db      1 GTGCGCGCCATCAAGCCGC 20

RESULT 270
US-10-304-125-30
; Sequence 30, Application US/10304125
; Publication No. US20040102405A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF SQUALENE SYNTHASE EXPRESSION
; FILE REFERENCE: PTS-0056
; CURRENT APPLICATION NUMBER: US/10/304,125
; CURRENT FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 145
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
```

```
US-10-304-125-30
Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 973 ACAGCTGGGATGTGGGCGAG 992
||| ||||| ||||| |||||
Db 1 ACATCTGGGATGTGGTGCAG 20

RESULT 271
US-10-304-125-100/c
; Sequence 100, Application US/10304125
; Publication No. US20040102405A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF SQUALENE SYNTHASE EXPRESSION
; FILE REFERENCE: PTS-0056
; CURRENT APPLICATION NUMBER: US/10/304,125
; CURRENT FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 145
; SEQ ID NO 100
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-304-125-100

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 973 ACAGCTGGGATGTGGGCGAG 992
||| ||||| ||||| |||||
Db 20 ACATCTGGGATGTGGTGCAG 1

RESULT 272
US-10-688-706-2869
; Sequence 2869, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Brochat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; CURRENT FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 3071
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 2869
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GFAT antisense
US-10-688-706-2869

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 845 GATCAAAATTCATTTCAGC 864
||| ||| ||||| |||||
Db 1 GATAAATATGTCATTTCAGC 20

US-10-304-019-23/c
; Sequence 23, Application US/10304019
; Publication No. US20040102622A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF HEPATOCYTE GROWTH FACTOR RECEPTOR EXPRESSION
; FILE REFERENCE: PTS-0043
; CURRENT APPLICATION NUMBER: US/10/304,019
; CURRENT FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-304-019-23

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1664 TACTTCCAAATTCCTGTGAT 1683
||| ||||| ||||| |||||
Db 20 TCCITTCCAAATACTTTGAT 1

RESULT 274
US-10-304-019-94
; Sequence 94, Application US/10304019
; Publication No. US20040102622A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF HEPATOCYTE GROWTH FACTOR RECEPTOR EXPRESSION
; FILE REFERENCE: PTS-0043
; CURRENT APPLICATION NUMBER: US/10/304,019
; CURRENT FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 147
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-304-019-94

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1664 TACTTCCAAATTCCTGTGAT 1683
||| ||||| ||||| |||||
Db 1 TCCITTCCAAATACTTTGAT 20

RESULT 275
US-10-318-819A-64/c
; Sequence 64, Application US/10318819A
; Publication No. US20040115645A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DRK2 EXPRESSION
; FILE REFERENCE: PTS-0069
; CURRENT APPLICATION NUMBER: US/10/318,819A
; CURRENT FILING DATE: 2002-12-12
; NUMBER OF SEQ ID NOS: 133
; SEQ ID NO 64
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-318-819A-64

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 501 CTTGGCAGCAGCATTGGGAC 520
Db 20 CTTGGCTACAGCAGTGGGAC 1

RESULT 276
US-10-318-819A-120
; Sequence 120, Application US/10318819A
; Publication No. US20040115645A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DRAX2 EXPRESSION
; FILE REFERENCE: PTS-0069
; CURRENT APPLICATION NUMBER: US/10/318,819A
; CURRENT FILING DATE: 2002-12-12
; NUMBER OF SEQ ID NOS: 133
; SEQ ID NO 120
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-318-819A-120

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 501 CTTGGCAGCAGCATTGGGAC 520
Db 1 CTTGGCTACAGCAGTGGGAC 20

RESULT 277
US-10-712-795-261/c
; Sequence 261, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-05-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 261
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-712-795-261

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 780 AAAATTCCAAACGCTGTAT 799
Db 20 AAAATTCAAACGCTATAT 1

RESULT 278
US-10-712-795-627
; Sequence 627, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-05-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 627
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-712-795-627

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 780 AAAATTCCAAACGCTGTAT 799
Db 1 AAAATTCAAACGCTATAT 20

RESULT 279
US-10-712-795-835
; Sequence 835, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-05-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 835
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-712-795-835

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 167 ATGCAAGAAATGGCATCTCTA 186
Db 1 ATGGAAGACTGGCAGCTCTA 20

RESULT 280
US-10-712-795-880/c
; Sequence 880, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
```



```
US-10-920-612-835
;
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
US-10-838-659-57
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 167 ATGCAGATGGCATCTCTA 186
Db 1 ATGGAAGACTGGCAGCTCTA 20
RESULT 285
US-10-920-612-880/c
; Sequence 880, Application US/10920612
; Publication No. US2005009088A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39634A
; CURRENT APPLICATION NUMBER: US/10/920,612
; CURRENT FILING DATE: 2004-08-17
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-11-15
; PRIOR APPLICATION NUMBER: US 10/712,795
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 880
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-920-612-880
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 941 AGAACAGGTTGTACTGTCTA 960
Db 20 AGAACAGGAGTCTGTCTA 1
RESULT 286
US-10-838-659-57/c
; Sequence 57, Application US/10838659
; Publication No. US20050032734A1
; GENERAL INFORMATION:
; APPLICANT: Davis, Heather L.
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schorr, Joachim
; APPLICANT: Wu, Tong
; TITLE OF INVENTION: Vectors and Methods for Immunization or
; FILE REFERENCE: C1039.700570US01
; CURRENT APPLICATION NUMBER: US/10/838,659
; CURRENT FILING DATE: 2004-05-03
; PRIOR APPLICATION NUMBER: US 09/965,101
; PRIOR FILING DATE: 2001-09-26
; PRIOR APPLICATION NUMBER: US 09/082,649
; PRIOR FILING DATE: 1998-05-20
; PRIOR APPLICATION NUMBER: US 60/047,233
; PRIOR FILING DATE: 1997-05-20
; PRIOR APPLICATION NUMBER: US 60/047,209
; PRIOR FILING DATE: 1997-05-20
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-22
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 346 ACCAGAGAAAGCCATCCAA 365
Db 20 ACCAGAGAAAGCCATCCAA 1
RESULT 288
US-10-831-901A-1686
; Sequence 1686, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-22
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 29 CCGCTCTCGCGCCGCTC 48
Db 20 CCGCGCGCGCGCGCGCC 1
RESULT 287
US-10-831-901A-22/c
; Sequence 22, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda P.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-22
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 346 ACCAGAGAAAGCCATCCAA 365
Db 20 ACCAGAGAAAGCCATCCAA 1
RESULT 288
US-10-831-901A-1686
; Sequence 1686, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
```

```
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1686
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1686

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      809 AGATGCGAAGATGATGCA 828
      ||||| ||||| ||||| |||||
Db      1 AGATGCCAAATGATGGCA 20

RESULT 289
US-10-831-901A-1687
; Sequence 1687, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1686
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1686

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      809 AGATGCGAAGATGATGCA 828
      ||||| ||||| ||||| |||||
Db      1 AGATGCCAAATGATGGCA 20

RESULT 289
US-10-831-901A-1687
; Sequence 1687, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1686
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1686
```

```
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1687
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1687

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      808 AAGATGCGAAGATGATGCA 827
      ||||| ||||| ||||| |||||
Db      1 AAGATGCCAAATGATGGCA 20

RESULT 290
US-10-831-901A-8645
; Sequence 8645, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8645
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-8645

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      816 GAAATGATGTCAGAAATGCC 835
      ||||| ||||| ||||| |||||
Db      1 GAAATGATGTCAGATGAC 20

RESULT 291
US-10-831-901A-8648
```

```
; Sequence 8648, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT FILING DATE: 2004-04-26
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8648
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-8648

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      813 GCAGAAATGATGTCACGAAT 832
Db      1 GTAGAAATGATGTCACGAGT 20

RESULT 292
US-10-831-901A-11564/c
; Sequence 11564, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT FILING DATE: 2004-04-26
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11564
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-11564

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      813 GCAGAAATGATGTCACGAAT 832
Db      1 GTAGAAATGATGTCACGAGT 20
```

```
; Sequence 8648, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT FILING DATE: 2004-04-26
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11564
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-11564

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1445 TGTGCTGCTGCTGTTGGG 1464
Db      20 TGTGCTGCTGCTACTTTGG 1

RESULT 293
US-10-831-901A-11565/c
; Sequence 11565, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT FILING DATE: 2004-04-26
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11565
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-11565

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

Qy 1446 GTTCTGCTGCTGTTGGC 1465
Db 20 GTTCTGCTGCTACTTGGC 1

RESULT 294

US-10-831-901A-21448
; Sequence 21448, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 21448
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-21448

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1616 CTTCAAGCACTCTATT 1635
Db 1 CTTGAACCACTCTGTT 20

RESULT 295

US-10-831-901A-23367
; Sequence 23367, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 25435
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-21448

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1616 CTTCAAGCACTCTATT 1635
Db 1 CTTGAACCACTCTGTT 20

RESULT 295

US-10-831-901A-23367
; Sequence 23367, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 25435
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-21448

FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23367
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-23367

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1774 TCTTAAAAACATTGTTCCA 1793
Db 1 TCTGGAATACATTGTTCCA 20

RESULT 296

US-10-831-901A-25435
; Sequence 25435, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 25435
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-21448

```
; OTHER INFORMATION: Antisense compound
US-10-831-901A-25435

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1820 TTTGGAAGATCTCTGAAAA 1839
      ||||| || ||||| |||||
Db 1 TTTGGTAGCGCTCTGAAAAA 20

RESULT 297
US-10-831-901A-25436
; Sequence 25436, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25436
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-25436

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1819 TTTTGAAGATCTCTGAAAA 1838
      ||||| || ||||| |||||
Db 1 TTTTGGTAGCGCTCTGAAAA 20

RESULT 298
US-10-663-451-166
; Sequence 166, Application US/10663451
; Publication No. US20050101555A1
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 7 EXPRESSION
; FILE REFERENCE: RTS-0201
; CURRENT APPLICATION NUMBER: US/10/663,451
```

```
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US/09/659,860A
; PRIOR FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 174
; SEQ ID NO 166
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-663-451-166

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1528 AAAGAAACGTTTTCATGCTT 1547
      ||||| ||||| ||||| |||||
Db 1 AAGGAAACCTTTTCATGCCT 20

RESULT 299
US-10-182-049-151/c
; Sequence 151, Application US/10182049
; Publication No. US20050113322A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION
; FILE REFERENCE: RTSP-0360
; CURRENT APPLICATION NUMBER: US/10/182,049
; CURRENT FILING DATE: 2002-07-27
; PRIOR APPLICATION NUMBER: 09/490,208
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 182
; SEQ ID NO 151
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-182-049-151

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 385 AGCAAGATGGCTGGAGAA 404
      ||||| ||||| ||||| |||||
Db 20 ACCAAGATGGCTGGAGGAA 1

RESULT 300
US-10-830-484-4/c
; Sequence 4, Application US/10830484
; Publication No. US20040220397A1
; GENERAL INFORMATION:
; APPLICANT: Leuck, Michael
; APPLICANT: Wolter, Andreas
; TITLE OF INVENTION: Solid Support For The Synthesis Of 3' Amino Oligonucleotides
; FILE REFERENCE: PRO13
; CURRENT APPLICATION NUMBER: US/10/830,484
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,269
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial
```

```
; FEATURE:
; OTHER INFORMATION: Synthetic Nucleic Acid Ligand
US-10-830-484-4

Query Match          0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 301
US-10-755-118-3/c
; Sequence 3, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: NH2
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Acr1
US-10-755-118-4

Query Match          0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 303
US-10-755-118-31/c
; Sequence 31, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 31
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: NH2
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Hydrogen
US-10-755-118-3

Query Match          0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 302
US-10-755-118-4/c
; Sequence 4, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
```


FEATURE:
OTHER INFORMATION: Synthetic Construct
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: BHA resins
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(15)
OTHER INFORMATION: (2'-aminoethyl)glycine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: text-butoxycarbonyl
US-10-755-118-38

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 307
US-10-755-118-39/c
; Sequence 39, Application US/10755118
; Publication No. US20050009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
OTHER INFORMATION: Synthetic Construct
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: BHA resin
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(15)
OTHER INFORMATION: (2'-aminoethyl)glycine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: Acrl
US-10-755-118-39

Query Match 0.8%; Score 15; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 308
US-10-755-118-40/c
; Sequence 40, Application US/10755118
; Publication No. US20050009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
OTHER INFORMATION: Synthetic Construct
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(1)
OTHER INFORMATION: BHA resin
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)..(15)
OTHER INFORMATION: (2'-aminoethyl)glycine
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: Hydrogen
US-10-755-118-40

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 309
US-10-755-118-43/c
; Sequence 43, Application US/10755118
; Publication No. US20050009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik

```
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: NH2
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Hydrogen
; OTHER INFORMATION:
US-10-755-118-43

Query Match          0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 310
US-10-755-118-44/c
; Sequence 44, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 45
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys (Cl2)-BHA resin
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc_feature
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys-NH2
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Acrl
; OTHER INFORMATION:
US-10-755-118-44

Query Match          0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 311
US-10-755-118-45/c
; Sequence 45, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 45
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys (Cl2)-BHA resin
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc_feature
```

```

; LOCATION: (15)..(15)
; OTHER INFORMATION: tert-butoxycarbonyl
US-10-755-118-45

Query Match
Best Local Similarity 0.8%; Score 15; DB 1; Length 15;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
DB 15 AAAAAAAAAAAAAA 1

RESULT 312
US-10-755-118-48/c
; Sequence 48, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Bigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 48
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys (Cl2)-BHA resin
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Hydrogen
; US-10-755-118-49

Query Match
Best Local Similarity 0.8%; Score 15; DB 1; Length 15;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
DB 15 AAAAAAAAAAAAAA 1

RESULT 313
US-10-755-118-49/c
; Sequence 49, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Bigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys (Cl2)-BHA resin
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Acrl
; US-10-755-118-48

Query Match
Best Local Similarity 0.8%; Score 15; DB 1; Length 15;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
DB 15 AAAAAAAAAAAAAA 1

RESULT 313
US-10-755-118-49/c
; Sequence 49, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Bigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys (Cl2)-BHA resin
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Hydrogen
; US-10-755-118-49

Query Match
Best Local Similarity 0.8%; Score 15; DB 1; Length 15;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
DB 15 AAAAAAAAAAAAAA 1

RESULT 314
US-10-770-989-9/c
; Sequence 9, Application US/10770989
; Publication No. US20050019789A1
; GENERAL INFORMATION:
; APPLICANT: Ankenbauer, Waltraud
; APPLICANT: Schmitz-Agheguyan, Gudrun
; APPLICANT: Bonch-Osmolovskaya, Elizaveta
; APPLICANT: Svetlichny, Vitaly
; APPLICANT: Markau, Ursula
; APPLICANT: Augerer, Bernhard
; APPLICANT: Reiser, Astrid
; APPLICANT: Roche Molecular Systems, Inc.
; TITLE OF INVENTION: Thermostable DNA Polymerase from Anaerocellum
; FILE REFERENCE: 022101-000610US
; CURRENT APPLICATION NUMBER: US/10/770,989
; CURRENT FILING DATE: 2004-02-02
; PRIOR APPLICATION NUMBER: EP 96115877.1
; PRIOR FILING DATE: 1996-10-03
; PRIOR APPLICATION NUMBER: WO PCT/EP97/05390

```

; PRIOR FILING DATE: 1997-10-01
; PRIOR APPLICATION NUMBER: US 09/269,858
; PRIOR FILING DATE: 1999-06-10
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: (dt) -15,
; OTHER INFORMATION: oligo dt primer
US-10-770-989-9

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 315
US-10-833-502-9/c
; Sequence 9, Application US/10833502
; Publication No. US20050026279A1
; GENERAL INFORMATION:
; APPLICANT: TSENG, SCHEFFER C.G.
; APPLICANT: ESPANA, EDGAR M.
; TITLE OF INVENTION: SURGICAL GRAFTS AND METHODS OF PREPARATION
; FILE REFERENCE: TIS-107
; CURRENT APPLICATION NUMBER: US/10/833,502
; PRIOR FILING DATE: 2002-04-28
; PRIOR APPLICATION NUMBER: 60/465,989
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/473,007
; PRIOR FILING DATE: 2003-05-22
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 9
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-833-502-9

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 316
US-10-939-214-54/c
; Sequence 54, Application US/10939214
; Publication No. US20050026817A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; TITLE OF INVENTION: PREPARATION AND USE
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/10/939,214
; CURRENT FILING DATE: 2004-09-10
; PRIOR APPLICATION NUMBER: US/09/793,146
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14

; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 54
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-10-939-214-54

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 317
US-10-939-214-55/c
; Sequence 55, Application US/10939214
; Publication No. US20050026817A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; TITLE OF INVENTION: PREPARATION AND USE
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/10/939,214
; CURRENT FILING DATE: 2004-09-10
; PRIOR APPLICATION NUMBER: US/09/793,146
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 55
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-10-939-214-55

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 318
US-10-601-140A-5/c
; Sequence 5, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45

```
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 5
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified base
; LOCATION: (1)..(15)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-5

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 319
US-10-601-140A-16/c
; Sequence 16, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601.140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-16

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 320
US-10-601-140A-19/c
; Sequence 19, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601.140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
```

```
; SEQ ID NO 19
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-19

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 321
US-10-239-919A-4/c
; Sequence 4, Application US/10239919A
; Publication No. US20050054831A1
; GENERAL INFORMATION:
; APPLICANT: HWANG, IN-HWAN
; APPLICANT: LIM, JEONG-HWA
; APPLICANT: PIH, KYOUNG-TAE
; TITLE OF INVENTION: AN OSMOTIC STRESS-INDUCIBLE PROTEIN FUNCTIONING AS A
; TITLE OF INVENTION: NEGATIVE REGULATOR IN OSMOTIC STRESS SIGNALING PATHWAY
; FILE REFERENCE: 7022-0004
; CURRENT APPLICATION NUMBER: US/10/239,919A
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/KR02/00152
; PRIOR FILING DATE: 2002-02-01
; PRIOR APPLICATION NUMBER: KR 2001/5097
; PRIOR FILING DATE: 2001-02-02
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-239-919A-4

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1
```

RESULT 322

US-10-938-661A-22/c

; Sequence 22, Application US/10938661A

; Publication No. US20050070000A1

; GENERAL INFORMATION:

; APPLICANT: Pecker, Iris

; APPLICANT: Michal, Israel

; APPLICANT: Itzhaki, Hanan

; TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES ENCODED THEREBY DISTANTLY

; FILE REFERENCE: 3462.1003-000

; CURRENT APPLICATION NUMBER: US/10/938,661A

; PRIOR FILING DATE: 2004-09-13

; NUMBER OF SEQ ID NOS: 25

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 22

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Artificial sequence

; FEATURE:

; OTHER INFORMATION: Synthetic oligonucleotide

US-10-938-661A-22

Query Match 0.8%; Score 15; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1835 AAAAAAAAAAAAAA 1849

Db

15 AAAAAAAAAAAAAA 1

RESULT 323

US-10-238-700-1285/c

; Sequence 1285, Application US/10238700

; Publication No. US2003013521A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level

; FILE REFERENCE: 400/057 (MHB01-1158-A)

; CURRENT APPLICATION NUMBER: US/10/238,700

; PRIOR FILING DATE: 2002-09-18

; PRIOR APPLICATION NUMBER: PCT/US 02/16840

; PRIOR FILING DATE: 2002-05-29

; PRIOR APPLICATION NUMBER: US 60/318,471

; NUMBER OF SEQ ID NOS: 4666

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1285

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-238-700-1285

Query Match

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1443 AATGTCGCTGCTGCT 1457

Db

16 AATGTCGCTGCTGCT 2

RESULT 324

US-10-608-863-3/c

; Sequence 3, Application US/10608863

; Publication No. US20040214192A1

; GENERAL INFORMATION:

; APPLICANT: Hashida, Ryoichi

; APPLICANT: Kagaya, Shinji

; APPLICANT: Yayoi, Yoshihiro

; APPLICANT: Sugita, Yuji

; APPLICANT: Saito, Hirohisa

; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREAT

; FILE REFERENCE: 3462.1003-000

; CURRENT APPLICATION NUMBER: US/10/608,863

; PRIOR FILING DATE: 2003-06-27

; PRIOR APPLICATION NUMBER: JP 2002-188490

; NUMBER OF SEQ ID NOS: 18

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 3

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence:Artificially

; OTHER INFORMATION: Synthesized Primer Sequence

US-10-608-863-3

Query Match 0.8%; Score 15; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1835 AAAAAAAAAAAAAA 1849

Db

16 AAAAAAAAAAAAAA 2

RESULT 325

US-10-608-863-5/c

; Sequence 5, Application US/10608863

; Publication No. US20040214192A1

; GENERAL INFORMATION:

; APPLICANT: Hashida, Ryoichi

; APPLICANT: Kagaya, Shinji

; APPLICANT: Yayoi, Yoshihiro

; APPLICANT: Sugita, Yuji

; APPLICANT: Saito, Hirohisa

; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREAT

; FILE REFERENCE: 3462.1003-000

; CURRENT APPLICATION NUMBER: US/10/608,863

; PRIOR FILING DATE: 2003-06-27

; PRIOR APPLICATION NUMBER: JP 2002-188490

; NUMBER OF SEQ ID NOS: 18

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 5

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence:Artificially

; OTHER INFORMATION: Synthesized Primer Sequence

US-10-608-863-5

Query Match

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1835 AAAAAAAAAAAAAA 1849

Db

16 AAAAAAAAAAAAAA 2

RESULT 326

US-10-724-270-1285/c

; Sequence 1285, Application US/10724270

; Publication No. US20050080031A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE OF INVENTION: RAS, HER2 and HIV
; FILE REFERENCE: 400/046-US (MHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1285
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-1285

Query Match 0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1443 AATGTTGCTGCTGCT 1457
Db 16 AATGTTGCTGCTGCT 2

RESULT 327
US-10-644-052A-376/c
; Sequence 376, Application US/10644052A
; Publication No. US20050059619A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M
; APPLICANT: Samulowitz, Ulrike
; APPLICANT: Vollmer, Joerg
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Jurk, Marion
; APPLICANT: Lipford, Grayson
; APPLICANT: Rankin, Robert
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS
; FILE REFERENCE: C1037.70048US00
; CURRENT APPLICATION NUMBER: US/10/644,052A
; CURRENT FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: US 60/404,479
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/404,820
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/429,701
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: US 60/447,377
; PRIOR FILING DATE: 2003-02-14
; NUMBER OF SEQ ID NOS: 388
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 377
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligodeoxynucleotide
US-10-644-052A-377

Query Match 0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 20 AAAAAAAAAAAAAA 6

RESULT 329
US-10-479-472A-8/c
; Sequence 8, Application US/10479472A
; Publication No. US20050118581A1
; GENERAL INFORMATION:
; APPLICANT: DEL-FAVERO, JURGEN PETER LODE
; APPLICANT: VAN BROECKHOVEN, CHRISTINE
; TITLE OF INVENTION: NOVEL BRAIN EXPRESSED GENE AND PROTEIN ASSOCIATED WITH
; FILE REFERENCE: JAB-1711
; CURRENT APPLICATION NUMBER: US/10/479,472A
; CURRENT FILING DATE: 2003-12-01
; PRIOR APPLICATION NUMBER: PCT/EP02/06316
; PRIOR FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 388
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 376
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligodeoxynucleotide
US-10-479-472A-377
```

; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Illustrative
; OTHER INFORMATION: oligonucleotide
US-10-479-472A-8

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 29 CCGCCTCCGTCGCGCGCG 46
||||| ||||| ||||| |||||
Db 18 CCGCGCGCGCGCGCGCG 1

RESULT 330

US-10-479-472A-9
; Sequence 9, Application US/10479472A
; Publication No. US20050118581A1
; GENERAL INFORMATION:
; APPLICANT: DEL-FAVERO, JURGEN PETER LODE
; APPLICANT: VAN BROECKHOVEN, CHRISTINE
; TITLE OF INVENTION: NOVEL BRAIN EXPRESSED GENE AND PROTEIN ASSOCIATED WITH
; TITLE OF INVENTION: BIPOLAR DISORDER
; FILE REFERENCE: JAB-1711
; CURRENT APPLICATION NUMBER: US/10/479,472A
; CURRENT FILING DATE: 2003-12-01
; PRIOR APPLICATION NUMBER: PCT/EP02/06316
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: EP 01202214.1
; PRIOR FILING DATE: 2001-06-11
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Illustrative
; OTHER INFORMATION: oligonucleotide
US-10-479-472A-9

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 29 CCGCCTCCGTCGCGCGCG 46
||||| ||||| ||||| |||||
Db 1 CCGCGCGCGCGCGCGCG 18

RESULT 331

US-10-349-143-6888/c
; Sequence 6888, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020Cp1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732

; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6888
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-21057 for SEQ 2954,
US-10-349-143-6888

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 GTTGTTTCTTATGTTGTT 1484
||||| ||||| ||||| |||||
Db 19 GTTCTTCTTATGTTGTT 2

RESULT 332

US-10-349-143-7139/c
; Sequence 7139, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020Cp1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7139
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-24768 for SEQ 3205,
US-10-349-143-7139

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1629 CTCATTTCATGCTTTCT 1646
||||| ||||| ||||| |||||
Db 19 CTCCTTCTTCTGCTTCT 2

RESULT 333

US-10-830-569-307
; Sequence 307, Application US/10830569
; Publication No. US20050054598A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: MCSwaggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; TITLE OF INVENTION: Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/153 (MBHB04-378-A)


```
; CURRENT APPLICATION NUMBER: US/10/830,569
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 307
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-830-569-307

Query Match          0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 2.5e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1829 TCTCTGAAAAA 1846
Db 2 UUGUGAAAAA 19

RESULT 334
US-10-569-614/c
; Sequence 614, Application US/10830569
; Publication No. US2005054598A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; FILE REFERENCE: 400/153 (MHRB04-378-A)
; CURRENT APPLICATION NUMBER: US/10/830,569
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
```

```
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 614
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-830-569-614

Query Match          0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1829 TCTCTGAAAAA 1846
Db 18 TTTCTGAAAAA 1

RESULT 335
US-10-840-731-35
; Sequence 35, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MHRB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 35
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-840-731-35

Query Match          0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 2.5e+02;
Matches 8; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1814 TAAATTTTGAAGACTCT 1831
Db 1 UAAAUUUUGGAGGAUGU 18
```

```
RESULT 336
US-10-840-731-130/c
; Sequence 130, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/155 (MBHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 130
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-840-731-130

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1814 TAAATTTTGGAGATCT 1831
Db 19 TAAATTTTGGAGATGT 2

RESULT 337
US-10-863-973-694
; Sequence 694, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Polisky, Barry
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 130
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-840-731-130

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1814 TAAATTTTGGAGATCT 1831
Db 19 TAAATTTTGGAGATGT 2

RESULT 338
US-10-863-973-765/c
; Sequence 765, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Polisky, Barry
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1832
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 694
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
```

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 765
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-863-973-765

Query Match          0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 820 TGATGTCGAAGTGCCTT 837
Db 19 TGATGTCGAAGTGCCTT 2

RESULT 339
US-10-164-915-3
; Sequence 3, Application US/10164915
; Publication No. US20030148391A1
; GENERAL INFORMATION:
; APPLICANT: Salafsky, Joshua S.
; TITLE OF INVENTION: Method using a Surface-Selective No. US20030148391A1linear Optica
; FILE REFERENCE: 11100-035-999
; CURRENT APPLICATION NUMBER: US/10/164,915
; CURRENT FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: 60/253,862
; PRIOR FILING DATE: 2000-11-29
; PRIOR APPLICATION NUMBER: 60/260,249
; PRIOR FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 60/265,775
; PRIOR FILING DATE: 2001-02-01
; PRIOR APPLICATION NUMBER: 60/278,941
; PRIOR FILING DATE: 2001-01-27
; NUMBER OF SEQ ID NOS: 6
; SEQ ID NO 3
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Oligonucleotide structure fo
US-10-164-915-3

Query Match          0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1834 GAAAAAACAACAAAAA 1849
Db 1 GAAAAAACAACAAAAA 16

RESULT 340
US-09-866-108-8364
; Sequence 8364, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
```

```
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8364
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8364

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 395 GCTGGAGAAAGTGCAC 410
Db 2 GCTGGAGAAAGTGCAC 17

RESULT 341
US-09-866-108-8365
; Sequence 8365, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8365
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8365

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 395 GCTGGAGAAAGTTCAC 410
|||||
Db 1 GCTGGAGAAAGTGCAC 16

RESULT 342

US-09-866-108-10030/c
; Sequence 10030, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10030
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10030

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1065 CGTCCAAAGAGGACTC 1080
|||||
Db 17 CGTCCACAGAGGACTC 2

RESULT 343

US-09-866-108-10031/c
; Sequence 10031, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752

```

; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10031
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10031

```

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. NO. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1065 CGTCCAAAGAGGACTC 1080
|||
Db 16 CGTCCACAGAGGACTC 1

RESULT 344
US-09-927-046-1622/c
; Sequence 1622; Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc
APPLICANT: McSwiggen, Jim
APPLICANT: Thompson, Jim
APPLICANT: McKenzie, Tim
APPLICANT: Avers, Dave
APPLICANT: Grupe, Andrew
APPLICANT: Szymkowski, Edmund
TITLE OF INVENTION: Method and Reagent for
TITLE OF INVENTION: Channel-1
FILE REFERENCE: 249/021

```

; SEQUENCE: 293/071
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5401
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1622
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1622

```

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1152 GTAAATATTTCCTCAACT 1167
|||
Db 16 GTAAATATTTCCTCATCT 1

RESULT 345
US-09-877-478-265/c
; Sequence 265, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:

GENERAL INFORMATION:
APPLICANT: Rhozyme Pharmaceuticals, Inc.
APPLICANT: Drapet, Kenneth
APPLICANT: Blatt, Larry
APPLICANT: McGswiggen, Jim
APPLICANT: Morrissey, Dave
TITLE OF INVENTION: Method and Reagent for
FILE REFERENCE: MBH00-845-H (400/029)
CURRENT APPLICATION NUMBER: US/09/877,478
CURRENT FILING DATE: 2001-12-31

PRIOR APPLICATION NUMBER: US 07/882,712	
PRIOR FILING DATE: 1992-05-14	
PRIOR APPLICATION NUMBER: US 09/531,025	
PRIOR FILING DATE: 2000-03-20	
PRIOR APPLICATION NUMBER: US 09/636,385	
PRIOR FILING DATE: 2000-08-09	
PRIOR APPLICATION NUMBER: US 09/696,347	
PRIOR FILING DATE: 2000-10-24	
PRIOR APPLICATION NUMBER: US 08/193,627	

RESULT 347
US-09-848-

US-09-848-754A-2911

```

; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 285
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
; US-09-877-478-265

```

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels

QY 530 AGGCATTACAGCAGAA 545
D6 17 AGGCATTAAAGCAGAA 2

RESULT 346

; Sequence 267. Application US/09877478
 ; Publication No. US20030068301A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Dr. Kenneth

APPLICANT: Draper, Kenneth
APPLICANT: Blatt, Larry
APPLICANT: McSwiggen, Jim
APPLICANT: Morrissey, Dave
TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
FILE REFERENCE: MBHB00-845-H (400/029)
CURRENT APPLICATION NUMBER: US/09/877,478
CURRENT FILING DATE: 2001-12-31
PRIOR APPLICATION NUMBER: US 07/882,712
PRIOR FILING DATE: 1932-05-14

```

, PRIOR APPLICATION NUMBER: US 09/531,026
, PRIOR FILING DATE: 2000-03-20
, PRIOR APPLICATION NUMBER: US 09/636,385
, PRIOR FILING DATE: 2000-08-09
, PRIOR APPLICATION NUMBER: US 09/696,347
, PRIOR FILING DATE: 2000-10-24
, PRIOR APPLICATION NUMBER: US 08/193,627
, PRIOR FILING DATE: 1994-02-07
, PRIOR APPLICATION NUMBER: US 08/433,993
, PRIOR FILING DATE: 1995-05-04
, PRIOR APPLICATION NUMBER: US 08/434,504
, PRIOR FILING DATE: 1995-05-04
, PRIOR APPLICATION NUMBER: US 09/436,430
, PRIOR FILING DATE: 1999-11-08
, NUMBER OF SEQ ID NOS: 6586
, SOFTWARE: PatentIn version 3.0
, SEQ ID NO 267
, LENGTH: 17
, TYPE: RNA
, ORGANISM: Hepatitis B virus
US-09-877-478-267

```

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels

Qy 529 AAGGCATTACAGCAGA 544
|||
Db 16 AAGGCATTAAAGCAGA 1

RESULT 347
US-09-848-

US-09-848-754A-2911

```
; Sequence 2911, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2911
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2911

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.2e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1327 ACTTTGGATCCCAAGC 1342
   ||::|||:|||||
Db 1 ACCUUGGAUCCAAGC 16

RESULT 348
US-09-848-754A-3506
; Sequence 3506, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3506
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3506

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.2e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1327 ACTTTGGATCCCAAGC 1342
   ||::|||:|||||
Db 2 ACCUUGGAUCCAAGC 17

RESULT 349
US-09-780-164-1033
; Sequence 1033, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1033
; LENGTH: 17
; TYPE: RNA
```

```
; ORGANISM: Homo sapiens
US-09-780-164-1033

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 202 AAATAAAGAGGAAT 217
   |||:|||||:
Db 1 AAUAAAGAGGAAGU 16

RESULT 350
US-09-740-332-1266/c
; Sequence 1266, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1266
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1266

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1005 GATGGCGGTGGAGCCT 1020
   |||||:|||||
Db 17 GATGGCGGTGGAGCCT 2

RESULT 351
US-09-740-332-1414/c
; Sequence 1414, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1414
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1414

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1173 CTGGTGAGTGTCTG 1188
   |||||:|||||
```

Db 16 CTGGTGATGGAGGCTG 1

RESULT 352

US-09-740-332-3289

Sequence 3289, Application US/09740332

Publication No. US20030125270A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals Inc.

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection

FILE REFERENCE: RPI 400/003

CURRENT APPLICATION NUMBER: US/09/740,332

CURRENT FILING DATE: 2001-03-26

NUMBER OF SEQ ID NOS: 26

SOFTWARE: PatentIn version 3.0

SEQ ID NO 3289

LENGTH: 17

TYPE: RNA

ORGANISM: artificial sequence

FEATURE:

NAME/KEY: misc_feature

LOCATION:

OTHER INFORMATION: oligonucleotide substrate

US-09-740-332-3289

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 2.2e+02;

Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1005 GATGGCGGTGGAGCCT 1020

Db 2 GAUGGGGUGGAGCCU 17

RESULT 353

US-09-817-879-1266/c

Sequence 1266, Application US/09817879

Publication No. US2003017131A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals Inc.

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection

FILE REFERENCE: MBH00-801-F

CURRENT APPLICATION NUMBER: US/09/817,879

CURRENT FILING DATE: 2001-03-26

NUMBER OF SEQ ID NOS: 9703

SOFTWARE: PatentIn version 3.0

SEQ ID NO 1266

LENGTH: 17

TYPE: RNA

ORGANISM: artificial sequence

FEATURE:

NAME/KEY: misc_feature

LOCATION:

OTHER INFORMATION: oligonucleotide substrate

US-09-817-879-1266

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1005 GATGGCGGTGGAGCCT 1020

Db 17 GATGGGGGTGGAGCCT 2

RESULT 354

US-09-817-879-1414/c

Sequence 1414, Application US/09817879

Publication No. US2003017131A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals Inc.

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection

FILE REFERENCE: MBH00-801-F

CURRENT APPLICATION NUMBER: US/09/817,879

CURRENT FILING DATE: 2001-03-26

NUMBER OF SEQ ID NOS: 9703

SOFTWARE: PatentIn version 3.0

SEQ ID NO 1414

LENGTH: 17

TYPE: RNA

ORGANISM: artificial sequence

FEATURE:

NAME/KEY: misc_feature

LOCATION:

OTHER INFORMATION: oligonucleotide substrate

US-09-817-879-1414

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1173 CTGGTGATGGAGCTG 1188

Db 16 CTGGTGATGGAGGCTG 1

RESULT 355

US-09-817-879-3289

Sequence 3289, Application US/09817879

Publication No. US2003017131A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals Inc.

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection

FILE REFERENCE: MBH00-801-F

CURRENT APPLICATION NUMBER: US/09/817,879

CURRENT FILING DATE: 2001-03-26

NUMBER OF SEQ ID NOS: 9703

SOFTWARE: PatentIn version 3.0

SEQ ID NO 3289

LENGTH: 17

TYPE: RNA

ORGANISM: artificial sequence

FEATURE:

NAME/KEY: misc_feature

LOCATION:

OTHER INFORMATION: oligonucleotide substrate

US-09-817-879-3289

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1005 GATGGCGGTGGAGCCT 1020

Db 2 GAUGGGGUGGAGCCU 17

RESULT 356

US-10-238-700-1286/c

Sequence 1286, Application US/10238700

Publication No. US2003015321A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level 1

FILE REFERENCE: 400/057 (MBH01-1158-A)

CURRENT APPLICATION NUMBER: US/10/238,700

CURRENT FILING DATE: 2002-09-18

PRIOR APPLICATION NUMBER: PCT/US 02/16840

PRIOR FILING DATE: 2002-05-29

PRIOR APPLICATION NUMBER: US 60/318,471

PRIOR FILING DATE: 2001-09-10

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection

FILE REFERENCE: MBH00-801-F

CURRENT APPLICATION NUMBER: US/09/817,879

CURRENT FILING DATE: 2001-03-26

NUMBER OF SEQ ID NOS: 9703

SOFTWARE: PatentIn version 3.0

SEQ ID NO 1414

LENGTH: 17

TYPE: RNA

ORGANISM: artificial sequence

FEATURE:

NAME/KEY: misc_feature

LOCATION:

OTHER INFORMATION: oligonucleotide substrate

US-09-817-879-1414

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 2.2e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1173 CTGGTGATGGAGCTG 1188

Db 16 CTGGTGATGGAGGCTG 1

RESULT 355

US-09-817-879-3289

Sequence 3289, Application US/09817879

Publication No. US2003017131A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals Inc.

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection

FILE REFERENCE: MBH00-801-F

CURRENT APPLICATION NUMBER: US/09/817,879

CURRENT FILING DATE: 2001-03-26

NUMBER OF SEQ ID NOS: 9703

SOFTWARE: PatentIn version 3.0

SEQ ID NO 3289

LENGTH: 17

TYPE: RNA

ORGANISM: artificial sequence

FEATURE:

NAME/KEY: misc_feature

LOCATION:

OTHER INFORMATION: oligonucleotide substrate

US-09-817-879-3289

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 2.2e+02;

Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1005 GATGGCGGTGGAGCCT 1020

Db 2 GAUGGGGUGGAGCCU 17

RESULT 356

US-10-238-700-1286/c

Sequence 1286, Application US/10238700

Publication No. US2003015321A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level 1

FILE REFERENCE: 400/057 (MBH01-1158-A)

CURRENT APPLICATION NUMBER: US/10/238,700

CURRENT FILING DATE: 2002-09-18

PRIOR APPLICATION NUMBER: PCT/US 02/16840

PRIOR FILING DATE: 2002-05-29

PRIOR APPLICATION NUMBER: US 60/318,471

PRIOR FILING DATE: 2001-09-10

```
; NUMBER OF SEQ ID NOS: 4566
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1286
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-1286

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1440 ATGAATGTTGCTGCTG 1455
Db 16 ATTAATGTTGCTGCTG 1

RESULT 357
US-10-342-902-265/c
; Sequence 265, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBHB00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 265
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-265

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 530 AGGCATTACAGCAGAA 545
Db 17 AGGCATTAAAGCAGAA 2

RESULT 358
US-10-342-902-267/c
; Sequence 267, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
```

```
; FILE REFERENCE: 400/075 (MBHB00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 267
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-267

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 529 AAGGCATTACAGCAGA 544
Db 16 AAGGCATTAAAGCAGA 1

RESULT 359
US-10-138-674-4471
; Sequence 4471, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4471
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4471

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1204 TACCCACTGGGCTGCA 1219
Db 2 UACCCACUGGGCAGCA 17

RESULT 360
US-10-138-674-7673/c
; Sequence 7673, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
```



```
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7673
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7673

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1280 CCTCAATATCACTCAG 1295
Db 17 CCTCAATCACTCAG 2

RESULT 361
US-10-138-674-8905
; Sequence 8905, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8905
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8905

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.2e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1566 TCTGCAACTTTGGAAA 1581
Db 2 UCUGCAAAUUGGAAA 17

RESULT 362
US-10-287-949A-4471
; Sequence 4471, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4471
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4471

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1204 TACCACTGGGCTGCA 1219
Db 2 UACCCACUGGCGCAGA 17

RESULT 363
US-10-287-949A-7673/c
; Sequence 7673, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7673
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7673

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1280 CCTCAATATCACTCAG 1295
Db 17 CCTCAATCACTCAG 2

RESULT 364
US-10-287-949A-8905
; Sequence 8905, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8905
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8905

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.2e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1566 TCTGCAACTTTGGAAA 1581
Db 2 UCUGCAAAUUGGAAA 17

RESULT 365
US-10-287-949A-4471
; Sequence 4471, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
```

Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1566 TCTGCACTTTGAAA 1581
:|||||:|||||
Db 2 UCUGCAAAUUGAAA 17

RESULT 365
US-10-669-841-265/c
; Sequence 265, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 265
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-265

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 530 AGGCATTACAGCAA 545
|||||:|||||
Db 17 AGGCATTAAAGCAA 2

RESULT 366
US-10-669-841-267/c
; Sequence 267, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen

; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 267
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-267

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 529 AAGGCATTACAGCAGA 544
|||||:|||||
Db 16 AAGGCATTAAAGCAGA 1

RESULT 367
US-10-669-841-3859/c
; Sequence 3859, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24

;; PRIOR APPLICATION NUMBER: US 60/337,055
;; PRIOR FILING DATE: 2001-12-05
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 09/817,879
;; PRIOR FILING DATE: 2001-03-26
;; PRIOR APPLICATION NUMBER: US 09/740,332
;; PRIOR FILING DATE: 2000-12-18
;; PRIOR APPLICATION NUMBER: US 09/611,931
;; PRIOR FILING DATE: 2000-07-07
;; PRIOR APPLICATION NUMBER: US 09/504,321
;; PRIOR FILING DATE: 2000-02-15
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 16207
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 3859
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION:
;; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-3859

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1005 GATGGCGGTGAGCCT 1020
|||||
Db 17 GATGGCGGTGAGCCT 2

RESULT 368
US-10-669-841-4007/c
;; Sequence 4007, Application US/10669841
;; Publication No. US20040127446A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: Lawrence, Blatt
;; APPLICANT: Dennis, Macejak
;; APPLICANT: James, McSwiggen
;; APPLICANT: David, Morrissey
;; APPLICANT: Pamela, Pavco
;; APPLICANT: Patrice, Lee
;; APPLICANT: Kenneth, Draper
;; APPLICANT: Elisabeth, Roberts
;; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
;; TITLE OF INVENTION: VIRUS REPLICATION
;; FILE REFERENCE: 400/042US (MBH02-249-E)
;; CURRENT APPLICATION NUMBER: US/10/669,841
;; CURRENT FILING DATE: 2003-09-23
;; PRIOR APPLICATION NUMBER: PCT/US02/09187
;; PRIOR FILING DATE: 2002-03-26
;; PRIOR APPLICATION NUMBER: US 60/296,876
;; PRIOR FILING DATE: 2001-06-08
;; PRIOR APPLICATION NUMBER: US 60/335,059
;; PRIOR FILING DATE: 2001-10-24
;; PRIOR APPLICATION NUMBER: US 09/817,879
;; PRIOR FILING DATE: 2001-03-26
;; PRIOR APPLICATION NUMBER: US 09/740,332
;; PRIOR FILING DATE: 2001-12-18
;; PRIOR APPLICATION NUMBER: US 09/611,931
;; PRIOR FILING DATE: 2000-07-07
;; PRIOR APPLICATION NUMBER: US 09/504,321
;; PRIOR FILING DATE: 2000-02-15
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 16207
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 3859
;; LENGTH: 17
;; TYPE: RNA

;; PRIOR APPLICATION NUMBER: US 09/611,931
;; PRIOR FILING DATE: 2000-07-07
;; PRIOR APPLICATION NUMBER: US 09/504,321
;; PRIOR FILING DATE: 2000-02-15
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 16207
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 4007
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION:
;; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4007

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1173 CTGCTGATGGAGTCTG 1188
|||||
Db 16 CTGCTGATGGAGTCTG 1

RESULT 369
US-10-669-841-5882
;; Sequence 5882, Application US/10669841
;; Publication No. US20040127446A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: Lawrence, Blatt
;; APPLICANT: Dennis, Macejak
;; APPLICANT: James, McSwiggen
;; APPLICANT: David, Morrissey
;; APPLICANT: Pamela, Pavco
;; APPLICANT: Patrice, Lee
;; APPLICANT: Kenneth, Draper
;; APPLICANT: Elisabeth, Roberts
;; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
;; TITLE OF INVENTION: VIRUS REPLICATION
;; FILE REFERENCE: 400/042US (MBH02-249-E)
;; CURRENT APPLICATION NUMBER: US/10/669,841
;; CURRENT FILING DATE: 2003-09-23
;; PRIOR APPLICATION NUMBER: PCT/US02/09187
;; PRIOR FILING DATE: 2002-03-26
;; PRIOR APPLICATION NUMBER: US 60/296,876
;; PRIOR FILING DATE: 2001-06-08
;; PRIOR APPLICATION NUMBER: US 60/335,059
;; PRIOR FILING DATE: 2001-10-24
;; PRIOR APPLICATION NUMBER: US 09/817,879
;; PRIOR FILING DATE: 2001-12-05
;; PRIOR APPLICATION NUMBER: US 09/740,332
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 09/611,931
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 09/504,321
;; PRIOR FILING DATE: 2000-07-07
;; PRIOR APPLICATION NUMBER: US 09/504,321
;; PRIOR FILING DATE: 2000-02-15
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 16207
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 5882
;; LENGTH: 17
;; TYPE: RNA

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5882
```

```
Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 1; Indels 0; Gaps 0;
```

```
Qy      1005 GATGGCGGTGAGCCT 1020
      ||:||:||:||:||:||:
Db       2 GAUGGGGGGAGGCCU 17
```

RESULT 370

```
US-10-723-361-8364
; Sequence 8364, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8364
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8365
```

```
Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      395 GCTGGAGAAAGTTTCA 410
      |||||
Db       1 GCTGGAGAAAGTGCAC 16
```

```
RESULT 372
US-10-723-361-10030/c
; Sequence 10030, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
```

```
Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      395 GCTGGAGAAAGTTCA 410
      |||||
Db       2 GCTGGAGAAAGTGCAC 17
```

RESULT 371

```
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10030
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10030

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1065 CGTCCAAAGAGGACTC 1080
Db      17  CGTCCACAGAGGACTC 2

RESULT 373
US-10-723-361-10031/c
; Sequence 10031, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
```

```
; SEQ ID NO 10031
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10031

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1065 CGTCCAAAGAGGACTC 1080
Db      16  CGTCCACAGAGGACTC 1

RESULT 374
US-10-712-633-729/c
; Sequence 729, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 729
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-729

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1280 CCTCAATATCACTCAG 1295
Db      17  CCTCAACATCACTCAG 2

RESULT 375
US-10-712-633-4103
; Sequence 4103, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
```

```
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; FILE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4103
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-4103

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.2e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy      1566 TCCTGCACTTTGAAA 1581
Db      2 UCUGCAAAUUGAAA 17

RESULT 376
US-10-724-270-1286/c
; Sequence 1286, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE OF INVENTION: RAS, HER2 and HIV
; FILE REFERENCE: 400/046-US (MHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1286
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-1286

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1440 ATGAATGTTGCTGCTG 1455
Db      16 ATTAATGTTGCTGCTG 1

RESULT 377
US-09-263-959-1276/c
; Sequence 1276, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 1276:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-263-959-1276

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1335 ATCCAAGCTGGAGTGC 1350
Db      17 ATCCAGGCTGGAGTGC 2

RESULT 378
US-09-995-529-189
; Sequence 189, Application US/09995529
; Publication No. US2003009655A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; APPLICANT: Huse, William D.
; APPLICANT: Tang, Ying
; TITLE OF INVENTION: Humanized Collagen Antibodies and
; TITLE OF INVENTION: Related Methods
```

; FILE REFERENCE: P-IX 4976
; CURRENT APPLICATION NUMBER: US/09/995,529
; CURRENT FILING DATE: 2001-11-26
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 189
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-995-529-189

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 75.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1444 ATGTTGCTGCTGCTGT 1459
Db 1 RRTTSCGTGCTGCTRT 16

RESULT 379

US-09-995-529-189
; Sequence 189, Application US/09995529
; Publication No. US20040091482A9
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; APPLICANT: Huse, William D.
; APPLICANT: Tang, Ying
; TITLE OF INVENTION: Humanized Collagen Antibodies and
; TITLE OF INVENTION: Related Methods
; FILE REFERENCE: P-IX 4976
; CURRENT APPLICATION NUMBER: US/09/995,529
; CURRENT FILING DATE: 2001-11-26
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 189
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-995-529-189

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 75.0%; Pred. No. 2.5e+02;
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1444 ATGTTGCTGCTGCTGT 1459
Db 1 RRTTSCGTGCTGCTRT 16

RESULT 380

US-10-214-670-29/c
; Sequence 29, Application US/10214670
; Publication No. US20030180715A1
; GENERAL INFORMATION:
; APPLICANT: Tibotec Pharmaceuticals Ltd.
; TITLE OF INVENTION: Methods and means for assessing HIV envelope inhibitor
; TITLE OF INVENTION: therapy
; FILE REFERENCE: VIP-0021 seq listing
; CURRENT APPLICATION NUMBER: US/10/214,670
; CURRENT FILING DATE: 2002-08-08
; PRIOR APPLICATION NUMBER: EP 01203011.0
; PRIOR FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: US 60/310497
; PRIOR FILING DATE: 2001-08-08
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 18

; TYPE: DNA
; ORGANISM: Human immunodeficiency virus
US-10-214-670-29

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1104 GAAGAACAAAGCTGGAG 1119
Db 18 GAAGAGAGAGTGGAG 3

RESULT 381

US-10-277-216-327
; Sequence 327, Application US/10277216
; Publication No. US20040002470A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; TITLE OF INVENTION: OBESITY, AND INFLAMMATORY BOWEL DISEASE
; FILE REFERENCE: 2976-4051
; CURRENT APPLICATION NUMBER: US/10/277,216
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 10/126,022
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 327
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-277-216-327

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 453 TCAGCTGCTGATGCTGG 468
Db 3 TCAGCTGCTGCTGG 18

RESULT 382

US-10-126-022-327
; Sequence 327, Application US/10126022
; Publication No. US20040023215A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; TITLE OF INVENTION: OBESITY, AND INFLAMMATORY BOWEL DISEASE
; FILE REFERENCE: 2976-4039US2
; CURRENT APPLICATION NUMBER: US/10/126,022
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 327
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-126-022-327

```
Query Match          0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 453 TCAGCTGTGATGGTGG 468
Db      ||||| ||||| |||||
3 TCAGCTGTGCTGGTGG 18

RESULT 383
US-10-416-708A-8/c
; Sequence 8, Application US/10416708A
; Publication No. US20040161753A1
; GENERAL INFORMATION:
; APPLICANT: Wise, John G.
; APPLICANT: Frommnecht, Katja
; TITLE OF INVENTION: CREATION AND IDENTIFICATION OF PROTEINS HAVING NEW DNA BINDING
; TITLE OF INVENTION: SPECIFICITIES
; FILE REFERENCE: 37779-0004
; CURRENT APPLICATION NUMBER: US/10/416, 708A
; CURRENT FILING DATE: 2004-01-28
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cauliflower mosaic virus derived sequence
US-10-416-708A-8

Query Match          0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 97 AAATGAAATTCCTTAT 112
Db      ||||| ||||| |||||
16 AAATGAACTTCCTTAT 1

RESULT 384
US-10-604-944-221/c
; Sequence 221, Application US/10604944
; Publication No. US20040219515A1
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL HIV REGULATORY GENES
; TITLE OF INVENTION: AND USES THEREOF
; FILE REFERENCE: 55008
; CURRENT APPLICATION NUMBER: US/10/604, 944
; CURRENT FILING DATE: 2003-08-28
; NUMBER OF SEQ ID NOS: 406
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 221
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus 1
US-10-604-944-221

Query Match          0.8%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 692 GCCTTTGGCATCTCTC 707
Db      ||||| ||||| |||||
19 GCCTTTGGCATCTCTC 4

RESULT 385
US-10-840-731-31
; Sequence 31, Application US/10840731
; Publication No. US20050137153A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MEHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 31
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-840-731-31

Query Match          0.8%; Score 14.4; DB 1; Length 19;
Best Local Similarity 56.2%; Pred. No. 2.8e+02;
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1813 ATAAATTTTGGAGA 1828
Db      |:|:|:|:|:|:|:|
4 AUAUUUUUUGGAGGA 19

RESULT 386
US-10-840-731-126/c
; Sequence 126, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MEHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
```



```
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 126
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-840-731-126

Query Match      0.8%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1813 ATAAATTTTGGAGCA 1828
Db 16 ATAAATTTTGGAGCA 1

RESULT 387
US-10-671-034-5/c
; Sequence 5, Application US/10671034
; Publication No. US20050096268A1
; GENERAL INFORMATION:
; APPLICANT: Wynn, Thomas
; Chiaromonte, Monica
; Collins, Mary
; Donaldson, Debra
; Fitz, Lori
; Neben, Tamlyn
; Whitters, Matthew
; Wood, Clive
; TITLE OF INVENTION: TREATMENT OF FIBROSIS BY ANTAGONISM OF IL-13
; AND IL-13 RECEPTOR CHAINS
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 Cambridgepark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA
; ZIP: 02140
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/671,034
; FILING DATE: 25-Sep-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/301,808
; FILING DATE: 1999-11-29
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15268A2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
```

```
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-671-034-5

Query Match      0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.3e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGCCA 1359
Db 17 TGGAGYGMVTGGAGYSM 1

RESULT 388
US-10-830-484-3/c
; Sequence 3, Application US/10830484
; Publication No. US20040220397A1
; GENERAL INFORMATION:
; APPLICANT: Leuck, Michael
; APPLICANT: Wolter, Andreas
; TITLE OF INVENTION: Solid Support For The Synthesis Of 3' Amino Oligonucleotides
; FILE REFERENCE: PRO13
; CURRENT APPLICATION NUMBER: US/10/830,484
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,269
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Nucleic Acid Ligand
; NAME/KEY: misc feature
; LOCATION: (1)..(14)
; OTHER INFORMATION: 3' NH2
; US-10-830-484-3

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1848
Db 14 AAAAAAAAAAAAAA 1

RESULT 389
US-10-764-393-11
; Sequence 11, Application US/10764393
; Publication No. US20040229248A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABBANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; ACID DETERMINATIONS AND ANALYSES
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/764,393
; CURRENT FILING DATE: 2004-01-23
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-764-393-11

Query Match          0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1848
Db 1 AAAAAAAAAAAAAA 14

RESULT 390
US-10-764-389-11
; Sequence 11, Application US/10764389
; Publication No. US20040230036A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABBANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/764,389
; CURRENT FILING DATE: 2004-01-23
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-764-389-11

Query Match          0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1848
Db 1 AAAAAAAAAAAAAA 14

RESULT 391
US-10-955-595-21/c
; Sequence 21, Application US/10855595
; Publication No. US20040235057A1
; GENERAL INFORMATION:
; APPLICANT: Petkovich, P. Martin, White, Jay A.,
; Beckett, Barbara R., Jones, Glenville
; TITLE OF INVENTION: Retinoid Metabolizing Protein
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Blake, Cassels & Graydon
; STREET: Box 25, Commerce Court West
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5L 1A9
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage
; COMPUTER: COMPAQ, IBM PC compatible
; OPERATING SYSTEM: MS-DOS 5.1
; SOFTWARE: WORD PERFECT
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/855,595
; FILING DATE: 28-May-2004
; PRIOR APPLICATION DATA:

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-763-076-11

Query Match          0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1833 TGAATAAAAAAAAA 1846
Db 14 TGAATAAAAAAAAA 1

RESULT 392
US-10-763-076-11
; Sequence 11, Application US/10763076
; Publication No. US20040254355A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABBANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/763,076
; CURRENT FILING DATE: 2004-01-22
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-763-076-11

Query Match          0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1848
Db 1 AAAAAAAAAAAAAA 14

RESULT 393
US-10-855-532-21/c
; Sequence 21, Application US/10855532
; Publication No. US20040259074A1
; GENERAL INFORMATION:
; APPLICANT: Petkovich, P. Martin, White, Jay A.,
```

```

; Beckett, Barbara R., Jones, Glenville
; TITLE OF INVENTION: Retinoid Metabolizing Protein
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Blake, Cassels & Graydon
; STREET: Box 25, Commerce Court West
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5L 1A9
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage
; COMPUTER: COMPAQ, IBM PC compatible
; OPERATING SYSTEM: MS-DOS 5.1
; SOFTWARE: WORD PERFECT
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/855,532
; FILING DATE: 28-May-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/668,482
; FILING DATE: 25-Sep-2000
; APPLICATION NUMBER: 08/882,164
; FILING DATE: June 25, 1997
; APPLICATION NUMBER: 08/667,546
; FILING DATE: June 21, 1996
; APPLICATION NUMBER: 08/724,466
; FILING DATE: October 1, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunt, John C.
; REGISTRATION NUMBER: 36,424
; REFERENCE/DOCKET NUMBER: 50767/00010
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 863-4344
; TELEFAX: (416) 863-2653
; INFORMATION FOR SEQ ID NO: 21
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FILE REFERENCE: ENZ-21
; SEQUENCE DESCRIPTION: SEQ ID NO: 21
US-10-855-532-21

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1833 TCAAAAAAAAAAAAAA 1846
Db      14 TCAAAAAAAAAAAAAA 1

RESULT 394
US-10-764-388-11
; Sequence 11, Application US/10764388
; Publication No. US20050004350A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/764,388
; CURRENT FILING DATE: 2004-01-23
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-764-388-11

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1835 AAAAAAAAAAAAAA 1848
Db      1 AAAAAAAAAAAAAA 14

RESULT 395
US-10-096-076-11
; Sequence 11, Application US/10096076
; Publication No. US20050137388A1
; GENERAL INFORMATION:
; APPLICANT: RABANI, ELAZAR
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: DONEGAN, JAMES J.
; APPLICANT: COLEMAN, JACK
; APPLICANT: LIU, DAKAI
; TITLE OF INVENTION: REAL-TIME NUCLEIC ACID DETECTION PROCESSES AND
; TITLE OF INVENTION: COMPOSITIONS
; FILE REFERENCE: ENZ-62
; CURRENT APPLICATION NUMBER: US/10/096,076
; CURRENT FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-096-076-11

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1835 AAAAAAAAAAAAAA 1848
Db      1 AAAAAAAAAAAAAA 14

RESULT 396
US-09-866-108-2590
; Sequence 2590, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
```

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2590
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2590

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGGTGCCATGGA 1003
|||||
Db 4 CAGGGTGCCATGGA 17

RESULT 397

US-09-866-108-2591
; Sequence 2591, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2591
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2591

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGGTGCCATGGA 1003
|||||
Db 3 CAGGGTGCCATGGA 16

RESULT 398

US-09-866-108-2592
; Sequence 2592, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2592
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2592

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGTGCCATGGA 1003
|||||
Db 2 CAGGTGCCATGGA 15

RESULT 399
US-09-866-108-2593
; Sequence 2593, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2593
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2593

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGTGCCATGGA 1003
|||||
Db 1 CAGGTGCCATGGA 14

RESULT 400
US-09-780-164-156
; Sequence 156, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 156
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-156

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 201 GAAATAAAGAAGA 214
|||||
Db 4 GAAATAAAGAAGA 17

RESULT 401
US-10-156-306-1555
; Sequence 1555, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1555
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1555

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 272 AGCCGAGACAGAT 285
|||||
Db 4 AGCCGAGACAGAU 17

RESULT 402
US-10-156-306-2842
; Sequence 2842, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2842
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-2842

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 272 AGCCGAGAACAGAT 285
Db 1 AGCCGAGAACAGAU 14

RESULT 403
US-10-156-306-3723
; Sequence 3723, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3723
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-3723

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 272 AGCCGAGAACAGAT 285
Db 3 AGCCGAGAACAGAU 16

RESULT 404
US-10-723-361-2590
; Sequence 2590, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2591
```

```
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2590
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2590

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGGTGCCATGGA 1003
Db 4 CAGGGTGCCATGGA 17

RESULT 405
US-10-723-361-2591
; Sequence 2591, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2591
```

;
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2591

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGGTGCCATGGA 1003
|||||
Db 3 CAGGGTGCCATGGA 16

RESULT 406

US-10-723-361-2592
; Sequence 2592, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2592

; LENGTH: 17

; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2592

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGGTGCCATGGA 1003
|||||
Db 2 CAGGGTGCCATGGA 15

RESULT 407

US-10-723-361-2593
; Sequence 2593, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART A

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2593

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens
US-10-723-361-2593

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGGTGCCATGGA 1003
|||||
Db 1 CAGGGTGCCATGGA 14

RESULT 408

US-10-494-343-165/c
; Sequence 165, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:

; APPLICANT: Phann, Thuymy
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned

; PRIOR APPLICATION NUMBER: PCT/US2002/035129

; PRIOR FILING DATE: 2002-11-01

; PRIOR APPLICATION NUMBER: US 60/334,773

; PRIOR FILING DATE: 2001-11-01

; NUMBER OF SEQ ID NOS: 870

; SOFTWARE: Aeomica Sequence Listing Engine

; SEQ ID NO 165

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-494-343-165

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458
|||||
Db 17 TGTGCTGCTGCTG 4

RESULT 409
US-10-494-343-166/c
; Sequence 166, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 166
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-166

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458
|||||
Db 16 TGTGCTGCTGCTG 3

RESULT 410
US-10-494-343-167/c
; Sequence 167, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 167
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-167

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458
|||||
Db 15 TGTGCTGCTGCTG 2

RESULT 411
US-10-494-343-168/c
; Sequence 168, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 168
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-168

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458
|||||
Db 14 TGTGCTGCTGCTG 1

RESULT 412
US-10-494-343-182
; Sequence 182, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; APPLICANT: Phan, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 182
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-182

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 662 GCAGGGGGCGGTGG 675
|||||
Db 4 GCAGGGGGCGGTGG 17


```

; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1536

```

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels

Qy 1081 TCGGGCTGGTCTCTGG 1097
Db 1 TCGGGCTGGTGCCCTGG 17

```

RESULT 417
US-09-866-108-1537
; Sequence 1537, Application US/09866108
; Patent No. US2002004800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

```

```

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1082 GCGGCTGCTGCTCTGGA 1098
Db      1 GGGGCTGCTGCCCTTGA 17

```

RESULT 418
US-09-866-108-8360
; Sequence 8360, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Shaaron G.
; APPLICANT: HANZEL, David K.

Query Match	0.7%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	89.2%	Pred. No. 2.6e+03;		
Matches 15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
Qy	390	GATGGGCTGGAGAAAGT	406	
Db	1	GAGGAGCTGGAGAAAGT	17	

RESULT 419

```

; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9572
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9572

Query Match 0.7% ; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 CTCGACAGCTGGGATGT 985
Db 17 CTCGACAGCGGGATGT 1
|||||
|||||

RESULT 421
US-09-730-289B-153/c
; Sequence 153, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
; FILE REFERENCES: MBHB00-864-A (400/006)
; CURRENT APPLICATION NUMBER: US/09/730,289B
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/169,100
; PRIOR FILING DATE: 1999-12-06
; NUMBER OF SEQ ID NOS: 3897
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 153
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-730-289B-153

```

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1795 TTTTAAAGTAACACTT 1811
||||| ||||| |||
Db 17 TTTTAAACTAACTCTT 1

RESULT 422
US-09-780-533A-2550
; Sequence 2550, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MEHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2550
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2550

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAATAAAGAGAAAT 217
|:|:|:|:|:|:|:
Db 1 GGAUAUAAGGAAGAAU 17

RESULT 423
US-09-927-046-198/c
; Sequence 198, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 198
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-198

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1722 ATAGAATCAACATATGG 1738

Db 17 ATAGAATCAACATGTTG 1
||||| ||||| |||

RESULT 424
US-09-927-046-264
; Sequence 264, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 264
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-264

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.6e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 210 GAAGAAATAGCCAGCTG 226
|||||:|:|:|:
Db 1 GAAGAAUAUCCAACUG 17

RESULT 425
US-09-848-754A-431
; Sequence 431, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MEHB00-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 431
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-431

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 174 AATGGCATCTCTAAGAG 190
||:||||:|:|:
Db 1 A AUGGCAUCUUAAGGG 17

RESULT 426
US-09-848-754A-2212/c
; Sequence 2212, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors

;; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
;; FILE REFERENCE: MBHB00-958-1 (400/018)
;; CURRENT APPLICATION NUMBER: US/09/848,754A
;; CURRENT FILING DATE: 2001-05-03
;; NUMBER OF SEQ ID NOS: 9645
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 2212
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-848-754A-2212

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 674 GGAAGCTGCCAGGTGG 690
Db 17 GGCAGTGCCTCCAGGTGG 1

RESULT 427
US-09-776-474-20/c
;; Sequence 20, Application US/09776474
;; Publication No. US20030087847A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.
;; APPLICANT: Jarvis, Thale
;; APPLICANT: Boher, Robert
;; APPLICANT: Holman, Patricia
;; APPLICANT: Fattaey, Ali
;; APPLICANT: McSwiggen, Jim
;; TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK1)
;; FILE REFERENCE: MBHB00-958-A (400/008)
;; CURRENT APPLICATION NUMBER: US/09/776,474
;; CURRENT FILING DATE: 2001-02-02
;; PRIOR APPLICATION NUMBER: US 60/179,983
;; PRIOR FILING DATE: 2000-03-02
;; NUMBER OF SEQ ID NOS: 2992
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 20
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-776-474-20

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1654 TCTTCTTGATCTTC 1670
Db 17 TCTTCTTAATATTC 1

RESULT 428
US-09-827-395A-6/c
;; Sequence 6, Application US/09827395A
;; Publication No. US20030113891A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.
;; APPLICANT: Lawrence Blatt
;; APPLICANT: James McSwiggen
;; APPLICANT: Bharat Chowrira
;; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
;; FILE REFERENCE: MBHB00-878-C (400/017)
;; CURRENT APPLICATION NUMBER: US/09/827,395A
;; CURRENT FILING DATE: 2001-04-05
;; PRIOR APPLICATION NUMBER: 09/780,533
;; PRIOR FILING DATE: 2001-02-09

;; PRIOR APPLICATION NUMBER: 60/181,797
;; PRIOR FILING DATE: 2000-02-11
;; NUMBER OF SEQ ID NOS: 2617
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 6
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-827-395A-6

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 382 TGCAGCAAGATGGCGCTG 398
Db 17 TGCAGCAAGATGGCGCTG 1

RESULT 429
US-09-827-395A-540
;; Sequence 540, Application US/09827395A
;; Publication No. US20030113891A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.
;; APPLICANT: Lawrence Blatt
;; APPLICANT: James McSwiggen
;; APPLICANT: Bharat Chowrira
;; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
;; FILE REFERENCE: MBHB00-878-C (400/017)
;; CURRENT APPLICATION NUMBER: US/09/827,395A
;; CURRENT FILING DATE: 2001-04-05
;; PRIOR APPLICATION NUMBER: 09/780,533
;; PRIOR FILING DATE: 2001-02-09
;; PRIOR APPLICATION NUMBER: 60/181,797
;; PRIOR FILING DATE: 2000-02-11
;; NUMBER OF SEQ ID NOS: 2617
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 540
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-827-395A-540

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1085 GCTGGTCTCTGGACTG 1101
Db 1 GCUGGUGCUGGACAG 17

RESULT 430
US-09-740-332-1531
;; Sequence 1531, Application US/09740332
;; Publication No. US20030125270A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals Inc.
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
;; FILE REFERENCE: RPI 400/003
;; CURRENT APPLICATION NUMBER: US/09/740,332
;; CURRENT FILING DATE: 2001-03-26
;; NUMBER OF SEQ ID NOS: 9704
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 1531
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: artificial sequence
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION:

; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1531

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1287 ATCACTCAGTCTCTGAG 1303
|:|||||:|:|:|

Db 1 AUCACUCAGCUGCUGAG 17

RESULT 431

US-09-740-332-3141
; Sequence 3141, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 3141
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3141

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1171 GTCGTGGTGGAGTCT 1187
|:|||||:|:|:|

Db 1 GGCUGGUGAGGAGGCU 17

RESULT 432

US-09-817-879-1531
; Sequence 1531, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1531
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1531

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1287 ATCACTCAGTCTCTGAG 1303
|:|||||:|:|:|

Db 1 AUCACUCAGCUGCUGAG 17

RESULT 433

US-09-817-879-3141
; Sequence 3141, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 3141
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3141

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1171 GTCGTGGTGGAGTCT 1187
|:|||||:|:|:|

Db 1 GGCUGGUGAGGAGGCU 17

RESULT 434

US-10-060-830-43
; Sequence 43, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 43
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-43

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1518 AACACGTAAGAAAGAAA 1534
||||| ||||| |||||
Db 1 AACACAGAAAGAAAGAAA 17

RESULT 435
US-10-060-830-44
; Sequence 44, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 44
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-44

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1519 AACAGTAAGAAAGAAC 1535
||||| ||||| |||||
Db 1 AACAGAAAGAAAGAAC 17

RESULT 436
US-10-060-756A-4251/c
; Sequence 4251, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761

; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 4251
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-4251

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 ATTATCTTAACAAGAAA 81
||||| ||||| |||||
Db 17 AATATCATACAAGAAA 1

RESULT 437
US-10-060-998-715/c
; Sequence 715, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 715
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-715

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 911 TGTAGCAGATCACTG 927
||||| ||||| |||||
Db 17 TGTAGCAGATCACTG 1

RESULT 438
US-10-060-998-716/c
; Sequence 716, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 716
; LENGTH: 17

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-716

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 910 CTGTAGCAGATCACT 926
Db 17 CTGTAGCAGATCACT 1

RESULT 439
US-10-156-306-368
; Sequence 368, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 368
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-368

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1822 TGGAGATCTCTGAAAA 1838
Db 1 UGUACAUCUCUGAAAA 17

RESULT 440
US-10-156-306-1548
; Sequence 1548, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1548
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1548

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1823 GGAAGATCTCTGAAAA 1839
Db 1 GUACAUCUCUGAAAA 17

RESULT 441
US-10-238-700-2801/c
```

```
; Sequence 2801, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels of IKK-Gamma and PKR
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2801
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2801

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 CGCCTCCGTCGCCGCG 46
Db 17 CGCCGCCGCCGCGCG 1

RESULT 442
US-10-430-882-6/c
; Sequence 6, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-6

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 382 TGCAGCAAGATGGCTG 398
Db 17 TGCAGGAAGATGGCTG 1

RESULT 443
US-10-430-882-540
```


; Sequence 540, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haeblerl
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 540
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-540

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1085 GCTGCTCTCTGGACTG 1101
Db 1 GCUGGUGCUGUGGACAG 17

RESULT 444

US-10-674-1931
; Sequence 1931, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1931
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1931

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTGGAAAC 1583
Db 1 CUGCAAAUUGGAAACC 17

RESULT 445

US-10-138-674-1932

; Sequence 1932, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1932
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1932

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.6e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1568 TGCAACTTTGGAAACT 1584
Db 1 UGCAAAUUGGAAACCU 17

RESULT 446

US-10-138-674-2017/c
; Sequence 2017, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2017
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-2017

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGTAAATATTTCCCA 1165
Db 17 AAGGAAATATTTCCCA 1

RESULT 447

US-10-138-674-2613
; Sequence 2613, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

```
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2613
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2613

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTGCAACTTTTGAAAC 1583
Db 1 CUGCAAGUUUGAAACC 17

RESULT 448
US-10-138-674-2614
; Sequence 2614, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2614
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2614

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.6e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCAACTTTTGAAACT 1584
Db 1 UGCAAGUUUGAAACCU 17

RESULT 449
US-10-138-674-3602/c
; Sequence 3602, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3602
; LENGTH: 17
; TYPE: RNA
```

```
; ORGANISM: Mus musculus
US-10-138-674-3602

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAA 1851
Db 17 AAAAAAAAAAAAAAA 1

RESULT 450
US-10-138-674-3603/c
; Sequence 3603, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3603
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3603

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAA 1851
Db 17 AAAAAAAAAAAAAAA 1

RESULT 451
US-10-138-674-6261/c
; Sequence 6261, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6261
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6261

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1470 GTTCTTATGTTGTC 1486
|||||
```

Db 17 GTTCTTATGCTGATGC 1

RESULT 452

US-10-138-674-7493/c
; Sequence 7493, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7493
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7493

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1643 TTCTGTTATTATCTTTC 1659

Db 17 TTCTGTTATTAACTGTC 1

RESULT 453

US-10-287-949A-1931
; Sequence 1931, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1931
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1931

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTGGAAAC 1583

Db 1 CUGCAAAUUGGAAACC 17

RESULT 454

US-10-287-949A-1932
; Sequence 1932, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1932
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1932

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.6e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1568 TGCAACTTTGGAAACT 1584

Db 1 UGCAAAUUGGAAACCU 17

RESULT 455

US-10-287-949A-2017/c
; Sequence 2017, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2017
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-2017

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGGTAAATATTTCCAA 1165

Db 17 AAGGAAAAATATTTCCCA 1

RESULT 456

US-10-287-949A-2613
; Sequence 2613, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11

; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2613
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2613

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTGCAACTTTGGAAC 1583
|:||||:|||||
DB 1 CUGCAAGUUUGGAACC 17

RESULT 457
US-10-287-949A-2614
; Sequence 2614, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2614
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2614

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.6e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCAACTTTGGAAC 1584
:||||:|||||
DB 1 UGCAAGUUUGGAACCU 17

RESULT 458
US-10-287-949A-3602/c
; Sequence 3602, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3602
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3602

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1851
||| ||||| |||||
DB 17 AAACAAACCAAAAAA 1

RESULT 459
US-10-287-949A-3603/c
; Sequence 3603, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3603
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3603

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1851
||| ||||| |||||
DB 17 AAACAAACCAAAAAA 1

RESULT 460
US-10-287-949A-6261/c
; Sequence 6261, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6261
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6261

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1470 GTTCTTATGTTGTC 1486
||| ||||| |||||
DB 17 GTTCTTATGCTGATGC 1

RESULT 461


```
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5734
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5734

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1171 GTCGTGGTGGAGTCT 1187
Db 1 GGCUGGUGAGGAGGCU 17

RESULT 465
US-10-723-361-1536
; Sequence 1536, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1537
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1537
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1536

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1081 TGGCGCTGGTCTCTGG 1097
Db 1 TGGGGCTGGTGCCCTGG 17

RESULT 466
US-10-723-361-1537
; Sequence 1537, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1537
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1537
```

```
Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1082 GCGGCTGCTGCTCGGA 1098
Db 1 GGGGCTGGTGCCTCGGA 17

RESULT 467
US-10-723-361-8360
; Sequence 8360, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8360
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8363

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 393 GGGCTGGAGAAAGTTCA 409
Db 1 GAGCTGGAGAAAGTGCA 17

RESULT 468
US-10-723-361-9572/c
; Sequence 9572, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 9572
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9572

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 CTCGACAGCTGGGATGT 985
Db 17 CTCGACAGCGGGATGT 1

RESULT 470
US-10-712-633-479/c
; Sequence 479, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT FILING DATE: 2003-11-13
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-479

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1643 TTCTGTATTATCTTTC 1659
Db 17 TTCTGTATTAACTGTC 1

RESULT 471
US-10-712-633-479/c
; Sequence 479, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT FILING DATE: 2003-11-13
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-479
```

```
US-10-712-633-3660/c
; Sequence 3660, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT FILING DATE: 2003-11-13
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3660
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-3660

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1470 GTTCTTATGTGTGTC 1486
Db 17 GTTCTTATGCTGATGC 1

RESULT 472
US-10-712-633-4212/c
; Sequence 4212, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT FILING DATE: 2003-11-13
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 472
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-4212
```


; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4212
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-4212

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGGTAATATTTCCAA 1165
Db 17 AAGGAAATATTTCCCA 1

RESULT 473
US-10-444-765-39
; Sequence 39, Application US/10444765
; Publication No. US20040248097A1
; GENERAL INFORMATION:
; APPLICANT: Chang, Ming-Shi
; TITLE OF INVENTION: INTERLEUKIN-20 VARIANTS AND PROMOTERS
; FILE REFERENCE: 15846-002001
; CURRENT APPLICATION NUMBER: US/10/444,765
; CURRENT FILING DATE: 2003-05-23
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 39
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-444-765-39

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 778 CCAAAATTCACACGCC 794
Db 1 CCACAATTCACACTGCC 17

RESULT 474
US-10-498-462-2053/c
; Sequence 2053, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2053
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2053

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 511 GCATTGGGACTCTCCCA 527
Db 17 GCATTGGGACTCTCTA 1
RESULT 475
US-10-724-270-1480/c
; Sequence 1480, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MEHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1480
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-1480

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 30 CGCCTCGTCGCGCGCG 46
Db 17 CGCGCGCGCGCGCGCG 1

RESULT 476
US-10-890-776A-4251/c
; Sequence 4251, Application US/10890776A
; Publication No. US20050129683A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/890,776A
; CURRENT FILING DATE: 2004-07-14
; PRIOR APPLICATION NUMBER: US 10/060,756
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30

```
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4809
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 4251
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-890-776A-4251

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 ATTATCTTAACAGAAA 81
Db 17 AATATCATAACAGAAA 1

RESULT 477
US-08-983-605-93
; Sequence 93, Application US/08983605A
; Publication No. US20020066118A1
; GENERAL INFORMATION:
; APPLICANT: Roder, Marion
; TITLE OF INVENTION: Microsatellite Markers for Plants of the Species
; TITLE OF INVENTION: Triticum aestivum and Tribe Triticaceae and the Use of
; TITLE OF INVENTION: Said Markers
; FILE REFERENCE: 2936.10400
; CURRENT APPLICATION NUMBER: US/08/983,605A
; CURRENT FILING DATE: 1998-05-01
; EARLIER APPLICATION NUMBER: DE 195 25 284.5
; EARLIER FILING DATE: 1995-06-28
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 93
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Triticum aestivum
US-08-983-605-93

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1696 AATCATTTCCCTCC 1712
Db 2 AATCATTTCCCTCC 18

RESULT 478
US-09-735-787-31
; Sequence 31, Application US/09735787
; Patent No. US20010036910A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Grethe
; NAME/KEY: Mikkelsen, Jan Moller
; OTHER INFORMATION: Schulein, Martin
; OTHER INFORMATION: Patkar, Shankant A.
; OTHER INFORMATION: Hagen, Fred
; TITLE OF INVENTION: A Cellulase Preparation Comprising an
; ENDoglucanase Enzyme
; NUMBER OF SEQUENCES: 33
```

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. US20010036910A1o No. US20010036910A1disk of No. US2001003691
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/735,787
; FILING DATE: 13-Dec-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/189,028
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Lambiris, Elias J.
; REGISTRATION NUMBER: 33,728
; REFERENCE/DOCKET NUMBER: 3469.214-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-878-9655
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 31:
US-09-735-787-31

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 633 AACTACTCAAGGACGGT 649
Db 1 AGCTTCTCAAGGACGGT 17

RESULT 479
US-09-736-863-19
; Sequence 19, Application US/09736863
; Patent No. US20020037507A1
; GENERAL INFORMATION:
; APPLICANT: WalkerPeach, Cindy
; APPLICANT: Xiyuan, Hu
; TITLE OF INVENTION: Compositions, Methods and Kits for Allele Discrimination
; FILE REFERENCE: 25436/1730
; CURRENT APPLICATION NUMBER: US/09/736,863
; CURRENT FILING DATE: 2000-12-14
; PRIOR APPLICATION NUMBER: 60/171,126
; PRIOR FILING DATE: 1999-12-16
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 19
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: SDF1 forward PCR primer
; NAME/KEY: misc feature
; OTHER INFORMATION: SDF1 forward PCR primer
; OTHER INFORMATION: SDF1 forward PCR primer
US-09-736-863-19

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 722 CTCCTTCTCCATCACA 738
| | | | | | | | | | | | | |
Db 1 CCCCTTCTCCATCACA 17

RESULT 480
US-09-500-700-68/c
; Sequence 68, Application US/09500700
; Publication No. US20030059767A1
; GENERAL INFORMATION:
; APPLICANT: THE SCRIPPS RESEARCH INSTITUTE
; APPLICANT: BARBAS III, Carlos F.
; APPLICANT: GOTTESFELD, Joel M.
; APPLICANT: WRIGHT, Peter E.
; TITLE OF INVENTION: ZINC FINGER PROTEIN DERIVATIVES AND METHODS THEREFOR
; FILE REFERENCE: SCRIPI160-4
; CURRENT APPLICATION NUMBER: US/09/500,700
; CURRENT FILING DATE: 2003-01-10
; PRIOR FILING DATE: 1997-05-27
; PRIOR APPLICATION NUMBER: US 08/863,813
; PRIOR FILING DATE: 1996-12-30
; PRIOR APPLICATION NUMBER: PCT/US95/00829
; PRIOR FILING DATE: 1995-01-18
; PRIOR APPLICATION NUMBER: US 08/312,604
; PRIOR FILING DATE: 1994-09-28
; PRIOR APPLICATION NUMBER: US 08/183,119
; PRIOR FILING DATE: 1994-01-18
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 68
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: (GCG)6 probe
US-09-500-700-68

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 30 CGCCTCGTCGCCGCCG 46
| | | | | | | | | | | | | |
Db 18 CGCGCGCGCGCGCGCG 2

RESULT 481
US-10-181-603-45
; Sequence 45, Application US/10181603
; Publication No. US20030049662A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowbert
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD7 EXPRESSION
; FILE REFERENCE: RTSP-0342
; CURRENT APPLICATION NUMBER: US/10/181,603
; CURRENT FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: PCT/US01/01165
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: 09/487,444
; PRIOR FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 45
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-603-45

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 722 CTCCTTCTCCATCACA 738
| | | | | | | | | | | | | |
Db 1 CCCCTTCTCCATCACA 17

RESULT 482
US-10-314-405-45/c
; Sequence 45, Application US/10314405
; Publication No. US20030108940A1
; GENERAL INFORMATION:
; APPLICANT: HIGETOSHI, Inoko
; APPLICANT: Gen, Tamiya
; APPLICANT: Yasunari, Matsuzaka
; TITLE OF INVENTION: NOVEL POLYMORPHIC MICROSATELLITE MARKERS IN THE HUMAN MHC CLASS I
; FILE REFERENCE: 06501-089001
; CURRENT APPLICATION NUMBER: US/10/314,405
; CURRENT FILING DATE: 2002-12-06
; PRIOR APPLICATION NUMBER: US/09/713,616
; PRIOR FILING DATE: 2000-11-15
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 45
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-314-405-45

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 30 CGCCTCGTCGCCGCCG 46
| | | | | | | | | | | | | |
Db 18 CGCGCGCGCGCGCGCG 2

RESULT 483
US-10-138-870-31
; Sequence 31, Application US/10138870
; Publication No. US20030119167A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Grethe
; APPLICANT: Mikkelson, Jan Moller
; APPLICANT: Schulein, Martin
; APPLICANT: Patkar, Shankant A.
; APPLICANT: Hagen, Fred
; TITLE OF INVENTION: A Cellulase Preparation Comprising an
; Endoglucanase Enzyme
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSER: No. US20030119167A1o No. US20030119167Aldisk of No. US200301191
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/138,870
; FILING DATE: 03-May-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/735,787
; FILING DATE: 13-Dec-2000
; APPLICATION NUMBER: 09/189,028
; FILING DATE: <Unknown>
```

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Lambiris, Elias J.
; REGISTRATION NUMBER: 33,728
; REFERENCE/DOCKET NUMBER: 3469,214-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-878-9655
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 31:
US-10-138-870-31

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      633 AACTACTCAAGGACGGT 649
Db      1 AGCTTCTCAGGACGGT 17

RESULT 484
US-10-133-779-9/c
; Sequence 9, Application US/10133779
; Publication No. US20030165894A1
; GENERAL INFORMATION:
; APPLICANT: Chow, Robert
; APPLICANT: Tonai, Richard
; APPLICANT: StemCyt, Inc.
; TITLE OF INVENTION: High Throughput Methods of HLA Typing
; FILE REFERENCE: 020035-000210US
; CURRENT APPLICATION NUMBER: US/10/133,779
; CURRENT FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US/09/747,391
; PRIOR FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: US 60/172,768
; PRIOR FILING DATE: 1999-12-20
; NUMBER OF SEQ ID NOS: 278
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-133-779-9

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      382 TGCAGCAAGATGGGCTG 398
Db      17 TGCAGCACGAGGGGCTG 1

RESULT 485
US-10-133-779-125/c
; Sequence 125, Application US/10133779
; Publication No. US20030165894A1
; GENERAL INFORMATION:
; APPLICANT: Chow, Robert
; APPLICANT: Tonai, Richard
; APPLICANT: StemCyt, Inc.
; TITLE OF INVENTION: High Throughput Methods of HLA Typing
; FILE REFERENCE: 020035-000210US
; CURRENT APPLICATION NUMBER: US/10/133,779
; CURRENT FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US/09/747,391
; PRIOR FILING DATE: 2001-07-13
US-10-133-779-125

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      382 TGCAGCAAGATGGGCTG 398
Db      17 TGCAGCACGAGGGGCTG 1

RESULT 486
US-10-289-845-19/c
; Sequence 19, Application US/10289845
; Publication No. US20030170679A1
; GENERAL INFORMATION:
; APPLICANT: Wood, Linda
; APPLICANT: Wagner, Susanne
; APPLICANT: Parodi, Luis
; TITLE OF INVENTION: Single Nucleotide Polymorphisms in GH-1
; FILE REFERENCE: 00791.US1
; CURRENT APPLICATION NUMBER: US/10/289,845
; CURRENT FILING DATE: 2002-11-07
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
; LENGTH: 18
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-289-845-19

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1554 AGGAATCTCTGGGTCTGC 1570
Db      17 AGGACTCTCTGGGTCTGC 1

RESULT 487
US-10-289-845-48/c
; Sequence 48, Application US/10289845
; Publication No. US20030170679A1
; GENERAL INFORMATION:
; APPLICANT: Wood, Linda
; APPLICANT: Wagner, Susanne
; APPLICANT: Parodi, Luis
; TITLE OF INVENTION: Single Nucleotide Polymorphisms in GH-1
; FILE REFERENCE: 00791.US1
; CURRENT APPLICATION NUMBER: US/10/289,845
; CURRENT FILING DATE: 2002-11-07
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 48
; LENGTH: 18
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-289-845-48

Query Match      0.7%; Score 13.8; DB 1; Length 18;
```

Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1554 AGGAATCCTGGTCTGC 1570
|||||
Db 17 AGGACTCCTGGTCTGC 1

RESULT 488
US-10-326-495-14
; Sequence 14, Application US/10326495
; Publication No. US20030190674A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, Andrew David
; Hoogenboom, Hendricus RJM
; Marks, James David
; McCafferty, John
; Winter, Gregory Paul
; Griggs, Geoffrey Walter
; TITLE OF INVENTION: Production of anti-self antibodies from
; antibody segment repertoires and displayed on phage
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David W. Clough
; STREET: Katten Muchin Davis Rosenman
; 525 W. Monroe Street, Suite 1600
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60661-3693
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/326,495
; FILING DATE: 19-Dec-2002
; CLASSIFICATION: C12N 15/13, 15/62, C07K 13/00, C12P 21/08,
; G01N 33/531,
; 33/68
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 09/197,224
; FILING DATE: 20-NOV-1998
; APPLICATION NUMBER: US 08/244,597
; FILING DATE: 26-OCT-1994
; APPLICATION NUMBER: GB 9125579.4
; FILING DATE: 02-DEC-1991
; APPLICATION NUMBER: GB 9125582.8
; FILING DATE: 02-DEC-1991
; APPLICATION NUMBER: GB 9206318.9
; FILING DATE: 24-MAR-1992
; APPLICATION NUMBER: GB 9206372.6
; FILING DATE: 24-MAR-1992
; APPLICATION NUMBER: PCT/GB92/01755
; FILING DATE: 23-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 213839/00030
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-902-5464
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-10-326-495-14

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 TGTATTACGGTGAAGA 811
|||||
Db 2 TGTATTACTGTGAAGA 18

RESULT 489
US-10-365-742-173/c
; Sequence 173, Application US/10365742
; Publication No. US20030204868A1
; GENERAL INFORMATION:
; APPLICANT: Collmer, Alan
; APPLICANT: Alfano, James R.
; APPLICANT: Cartinhour, Samuel W.
; APPLICANT: Schneider, David J.
; APPLICANT: Tang, Xiaoyan
; TITLE OF INVENTION: PSEUDOMONAS AVR AND HOP PROTEINS, THEIR ENCODING
; FILE OF INVENTION: NUCLEIC ACIDS, AND USE THEREOF
; FILE REFERENCE: 19603/4112
; CURRENT APPLICATION NUMBER: US/10/365,742
; CURRENT FILING DATE: 2002-02-12
; PRIOR APPLICATION NUMBER: 60/356,408
; PRIOR FILING DATE: 2002-02-12
; PRIOR APPLICATION NUMBER: 60/380,185
; PRIOR FILING DATE: 2002-05-10
; NUMBER OF SEQ ID NOS: 209
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 173
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-365-742-173

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1416 ATGACTGTGATGATCC 1432
|||||
Db 18 ACGATTGTCATGATCC 2

RESULT 490
US-10-277-216-101
; Sequence 101, Application US/10277216
; Publication No. US20040002470A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; FILE OF INVENTION: OBESITY, AND INFLAMMATORY BOWEL DISEASE
; FILE REFERENCE: 2976-4051
; CURRENT APPLICATION NUMBER: US/10/277,216
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 10/126,022
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 101
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-277-216-101

Query Match 0.7%; Score 13.8; DB 1; Length 18;

Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1101 GCAGAGAGCAAGGTGG 1117
||||| ||| |||||
DB 2 GCAGAGGAGCAAGGTGG 18

RESULT 491
US-10-126-022-101
; Sequence 101, Application US/10126022
; Publication No. US20040023215A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; FILE REFERENCE: 2976-4039US2
; CURRENT APPLICATION NUMBER: US/10/126,022
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 101
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-126-022-101

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1101 GCAGAGAGCAAGGTGG 1117
||||| ||| |||||
DB 2 GCAGAGGAGCAAGGTGG 18

RESULT 492
US-10-333-429-261/c
; Sequence 261, Application US/10333429
; Publication No. US20040048265A1
; GENERAL INFORMATION:
; APPLICANT: GENSET
; TITLE OF INVENTION: Obesity Associated Biallelic Marker Maps
; FILE REFERENCE: G-083US02PCT
; CURRENT APPLICATION NUMBER: US/10/333,429
; CURRENT FILING DATE: 2003-01-17
; PRIOR APPLICATION NUMBER: PCT/IB01/01477
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: US 60/219,704
; PRIOR FILING DATE: 2000-07-18
; NUMBER OF SEQ ID NOS: 579
; SOFTWARE: Patent.pm
; SEQ ID NO 261
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-32166 for SEQ 90,
US-10-333-429-261

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 224 CTGTGAGATGTTGCTA 240

DB 17 CTGTGAAGATGATGCTA 1
||||| ||||| |||||

RESULT 493
US-10-376-770-205
; Sequence 205, Application US/10376770
; Publication No. US20040106102A1
; GENERAL INFORMATION:
; APPLICANT: Dhallan, Ravinder S.
; TITLE OF INVENTION: RAPID ANALYSIS OF VARIATIONS IN A GENOME
; FILE REFERENCE: 543312000320
; CURRENT APPLICATION NUMBER: US/10/376,770
; CURRENT FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 10/093,618
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/360,232
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 60/378,354
; PRIOR FILING DATE: 2002-05-08
; NUMBER OF SEQ ID NOS: 262
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 205
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)...(8)
; OTHER INFORMATION: These nucleotides may be absent
US-10-376-770-205

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAAATAAAAGAGAAAT 217
||||| ||||| |||||
DB 1 GAAATAAAAGAGAAAT 17

RESULT 494
US-10-745-377-138/c
; Sequence 138, Application US/10745377
; Publication No. US20040137423A1
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Pimstone, Simon
; APPLICANT: Brooks-Wilson, Angela R.
; APPLICANT: Clee, Susanne M.
; TITLE OF INVENTION: Compositions and Methods for Modulating
; FILE REFERENCE: 760050-109
; CURRENT APPLICATION NUMBER: US/10/745,377
; CURRENT FILING DATE: 2003-12-23
; PRIOR APPLICATION NUMBER: 09/654,323
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: US 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: US 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: US 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 60/151,977
; PRIOR FILING DATE: 1999-09-01
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: US 60/213,958
; PRIOR FILING DATE: 2000-06-23
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: Word for Windows Version 6.0 (ASCII Text)
; SEQ ID NO 138
; LENGTH: 18

```
; TYPE: DNA
; ORGANISM: homo sapien
US-10-745-377-138

Query Match      0.7%  Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1641 CTTTCTGTATATATCTT 1657
      ||||| |||||
Db 18 CTTTCTGATATCTCTT 2

RESULT 495
US-10-661-165-205
; Sequence 205, Application US/10661165
; Publication No. US20040137470A1
; GENERAL INFORMATION:
; APPLICANT: Dhallan, Ravinder S.
; TITLE OF INVENTION: METHODS FOR DETECTION OF GENETIC
; FILE REFERENCE: 543312000420
; CURRENT APPLICATION NUMBER: US/10/661,165
; CURRENT FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: PCT/US03/06198
; PRIOR FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 60/378,354
; PRIOR FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: US 10/093,618
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/360,232
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: PCT/US03/27308
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/376,770
; PRIOR FILING DATE: 2003-02-28
; NUMBER OF SEQ ID NOS: 628
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 205
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)...(8)
; OTHER INFORMATION: These nucleotides may be absent
US-10-661-165-205

Query Match      0.7%  Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAGAGAAAT 217
      ||||| |||||
Db 1 GAAATAAAGAGAAAGAT 17

RESULT 496
US-10-327-598-836
; Sequence 836, Application US/10327598
; Publication No. US20040181039A1
; GENERAL INFORMATION:
; APPLICANT: Krah, Eugene
; APPLICANT: Guo, Honliang
; APPLICANT: Aiyappa, Ashok
; APPLICANT: Lawton, Robert
; TITLE OF INVENTION: Canine Immunoglobulin Variable Domains, Caninized Antibodies, and
; TITLE OF INVENTION: for Making and Using Them
; FILE REFERENCE: 01-799-A
; CURRENT APPLICATION NUMBER: US/10/327,598
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/344,874
; PRIOR FILING DATE: 2001-12-21
```

```
; NUMBER OF SEQ ID NOS: 1139
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 836
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION:
US-10-327-598-836

Query Match      0.7%  Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1069 CAAAGAGGACTCTGCGG 1085
      ||||| |||||
Db 1 CTAAGAGCACTCTGCGG 17

RESULT 497
US-10-758-307-208/c
; Sequence 208, Application US/10758307
; Publication No. US20040209290A1
; GENERAL INFORMATION:
; APPLICANT: GENOMIC HEALTH, INC.
; APPLICANT: RUSH UNIVERSITY MEDICAL CENTER
; APPLICANT: Cobleigh, Melody
; APPLICANT: Shak, Steven
; APPLICANT: Baker, Joffre
; APPLICANT: Cronin, Maureen
; TITLE OF INVENTION: GENE EXPRESSION MARKERS FOR BREAST
; FILE REFERENCE: 39740/0008 US
; CURRENT APPLICATION NUMBER: US/10/758,307
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 60/440,861
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 440
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 208
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: probe
US-10-758-307-208

Query Match      0.7%  Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 673 TGGAGCTGCCAGGTG 689
      ||||| |||||
Db 17 TGGAGCTGCCAGGTG 1

RESULT 498
US-10-872-113-138/c
; Sequence 138, Application US/10872113
; Publication No. US20040229275A1
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Pimstone, Simon
; APPLICANT: Brooks-Wilson, Angela R.
; APPLICANT: Clee, Susanne M.
; TITLE OF INVENTION: Compositions and Methods for Modulating
; FILE REFERENCE: 760050-138
; CURRENT APPLICATION NUMBER: US/10/872,113
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 09/654,323
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: US 60/124,702
```

```
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: US 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: US 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 60/151,977
; PRIOR FILING DATE: 1999-09-01
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: US 60/213,958
; PRIOR FILING DATE: 2000-06-23
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: Word for Windows Version 6.0 (ASCII Text)
; SEQ ID NO 138
; TYPE: DNA
; LENGTH: 18
; ORGANISM: homo sapien
US-10-872-113-138

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1641 CTTTCTGTATTATCTT 1657
Db 18 CTTTCTGATATCTCTT 2

RESULT 499
US-10-714-195-213/c
; Sequence 213, Application US/10714195
; Publication No. US20050019785A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Joffre
; APPLICANT: Cronin, Maureen
; APPLICANT: Shak, Steve
; APPLICANT: Baselga, Jose
; TITLE OF INVENTION: GENE EXPRESSION PROFILING OF EGFR
; FILE REFERENCE: 39740-0005
; CURRENT APPLICATION NUMBER: US/10/714,195
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/427090
; PRIOR FILING DATE: 2003-11-15
; NUMBER OF SEQ ID NOS: 372
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 213
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-714-195-213

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 673 TGAAGCTGCCAAGGTG 689
Db 17 TGGCAGCTGCCCAGGTG 1

RESULT 500
US-10-852-797-102/c
; Sequence 102, Application US/10852797
; Publication No. US20050064455A1
; GENERAL INFORMATION:
; APPLICANT: Genomic Health, Inc.
; APPLICANT: Baker, Joffre
; APPLICANT: Miller, Kathy D.
; APPLICANT: Shak, Steven
; APPLICANT: Sledge, George

; APPLICANT: Soule, Sharon
; TITLE OF INVENTION: Gene Expression Markers for Predicting
; FILE REFERENCE: 39740-0010
; CURRENT APPLICATION NUMBER: US/10/852,797
; CURRENT FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: 60/473,970
; PRIOR FILING DATE: 2003-05-28
; NUMBER OF SEQ ID NOS: 372
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 102
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: probe
US-10-852-797-102

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 673 TCGAAGCTGCCAAGGTG 689
Db 17 TGGCAGCTGCCCAGGTG 1

RESULT 501
US-10-941-069-68/c
; Sequence 68, Application US/10941069
; Publication No. US20050084885A1
; GENERAL INFORMATION:
; APPLICANT: THE SCRIPPS RESEARCH INSTITUTE
; APPLICANT: BARBAS III, Carlos F.
; APPLICANT: GOTTESFELD, Joel M.
; APPLICANT: WRIGHT, Peter E.
; TITLE OF INVENTION: ZINC FINGER PROTEIN DERIVATIVES AND METHODS THEREFOR
; FILE REFERENCE: SCRIPT1160-4
; CURRENT APPLICATION NUMBER: US/10/941,069
; CURRENT FILING DATE: 2004-09-14
; PRIOR APPLICATION NUMBER: US/09/500,700
; PRIOR FILING DATE: 2000-02-09
; PRIOR APPLICATION NUMBER: US 08/863,813
; PRIOR FILING DATE: 1997-05-27
; PRIOR APPLICATION NUMBER: US 08/676,318
; PRIOR FILING DATE: 1996-12-30
; PRIOR APPLICATION NUMBER: PCT/US95/00829
; PRIOR FILING DATE: 1995-01-18
; PRIOR APPLICATION NUMBER: US 08/312,604
; PRIOR FILING DATE: 1994-09-28
; PRIOR APPLICATION NUMBER: US 08/183,119
; PRIOR FILING DATE: 1994-01-18
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 68
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: (GCG)6 probe
US-10-941-069-68

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 CGCCTCCGTCGCGCGCG 46
Db 18 CGCGCGCGCGCGCGCGCG 2

RESULT 502
US-10-481-613-152
```


; Sequence 152, Application US/10481613
; Publication No. US20050085627A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Youming
; APPLICANT: Moffatt, Miriam
; APPLICANT: Cookson, William
; APPLICANT: Tinsley, Jon
; TITLE OF INVENTION: Atopy
; FILE REFERENCE: 16721-0003US1 / P32688WO/KVC
; CURRENT APPLICATION NUMBER: US/10/481,613
; CURRENT FILING DATE: 2003-12-19
; PRIOR APPLICATION NUMBER: PCT/GB02/02859
; PRIOR FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: GB 0115211.5
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: GB 0115212.3
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: GB 0115213.1
; PRIOR FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 326
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 152
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-481-613-152

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 939 CCAGAACAGGTGTACT 955
||| ||||| |||||
Db 1 CCTGAACAGGCTGACT 17

RESULT 503
US-10-485-508B-51
; Sequence 51, Application US/10485508B
; Publication No. US20050106134A1
; GENERAL INFORMATION:
; APPLICANT: NIE, Quiying
; APPLICANT: SALAMONSEN, Lois Adrienne
; APPLICANT: FINDLAY, John Kerr
; TITLE OF INVENTION: Pregnancy-related enzyme activity
; FILE REFERENCE: 28943-0007
; CURRENT APPLICATION NUMBER: US/10/485,508B
; CURRENT FILING DATE: 2004-02-02
; PRIOR APPLICATION NUMBER: PCT/AU02/01020
; PRIOR FILING DATE: 2002-07-31
; PRIOR APPLICATION NUMBER: AU PR 6730
; PRIOR FILING DATE: 2001-07-31
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 51
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic nucleotide - primer
US-10-485-508B-51

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 509 CAGCATTGGGACTCCTC 525
||| ||||| |||||
Db 2 CAGCATTGGGACTCCTC 18

RESULT 504
US-10-498-794-77
; Sequence 77, Application US/10498794
; Publication No. US20050142552A1
; GENERAL INFORMATION:
; APPLICANT: Gurling, Hugh MD
; TITLE OF INVENTION: Susceptibility locus for schizophrenia
; FILE REFERENCE: 620-312
; CURRENT APPLICATION NUMBER: US/10/498,794
; CURRENT FILING DATE: 2004-06-14
; PRIOR APPLICATION NUMBER: PCT/GB2002/005630
; PRIOR FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: GB 0129758.9
; PRIOR FILING DATE: 2001-12-12
; NUMBER OF SEQ ID NOS: 103
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 77
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-794-77

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1514 CTAGAAACAGTAAGAAA 1530
||| ||||| |||||
Db 1 CTAGTAAGTAAGAAA 17

Search completed: July 12, 2005, 10:45:02
Job time : 13 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 12, 2005, 10:42:36 ; Search time 7 Seconds
(without alignments)
3.454 Million cell updates/sec

Title: US-09-745-763-35
Perfect score: 1851
Sequence: 1 GGTAGCGCGAGCTAGT.....CTGAAAAAAAAAAAAAAAAA 1851

Scoring table: IDENTITY NUC
Gap 10.0, Gapext 0.5

Searched: 378 seqs, 6532 residues

Total number of hits satisfying chosen parameters: 756

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 384 summaries

Database : rn135.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	19.8	1.1	25	1	US-09-396-196G-36103
C 2	19.2	1.0	25	1	US-09-396-196G-127295
C 3	18.8	1.0	25	1	US-09-396-196G-36101
C 4	17	0.9	17	1	US-09-766-253-132
C 5	17	0.9	17	1	US-09-685-664B-1075
C 6	17	0.9	18	1	US-09-809-545A-84
C 7	17	0.9	18	1	US-10-352-704-12
C 8	17	0.9	18	1	US-10-352-704-18
C 9	17	0.9	20	1	US-09-976-618A-55
C 10	17	0.9	20	1	US-09-976-968A-55
C 11	17	0.9	20	1	US-10-234-764-10
C 12	17	0.9	20	1	US-09-975-059A-55
C 13	17	0.9	20	1	US-09-859-736-3
C 14	17	0.9	20	1	US-09-859-736-4
C 15	17	0.9	20	1	US-09-859-736-6
C 16	16.4	0.9	18	1	US-09-422-978-4101
C 17	16.4	0.9	20	1	US-09-198-452A-3072
C 18	16.2	0.9	21	1	US-08-863-639A-67
C 19	16.2	0.9	21	1	US-08-863-639A-71
C 20	16.2	0.9	21	1	US-08-416-211A-11
C 21	16.2	0.9	21	1	US-09-765-111A-32
C 22	16	0.9	16	1	US-09-766-253-131
C 23	16	0.9	17	1	US-09-685-664B-1074
C 24	16	0.9	17	1	US-09-685-664B-1076
C 25	16	0.9	17	1	US-09-090-672B-107
C 26	16	0.9	18	1	US-09-904-744-1
C 27	16	0.9	19	1	US-09-696-791-479
C 28	15.8	0.9	19	1	US-09-037-990B-79
C 29	15.8	0.9	19	1	US-09-475-947A-12
C 30	15.8	0.9	19	1	US-09-696-791-3050
C 31	15.8	0.9	19	1	US-09-696-791-3051
C 32	15.8	0.9	20	1	US-08-215-138-16
C 33	15.8	0.9	20	1	US-08-407-344-16

C 34	15.8	0.9	20	1	US-09-198-452A-6169	Sequence 6169, Ap
C 35	15.8	0.9	21	1	US-08-863-639A-52	Sequence 52, Appl
C 36	15.8	0.9	21	1	US-08-863-639A-55	Sequence 55, Appl
C 37	15.8	0.9	21	1	US-08-863-639A-56	Sequence 56, Appl
C 38	15.8	0.9	21	1	US-08-863-639A-68	Sequence 68, Appl
C 39	15.4	0.8	17	1	US-09-685-664B-1077	Sequence 1077, Ap
C 40	15.4	0.8	18	1	US-08-282-197C-28	Sequence 28, Appl
C 41	15.4	0.8	18	1	US-08-857-946-8	Sequence 8, Appl
C 42	15.4	0.8	18	1	US-08-970-740-8	Sequence 8, Appl
C 43	15.4	0.8	18	1	US-09-710-794-8	Sequence 8, Appl
C 44	15.4	0.8	20	1	US-09-198-452A-6103	Sequence 6103, Ap
C 45	15.4	0.8	20	1	US-10-058-422A-14	Sequence 14, Appl
C 46	15.2	0.8	20	1	US-08-182-172-7	Sequence 7, Appl
C 47	15.2	0.8	20	1	US-09-418-641-57	Sequence 57, Appl
C 48	15.2	0.8	20	1	US-09-484-345-5	Sequence 75, Appl
C 49	15.2	0.8	20	1	US-09-000-092-11	Sequence 11, Appl
C 50	15.2	0.8	20	1	US-09-030-701-65	Sequence 65, Appl
C 51	15.2	0.8	20	1	US-09-082-649B-57	Sequence 57, Appl
C 52	15.2	0.8	20	1	US-09-198-452A-4294	Sequence 4294, Ap
C 53	15.2	0.8	20	1	US-09-710-693-10	Sequence 10, Appl
C 54	15.2	0.8	20	1	US-09-965-101-57	Sequence 57, Appl
C 55	15	0.8	15	1	US-10-352-704-10	Sequence 10, Appl
C 56	15	0.8	15	1	US-10-352-704-16	Sequence 16, Appl
C 57	15	0.8	17	1	US-09-685-664B-1073	Sequence 1073, Ap
C 58	15	0.8	17	1	US-09-090-672B-105	Sequence 105, App
C 59	15	0.8	17	1	US-09-090-672B-106	Sequence 106, App
C 60	15	0.8	18	1	US-09-904-744-2	Sequence 2, Appl
C 61	15	0.8	19	1	US-09-696-791-478	Sequence 478, App
C 62	15	0.8	20	1	US-09-344-914-53	Sequence 53, Appl
C 63	15	0.8	20	1	US-09-344-914-54	Sequence 54, Appl
C 64	15	0.8	20	1	US-09-344-914-55	Sequence 55, Appl
C 65	15	0.8	20	1	US-09-344-914-56	Sequence 56, Appl
C 66	15	0.8	20	1	US-09-344-914-57	Sequence 57, Appl
C 67	15	0.8	20	1	US-09-344-914-58	Sequence 58, Appl
C 68	14.8	0.8	19	1	US-08-215-138-9	Sequence 9, Appl
C 69	14.8	0.8	19	1	US-08-407-344-9	Sequence 9, Appl
C 70	14.8	0.8	19	1	US-09-422-978-6888	Sequence 6888, Ap
C 71	14.8	0.8	19	1	US-09-422-978-7139	Sequence 7139, Ap
C 72	14.8	0.8	19	1	US-09-938-077-19	Sequence 19, Appl
C 73	14.8	0.8	19	1	US-09-696-791-2728	Sequence 2728, Ap
C 74	14.8	0.8	19	1	US-09-696-791-3559	Sequence 3559, Ap
C 75	14.4	0.8	16	1	US-08-753-147-188	Sequence 188, App
C 76	14.4	0.8	17	1	US-09-371-772B-4471	Sequence 4471, Ap
C 77	14.4	0.8	17	1	US-09-866-108A-8364	Sequence 8364, Ap
C 78	14.4	0.8	17	1	US-09-866-108A-8365	Sequence 8365, Ap
C 79	14.4	0.8	17	1	US-09-866-108A-10030	Sequence 10030, A
C 80	14.4	0.8	17	1	US-09-866-108A-10031	Sequence 10031, A
C 81	14.4	0.8	17	1	US-09-685-664B-1078	Sequence 1078, Ap
C 82	14.4	0.8	18	1	US-09-289-377-28	Sequence 28, Appl
C 83	14.4	0.8	18	1	US-09-282-147-17	Sequence 17, Appl
C 84	14.4	0.8	18	1	US-09-696-791-4229	Sequence 4229, Ap
C 85	14.4	0.8	19	1	US-09-696-791-3052	Sequence 3052, Ap
C 86	14.2	0.8	17	1	US-08-609-572-5	Sequence 5, Appl
C 87	14.2	0.8	17	1	US-08-841-751-5	Sequence 5, Appl
C 88	14.2	0.8	17	1	US-08-846-340-5	Sequence 5, Appl
C 89	14.2	0.8	17	1	US-08-846-344-5	Sequence 5, Appl
C 90	14.2	0.8	17	1	US-09-301-808-5	Sequence 5, Appl
C 91	14	0.8	14	1	US-09-859-726-7	Sequence 7, Appl
C 92	14	0.8	15	1	US-09-491-356C-19	Sequence 19, Appl
C 93	14	0.8	17	1	US-09-866-108A-2590	Sequence 2590, Ap
C 94	14	0.8	17	1	US-09-866-108A-2591	Sequence 2591, Ap
C 95	14	0.8	17	1	US-09-866-108A-2592	Sequence 2592, Ap
C 96	14	0.8	17	1	US-09-866-108A-2593	Sequence 2593, Ap
C 97	14	0.8	17	1	US-09-685-664B-1072	Sequence 1072, Ap
C 98	14	0.8	18	1	US-08-143-219-10	Sequence 10, Appl
C 99	14	0.8	18	1	US-10-271-065-1	Sequence 1, Appl
C 100	13.8	0.7	17	1	US-08-985-162-431	Sequence 431, App
C 101	13.8	0.7	17	1	US-08-987-574-46	Sequence 46, Appl
C 102	13.8	0.7	17	1	US-08-535-168-46	Sequence 46, Appl
C 103	13.8	0.7	17	1	US-09-017-974-46	Sequence 46, Appl
C 104	13.8	0.7	17	1	US-08-682-255A-46	Sequence 46, Appl
C 105	13.8	0.7	17	1	US-08-584-040-4164	Sequence 4164, Ap
C 106	13.8	0.7	17	1	US-08-584-040-4165	Sequence 4165, Ap

c 107	13.8	0.7	17	1	US-08-584-040-4250	Sequence 4250, Ap	180	13.4	0.7	17	1	US-09-866-108A-8366	Sequence 8366, Ap
c 108	13.8	0.7	17	1	US-08-584-040-5734	Sequence 5734, Ap	181	13.4	0.7	17	1	US-09-866-108A-8587	Sequence 8587, Ap
c 109	13.8	0.7	17	1	US-08-584-040-5735	Sequence 5735, Ap	182	13.4	0.7	17	1	US-09-866-108A-8588	Sequence 8588, Ap
c 110	13.8	0.7	17	1	US-08-584-040-5820	Sequence 5820, Ap	183	13.4	0.7	17	1	US-09-866-108A-8589	Sequence 8589, Ap
c 111	13.8	0.7	17	1	US-08-584-040-7818	Sequence 7818, Ap	c 184	13.4	0.7	17	1	US-09-866-108A-10029	Sequence 10029, A
c 112	13.8	0.7	17	1	US-08-584-040-7819	Sequence 7819, Ap	c 185	13.4	0.7	17	1	US-09-866-108A-10032	Sequence 10032, A
c 113	13.8	0.7	17	1	US-09-429-130-46	Sequence 46, Appl	c 186	13.4	0.7	17	1	US-09-940-244-418	Sequence 418, App
c 114	13.8	0.7	17	1	US-09-371-7728-1931	Sequence 1931, Ap	c 187	13.4	0.7	17	1	US-09-685-6648-2018	Sequence 2018, Ap
c 115	13.8	0.7	17	1	US-09-371-7728-1932	Sequence 1932, Ap	c 188	13.4	0.7	17	1	PCT-US91-03680-7	Sequence 7, Appli
c 116	13.8	0.7	17	1	US-09-371-7728-2017	Sequence 2017, Ap	c 189	13.2	0.7	15	1	US-08-702-665A-8	Sequence 8, Appli
c 117	13.8	0.7	17	1	US-09-371-7728-2613	Sequence 2613, Ap	c 190	13.2	0.7	15	1	US-08-292-620A-370	Sequence 370, App
c 118	13.8	0.7	17	1	US-09-371-7728-2614	Sequence 2614, Ap	c 191	13	0.7	15	1	US-09-071-845-370	Sequence 370, App
c 119	13.8	0.7	17	1	US-09-371-7728-3602	Sequence 3602, Ap	c 192	13	0.7	15	1	US-09-701-947A-20	Sequence 20, Appl
c 120	13.8	0.7	17	1	US-09-371-7728-3603	Sequence 3603, Ap	c 193	13	0.7	15	1	US-09-701-947A-21	Sequence 21, Appl
c 121	13.8	0.7	17	1	US-09-371-7728-6261	Sequence 6261, Ap	c 194	13	0.7	15	1	US-09-701-947A-22	Sequence 22, Appl
c 122	13.8	0.7	17	1	US-09-401-063-431	Sequence 431, App	c 195	13	0.7	17	1	US-08-985-162-333	Sequence 333, App
c 123	13.8	0.7	17	1	US-09-866-108A-1536	Sequence 1536, Ap	c 196	13	0.7	17	1	US-09-017-974-74	Sequence 74, Appl
c 124	13.8	0.7	17	1	US-09-866-108A-1537	Sequence 1537, Ap	c 197	13	0.7	17	1	US-09-017-974-78	Sequence 78, Appl
c 125	13.8	0.7	17	1	US-09-866-108A-8360	Sequence 8360, Ap	c 198	13	0.7	17	1	US-09-098-628-8	Sequence 8, Appli
c 126	13.8	0.7	17	1	US-09-866-108A-8363	Sequence 8363, Ap	c 199	13	0.7	17	1	US-08-682-255A-74	Sequence 74, Appl
c 127	13.8	0.7	17	1	US-09-866-108A-9572	Sequence 9572, Ap	c 200	13	0.7	17	1	US-08-682-255A-78	Sequence 78, Appl
c 128	13.8	0.7	17	1	US-09-685-664B-1079	Sequence 1079, Ap	c 201	13	0.7	17	1	US-09-429-130-74	Sequence 74, Appl
c 129	13.8	0.7	17	1	US-09-685-664B-1931	Sequence 1931, Ap	c 202	13	0.7	17	1	US-09-429-130-78	Sequence 78, Appl
c 130	13.8	0.7	17	1	US-09-685-664B-1932	Sequence 1932, Ap	c 203	13	0.7	17	1	US-09-401-063-333	Sequence 333, App
c 131	13.8	0.7	17	1	US-09-685-664B-2017	Sequence 2017, Ap	c 204	13	0.7	17	1	US-09-866-108A-2589	Sequence 2589, Ap
c 132	13.8	0.7	17	1	US-09-685-664B-2613	Sequence 2613, Ap	c 205	13	0.7	17	1	US-09-866-108A-2594	Sequence 2594, Ap
c 133	13.8	0.7	17	1	US-09-685-664B-2614	Sequence 2614, Ap	c 206	13	0.7	17	1	US-09-404-912-265	Sequence 265, App
c 134	13.8	0.7	17	1	US-09-685-664B-3602	Sequence 3602, Ap	c 207	13	0.7	17	1	US-09-685-664B-1071	Sequence 1071, Ap
c 135	13.8	0.7	17	1	PCT-US96-11786-3603	Sequence 3603, Ap	c 208	13	0.7	17	1	PCT-US91-02186-12	Sequence 12, Appl
c 136	13.8	0.7	17	1	PCT-US96-11786-46	Sequence 46, Appl	c 209	13	0.7	17	1	5514566-19	Patent No. 5514566
c 137	13.8	0.7	18	1	US-08-050-232-12	Sequence 12, Appl	c 210	12.8	0.7	16	1	US-08-239-256-4	Sequence 4, Appli
c 138	13.8	0.7	18	1	US-08-661-767-12	Sequence 12, Appl	c 211	12.8	0.7	16	1	US-08-485-692-1	Sequence 1, Appli
c 139	13.8	0.7	18	1	US-08-468-580-17	Sequence 17, Appl	c 212	12.8	0.7	16	1	US-08-419-519-1	Sequence 1, Appli
c 140	13.8	0.7	18	1	US-08-384-324-2	Sequence 2, Appli	c 213	12.8	0.7	16	1	US-08-770-235A-22	Sequence 22, Appl
c 141	13.8	0.7	18	1	US-08-244-597-14	Sequence 14, Appl	c 214	12.8	0.7	16	1	US-08-757-024-273	Sequence 273, App
c 142	13.8	0.7	18	1	US-08-389-423-31	Sequence 31, Appl	c 215	12.8	0.7	16	1	US-08-987-574-47	Sequence 47, Appl
c 143	13.8	0.7	18	1	US-09-205-860-46	Sequence 46, Appl	c 216	12.8	0.7	16	1	US-08-535-168-47	Sequence 47, Appl
c 144	13.8	0.7	18	1	US-08-957-946-14	Sequence 14, Appl	c 217	12.8	0.7	16	1	US-09-017-974-47	Sequence 47, Appl
c 145	13.8	0.7	18	1	US-08-370-740-14	Sequence 14, Appl	c 218	12.8	0.7	16	1	US-08-682-255A-47	Sequence 47, Appl
c 146	13.8	0.7	18	1	US-09-487-444-45	Sequence 45, Appl	c 219	12.8	0.7	16	1	US-09-429-130-47	Sequence 47, Appl
c 147	13.8	0.7	18	1	US-09-189-028-31	Sequence 31, Appl	c 220	12.8	0.7	16	1	US-09-371-772B-7075	Sequence 7075, Ap
c 148	13.8	0.7	18	1	US-09-197-224-14	Sequence 14, Appl	c 221	12.8	0.7	16	1	US-09-756-301B-22	Sequence 22, Appl
c 149	13.8	0.7	18	1	US-09-197-221-14	Sequence 14, Appl	c 222	12.8	0.7	16	1	US-09-152-059-1	Sequence 1, Appli
c 150	13.8	0.7	18	1	US-09-572-392A-14	Sequence 14, Appl	c 223	12.8	0.7	16	1	US-09-152-059-57	Sequence 57, Appl
c 151	13.8	0.7	18	1	US-09-723-756-14	Sequence 14, Appl	c 224	12.8	0.7	16	1	US-09-152-059-59	Sequence 59, Appl
c 152	13.8	0.7	18	1	US-09-532-840-14	Sequence 14, Appl	c 225	12.8	0.7	16	1	US-09-152-059-63	Sequence 63, Appl
c 153	13.8	0.7	18	1	US-09-747-391-9	Sequence 9, Appli	c 226	12.8	0.7	16	1	US-09-093-972C-273	Sequence 273, App
c 154	13.8	0.7	18	1	US-08-983-605-93	Sequence 125, App	c 227	12.8	0.7	16	1	US-09-958-163A-1	Sequence 1, Appli
c 155	13.8	0.7	18	1	PCT-US93-12600-17	Sequence 68, Appl	c 228	12.8	0.7	16	1	PCT-US96-11786-47	Sequence 47, Appl
c 156	13.8	0.7	18	1	PCT-US93-12600-17	Sequence 17, Appl	c 229	12.8	0.7	16	1	5177193-9	Patent No. 5177193
c 157	13.8	0.7	18	1	PCT-US93-12600-17	Sequence 17, Appl	c 230	12.8	0.7	16	1	5177193-9	Patent No. 5177193
c 158	13.8	0.7	18	1	PCT-US96-01473-2	Sequence 2, Appli	c 231	12.8	0.7	17	1	US-08-985-162-333	Sequence 333, App
c 159	13.8	0.7	18	1	US-09-180-437-104	Sequence 104, App	c 232	12.8	0.7	17	1	US-09-098-628-8	Sequence 8, Appli
c 160	13.4	0.7	15	1	US-09-371-7728-5840	Sequence 5840, Ap	c 233	12.8	0.7	17	1	US-09-401-063-333	Sequence 333, App
c 161	13.4	0.7	16	1	US-09-017-974-66	Sequence 66, Appl	c 234	12.8	0.7	17	1	PCT-US91-02186-12	Sequence 12, Appl
c 162	13.4	0.7	17	1	US-09-017-974-73	Sequence 73, Appl	c 235	12.8	0.7	17	1	5514566-19	Patent No. 5514566
c 163	13.4	0.7	17	1	US-09-017-974-73	Sequence 73, Appl	c 236	12.8	0.7	17	1	US-08-145-704-33	Sequence 33, Appl
c 164	13.4	0.7	17	1	US-09-017-974-76	Sequence 76, Appl	c 237	12.8	0.7	17	1	US-08-469-177-7	Sequence 7, Appli
c 165	13.4	0.7	17	1	US-08-682-255A-66	Sequence 66, Appl	c 238	12.8	0.7	17	1	US-08-390-850-635	Sequence 635, App
c 166	13.4	0.7	17	1	US-08-682-255A-73	Sequence 73, Appl	c 239	12.8	0.7	17	1	US-08-290-978A-9	Sequence 9, Appli
c 167	13.4	0.7	17	1	US-08-682-255A-76	Sequence 76, Appl	c 240	12.8	0.7	17	1	US-08-373-124A-192	Sequence 192, App
c 168	13.4	0.7	17	1	US-08-682-255A-77	Sequence 77, Appl	c 241	12.8	0.7	17	1	US-08-373-124A-278	Sequence 278, App
c 169	13.4	0.7	17	1	US-08-584-040-4251	Sequence 4251, Ap	c 242	12.8	0.7	17	1	US-08-373-124A-512	Sequence 512, App
c 170	13.4	0.7	17	1	US-08-584-040-5821	Sequence 5821, Ap	c 243	12.8	0.7	17	1	US-08-373-124A-514	Sequence 514, App
c 171	13.4	0.7	17	1	US-09-429-130-66	Sequence 66, Appl	c 244	12.8	0.7	17	1	US-08-373-124A-960	Sequence 960, App
c 172	13.4	0.7	17	1	US-09-429-130-73	Sequence 73, Appl	c 245	12.8	0.7	17	1	US-08-373-124A-1192	Sequence 1192, Ap
c 173	13.4	0.7	17	1	US-09-429-130-76	Sequence 76, Appl	c 246	12.8	0.7	17	1	US-08-373-124A-2325	Sequence 2325, Ap
c 174	13.4	0.7	17	1	US-09-429-130-77	Sequence 77, Appl	c 247	12.8	0.7	17	1	US-08-462-917-3	Sequence 3, Appli
c 175	13.4	0.7	17	1	US-09-132-769-8	Sequence 8, Appli	c 248	12.8	0.7	17	1	US-08-435-634-635	Sequence 635, App
c 176	13.4	0.7	17	1	US-09-371-7728-2018	Sequence 2018, Ap	c 249	12.8	0.7	17	1	US-08-653-740-20	Sequence 20, Appl
c 177	13.4	0.7	17	1	US-09-866-108A-1538	Sequence 1538, Ap	c 250	12.8	0.7	17	1	US-08-758-306-379	Sequence 379, App
c 178	13.4	0.7	17	1	US-09-866-108A-1539	Sequence 1539, Ap	c 251	12.8	0.7	17	1	US-08-758-306-381	Sequence 381, App
c 179	13.4	0.7	17	1	US-09-866-108A-1539	Sequence 1539, Ap	c 252	12.8	0.7	17	1	US-08-435-628-192	Sequence 192, App

C 253	10.8	0.7	17	1	US-08-435-628-278	Sequence 278, App	326	12.8	0.7	17	1	US-09-827-998-1724	Sequence 1724, Ap
C 254	12.8	0.7	17	1	US-08-435-628-512	Sequence 512, App	327	12.8	0.7	17	1	US-09-827-998-1725	Sequence 1725, Ap
C 255	12.8	0.7	17	1	US-08-435-628-514	Sequence 514, App	328	12.8	0.7	17	1	US-09-866-108A-1535	Sequence 1535, Ap
C 256	12.8	0.7	17	1	US-08-435-628-960	Sequence 960, App	C 329	12.8	0.7	17	1	US-09-866-108A-2360	Sequence 2360, Ap
C 257	12.8	0.7	17	1	US-08-435-628-1192	Sequence 1192, App	C 330	12.8	0.7	17	1	US-09-866-108A-2361	Sequence 2361, Ap
C 258	12.8	0.7	17	1	US-08-435-628-2325	Sequence 2325, App	C 331	12.8	0.7	17	1	US-09-866-108A-6976	Sequence 6976, Ap
C 259	12.8	0.7	17	1	US-08-780-869-9	Sequence 9, Appl	C 332	12.8	0.7	17	1	US-09-866-108A-6977	Sequence 6977, Ap
C 260	12.8	0.7	17	1	US-09-073-594-20	Sequence 20, Appl	C 333	12.8	0.7	17	1	US-09-866-108A-7125	Sequence 7125, Ap
C 261	12.8	0.7	17	1	US-08-757-024-236	Sequence 236, App	C 334	12.8	0.7	17	1	US-09-866-108A-7126	Sequence 7126, Ap
C 262	12.8	0.7	17	1	US-08-757-024-272	Sequence 272, App	C 335	12.8	0.7	17	1	US-09-866-108A-8359	Sequence 8359, Ap
C 263	12.8	0.7	17	1	US-08-985-162-42	Sequence 42, Appl	C 336	12.8	0.7	17	1	US-09-866-108A-8361	Sequence 8361, Ap
C 264	12.8	0.7	17	1	US-08-985-162-665	Sequence 665, App	C 337	12.8	0.7	17	1	US-09-866-108A-8362	Sequence 8362, Ap
C 265	12.8	0.7	17	1	US-09-275-925-20	Sequence 20, Appl	C 338	12.8	0.7	17	1	US-09-866-108A-9536	Sequence 9536, Ap
C 266	12.8	0.7	17	1	US-08-987-574-33	Sequence 33, Appl	C 339	12.8	0.7	17	1	US-09-866-108A-9537	Sequence 9537, Ap
C 267	12.8	0.7	17	1	US-08-535-168-33	Sequence 33, Appl	C 340	12.8	0.7	17	1	US-09-866-108A-9571	Sequence 9571, Ap
C 268	12.8	0.7	17	1	US-08-720-625-9	Sequence 9, Appl	C 341	12.8	0.7	17	1	US-09-866-108A-9573	Sequence 9573, Ap
C 269	12.8	0.7	17	1	US-09-017-974-33	Sequence 33, Appl	C 342	12.8	0.7	17	1	US-09-866-108A-10256	Sequence 10256, A
C 270	12.8	0.7	17	1	US-09-017-974-58	Sequence 58, Appl	C 343	12.8	0.7	17	1	US-09-866-108A-10257	Sequence 10257, A
C 271	12.8	0.7	17	1	US-09-017-974-59	Sequence 59, Appl	C 344	12.8	0.7	17	1	US-09-404-912-155	Sequence 155, App
C 272	12.8	0.7	17	1	US-09-017-974-68	Sequence 68, Appl	C 345	12.8	0.7	17	1	US-09-155-885A-101	Sequence 101, App
C 273	12.8	0.7	17	1	US-09-017-974-72	Sequence 72, Appl	C 346	12.8	0.7	17	1	US-10-029-598-30	Sequence 30, Appl
C 274	12.8	0.7	17	1	US-09-017-974-80	Sequence 80, Appl	C 347	12.8	0.7	17	1	US-09-685-664B-333	Sequence 333, App
C 275	12.8	0.7	17	1	US-09-017-974-81	Sequence 81, Appl	C 348	12.8	0.7	17	1	US-09-685-664B-477	Sequence 477, App
C 276	12.8	0.7	17	1	US-09-017-974-87	Sequence 87, Appl	C 349	12.8	0.7	17	1	US-09-685-664B-1080	Sequence 1080, Ap
C 277	12.8	0.7	17	1	US-08-682-255A-33	Sequence 33, Appl	C 350	12.8	0.7	17	1	US-09-685-664B-1705	Sequence 1705, Ap
C 278	12.8	0.7	17	1	US-08-682-255A-58	Sequence 58, Appl	C 351	12.8	0.7	17	1	US-09-685-664B-2671	Sequence 2671, Ap
C 279	12.8	0.7	17	1	US-08-682-255A-59	Sequence 59, Appl	C 352	12.8	0.7	17	1	US-09-685-664B-3604	Sequence 3604, Ap
C 280	12.8	0.7	17	1	US-08-682-255A-68	Sequence 68, Appl	C 353	12.8	0.7	17	1	US-09-093-972C-236	Sequence 236, App
C 281	12.8	0.7	17	1	US-08-682-255A-72	Sequence 72, Appl	C 354	12.8	0.7	17	1	US-09-093-972C-272	Sequence 272, App
C 282	12.8	0.7	17	1	US-08-682-255A-80	Sequence 80, Appl	C 355	12.8	0.7	17	1	PCT-US96-11786-33	Sequence 33, Appl
C 283	12.8	0.7	17	1	US-08-682-255A-81	Sequence 81, Appl	C 356	12.6	0.7	15	1	US-08-431-048F-151	Sequence 151, App
C 284	12.8	0.7	17	1	US-08-682-255A-87	Sequence 87, Appl	C 357	12.4	0.7	14	1	US-08-294-424-46	Sequence 46, Appl
C 285	12.8	0.7	17	1	US-08-584-040-1788	Sequence 1788, Ap	C 358	12.4	0.7	14	1	US-09-152-059-116	Sequence 116, App
C 286	12.8	0.7	17	1	US-08-584-040-1932	Sequence 1932, Ap	C 359	12.4	0.7	14	1	US-08-875-553D-14	Sequence 14, Appl
C 287	12.8	0.7	17	1	US-08-584-040-3938	Sequence 3938, Ap	C 360	12.4	0.7	14	1	US-09-981-803-32	Sequence 32, Appl
C 288	12.8	0.7	17	1	US-08-584-040-5806	Sequence 5806, Ap	C 361	12.4	0.7	14	1	US-09-981-803-48	Sequence 48, Appl
C 289	12.8	0.7	17	1	US-08-584-040-7820	Sequence 7820, Ap	C 362	12.4	0.7	14	1	US-09-699-295-130	Sequence 130, App
C 290	12.8	0.7	17	1	US-09-429-130-33	Sequence 33, Appl	C 363	12.4	0.7	15	1	US-08-334-847-92	Sequence 92, Appl
C 291	12.8	0.7	17	1	US-09-429-130-58	Sequence 58, Appl	C 364	12.4	0.7	15	1	US-08-334-847-615	Sequence 615, App
C 292	12.8	0.7	17	1	US-09-429-130-59	Sequence 59, Appl	C 365	12.4	0.7	15	1	US-08-908-724-1	Sequence 1, Appl
C 293	12.8	0.7	17	1	US-09-429-130-68	Sequence 68, Appl	C 366	12.4	0.7	15	1	US-08-173-489C-87	Sequence 87, Appl
C 294	12.8	0.7	17	1	US-09-429-130-72	Sequence 72, Appl	C 367	12.4	0.7	15	1	US-09-115-446-3	Sequence 3, Appl
C 295	12.8	0.7	17	1	US-09-429-130-80	Sequence 80, Appl	C 368	12.4	0.7	15	1	US-08-584-040-8462	Sequence 8462, Ap
C 296	12.8	0.7	17	1	US-09-429-130-81	Sequence 81, Appl	C 369	12.4	0.7	15	1	US-09-475-947A-304	Sequence 304, App
C 297	12.8	0.7	17	1	US-09-429-130-87	Sequence 87, Appl	C 370	12.4	0.7	15	1	US-09-371-772B-4117	Sequence 4117, Ap
C 298	12.8	0.7	17	1	US-09-474-432B-558	Sequence 558, App	C 371	12.4	0.7	15	1	US-09-565-590-3	Sequence 3, Appl
C 299	12.8	0.7	17	1	US-09-474-432B-559	Sequence 559, App	C 372	12.4	0.7	15	1	US-09-685-664B-4117	Sequence 4117, Ap
C 300	12.8	0.7	17	1	US-09-474-432B-677	Sequence 677, App	C 373	12.4	0.7	15	1	PCT-US93-12600-18	Sequence 18, Appl
C 301	12.8	0.7	17	1	US-09-474-432B-876	Sequence 876, App	C 374	12.4	0.7	15	1	5182195-33	Patent No. 5182195
C 302	12.8	0.7	17	1	US-09-371-772B-333	Sequence 333, App	C 375	12.4	0.7	15	1	5182195-33	Patent No. 5182195
C 303	12.8	0.7	17	1	US-09-371-772B-477	Sequence 477, App	C 376	12.4	0.7	16	1	US-08-419-414-13	Sequence 13, Appl
C 304	12.8	0.7	17	1	US-09-371-772B-1705	Sequence 1705, Ap	C 377	12.4	0.7	16	1	US-09-564-805-92	Sequence 92, Appl
C 305	12.8	0.7	17	1	US-09-371-772B-2671	Sequence 2671, Ap	C 378	12.4	0.7	16	1	US-09-060-299-443	Sequence 443, App
C 306	12.8	0.7	17	1	US-09-371-772B-3604	Sequence 3604, Ap	C 379	12.4	0.7	16	1	US-09-402-923A-443	Sequence 443, App
C 307	12.8	0.7	17	1	US-09-371-772B-4280	Sequence 4280, Ap	C 380	12.4	0.7	16	1	US-09-371-772B-5841	Sequence 5841, Ap
C 308	12.8	0.7	17	1	US-09-371-772B-4407	Sequence 4407, Ap	C 381	12.4	0.7	16	1	US-09-371-772B-5844	Sequence 5844, Ap
C 309	12.8	0.7	17	1	US-09-371-772B-4766	Sequence 4766, Ap	C 382	12.4	0.7	16	1	US-09-750-401-6	Sequence 6, Appl
C 310	12.8	0.7	17	1	US-09-371-772B-4869	Sequence 4869, Ap	C 383	12.4	0.7	16	1	US-09-479-005A-332	Sequence 332, App
C 311	12.8	0.7	17	1	US-09-371-772B-5113	Sequence 5113, Ap	C 384	12.4	0.7	15	1	US-08-173-489C-87	Sequence 87, Appl
C 312	12.8	0.7	17	1	US-09-371-772B-5139	Sequence 5139, Ap							
C 313	12.8	0.7	17	1	US-09-371-772B-5170	Sequence 5170, Ap							
C 314	12.8	0.7	17	1	US-09-371-772B-5171	Sequence 5171, Ap							
C 315	12.8	0.7	17	1	US-09-371-772B-5340	Sequence 5340, Ap							
C 316	12.8	0.7	17	1	US-09-371-772B-5341	Sequence 5341, Ap							
C 317	12.8	0.7	17	1	US-09-371-772B-5349	Sequence 5349, Ap							
C 318	12.8	0.7	17	1	US-09-371-772B-6331	Sequence 6331, Ap							
C 319	12.8	0.7	17	1	US-09-371-772B-6591	Sequence 6591, Ap							
C 320	12.8	0.7	17	1	US-09-476-387-557	Sequence 557, App							
C 321	12.8	0.7	17	1	US-09-476-387-558	Sequence 558, App							
C 322	12.8	0.7	17	1	US-09-476-387-676	Sequence 676, App							
C 323	12.8	0.7	17	1	US-09-476-387-875	Sequence 875, App							
C 324	12.8	0.7	17	1	US-09-401-063-42	Sequence 42, Appl							
C 325	12.8	0.7	17	1	US-09-401-063-665	Sequence 665, App							

ALIGNMENTS

RESULT 1

US-09-396-196G-36103/c
; Sequence 36103, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.

```
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 36103
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-36103

Query Match      1.1%; Score 19.8; DB 1; Length 25;
Best Local Similarity 91.3%; Pred. No. 19;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 961 GTGGACATCTGGACAGCTGGGAT 983
Db 25 GTGGACATCTGGTCTGAGCTGGGGT 3

RESULT 2
US-09-396-196G-127295
; Sequence 127295, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 127295
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-127295

Query Match      1.0%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 25;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 138 CTTTATCCCTGCTGCTCTGGAAA 161
Db 1 CTTTATCCCTGCTGCTCTGGCAAA 24

RESULT 3
US-09-396-196G-36101/c
; Sequence 36101, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 36101

; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-36101

Query Match      1.0%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 29;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 962 TGGACATCTGGACAGCTGGGAT 983
Db 25 TGGACATCTGGTCTGAGCTGGGGT 4

RESULT 4
US-09-766-253-132/c
; Sequence 132, Application US/09766253
; Patent No. 6808880
; GENERAL INFORMATION:
; APPLICANT: Cech, Thomas R.
; APPLICANT: Lingner, Joachim
; APPLICANT: Nakamura, Toru
; APPLICANT: Chapman, Karen B.
; APPLICANT: Morin, Gregg B.
; APPLICANT: Harley, Calvin
; APPLICANT: Andrews, William H.
; TITLE OF INVENTION: No. 6808880el Telomerase
; NUMBER OF SEQUENCES: 171
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/766,253
; FILING DATE: 19-Jan-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/846,017
; FILING DATE: 1997-04-25
; APPLICATION NUMBER: US 08/724,643
; FILING DATE: 01-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 015389-002920US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 132:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 132:
US-09-766-253-132

Query Match      0.9%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 17 AAAAAAAAAAAAAAAAAA 1
```

RESULT 5

US-09-685-664B-1075/c
; Sequence 1075, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1075
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1075

Query Match 0.9%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAAAAAAAAAAAA 1850
Db 17 GAAAAAAAAAAAAAAAAA 1

RESULT 6

US-09-809-545A-84/c
; Sequence 84, Application US/09809545A
; Patent No. 6800455
; GENERAL INFORMATION:
; APPLICANT: Stanton, Lawrence W.
; APPLICANT: White, R. Tyler
; TITLE OF INVENTION: SECRETED FACTORS
; FILE REFERENCE: SCIOS.017A
; CURRENT APPLICATION NUMBER: US/09/809,545A
; CURRENT FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 84
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligos corresponding to polylinker sequence.
US-09-809-545A-84

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 7

US-10-352-704-12/c
; Sequence 12, Application US/10352704
; Patent No. 6825339

GENERAL INFORMATION:

APPLICANT: Chatelain, Francois
Kumarev, Viktor
TITLE OF INVENTION: Process for Preparing Polynucleotides on
a Solid Support and Apparatus Permitting its
Implementation
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Jacobson, Price, Holman & Stern
STREET: 400 Seventh St. N.W.
CITY: Washington D.C.
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/352,704
FILING DATE: 28-Jan-2003
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/358,556A
FILING DATE: 14-DEC-1994
APPLICATION NUMBER: FR 9315164
FILING DATE: 16-DEC-1993
ATTORNEY/AGENT INFORMATION:
NAME: Player, William E.
REGISTRATION NUMBER: 31,409
REFERENCE/DOCKET NUMBER: 10577/P58418
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 638-6666
TELEFAX: (202) 393-5350
TELEX: RCA 248593 IDEA UR
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: N-terminal
FEATURE:
NAME/KEY: CDS
LOCATION: 1..18
SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-10-352-704-12
Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2
RESULT 8
US-10-352-704-18
; Sequence 18, Application US/10352704
; Patent No. 6825339
; GENERAL INFORMATION:
; APPLICANT: Chatelain, Francois
; Kumarev, Viktor
; TITLE OF INVENTION: Process for Preparing Polynucleotides on
; a Solid Support and Apparatus Permitting its
; Implementation
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:

ADDRESSEE: Jacobson, Price, Holman & Stern
STREET: 400 Seventh St. N.W.
CITY: Washington D.C.
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20004
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/352,704
FILING DATE: 28-Jan-2003
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/358,556A
FILING DATE: 14-DEC-1994
APPLICATION NUMBER: FR 9315164
FILING DATE: 16-DEC-1993
ATTORNEY/AGENT INFORMATION:
NAME: Player, William E.
REGISTRATION NUMBER: 31,409
REFERENCE/DOCKET NUMBER: 10577/P58418
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202)638-6666
TELEFAX: (202) 393-5350
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: N-terminal
FEATURE:
NAME/KEY: CDS
LOCATION: 1..18
SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-352-704-18
Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 1 AAAAAAAAAAAAAAAAAA 17
RESULT 9
US-09-976-618A-55
Sequence 55, Application US/09976618A
Patent No. 6812334
GENERAL INFORMATION:
APPLICANT: Mirkin, Chad A.
APPLICANT: Letsinger, Robert L.
APPLICANT: Mucic, Robert C.
APPLICANT: Storhoff, James J.
APPLICANT: Elghanian, Robert
APPLICANT: Taton, Thomas A.
TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
FILE REFERENCE: 00-713-121
CURRENT APPLICATION NUMBER: US/09/976,618A
CURRENT FILING DATE: 2001-10-12
PRIOR APPLICATION NUMBER: 09/603,830
PRIOR FILING DATE: 2000-06-26
PRIOR APPLICATION NUMBER: 09/344,667
PRIOR FILING DATE: 1999-06-25

PRIOR APPLICATION NUMBER: 09/240,755
PRIOR FILING DATE: 1999-01-29
PRIOR APPLICATION NUMBER: PCT/US97/12783
PRIOR FILING DATE: 1997-07-21
PRIOR APPLICATION NUMBER: 60/031,809
PRIOR FILING DATE: 1996-07-29
PRIOR APPLICATION NUMBER: 60/200,161
PRIOR FILING DATE: 2000-04-26
NUMBER OF SEQ ID NOS: 64
SOFTWARE: Microsoft Word 2000
SEQ ID NO 55
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: random
US-09-976-618A-55
Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 1 AAAAAAAAAAAAAAAAAA 17
RESULT 10
US-09-976-968A-55
Sequence 55, Application US/09976968A
Patent No. 6818753
GENERAL INFORMATION:
APPLICANT: Mirkin, Chad A.
APPLICANT: Letsinger, Robert L.
APPLICANT: Mucic, Robert C.
APPLICANT: Storhoff, James J.
APPLICANT: Elghanian, Robert
APPLICANT: Taton, Thomas A.
TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
FILE REFERENCE: 00-713-117
CURRENT APPLICATION NUMBER: US/09/976,968A
CURRENT FILING DATE: 2001-10-12
PRIOR APPLICATION NUMBER: 09/603,830
PRIOR FILING DATE: 2000-06-26
PRIOR APPLICATION NUMBER: 09/344,667
PRIOR FILING DATE: 1999-06-25
PRIOR APPLICATION NUMBER: 09/240,755
PRIOR FILING DATE: 1999-01-29
PRIOR APPLICATION NUMBER: PCT/US97/12783
PRIOR FILING DATE: 1997-07-21
PRIOR APPLICATION NUMBER: 60/031,809
PRIOR FILING DATE: 1996-07-29
PRIOR APPLICATION NUMBER: 60/200,161
PRIOR FILING DATE: 2000-04-26
NUMBER OF SEQ ID NOS: 64
SOFTWARE: Microsoft Word 2000
SEQ ID NO 55
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: random
US-09-976-968A-55
Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 1 AAAAAAAAAAAAAAAAAA 17


```
Db      1 AAAAAAAAAAAAAAAAAA 17

RESULT 11
US-10-234-764-10/c
; Sequence 10, Application US/10234764
; Patent No. 6825331
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Lonnberg, Harri
; APPLICANT: Salo, Harri
; APPLICANT: Virta, Pasi
; TITLE OF INVENTION: Aminoxy Functionalized Oligomers
; FILE REFERENCE: ISIS5089
; CURRENT APPLICATION NUMBER: US/10/234,764
; CURRENT FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: 09/016,520
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 09/344,260
; PRIOR FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-234-764-10

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1835 AAAAAAAAAAAAAAAAAA 1851
        |||||
Db      20 AAAAAAAAAAAAAAAAAA 4

RESULT 12
US-09-975-059A-55
; Sequence 55, Application US/09975059A
; Patent No. 6828432
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Strohoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-i15
; CURRENT APPLICATION NUMBER: US/09/975,059A
; CURRENT FILING DATE: 2001-10-11
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
US-09-975-059A-55

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1835 AAAAAAAAAAAAAAAAAA 1851
        |||||
Db      20 AAAAAAAAAAAAAAAAAA 4

RESULT 13
US-09-859-736-3/c
; Sequence 3, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-859-736-3

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1835 AAAAAAAAAAAAAAAAAA 1851
        |||||
Db      20 AAAAAAAAAAAAAAAAAA 4

RESULT 14
US-09-859-736-4/c
; Sequence 4, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-859-736-4

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 44;
```



```
; MOLECULE TYPE: Other nucleic acid
US-08-863-639A-67

Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 67;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 28 GCGGCTCCGTCGCGCGGTC 48
    ||||| ||||| ||||| |||||
Db 1 GCGGCGCGCGCGCGCGCGCC 21

RESULT 19
US-08-863-639A-71/c
; Sequence 71, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Matson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel WordPerfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863.639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Mueth
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-08-863-639A-71

Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 67;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 28 GCGGCTCCGTCGCGCGGTC 48
    ||||| ||||| ||||| |||||
Db 21 GCGGCGCGCGCGCGCGGCC 1

RESULT 20
US-08-416-214A-11/c
; Sequence 11, Application US/08416214A
; Patent No. 5998596
; GENERAL INFORMATION:
; APPLICANT: Bergan, Raymond; Neckers, Len
; TITLE OF INVENTION: Inhibition Of Protein
; TITLE OF INVENTION: Kinase Activity By Aptameric Action Of
; TITLE OF INVENTION: Oligonucleotides
```

```
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/416,214A
; FILING DATE: 04-APR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Kathryn M.
; REGISTRATION NUMBER: 34,556
; REFERENCE/DOCKET NUMBER: 2026-4166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; TELEX: 421792
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: Nucleic acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; MOLECULE TYPE: Other nucleic acid
; HYPOTHETICAL: Yes
; ANTI-SENSE: NO
US-08-416-214A-11

Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 67;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 28 GCGGCTCCGTCGCGCGGTC 48
    ||||| ||||| ||||| |||||
Db 21 GCGGCGCGCGCGCGCGGCC 1

RESULT 21
US-09-765-111A-32
; Sequence 32, Application US/09765111A
; Patent No. 6723506
; GENERAL INFORMATION:
; APPLICANT: Fletcher, Jonathan A.
; APPLICANT: Kroll, Todd G.
; TITLE OF INVENTION: PAX8-PPARGAMMA NUCLEIC ACID MOLECULES
; TITLE OF INVENTION: AND POLYPEPTIDES AND USES THEREOF
; FILE REFERENCE: B0801/7196/ERP/MAT
; CURRENT APPLICATION NUMBER: US/09/765,111A
; CURRENT FILING DATE: 2001-01-18
; PRIOR APPLICATION NUMBER: US 60/177,109
; PRIOR FILING DATE: 2000-01-20
; PRIOR APPLICATION NUMBER: US 60/225,079
; PRIOR FILING DATE: 2000-08-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 32
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-765-111A-32

Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 67;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 886 ACCAGACTACTGATTCCTTCA 906
```

Db 1 ACCCAGAAAGCGATTCCTTCA 21
||||| | |||||

RESULT 22

US-09-766-253-131
; Sequence 131, Application US/09766253
; Patent No. 6808880

GENERAL INFORMATION:

; APPLICANT: Cech, Thomas R.
; Lingner, Joachim
; Nakamura, Toru
; Chapman, Karen B.
; Morin, Gregg B.
; Harley, Calvin
; Andrews, William H.

TITLE OF INVENTION: No. 6808880el Telomerase

NUMBER OF SEQUENCES: 171

CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94111

COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/766,253

; FILING DATE: 19-Jan-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/846,017

; FILING DATE: 1997-04-25

; APPLICATION NUMBER: US 08/724,643

; FILING DATE: 01-OCT-1996

ATTORNEY/AGENT INFORMATION:

; NAME: Apple, Randolph T.

; REGISTRATION NUMBER: 36,429

REFERENCE/DOCKET NUMBER: 015389-002920US

TELECOMMUNICATION INFORMATION:

; TELEPHONE: (415) 576-0200

; TELEFAX: (415) 576-0300

INFORMATION FOR SEQ ID NO: 131:

SEQUENCE CHARACTERISTICS:

; LENGTH: 16 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 131:

US-09-766-253-131

Query Match 0.9%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1850

Db 1 AAAAAAAAAAAAAA 16
|||||

RESULT 23

US-09-685-664B-1074/c
; Sequence 1074, Application US/09685664B
; Patent No. 6818447

GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)

; CURRENT APPLICATION NUMBER: US/09/685,664B

; CURRENT FILING DATE: 2000-10-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; PRIOR APPLICATION NUMBER: US 09/371,772

; PRIOR FILING DATE: 1999-08-10

; NUMBER OF SEQ ID NOS: 8231

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1074

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-685-664B-1074

Query Match 0.9%; Score 16; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 51;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1850

Db 17 AAAAAAAAAAAAAA 2
|||||

RESULT 24

US-09-685-664B-1076/c

; Sequence 1076, Application US/09685664B

; Patent No. 6818447

GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBH00-876-K (400/021)

; CURRENT APPLICATION NUMBER: US/09/685,664B

; CURRENT FILING DATE: 2000-10-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; PRIOR APPLICATION NUMBER: US 09/371,772

; PRIOR FILING DATE: 1999-08-10

; NUMBER OF SEQ ID NOS: 8231

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1076

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-685-664B-1076

Query Match 0.9%; Score 16; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 51;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1834 GAAAAAAAAAAAAA 1849

Db 16 GAAAAAAAAAAAAA 1
|||||

RESULT 25

US-09-090-672B-107/c

; Sequence 107, Application US/09090672B

; Patent No. 6828428

GENERAL INFORMATION:

; APPLICANT: Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura,

APPLICANT: Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,
APPLICANT: Shigemasa; Takei, Masami
TITLE OF INVENTION: IGA Nephropathy-Related Genes
NUMBER OF SEQUENCES: 111
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
ZIP: 10112-3801
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: Compaq PC
OPERATING SYSTEM: Windows 95
SOFTWARE: WordPerfect 8.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/090,672B
FILING DATE: 04-JUNE-1998
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/JP97/04468
FILING DATE: 05-DEC-1997
APPLICATION NUMBER: JP-8-325763
FILING DATE: 05-DEC-1996
ATTORNEY/AGENT INFORMATION:
NAME: Perry, Lawrence S.
REGISTRATION NUMBER: 31865
REFERENCE/DOCKET NUMBER: 766.21
TELEPHONE: (212) 218-2100
TELEFAX: (212) 218-2200
INFORMATION FOR SEQ ID NO: 107:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid, synthetic DNA
US-09-090-672B-107

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 51;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAAAAAAAAAAAA 1849
Db 17 GAAAAAAAAAAAAAAAAA 2

RESULT 26
US-09-904-744-1
Sequence 1, Application US/09904744
Patent No. 6828142
GENERAL INFORMATION:
APPLICANT: Barbera-Guillem, Emilio
APPLICANT: Nelson, M. Bud
APPLICANT: Castro, Stephanie
TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
TITLE OF INVENTION: dendrimers in a signal amplification system
FILE REFERENCE: B-73
CURRENT APPLICATION NUMBER: US/09/904,744
CURRENT FILING DATE: 2001-07-13
PRIOR APPLICATION NUMBER: 09/437076
PRIOR FILING DATE: 1999-11-09
PRIOR APPLICATION NUMBER: 60/107828
PRIOR FILING DATE: 1998-11-10
NUMBER OF SEQ ID NOS: 6
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:

APPLICANT: Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,
APPLICANT: Shigemasa; Takei, Masami
TITLE OF INVENTION: IGA Nephropathy-Related Genes
NUMBER OF SEQUENCES: 111
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
ZIP: 10112-3801
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: Compaq PC
OPERATING SYSTEM: Windows 95
SOFTWARE: WordPerfect 8.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/090,672B
FILING DATE: 04-JUNE-1998
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/JP97/04468
FILING DATE: 05-DEC-1997
APPLICATION NUMBER: JP-8-325763
FILING DATE: 05-DEC-1996
ATTORNEY/AGENT INFORMATION:
NAME: Perry, Lawrence S.
REGISTRATION NUMBER: 31865
REFERENCE/DOCKET NUMBER: 766.21
TELEPHONE: (212) 218-2100
TELEFAX: (212) 218-2200
INFORMATION FOR SEQ ID NO: 107:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid, synthetic DNA
US-09-090-672B-107

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 51;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAAAAAAAAAAAA 1849
Db 17 GAAAAAAAAAAAAAAAAA 2

RESULT 26
US-09-904-744-1
Sequence 1, Application US/09904744
Patent No. 6828142
GENERAL INFORMATION:
APPLICANT: Barbera-Guillem, Emilio
APPLICANT: Nelson, M. Bud
APPLICANT: Castro, Stephanie
TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
TITLE OF INVENTION: dendrimers in a signal amplification system
FILE REFERENCE: B-73
CURRENT APPLICATION NUMBER: US/09/904,744
CURRENT FILING DATE: 2001-07-13
PRIOR APPLICATION NUMBER: 09/437076
PRIOR FILING DATE: 1999-11-09
PRIOR APPLICATION NUMBER: 60/107828
PRIOR FILING DATE: 1998-11-10
NUMBER OF SEQ ID NOS: 6
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: synthesized
US-09-904-744-1

Query Match 0.9%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 56;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAAAAAAAAAAAA 1849
Db 3 GAAAAAAAAAAAAAAAAA 18

RESULT 27
US-09-696-791-479/c
Sequence 479, Application US/09696791.
Patent No. 6770633
GENERAL INFORMATION:
APPLICANT: Robbins, Joan M.
APPLICANT: Tritz, Richard
TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
TITLE OF INVENTION: SKIN AND EYE DISEASES
FILE REFERENCE: 480124.407
CURRENT APPLICATION NUMBER: US/09/696,791
CURRENT FILING DATE: 2000-10-25
NUMBER OF SEQ ID NOS: 4523
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 479
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
OTHER INFORMATION: Cdk4 ribozyme binding site
US-09-696-791-479

Query Match 0.9%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1095 TGGACTGCAGAGAAC 1110
Db 19 TGGACTGCAGAGAAC 4

RESULT 28
US-09-037-990B-79
Sequence 79, Application US/09037990B
Patent No. 6248519.
GENERAL INFORMATION:
APPLICANT: ENGEL, Stacia R.
DESCENZO, Richard A.
MORENZONI, Richard A.
IRELAN, Nancy A.
TITLE OF INVENTION: DETECTION OF FERMENTATION-RELATED
MICROORGANISMS
NUMBER OF SEQUENCES: 100
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/037,990B
FILING DATE: 11-Mar-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: <Unknown>

```
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Sharp, Jeffrey S.
; REGISTRATION NUMBER: 31,879
; REFERENCE/DOCKET NUMBER: 29520/30001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 79:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 79:
US-09-037-990B-79

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1696 AATCATTCCTCCCTCCCTC 1714
Db 1 AATCATTCCTCCCTCACTC 19

RESULT 29
US-09-475-947A-12/c
; Sequence 12, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 19
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-12

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1516 AGAACAAGTAAGAAAGAA 1534
Db 19 AGAACAAGTAAGAAAGAA 1

RESULT 30
US-09-696-791-3050/c
; Sequence 3050, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3050
; LENGTH: 19

; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Sharp, Jeffrey S.
; REGISTRATION NUMBER: 31,879
; REFERENCE/DOCKET NUMBER: 29520/30001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 79:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 79:
US-09-037-990B-79

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1696 AATCATTCCTCCCTCCCTC 1714
Db 1 AATCATTCCTCCCTCACTC 19

RESULT 29
US-09-475-947A-12/c
; Sequence 12, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 19
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-12

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1516 AGAACAAGTAAGAAAGAA 1534
Db 19 AGAACAAGTAAGAAAGAA 1

RESULT 30
US-09-696-791-3050/c
; Sequence 3050, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3050
; LENGTH: 19

; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin A1 ribozyme binding site
US-09-696-791-3050

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 436 GGGAGAGGGGAGGAATC 454
Db 19 GGGAGAGGGGAGGATGATC 1

RESULT 31
US-09-696-791-3051/c
; Sequence 3051, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3051
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin A1 ribozyme binding site
US-09-696-791-3051

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 434 CTGGGAGAGGGGAGAGAA 452
Db 19 CTGGGAGAGGGGAGAGATGA 1

RESULT 32
US-08-215-138-16
; Sequence 16, Application US/08215138
; Patent No. 5470719
; GENERAL INFORMATION:
; APPLICANT: Meng, Shi-Yuan
; APPLICANT: Morris, Charles F.
; APPLICANT: Tsai, Larry B.
; TITLE OF INVENTION: Enhanced Secretion of Polypeptides
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc., U.S. Patent Operations/NAO
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: CA
; COUNTRY: USA
; ZIP: 91320
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/215,138
; FILING DATE:
; CLASSIFICATION: 530
; INFORMATION FOR SEQ ID NO: 16:
```

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-215-138-16

Query Match          0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1680 TGATTCTAGAAAAAGGAAT 1698
Db 2 TGATTCTAGAGGAGGAAT 20

RESULT 33
US-08-407-344-16
; Sequence 16, Application US/08407344
; Patent No. 5608036
; GENERAL INFORMATION:
; APPLICANT: Meng, Shi-Yuan
; APPLICANT: Morris, Charles F.
; APPLICANT: Tsai, Larry B.
; TITLE OF INVENTION: Enhanced Secretion of Polypeptides
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc., U.S. Patent Operations/NAO
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: CA
; COUNTRY: USA
; ZIP: 91320
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/407,344
; FILING DATE:
; CLASSIFICATION: 530
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-407-344-16

Query Match          0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1680 TGATTCTAGAAAAAGGAAT 1698
Db 2 TGATTCTAGAGGAGGAAT 20

RESULT 34
US-09-198-452A-6169/c
; Sequence 6169, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24

; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-6169

Query Match          0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1440 ATGAATGTTGCTGCTGCTG 1458
Db 19 ATGATTGTTGCTGCTGCGG 1

RESULT 35
US-08-863-639A-52
; Sequence 52, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Matson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampel, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel Wordperfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Mueth
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-08-863-639A-52

Query Match          0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 79;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCCCTCGCTCGCGCCG 46
Db 3 GCCGCCCGCCGCCGCCG 21

RESULT 36
US-08-863-639A-55
; Sequence 55, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
```

APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Mueth
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 55:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-55

Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 79;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCTCGTCGCCGCCG 46
|||||
Db 2 GCCGCGCCGCCGCCGCCG 20

RESULT 37
US-08-863-639A-56/c
Sequence 56, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997

CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Mueth
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 56:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-56

Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 79;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCTCGTCGCCGCCG 46
|||||
Db 19 GCCGCGCCGCCGCCGCCG 1

RESULT 38
US-08-863-639A-68/c
Sequence 68, Application US/08863639A
Patent No. 5981185
GENERAL INFORMATION:
APPLICANT: Matson, Robert S.
APPLICANT: Coassin, Peter J.
APPLICANT: Rampal, Jang B.
APPLICANT: Caskey, C. T.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sheldon & Mak
STREET: 225 South Lake Avenue, 9th Floor
CITY: Pasadena
STATE: CA
COUNTRY: USA
ZIP: 91101
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: Corel WordPerfect 8 version
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,639A
FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Mueth
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELEPHONE: (626) 796-4000
TELEFAX: (626) 795-6321
INFORMATION FOR SEQ ID NO: 68:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-68

Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 79;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;


```

RESULT 40
US-08-282-197C-28
; Sequence 28, Application US/08282197C
; Patent No. 5871730
; GENERAL INFORMATION:
; APPLICANT: Brzezinski, Ryszard
; APPLICANT: Dery, Claude V
; APPLICANT: Beaulieu, Carole
; TITLE OF INVENTION: Thermostable Xylanase DNA, Protein and
; TITLE OF INVENTION: Methods of Use
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
; STREET: 1100 New York Ave., NW
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/282,197C
; FILING DATE: 29-JUL-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Cimbala, Michele A
; REGISTRATION NUMBER: 33.851

```

```
RESULT 42
US-08-970-740-8/c
; Sequence 8, Application US/08970740
; Patent No. 6015670
; GENERAL INFORMATION:
; APPLICANT: Goodfellow, P.N.
; TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A
; TITLE OF INVENTION: GENE OF INTEREST
; NUMBER OF SEQUENCES: 162
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Inc.
; STREET: 28 State Street, 28th Floor
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/970,740
; FILING DATE: 14-NOV-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/857,946
; FILING DATE: 16-MAY-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/017,824
; FILING DATE: 17-MAY-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathleen M. Williams
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: 3529/59829
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-227-7111
; TELEFAX: 617-227-4399
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; US-08-970-740-8

Query Match      0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 73;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 30 CGCCTCCGTCGCGCCG 46
Db 18 CGCGCGCGTCGCGCCG 2

RESULT 43
US-09-710-794-8
; Sequence 8, Application US/09710794
; Patent No. 6573069
; GENERAL INFORMATION:
; APPLICANT: Holloway, James L.
; APPLICANT: Gao, Zeren
; APPLICANT: Whitmore, Theodore E.
; TITLE OF INVENTION: NOVEL CRIB PROTEIN ZMSE1
; FILE REFERENCE: 99-76
; CURRENT APPLICATION NUMBER: US/09/710,794
; CURRENT FILING DATE: 2000-11-09
; PRIOR APPLICATION NUMBER: US 60/164,685
; PRIOR FILING DATE: 1999-11-10
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
```

```
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC18860
US-09-710-794-8

Query Match      0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 73;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 714 TCCGTGGCCTCTCTTC 730
Db 1 TCCGGGCGCCTCTCTTC 17

RESULT 44
US-09-198-452A-6103
; Sequence 6103, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Grifais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6103
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
; US-09-198-452A-6103

Query Match      0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 150 TGCTCTGGGAAAGCTAT 166
Db 2 TGCTCTGGGAAAGCTAT 18

RESULT 45
US-10-058-422A-14/c
; Sequence 14, Application US/10058422A
; Patent No. 6815165
; GENERAL INFORMATION:
; APPLICANT: LEE, HyeYoung
; APPLICANT: CHO, Sang-Nae
; TITLE OF INVENTION: A method for identifying Mycobacterium tuberculosis and
; TITLE OF INVENTION: non-tuberculosis Mycobacteria, together with detecting resistance
; TITLE OF INVENTION: to an antituberculosis drug of Mycobacteria obtained by mutation
; TITLE OF INVENTION: of rpoB gene
; FILE REFERENCE: 912-27
; CURRENT APPLICATION NUMBER: US/10/058,422A
; CURRENT FILING DATE: 2002-01-30
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: KopatentIn 1.71
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligomer probe for M. abscessus
US-10-058-422A-14

Query Match      0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 126 GGTGTGTTCACCTTTT 142
```

Db 17 GGTGGGTGTCACCTTT 1

RESULT 46
US-08-182-172-7/c
; Sequence 7, Application US/08182172
; Patent No. 5714318
; GENERAL INFORMATION:
; APPLICANT: Sagner, Gregor
; APPLICANT: Kessler, Christoph
; APPLICANT: Blum, Helmut
; APPLICANT: Domdey, Horst
; TITLE OF INVENTION: SIMULTANEOUS SEQUENCING OF NUCLEIC ACIDS
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nikaido, Marmelstein, Murray & Oram
; STREET: 655 Fifteenth Street N.W. Suite 330
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-5701
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,172
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murray, Robert B.
; REGISTRATION NUMBER: 22,980
; REFERENCE/DOCKET NUMBER: P564-4006
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)638-5000
; TELEFAX: (202)638-4810
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-182-172-7

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 620 CCAACCTTACACTACT 639
Db 20 CCAACCTTACACTTCT 1

RESULT 47
US-09-418-641-57
; Sequence 57, Application US/09418641A
; Patent No. 6124133
; GENERAL INFORMATION:
; APPLICANT: Jennifer K. Taylor
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF FRA-1 EXPRESSION
; FILE REFERENCE: RTS-0105
; CURRENT APPLICATION NUMBER: US/09/418,641A
; CURRENT FILING DATE: 1999-10-15
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide
US-09-418-641-57

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1270 TGCTGCAGCCCTCAATATC 1289
Db 1 TTCTGCAGCTCTCAATCTC 20

RESULT 48
US-09-484-345-75/c
; Sequence 75, Application US/09484345
; Patent No. 6159734
; GENERAL INFORMATION:
; APPLICANT: Robert McKay
; APPLICANT: Alexander H. Borchers
; APPLICANT: Brenda P. Baker
; TITLE OF INVENTION: ANTISENSE MODULATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
; FILE REFERENCE: RTS-0104
; CURRENT APPLICATION NUMBER: US/09/484,345
; CURRENT FILING DATE: 2000-01-18
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-484-345-75

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 887 CCCAGATACCTGATTCCTTCA 906
Db 20 CCCAGAAAGCGATTCCTTCA 1

RESULT 49
US-09-000-092-11
; Sequence 11, Application US/09000092
; Patent No. 6160203
; GENERAL INFORMATION:
; APPLICANT: Ferri, Stefano
; APPLICANT: Toguri, Toshihiro
; TITLE OF INVENTION: DNA STRANDS CODING FOR
; TITLE OF INVENTION: GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FOLEY & LARDNER
; STREET: 3000 K Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/000,092
; FILING DATE: 26-JAN-1998
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/JF96/01844
; FILING DATE: 03-JUL-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 192123/1995

```
; FILING DATE: 27-JUL-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Bent, Stephen A.
; REGISTRATION NUMBER: 29,768
; REFERENCE/DOCKET NUMBER: 16887/916
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 672-5300
; TELEFAX: (202) 672-5399
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Primer"
US-09-000-092-11

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1480 TTGTTGCAGACATGGAAGAA 1499
   ||| ||||| ||||| |||||
Db 1 TTGCTGCAGGATGGAAGAA 20

RESULT 50
US-09-030-701-65/c
; Sequence 65, Application US/09030701B
; Patent No. 6214806
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schwartz, David A.
; TITLE OF INVENTION: USE OF NUCLEIC ACIDS CONTAINING
; TITLE OF INVENTION: UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF
; TITLE OF INVENTION: LPS-ASSOCIATED DISORDERS
; FILE REFERENCE: C1039/7011
; CURRENT APPLICATION NUMBER: US/09/030,701B
; CURRENT FILING DATE: 1998-02-25
; PRIOR FILING DATE: 1997-02-28
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
US-09-030-701-65

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCTCCGTCGCGCGCGTC 48
   ||||| ||||| ||||| |||||
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 51
US-09-082-649B-57/c
; Sequence 57, Application US/09082649B
; Patent No. 6339068
; GENERAL INFORMATION:
; APPLICANT: Davis, Heather L.
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schorr, Joachim
; APPLICANT: Wu, Tong
; TITLE OF INVENTION: Vectors and Methods for Immunization or
; TITLE OF INVENTION: Therapeutic Protocols
; FILE REFERENCE: C1039/7009
```

```
; CURRENT APPLICATION NUMBER: US/09/082,649B
; CURRENT FILING DATE: 1998-05-20
; PRIOR APPLICATION NUMBER: US 60/047,233
; PRIOR FILING DATE: 1997-05-20
; PRIOR APPLICATION NUMBER: US 60/047,209
; PRIOR FILING DATE: 1997-05-20
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
US-09-082-649B-57

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCTCCGTCGCGCGCGTC 48
   ||||| ||||| ||||| |||||
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 52
US-09-198-452A-4294
; Sequence 4294, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griflais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4294
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-4294

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1428 GATCCAAAGCAGATGAATGT 1447
   ||||| ||||| ||||| |||||
Db 1 GCTCCGACACAGATGAATGT 20

RESULT 53
US-09-710-693-10
; Sequence 10, Application US/09710693
; Patent No. 6642370
; GENERAL INFORMATION:
; APPLICANT: WISE, CAROL A
; TITLE OF INVENTION: GENETIC MARKER FOR AUTOIMMUNE DISORDER
; FILE REFERENCE: SEQ FOR TEX871
; CURRENT APPLICATION NUMBER: US/09/710,693
; CURRENT FILING DATE: 2000-11-08
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-710-693-10

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
```


; REFERENCE/DOCKET NUMBER: 10577/P58418
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 638-6666
; TELEFAX: (202) 393-5350
; TELEX: RCA 248593 IDEA UR
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: N-terminal
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..15
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-352-704-16

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 64;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849

Db 1 AAAAAAAAAAAAAA 15

RESULT 57

US-09-685-664B-1073/c
; Sequence 1073, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/594,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1073
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1073

Query Match 0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849

Db 17 AAAAAAAAAAAAAA 3

RESULT 58

US-09-090-672B-105/c
; Sequence 105, Application US/09090672B
; Patent No. 6828428
; GENERAL INFORMATION:

; APPLICANT: Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura,
; APPLICANT: Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,
; APPLICANT: Shigemasa; Takei, Masami
; TITLE OF INVENTION: Iga Nephropathy-Related Genes
; NUMBER OF SEQUENCES: 111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; ZIP: 10112-3801
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: Compaq PC
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect 8.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/090,672B
; FILING DATE: 04-JUNE-1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP97/04468
; FILING DATE: 05-DEC-1997
; APPLICATION NUMBER: JP-8-325763
; FILING DATE: 05-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Perry, Lawrence S.
; REGISTRATION NUMBER: 31865
; REFERENCE/DOCKET NUMBER: 766.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 218-2100
; TELEFAX: (212) 218-2200
; INFORMATION FOR SEQ ID NO: 105:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid, synthetic DNA
US-09-090-672B-105

Query Match 0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849

Db 16 AAAAAAAAAAAAAA 2

RESULT 59

US-09-090-672B-106/c
; Sequence 106, Application US/09090672B
; Patent No. 6828428
; GENERAL INFORMATION:
; APPLICANT: Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura,
; APPLICANT: Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,
; APPLICANT: Shigemasa; Takei, Masami
; TITLE OF INVENTION: Iga Nephropathy-Related Genes
; NUMBER OF SEQUENCES: 111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; ZIP: 10112-3801
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: Compaq PC
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect 8.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/090,672B

```

; FILING DATE: 04-JUNE-1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP97/04468
; FILING DATE: 05-DEC-1997
; APPLICATION NUMBER: JP-8-325763
; FILING DATE: 05-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Perry, Lawrence S.
; REGISTRATION NUMBER: 31865
; REFERENCE/DOCKET NUMBER: 766.21
; TELEPHONE: (212) 218-2100
; TELEFAX: (212) 218-2200
; INFORMATION FOR SEQ ID NO: 106:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid, synthetic DNA
US-09-090-672B-106

Query Match          0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 16 AAAAAAAAAAAAAA 2

RESULT 60
US-09-904-744-2/c
; Sequence 2, Application US/09904744
; Patent No. 6828142
; GENERAL INFORMATION:
; APPLICANT: Barbera-Guillem, Emilio
; APPLICANT: Nelson, M. Bud
; APPLICANT: Castro, Stephanie
; TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
; TITLE OF INVENTION: dendrimers in a signal amplification system
; FILE REFERENCE: B-73
; CURRENT APPLICATION NUMBER: US/09/904,744
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: 09/437076
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/107828
; PRIOR FILING DATE: 1998-11-10
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthesized
US-09-904-744-2

Query Match          0.8%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 86;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 18 AAAAAAAAAAAAAA 4

RESULT 61
US-09-696-791-478/c
; Sequence 478, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:

```

```

; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 478
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdk4 ribozyme binding site
US-09-696-791-478

Query Match          0.8%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 94;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1096 GGACTGCAGAGAAC 1110
Db 19 GGACTGCAGAGAAC 5

RESULT 62
US-09-344-914-53
; Sequence 53, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-53

Query Match          0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTTT 1461
Db 1 TTGCTGCTGCTGTTT 15

RESULT 63
US-09-344-914-54
; Sequence 54, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-54

```

```
Query Match      0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1447 TTGCTGCTGCTGTTT 1461
Db      2 TTGCTGCTGCTGTTT 16

RESULT 64
US-09-344-914-55
; Sequence 55, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-55

Query Match      0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1447 TTGCTGCTGCTGTTT 1461
Db      3 TTGCTGCTGCTGTTT 17

RESULT 65
US-09-344-914-56
; Sequence 56, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-56

Query Match      0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1447 TTGCTGCTGCTGTTT 1461
Db      4 TTGCTGCTGCTGTTT 18

RESULT 66
US-09-344-914-57
; Sequence 57, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
```

```
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-57

Query Match      0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1447 TTGCTGCTGCTGTTT 1461
Db      5 TTGCTGCTGCTGTTT 19

RESULT 67
US-09-344-914-58
; Sequence 58, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-58

Query Match      0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1447 TTGCTGCTGCTGTTT 1461
Db      6 TTGCTGCTGCTGTTT 20

RESULT 68
US-08-215-138-9
; Sequence 9, Application US/08215138
; Patent No. 5470719
; GENERAL INFORMATION:
; APPLICANT: Meng, Shi-Yuan
; APPLICANT: Morris, Charles F.
; APPLICANT: Tsai, Larry B
; TITLE OF INVENTION: Enhanced Secretion of Polypeptides
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc., U.S. Patent Operations/NAO
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: CA
; COUNTRY: USA
; ZIP: 91320
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/215,138
; FILING DATE:
```


; CLASSIFICATION: 530
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-215-138-9

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1680 TGATTCTAGAAAAGGAA 1697
|||||
Db 2 TGATTCTAGAAAGGAGAA 19

RESULT 69
US-08-407-344-9
; Sequence 9, Application US/08407344
; Patent No. 5608036
; GENERAL INFORMATION:
; APPLICANT: Meng, Shi-Yuan
; APPLICANT: Morris, Charles F.
; APPLICANT: Tsai, Larry B
; TITLE OF INVENTION: Enhanced Secretion of Polypeptides
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc., U.S. Patent Operations/NAO
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: CA
; COUNTRY: USA
; ZIP: 91320

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/407,344
; FILING DATE:
; CLASSIFICATION: 530
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-407-344-9

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1680 TGATTCTAGAAAAGGAA 1697
|||||
Db 2 TGATTCTAGAAAGGAGAA 19

RESULT 70
US-09-422-978-6888/c
; Sequence 6888, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020Cp1

; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6888
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-21057 for SEQ 2954,
US-09-422-978-6888

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1467 GTTCTTTCTTATGTTGTT 1484
|||||
Db 19 GTTCTTTCTTATGTTGTT 2

RESULT 71
US-09-422-978-7139/c
; Sequence 7139, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020Cp1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7139
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-24768 for SEQ 3205,
US-09-422-978-7139

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1629 CTCTATTTCATGCTTTCT 1646
|||||
Db 19 CTCTTTCTTCTTCTTCT 2

RESULT 72
US-09-938-077-19/c
; Sequence 19, Application US/09938077
; Patent No. 6730500
; GENERAL INFORMATION:
; APPLICANT: Lok, Si
; TITLE OF INVENTION: Methods for Generating a Continuous

```
; TITLE OF INVENTION: Nucleotide Sequence from No. 6730500contiguous Nucleotide Sequence
; Patent No. 6730500
; FILE REFERENCE: 00-68
; CURRENT APPLICATION NUMBER: US/09/938,077
; CURRENT FILING DATE: 2001-08-23
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Fast-Seq for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Illustrative nucleotide sequence.
US-09-938-077-19

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1065 CGTCCAAAGAGGACTCTG 1082
Db 19 CTTCATAGAGGACTCTG 2

RESULT 73
US-09-696-791-2728/c
; Sequence 2728, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2728
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin G1 ribozyme binding site
US-09-696-791-2728

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1326 AACATTGGATCCAGCT 1343
Db 18 AACATTGGATCAAGCT 1

RESULT 74
US-09-696-791-3559/c
; Sequence 3559, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3559
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdc25 hs ribozyme binding site
US-09-696-791-3559

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 963 GGACATCTGGACAGCTGG 980
Db 19 GGACATCTGGACAGACGG 2

RESULT 75
US-08-753-147-188/c
; Sequence 188, Application US/08753147
; Patent No. 5770372
; GENERAL INFORMATION:
; APPLICANT: Concannon, Patrick
; TITLE OF INVENTION: Detection of Mutations in the Human ATM Gene
; NUMBER OF SEQUENCES: 196
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Christensen O'Connor Johnson and Kindness
; STREET: 1420 5th Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98101-2347
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/753,147
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sheiness, Diana K.
; REGISTRATION NUMBER: 35,356
; REFERENCE/DOCKET NUMBER: VMRC-1-9714
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 743-4387
; TELEFAX: (206) 224 0779
; INFORMATION FOR SEQ ID NO: 188:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
US-08-753-147-188

Query Match      0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 81 AACCAACTGGAAAAA 96
Db 16 AACCAACTGGAGAAA 1

RESULT 76
US-09-371-772B-4471
; Sequence 4471, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
```

```
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4471
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4471

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1204 TACCACCTGGGCTGCA 1219
Db 2 UACCCACUGGCGACGA 17

RESULT 77
US-09-866-108A-8364
; Sequence 8364, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8364
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8364

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 395 GCTGGAGAAAAGTTCAC 410
Db 2 GCTGGAGAAAAGTGCAC 17

RESULT 78
US-09-866-108A-8365
; Sequence 8365, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8364
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8365

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 395 GCTGGAGAAAAGTTCAC 410
Db 1 GCTGGAGAAAAGTGCAC 16

RESULT 79
US-09-866-108A-10030/c
; Sequence 10030, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

```
US-09-866-108A-8364

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 395 GCTGGAGAAAAGTTCAC 410
Db 2 GCTGGAGAAAAGTGCAC 17

RESULT 78
US-09-866-108A-8365
; Sequence 8365, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8365
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8365

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 395 GCTGGAGAAAAGTTCAC 410
Db 1 GCTGGAGAAAAGTGCAC 16

RESULT 79
US-09-866-108A-10030/c
; Sequence 10030, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10030
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10030

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1065 CGTCCAAAGAGGACTC 1080
Db 17 CGTCCACAGAGGACTC 2

RESULT 80
US-09-866-108A-10031/c
; Sequence 10031, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10031
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10031

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1065 CGTCCAAAGAGGACTC 1080
Db 16 CGTCCACAGAGGACTC 1

RESULT 81
US-09-685-664B-1078/c
; Sequence 1078, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH800-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1078
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1078

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1833 TGAATAAAAAAAAAA 1848
Db 16 TGAATAAAAAAAAAA 1

RESULT 82
US-09-289-377-28/c
; Sequence 28, Application US/09289377
; Patent No. 6046321
; GENERAL INFORMATION:

; APPLICANT: Lex M. Cowseert
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-I1 EXPRESSION
; FILE REFERENCE: RTS-0058
; CURRENT APPLICATION NUMBER: US/09/289,377
; CURRENT FILING DATE: 1999-04-09
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-289-377-28

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 807 GAAGATGCAGAAATCA 822
Db 16 GAAGATGAAGAAATCA 1

RESULT 83

US-09-282-147-17
; Sequence 17, Application US/09282147
; Patent No. 6274147
; GENERAL INFORMATION:
; APPLICANT: VAKHARIA, Vikram
; APPLICANT: YAO, Kun
; TITLE OF INVENTION: METHOD FOR GENERATING NONPATHOGENIC, INFECTIOUS
; TITLE OF INVENTION: PANCREATIC NECROSIS VIRUS (IPNV) FROM SYNTHETIC RNA
; TITLE OF INVENTION: TRANSCRIPTS
; FILE REFERENCE: 8288-9023
; CURRENT APPLICATION NUMBER: US/09/282,147
; CURRENT FILING DATE: 1999-03-31
; EARLIER APPLICATION NUMBER: US/60/080,278
; EARLIER FILING DATE: 1998-03-31
; EARLIER APPLICATION NUMBER: PCT/US97/12955
; EARLIER FILING DATE: 1998-03-31
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 17
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
US-09-282-147-17

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 450 GAATCAGCTGTGATGC 465
Db 3 GAATCAGGTGTGATGC 18

RESULT 84

US-09-696-791-4229/c
; Sequence 4229, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 4229
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Hammerhead ribozyme recognition site for cdc 2 kinase
US-09-696-791-4229

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1376 ATCAACTATTTCCTC 1391
Db 16 ATCCAAGTATTTCCTC 1

RESULT 85

US-09-696-791-3052/c
; Sequence 3052, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3052
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin A1 ribozyme binding site
US-09-696-791-3052

Query Match 0.8%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 433 ACTGGGAGAGGGGAGA 448
Db 17 ACTGGGAGAGGGGAGA 2

RESULT 86

US-08-609-572-5/c
; Sequence 5, Application US/08609572
; Patent No. 5710023
; GENERAL INFORMATION:
; APPLICANT: Collins, Mary
; APPLICANT: Donaldson, Debra
; APPLICANT: Fitz, Lori
; APPLICANT: Neben, Tamlyn
; APPLICANT: Whitters, Matthew
; APPLICANT: Wood, Clive
; TITLE OF INVENTION: CYTOKINE RECEPTOR CHAIN
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 CambridgePark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/609,572
; FILING DATE:
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15268
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
US-08-609-572-5

Query Match      0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1343 TGGAGTGCCTGGAGCCA 1359
        |||||:|:|||||:|:|
Db      17 TGGAGYGMVTGGAGYSM 1

RESULT 87
US-08-841-751-5/c
; Sequence 5, Application US/08841751
; Patent No. 6214559
; GENERAL INFORMATION:
; APPLICANT: Collins, Mary
; APPLICANT: Donaldson, Debra
; APPLICANT: Fitz, Lori
; APPLICANT: Neben, Tamlyn
; APPLICANT: Whitters, Matthew
; APPLICANT: Wood, Clive
; TITLE OF INVENTION: CYTOKINE RECEPTOR CHAIN
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 CambridgePark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/841,751
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/609,572
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15268
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
US-08-841-751-5

Query Match      0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1343 TGGAGTGCCTGGAGCCA 1359
        |||||:|:|||||:|:|
Db      17 TGGAGYGMVTGGAGYSM 1

RESULT 89
US-08-846-344-5/c
; Sequence 5, Application US/08846344
; Patent No. 6248714
; GENERAL INFORMATION:
; APPLICANT: Collins, Mary
; APPLICANT: Donaldson, Debra
; APPLICANT: Fitz, Lori
; APPLICANT: Neben, Tamlyn
; APPLICANT: Whitters, Matthew
; APPLICANT: Wood, Clive
; TITLE OF INVENTION: CYTOKINE RECEPTOR CHAIN
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 CambridgePark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/846,340
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/609,572
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15268
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
US-08-846-340-5

Query Match      0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1343 TGGAGTGCCTGGAGCCA 1359
        |||||:|:|||||:|:|
Db      17 TGGAGYGMVTGGAGYSM 1

RESULT 89
US-08-846-344-5/c
; Sequence 5, Application US/08846344
```

Patent No. 6268480
GENERAL INFORMATION:
APPLICANT: Collins, Mary
APPLICANT: Donaldson, Debra
APPLICANT: Fitz, Lori
APPLICANT: Neben, Tamlyn
APPLICANT: Whitters, Matthew
APPLICANT: Wood, Clive
TITLE OF INVENTION: CYTOKINE RECEPTOR CHAIN
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genetics Institute, Inc.
STREET: 87 CambridgePark Drive
CITY: Cambridge
STATE: MA
COUNTRY: USA
ZIP: 02140
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/846.344
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION NUMBER: 08/609,572
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Brown, Scott A.
REGISTRATION NUMBER: 32,724
REFERENCE/DOCKET NUMBER: G15268
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 498-8224
TELEFAX: (617) 876-5851
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: oligonucleotide
US-08-846-344-5

Query Match 0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGCCA 1359
Db 17 TGGAGYGMVTTGGAGYSM 1

RESULT 90
US-09-301-808-5/c
Sequence 5, Application US/09301808
Patent No. 6664227
GENERAL INFORMATION:
APPLICANT: Wynn, Thomas
APPLICANT: Chiaramonte, Monica
APPLICANT: Collins, Mary
APPLICANT: Donaldson, Debra
APPLICANT: Fitz, Lori
APPLICANT: Neben, Tamlyn
APPLICANT: Whitters, Matthew
APPLICANT: Wood, Clive
TITLE OF INVENTION: TREATMENT OF FIBROSIS BY ANTAGONISM OF IL-13
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genetics Institute, Inc.
STREET: 87 CambridgePark Drive

CITY: Cambridge
STATE: MA
COUNTRY: USA
ZIP: 02140
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/301,808
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Brown, Scott A.
REGISTRATION NUMBER: 32,724
REFERENCE/DOCKET NUMBER: G15268A2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 498-8224
TELEFAX: (617) 876-5851
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: oligonucleotide
US-09-301-808-5

Query Match 0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGCCA 1359
Db 17 TGGAGYGMVTTGGAGYSM 1

RESULT 91
US-09-859-736-7/c
Sequence 7, Application US/09859736
Patent No. 6838244
GENERAL INFORMATION:
APPLICANT: LI, WAN-LIANG ROBERT
APPLICANT: ZHOU, JIAN S.
TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
FILE REFERENCE: 18517.248
CURRENT APPLICATION NUMBER: US/09/859,736
CURRENT FILING DATE: 2001-05-18
PRIOR APPLICATION NUMBER: 60/205,452
PRIOR FILING DATE: 2000-05-19
NUMBER OF SEQ ID NOS: 7
SOFTWARE: Patent In Ver. 2.1
SEQ ID NO 7
LENGTH: 14
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: dt oligonucleotide
US-09-859-736-7

Query Match 0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 87;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1848
Db 14 AAAAAAAAAAAAAA 1

RESULT 92
US-09-491-356C-19/c

```
; Sequence 19, Application US/09491356C
; Patent No. 6566061
; GENERAL INFORMATION:
; APPLICANT: Philibert, Robert A.
; APPLICANT: Ginns, Edward I.
; APPLICANT: Delisi, Lynn
; TITLE OF INVENTION: IDENTIFICATION OF POLYMORPHISMS IN THE PCTG4 REGION OF XQ13
; FILE REFERENCE: 9465.6US11
; CURRENT APPLICATION NUMBER: US/09/491,356C
; CURRENT FILING DATE: 2000-01-26
; PRIOR APPLICATION NUMBER: PCT/US99/09365
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 60/083,465
; PRIOR FILING DATE: 1998-04-29
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 19
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-491-356C-19

Query Match      0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 98;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1445 TGTGCTGCTGCTG 1458
Db      14  TGTGCTGCTGCTG 1

RESULT 93
US-09-866-108A-2590
; Sequence 2590, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2590
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2591

Query Match      0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 98;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1445 TGTGCTGCTGCTG 1458
Db      14  TGTGCTGCTGCTG 1

RESULT 94
US-09-866-108A-2591
; Sequence 2591, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2591
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2591

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      990 CAGGGTGCCATGGA 1003
Db      4  CAGGGTGCCATGGA 17

RESULT 95
US-09-866-108A-2592
; Sequence 2592, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2590
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2590

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      990 CAGGGTGCCATGGA 1003
Db      3  CAGGGTGCCATGGA 16

RESULT 95
US-09-866-108A-2592
; Sequence 2592, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
```


Patent No. 5670330
GENERAL INFORMATION:
APPLICANT: Sonenberg, Nahum
APPLICANT: Katze, Michael G.
APPLICANT: Roy, Sophie
APPLICANT: Koromilas, Antonis E.
APPLICANT: Barber, Glen N.
TITLE OF INVENTION: TUMOR-CELL ASSAY METHOD AND KIT
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 611 West Sixth Street
CITY: Los Angeles
STATE: CA
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM compatible
OPERATING SYSTEM: PC-DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/143,219
FILING DATE: October 25, 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/141,244
FILING DATE: October 22, 1993
APPLICATION NUMBER: 07/953,681
FILING DATE: September 29, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Douglas E. Olson
REGISTRATION NUMBER: 22,798
REFERENCE/DOCKET NUMBER: 204/139
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: COMPLEMENTARY SEQUENCE TO R8 PRIMER,
INDIVIDUAL ISOLATE: FIGURE 5
US-08-143-219-10

Query Match 0.8%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 272 AGCCGAGAACAGAT 285
Db 1 AGCCGAGAACAGAT 14

RESULT 99
US-10-271-065-1
Sequence 1, Application US/10271065
Patent No. 6759580
GENERAL INFORMATION:
APPLICANT: Charles Thomas Cunningham
TITLE OF INVENTION: Inbred Maize Line PH87H
FILE REFERENCE: 1467
CURRENT APPLICATION NUMBER: US/10/271.065
CURRENT FILING DATE: 2002-10-15
PRIOR APPLICATION NUMBER: US 60/352,291

PRIOR FILING DATE: 2002-01-28
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 1
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Lprimer for PH1279122
US-10-271-065-1

Query Match 0.8%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1084 GGCTGGTCTCTGG 1097
Db 4 GGCTGGTCTCTGG 17

RESULT 100
US-08-985-162-431
Sequence 431, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 431:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-431

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```
OY 174 AATGGCATCTCTTAAGAG 190
||:|||||:|:|
Db 1 RAUGGCAUCUUUAGGG 17

RESULT 101
US-08-987-574-46/c
; Sequence 46, Application US/08987574
; Patent No. 6150339
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Pennewald, Susan
; APPLICANT: Zendegui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski
; STREET: 1301 McKinney, Suite 5100
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77010-3095
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/987,574
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04529
; FILING DATE: 28-OCT-1993
; APPLICATION NUMBER: US 08/053,027
; FILING DATE: 23-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul, Thomas D.
; REGISTRATION NUMBER: 32,714
; REFERENCE/DOCKET NUMBER: D-5574-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/651-5151
; TELEFAX: 713/651-5246
; TELEX: 762829
; INFORMATION FOR SEQ ID NO: 46:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-987-574-46

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1705 CCCCTCCCTCCACCAC 1721
||| ||| ||| ||| |||
Db 17 CCCACCACCCACCAC 1

RESULT 103
US-09-017-974-46/c
; Sequence 46, Application US/09017974
; Patent No. 6286042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cosum, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912

OY 174 AATGGCATCTCTTAAGAG 190
||:|||||:|:|
Db 1 RAUGGCAUCUUUAGGG 17

RESULT 102
US-08-535-168-46/c
; Sequence 46, Application US/08535168
; Patent No. 6184369
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Pennewald, Susan
```

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/017,974
FILING DATE:

CLASSIFICATION:
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/037,374
FILING DATE: 04-FEB-97

APPLICATION NUMBER:
FILING DATE: 09-DEC-97

ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven

REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06223

TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008

INFORMATION FOR SEQ ID NO: 46:
SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)
US-09-017-974-46

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1705 CCCTCCCTCCACCAC 1721
|||||

Db 17 CCCACCACCACCAC 1

RESULT 104

US-08-682-255A-46/c

Sequence 46, Application US/08682255A
Patent No. 632185

GENERAL INFORMATION:
APPLICANT: Rando, Robert F.

APPLICANT: Fennwald, Susan
APPLICANT: Zendequi, Joseph G.

APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.

APPLICANT: Pommier, Yves
APPLICANT: Mazumder, Abhijit

TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides

NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:

ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850

CITY: Houston
STATE: Texas

COUNTRY: U.S.A.
ZIP: 77002-2912

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95

SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/682,255A
FILING DATE: 17-JULY-1996

CLASSIFICATION: 435
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/535,168
FILING DATE: 23-OCT-95

APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96

APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/015,714
FILING DATE: 17-APRIL-96

APPLICATION NUMBER: 60/016,271
FILING DATE: 23-APRIL-96
ATTORNEY/AGENT INFORMATION:

NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962

REFERENCE/DOCKET NUMBER: 1472-06214
TELEPHONE: 713/238-8010

TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 46:

SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs

TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)

US-08-682-255A-46

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1705 CCCTCCCTCCACCAC 1721
|||||

Db 17 CCCACCACCACCAC 1

RESULT 105

US-08-584-040-4164

Sequence 4164, Application US/08584040
Patent No. 6346398

GENERAL INFORMATION:
APPLICANT: Pavco, Pamela

APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.

APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE

TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS

TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR

NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street

CITY: Los Angeles
STATE: California

COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage
COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040

FILING DATE: January 11, 1996
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974

FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 218/064
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 4164:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-584-040-4164

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 1.3e+02;
 Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTGGAAAC 1583
 Db 1 CUGCAAAUUGGAAACC 17

RESULT 106

US-08-584-040-4165
 Sequence 4165, Application US/08584040
 Patent No. 6346398

GENERAL INFORMATION:
 APPLICANT: Pavco, Pamela
 APPLICANT: McSwiggen, James
 APPLICANT: Stinchcomb, Dan T.
 APPLICANT: Escobedo, Jaime
 TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 TITLE OF INVENTION: TREATMENT OF DISEASES OR
 TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
 TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
 TITLE OF INVENTION: GROWTH FACTOR
 NUMBER OF SEQUENCES: 8502
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071-2066

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/584,040
 FILING DATE: January 11, 1996
 CLASSIFICATION: 514

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 60/005,974
 FILING DATE: October 26, 1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard J.
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 218/064

TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 4165:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear

Qy 1149 AAGGTAATATTTCCAA 1165
 Db 17 AAGGTAATATTTCCCA 1

RESULT 108

US-08-584-040-4165

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 58.8%; Pred. No. 1.3e+02;
 Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1568 TGCAACTTTGGAAACT 1584
 Db 1 UGCAAAUUGGAAACC 17

RESULT 107

US-08-584-040-4250/c
 Sequence 4250, Application US/08584040
 Patent No. 6346398

GENERAL INFORMATION:
 APPLICANT: Pavco, Pamela
 APPLICANT: McSwiggen, James
 APPLICANT: Stinchcomb, Dan T.
 APPLICANT: Escobedo, Jaime
 TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 TITLE OF INVENTION: TREATMENT OF DISEASES OR
 TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
 TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
 TITLE OF INVENTION: GROWTH FACTOR
 NUMBER OF SEQUENCES: 8502
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071-2066

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/584,040
 FILING DATE: January 11, 1996
 CLASSIFICATION: 514

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 60/005,974
 FILING DATE: October 26, 1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard J.
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 218/064

TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 4250:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear

US-08-584-040-4250

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGGTAATATTTCCAA 1165
 Db 17 AAGGTAATATTTCCCA 1

```
US-08-584-040-5734
; Sequence 5734, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5734:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5735
; Query Match 0.7%; Score 13.8; DB 1; Length 17;
; Best Local Similarity 64.7%; Pred. No. 1.3e+02;
; Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTCGCACTTTGGAAAC 1583
Db 1 CUGCAAGUUGGAAC 17

RESULT 109
US-08-584-040-5735
; Sequence 5735, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5734:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5734
; Query Match 0.7%; Score 13.8; DB 1; Length 17;
; Best Local Similarity 64.7%; Pred. No. 1.3e+02;
; Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTCGCACTTTGGAAAC 1583
Db 1 CUGCAAGUUGGAAC 17

RESULT 110
US-08-584-040-5820/C
; Sequence 5820, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5735:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5735
; Query Match 0.7%; Score 13.8; DB 1; Length 17;
; Best Local Similarity 58.8%; Pred. No. 1.3e+02;
; Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1568 TGCACCTTTGGAAACT 1584
Db 1 UGCAAGUUGGAACCU 17

RESULT 110
US-08-584-040-5820/C
; Sequence 5820, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
```

```

; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5820:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5820

```

```

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 1149 AAGGTAATATTTCCAA 1165
Db 17 AAGGAAATATTTCCTCA 1

```

```

RESULT 111
US-08-584-040-7818/c
; Sequence 7818, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:

```

```

; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7818:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7818

```

```

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 17 AACACAAACACAAAAA 1

```

```

RESULT 112
US-08-584-040-7819/c
; Sequence 7819, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7819:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

```

; TOPOLOGY: linear

US-08-584-040-7819

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
||||| ||||| |||||
Db 17 AAAAAAAAAACAAAAA 1

RESULT 113

US-09-429-130-46/c

; Sequence 46, Application US/09429130

; Patent No. 6355785

; GENERAL INFORMATION:

; APPLICANT: Rando, Robert F.

; Fennewald, Susan

; Zendequi, Joseph G.

; Ojwang, Joshua O.

; Hogan, Michael E.

; Pommier, Evves

; Mazumder, Abhijit

; 60/015,714

; TITLE OF INVENTION: Anti-Viral Guanosine-Rich

; Oligonucleotides

; NUMBER OF SEQUENCES: 87

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Conley, Rose & Tayon, P.C.

; STREET: 600 Travis, Suite 1850

; CITY: Houston

; STATE: Texas

; COUNTRY: U.S.A.

; ZIP: 77002-2912

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; OPERATING SYSTEM: MS Windows 95

; SOFTWARE: MS Word 97 (saved as .txt file)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/429,130

; FILING DATE: 28-Oct-1999

; CLASSIFICATION: <Unknown>

; 19-JULY-95

; 25-MARCH-96

; 19-MARCH-96

; 17-APRIL-96

; 23-APRIL-96

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/682,255

; FILING DATE: <Unknown>

; APPLICATION NUMBER: 60/001,505

; FILING DATE: 19-JULY-95

; APPLICATION NUMBER: 60/014,007

; FILING DATE: 25-MARCH-96

; APPLICATION NUMBER: 60/013,688

; FILING DATE: 19-MARCH-96

; APPLICATION NUMBER: 60/016,271

; FILING DATE: 17-APRIL-96

; ATTORNEY/AGENT INFORMATION:

; NAME: McDaniel, C. Steven

; REGISTRATION NUMBER: 33,962

; REFERENCE/DOCKET NUMBER: 1472-06214

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 713/238-8010

; TELEFAX: 713/238-8008

; INFORMATION FOR SEQ ID NO: 46:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 46:

US-09-429-130-46

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1705 CCCCTCCCTCCACCAC 1721
||||| ||||| ||||| |||||
Db 17 CCCACCCACCACCAC 1

RESULT 114

US-09-371-772B-1931

; Sequence 1931, Application US/09371772B

; Patent No. 6566127

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; FILE REFERENCE: MBH00, 876-J (237/198)

; CURRENT APPLICATION NUMBER: US/09/371,772B

; CURRENT FILING DATE: 1999-08-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; NUMBER OF SEQ ID NOS: 14225

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1931

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-371-772B-1931

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTCGACCTTTGGAAAC 1583
|:|||||:|||||
Db 1 CUGCAAAUUUGGAACC 17

RESULT 115

US-09-371-772B-1932

; Sequence 1932, Application US/09371772B

; Patent No. 6566127

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; FILE REFERENCE: MBH00, 876-J (237/198)

; CURRENT APPLICATION NUMBER: US/09/371,772B

; CURRENT FILING DATE: 1999-08-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; NUMBER OF SEQ ID NOS: 14225

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1932

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens
US-09-371-772B-1932

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.3e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1568 TGCACACTTTGGAAACT 1584
:||||:|||||:
Db 1 UGCAAAUUGGAAACCU 17

RESULT 116

US-09-371-772B-2017/c
; Sequence 2017, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2017
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2017

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGTAAATATTTCAC 1165
:|||||:
Db 17 AAGGAAATATTTCAC 1

RESULT 117

US-09-371-772B-2613
; Sequence 2613, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2613
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.

US-09-371-772B-2613

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTGGAAAC 1583
:||||:|||||:
Db 1 CUGCAAGUUGGAAACCU 17

RESULT 118

US-09-371-772B-2614
; Sequence 2614, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2614
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2614

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.3e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1568 TGCACACTTTGGAAACT 1584
:||||:|||||:
Db 1 UGCAAGUUGGAAACCU 17

RESULT 119

US-09-371-772B-3602/c
; Sequence 3602, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3602
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3602


```

; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-1536

Query Match . 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps

QY 1081 TCGGCTGTGGTCTGG 1097
   |||||||
DB 1 TGGGGCTGTGCCCTGG 17

RESULT 124
US-09-866-108A-1537
; Sequence 1537, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359

```

```
; Patent No. 6686188
; SEQ ID NO 8360
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8360

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 390 GATGGCTGGAGAAAGT 406
Db 1 GAGGAGCTGGAGAAAGT 17

RESULT 126
US-09-866-108A-8363
; Sequence 8363, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9572
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9572

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 CTGCACAGCTGGGATGT 985
Db 17 CTCGACAGCGGGATGT 1

RESULT 128
US-09-685-664B-1079/c
; Sequence 1079, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Strinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH900-876-K (400/021)
; FILE REFERENCE: MBH900-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
```

; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1079
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1079

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1831 TCTGAAAAAATAAAAA 1847
Db 17 TTTGAAAAAATAAAAA 1

RESULT 129

US-09-685-664B-1931
; Sequence 1931, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1931
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1931

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTGAAAAAC 1583
Db 1 CUGCAAAUUUGAAACC 17

RESULT 130

US-09-685-664B-1932
; Sequence 1932, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1932
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1932

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.3e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1568 TGCACCTTTGAAAACT 1584
Db 1 UGCAAAUUUGAAACCU 17

RESULT 131

US-09-685-664B-2017/c
; Sequence 2017, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2017
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-2017

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGTAAATATTTCCAA 1165
Db 17 AAGCAAAATATTTCCCA 1

RESULT 132

US-09-685-664B-2613
; Sequence 2613, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B

; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2613
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2613

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTGCAACTTTGGAAAC 1583
|:||||:|:|||||
Db 1 CUGCAAGUUGGAAACC 17

RESULT 133
US-09-685-664B-2614
; Sequence 2614, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2614
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2614

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.3e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCAACTTTGGAAACT 1584
|:||||:|:|||||
Db 1 UGCAAGUUGGAAACCU 17

RESULT 134
US-09-685-664B-3602/c
; Sequence 3602, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3602
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3602

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
|:||||:|:|||||
Db 17 AAACAAACAAACAAAAA 1

RESULT 135
US-09-685-664B-3603/c
; Sequence 3603, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3603
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3603

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
|:||||:|:|||||
Db 17 AAACAAACAAACAAAAA 1

RESULT 136
PCT-US96-11786-46/c
; Sequence 46, Application PC/TUS9611786
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zendegei, Joseph G.
; APPLICANT: Ojwang, Joshua O.

APPLICANT: Hogan, Michael E.
APPLICANT: Pommier, Yves
APPLICANT: Mazumder, Abhijit
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/11786
FILING DATE: 17-JULY-1996
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/535,168; 60/001,505; 60/014,007; 60/013,688;
APPLICATION NUMBER: 60/015,714; 60/016,271
FILING DATE: 23-OCT-95; 17-JULY-96; 25-MARCH-96; 19-MARCH-96; 23-
FILING DATE: APRIL-96; 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 46:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US96-11786-46

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1705 CCCCTCCCTCCACCAC 1721
Db 17 CCCACCACCACCACCAC 1

RESULT 137
US-08-050-232-12
Sequence 12, Application US/08050232
Patent No. 5525492
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: Process for Amplifying Nucleic Acid
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marks & Murase
STREET: 2001 L Street, N.W., Suite 750
CITY: Washington
STATE: D.C.
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: Wordstar
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/050,232
FILING DATE: 14-MAY-1993

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9024005.2
FILING DATE: 05-NOV-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO PCT/GB91/01935
FILING DATE: 05-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: Michael D. Bednarek
REGISTRATION NUMBER: 32,329
REFERENCE/DOCKET NUMBER: SH-PCT-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-955-4900
TELEFAX: 202-955-4932
TELEX: 248749
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: CDS
LOCATION: 1..18
US-08-050-232-12

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 504 GGCAGCAGCATTGGGAC 520
Db 2 GGCAGCAGCATTGGGAC 18

RESULT 138
US-08-661-767-12
Sequence 12, Application US/08661767
Patent No. 5824515
GENERAL INFORMATION:
APPLICANT: Adrian Vivian Sinton Hill
TITLE OF INVENTION: Process for Amplifying Nucleic Acid
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: WENDEROOTH, LIND & PONACK
STREET: 805 Fifteenth Street, Suite 700
CITY: Washington
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch, 1.44 mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/661,767
FILING DATE: June 11, 1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9024005.2
FILING DATE: 05-NOV-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: WO PCT/GB91/01935
FILING DATE: 05-NOV-1991
ATTORNEY/AGENT INFORMATION:
NAME: Warren M. Cheek, Jr.
REGISTRATION NUMBER: 33,367
REFERENCE/DOCKET NUMBER: 263/KPVM1540US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-371-8850
TELEFAX: 202-371-8856

```
;
;
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..18
; US-08-661-767-12

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 504 GGCAGCAGCATTTGGGAC 520
Db 2 GCGCGAGCATTTGGGAC 18

RESULT 139
US-08-468-580-17/c
; Sequence 17, Application US/08468580
; Patent No. 5824642
; GENERAL INFORMATION:
; APPLICANT: Attie, Kenneth
; APPLICANT: Carlsson, Lena
; APPLICANT: Gesundheit, Neil
; APPLICANT: Goddard, Audrey
; TITLE OF INVENTION: Treatment of Partial Growth Hormone Insensitivity Syndrome
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/468,580
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/410452
; FILING DATE: 24-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/224982
; FILING DATE: 07-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Hasak, Janet E.
; REGISTRATION NUMBER: 28,616
; REFERENCE/DOCKET NUMBER: P0884P1C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1896
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-468-580-17

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 264 TATGTTAAAGCCCGAGAA 280
Db 17 TAAGGTTAAAGCCCGAGCA 1

RESULT 140
US-08-384-324-2/c
; Sequence 2, Application US/08384324
; Patent No. 5844110
; GENERAL INFORMATION:
; APPLICANT: Gold, Barry I.
; TITLE OF INVENTION: Synthetic Triple Helix-Forming Compounds
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dann, Dorfman, Herrell and Skillman
; STREET: 1601 Market Street, Suite 720
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/384,324
; FILING DATE: 31-JAN-1995
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Reed, Janet E.
; REGISTRATION NUMBER: 36,252
; REFERENCE/DOCKET NUMBER: 63076
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 563-4100
; TELEFAX: (215) 563-4044
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: not relevant
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: YES
; ANTI-SENSE: YES
; US-08-384-324-2

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1834 GAAAAAAGAAAAA 1850
Db 17 GAAAAAAGAAAAA 1

RESULT 141
US-08-244-597-14
; Sequence 14, Application US/08244597
; Patent No. 5885793
; GENERAL INFORMATION:
; APPLICANT: Griffiths, Andrew David
; APPLICANT: Hoogenboom, Hendricus RJM
; APPLICANT: Marks, James David
; APPLICANT: McCafferty, John
; APPLICANT: Winter, Gregory Paul
; APPLICANT: Grigg, Geoffrey Walter
; TITLE OF INVENTION: Production of anti-self antibodies from
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
```


ADDRESSEE: David W. Clough
STREET: Marshall, O'Toole, Gerstein, Murray & Borun
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/244,597
FILING DATE: 01-JUN-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125579.4
FILING DATE: 02-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125582.8
FILING DATE: 02-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206372.6
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/01755
FILING DATE: 23-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/32094
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-244-597-14

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 TGTATTACGGTGGAGA 811
Db 2 TGTATTACGGTGGAGA 18

RESULT 142
US-08-389-423-31
Sequence 31, Application US/08389423
Patent No. 5948672
GENERAL INFORMATION:
APPLICANT: Rasmussen, Grethe
APPLICANT: Mikkelsen, Jan Moller
APPLICANT: Schulein, Martin
APPLICANT: Patkar, Shankant A.
APPLICANT: Hagen, Fred
TITLE OF INVENTION: A Cellulase Preparation Comprising an
TITLE OF INVENTION: Endoglucanase Enzyme
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 5948672 of No. 5948672 disk of No. 5948672th America, Inc.
STREET: 405 Lexington Avenue, 64th Floor
CITY: New York
STATE: New York

COUNTRY: United States of America
ZIP: 10174-6401
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/389,423
FILING DATE: 14-FEB-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Lamdiris, Elias J.
REGISTRATION NUMBER: 33,728
REFERENCE/DOCKET NUMBER: 3469.214-US
TELEPHONE: 212-867-0123
TELEFAX: 212-878-9655
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-389-423-31

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 633 AACTACTCAAGGACGGT 649
Db 1 AGCTTCTCAAGGACGGT 17

RESULT 143
US-09-205-860-46
Sequence 46, Application US/09205860
Patent No. 5981732
GENERAL INFORMATION:
APPLICANT: Lex M. Cowsert
TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-13 EXPRESSION
FILE REFERENCE: RTS-0031
CURRENT APPLICATION NUMBER: US/09/205,860
CURRENT FILING DATE: 1998-12-04
NUMBER OF SEQ ID NOS: 87
SEQ ID NO 46
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-860-46

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1778 AAAAACATTGTTTCCAC 1794
Db 2 AAAACCTTGTGTTCCAC 18

RESULT 144
US-08-857-946-14/c
Sequence 14, Application US/08857946
Patent No. 5994075
GENERAL INFORMATION:
APPLICANT: Goodfellow, P.N.
TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A
TITLE OF INVENTION: GENE OF INTEREST
NUMBER OF SEQUENCES: 162

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Inc.
; STREET: 75 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1807
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/857,946
; FILING DATE: 16-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/017,824
; FILING DATE: 17-MAY-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathleen M. Williams
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: 3529/05573
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-345-9100
; TELEFAX: 617-345-9111
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; US-08-857-946-14

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 GCCGCTTCGTCGCCGC 44
Db      17 GCCGCGCGCGCGCGC 1

RESULT 145
US-08-970-740-14/c
; Sequence 14, Application US/08970740
; Patent No. 6015670
; GENERAL INFORMATION:
; APPLICANT: Goodfellow, P. N.
; TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A
; FILE OF INVENTION: GENE OF INTEREST
; NUMBER OF SEQUENCES: 162
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Inc.
; STREET: 28 State Street, 28th Floor
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/970,740
; FILING DATE: 14-NOV-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/857,946
; FILING DATE: 16-MAY-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/017,824
```

```
; FILING DATE: 17-MAY-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathleen M. Williams
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: 3529/59829
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-227-7111
; TELEFAX: 617-227-4399
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; US-08-970-740-14

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 GCCGCTTCGTCGCCGC 44
Db      17 GCCGCGCGCGCGCGC 1

RESULT 146
US-09-487-444-45
; Sequence 45, Application US/09487444
; Patent No. 6159697
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD7 EXPRESSION
; FILE REFERENCE: RTS-0133
; CURRENT APPLICATION NUMBER: US/09/487,444
; CURRENT FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 45
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-487-444-45

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      196 TTGAAGAAATAAAGAA 212
Db      2 TAGAAGAAATAAAGAA 18

RESULT 147
US-09-189-028-31
; Sequence 31, Application US/09189028
; Patent No. 6423524
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Grethe
; APPLICANT: Mikkelsen, Jan Moller
; APPLICANT: Schulein, Martin
; APPLICANT: Patkar, Shankant A.
; APPLICANT: Hagen, Fred
; TITLE OF INVENTION: A Cellulase Preparation Comprising an
; TITLE OF INVENTION: Endoglucanase Enzyme
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 6423524o No. 6423524disk of No. 6423524th America, Inc.
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York
; STATE: New York
```

COUNTRY: United States of America
ZIP: 10174-6401
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/189,028
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/389,423
FILING DATE: 14-FEB-1995
ATTORNEY/AGENT INFORMATION:
NAME: Lambiris, Elias J.
REGISTRATION NUMBER: 33,728
REFERENCE/DOCKET NUMBER: 3469,214-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-867-0123
TELEFAX: 212-878-9655
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-09-189-028-31

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 633 AACTACTCAAGGACGGT 649
Db 1 AGCTTCTCAAGGACGGT 17

RESULT 148
US-09-197-224-14
Sequence 14, Application US/09197224
Patent No. 6521404
GENERAL INFORMATION:
APPLICANT: Griffiths, Andrew David
APPLICANT: Hoogenboom, Hendricus RJM
APPLICANT: Marks, James David
APPLICANT: McCafferty, John
APPLICANT: Winter, Gregory Paul
TITLE OF INVENTION: Production of anti-self antibodies from
TITLE OF INVENTION: antibody segment repertoires and displayed on phage
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: David W. Clough
STREET: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/197,224
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/244,597
FILING DATE: 01-JUN-1994

APPLICATION NUMBER: GB 9125579.4
FILING DATE: 02-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9125582.8
FILING DATE: 02-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206318.9
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9206372.6
FILING DATE: 24-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB92/01755
FILING DATE: 23-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 28111/32094
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-197-224-14

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 TGTATTACGGTGAAGA 811
Db 2 TGTATTACTGTGCAAGA 18

RESULT 149
US-09-197-221-14
Sequence 14, Application US/09197221
Patent No. 654731
GENERAL INFORMATION:
APPLICANT: Griffiths, Andrew David
APPLICANT: Hoogenboom, Hendricus RJM
APPLICANT: Marks, James David
APPLICANT: McCafferty, John
APPLICANT: Winter, Gregory Paul
TITLE OF INVENTION: Production of anti-self antibodies from
TITLE OF INVENTION: antibody segment repertoires and displayed on phage
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: David W. Clough
STREET: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/197,221
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/244,597
FILING DATE: 01-JUN-1994
APPLICATION NUMBER: GB 9125579.4
FILING DATE: 02-DEC-1991

```
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9125582.8
/ FILING DATE: 02-DEC-1991
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9206318.9
/ FILING DATE: 24-MAR-1992
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9206372.6
/ FILING DATE: 24-MAR-1992
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: PCT/GB92/01755
/ FILING DATE: 23-SEP-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Clough, David W
/ REGISTRATION NUMBER: 36,107
/ REFERENCE/DOCKET NUMBER: 28111/32094
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 312-474-6300
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-09-197-221-14
/
/ Query Match 0.7%; Score 13.8; DB 1; Length 18;
/ Best Local Similarity 88.2%; Pred. No. 1.4e+02;
/ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 795 TGTATTACGGTGAAGA 811
/ Db 2 TGTATTACTGTGCAAGA 18
/
/ RESULT 150
/ US-09-572-392A-14
/ Sequence 14, Application US/09572392A
/ Patent No. 655313
/ GENERAL INFORMATION:
/ APPLICANT: Griffiths, Andrew
/ APPLICANT: Hoogenboom, Hendricus
/ APPLICANT: Marks, James
/ APPLICANT: McCafferty, John
/ APPLICANT: Winter, Gregory
/ APPLICANT: Griffing, Geoffrey
/ TITLE OF INVENTION: Production of Anti-Self Antibodies from Antibody Segment Reperto
/ FILE REFERENCE: 28111/32094A
/ CURRENT APPLICATION NUMBER: US/09572,392A
/ CURRENT FILING DATE: 2000-05-16
/ PRIOR APPLICATION NUMBER: US 09/197,224
/ PRIOR FILING DATE: 1998-11-20
/ PRIOR APPLICATION NUMBER: PCT/GB92/02240
/ PRIOR FILING DATE: 1992-12-02
/ NUMBER OF SEQ ID NOS: 21
/ SOFTWARE: Patentin version 3.0
/ SEQ ID NO 14
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: oligonucleotide CDRBACK
/
/ US-09-572-392A-14
/
/ Query Match 0.7%; Score 13.8; DB 1; Length 18;
/ Best Local Similarity 88.2%; Pred. No. 1.4e+02;
/ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 795 TGTATTACGGTGAAGA 811
/ Db 2 TGTATTACTGTGCAAGA 18
/
/ RESULT 151
/ US-09-572-392A-14
/ Sequence 14, Application US/09572392A
/ Patent No. 655313
/ GENERAL INFORMATION:
/ APPLICANT: Griffiths, Andrew
/ APPLICANT: Hoogenboom, Hendricus
/ APPLICANT: Marks, James
/ APPLICANT: McCafferty, John
/ APPLICANT: Winter, Gregory
/ APPLICANT: Griffing, Geoffrey
/ TITLE OF INVENTION: Production of Anti-Self Antibodies from Antibody Segment Reperto
/ FILE REFERENCE: 28111/32094A
/ CURRENT APPLICATION NUMBER: US/09572,392A
/ CURRENT FILING DATE: 2000-05-16
/ PRIOR APPLICATION NUMBER: US 09/197,224
/ PRIOR FILING DATE: 1998-11-20
/ PRIOR APPLICATION NUMBER: PCT/GB92/02240
/ PRIOR FILING DATE: 1992-12-02
/ NUMBER OF SEQ ID NOS: 21
/ SOFTWARE: Patentin version 3.0
/ SEQ ID NO 14
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: oligonucleotide CDRBACK
/
/ US-09-572-392A-14
/ Sequence 14, Application US/09723756
/ Patent No. 6582915
/ GENERAL INFORMATION:
/ APPLICANT: Griffiths, Andrew David
/ APPLICANT: Hoogenboom, Hendricus RJM
/ APPLICANT: Marks, James David
/ APPLICANT: McCafferty, John
/ APPLICANT: Winter, Gregory Paul
/ APPLICANT: Griffing, Geoffrey Walter
/ TITLE OF INVENTION: Production of anti-self antibodies from
/ antibody segment repertoires and displayed on phage
/ NUMBER OF SEQUENCES: 21
/ CORRESPONDENCE ADDRESS:
/ ADDRESSER: David W. Clough
/ STREET: Marshall, O'Toole, Gerstein, Murray & Borun
/ 6300 Sears Tower, 233 South Wacker Drive
/ CITY: Chicago
/ STATE: Illinois
/ COUNTRY: USA
/ ZIP: 60606-6402
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/723,756
/ FILING DATE: 28-No. 6582915-2000
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9125579.4
/ FILING DATE: 02-DEC-1991
/ APPLICATION NUMBER: GB 9125582.8
/ FILING DATE: 02-DEC-1991
/ APPLICATION NUMBER: GB 9206318.9
/ FILING DATE: 24-MAR-1992
/ APPLICATION NUMBER: GB 9206372.6
/ FILING DATE: 24-MAR-1992
/ APPLICATION NUMBER: PCT/GB92/01755
/ FILING DATE: 23-SEP-1992
/ APPLICATION NUMBER: PCT/GB92/02240
/ FILING DATE: 02-DEC-1992
/ APPLICATION NUMBER: US 08/244,597
/ FILING DATE: 26-OCT-1994
/ APPLICATION NUMBER: US 09/197,224
/ FILING DATE: 20-NOV-1998
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Clough, David W
/ REGISTRATION NUMBER: 36,107
/ REFERENCE/DOCKET NUMBER: 28111/32094E
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 312-474-6300
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ SEQUENCE DESCRIPTION: SEQ ID NO: 14:
/
/ US-09-723-756-14
/
/ Query Match 0.7%; Score 13.8; DB 1; Length 18;
/ Best Local Similarity 88.2%; Pred. No. 1.4e+02;
/ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 795 TGTATTACGGTGAAGA 811
/ Db 2 TGTATTACTGTGCAAGA 18
/
/ RESULT 152
/ US-09-532-840-14
```

```
US-09-723-756-14
/ Sequence 14, Application US/09723756
/ Patent No. 6582915
/ GENERAL INFORMATION:
/ APPLICANT: Griffiths, Andrew David
/ APPLICANT: Hoogenboom, Hendricus RJM
/ APPLICANT: Marks, James David
/ APPLICANT: McCafferty, John
/ APPLICANT: Winter, Gregory Paul
/ APPLICANT: Griffing, Geoffrey Walter
/ TITLE OF INVENTION: Production of anti-self antibodies from
/ antibody segment repertoires and displayed on phage
/ NUMBER OF SEQUENCES: 21
/ CORRESPONDENCE ADDRESS:
/ ADDRESSER: David W. Clough
/ STREET: Marshall, O'Toole, Gerstein, Murray & Borun
/ 6300 Sears Tower, 233 South Wacker Drive
/ CITY: Chicago
/ STATE: Illinois
/ COUNTRY: USA
/ ZIP: 60606-6402
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/723,756
/ FILING DATE: 28-No. 6582915-2000
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9125579.4
/ FILING DATE: 02-DEC-1991
/ APPLICATION NUMBER: GB 9125582.8
/ FILING DATE: 02-DEC-1991
/ APPLICATION NUMBER: GB 9206318.9
/ FILING DATE: 24-MAR-1992
/ APPLICATION NUMBER: GB 9206372.6
/ FILING DATE: 24-MAR-1992
/ APPLICATION NUMBER: PCT/GB92/01755
/ FILING DATE: 23-SEP-1992
/ APPLICATION NUMBER: PCT/GB92/02240
/ FILING DATE: 02-DEC-1992
/ APPLICATION NUMBER: US 08/244,597
/ FILING DATE: 26-OCT-1994
/ APPLICATION NUMBER: US 09/197,224
/ FILING DATE: 20-NOV-1998
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Clough, David W
/ REGISTRATION NUMBER: 36,107
/ REFERENCE/DOCKET NUMBER: 28111/32094E
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 312-474-6300
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ SEQUENCE DESCRIPTION: SEQ ID NO: 14:
/
/ US-09-723-756-14
/
/ Query Match 0.7%; Score 13.8; DB 1; Length 18;
/ Best Local Similarity 88.2%; Pred. No. 1.4e+02;
/ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 795 TGTATTACGGTGAAGA 811
/ Db 2 TGTATTACTGTGCAAGA 18
/
/ RESULT 152
/ US-09-532-840-14
```

; Sequence 14, Application US/09532840
; Patent No. 6593081
; GENERAL INFORMATION:
; APPLICANT: Griffiths, Andrew
; APPLICANT: Hoogenboom, Hendricus
; APPLICANT: Marks, James
; APPLICANT: McCafferty, John
; APPLICANT: Winter, Gregory
; APPLICANT: Grigg, Geoffrey
; TITLE OF INVENTION: Production of Anti-Self Antibodies from Antibody Segment Repet
; FILE REFERENCE: 28111/32094D
; CURRENT APPLICATION NUMBER: US/09/532,840
; CURRENT FILING DATE: 2000-03-21
; PRIOR APPLICATION NUMBER: US 08/244,597
; PRIOR FILING DATE: 1994-06-01
; PRIOR APPLICATION NUMBER: GB 9125582.8
; PRIOR FILING DATE: 1991-12-02
; PRIOR APPLICATION NUMBER: GB 9206318.9
; PRIOR FILING DATE: 1992-03-24
; PRIOR APPLICATION NUMBER: GB 9206372.6
; PRIOR FILING DATE: 1992-03-24
; PRIOR APPLICATION NUMBER: GB 9125579.4
; PRIOR FILING DATE: 1991-12-02
; PRIOR APPLICATION NUMBER: PCT/GB92/01755
; PRIOR FILING DATE: 1992-09-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 18
; TYPE: DNA
; ORGANISM: oligonucleotide CDRBACK
US-09-532-840-14

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 TGTATTACGTGGAGA 811
Db 2 TGTATTACTGTGCAAGA 18
|||||

RESULT 153

US-09-747-391-9/c
; Sequence 9, Application US/09747391
; Patent No. 6670124
; GENERAL INFORMATION:
; APPLICANT: Chow, Robert
; APPLICANT: Tonai, Richard
; APPLICANT: StemCye, Inc.
; TITLE OF INVENTION: High Throughput Methods of HLA Typing
; FILE REFERENCE: 020035-000210US
; CURRENT APPLICATION NUMBER: US/09/747,391
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: US 60/172,768
; PRIOR FILING DATE: 1999-12-20
; NUMBER OF SEQ ID NOS: 278
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-747-391-9

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 382 TGCAGCAGATGGGCTG 398
Db 17 TGCAGCAGGAGGGGCTG 1
|||||

RESULT 154
US-09-747-391-125/c
; Sequence 125, Application US/09747391
; Patent No. 6670124
; GENERAL INFORMATION:
; APPLICANT: Chow, Robert
; APPLICANT: Tonai, Richard
; APPLICANT: StemCye, Inc.
; TITLE OF INVENTION: High Throughput Methods of HLA Typing
; FILE REFERENCE: 020035-000210US
; CURRENT APPLICATION NUMBER: US/09/747,391
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: US 60/172,768
; PRIOR FILING DATE: 1999-12-20
; NUMBER OF SEQ ID NOS: 278
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 125
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-747-391-125

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 382 TGCAGCAGATGGGCTG 398
Db 17 TGCAGCAGGAGGGGCTG 1
|||||

RESULT 155

US-08-983-605-93
; Sequence 93, Application US/08983605A
; Patent No. 6720137
; GENERAL INFORMATION:
; APPLICANT: Roder, Marion
; TITLE OF INVENTION: Microsatellite Markers for plants of the Species
; TITLE OF INVENTION: Triticum Aestivum and Tribe Triticeae and the Use of
; TITLE OF INVENTION: Said Markers
; FILE REFERENCE: 2936.10400
; CURRENT APPLICATION NUMBER: US/08/983,605A
; CURRENT FILING DATE: 1998-05-01
; EARLIER APPLICATION NUMBER: DE 195 25 284.5
; EARLIER FILING DATE: 1995-06-28
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 93
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Triticum aestivum
US-08-983-605-93

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1696 AATCATTCTCCCTCCC 1712
Db 2 AATCATTCTCCCTCCC 18
|||||

RESULT 156

US-09-500-700-68/c
; Sequence 68, Application US/09500700
; Patent No. 6790941
; GENERAL INFORMATION:
; APPLICANT: THE SCRIPPS RESEARCH INSTITUTE
; APPLICANT: BARBAS III, Carlos F.
; APPLICANT: GOTTESFELD, Joel M.
; APPLICANT: WRIGHT, Peter E.
; TITLE OF INVENTION: ZINC FINGER PROTEIN DERIVATIVES AND METHODS THEREFOR

```
; FILE REFERENCE: SCRIP1160-4
; CURRENT APPLICATION NUMBER: US/09/500,700
; CURRENT FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: US 08/863,813
; PRIOR FILING DATE: 1997-05-27
; PRIOR APPLICATION NUMBER: US 08/676,318
; PRIOR FILING DATE: 1996-12-30
; PRIOR APPLICATION NUMBER: PCT/US95/00829
; PRIOR FILING DATE: 1995-01-18
; PRIOR APPLICATION NUMBER: US 08/312,604
; PRIOR FILING DATE: 1994-09-28
; PRIOR APPLICATION NUMBER: US 08/183,119
; PRIOR FILING DATE: 1994-01-18
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 68
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: (GCG)6 probe
; US-09-500-700-68

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 CGCCTCGTCGCGCGCG 46
Db 18 CGCGCGCGCGCGCGCG 2

RESULT 157
PCT-US93-12600-17/c
; Sequence 17, Application PC/TUS9312600
; GENERAL INFORMATION:
; APPLICANT: Denner, Larry A.
; APPLICANT: Rege, Ajay A.
; APPLICANT: Dixon, Richard A.F.
; TITLE OF INVENTION: ANTISENSE MOLECULES DIRECTED AGAINST A
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR RECEPTOR GENE FAMILY
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dressler, Goldsmith, Shore &
; ADDRESSEE: Minamow, Ltd.
; STREET: 180 North Stetson, Suite 4700
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/12600
; FILING DATE: 28-DEC-1993
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/999,706
; FILING DATE: December 31, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Katz, Martin L.
; REGISTRATION NUMBER: 25,011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312)616-5400
; TELEFAX: (312)616-5460
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
```

```
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; PCT-US93-12600-17

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 977 CTGGGATGTGGCAGG 993
Db 17 CTGGGATGTGGGCTGG 1

RESULT 158
PCT-US95-03731-17/c
; Sequence 17, Application PC/TUS9503731
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; TITLE OF INVENTION: Treatment of Partial Growth Hormone Insensitivity Syndrome
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/03731
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/224982
; FILING DATE: 07-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Hasak, Janet E.
; REGISTRATION NUMBER: 28,616
; REFERENCE/DOCKET NUMBER: 884P1PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1896
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; PCT-US95-03731-17

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 264 TATGGTAAAGCCAGAA 280
Db 17 TAAGGTAAAGCCAGCA 1

RESULT 159
PCT-US96-01473-2/c
; Sequence 2, Application PC/TUS9601473
; GENERAL INFORMATION:
; APPLICANT: University of Nebraska, Board of Regents
; APPLICANT: Gold, Barry I.
; TITLE OF INVENTION: Synthetic Triple Helix-Forming Compounds
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
```

ADDRESSEE: Dann, Dorfman, Herrell and Skillman
STREET: 1601 Market Street Suite 720
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103-2307
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/01473
FILING DATE: 29-JAN-1996
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/384,324
FILING DATE: 01-FEB-1995
ATTORNEY/AGENT INFORMATION:
NAME: Reed, Janet E.
REGISTRATION NUMBER: 36,252
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 563-4100
TELEFAX: (215) 563-4044
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: not relevant
MOLECULE TYPE: other nucleic acid
HYPOTHETICAL: YES
ANTI-SENSE: YES
PCT-US96-01473-2

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1834 GAAAAAAGAAAAA 1850
DB 17 GAAAAAAGAAAAA 1

RESULT 160
US-09-180-437-104/c
Sequence 104, Application US/09180437
Patent No. 6251873
GENERAL INFORMATION:
APPLICANT: FUKUSAKO, Shioji
APPLICANT: MORISAWA, Yoshifumi
APPLICANT: KUSUYAMA, Takeshi
TITLE OF INVENTION: Antisense Compounds to CD14
FILE REFERENCE: 1110-209P
CURRENT APPLICATION NUMBER: US/09/180,437
CURRENT FILING DATE: 1998-11-06
EARLIER APPLICATION NUMBER: PCT/JP98/00953
EARLIER FILING DATE: 1998-03-09
EARLIER APPLICATION NUMBER: 09-053518 JAPAN
EARLIER FILING DATE: 1997-03-07
NUMBER OF SEQ ID NOS: 289
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 104
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: other nucleic acid
US-09-180-437-104

Query Match 0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1446 GTTGCTGCTGCTGT 1460
DB 15 GTTGCTGCTGCTGCT 1

RESULT 161

US-09-371-772B-5840/c
Sequence 5840, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 5840
LENGTH: 16
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-5840

Query Match 0.7%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1281 CTCACATCACTCAG 1295
DB 16 CTCACATCACTCAG 2

RESULT 162

US-09-017-974-66/c
Sequence 66, Application US/09017974
Patent No. 6288042
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Wallace, Thomas L.
APPLICANT: Cossum, Paul A.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Tetrad Forming Oligonucleotides
NUMBER OF SEQUENCES: 88
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1800
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/017,974
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 13
; OTHER INFORMATION: /note= "C-5 propynl dU"
;
US-09-017-974-66

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCCTCCCTCCACCAC 1721
Db 16 CCNCCCAACCACCAC 1

RESULT 163
US-09-017-974-73/c
; Sequence 73, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossam, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TETRAD FORMING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tavon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 76:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
;
US-09-017-974-76/c
; Sequence 76, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossam, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TETRAD FORMING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tavon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 73:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
;
US-09-017-974-73
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 73:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 13
; OTHER INFORMATION: /note= "5-bromo dU"
;
US-09-017-974-73

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCCTCCCTCCACCAC 1721
Db 16 CCNCCCAACCACCAC 1

RESULT 164
US-09-017-974-76/c
; Sequence 76, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossam, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TETRAD FORMING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tavon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 76:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
;
US-09-017-974-76
```


; LOCATION: 9
; OTHER INFORMATION: /note= "5-iodo dU"
US-09-017-974-76

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721
DB 16 CCACCCCCACCAC 1

RESULT 165

US-09-017-974-77/c

; Sequence 77, Application US/09017974

; Patent No. 6288042

; GENERAL INFORMATION:

; APPLICANT: Rando, Robert F.

; APPLICANT: Ojwang, Joshua O.

; APPLICANT: Hogan, Michael E.

; APPLICANT: Wallace, Thomas L.

; APPLICANT: Cossum, Paul A.

; TITLE OF INVENTION: Anti-Viral Guanosine-Rich

; TITLE OF INVENTION: Tetrad Forming Oligonucleotides.

; NUMBER OF SEQUENCES: 88

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Conley, Rose & Tayon, P.C.

; STREET: 600 Travis, Suite 1800

; CITY: Houston

; STATE: Texas

; COUNTRY: U.S.A.

; ZIP: 77002-2912

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: MS Word 97 (saved as .txt file)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/017,974

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/037,374

; FILING DATE: 04-FEB-97

; APPLICATION NUMBER:

; FILING DATE: 09-DEC-97

; ATTORNEY/AGENT INFORMATION:

; NAME: McDaniel, C. Steven

; REGISTRATION NUMBER: 33,962

; REFERENCE/DOCKET NUMBER: 1472-06223

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 713/238-8010

; TELEFAX: 713/238-8008

; INFORMATION FOR SEQ ID NO: 77:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: DNA (genomic)

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: 13

; OTHER INFORMATION: /note= "5-iodo dU"

US-09-017-974-77

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721
DB 16 CCACCCCCACCAC 1

Db 16 CCNCCCCACCACCAC 1

RESULT 166

US-08-682-255A-66/c

; Sequence 66, Application US/08682255A

; Patent No. 6323185

; GENERAL INFORMATION:

; APPLICANT: Rando, Robert F.

; APPLICANT: Pennewald, Susan

; APPLICANT: Zendegui, Joseph G.

; APPLICANT: Ojwang, Joshua O.

; APPLICANT: Hogan, Michael E.

; APPLICANT: Pommier, Yves

; APPLICANT: Mazumder, Abhijit

; TITLE OF INVENTION: Anti-Viral Guanosine-Rich

; TITLE OF INVENTION: Oligonucleotides

; NUMBER OF SEQUENCES: 87

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Conley, Rose & Tayon, P.C.

; STREET: 600 Travis, Suite 1850

; CITY: Houston

; STATE: Texas

; COUNTRY: U.S.A.

; ZIP: 77002-2912

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: MS Windows 95

; SOFTWARE: MS Word 97 (saved as .txt file)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/682,255A

; FILING DATE: 17-JULY-1996

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/535,168

; FILING DATE: 23-OCT-95

; APPLICATION NUMBER: 60/001,505

; FILING DATE: 19-JULY-95

; APPLICATION NUMBER: 60/014,007

; FILING DATE: 25-MARCH-96

; APPLICATION NUMBER: 60/013,688

; FILING DATE: 19-MARCH-96

; APPLICATION NUMBER: 60/015,714

; FILING DATE: 17-APRIL-96

; APPLICATION NUMBER: 60/016,271

; FILING DATE: 23-APRIL-96

; ATTORNEY/AGENT INFORMATION:

; NAME: McDaniel, C. Steven

; REGISTRATION NUMBER: 33,962

; REFERENCE/DOCKET NUMBER: 1472-06214

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 713/238-8010

; TELEFAX: 713/238-8008

; INFORMATION FOR SEQ ID NO: 66:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: DNA (genomic)

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: 13

; OTHER INFORMATION: /note= "C-5 propynyl dU"

US-08-682-255A-66

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721
DB 16 CCNCCCCACCACCAC 1

Db 16 CCNCCCACCCACCAC 1

RESULT 167
US-08-682-255A-73/c
; Sequence 73, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennewald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tavon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 73:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 13
; OTHER INFORMATION: /note= "5-bromo dU"
US-08-682-255A-73

Query Match 0.78; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1706 CCCTCCCTCCACCCAC 1721
||| ||| |||||

Db 16 CCNCCCACCCACCAC 1

RESULT 168
US-08-682-255A-76/c
; Sequence 76, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennewald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tavon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 76:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 9
; OTHER INFORMATION: /note= "5-iodo dU"
US-08-682-255A-76

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1706 CCCTCCCTCCACCCAC 1721
||| ||| |||||

Db 16 CCCACCCNCCCACCAC 1

RESULT 169

US-08-682-255A-77/c
; Sequence 77, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Yves
; APPLICANT: Mazunder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 77:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 13
; OTHER INFORMATION: /note= "5-iodo dU"
US-08-682-255A-77

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
|||||

Db 16 CCCNCCCACCACCAC 1

RESULT 170

US-08-584-040-4251/c
; Sequence 4251, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 4251:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-4251

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1149 AAGTAAATATTTC 1163
|||||

Db 15 AAGGAAATATTTC 1

RESULT 171

US-08-584-040-5821/c
; Sequence 5821, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime

```

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5821:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5821

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1149 AAGGTAATATTTC 1163
Db 15 AAGGAATATTTC 1

RESULT 172
US-09-429-130-66/c
; Sequence 66, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; Fennewald, Susan
; Zengdegui, Joseph G.
; Ojwang, Joshua O.
; Hogan, Michael E.
; Pommer, Yves
; Mazumder, Abhijit
; 60/015,714
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/429,130
; FILING DATE: 28-Oct-1999
; CLASSIFICATION: <Unknown>
; 19-JULY-95
; 25-MARCH-96
; 19-MARCH-96
; 17-APRIL-96
; 23-APRIL-96
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/682,255
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 17-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 13
; OTHER INFORMATION: /note= "C-5 propynl du"
; SEQUENCE DESCRIPTION: SEQ ID NO: 66:
US-09-429-130-66

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCNCCACCACCACCAC 1

RESULT 173
US-09-429-130-73/c
; Sequence 73, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; Fennewald, Susan
; Zengdegui, Joseph G.
; Ojwang, Joshua O.
; Hogan, Michael E.
; Pommer, Yves
; Mazumder, Abhijit
; 60/015,714
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; Oligonucleotides
; NUMBER OF SEQUENCES: 87
```

;;
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/429,130
; FILING DATE: 28-Oct-1999
; CLASSIFICATION: <Unknown>
; 19-JULY-95
; 25-MARCH-96
; 19-MARCH-96
; 17-APRIL-96
; 23-APRIL-96
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/682,255
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 17-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 73:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 13
; OTHER INFORMATION: /note= "5-bromo du"
; SEQUENCE DESCRIPTION: SEQ ID NO: 73:
US-09-429-130-73

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db ||||| ||||| |||||

RESULT 174
US-09-429-130-76/c
; Sequence 76, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; Pennewald, Susan
; Zendequi, Joseph G.
; Olwang, Joshua O.
; Hogan, Michael E.
; Pommier, Eyes

;;
; Mazunder, Abhijit
; 60/015,714
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/429,130
; FILING DATE: 28-Oct-1999
; CLASSIFICATION: <Unknown>
; 19-JULY-95
; 25-MARCH-96
; 19-MARCH-96
; 17-APRIL-96
; 23-APRIL-96
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/682,255
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 17-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 76:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 9
; OTHER INFORMATION: /note= "5-iodo du"
; SEQUENCE DESCRIPTION: SEQ ID NO: 76:
US-09-429-130-76

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db ||||| ||||| |||||

RESULT 175
US-09-429-130-77/c
; Sequence 77, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.

Fennwald, Susan
Zengdegui, Joseph G.
Ojwang, Joshua O.
Hogan, Michael E.
Pommer, Eyles
Mazumder, Abhijit
60/015.714
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
FILING DATE: US/09/429,130
FILING DATE: 28-Oct-1999
CLASSIFICATION: <Unknown>
19-JULY-95
25-MARCH-96
19-MARCH-96
17-APRIL-96
23-APRIL-96
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/682,255
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 77:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc.feature
LOCATION: 13
OTHER INFORMATION: /note= "5-iodo dU"
SEQUENCE DESCRIPTION: SEQ ID NO: 77:
US-09-429-130-77

Query Match . 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721
DB 16 CCNCCACCACCAC 1

RESULT 176

US-09-132-769-8/c
; Sequence 8, Application US/09132769A
; Patent No. 6525023
; GENERAL INFORMATION:
; APPLICANT: Motoo Yamasaki
; APPLICANT: Kenji Shibata
; APPLICANT: No. 6525023uo Hanai
; APPLICANT: Akiko Furuya
; APPLICANT: Kaoru Miyamoto
; TITLE OF INVENTION: NOVEL VASCULAR SMOOTH MUSCLE CELL GROWTH FACTOR
; FILE REFERENCE: 11078
; CURRENT APPLICATION NUMBER: US/09/132,769A
; CURRENT FILING DATE: 1998-08-12
; EARLIER APPLICATION NUMBER: HEI9-218491
; EARLIER FILING DATE: 1997-08-13
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 8
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA
US-09-132-769-8

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.5e+02;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1384 ATTCTTCTTCATC 1398
DB 17 ATYTCYTCYTCATY 3

RESULT 177

US-09-371-772B-2018/c
; Sequence 2018, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 2018
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2018

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1149 AAGGTAATATTTCC 1163
DB 15 AAGGTAATATTTCC 1

RESULT 178
US-09-866-108A-1538
; Sequence 1538, Application US/09866108A

```
; Patent No. 686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 686188
; SEQ ID NO 1538
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1538

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1084 GGCTGGTGCTCTGGA 1098
Db 2 GGCTGGTGCTCTGGA 16

RESULT 179
US-09-866-108A-1539
; Sequence 1539, Application US/09866108A
; Patent No. 686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 686188
; SEQ ID NO 1538
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1538
```

```
; Patent No. 686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 686188
; SEQ ID NO 1539
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1539

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1084 GGCTGGTGCTCTGGA 1098
Db 1 GGCTGGTGCTCTGGA 15

RESULT 180
US-09-866-108A-8366
; Sequence 8366, Application US/09866108A
; Patent No. 686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
```

; Patent No. 6686188
; SEQ ID NO 8366
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8366

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 396 CTGAGAAAGTTTCAC 410
Db 1 CTGAGAAAGTGCAC 15

RESULT 181

US-09-866-108A-8587
; Sequence 8587, Application US/09866108A
; Patent No. 6686188

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aemica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 8587

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-8587

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAGAACAGG 1114
Db 3 TGCAGAGCACAGG 17

RESULT 182

US-09-866-108A-8588

; Sequence 8588, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aemica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 8588

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-8588

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAGAACAGG 1114
Db 2 TGCAGAGCACAGG 16

RESULT 183

US-09-866-108A-8589

; Sequence 8589, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04


```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8589
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8589

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1100 TGCAGAGCAACAGG 1114
Db      1 TGCAGAGCAACAGG 15

RESULT 184
US-09-866-108A-10029/c
; Sequence 10029, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8589
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8589

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1100 TGCAGAGCAACAGG 1114
Db      1 TGCAGAGCAACAGG 15

RESULT 184
US-09-866-108A-10029/c
; Sequence 10029, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
```

```
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10029
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10029

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1066 GTCCAAAGAGGACTC 1080
Db      17 GTCCACAGAGGACTC 3

RESULT 185
US-09-866-108A-10032/c
; Sequence 10032, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10032
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10032

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1065 CGTCCAAAGAGGACT 1079
Db      15 CGTCCACAGAGGACT 1

RESULT 186
```

```
US-09-940-244-418/c
; Sequence 418, Application US/09940244
; Patent No. 6692917
; GENERAL INFORMATION:
; APPLICANT: Neri, Bruce P.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Smith, Lloyd M.
; TITLE OF INVENTION: Reactions on Dendrimers
; FILE REFERENCE: FORS-06478
; CURRENT APPLICATION NUMBER: US/09/940,244
; CURRENT FILING DATE: 2002-05-06
; NUMBER OF SEQ ID NOS: 422
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 418
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-940-244-418

Query Match          0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 566 CGATGAACGTCAGAG 580
DB 16 CGATGACCTGCAGAG 2
||||| |||||||

RESULT 187
US-09-685-664B-2018/c
; Sequence 2018, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2018
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-2018

Query Match          0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1149 AAGGTAAATATTTC 1163
DB 15 AAGGAAATATTTC 1
||||| |||||||

RESULT 188
PCT-US91-03680-7/c
; Sequence 7, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: DUPLEX DNA
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/03680
; FILING DATE: 19910524
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4610-0011.40
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-327-7250
; TELEFAX: 415-327-2951
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 8
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "N4,N4-ethanocytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 14
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 17
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "1,3-propanediol"
; PCT-US91-03680-7

Query Match          0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1850
DB 16 AAGAAAAAANAANA 1
||||| |||||||

RESULT 189
US-08-702-665A-8/c
; Sequence 8, Application US/08702665A
; Patent No. 6274708
; GENERAL INFORMATION:
; APPLICANT: Hilton, Douglas J.
; TITLE OF INVENTION: A NOVEL HAEMOPOIETIN RECEPTOR
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSER: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 Garden City Plaza
```

```

; CITY: Garden City
; STATE: New York
; COUNTRY: United States of America
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/702,665A
; FILING DATE: 20-DEC-1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Presser, Leopold
; REGISTRATION NUMBER: 19,827
; REFERENCE/DOCKET NUMBER: 10296
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 203 901 SANS UR
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..2
; OTHER INFORMATION: /note= "R at Position 1 is A or G"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 7..8
; OTHER INFORMATION: /note= "N at Position 7 is N"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 10..11
; OTHER INFORMATION: /note= "R at Position 10 is A or G"
; US-08-702-665A-8

```

```

Query Match 0.7%; Score 13.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 1343 TGGAGTGCCTGAGC 1357
Db 15 TGGAGTGCCTGAGY 1

```

```

RESULT 190
US-08-292-620A-370/c
; Sequence 370, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California

```

```

; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 370:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-370

```

```

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1829 TCTCTGAAAAAAA 1841
Db 13 TCTCTGAAAAAAA 1

```

```

RESULT 191
US-09-071-845-370/c
; Sequence 370, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0

```

two

```
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 370:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-071-845-370
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1829 TCTCTGAAAAAA 1841
Db 13 TCTCTGAAAAAA 1

RESULT 192
US-09-701-947A-20/c
; Sequence 20, Application US/09701947A
; Patent No. 6818611
; GENERAL INFORMATION:
; APPLICANT: Altman, Elliot
; TITLE OF INVENTION: STABILIZED BIOACTIVE PEPTIDES AND METHODS OF
; FILE REFERENCE: 235.00010101
; CURRENT APPLICATION NUMBER: US/09/701,947A
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: 60/104,013
; PRIOR FILING DATE: 1998-10-13
; PRIOR FILING DATE: 1998-12-14
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
; OTHER INFORMATION: fragment
US-09-701-947A-20
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GAATTCATAGAT 487
Db 15 GAATTCATAGAT 3

RESULT 193
US-09-701-947A-20/c
; Sequence 20, Application US/09701947A
; Patent No. 6818611
; GENERAL INFORMATION:
; APPLICANT: Altman, Elliot
; TITLE OF INVENTION: STABILIZED BIOACTIVE PEPTIDES AND METHODS OF
; FILE REFERENCE: 235.00010101
; CURRENT APPLICATION NUMBER: US/09/701,947A
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: 60/104,013
; PRIOR FILING DATE: 1998-10-13
; PRIOR FILING DATE: 1998-12-14
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
; OTHER INFORMATION: fragment
US-09-701-947A-20
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GAATTCATAGAT 487
Db 15 GAATTCATAGAT 3

RESULT 195
US-08-985-162-333
; Sequence 333, Application US/08985162
; Patent No. 6057156
```

```
US-09-701-947A-21/c
; Sequence 21, Application US/09701947A
; Patent No. 6818611
; GENERAL INFORMATION:
; APPLICANT: Altman, Elliot
; TITLE OF INVENTION: STABILIZED BIOACTIVE PEPTIDES AND METHODS OF
; FILE REFERENCE: 235.00010101
; CURRENT APPLICATION NUMBER: US/09/701,947A
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: 60/104,013
; PRIOR FILING DATE: 1998-10-13
; PRIOR FILING DATE: 1998-12-14
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
; OTHER INFORMATION: fragment
US-09-701-947A-21
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GAATTCATAGAT 487
Db 15 GAATTCATAGAT 3

RESULT 194
US-09-701-947A-22/c
; Sequence 22, Application US/09701947A
; Patent No. 6818611
; GENERAL INFORMATION:
; APPLICANT: Altman, Elliot
; TITLE OF INVENTION: STABILIZED BIOACTIVE PEPTIDES AND METHODS OF
; FILE REFERENCE: 235.00010101
; CURRENT APPLICATION NUMBER: US/09/701,947A
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: 60/104,013
; PRIOR FILING DATE: 1998-10-13
; PRIOR FILING DATE: 1998-12-14
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
; OTHER INFORMATION: fragment
US-09-701-947A-22
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GAATTCATAGAT 487
Db 15 GAATTCATAGAT 3

RESULT 195
US-08-985-162-333
; Sequence 333, Application US/08985162
; Patent No. 6057156
```

GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Fast-Seq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 333:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-333

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1330 TTGGATCCAGC 1342
Db 2 UUUGGAUCCAGC 14
:::|||||

RESULT 196
US-09-017-974-74/c
Sequence 74, Application US/09017974
Patent No. 6288042
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Wallace, Thomas L.
APPLICANT: Cossum, Paul A.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Tetrad Forming Oligonucleotides
NUMBER OF SEQUENCES: 88
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1800
CITY: Houston
STATE: Texas

COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/017,974
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/037,374
FILING DATE: 04-FEB-97
APPLICATION NUMBER:
FILING DATE: 09-DEC-97
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06223
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 74:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc feature
LOCATION: 5,9,13
OTHER INFORMATION: /note= "5-bromo dU"
US-09-017-974-74

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1706 CCTCTCCTCCACCAC 1721
Db 16 CCNCCNCCNCCAC 1
||| ||| ||| |||

RESULT 197
US-09-017-974-78/c
Sequence 78, Application US/09017974
Patent No. 6288042
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Wallace, Thomas L.
APPLICANT: Cossum, Paul A.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Tetrad Forming Oligonucleotides
NUMBER OF SEQUENCES: 88
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1800
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/017,974
FILING DATE:

```
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA: 60/037,374
/ FILING DATE: 04-FEB-97
/ APPLICATION NUMBER:
/ FILING DATE: 09-DEC-97
/ ATTORNEY/AGENT INFORMATION:
/ NAME: McDaniel, C. Steven
/ REGISTRATION NUMBER: 33,962
/ REFERENCE/DOCKET NUMBER: 1472-06223
/ TELEPHONE: 713/238-8010
/ TELEFAX: 713/238-8008
/ INFORMATION FOR SEQ ID NO: 78:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: 5,9,13
/ OTHER INFORMATION: /note="5-iodo dU"
US-09-017-974-78

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACAC 1721
Db 16 CCNCCNCCNCCAC 1

RESULT 198
US-09-628-628-8/c
; Sequence 8, Application US/09098628
; Patent No. 6294359
; GENERAL INFORMATION:
; APPLICANT: FIDDES, J.C.
; APPLICANT: ABRAHAM, J.D.
; TITLE OF INVENTION: HUMAN BASIC FIBROBLAST GROWTH
; TITLE OF INVENTION: FACTOR ANALOG
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/098,628
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Lehnhardt, Susan K
; REGISTRATION NUMBER: 33,943
; REFERENCE/DOCKET NUMBER: 21900-20089.10
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 8:
```

```
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-09-098-628-8

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1329 TTTTGATCCAAG 1341
Db 14 TTTTGATCCAAG 2

RESULT 199
US-08-682-255A-74/c
; Sequence 74, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennewald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommer, Eyles
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 74:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

```
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 5,9,13
; OTHER INFORMATION: /note= "5-bromo dU"
US-08-682-255A-74

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCCAC 1721
Db 16 CCNCCNCCNCCNCCAC 1

RESULT 200
US-08-682-255A-78/c
; Sequence 78, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zengdegui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 78:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

```
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 5,9,13
; OTHER INFORMATION: /note= "5-iodo dU"
US-08-682-255A-78

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCCAC 1721
Db 16 CCNCCNCCNCCNCCAC 1

RESULT 201
US-09-429-130-74/c
; Sequence 74, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zengdegui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/429,130
; FILING DATE: 28-Oct-1999
; CLASSIFICATION: <Unknown>
; 19-JULY-95
; 25-MARCH-96
; 19-MARCH-96
; 17-APRIL-96
; 23-APRIL-96
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/682,255
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 17-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 74:
; SEQUENCE CHARACTERISTICS:
```

```
;
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
;   NAME/KEY: misc feature
;   LOCATION: 5,9,13
;   OTHER INFORMATION: /note= "5-bromo dU"
;   SEQUENCE DESCRIPTION: SEQ ID NO: 74:
US-09-429-130-74
;
; Query Match          0.7%; Score 13; DB 1; Length 17;
; Best Local Similarity 81.2%; Pred. No. 1.8e+02;
; Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
;
QY 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCNCCNCCNCCAC 1

RESULT 202
US-09-429-130-78/c
; Sequence 78, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
;   APPLICANT: Rando, Robert F.
;   FENNEWALD, Susan
;   ZENDEGUI, Joseph G.
;   OJWANG, Joshua O.
;   HOGAN, Michael E.
;   POMMIER, Byves
;   MAZUMDER, Abhijit
;   60/015,714
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
;   Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Conley, Rose & Tayon, P.C.
;   STREET: 600 Travis, Suite 1850
;   CITY: Houston
;   STATE: Texas
;   COUNTRY: U.S.A.
;   ZIP: 77002-2912
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: Floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: MS Windows 95
;   SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/09/429,130
;   FILING DATE: 28-Oct-1999
;   CLASSIFICATION: <Unknown>
;   19-JULY-95
;   25-MARCH-96
;   19-MARCH-96
;   17-APRIL-96
;   23-APRIL-96
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: 08/682,255
;   FILING DATE: <Unknown>
;   APPLICATION NUMBER: 60/001,505
;   FILING DATE: 19-JULY-95
;   APPLICATION NUMBER: 60/014,007
;   FILING DATE: 25-MARCH-96
;   APPLICATION NUMBER: 60/013,688
;   FILING DATE: 19-MARCH-96
;   APPLICATION NUMBER: 60/016,271
;   FILING DATE: 17-APRIL-96
; ATTORNEY/AGENT INFORMATION:
;   NAME: McDaniel, C. Steven
;   REGISTRATION NUMBER: 33,962
;   REFERENCE/DOCKET NUMBER: 1472-06214
;
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 713/238-8010
;   TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 78:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: DNA (genomic)
;   FEATURE:
;     NAME/KEY: misc feature
;     LOCATION: 5,9,13
;     OTHER INFORMATION: /note= "5-iodo dU"
;     SEQUENCE DESCRIPTION: SEQ ID NO: 78:
US-09-429-130-78
;
; Query Match          0.7%; Score 13; DB 1; Length 17;
; Best Local Similarity 81.2%; Pred. No. 1.8e+02;
; Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
;
QY 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCNCCNCCNCCAC 1

RESULT 203
US-09-401-063-333
; Sequence 333, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
;   APPLICANT: Akhtar, Saghir
;   APPLICANT: Fell, Patricia
;   APPLICANT: McSwiggen, James
;   TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
;   TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
;   TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
;   TITLE OF INVENTION: FACTOR RECEPTORS
;   NUMBER OF SEQUENCES: 1877
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071-2066
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;     COMPUTER: IBM Compatible
;     OPERATING SYSTEM: IBM P.C. DOS 5.0
;     SOFTWARE: FastSeq for Windows 2.0
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER: US/09/401,063
;     FILING DATE:
;   CLASSIFICATION:
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER: 08/985,162
;       FILING DATE: 04 December 1997
;       APPLICATION NUMBER: 60/036,476
;       FILING DATE: 31 January 1997
;     ATTORNEY/AGENT INFORMATION:
;       NAME: Warburg, Richard J.
;       REGISTRATION NUMBER: 32,327
;       REFERENCE/DOCKET NUMBER: 230/107
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE: (213) 489-1600
;       TELEFAX: (213) 955-0440
;       TELEX: 67-3510
;     INFORMATION FOR SEQ ID NO: 333:
;       SEQUENCE CHARACTERISTICS:
;         LENGTH: 17 base pairs
```


; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-333

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 69.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1330 TTGGTATCCCAAGC 1342

Db 2 UUUGGAUCCCAAGC 14

RESULT 204

US-09-866-108A-2589
; Sequence 2589, Application US/09866108A
; Patent No. 6686188

GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866.108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2589
; LENGTH: 17

TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-2594

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 991 AGGGTGCCATGGA 1003

Db 1 AGGGTGCCATGGA 13

RESULT 206

US-09-404-912-265
; Sequence 265, Application US/09404912
; Patent No. 6703228

GENERAL INFORMATION:

; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; TITLE OF INVENTION: Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; CURRENT FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 265
; LENGTH: 17

Qy 990 CAGGGTGCCATGG 1002

Db 5 CAGGGTGCCATGG 17

RESULT 205

US-09-866-108A-2594
; Sequence 2594, Application US/09866108A
; Patent No. 6686188

```
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-404-912-265

Query Match          0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1594 ATAACAATTTCAT 1606
Db 5 ATAACAATTTCAT 17

RESULT 207
US-09-685-664B-1071/c
; Sequence 1071, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH800-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1071
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1071

Query Match          0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1847
Db 17 AAAAAAAAAAAAAA 5

RESULT 208
PCT-US91-02186-12/c
; Sequence 12, Application PC/TUS9102186
; GENERAL INFORMATION:
; APPLICANT: California Biotechnology Inc.
; APPLICANT: Inventors: Thompson, Stewart A.
; APPLICANT: Abraham, Judith A.
; TITLE OF INVENTION: High Level Expression of Basic Fibroblast Growth Factor Having a Homogeneous N-terminus
; TITLE OF INVENTION: Fibroblast Growth Factor Having a Homogeneous N-terminus
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Irell & Manella
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025-3471
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
```

```
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/02186
; FILING DATE: 19910702
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 1900-0275.41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-327-7250
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
PCT-US91-02186-12

Query Match          0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1329 TTTTGGATCCAAG 1341
Db 14 TTTTGGATCCAAG 2

RESULT 209
5514566-19/c
; Patent No. 5514566
; APPLICANT: FIDDES, JOHN C.; ABRAHAM, JUDITH A.
; TITLE OF INVENTION: METHODS OF PRODUCING RECOMBINANT FIBROBLASTS GROWTH FACTORS
; NUMBER OF SEQUENCES: 21
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/417,022
; FILING DATE: 05-APR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 809,163
; FILING DATE: 16-DEC-1985
; APPLICATION NUMBER: 775,521
; FILING DATE: 12-SEP-1985
; SEQ ID NO:19:
; LENGTH: 17
5514566-19

Query Match          0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1329 TTTTGGATCCAAG 1341
Db 14 TTTTGGATCCAAG 2

RESULT 210
US-08-239-256-4
; Sequence 4, Application US/08239256
; Patent No. 5585345
; GENERAL INFORMATION:
; APPLICANT: BOIME, IRVING
; APPLICANT: MATZUK, MARTIN M.
; APPLICANT: KEENE, JEFFREY L.
; TITLE OF INVENTION: CTP EXTENDED FORM OF LH
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 2000 Pennsylvania Ave. N.W.
; CITY: Washington, D.C.
; COUNTRY: USA
; ZIP: 20006-1812
```

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/239,256
FILING DATE: 06-MAY-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: MURASHIGE, KATE H.
REGISTRATION NUMBER: 29,959
REFERENCE/DOCKET NUMBER: 29500-20030.12
TELEPHONE: (202) 887-1500
TELEFAX: (202) 887-0763
TELEX: 90-4030
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: CDS
LOCATION: 1..12
US-08-239-256-4

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAAGAGAAA 216
|||||
Db 1 GAAATGAAGATATA 16

RESULT 211
US-08-485-692-1
Sequence 1, Application US/08485692
Patent No. 5759818
GENERAL INFORMATION:
APPLICANT: BOIME, IRVING
TITLE OF INVENTION: MODIFIED PROTEIN AND PEPTIDE
TITLE OF INVENTION: PHARMACEUTICALS
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORRISON & FOERSTER
STREET: 2000 Pennsylvania Ave. N.W.
CITY: Washington, D.C.
COUNTRY: USA
ZIP: 20006-1812
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,692
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/049,869
FILING DATE: 20-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: MURASHIGE, KATE H.
REGISTRATION NUMBER: 29,959
REFERENCE/DOCKET NUMBER: 29500-20030.21
TELEPHONE: (202) 887-1500
TELEFAX: (202) 887-0763
TELEX: 90-4030
INFORMATION FOR SEQ ID NO: 1:

SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: CDS
LOCATION: 1..12
US-08-485-692-1

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAAGAGAAA 216
|||||
Db 1 GAAATGAAGATATA 16

RESULT 212
US-08-419-519-1
Sequence 1, Application US/08419519
Patent No. 5792460
GENERAL INFORMATION:
APPLICANT: BOIME, IRVING
TITLE OF INVENTION: MODIFIED PROTEIN AND PEPTIDE
TITLE OF INVENTION: PHARMACEUTICALS
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORRISON & FOERSTER
STREET: 2000 Pennsylvania Ave. N.W.
CITY: Washington, D.C.
COUNTRY: USA
ZIP: 20006-1812
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/419,519
FILING DATE:
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/049,869
FILING DATE: 20-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: MURASHIGE, KATE H.
REGISTRATION NUMBER: 29,959
REFERENCE/DOCKET NUMBER: 29500-20030.21
TELEPHONE: (202) 887-1500
TELEFAX: (202) 887-0763
TELEX: 90-4030
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: CDS
LOCATION: 1..12
US-08-419-519-1

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAAGAGAAA 216
|||||
Db 1 GAAATGAAGATATA 16

INFORMATION FOR SEQ ID NO: 1:

```
RESULT 213
US-08-770-235A-22
; Sequence 22, Application US/08770235A
; Patent No. 5939538
; GENERAL INFORMATION:
; APPLICANT: Leavitt, Markley C.
; APPLICANT: Tritz, Richard
; APPLICANT: Feng, Yu
; APPLICANT: Barber, Jack
; APPLICANT: Yu, Mang
; TITLE OF INVENTION: Methods and Compositions for Inhibiting
; TITLE OF INVENTION: HIV Infection of Cells By Cleaving HIV Co-Receptor RNA
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 19-DEC-1996
; APPLICATION NUMBER: US/08/770,235A
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/027,875
; FILING DATE: 25-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: QUINE, Jonathan A.
; REGISTRATION NUMBER: P-41,261
; REFERENCE/DOCKET NUMBER: 016556-001610US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA
US-08-770-235A-22

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 484 AGATAGCCATCCTGGG 499
Db 1 AGAAGCAUCUUGGG 16

RESULT 214
US-08-757-024-273
; Sequence 273, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: NC 28234
; COUNTRY: USA
; ZIP: 28234
```

```
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 273:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-757-024-273

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 CTGGACAGCTGGGATG 984
Db 1 CTGGAAGCTGAGATG 16

RESULT 215
US-08-987-574-47/c
; Sequence 47, Application US/08987574
; Patent No. 6150339
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennewald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski
; STREET: 1301 McKinney, Suite 5100
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77010-3095
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/987,574
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04529
; FILING DATE: 28-OCT-1993
; APPLICATION NUMBER: US 08/053,027
; FILING DATE: 23-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul, Thomas D.
; REGISTRATION NUMBER: 32,714
; REFERENCE/DOCKET NUMBER: D-5574-CIP
```

TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/651-5151
TELEFAX: 713/651-5246
TELEX: 762829
INFORMATION FOR SEQ ID NO: 47:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-987-574-47

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 216

US-08-535-168-47/c
Sequence 47, Application US/08535168
Patent No. 6184369

GENERAL INFORMATION:

APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan G.
APPLICANT: Zendegeui, Joseph G.
APPLICANT: Ojwang, Joshua E.
APPLICANT: Hogan, Michael E.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 52

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fulbright & Jaworski
STREET: 1301 McKinney, Suite 5100
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77010-3095

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
FILING DATE:
CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/US94/04529
FILING DATE: 28-OCT-1993
APPLICATION NUMBER: US-08/053,027
FILING DATE: 23-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Paul, Thomas D.
REGISTRATION NUMBER: 32,714
REFERENCE/DOCKET NUMBER: D-5574-CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/651-5151
TELEFAX: 713/651-5246
TELEX: 762829

INFORMATION FOR SEQ ID NO: 47:

SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-535-168-47

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 217

US-09-017-974-47/c
Sequence 47, Application US/09017974
Patent No. 6288042

GENERAL INFORMATION:

APPLICANT: Rando, Robert F.
APPLICANT: Ojwang, Joshua E.
APPLICANT: Hogan, Michael E.
APPLICANT: Wallace, Thomas L.
APPLICANT: Cossum, Paul A.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Tetrad Forming Oligonucleotides
NUMBER OF SEQUENCES: 88

CORRESPONDENCE ADDRESS:

ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1800
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/017,974
FILING DATE:
CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/037,374
FILING DATE: 04-FEB-97
APPLICATION NUMBER:
FILING DATE: 09-DEC-97
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962

REFERENCE/DOCKET NUMBER: 1472-06223

TELECOMMUNICATION INFORMATION:

TELEPHONE: 713/238-8010

TELEFAX: 713/238-8008

INFORMATION FOR SEQ ID NO: 47:

SEQUENCE CHARACTERISTICS:

LENGTH: 16 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

US-09-017-974-47

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 218

US-08-682-255A-47/c
Sequence 47, Application US/08682255A
Patent No. 6323185

GENERAL INFORMATION:

APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan
APPLICANT: Zengdegui, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommier, Yves
APPLICANT: Mazumder, Abhijit
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/682,255A
FILING DATE: 17-JULY-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/535,168
FILING DATE: 23-OCT-95
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/015,714
FILING DATE: 17-APRIL-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 23-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 47:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-682-255A-47

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCACCACCACCAC 1

RESULT 219

US-09-429-130-47/c
Sequence 47, Application US/09429130
Patent No. 6355785
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
Fennwald, Susan
Zengdegui, Joseph G.
Ojwang, Joshua O.

Hogan, Michael E.
Pommier, Yves
Mazumder, Abhijit
60/015,714
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/429,130
FILING DATE: 28-OCT-1999
CLASSIFICATION: <Unknown>
19-JULY-95
25-MARCH-96
19-MARCH-96
17-APRIL-96
23-APRIL-96
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/682,255
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 47:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 47:
US-09-429-130-47

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCACCACCACCAC 1

RESULT 220

US-09-371-772B-7075
Sequence 7075, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim

```

; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7075
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-7075

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      1007 TGGCGGTGGAGCTTT 1022
      :||| |:||| |:::
Db      1 UGGCGGUGGUCUUU 16

RESULT 221
US-09-756-301B-22
; Sequence 22, Application US/09756301B
; Patent No. 6790444
; GENERAL INFORMATION:
; APPLICANT: Le, Junning
; APPLICANT: Vilcek, Jan
; APPLICANT: Daddona, Peter
; APPLICANT: Grayeb, John
; APPLICANT: Knight, David M.
; APPLICANT: Siegel, Scott
; TITLE OF INVENTION: Anti-TNF Antibodies and Peptides of
; FILE REFERENCE: 0975.1005-008
; CURRENT APPLICATION NUMBER: US/09/756,301B
; CURRENT FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: U.S. 09/133,119
; PRIOR FILING DATE: 1998-08-12
; PRIOR APPLICATION NUMBER: U.S. 08/570,674
; PRIOR FILING DATE: 1995-12-11
; PRIOR APPLICATION NUMBER: U.S. 08/324,799
; PRIOR FILING DATE: 1994-10-18
; PRIOR APPLICATION NUMBER: U.S. 08/192,102
; PRIOR FILING DATE: 1994-02-04
; PRIOR APPLICATION NUMBER: U.S. 08/192,861
; PRIOR FILING DATE: 1994-02-04
; PRIOR APPLICATION NUMBER: U.S. 08/192,093
; PRIOR FILING DATE: 1994-02-04
; PRIOR APPLICATION NUMBER: U.S. 08/010,406
; PRIOR FILING DATE: 1993-01-29
; PRIOR APPLICATION NUMBER: U.S. 08/013,413
; PRIOR FILING DATE: 1993-02-02
; PRIOR APPLICATION NUMBER: U.S. 07/943,852
; PRIOR FILING DATE: 1992-09-11
; PRIOR APPLICATION NUMBER: U.S. 07/853,606
; PRIOR FILING DATE: 1992-03-18
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Partial sequence of pH707

US-09-756-301B-22
Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      746 CACAGGTATTCAGGAA 761
      ||||| |||||
Db      1 CACAGGTATTCAGGCA 16

RESULT 222
US-09-152-059-1/c
; Sequence 1, Application US/09152059
; Patent No. 6794499
; GENERAL INFORMATION:
; APPLICANT: WENGEL, JESPER
; APPLICANT: NIELSEN, POUL
; TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
; FILE REFERENCE: 49165 (71994)
; CURRENT APPLICATION NUMBER: US/09/152,059
; CURRENT FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/058,541
; PRIOR FILING DATE: 1997-09-12
; PRIOR APPLICATION NUMBER: 60/068,293
; PRIOR FILING DATE: 1997-12-19
; PRIOR APPLICATION NUMBER: 60/071,682
; PRIOR FILING DATE: 1998-01-16
; PRIOR APPLICATION NUMBER: 60/076,591
; PRIOR FILING DATE: 1998-03-03
; PRIOR APPLICATION NUMBER: 60/083,507
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/088,309
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/094,355
; PRIOR FILING DATE: 1998-07-28
; NUMBER OF SEQ ID NOS: 146
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(15)
; OTHER INFORMATION: LNA monomer
; OTHER INFORMATION: Description of Artificial Sequence: LNA modified
; OTHER INFORMATION: oligonucleotide
US-09-152-059-1

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1594 ATACAAATTCATCCA 1609
      ||||| |||||
Db      16 ATACAAATTCACACA 1

RESULT 223
US-09-152-059-57/c
; Sequence 57, Application US/09152059
; Patent No. 6794499
; GENERAL INFORMATION:
; APPLICANT: WENGEL, JESPER
; APPLICANT: NIELSEN, POUL
; TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
; FILE REFERENCE: 49165 (71994)
; CURRENT APPLICATION NUMBER: US/09/152,059
; CURRENT FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/058,541
; PRIOR FILING DATE: 1997-09-12
; PRIOR APPLICATION NUMBER: 60/068,293
```

;; PRIOR FILING DATE: 1997-12-19
;; PRIOR APPLICATION NUMBER: 60/071,682
;; PRIOR FILING DATE: 1998-01-16
;; PRIOR APPLICATION NUMBER: 60/076,591
;; PRIOR FILING DATE: 1998-03-03
;; PRIOR APPLICATION NUMBER: 60/083,507
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/088,309
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/094,355
;; PRIOR FILING DATE: 1998-07-28
;; NUMBER OF SEQ ID NOS: 146
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 57
;; LENGTH: 16
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; NAME/KEY: modified base
;; LOCATION: (1)...(15)
;; OTHER INFORMATION: LNA monomer
;; OTHER INFORMATION: Description of Artificial Sequence: LNA modified
;; OTHER INFORMATION: oligonucleotide
US-09-152-059-57

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1594 ATAACAATTTTCATCCA 1609
Db 16 ATAACAATTTTCACACA 1

RESULT 224
US-09-152-059-59/c
;; Sequence 59, Application US/09152059
;; Patent No. 6794499
;; GENERAL INFORMATION:
;; APPLICANT: WENGEL, JESPER
;; APPLICANT: NIELSEN, POUL
;; TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
;; FILE REFERENCE: 49165 (71994)
;; CURRENT APPLICATION NUMBER: US/09/152,059
;; CURRENT FILING DATE: 1998-09-11
;; PRIOR FILING DATE: 1997-09-12
;; PRIOR APPLICATION NUMBER: 60/058,541
;; PRIOR FILING DATE: 1997-12-19
;; PRIOR APPLICATION NUMBER: 60/068,293
;; PRIOR FILING DATE: 1997-12-19
;; PRIOR APPLICATION NUMBER: 60/071,682
;; PRIOR FILING DATE: 1998-01-16
;; PRIOR APPLICATION NUMBER: 60/076,591
;; PRIOR FILING DATE: 1998-03-03
;; PRIOR APPLICATION NUMBER: 60/083,507
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/088,309
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/094,355
;; PRIOR FILING DATE: 1998-07-28
;; NUMBER OF SEQ ID NOS: 146
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 59
;; LENGTH: 16
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; NAME/KEY: modified base
;; LOCATION: (1)...(15)
;; OTHER INFORMATION: LNA monomer
;; OTHER INFORMATION: Description of Artificial Sequence: LNA modified
;; OTHER INFORMATION: oligonucleotide
US-09-152-059-59

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1594 ATAACAATTTTCATCCA 1609
Db 16 ATAACAATTTTCACACA 1

RESULT 225

US-09-152-059-63/c
;; Sequence 63, Application US/09152059
;; Patent No. 6794499
;; GENERAL INFORMATION:
;; APPLICANT: WENGEL, JESPER
;; APPLICANT: NIELSEN, POUL
;; TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
;; FILE REFERENCE: 49165 (71994)
;; CURRENT APPLICATION NUMBER: US/09/152,059
;; CURRENT FILING DATE: 1998-09-11
;; PRIOR FILING DATE: 1997-09-12
;; PRIOR APPLICATION NUMBER: 60/058,541
;; PRIOR FILING DATE: 1997-12-19
;; PRIOR APPLICATION NUMBER: 60/068,293
;; PRIOR FILING DATE: 1997-12-19
;; PRIOR APPLICATION NUMBER: 60/071,682
;; PRIOR FILING DATE: 1998-01-16
;; PRIOR APPLICATION NUMBER: 60/076,591
;; PRIOR FILING DATE: 1998-03-03
;; PRIOR APPLICATION NUMBER: 60/083,507
;; PRIOR FILING DATE: 1998-04-29
;; PRIOR APPLICATION NUMBER: 60/088,309
;; PRIOR FILING DATE: 1998-06-05
;; PRIOR APPLICATION NUMBER: 60/094,355
;; PRIOR FILING DATE: 1998-07-28
;; NUMBER OF SEQ ID NOS: 146
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 63
;; LENGTH: 16
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; NAME/KEY: modified base
;; LOCATION: (1)...(15)
;; OTHER INFORMATION: LNA monomer
;; OTHER INFORMATION: Description of Artificial Sequence: LNA modified
;; OTHER INFORMATION: oligonucleotide
US-09-152-059-63

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1594 ATAACAATTTTCATCCA 1609
Db 16 ATAACAATTTTCACACA 1

RESULT 226

US-09-093-972C-273
;; Sequence 273, Application US/09093972C
;; Patent No. 6825174
;; GENERAL INFORMATION:
;; APPLICANT: NYCE, Jonathan W.
;; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
;; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
;; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION
;; NUMBER OF SEQUENCES: 996
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
;; STREET: 7 Clarke Drive
;; CITY: Cranbury
;; STATE: New Jersey
;; COUNTRY: USA

ZIP: 08512
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/093,972C
FILING DATE: 09-Jun-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00672
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 273:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 273:
US-09-093-972C-273
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 969 CTGGACAGCTGGGATG 984
||||| ||||| |||||
Db 1 CTGGAAAGCTGAGATG 16
RESULT 227
US-09-958-163A-1
Sequence 1, Application US/09958163A
Patent No. 6831071
GENERAL INFORMATION:
APPLICANT: Sergeev, Pavel
TITLE OF INVENTION: Synthesis of biologically active compounds in cells
FILE REFERENCE: sergeev
CURRENT APPLICATION NUMBER: US/09/958.163A
CURRENT FILING DATE: 2001-10-03
NUMBER OF SEQ ID NOS: 44
SOFTWARE: PatentIn version 3.2
SEQ ID NO 1
LENGTH: 16
TYPE: DNA
ORGANISM: Human immunodeficiency virus type 1
PUBLICATION INFORMATION:
DATABASE ACCESSION NUMBER: X01762
DATABASE ENTRY DATE: 1985-01-01
PATENT DOCUMENT NUMBER: US 5,571,937
PATENT FILING DATE: 1994-05-13
PUBLICATION DATE: 1996-01-11
RELEVANT RESIDUES: (1)..(16)
US-09-958-163A-1
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 198 GAAGAAATAAAGAG 213
||||| ||||| |||||
Db 1 GAAGAAATAGAGAG 16
RESULT 228
PCT-US96-11786-47/c
Sequence 47, Application PC/TUS9611786
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan
APPLICANT: Zengdegui, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommier, Eyles
APPLICANT: Mazumder, Abhijit
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/11786
FILING DATE: 17-JULY-1996
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/535,168; 60/001,505; 60/014,007; 60/013,688;
APPLICATION NUMBER: 60/015,714; 60/016,271
FILING DATE: 23-OCT-95; 17-JULY-96; 25-MARCH-96; 19-MARCH-96; 23-
FILING DATE: APRIL-96; 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 47:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US96-11786-47
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1706 CCTCTCCCTCCACCAC 1721
||||| ||||| |||||
Db 16 CCACCCACCACCAC 1
RESULT 229
5177193-9
Patent No. 5177193
APPLICANT: BOIME, IRVING; MATZUK, MARTIN M.
TITLE OF INVENTION: MODIFIED FORMS OF REPRODUCTIVE HORMONES
NUMBER OF SEQUENCES: 26

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/532,254
; FILING DATE: 01-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 313,646
; FILING DATE: 21-FEB-1989
; SEQ ID NO:9:
; LENGTH: 16
5177193-9

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAAGAGAAA 216
      ||||| ||||| |||
Db 1 GAAATGAAGAATAAAA 16

RESULT 230
5177193-9
; Patent No. 5177193
; APPLICANT: BOIME, IRVING; MATZUK, MARTIN M.
; TITLE OF INVENTION: MODIFIED FORMS OF REPRODUCTIVE HORMONES
; NUMBER OF SEQUENCES: 26
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/532,254
; FILING DATE: 01-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 313,646
; FILING DATE: 21-FEB-1989
; SEQ ID NO:9:
; LENGTH: 16
5177193-9

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAAGAGAAA 216
      ||||| ||||| |||
Db 1 GAAATGAAGAATAAAA 16

RESULT 231
US-08-985-162-333/c
; Sequence 333, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
```

```
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 333:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-985-162-333

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1421 TGTCTGATGGATCCAAAG 1436
      ||||| ||||| |||||
Db 16 TGGCTTGGATCCAAAG 1

RESULT 232
US-09-098-628-8
; Sequence 8, Application US/09098628
; Patent No. 6294359
; GENERAL INFORMATION:
; APPLICANT: FIDDES, J.C.
; APPLICANT: ABRAHAM, J.D.
; TITLE OF INVENTION: HUMAN BASIC FIBROBLAST GROWTH
; TITLE OF INVENTION: FACTOR ANALOG
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/098,628
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Lehnhardt, Susan K
; REGISTRATION NUMBER: 33,943
; REFERENCE/DOCKET NUMBER: 21900-20089.10
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

US-09-098-628-8

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1424 CATGGATCCAAAGCAG 1439
Db 2 CTTGGATCCAAACAG 17

RESULT 233

US-09-401-063-333/c
Sequence 333, Application US/09401063
Patent No. 6623962

GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877

CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/401,063
FILING DATE:

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/985,162
FILING DATE: 04 December 1997
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 333:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-401-063-333

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1421 TGTGATGATCCAAAG 1436
Db 16 TGGCTTGGATCCAAAG 1

RESULT 234

PCT-US91-02186-12

Sequence 12, Application PC/TUS9102186
GENERAL INFORMATION:
APPLICANT: California Biotechnology Inc.
APPLICANT: Inventors: Thompson, Stewart A.
APPLICANT: Abraham, Judith A.
TITLE OF INVENTION: High Level Expression of Basic
TITLE OF INVENTION: Fibroblast Growth Factor Having a Homogeneous
TITLE OF INVENTION: N-terminus
NUMBER OF SEQUENCES: 26

CORRESPONDENCE ADDRESS:
ADDRESSEE: Irell & Manella
STREET: 545 Middlefield Road, Suite 200
CITY: Menlo Park
STATE: California
COUNTRY: USA

ZIP: 94025-3471
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US91/02186
FILING DATE: 19910702
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Murashige, Kate H.
REGISTRATION NUMBER: 29,959
REFERENCE/DOCKET NUMBER: 1900-0275.41
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-327-7250

INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA

PCT-US91-02186-12

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1424 CATGGATCCAAAGCAG 1439
Db 2 CTTGGATCCAAACAG 17

RESULT 235

5514566-19
Patent No. 5514566
APPLICANT: FIDDES, JOHN C.; ABRAHAM, JUDITH A.
TITLE OF INVENTION: METHODS OF PRODUCING RECOMBINANT
FIBROBLASTS GROWTH FACTORS
NUMBER OF SEQUENCES: 21
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/417,022
FILING DATE: 05-APR-1995

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 809,163
FILING DATE: 16-DEC-1985
APPLICATION NUMBER: 775,521
FILING DATE: 12-SEP-1985
SEQ ID NO: 19:
LENGTH: 17

5514566-19

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1424 CATGGATCCAAAGCAG 1439
 Db 2 CTTGGATCCAAAGCAG 17

RESULT 236

US-08-145-704-33/c
 ; Sequence 33, Application US/08145704
 ; Patent No. 5567604
 ; GENERAL INFORMATION:
 ; APPLICANT: Rando, Robert F.
 ; APPLICANT: Fennewald, Susan
 ; APPLICANT: Zendegei, Joseph G.
 ; APPLICANT: Joshua O. Ojwang
 ; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
 ; TITLE OF INVENTION: Oligonucleotides
 ; NUMBER OF SEQUENCES: 45
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Fulbright & Jaworski
 ; STREET: 1301 McKinney, Suite 5100
 ; CITY: Houston
 ; STATE: Texas
 ; COUNTRY: U.S.A.
 ; ZIP: 77010-3095
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/145,704
 ; FILING DATE: 28-OCT-1993
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/053,027
 ; FILING DATE: 23-APR-1993
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Paul, Thomas D.
 ; REGISTRATION NUMBER: 32,714
 ; REFERENCE/DOCKET NUMBER: D-5574-CIP
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 713/651-5151
 ; TELEFAX: 713/651-5246
 ; TELEX: 762829
 ; INFORMATION FOR SEQ ID NO: 33:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA (genomic)
 ; FEATURE:
 ; NAME/KEY: misc_feature
 ; LOCATION: 17
 ; OTHER INFORMATION: /note= "Amine moiety attached to 3'
 ; OTHER INFORMATION: end"
 ; US-08-145-704-33

Query Match 0.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721
 Db 16 CCCACCACCACCAC 1

RESULT 237

US-08-469-177-7/c
 ; Sequence 7, Application US/08469177
 ; Patent No. 5607924
 ; GENERAL INFORMATION:
 ; APPLICANT: MAGDA, Darren

; APPLICANT: SESSLER, Jonathan L.
 ; APPLICANT: IVERSON, Brent L.
 ; APPLICANT: SANSON, Petra I.
 ; APPLICANT: WRIGHT, Meredith
 ; TITLE OF INVENTION: DNA PHOTOCLEAVAGE USING TEXAPHYRINS
 ; NUMBER OF SEQUENCES: 10
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Pharmacyclics, Inc.
 ; STREET: 995 East Arques Avenue
 ; CITY: Sunnyvale
 ; STATE: California
 ; COUNTRY: United States of America
 ; ZIP: 94086
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/469,177
 ; FILING DATE: 06-JUN-1995
 ; CLASSIFICATION: 514
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Larson, Jacqueline S.
 ; REGISTRATION NUMBER: 30,279
 ; REFERENCE/DOCKET NUMBER: PHAY:057
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (408) 774-3363
 ; TELEFAX: (408) 774-0340
 ; INFORMATION FOR SEQ ID NO: 7:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: other nucleic acid
 ; DESCRIPTION: /desc = "RNA"
 ; US-08-469-177-7

Query Match 0.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 199 AAGAAATAAAGAAGA 214
 Db 16 AAGAAAGAAGAAGA 1

RESULT 238

US-08-390-850-635/c
 ; Sequence 635, Application US/08390850
 ; Patent No. 5612215
 ; GENERAL INFORMATION:
 ; APPLICANT: Draper, Kenneth G.
 ; APPLICANT: Pavco, Pamela
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Gustofson, John T.
 ; APPLICANT: Stinchcomb, Dan T.
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
 ; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
 ; NUMBER OF SEQUENCES: 1151
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible

Query Match 0.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390.850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 635:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-390-850-635

```

```

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 197 TGAAGAAATAAAAGAA 212
Db 17 TGAAGAAATAAGAAA 2

```

```

RESULT 239
US-08-290-978A-9/c
; Sequence 9, Application US/08290978A
; Patent No. 5624834
; GENERAL INFORMATION:
; APPLICANT: KUSTERS-VAN SOMEREN, MARGO A.
; APPLICANT: MULLER, YVONNE
; APPLICANT: KESTER, HERMANUS C.M.
; APPLICANT: VISSER, JACOB
; APPLICANT: VAN OUYEN, ALBERT J.J.
; APPLICANT: ROLIN, CLAUD
; TITLE OF INVENTION: CLONING AND EXPRESSION OF THE
; TITLE OF INVENTION: EXO-POLYGALACTURONASE GENE FROM ASPERGILLUS
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 2000 Pennsylvania Avenue N.W.
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20006-1812
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/290,978A
; FILING DATE: 17-OCT-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: MURASHIGE, KATE H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4615-0044.00
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 887-1500

```

```

; TELEFAX: (202) 887-0763
; TELEX: 90-4030
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: pgax NcoI antisense
; US-08-290-978A-9

```

```

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 1303 GCCATGGAGGAGGCAC 1318
Db 17 GCCATGGAGATGGCAC 2

```

```

RESULT 240
US-08-373-124A-192
; Sequence 192, Application US/08373124A
; Patent No. 5645042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 192:
; SEQUENCE CHARACTERISTICS:

```

; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-192

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 716 CGTGGCTCTCTCTCC 731
||:||||:|
Db 1 CGUGACCUCCUCC 16

RESULT 241

US-08-373-124A-278/c
; Sequence 278, Application US/08373124A
; Patent No. 5646042

; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440

; INFORMATION FOR SEQ ID NO: 278:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

; US-08-373-124A-278

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1326 AACTTTGGATCCAG 1341
|||||
Db 17 AACTTCTGGATTCAG 2

RESULT 242

US-08-373-124A-512/c
; Sequence 512, Application US/08373124A
; Patent No. 5646042

; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440

; INFORMATION FOR SEQ ID NO: 512:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

; US-08-373-124A-512

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1510 GGTCTAGAAACAGTA 1525
|||||
Db 17 GGTCTAGAAACAGTA 2

RESULT 243

US-08-373-124A-514/c
; Sequence 514, Application US/08373124A

Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 514:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-514
Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1510 GGCTCTAGAAACAGTA 1525
Db 16 GGTTCTAAACAGTA 1
RESULT 244
US-08-373-124A-960/c
Sequence 960, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES

NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 960:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-960
Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1375 TATACAAAGTATTTCCTT 1390
Db 17 TATAAAACTATTTCCTT 2
RESULT 245
US-08-373-124A-1192
Sequence 1192, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

```
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1192:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-1192

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1559 TCCTGGGTCGTGCAACT 1574
Db 1 UCCUGUGUUGCAACU 16

RESULT 246
US-08-373-124A-2325/c
; Sequence 2325, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995

;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1192:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-1192

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1326 AACTTTGGATGCAAG 1341
Db 17 AACTTTGGATGCAAG 2

RESULT 247
US-08-462-917-3
; Sequence 3, Application US/08462917
; Patent No. 5661008
; GENERAL INFORMATION:
; APPLICANT: ALMSTEDT, Annelie B
; APPLICANT: GRAY (HELLSTROM), Eva Maria
; APPLICANT: LIND, Peter
; APPLICANT: LJUNG, Catherine
; APPLICANT: SANDBERG, Helena Inga
; APPLICANT: SPIRA, Jack
; APPLICANT: SYDOW-BACKMAN, Mona
; APPLICANT: WINAN, Helena
; TITLE OF INVENTION: RECOMBINANT HUMAN FACTOR VIII
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Burns, Doane, Swecker & Mathis
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,917
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/934,495
; FILING DATE: 17-DEC-1992
; APPLICATION NUMBER: SE 9100799-7
; FILING DATE: 15-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Crane-Feury, Sharon E
```



```
;
; REGISTRATION NUMBER: 36,113
; REFERENCE/DOCKET NUMBER: 003300-283
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-462-917-3

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1594 ATAACAATTTCATCCA 1609
Db 2 ATAACAATTTCACACA 17

RESULT 248
US-08-435-634-635/c
; Sequence 635, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295 September 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 635:
; SEQUENCE CHARACTERISTICS:
```

```
;
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-635

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 197 TGAAGAAATAAAGAA 212
Db 17 TGAAGAAATAAAGAAA 2

RESULT 249
US-08-653-740-20
; Sequence 20, Application US/08653740
; Patent No. 5792850
; GENERAL INFORMATION:
; APPLICANT: James W. Baumgartner
; APPLICANT: Donald C. Foster
; APPLICANT: Frank J. Grant
; APPLICANT: Cindy A. Sprecher
; TITLE OF INVENTION: HEMATOPOIETIC CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/653,740
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, Gary E
; REGISTRATION NUMBER: 31,648
; REFERENCE/DOCKET NUMBER: 95-31
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6673
; TELEFAX: 206-442-6678
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: 9559
US-08-653-740-20

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.9e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGC 1357
Db 3 TGGAGYGMTGGAGY 17

RESULT 250
US-08-758-306-379/c
; Sequence 379, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
```

```
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 379:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-758-306-379

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 774 GTGCCCAAAATTCCAA 789
Db 17 GGCACAAAATTCCAA 2

RESULT 251
US-08-758-306-381/c
; Sequence 381, Application US/08/758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
```

```

; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 192:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-192

```

```

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 716 COTGGCCCTCTCTCC 731
DB 1 CGUGACCUCCUCC 16

```

```

RESULT 253
US-08-435-628-278/c
; Sequence 278, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327

```

```

; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 278:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-278

```

```

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 1326 AACTTTGGATCCAAG 1341
DB 17 AACTTCTGGATCCAAG 2

```

```

RESULT 254
US-08-435-628-512/c
; Sequence 512, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327

```

; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 512:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-512

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1510 GGTCCTAGAAACAGTA 1525
Db 17 GGTTCTAAACACAGTA 2

RESULT 255
US-08-435-628-514/c
; Sequence 514, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 514:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-514

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1510 GGTCCTAGAAACAGTA 1525
Db 16 GGTTCTAAACACAGTA 1

RESULT 256
US-08-435-628-960/c
; Sequence 960, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 960:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-960

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1375 TATACAGTATTCTT 1390
Db 17 TATAAACTATTCTT 2

RESULT 257
US-08-435-628-1192
; Sequence 1192, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1192:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-1192

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1559 TCCTGGGTCTGCACT 1574

Db 1 UCCUGUGUUGCAACU 16

RESULT 258
US-08-435-628-2325/c
; Sequence 2325, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 2325:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-2325

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1326 AACTTTTGATCCAAAG 1341
Db 17 AACTTCTGGATTCAAG 2

RESULT 259
US-08-780-869-9/c

```

; Sequence 9, Application US/08780869
; Patent No. 5830737
; GENERAL INFORMATION:
; APPLICANT: KUSTERS-VAN SOMEREN, MARGO A.
; APPLICANT: KESTER, YVONNE
; APPLICANT: MULLER, HERMANUS C.M.
; APPLICANT: VISSER, JACOB
; APPLICANT: VAN OYEN, ALBERT J.J.
; APPLICANT: ROLIN, CLAUDE
; TITLE OF INVENTION: CLONING AND EXPRESSION OF THE
; TITLE OF INVENTION: EXO-POLY GALACTURONASE GENE FROM ASPERGILLUS
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 2000 Pennsylvania Avenue N.W.
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20006-1812
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/780,869
; FILING DATE: 24-JAN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/290,978
; FILING DATE: 17-OCT-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: MURASHIGE, KATE H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4615-0044.00
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 887-1500
; TELEFAX: (202) 887-0763
; TELEX: 90-4030
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: pgaX NcoI antisense
; US-08-780-869-9

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1303 GCCATGGAGAGGCAC 1318
Db 17 GCCATGGAGATGGCAC 2

RESULT 260
US-09-073-594-20
; Sequence 20, Application US/09073594
; Patent No. 5925735
; GENERAL INFORMATION:
; APPLICANT: James W. Baumgartner
; APPLICANT: Donald C. Foster
; APPLICANT: Frank J. Grant
; APPLICANT: Cindy A. Sprecher
; TITLE OF INVENTION: HEMATOPOIETIC CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:

```

```

; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/073,594
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, Gary E
; REGISTRATION NUMBER: 31,648
; REFERENCE/DOCKET NUMBER: 95-31
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6673
; TELEFAX: 206-442-6678
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: 9559
; US-09-073-594-20

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.9e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCTGGGAGC 1357
Db 3 TGGAGYGMGTGGAGY 17

RESULT 261
US-08-757-024-236
; Sequence 236, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102

```

; INFORMATION FOR SEQ ID NO: 236:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA (genomic)
 ; US-08-757-024-236

Query Match 0.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 CTGGACAGCTGGGATG 984
 Db 2 CTGGAAGCTGAGATG 17

RESULT 262
 US-08-757-024-272
 ; Sequence 272, Application US/08757024
 ; Patent No. 6025339
 ; GENERAL INFORMATION:
 ; APPLICANT: Nyce, Jonathan W.
 ; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
 ; NUMBER OF SEQUENCES: 952
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
 ; STREET: P.O. Drawer 34009
 ; CITY: Charlotte
 ; STATE: No. 6025339th Carolina
 ; COUNTRY: USA
 ; ZIP: 28234
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/757,024
 ; FILING DATE: 26-NOV-1996
 ; CLASSIFICATION: 514
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Sibley, Kenneth D.
 ; REGISTRATION NUMBER: 31,665
 ; REFERENCE/DOCKET NUMBER: 5218-41
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 919-881-3140
 ; TELEFAX: 919-881-3175
 ; TELEX: 575102
 ; INFORMATION FOR SEQ ID NO: 272:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA (genomic)
 ; US-08-757-024-272

Query Match 0.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 CTGGACAGCTGGGATG 984
 Db 1 CTGGAAGCTGAGATG 16

RESULT 263
 US-08-985-162-42/c
 ; Sequence 42, Application US/08985162
 ; Patent No. 6057156
 ; GENERAL INFORMATION:

; APPLICANT: Akhtar, Saghir
 ; APPLICANT: Fell, Patricia
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
 ; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
 ; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
 ; TITLE OF INVENTION: FACTOR RECEPTORS
 ; NUMBER OF SEQUENCES: 1877
 ; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: FastSEQ for Windows 2.0

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/985,162

; FILING DATE: 04 December 1997

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/036,476

; FILING DATE: 31 January 1997

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 230/107

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 42:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; US-08-985-162-42

Query Match 0.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1664 TACTTCCAAATCTC 1679
 Db 17 TAATTCCAAATCCC 2

RESULT 264
 US-08-985-162-665/c
 ; Sequence 665, Application US/08985162
 ; Patent No. 6057156
 ; GENERAL INFORMATION:

; APPLICANT: Akhtar, Saghir
 ; APPLICANT: Fell, Patricia
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
 ; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
 ; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
 ; TITLE OF INVENTION: FACTOR RECEPTORS
 ; NUMBER OF SEQUENCES: 1877
 ; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California

```

; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 665:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-985-162-665

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAAATAAAAGAGAAA 216
DB 16 GAAGTAAAGAGAAA 1

RESULT 265
US-09-275-925-20
; Sequence 20, Application US/09275925
; Patent No. 6080406
; GENERAL INFORMATION:
; APPLICANT: James W. Baumgartner
; APPLICANT: Donald C. Foster
; APPLICANT: Frank J. Grant
; APPLICANT: Cindy A. Sprecher
; TITLE OF INVENTION: HEMATOPOIETIC CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/275,925
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, Gary E
; REGISTRATION NUMBER: 31,648
; REFERENCE/DOCKET NUMBER: 95-31
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6673

```

```

; TELEFAX: 206-442-6678
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: 9559
; US-09-275-925-20

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.9e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1343 TGGAGTGCCTGGAGC 1357
DB 3 TGGAGYGMNTGGAGY 17

RESULT 266
US-08-987-574-33/c
; Sequence 33, Application US/08987574
; Patent No. 6150339
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennewald, Susan
; APPLICANT: Zendegeui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski
; STREET: 1301 McKinney, Suite 5100
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77010-3095
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/987,574
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04529
; FILING DATE: 28-OCT-1993
; APPLICATION NUMBER: US 08/053,027
; FILING DATE: 23-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul, Thomas D.
; REGISTRATION NUMBER: 32,714
; REFERENCE/DOCKET NUMBER: D-5574-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/651-5151
; TELEFAX: 713/651-5246
; TELEX: 762829
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 17
; OTHER INFORMATION: /note= "Amine moiety

```



```
OTHER INFORMATION: attached to 3' end"
US-08-987-574-33

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721
DB 16 CCCACCCACCAC 1

RESULT 267
US-08-535-168-33/c
; Sequence 33, Application US/08535168
; Patent No. 6184369
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zendegeui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski
; STREET: 1301 McKinney, Suite 5100
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77010-3095
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/535,168
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04529
; FILING DATE: 28-OCT-1993
; APPLICATION NUMBER: US 08/053,027
; FILING DATE: 23-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul, Thomas D.
; REGISTRATION NUMBER: 32,714
; REFERENCE/DOCKET NUMBER: D-5574-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/651-5151
; TELEFAX: 713/651-5246
; TELEX: 762829
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 17
; OTHER INFORMATION: /note="Amine moiety
; OTHER INFORMATION: attached to 3' end"
US-08-535-168-33

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721
```

```
DB 16 CCCACCCACCAC 1

RESULT 268
US-08-720-625-9
; Sequence 9, Application US/08720625
; Patent No. 6242587
; GENERAL INFORMATION:
; APPLICANT: Naik, Ulhas P.
; APPLICANT: Parise, Leslie V.
; TITLE OF INVENTION: CALCIUM-INTEGRIN BINDING PROTEIN
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bell, Seltzer, Park & Gibson
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6242587th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/720,625
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5470-138
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-420-2200
; TELEFAX: 919-881-3175
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA primer"
US-08-720-625-9

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1055 TCTTGGGCTCGTCCA 1070
DB 2 TCGTTGGCTCGTCCA 17

RESULT 269
US-09-017-974-33/c
; Sequence 33, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossum, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
```

```
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; TOPOLOGY: linear
; STRANDEDNESS: single
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 17
; OTHER INFORMATION: /note= "Amine moiety
; OTHER INFORMATION: attached to 3' end"
US-09-017-974-33

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 270
US-09-017-974-58/c
; Sequence 58, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossam, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
```

```
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 58:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; TOPOLOGY: linear
; STRANDEDNESS: single
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 11
; OTHER INFORMATION: /note= "the base is
; OTHER INFORMATION: removed from this nucleotide"
US-09-017-974-58

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 271
US-09-017-974-59/c
; Sequence 59, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossam, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
```

REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06223
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 59:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA (genomic)
US-09-017-974-59

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 272
US-09-017-974-68/c
Sequence 68, Application US/09017974
Patent No. 6288042
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Wallace, Thomas L.
APPLICANT: Cossum, Paul A.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Tetrad Forming Oligonucleotides
NUMBER OF SEQUENCES: 88
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1800
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/017,974
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/037,374
FILING DATE: 04-FEB-97
APPLICATION NUMBER:
FILING DATE: 09-DEC-97
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06223
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 68:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature

LOCATION: 2
OTHER INFORMATION: /note= "the base is
FEATURE:
NAME/KEY: misc_feature
LOCATION: 5,13
OTHER INFORMATION: /note= "C-5 propynl dU"
US-09-017-974-68

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 273
US-09-017-974-72/c
Sequence 72, Application US/09017974
Patent No. 6288042
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Wallace, Thomas L.
APPLICANT: Cossum, Paul A.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Tetrad Forming Oligonucleotides
NUMBER OF SEQUENCES: 88
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1800
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/017,974
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/037,374
FILING DATE: 04-FEB-97
APPLICATION NUMBER:
FILING DATE: 09-DEC-97
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06223
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 13
OTHER INFORMATION: /note= "3' cholesterol via
OTHER INFORMATION: triglycyl linker"
US-09-017-974-72

Query Match 0.7% Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 274
US-09-017-974-80/c
; Sequence 80, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossum, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-09-017-974-80

Query Match 0.7% Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 275
US-09-017-974-81/c
; Sequence 81, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossum, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 80:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-09-017-974-80

Query Match 0.7% Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 276
US-09-017-974-87/c
; Sequence 87, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossum, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.

APPLICANT: Rando, Robert F.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Wallace, Thomas L.
APPLICANT: Cossum, Paul A.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Tetrad Forming Oligonucleotides
NUMBER OF SEQUENCES: 88
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1800
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/017,974
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/037,374
FILING DATE: 04-FEB-97
APPLICATION NUMBER:
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06223
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 81:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-017-974-81

Query Match 0.7% Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCCCTCCACCAC 1721
Db 16 CCCGCCCCCACCAC 1

RESULT 276
US-09-017-974-87/c
; Sequence 87, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossum, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.

ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/017,974
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/037,374
FILING DATE: 04-FEB-97
APPLICATION NUMBER:
FILING DATE: 09-DEC-97
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06223
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 87:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-017-974-87

Query Match 0.7% Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 277
US-08-682-255A-33/c
Sequence 33, Application US/08682255A
Patent No. 6323185
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan
APPLICANT: Zendegeui, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommier, Yves
APPLICANT: Mazumder, Abhijit
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/682,255A
FILING DATE: 17-JULY-1996
CLASSIFICATION: 435
PRIOR APPLICATION NUMBER: US 08/535,168

FILING DATE: 23-OCT-95
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/015,714
FILING DATE: 17-APRIL-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 23-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 17
OTHER INFORMATION: /note= "Amine moiety
OTHER INFORMATION: attached to 3' end"
US-08-682-255A-33

Query Match 0.7% Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 278
US-08-682-255A-58/c
Sequence 58, Application US/08682255A
Patent No. 6323185
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennwald, Susan
APPLICANT: Zendegeui, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommier, Yves
APPLICANT: Mazumder, Abhijit
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/682,255A
FILING DATE: 17-JULY-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 58:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 11
; OTHER INFORMATION: /note= "the base is
; OTHER INFORMATION: removed from this nucleotide"
;
US-08-682-255A-58

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721
DB 16 CCCACCCACCACCAC 1

RESULT 279
US-08-682-255A-59/c
; Sequence 59, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennewald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tavon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA (genomic)
;
US-08-682-255A-59

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721
DB 16 CCCACCCACCACCAC 1

RESULT 280
US-08-682-255A-68/c
; Sequence 68, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennewald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tavon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
```

;; FILING DATE: 19-JULY-95
;; APPLICATION NUMBER: 60/014,007
;; FILING DATE: 25-MARCH-96
;; APPLICATION NUMBER: 60/013,688
;; FILING DATE: 19-MARCH-96
;; APPLICATION NUMBER: 60/015,714
;; FILING DATE: 17-APRIL-96
;; APPLICATION NUMBER: 60/016,271
;; FILING DATE: 23-APRIL-96
;; ATTORNEY/AGENT INFORMATION:
;; NAME: McDaniel, C. Steven
;; REGISTRATION NUMBER: 33,962
;; REFERENCE/DOCKET NUMBER: 1472-06214
;; TELEPHONE: 713/238-8010
;; TELEFAX: 713/238-8008
;; INFORMATION FOR SEQ ID NO: 68:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: 2
;; OTHER INFORMATION: /note="the base is
;; OTHER INFORMATION: removed from this nucleotide"
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: 5,13
;; OTHER INFORMATION: /note="C-5 propynl dU"
US-08-682-255A-68

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 281
US-08-682-255A-72/c
; Sequence 72, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zendegeui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Byves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996

;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/535,168
;; FILING DATE: 23-OCT-95
;; APPLICATION NUMBER: 60/001,505
;; FILING DATE: 19-JULY-95
;; APPLICATION NUMBER: 60/014,007
;; FILING DATE: 25-MARCH-96
;; APPLICATION NUMBER: 60/013,688
;; FILING DATE: 19-MARCH-96
;; APPLICATION NUMBER: 60/015,714
;; FILING DATE: 17-APRIL-96
;; APPLICATION NUMBER: 60/016,271
;; FILING DATE: 23-APRIL-96
;; ATTORNEY/AGENT INFORMATION:
;; NAME: McDaniel, C. Steven
;; REGISTRATION NUMBER: 33,962
;; REFERENCE/DOCKET NUMBER: 1472-06214
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 713/238-8010
;; TELEFAX: 713/238-8008
;; INFORMATION FOR SEQ ID NO: 72:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: 13
;; OTHER INFORMATION: /note="3' cholesterol via
;; OTHER INFORMATION: triglycyl linker"
US-08-682-255A-72

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 282
US-08-682-255A-80/c
; Sequence 80, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zendegeui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Byves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A

```
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 80:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-682-255A-80

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCTCCACAC 1721
Db 16 CCCACCCGCCACAC 1

RESULT 283
US-08-682-255A-81/c
; Sequence 81, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommer, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
```

```
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-682-255A-81

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCTCCACAC 1721
Db 16 CCCGCCACCCACAC 1

RESULT 284
US-08-682-255A-87/c
; Sequence 87, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommer, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
```


; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 87:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-682-255A-87

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
DB 16 CCCACCCACCACCAC 1

RESULT 285
US-08-584-040-1788/c
; Sequence 1788, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1932:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-1932

Query Match 0.7%; Score 12.8; DB 1; Length 17;

; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1788:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-1788

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1644 TCTGTTATTATCTTC 1659
DB 17 TCTGTTATTAACTGC 2

RESULT 286
US-08-584-040-1932
; Sequence 1932, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1932:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-1932

Query Match 0.7%; Score 12.8; DB 1; Length 17;

```
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1154 AAATATTTCACATC 1169
Db 1 AAAACUCUCCACUAC 16

RESULT 287
US-08-584-040-3938/c
; Sequence 3938, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3938:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3938

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 823 TGTCAAGAAATGGCTTC 838
Db 16 TGTCAAAATGGCTTC 1

RESULT 289
US-08-584-040-7820/c
; Sequence 7820, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3938:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3938

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1736 TGTGAGGATACAGT 1751
Db 16 TGTGAGGATACAGT 1

RESULT 288
US-08-584-040-5806/c
; Sequence 5806, Application US/08584040
; Patent No. 6346398
```

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
SUITE: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7820:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7820

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1850
Db 16 AAAAAAAAAAAAAA 1

RESULT 290
US-09-429-130-33/c
Sequence 33 Application US/09429130
Patent No. 6355785
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
Fennwald, Susan
Zendegui, Joseph G.
Ojwang, Joshua O.
Hogan, Michael E.
Pommier, Eyles
Mazumder, Abhijit
60/015,714
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/429,130
FILING DATE: 28-Oct-1999
CLASSIFICATION: <Unknown>
19-JULY-95
25-MARCH-96
19-MARCH-96
17-APRIL-96
23-APRIL-96
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/682,255
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 17
OTHER INFORMATION: /note= "Amine moiety
attached to 3' end"
SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-09-429-130-33

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCCTCCACCAC 1721
Db 16 CCCACCACCACCAC 1

RESULT 291
US-09-429-130-58/c
Sequence 58 Application US/09429130
Patent No. 6355785
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
Fennwald, Susan
Zendegui, Joseph G.
Ojwang, Joshua O.
Hogan, Michael E.
Pommier, Eyles
Mazumder, Abhijit
60/015,714
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.

NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/429,130
FILING DATE: 28-Oct-1999
CLASSIFICATION: <Unknown>
19-JULY-95
25-MARCH-96
17-APRIL-96
23-APRIL-96
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/682,255
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 68:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 2
OTHER INFORMATION: /note= "the base is removed from this nucleotide"
FEATURE:
NAME/KEY: misc_feature
LOCATION: 5,13
OTHER INFORMATION: /note= "C-5 propynyl dU"
SEQUENCE DESCRIPTION: SEQ ID NO: 68:
US-09-429-130-68

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db 16 CCACCCACCACCAC 1

RESULT 294

US-09-429-130-72/c
Sequence 72, Application US/09429130
Patent No. 6355785
GENERAL INFORMATION:

APPLICANT: Rando, Robert F.
Fennwald, Susan
Zendequi, Joseph G.
Ojwang, Joshua O.
Hogan, Michael E.
Pommier, Byves
Mazumder, Abhijit
60/015,714
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/429,130
FILING DATE: 28-Oct-1999
CLASSIFICATION: <Unknown>
19-JULY-95
25-MARCH-96
17-APRIL-96
23-APRIL-96
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/682,255
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 17-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 72:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 13
OTHER INFORMATION: /note= "3' cholesterol via triglycyl linker"
SEQUENCE DESCRIPTION: SEQ ID NO: 72:
US-09-429-130-72

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db 16 CCACCCACCACCAC 1

RESULT 295

US-09-429-130-80/c
; Sequence 80, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:

APPLICANT: Rando, Robert F.
; Fennewald, Susan
; Zendegeui, Joseph G.
; Ojwang, Joshua O.
; Hogan, Michael E.
; Pommier, Eyles
; Mazumder, Abhijit
60/015,714

TITLE OF INVENTION: Anti-Viral Guanosine-Rich
Oligonucleotides

NUMBER OF SEQUENCES: 87

CORRESPONDENCE ADDRESS:

ADDRESSEE: Conley, Rose & Tayon, P.C.

STREET: 600 Travis, Suite 1850

CITY: Houston

STATE: Texas

COUNTRY: U.S.A.

ZIP: 77002-2912

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: MS Windows 95

SOFTWARE: MS word 97 (saved as .txt file)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/429,130

FILING DATE: 28-Oct-1999

CLASSIFICATION: <Unknown>

19-JULY-95

25-MARCH-96

19-MARCH-96

17-APRIL-96

23-APRIL-96

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/682,255

FILING DATE: <Unknown>

APPLICATION NUMBER: 60/001,505

FILING DATE: 19-JULY-95

APPLICATION NUMBER: 60/014,007

FILING DATE: 25-MARCH-96

APPLICATION NUMBER: 60/013,688

FILING DATE: 19-MARCH-96

APPLICATION NUMBER: 60/016,271

FILING DATE: 17-APRIL-96

ATTORNEY/AGENT INFORMATION:

NAME: McDaniel, C. Steven

REGISTRATION NUMBER: 33,962

REFERENCE/DOCKET NUMBER: 1472-06214

TELECOMMUNICATION INFORMATION:

TELEPHONE: 713/238-8010

TELEFAX: 713/238-8008

INFORMATION FOR SEQ ID NO: 80:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

SEQUENCE DESCRIPTION: SEQ ID NO: 80:

US-09-429-130-80

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721
DB 16 CCACCCGCCACCAC 1

RESULT 296

US-09-429-130-81/c
; Sequence 81, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:

APPLICANT: Rando, Robert F.
; Fennewald, Susan
; Zendegeui, Joseph G.
; Ojwang, Joshua O.
; Hogan, Michael E.
; Pommier, Eyles
; Mazumder, Abhijit
60/015,714

TITLE OF INVENTION: Anti-Viral Guanosine-Rich
Oligonucleotides

NUMBER OF SEQUENCES: 87

CORRESPONDENCE ADDRESS:

ADDRESSEE: Conley, Rose & Tayon, P.C.

STREET: 600 Travis, Suite 1850

CITY: Houston

STATE: Texas

COUNTRY: U.S.A.

ZIP: 77002-2912

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: MS Windows 95

SOFTWARE: MS word 97 (saved as .txt file)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/429,130

FILING DATE: 28-Oct-1999

CLASSIFICATION: <Unknown>

19-JULY-95

25-MARCH-96

19-MARCH-96

17-APRIL-96

23-APRIL-96

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/682,255

FILING DATE: <Unknown>

APPLICATION NUMBER: 60/001,505

FILING DATE: 19-JULY-95

APPLICATION NUMBER: 60/014,007

FILING DATE: 25-MARCH-96

APPLICATION NUMBER: 60/013,688

FILING DATE: 19-MARCH-96

APPLICATION NUMBER: 60/016,271

FILING DATE: 17-APRIL-96

ATTORNEY/AGENT INFORMATION:

NAME: McDaniel, C. Steven

REGISTRATION NUMBER: 33,962

REFERENCE/DOCKET NUMBER: 1472-06214

TELECOMMUNICATION INFORMATION:

TELEPHONE: 713/238-8010

TELEFAX: 713/238-8008

INFORMATION FOR SEQ ID NO: 81:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

SEQUENCE DESCRIPTION: SEQ ID NO: 81:

US-09-429-130-81

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721
DB 16 CCACCCGCCACCAC 1

Db 16 CCCGCCACCACCAC 1

RESULT 297

US-09-429-130-87/c
; Sequence 87, Application US/09429130
; Patent No. 6355785

GENERAL INFORMATION:

APPLICANT: Rando, Robert F.
; Fennwald, Susan
; Zendequi, Joseph G.
; Ojwang, Joshua O.
; Hogan, Michael E.
; Pomnier, Yves
; Mazunder, Abhijit
; 60/015,714

TITLE OF INVENTION: Anti-Viral Guanosine-Rich

Oligonucleotides

NUMBER OF SEQUENCES: 87

CORRESPONDENCE ADDRESS:

ADDRESSEE: Conley, Rose & Tayon, P.C.

STREET: 600 Travis, Suite 1850

CITY: Houston

STATE: Texas

COUNTRY: U.S.A.

ZIP: 77002-2912

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: MS Windows 95

SOFTWARE: MS Word 97 (saved as .txt file)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/429,130

FILING DATE: 28-Oct-1999

CLASSIFICATION: <Unknown>

19-JULY-95

23-MARCH-96

17-APRIL-96

23-APRIL-96

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/682,255

FILING DATE: <Unknown>

APPLICATION NUMBER: 60/001,505

FILING DATE: 19-JULY-95

APPLICATION NUMBER: 60/014,007

FILING DATE: 25-MARCH-96

APPLICATION NUMBER: 60/013,688

FILING DATE: 19-MARCH-96

APPLICATION NUMBER: 60/016,271

FILING DATE: 17-APRIL-96

ATTORNEY/AGENT INFORMATION:

NAME: McDaniel, C. Steven

REGISTRATION NUMBER: 33,962

REFERENCE/DOCKET NUMBER: 1472-06214

TELECOMMUNICATION INFORMATION:

TELEPHONE: 713/238-8010

TELEFAX: 713/238-8008

INFORMATION FOR SEQ ID NO: 87:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

SEQUENCE DESCRIPTION: SEQ ID NO: 87:

US-09-429-130-87

Query Match 0.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721

Db 16 CCCACCACCACCAC 1

RESULT 298

US-09-474-432B-558/c

; Sequence 558, Application US/09474432B

; Patent No. 6528640

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Beigelman, Leo

; APPLICANT: Burgin, Alex

; APPLICANT: Beaudry, Amber

; APPLICANT: Karpeisky, Alex

; APPLICANT: Adamic, Jasenka

; APPLICANT: Sweedler, David

; APPLICANT: Zinnen, Shawn

TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot

; FILE REFERENCE: MEHB00-831-B (247/276)

; CURRENT APPLICATION NUMBER: US/09/474,432B

; CURRENT FILING DATE: 1999-12-19

; PRIOR FILING DATE: 1997-11-05

; PRIOR APPLICATION NUMBER: US 60/064,866

; PRIOR FILING DATE: 1998-04-29

; PRIOR APPLICATION NUMBER: US 09/186,675

; PRIOR FILING DATE: 1998-11-04

; PRIOR APPLICATION NUMBER: US 09/301,511

; PRIOR FILING DATE: 1999-04-28

; NUMBER OF SEQ ID NOS: 1526

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 558

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-474-432B-558

Query Match 0.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1850

Db 17 AACACAAACCAAAAAA 2

RESULT 299

US-09-474-432B-559/c

; Sequence 559, Application US/09474432B

; Patent No. 6528640

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Beigelman, Leo

; APPLICANT: Burgin, Alex

; APPLICANT: Beaudry, Amber

; APPLICANT: Karpeisky, Alex

; APPLICANT: Adamic, Jasenka

; APPLICANT: Sweedler, David

; APPLICANT: Zinnen, Shawn

TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot

; FILE REFERENCE: MEHB00-831-B (247/276)

; CURRENT APPLICATION NUMBER: US/09/474,432B

; CURRENT FILING DATE: 1999-12-19

; PRIOR APPLICATION NUMBER: US 60/064,866

; PRIOR FILING DATE: 1997-11-05

; PRIOR APPLICATION NUMBER: US 60/084,727

; PRIOR FILING DATE: 1998-04-29

; PRIOR APPLICATION NUMBER: US 09/186,675

; PRIOR FILING DATE: 1998-11-04

; PRIOR APPLICATION NUMBER: US 09/301,511

; PRIOR FILING DATE: 1999-04-28

; NUMBER OF SEQ ID NOS: 1526

; SOFTWARE: PatentIn version 3.0

```
; SEQ ID NO 559
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-559

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAA...AAAAA 1850
Db 16 AAAAAA...AAAAA 1

RESULT 300
US-09-474-432B-677
; Sequence 677, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MBH800-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 677
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-677

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 951 GTACTGGTCAGTGGAC 966
Db 2 GAACUGGCGACUGGAC 17

RESULT 301
US-09-474-432B-876/c
; Sequence 876, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MBH800-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
```

```
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 876
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-876

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 578 GAGAGGGGCTCAGAA 593
Db 17 GGGCAGGGGCTCAGAA 2

RESULT 302
US-09-371-772B-333/c
; Sequence 333, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Receptor
; FILE REFERENCE: MBH800,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 333
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-333

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1644 TCTGTATTATCTTTC 1659
Db 17 TCTGTATTAACTGTC 2

RESULT 303
US-09-371-772B-477
; Sequence 477, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Receptor
```



```
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 477
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-477

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1154 AAATATTTCCTACTAC 1169
    |||: :|||:|
Db 1 AAACUCUCCAAACUAC 16

RESULT 304
US-09-371-772B-1705/c
; Sequence 1705, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1705
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1705

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1736 TGGTAGGCTTACACT 1751
    ||||| |||||
Db 16 TGGTAAGGATGACACT 16

RESULT 305
US-09-371-772B-2671/c
; Sequence 2671, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
```

```
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2671
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2671

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 823 TGTCAGAATGGCTTC 838
    ||||| |||||
Db 16 TGTCAAAAATGGTTTC 16

RESULT 306
US-09-371-772B-3604/c
; Sequence 3604, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3604
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3604

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAA 1850
    ||||| |||||
Db 16 AAACAAAAAACAAAA 16

RESULT 307
US-09-371-772B-4280/c
; Sequence 4280, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
```

; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4280
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4280

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 889 CAGATACCTGATTCCTT 904
|||||:|||||
Db 16 CAGATTCGTTCCTT 1

RESULT 308
US-09-371-772B-4407
; Sequence 4407, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4407
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4407

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 237 GCTAAAGCAATCATCA 252
|:|||||:|:
Db 1 GAUAAAGCAUUCAUCA 16

RESULT 309
US-09-371-772B-4766
; Sequence 4766, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B

; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4766
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4766

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 1154 AAATATTTCCAACTAC 1169
||||:|||||
Db 2 AAAUCUCUCCAAUAC 17

RESULT 310
US-09-371-772B-4869
; Sequence 4869, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4869
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4869

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 186 AAGAGGACTTTTGAAG 201
|:|||||:|:
Db 1 AUGAGGACUUCUUGCAG 16

RESULT 311
US-09-371-772B-5113
; Sequence 5113, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B

; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5113
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5113

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 427 TACCCCACTGGGAGAG 442
Db 1 UACCCACUGGCCAG 16

RESULT 312

US-09-371-772B-5139/c
; Sequence 5139, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5139
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5139

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 229 GAGATGTTGCTAAGC 244
Db 16 GAGATGTTGCTCAGC 1

RESULT 313

US-09-371-772B-5170/c
; Sequence 5170, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5170
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5170

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1306 ATGGAGAAGGACAGA 1321
Db 17 ATGTAGAAGGTCAGA 2

RESULT 314

US-09-371-772B-5171/c
; Sequence 5171, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5171
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5171

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1306 ATGGAGAAGGACAGA 1321
Db 16 ATGTAGAAGGTCAGA 1

RESULT 315

US-09-371-772B-5340
; Sequence 5340, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26

; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 6591
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-371-772B-6591

Query Match 0.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 404 AGTTCACCTGGAGCCA 419
 ||||| ||||| |||||
 DB 17 AGTTCATCTGGATCCA 2

RESULT 320

US-09-476-387-557/c
 ; Sequence 557, Application US/09476387
 ; Patent No. 6617438

GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka Matulic
 ; APPLICANT: Sweedler, Dave
 ; APPLICANT: Zinnen, Shawn

; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot

; FILE REFERENCE: MBH00-831-C (249/073)

; CURRENT APPLICATION NUMBER: US/09476,387

; CURRENT FILING DATE: 2001-04-04

; PRIOR APPLICATION NUMBER: 09/474,432

; PRIOR FILING DATE: 1999-12-29

; PRIOR FILING DATE: 1999-04-28

; PRIOR FILING DATE: 1998-11-04

; PRIOR FILING DATE: 1998-04-29

; PRIOR FILING DATE: 1998-04-29

; PRIOR FILING DATE: 1997-11-05

; NUMBER OF SEQ ID NOS: 1524

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 557

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-476-387-557

Query Match 0.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1850
 ||||| ||||| |||||
 DB 17 AACACAAACAAAAA 2

RESULT 321

US-09-476-387-558/c

; Sequence 558, Application US/09476387

; Patent No. 6617438

GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka Matulic
 ; APPLICANT: Sweedler, Dave
 ; APPLICANT: Zinnen, Shawn

; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot

; FILE REFERENCE: MBH00-831-C (249/073)
 ; CURRENT APPLICATION NUMBER: US/09476,387
 ; CURRENT FILING DATE: 2001-04-04

; PRIOR APPLICATION NUMBER: 09/474,432

; PRIOR FILING DATE: 1999-12-29

; PRIOR APPLICATION NUMBER: 09/301,511

; PRIOR FILING DATE: 1999-04-28

; PRIOR APPLICATION NUMBER: 09/186,675

; PRIOR FILING DATE: 1998-11-04

; PRIOR APPLICATION NUMBER: 60/083,727

; PRIOR FILING DATE: 1998-04-29

; PRIOR APPLICATION NUMBER: 60/064,866

; PRIOR FILING DATE: 1997-11-05

; NUMBER OF SEQ ID NOS: 1524

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 558

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-476-387-558

Query Match 0.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1850
 ||||| ||||| |||||
 DB 16 AAAAAAAAAACAAA 1

RESULT 322

US-09-476-387-676

; Sequence 676, Application US/09476387

; Patent No. 6617438

GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka Matulic
 ; APPLICANT: Sweedler, Dave
 ; APPLICANT: Zinnen, Shawn

; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot

; FILE REFERENCE: MBH00-831-C (249/073)

; CURRENT APPLICATION NUMBER: US/09476,387

; CURRENT FILING DATE: 2001-04-04

; PRIOR APPLICATION NUMBER: 09/474,432

; PRIOR FILING DATE: 1999-12-29

; PRIOR APPLICATION NUMBER: 09/301,511

; PRIOR FILING DATE: 1999-04-28

; PRIOR APPLICATION NUMBER: 09/186,675

; PRIOR FILING DATE: 1998-11-04

; PRIOR APPLICATION NUMBER: 60/083,727

; PRIOR FILING DATE: 1998-04-29

; PRIOR APPLICATION NUMBER: 60/064,866

; PRIOR FILING DATE: 1997-11-05

; NUMBER OF SEQ ID NOS: 1524

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 676

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-476-387-676

Query Match 0.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 1.9e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 951 GTACTGCTCAGTGCAC 966
 ||||| ||||| |||||
 DB 2 GAACUGGGCAGUGGAC 17

```
RESULT 323
US-09-476-387-875/c
; Sequence 875, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleob
; FILE REFERENCE: MHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR FILING DATE: 1998-11-04
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 875
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-875

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      578 GAGAGGGGCTCAGAA 593
Db      17 GGCAGGGGCTCAGAA 2

RESULT 324
US-09-401-063-42/c
; Sequence 42, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
```

```
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-42

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1664 TACTTCCAAATCTC 1679
Db      17 TAATTTCCAAATCTCC 2

RESULT 325
US-09-401-063-665/c
; Sequence 665, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
```

```
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 665:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-665

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAAATAAAAGAGAAA 216
Db 16 GAAGTAAAGGAGAAA 1

RESULT 326
US-09-827-998-1724
; Sequence 1724, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 1724
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-1724

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTGT 1460
Db 2 TGTGCTGCTGCTGT 17

RESULT 327
US-09-827-998-1725
; Sequence 1725, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 1725
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-1725

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1081 TGGGGCTGGTCTGT 1096
Db 2 TGGGGCTGGTCTGT 17

RESULT 329
US-09-866-108A-2360/c
; Sequence 2360, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1535
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1535

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTGT 1460
Db 1 TGTGCTGCTGCTGT 16

RESULT 328
US-09-866-108A-1535
; Sequence 1535, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1535
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1535

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1081 TGGGGCTGGTCTGT 1096
Db 2 TGGGGCTGGTCTGT 17

RESULT 329
US-09-866-108A-2360/c
; Sequence 2360, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOmica-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 1725
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-1725
```

```
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2360
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-2360

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 ATCAGCTGTGATCGTG 467
Db 17 AGCAGCTGTGATCGG 2

RESULT 330
US-09-866-108A-2361/c
; Sequence 2361, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2360
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-2360

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 ATCAGCTGTGATCGTG 467
Db 17 AGCAGCTGTGATCGG 2

RESULT 330
US-09-866-108A-2361/c
; Sequence 2361, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2361
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-2361

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 ATCAGCTGTGATCGTG 467
Db 16 AGCAGCTGTGATCGG 1

RESULT 331
US-09-866-108A-6976
; Sequence 6976, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6976
; LENGTH: 17
```



```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6976

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1437 CAGATGAATGTTGCTG 1452
Db 2 CAGAAGAATGGGCTG 17

RESULT 332
US-09-866-108A-6977
; Sequence 6977, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A6MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: A6MICA Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7125
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7125

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1671 CAAATTCCTGATTC 1686
Db 17 CAACTTCCTGATTT 2

RESULT 334
US-09-866-108A-7126/c
; Sequence 7126, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A6MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666

; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6977

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1437 CAGATGAATGTTGCTG 1452
Db 1 CAGAAGAATGGGCTG 16

RESULT 333
US-09-866-108A-7125/c
; Sequence 7125, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
```



```
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8362
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8362

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 393 GGGCTGGAGGAAGTTC 408
DB 2 GAGCTGGAGGAAGTGC 17

RESULT 338
US-09-866-108A-9536/c
; Sequence 9536, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8362
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9536/c

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 441 AGGGGAGGAAGTATCAG 456
DB 17 AGGGGAGGAAGTATCAG 2

RESULT 339
US-09-866-108A-9537/c
; Sequence 9537, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9536

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 441 AGGGGAGGAAGTATCAG 456
DB 17 AGGGGAGGAAGTATCAG 2

RESULT 339
US-09-866-108A-9537/c
; Sequence 9537, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
```

```

; SEQ ID NO 9537
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9537

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

441 AGGGGAGGAATCAG 456
16 AGGGGAGGAGGAGCAG 1

RESULT 340
US-09-866-108A-9571/c
; Sequence 9571, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9573
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9573

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      969 CTGCACAGCTGGGATG 984
Db      16 CTCGACAGCGGGATG 1

RESULT 342
US-09-866-108A-10256/c
; Sequence 10256, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9571
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9571

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      970 TGCACAGCTGGGATGT 985
Db      17 TCGACAGCGGGATGT 2

RESULT 341
US-09-866-108A-9573/c
; Sequence 9573, Application US/09866108A

```

```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10256
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10256

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1195 GAACCTTCTTACCCAC 1210
      ||||| ||||| |||||
Db      17  GAACCGTCTTGCCAC 2

RESULT 343
US-09-866-108A-10257/c
; Sequence 10257, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEONICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10256
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10256

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1195 GAACCTTCTTACCCAC 1210
      ||||| ||||| |||||
Db      17  GAACCGTCTTGCCAC 2

RESULT 344
US-09-404-912-155
; Sequence 155, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; CURRENT FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 155
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-404-912-155

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1670 CCAAATTCCTGATTC 1685
      ||||| ||||| |||||
Db      1  CCAAATTCCTGATTC 16

RESULT 345
US-09-155-885A-101/c
; Sequence 101, Application US/09155885A
; Patent No. 6709812
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: ROSSAU, RUDI
; APPLICANT: MAERTENS, GEERT
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHUYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
```

```
; Patent No. 6686188
; SEQ ID NO 10257
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10257

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1195 GAACCTTCTTACCCAC 1210
      ||||| ||||| |||||
Db      16  GAACCGTCTTGCCAC 1

RESULT 344
US-09-404-912-155
; Sequence 155, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; Genotyping and DNA Analysis
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; CURRENT FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 155
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-404-912-155

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1670 CCAAATTCCTGATTC 1685
      ||||| ||||| |||||
Db      1  CCAAATTCCTGATTC 16

RESULT 345
US-09-155-885A-101/c
; Sequence 101, Application US/09155885A
; Patent No. 6709812
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: ROSSAU, RUDI
; APPLICANT: MAERTENS, GEERT
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHUYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
```

/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/155,885A
/ FILING DATE: 08-Oct-1998
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: PCT/EP97/02002
/ FILING DATE: 21-APR-1997
/ APPLICATION NUMBER: EP 96870053.4
/ FILING DATE: 19-APR-1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: SADOFF, B.J.
/ REGISTRATION NUMBER: 36,663
/ REFERENCE/DOCKET NUMBER: 2551-5
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (703) 816-4000
/ TELEFAX: (703) 816-4100
/ INFORMATION FOR SEQ ID NO: 101:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ HYPOTHETICAL: NO
/ ANTI-SENSE: NO
/ SEQUENCE DESCRIPTION: SEQ ID NO: 101:
US-09-155-885A-101

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 246 ATCATCAACTAGCTG 261
Db 17 ATCATCCACATAGCTG 2

RESULT 346
US-10-029-598-30/c
/ Sequence 30, Application US/10029598
/ Patent No. 6747014
/ GENERAL INFORMATION:
/ APPLICANT: Teng, Ching-Leou
/ APPLICANT: Cook, Phillip Dan
/ APPLICANT: Tillman, Lloyd
/ APPLICANT: Hardee, Gregory E.
/ APPLICANT: Ecker, David J.
/ APPLICANT: Manoharan, Muthiah
/ TITLE OF INVENTION: Compositions And Methods For No. 6747014-Parental Delivery Of Oil
/ FILE REFERENCE: US184945
/ CURRENT APPLICATION NUMBER: US/10/029,598
/ CURRENT FILING DATE: 2001-12-21
/ PRIOR APPLICATION NUMBER: 08/082,624
/ PRIOR FILING DATE: 1998-05-21
/ PRIOR APPLICATION NUMBER: 09/315,298
/ PRIOR FILING DATE: 1999-05-20
/ NUMBER OF SEQ ID NOS: 58
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 30
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Sequence
US-10-029-598-30

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCACCCACCCACCAC 1

RESULT 347

US-09-685-664B-333/c
/ Sequence 333, Application US/09685664B
/ Patent No. 6818447
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MBH00-876-K (400/021)
/ CURRENT APPLICATION NUMBER: US/09/685,664B
/ CURRENT FILING DATE: 2000-10-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ PRIOR APPLICATION NUMBER: US 09/371,772
/ PRIOR FILING DATE: 1999-08-10
/ NUMBER OF SEQ ID NOS: 8231
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 333
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-685-664B-333

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1644 TCTGTATTATCTTTC 1659
Db 17 TCTGTATTATCTGTC 2

RESULT 348

US-09-685-664B-477
/ Sequence 477, Application US/09685664B
/ Patent No. 6818447
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MBH00-876-K (400/021)
/ CURRENT APPLICATION NUMBER: US/09/685,664B
/ CURRENT FILING DATE: 2000-10-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ PRIOR APPLICATION NUMBER: US 09/371,772
/ PRIOR FILING DATE: 1999-08-10
/ NUMBER OF SEQ ID NOS: 8231
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 477
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-09-685-664B-477

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1154 AAATATTTCCTAC 1169
|||: : |||||: ||
Db 1 AAUCUCUCCAAUC 16

RESULT 349
 US-09-685-664B-1080/c
 ; Sequence 1080, Application US/09685664B
 ; Patent No. 6818447
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyne Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MBH00-876-K (400/021)
 ; CURRENT APPLICATION NUMBER: US/09/685,664B
 ; CURRENT FILING DATE: 2000-10-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; PRIOR APPLICATION NUMBER: US 09/371,772
 ; PRIOR FILING DATE: 1999-08-10
 ; NUMBER OF SEQ ID NOS: 8231
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 1080
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-685-664B-1080

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1831 TCTGAAAAAAAAAAAAA 1846
Db 16 TTTGGAAAAAAAAAAAAA 1

RESULT 350
US-09-685-664B-1705/c
; Sequence 1705, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1705
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1705

Query Match 0.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity	87.5%;	Pred. No. 1.9e+02;
Matches	14; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
Qy	1736	TGTTAGGGATTACAGT 1751
Db	16	TGTTAAGGATCAGCT 1

RESULT 351
US-09-685-664B-2671/c
; Sequence 2671, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2671
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2671

```
Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Qy 823 TGTC AAGAAATGGCTTC 838
|||||
Db 16 TGTC AAAAAATGGTTTC 1

RESULT 352
US-09-685-664B-3604/c
Sequence 3604, Application US/09685664B
Patent No. 6818447
GENERAL INFORMATION:
APPLICANT: Ribozyne Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
FILE REFERENCE: MSHB00-876-K (400/021)
CURRENT APPLICATION NUMBER: US/09/685,664B
CURRENT FILING DATE: 2000-10-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
PRIOR APPLICATION NUMBER: US 09/371,772
PRIOR FILING DATE: 1999-08-10
NUMBER OF SEQ ID NOS: 8231
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3604
LENGTH: 17
TYPE: RNA
ORGANISM: Mus musculus

US-09-685-664B-3604

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1850
Db 16 AAAAAAAAAAAAAA 1

RESULT 353

US-09-093-972C-236
; Sequence 236, Application US/09093972C
; Patent No. 6825174
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION

NUMBER OF SEQUENCES: 996
CORRESPONDENCE ADDRESS:
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: New Jersey
COUNTRY: USA
ZIP: 08512

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/093,972C
FILING DATE: 09-June-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00672
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 236:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 236:

US-09-093-972C-236

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 CTGACAGCTGGGATG 984
Db 2 CTGGAAGCTGAGATG 17

RESULT 354

US-09-093-972C-272
; Sequence 272, Application US/09093972C
; Patent No. 6825174
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION

NUMBER OF SEQUENCES: 996
CORRESPONDENCE ADDRESS:
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: New Jersey
COUNTRY: USA
ZIP: 08512

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/093,972C
FILING DATE: 09-June-1998
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Amzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00672
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 272:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 272:

US-09-093-972C-272

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 CTGACAGCTGGGATG 984
Db 1 CTGGAAGCTGAGATG 16

RESULT 355

PCT-US96-11786-33/c
; Sequence 33, Application PC/TUS9611786
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennewald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Yves
; APPLICANT: Mazumder, Abhijit

;; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
;; TITLE OF INVENTION: Oligonucleotides
;; NUMBER OF SEQUENCES: 52
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Conley, Rose & Tayon, P.C.
;; STREET: 600 Travis, Suite 1850
;; CITY: Houston
;; STATE: Texas
;; COUNTRY: U.S.A.
;; ZIP: 77002-2912
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: PCT/US96/11786
;; FILING DATE: 17-JULY-1996
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/535,168; 60/001,505; 60/014,007; 60/013,688;
;; APPLICATION NUMBER: 60/015,714; 60/016,271
;; FILING DATE: 23-OCT-95; 17-JULY-96; 25-MARCH-96; 19-MARCH-96; 23-
;; FILING DATE: APRIL-96; 17-APRIL-96
;; ATTORNEY/AGENT INFORMATION:
;; NAME: McDaniel, C. Steven
;; REGISTRATION NUMBER: 33,962
;; REFERENCE/DOCKET NUMBER: 1472-06214
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 713/238-8010
;; TELEFAX: 713/238-8008
;; INFORMATION FOR SEQ ID NO: 33:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: 17
;; OTHER INFORMATION: /note="Amine moiety"
;; OTHER INFORMATION: attached to 3' end"
PCT-US96-11786-33

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCACCACCACCAC 1

RESULT 356
US-08-431-048F-151/c
; Sequence 151, Application US/08431048F
; Patent No. 6531586
; GENERAL INFORMATION:
; APPLICANT: ST. GEORGE-HYSLOP, PETER H
; ROMMENS, JOHANNA M
; FRASER, PAUL E
; TITLE OF INVENTION: GENETIC SEQUENCES AND PROTEINS RELATED
; TO ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 155
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DARBY & DARBY P.C.
; STREET: 805 THIRD AVENUE
; CITY: NEW YORK
; STATE: N.Y.
; COUNTRY: U.S.A.
; ZIP: 10022-7513
; COMPUTER READABLE FORM:

;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/431,048F
;; FILING DATE: 28-Apr-1995
;; CLASSIFICATION: <Unknown>
;; ATTORNEY/AGENT INFORMATION:
;; NAME: FEHLNER, PAUL F.
;; REGISTRATION NUMBER: 35135
;; REFERENCE/DOCKET NUMBER: 1034/0F808
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 212-527-7700
;; TELEFAX: 212-527-6237
;; INFORMATION FOR SEQ ID NO: 151:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
;; SEQUENCE DESCRIPTION: SEQ ID NO: 151:
US-08-431-048F-151

Query Match 0.7%; Score 12.6; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 328 GACTGAGTGGCTC 340
Db 13 GACTGAGTGGCTC 1

RESULT 357
US-08-294-424-46
; Sequence 46, Application US/08294424
; Patent No. 5800984
; GENERAL INFORMATION:
; APPLICANT: Vary, Calvin
; TITLE OF INVENTION: NUCLEIC ACID SEQUENCE DETECTION BY
; TITLE OF INVENTION: TRIPLE HELIX FORMATION
; NUMBER OF SEQUENCES: 49
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3 5" Diskette, 1.44 Mb storage
; COMPUTER: IBM PS/2 Model 502 or 55SX
; OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
; SOFTWARE: WordPerfect (Version 5.0)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/294,424
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/000,922
; FILING DATE: 16 JAN 1993
; APPLICATION NUMBER: US/07/629,601B
; FILING DATE: 17-DEC-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Freeman, John W.
; REGISTRATION NUMBER: 29,066
; REFERENCE/DOCKET NUMBER: 00088-037001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 46 :

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-294-424-46

Query Match          0.7%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 722 CTCCTTCTCCATCT 735
Db 1 CTCCTTCTCTTCT 14

RESULT 358
US-09-152-059-116
; Sequence 116, Application US/09152059
; Patent No. 6794499
; GENERAL INFORMATION:
; APPLICANT: WENGEL, JESPER
; APPLICANT: NIELSEN, POUL
; TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
; FILE REFERENCE: 49165 (71994)
; CURRENT APPLICATION NUMBER: US/09/152,059
; CURRENT FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/058,541
; PRIOR FILING DATE: 1997-09-12
; PRIOR APPLICATION NUMBER: 60/068,293
; PRIOR FILING DATE: 1997-12-19
; PRIOR APPLICATION NUMBER: 60/071,682
; PRIOR FILING DATE: 1998-01-16
; PRIOR APPLICATION NUMBER: 60/076,591
; PRIOR FILING DATE: 1998-03-03
; PRIOR APPLICATION NUMBER: 60/083,507
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/088,309
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/094,355
; PRIOR FILING DATE: 1998-07-28
; NUMBER OF SEQ ID NOS: 146
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 116
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-09-152-059-116

Query Match          0.7%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1848
Db 1 AAAAAAAAAAAAAA 14

RESULT 359
US-08-875-553D-14/c
; Sequence 14, Application US/08875553D
; Patent No. 6811972
; GENERAL INFORMATION:
; APPLICANT: Paul B. Fisher and Ruochuan Shen
; TITLE OF INVENTION: DEVELOPMENT OF DNA PROBES AND IMMUNOLOGICAL REAGENTS SPECIFIC FOR
; TITLE OF INVENTION: SURFACE-EXPRESSED MOLECULES AND TRANSFORMATION-ASSOCIATED GENES
; FILE REFERENCE: 0667/37590-C-PCT-US
; CURRENT APPLICATION NUMBER: US/08/875,553D
; CURRENT FILING DATE: 1998-05-26
; NUMBER OF SEQ ID NOS: 43
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1..1)
; OTHER INFORMATION: Primer
US-08-875-553D-14

Query Match          0.7%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1834 GAAAAAAAAAAAAA 1847
Db 14 GCAAAAAAAAAAAAAA 1

RESULT 360
US-09-981-803-32
; Sequence 32, Application US/09981803
; Patent No. 6825012
; GENERAL INFORMATION:
; APPLICANT: Joel CROUZET
; APPLICANT: Daniel SCHERMAN
; APPLICANT: Beatrice CAMERON
; APPLICANT: Pierre WILS
; APPLICANT: Anne-Marie DARQUET
; TITLE OF INVENTION: DNA MOLECULES, PREPARATION AND USE IN GENE THERAPY
; FILE REFERENCE: MINICIRCLE
; CURRENT APPLICATION NUMBER: US/09/981,803
; CURRENT FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 32
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Description of the artificial sequence:
; OTHER INFORMATION: oligonucleotide
US-09-981-803-32

Query Match          0.7%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 199 AAGAAATAAAGAA 212
Db 1 AAGAAATAAAGAA 14

RESULT 361
US-09-981-803-48/c
; Sequence 48, Application US/09981803
; Patent No. 6825012
; GENERAL INFORMATION:
; APPLICANT: Joel CROUZET
; APPLICANT: Daniel SCHERMAN
; APPLICANT: Beatrice CAMERON
; APPLICANT: Pierre WILS
; APPLICANT: Anne-Marie DARQUET
; TITLE OF INVENTION: DNA MOLECULES, PREPARATION AND USE IN GENE THERAPY
; FILE REFERENCE: MINICIRCLE
; CURRENT APPLICATION NUMBER: US/09/981,803
; CURRENT FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 48
; LENGTH: 14
; TYPE: DNA
```

```

1  ZIP: 90071-2066
2  COMPUTER READABLE FORM:
3  MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
4  MEDIUM TYPE: storage
5  COMPUTER: IBM Compatible
6  OPERATING SYSTEM: IBM P.C. DOS 5.0
7  SOFTWARE: Word Perfect 5.1
8  CURRENT APPLICATION DATA:
9  APPLICATION NUMBER: US/08/334,847
10 FILING DATE: No. 5693532ember 4, 1994
11 PRIOR APPLICATION DATA:
12 APPLICATION NUMBER:
13 FILING DATE:
14 ATTORNEY/AGENT INFORMATION:
15 NAME: Warburg, Richard J.
16 REGISTRATION NUMBER: 32,327
17 REFERENCE/DOCKET NUMBER: 209/032
18 TELECOMMUNICATION INFORMATION:
19 TELEPHONE: (213) 489-1600
20 TELEFAX: (213) 955-0440
21 TELEX: 67-3510
22 INFORMATION FOR SEQ ID NO: 92:
23 SEQUENCE CHARACTERISTICS:
24 LENGTH: 15 base pairs
25 TYPE: nucleic acid
26 STRANDEDNESS: single
27 TOPOLOGY: linear
28
29 US-08-334-847-92
30
31 Query Match 0.7%; Score 12.4; DB 1; Length 15;
32 Best Local Similarity 64.3%; Pred. No. 1.9e+02;
33 Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
34
35 QY 1360 GTCTACTTGATGAC 1373
36 |:|:|:|:|:|:|
37 Db 1 GUCUACUAGAUGAC 14
38
39 RESULT 364
40 US-08-334-847-615/c
41 Sequence 615, Application US/08334847
42 Patent No. 5693532
43 GENERAL INFORMATION:
44 APPLICANT: McSwiggen, James
45 APPLICANT: Draper, Kenneth
46 APPLICANT: Pavco, Pam
47 APPLICANT: Woolf, Tod
48 TITLE OF INVENTION: METHOD AND REAGENT FOR
49 TITLE OF INVENTION: INHIBITING RESPIRATORY
50 TITLE OF INVENTION: SYNCYTIAL VIRUS
51 NUMBER OF SEQUENCES: 909
52 CORRESPONDENCE ADDRESS:
53 ADDRESSEE: Lyon & Lyon
54 STREET: 633 West Fifth Street
55 STREET: Suite 4700
56 CITY: Los Angeles
57 STATE: California
58 COUNTRY: U.S.A.
59 ZIP: 90071-2066
60
61 COMPUTER READABLE FORM:
62 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
63 MEDIUM TYPE: storage
64 COMPUTER: IBM Compatible
65 OPERATING SYSTEM: IBM P.C. DOS 5.0
66 SOFTWARE: Word Perfect 5.1
67 CURRENT APPLICATION DATA:
68 APPLICATION NUMBER: US/08/334,847
69 FILING DATE: No. 5693532ember 4, 1994
70 PRIOR APPLICATION DATA:
71 APPLICATION NUMBER:
72 FILING DATE:
73 ATTORNEY/AGENT INFORMATION:
74 NAME: Warburg, Richard J.

```

```
;
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 615:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-334-847-615
;
Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

;
; 1728 TCAACATATGGTAG 1741
; 14 TCAATATATGGTAG 1
;
Db
;
RESULT 365
US-08-908-724-1/c
; Sequence 1, Application US/08908724
; Patent No. 5840728
; GENERAL INFORMATION:
; APPLICANT: Marquez, Victor E.
; APPLICANT: Nicklaus, Marc C.
; APPLICANT: Barchi, Joseph J.
; APPLICANT: Rodriguez, Juan B.
; APPLICANT: Siddiqui, Maqbool A.
; TITLE OF INVENTION: CONFORMATIONALLY LOCKED NUCLEOSIDE
; TITLE OF INVENTION: ANALOGS AS ANTITHERPETIC AGENTS
; NUMBER OF SEQUENCES: 1
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive, 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/908,724
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Bartfield, Neil S
; REGISTRATION NUMBER: 39,901
; REFERENCE/DOCKET NUMBER: NIH130.001PR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-235-8550
; TELEFAX: 619-235-0176
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE:
;
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 615:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE:
;
US-08-908-724-1
; ORIGINAL SOURCE:
;
Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

;
; 90 GAAGAAAAAATGAA 103
; 15 GAAGAAAAAATGAA 2
;
Db
;
RESULT 366
US-08-173-489C-87/c
; Sequence 87, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 87:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; DESCRIPTION: retinoblastoma gene (Accession #
; DESCRIPTION: M33647, J02994) nucleotides 4062 to 4076
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: chromosome 13
; MAP POSITION: 13q14.2
; PUBLICATION INFORMATION:
; AUTHORS: Friend, S H, Horowitz, J M, Gerber, M R,
; AUTHORS: Wang X F, Bogenmann, E, Li, F P, Weinberg,
; AUTHORS: R A.
; TITLE: Deletions of a DNA sequence
; TITLE: in retinoblastomas and mesenchymal tumors:
; TITLE: Organization of the sequence and its encoded
; TITLE: protein
; JOURNAL: Proceedings of the National Academy of
```

JOURNAL: Sciences, USA
VOLUME: 84
PAGES: 9059-9063
DATE: 1987
RELEVANT RESIDUES IN SEQ ID NO: 87 : FROM 1 TO 15
US-08-173-489C-87

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 437 GGAGAGGGGAGAG 450
Db 14 GGGAGGGGAGAG 1

RESULT 367

US-09-115-446-3/c
Sequence 3, Application US/09115446
Patent No. 6165719
GENERAL INFORMATION:
APPLICANT: Chandy, George K.
APPLICANT: Gargus, Jay J.
APPLICANT: Gutman, George
APPLICANT: Fantino, Emmanuelle
APPLICANT: Kalman, Katarin
TITLE OF INVENTION: hKCA3/KCNN3 SMALL CONDUCTANCE CALCIUM
TITLE OF INVENTION: ACTIVATED POTASSIUM CHANNEL: A DIAGNOSTIC
TITLE OF INVENTION: MARKER AND THERAPEUTIC TARGET
FILE REFERENCE: 07306/014001
CURRENT APPLICATION NUMBER: US/09/115,446
CURRENT FILING DATE: 1998-07-14
EARLIER APPLICATION NUMBER: 60/052,556
EARLIER FILING DATE: 1997-07-15
EARLIER APPLICATION NUMBER: 60/070,741
EARLIER FILING DATE: 1998-01-08
NUMBER OF SEQ ID NOS: 15
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 3
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-115-446-3

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1834 GAAAAAAGAAAAA 1847
Db 14 GAAAAAAGAAAAA 1

RESULT 368

US-08-584-040-8462
Sequence 8462, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles

STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 8462:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-8462

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 1.9e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1568 TGCAACTTTGGAAA 1581
Db 1 UGCAAAUUGGAAA 14

RESULT 369

US-09-475-947A-304/c
Sequence 304, Application US/09475947A
Patent No. 6472154
GENERAL INFORMATION:
APPLICANT: Garner, Harold R.
APPLICANT: Wren, Jonathan D.
APPLICANT: Minna, John D.
TITLE OF INVENTION: Polymorphic Repeats in Human Genes
FILE REFERENCE: UTS0667
CURRENT APPLICATION NUMBER: US/09/475,947A
CURRENT FILING DATE: 1999-12-31
NUMBER OF SEQ ID NOS: 346
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 304
LENGTH: 15
TYPE: DNA
ORGANISM: human
US-09-475-947A-304

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGT 1460
Db 15 TTGCTGCTGCTGT 2

RESULT 370

US-09-371-772B-4117
Sequence 4117, Application US/09371772B

; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4117
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-4117

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 1.9e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1568 TGCACACTTTGGAAA 1581
:||||| :|||
Db 1 UGCAGAAUUGGAAA 14

RESULT 371

US-09-565-590-3/c
; Sequence 3, Application US/09565590
; Patent No. 6653100
; GENERAL INFORMATION:
; APPLICANT: Chandy, George K.
; APPLICANT: Gargus, Jay J.
; APPLICANT: Gutman, George
; APPLICANT: Fantino, Emmanuelle
; APPLICANT: Kalman, Katarin
; TITLE OF INVENTION: hKCA3/KCN3 SMALL CONDUCTANCE CALCIUM
; TITLE OF INVENTION: ACTIVATED POTASSIUM CHANNEL: A DIAGNOSTIC
; FILE REFERENCE: 07306/014001
; CURRENT APPLICATION NUMBER: US/09/565,590
; CURRENT FILING DATE: 2000-05-04
; PRIOR APPLICATION NUMBER: 09/115,446
; PRIOR FILING DATE: 1998-07-14
; PRIOR APPLICATION NUMBER: 60/070,741
; PRIOR FILING DATE: 1998-01-08
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-565-590-3

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1834 GAAAAAAGAAAAA 1847
:||||| :|||
Db 14 GAAAAAAGAAAAA 1

RESULT 372
US-09-685-664B-4117
; Sequence 4117, Application US/09685664B

; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4117
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-4117

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 1.9e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1568 TGCACACTTTGGAAA 1581
:||||| :|||
Db 1 UGCAGAAUUGGAAA 14

RESULT 373

PCT-US93-12600-18/c
; Sequence 18, Application PC/TUS9312600
; GENERAL INFORMATION:
; APPLICANT: Denner, Larry A.
; APPLICANT: Rege, Ajay A.
; APPLICANT: Dixon, Richard A.F.
; TITLE OF INVENTION: ANTISENSE MOLECULES DIRECTED AGAINST A
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR RECEPTOR GENE FAMILY
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dressler, Goldsmith, Shore &
; ADDRESSEE: Milnamow, Ltd.
; STREET: 180 North Stetson, Suite 4700
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/12600
; FILING DATE: 28-DEC-1993
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/999,706
; FILING DATE: December 31, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Katz, Martin L.
; REGISTRATION NUMBER: 25,011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 616-5400
; TELEFAX: (312) 616-5460
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:

```
;
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US93-12600-18

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 977 CTGGGATCTGGGC 990
Db 14 CTGGGATCTGGGC 1

RESULT 374
5182195-33/c
; Patent No. 5182195
; APPLICANT: NAKAHAMA, KAZUO; KAISHO, YOSHIHIKO; YOSHIMURA, KOJI
; TITLE OF INVENTION: METHOD FOR INCREASING USING PROTEASE
; DEFICIENT YEASTS
; NUMBER OF SEQUENCES: 71
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/269,140
; FILING DATE: 09-NOV-1988
; SEQ ID NO: 33:
; LENGTH: 15
5182195-33

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTT 1460
Db 14 TTGCTGATGCTGTT 1

RESULT 375
5182195-33/c
; Patent No. 5182195
; APPLICANT: NAKAHAMA, KAZUO; KAISHO, YOSHIHIKO; YOSHIMURA, KOJI
; TITLE OF INVENTION: METHOD FOR INCREASING USING PROTEASE
; DEFICIENT YEASTS
; NUMBER OF SEQUENCES: 71
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/269,140
; FILING DATE: 09-NOV-1988
; SEQ ID NO: 33:
; LENGTH: 15
5182195-33

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTT 1460
Db 14 TTGCTGATGCTGTT 1

RESULT 376
US-08-419-414-13/c
; Sequence 13, Application US/08419414
; Patent No. 5753787
; GENERAL INFORMATION:
; APPLICANT: Hawdon, John M.
; APPLICANT: Hotez, Peter J.
; APPLICANT: Jones, Brian F.
; TITLE OF INVENTION: Hookworm Vaccine
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:

; ADDRESSSEE: Patrea L. Pabst
; STREET: 2800 One Atlantic Center
; STREET: 1201 West Peachtree Street
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30309-3450
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/419,414
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Pabst, Patrea L.
; REGISTRATION NUMBER: 31,284
; REFERENCE/DOCKET NUMBER: YU113
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404) 873-8795
; TELEFAX: (404) 873-8795
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA primer"
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-419-414-13

Query Match          0.7%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1078 CTCGCGGCTGGTG 1091
Db 15 CTCGCGGCTGGTG 2

RESULT 377
US-09-564-805-92/c
; Sequence 92, Application US/09564805
; Patent No. 6333403
; GENERAL INFORMATION:
; APPLICANT: Tavtigian, Sean V.
; APPLICANT: Teng, David H.F.
; APPLICANT: Simard, Jacques
; APPLICANT: Rommens, Johanna M.
; APPLICANT: Myriad Genetics, Inc.
; TITLE OF INVENTION: Chromosome 17p-Linked Prostate Cancer Susceptibility
; FILE REFERENCE: 2318-258
; CURRENT APPLICATION NUMBER: US/09/564,805
; CURRENT FILING DATE: 2000-05-05
; PRIOR APPLICATION NUMBER: US 60/107,468
; PRIOR FILING DATE: 1998-11-06
; PRIOR APPLICATION NUMBER: 09/434,382
; PRIOR FILING DATE: 1999-11-05
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 92
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-564-805-92

Query Match          0.7%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.1e+02;
```

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 571 AACTGCAGACG 584
Db 15 AACTGCGAGAGG 2

RESULT 378

US-09-060-299-443

; Sequence 443, Application US/09060299

; Patent No. 6545137

; GENERAL INFORMATION:

; APPLICANT: Todd, John A

; APPLICANT: Hess, John W

; APPLICANT: Caskey, Charles T

; APPLICANT: Cox, Roger D

; APPLICANT: Gerhold, David

; APPLICANT: Hammond, Holly

; APPLICANT: Hey, Patricia

; APPLICANT: Kawaguchi, Yoshihiko

; APPLICANT: Merriman, Tony R

; APPLICANT: Metzker, Michael L

; TITLE OF INVENTION: No. 6545137el Receptor

; NUMBER OF SEQUENCES: 455

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Nixon and Vanderhye

; STREET: 1100 No. 6545137th Glebe Road, Eighth Floor

; CITY: Arlington

; STATE: Virginia

; COUNTRY: US

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent In Release #1.0, Version #1.25 (BPO)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/060,299

; FILING DATE: 15-APR-1998

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 60/043,553

; FILING DATE: 15-APR-1997

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 60/048,740

; FILING DATE: 05-JUN-1997

; ATTORNEY/AGENT INFORMATION:

; NAME: B.J.Sadoff

; REGISTRATION NUMBER: 36,663

; REFERENCE/DOCKET NUMBER: 620-35

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (703)816-4091

; TELEFAX: (703)816-4100

; INFORMATION FOR SEQ ID NO: 443:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 16 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: double

; TOPOLOGY: linear

; US-09-060-299-443

Query Match 0.7%; Score 12.4; DB 1; Length 16;

Best Local Similarity 92.9%; Pred. No. 2.le+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 499 GTCTTGCAGCAGC 512
Db 1 GTCTTGCAGCAGC 14

RESULT 379

US-09-402-923A-443

; Sequence 443, Application US/09402923A

; Patent No. 6555654

GENERAL INFORMATION:

APPLICANT: Todd, John A

Hess, John W

Caskey, Charles T

Cox, Roger D

Gerhold, David

Hammond, Holly

Hey, Patricia

Kawaguchi, Yoshihiko

Merriman, Tony R

Metzker, Michael L

TITLE OF INVENTION: No. 6555654el LDL-Receptor

NUMBER OF SEQUENCES: 455

CORRESPONDENCE ADDRESS:

ADDRESSEE: Nixon and Vanderhye

STREET: 1100 No. 6555654th Glebe Road, Eighth Floor

CITY: Arlington

STATE: Virginia

COUNTRY: US

ZIP: VA 22201-4714

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.25 (BPO)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/402,923A

FILING DATE: 14-Feb-2001

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/GB98/01102

FILING DATE: 15-APR-1998

APPLICATION NUMBER: US 60/043,553

FILING DATE: 15-APR-1997

APPLICATION NUMBER: US 60/048,740

FILING DATE: 05-JUN-1997

ATTORNEY/AGENT INFORMATION:

NAME: B.J.Sadoff

REGISTRATION NUMBER: 36,663

REFERENCE/DOCKET NUMBER: 620-81

TELECOMMUNICATION INFORMATION:

TELEPHONE: (703)816-4091

TELEFAX: (703)816-4100

INFORMATION FOR SEQ ID NO: 443:

SEQUENCE CHARACTERISTICS:

LENGTH: 16 base pairs

TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 443:

US-09-402-923A-443

Query Match 0.7%; Score 12.4; DB 1; Length 16;

Best Local Similarity 92.9%; Pred. No. 2.le+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 499 GTCTTGCAGCAGC 512
Db 1 GTCTTGCAGCAGC 14

RESULT 380

US-09-371-772B-5841/c

; Sequence 5841, Application US/09371772B

; Patent No. 6566127

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBH800,876-J (237/198)

; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5841
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5864

Query Match 0.7%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1280 CCTCAATATCACTC 1293
|||||
Db 14 CCTCAATCACTC 1

RESULT 381
US-09-371-772B-5864
; Sequence 5864, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5864
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5864

Query Match 0.7%; Score 12.4; DB 1; Length 16;
Best Local Similarity 64.3%; Pred. No. 2.1e+02;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 188 GAGGACTTTTGAAG 201
|||||
Db 1 GAGGACUUUUGCAG 14

RESULT 382
US-09-750-401-6/c
; Sequence 6, Application US/09750401
; Patent No. 6635422
; GENERAL INFORMATION:
; APPLICANT: Keene, Jack D.
; APPLICANT: Carson, Craig C.
; APPLICANT: Tenenbaum, Scott A.
; TITLE OF INVENTION: Methods for isolating and characterizing endogenous mRNA-protein
; TITLE OF INVENTION: complexes
; FILE REFERENCE: REN-001
; CURRENT APPLICATION NUMBER: US/09/750,401
; CURRENT FILING DATE: 2000-12-28
; PRIOR APPLICATION NUMBER: US 60/173,338

; PRIOR FILING DATE: 1999-12-28
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 3'-UTR sequence of HOX 2.5
US-09-750-401-6

Query Match 0.7%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1808 ACTTAATAAATTTT 1821
|||||
Db 14 ACTTAATAAATTT 1

RESULT 383
US-09-479-005A-332/c
; Sequence 332, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MHB00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 332
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-332

Query Match 0.7%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1589 TTCACATAACAATT 1602
|||||
Db 15 TTCACATAGCAATT 2

RESULT 384
US-08-173-489C-87
; Sequence 87, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C.-G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT

OPERATING SYSTEM: MS-DOS version 6.2
SOFTWARE: Wordperfect Version 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/173,489C
FILING DATE: 22 DEC 1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELECOMMUNICATION INFORMATION:
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 87:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: Genomic DNA
DESCRIPTION: retinoblastoma gene (Accession #
M33647, J02994) nucleotides 4062 to 4076
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
POSITION IN GENOME:
CHROMOSOME/SEGMENT: chromosome 13
MAP POSITION: 13q14.2
PUBLICATION INFORMATION:
AUTHORS: Friend, S H, Horowitz, J M, Gerber, M R,
AUTHORS: Wang X F, Bogenmann, E, Li, F P, Weinberg,
AUTHORS: R A.
TITLE: Deletions of a DNA sequence
TITLE: in retinoblastomas and mesenchymal tumors:
TITLE: Organization of the sequence and its encoded
TITLE: protein
JOURNAL: Proceedings of the National Academy of
JOURNAL: Sciences, USA
VOLUME: 84
PAGES: 9059-9063
DATE: 1987
RELEVANT RESIDUES IN SEQ ID NO: 87 :FROM 1 TO 15
US-08-173-489C-87

Query Match 0.6% Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1701 TTCTCCCTCC 1712
Db 2 TTCTCCCTCC 13

Search completed: July 12, 2005, 10:42:44
Job time : 8 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 12, 2005, 10:37:23 ; Search time 7 Seconds
(without alignments)
3.416 Million cell updates/sec

Title: US-09-745-763-35
Perfect score: 1851
Sequence: 1 GGCTAGCCCGGAGCTTAGT.....CTGAAAAA.....AAAAA 1851

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 364 seqs, 6460 residues

Total number of hits satisfying chosen parameters: 728

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 369 summaries

Database : rge35.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	28	1.5	29	1	BD106421
C 2	18.4	1.0	20	1	AR562157
C 3	18	1.0	20	1	AR562158
C 4	17.8	1.0	23	1	AG9549
C 5	17.2	0.9	19	1	AR528447
C 6	17	0.9	19	1	AR541350
C 7	17	0.9	19	1	AR541351
C 8	17	0.9	19	1	AR541352
C 9	17	0.9	19	1	AR541353
C 10	17	0.9	19	1	AR541361
C 11	17	0.9	20	1	AR532682
C 12	17	0.9	20	1	AR559396
C 13	17	0.9	20	1	AR559411
C 14	17	0.9	20	1	AR561993
C 15	17	0.9	20	1	AR562156
C 16	17	0.9	20	1	AR565165
C 17	16.4	0.9	18	1	AR292366
C 18	16.4	0.9	20	1	CQ882062
C 19	16.4	0.9	20	1	CQ812535
C 20	16.4	0.9	20	1	DOGVWFB
C 21	16.2	0.9	21	1	AR084578
C 22	16.2	0.9	21	1	AR084582
C 23	16.2	0.9	21	1	AR093142
C 24	16.2	0.9	21	1	AR528824
C 25	16.2	0.9	21	1	AX922788
C 26	16	0.9	16	1	AR561628
C 27	16	0.9	16	1	AR561693
C 28	16	0.9	19	1	AX129261
C 29	15.8	0.9	19	1	AR241724
C 30	15.8	0.9	19	1	AX131832
C 31	15.8	0.9	19	1	AX131833
C 32	15.8	0.9	20	1	BD272150
C 33	15.8	0.9	20	1	II5679

34	15.8	0.9	20	1	I36684
C 35	15.8	0.9	20	1	AR315632
C 36	15.8	0.9	20	1	AX040095
C 37	15.8	0.9	20	1	AX956227
C 38	15.8	0.9	21	1	AR084563
C 39	15.8	0.9	21	1	AR084566
C 40	15.8	0.9	21	1	AR084567
C 41	15.8	0.9	21	1	AR084579
C 42	15.8	0.9	21	1	CQ830490
C 43	15.8	0.9	21	1	CQ830491
C 44	15.8	0.9	21	1	CQ830492
C 45	15.8	0.9	21	1	CQ830496
C 46	15.8	0.9	21	1	BD056667
C 47	15.4	0.8	17	1	AX725153
C 48	15.4	0.8	17	1	AX727863
C 49	15.4	0.8	17	1	AX733002
C 50	15.4	0.8	18	1	A67588
C 51	15.4	0.8	18	1	AR035168
C 52	15.4	0.8	18	1	AR089726
C 53	15.4	0.8	18	1	CQ786327
C 54	15.4	0.8	18	1	AR340812
C 55	15.4	0.8	18	1	AX141245
C 56	15.4	0.8	20	1	BD142414
C 57	15.4	0.8	20	1	AR315566
C 58	15.4	0.8	20	1	AX149057
C 59	15.4	0.8	20	1	AX554362
C 60	15.2	0.8	20	1	AR121539
C 61	15.2	0.8	20	1	AR121992
C 62	15.2	0.8	20	1	CQ786367
C 63	15.2	0.8	20	1	CQ796907
C 64	15.2	0.8	20	1	I83426
C 65	15.2	0.8	20	1	AR182885
C 66	15.2	0.8	20	1	AR313757
C 67	15.2	0.8	20	1	AR429256
C 68	15.2	0.8	20	1	AX104051
C 69	15.2	0.8	20	1	AX298435
C 70	15.2	0.8	20	1	AX355382
C 71	15.2	0.8	20	1	AX458688
C 72	15.2	0.8	20	1	AX547104
C 73	15.2	0.8	20	1	AX556882
C 74	15.2	0.8	20	1	BD069976
C 75	15.2	0.8	20	1	BD088317
C 76	15.2	0.8	20	1	AB068428
C 77	15	0.8	19	1	AX129260
C 78	15	0.8	20	1	AR107613
C 79	15	0.8	20	1	AR107614
C 80	15	0.8	20	1	AR107615
C 81	15	0.8	20	1	AR107616
C 82	15	0.8	20	1	AR107617
C 83	15	0.8	20	1	AR107618
C 84	14.8	0.8	19	1	II5672
C 85	14.8	0.8	19	1	I36677
C 86	14.8	0.8	19	1	AR295153
C 87	14.8	0.8	19	1	AR295404
C 88	14.8	0.8	19	1	AR533334
C 89	14.8	0.8	19	1	AX131510
C 90	14.8	0.8	19	1	AX132341
C 91	14.8	0.8	19	1	AX149169
C 92	14.4	0.8	17	1	CQ623624
C 93	14.4	0.8	17	1	CQ623625
C 94	14.4	0.8	17	1	CQ625290
C 95	14.4	0.8	17	1	CQ625291
C 96	14.4	0.8	17	1	AR327069
C 97	14.4	0.8	17	1	AR464687
C 98	14.4	0.8	17	1	AR464688
C 99	14.4	0.8	17	1	AR466353
C 100	14.4	0.8	17	1	AR466354
C 101	14.4	0.8	17	1	AX218292
C 102	14.4	0.8	17	1	AX579784
C 103	14.4	0.8	17	1	AX722986
C 104	14.4	0.8	17	1	AX723927
C 105	14.4	0.8	17	1	AX724619
C 106	14.4	0.8	17	1	AX725224

C 107	14.4	0.8	17	1	AX726651	ACCESSION:AX726651	180	13.8	0.7	17	1	AX475498	ACCESSION:AX475498
C 108	14.4	0.8	17	1	AX73552	ACCESSION:AX73552	C 181	13.8	0.7	17	1	AX502944	ACCESSION:AX502944
C 109	14.4	0.8	17	1	AX736376	ACCESSION:AX736376	C 182	13.8	0.7	17	1	AX578360	ACCESSION:AX578360
C 110	14.4	0.8	18	1	AR164526	ACCESSION:AR164526	183	13.8	0.7	17	1	AX578426	ACCESSION:AX578426
C 111	14.4	0.8	18	1	AX133011	ACCESSION:AX133011	184	13.8	0.7	17	1	AX615236	ACCESSION:AX615236
C 112	14.4	0.8	18	1	AX327131	ACCESSION:AX327131	185	13.8	0.7	17	1	AX615237	ACCESSION:AX615237
C 113	14.4	0.8	18	1	AX697910	ACCESSION:AX697910	C 186	13.8	0.7	17	1	AX648875	ACCESSION:AX648875
C 114	14.4	0.8	19	1	AX131834	ACCESSION:AX131834	C 187	13.8	0.7	17	1	AX648876	ACCESSION:AX648876
C 115	14.2	0.8	17	1	181221	ACCESSION:181221	C 188	13.8	0.7	17	1	AX648877	ACCESSION:AX648877
C 116	14.2	0.8	17	1	AR438875	ACCESSION:AR438875	C 189	13.8	0.7	17	1	AX693083	ACCESSION:AX693083
C 117	14	0.8	15	1	AR322168	ACCESSION:AR322168	C 190	13.8	0.7	17	1	AX724533	ACCESSION:AX724533
C 118	14	0.8	17	1	CQ617850	ACCESSION:CQ617850	191	13.8	0.7	17	1	AX728002	ACCESSION:AX728002
C 119	14	0.8	17	1	CQ617851	ACCESSION:CQ617851	192	13.8	0.7	17	1	AX730762	ACCESSION:AX730762
C 120	14	0.8	17	1	CQ617852	ACCESSION:CQ617852	193	13.8	0.7	17	1	AX734915	ACCESSION:AX734915
C 121	14	0.8	17	1	CQ617853	ACCESSION:CQ617853	C 194	13.8	0.7	17	1	AX736157	ACCESSION:AX736157
C 122	14	0.8	17	1	AR458913	ACCESSION:AR458913	195	13.8	0.7	17	1	AX736485	ACCESSION:AX736485
C 123	14	0.8	17	1	AR458914	ACCESSION:AR458914	C 196	13.8	0.7	17	1	AX737865	ACCESSION:AX737865
C 124	14	0.8	17	1	AR458915	ACCESSION:AR458915	197	13.8	0.7	17	1	AX783722	ACCESSION:AX783722
C 125	14	0.8	17	1	AR458916	ACCESSION:AR458916	C 198	13.8	0.7	17	1	BD067591	ACCESSION:BD067591
C 126	14	0.8	17	1	AX217415	ACCESSION:AX217415	C 199	13.8	0.7	18	1	AX14295	ACCESSION:AX14295
C 127	14	0.8	17	1	AX688102	ACCESSION:AX688102	C 200	13.8	0.7	18	1	AX18146	ACCESSION:AX18146
C 128	14	0.8	17	1	AX688103	ACCESSION:AX688103	C 201	13.8	0.7	18	1	AX65728	ACCESSION:AX65728
C 129	14	0.8	17	1	AX688104	ACCESSION:AX688104	202	13.8	0.7	18	1	AX67594	ACCESSION:AX67594
C 130	14	0.8	17	1	AX688105	ACCESSION:AX688105	C 203	13.8	0.7	18	1	AR049397	ACCESSION:AR049397
C 131	14	0.8	17	1	AX733399	ACCESSION:AX733399	C 204	13.8	0.7	18	1	AR049649	ACCESSION:AR049649
C 132	14	0.8	17	1	AX733818	ACCESSION:AX733818	205	13.8	0.7	18	1	AR063241	ACCESSION:AR063241
C 133	14	0.8	17	1	AX733819	ACCESSION:AX733819	C 206	13.8	0.7	18	1	AR072949	ACCESSION:AR072949
C 134	14	0.8	17	1	AX733820	ACCESSION:AX733820	C 207	13.8	0.7	18	1	AR085610	ACCESSION:AR085610
C 135	14	0.8	17	1	AX733821	ACCESSION:AX733821	C 208	13.8	0.7	18	1	AR089732	ACCESSION:AR089732
C 136	14	0.8	17	1	AX733825	ACCESSION:AX733825	209	13.8	0.7	18	1	AR121149	ACCESSION:AR121149
C 137	14	0.8	17	1	AX733836	ACCESSION:AX733836	210	13.8	0.7	18	1	BD171756	ACCESSION:BD171756
C 138	14	0.8	17	1	AX733837	ACCESSION:AX733837	C 211	13.8	0.7	18	1	BD171760	ACCESSION:BD171760
C 139	14	0.8	17	1	AX733838	ACCESSION:AX733838	C 212	13.8	0.7	18	1	CQ795193	ACCESSION:CQ795193
C 140	14	0.8	18	1	166351	ACCESSION:166351	C 213	13.8	0.7	18	1	CQ807790	ACCESSION:CQ807790
C 141	14	0.8	18	1	AR564469	ACCESSION:AR564469	C 214	13.8	0.7	18	1	CQ876358	ACCESSION:CQ876358
C 142	13.8	0.7	17	1	AR168820	ACCESSION:AR168820	215	13.8	0.7	18	1	E29787	ACCESSION:E29787
C 143	13.8	0.7	17	1	BD198938	ACCESSION:BD198938	216	13.8	0.7	18	1	I21931	ACCESSION:I21931
C 144	13.8	0.7	17	1	BD201322	ACCESSION:BD201322	217	13.8	0.7	18	1	AR220082	ACCESSION:AR220082
C 145	13.8	0.7	17	1	CQ616796	ACCESSION:CQ616796	218	13.8	0.7	18	1	AR281858	ACCESSION:AR281858
C 146	13.8	0.7	17	1	CQ616797	ACCESSION:CQ616797	219	13.8	0.7	18	1	AR303208	ACCESSION:AR303208
C 147	13.8	0.7	17	1	CQ623620	ACCESSION:CQ623620	220	13.8	0.7	18	1	AR308314	ACCESSION:AR308314
C 148	13.8	0.7	17	1	CQ623621	ACCESSION:CQ623621	221	13.8	0.7	18	1	AR344645	ACCESSION:AR344645
C 149	13.8	0.7	17	1	CQ624832	ACCESSION:CQ624832	C 222	13.8	0.7	18	1	AR353533	ACCESSION:AR353533
C 150	13.8	0.7	17	1	AR188676	ACCESSION:AR188676	C 223	13.8	0.7	18	1	AR442110	ACCESSION:AR442110
C 151	13.8	0.7	17	1	AR188677	ACCESSION:AR188677	C 224	13.8	0.7	18	1	AR442224	ACCESSION:AR442224
C 152	13.8	0.7	17	1	AR188762	ACCESSION:AR188762	225	13.8	0.7	18	1	AR493061	ACCESSION:AR493061
C 153	13.8	0.7	17	1	AR190246	ACCESSION:AR190246	C 226	13.8	0.7	18	1	AX092726	ACCESSION:AX092726
C 154	13.8	0.7	17	1	AR190247	ACCESSION:AR190247	227	13.8	0.7	18	1	AX113887	ACCESSION:AX113887
C 155	13.8	0.7	17	1	AR190332	ACCESSION:AR190332	C 228	13.8	0.7	18	1	AX326905	ACCESSION:AX326905
C 156	13.8	0.7	17	1	AR192330	ACCESSION:AR192330	229	13.8	0.7	18	1	AX378472	ACCESSION:AX378472
C 157	13.8	0.7	17	1	AR192331	ACCESSION:AR192331	C 230	13.8	0.7	18	1	AX699211	ACCESSION:AX699211
C 158	13.8	0.7	17	1	AR200289	ACCESSION:AR200289	C 231	13.8	0.7	18	1	AX785466	ACCESSION:AX785466
C 159	13.8	0.7	17	1	AR262421	ACCESSION:AR262421	C 232	13.8	0.7	18	1	AX959634	ACCESSION:AX959634
C 160	13.8	0.7	17	1	AR324529	ACCESSION:AR324529	C 233	13.8	0.7	18	1	BD002174	ACCESSION:BD002174
C 161	13.8	0.7	17	1	AR324530	ACCESSION:AR324530	234	13.8	0.7	18	1	BD002275	ACCESSION:BD002275
C 162	13.8	0.7	17	1	AR324615	ACCESSION:AR324615	C 235	13.4	0.7	15	1	BD010879	ACCESSION:BD010879
C 163	13.8	0.7	17	1	AR325211	ACCESSION:AR325211	C 236	13.4	0.7	16	1	BD244856	ACCESSION:BD244856
C 164	13.8	0.7	17	1	AR325212	ACCESSION:AR325212	C 237	13.4	0.7	16	1	BD284438	ACCESSION:BD284438
C 165	13.8	0.7	17	1	AR326200	ACCESSION:AR326200	C 238	13.4	0.7	17	1	AX928000	ACCESSION:AX928000
C 166	13.8	0.7	17	1	AR326201	ACCESSION:AR326201	C 239	13.4	0.7	17	1	AR168840	ACCESSION:AR168840
C 167	13.8	0.7	17	1	AR328859	ACCESSION:AR328859	C 240	13.4	0.7	17	1	AR168847	ACCESSION:AR168847
C 168	13.8	0.7	17	1	AR402091	ACCESSION:AR402091	C 241	13.4	0.7	17	1	AR168850	ACCESSION:AR168850
C 169	13.8	0.7	17	1	AR457859	ACCESSION:AR457859	C 242	13.4	0.7	17	1	AR168851	ACCESSION:AR168851
C 170	13.8	0.7	17	1	AR457860	ACCESSION:AR457860	C 243	13.4	0.7	17	1	BD198937	ACCESSION:BD198937
C 171	13.8	0.7	17	1	AR464683	ACCESSION:AR464683	C 244	13.4	0.7	17	1	BD201049	ACCESSION:BD201049
C 172	13.8	0.7	17	1	AR464686	ACCESSION:AR464686	C 245	13.4	0.7	17	1	BD201115	ACCESSION:BD201115
C 173	13.8	0.7	17	1	AR465895	ACCESSION:AR465895	C 246	13.4	0.7	17	1	BD254875	ACCESSION:BD254875
C 174	13.8	0.7	17	1	AX217108	ACCESSION:AX217108	247	13.4	0.7	17	1	CQ616798	ACCESSION:CQ616798
C 175	13.8	0.7	17	1	AX226648	ACCESSION:AX226648	248	13.4	0.7	17	1	CQ616799	ACCESSION:CQ616799
C 176	13.8	0.7	17	1	AX255600	ACCESSION:AX255600	249	13.4	0.7	17	1	CQ623626	ACCESSION:CQ623626
C 177	13.8	0.7	17	1	AX421858	ACCESSION:AX421858	250	13.4	0.7	17	1	CQ623847	ACCESSION:CQ623847
C 178	13.8	0.7	17	1	AX423222	ACCESSION:AX423222	251	13.4	0.7	17	1	CQ623848	ACCESSION:CQ623848
C 179	13.8	0.7	17	1	AX423319	ACCESSION:AX423319	C 252	13.4	0.7	17	1	CQ625289	ACCESSION:CQ625289

C 253 13.4 0.7 17 1 C0625292
 C 254 13.4 0.7 17 1 E32474
 C 255 13.4 0.7 17 1 AR188763
 C 256 13.4 0.7 17 1 AR190333
 C 257 13.4 0.7 17 1 AR200309
 C 258 13.4 0.7 17 1 AR200316
 C 259 13.4 0.7 17 1 AR200319
 C 260 13.4 0.7 17 1 AR200320
 C 261 13.4 0.7 17 1 AR262440
 C 262 13.4 0.7 17 1 AR262447
 C 263 13.4 0.7 17 1 AR262450
 C 264 13.4 0.7 17 1 AR262451
 C 265 13.4 0.7 17 1 AR324616
 C 266 13.4 0.7 17 1 AR457861
 C 267 13.4 0.7 17 1 AR457862
 C 268 13.4 0.7 17 1 AR464689
 C 269 13.4 0.7 17 1 AR464910
 C 270 13.4 0.7 17 1 AR464911
 C 271 13.4 0.7 17 1 AR464912
 C 272 13.4 0.7 17 1 AR464912
 C 273 13.4 0.7 17 1 AR466352
 C 274 13.4 0.7 17 1 AR466355
 C 275 13.4 0.7 17 1 AR475031
 C 276 13.4 0.7 17 1 AR183650
 C 277 13.4 0.7 17 1 AR217109
 C 278 13.4 0.7 17 1 AR264296
 C 279 13.4 0.7 17 1 AR264297
 C 280 13.4 0.7 17 1 AR502942
 C 281 13.4 0.7 17 1 AR502943
 C 282 13.4 0.7 17 1 AR532149
 C 283 13.4 0.7 17 1 AR532150
 C 284 13.4 0.7 17 1 AR532151
 C 285 13.4 0.7 17 1 AR579854
 C 286 13.4 0.7 17 1 AR579854
 C 287 13.4 0.7 17 1 AR579854
 C 288 13.4 0.7 17 1 AR579854
 C 289 13.4 0.7 17 1 AR579854
 C 290 13.4 0.7 17 1 AR579854
 C 291 13.4 0.7 17 1 AR579854
 C 292 13.4 0.7 17 1 AR579854
 C 293 13.4 0.7 17 1 AR579854
 C 294 13.4 0.7 17 1 AR579854
 C 295 13.4 0.7 17 1 AR579854
 C 296 13.4 0.7 17 1 AR579854
 C 297 13.4 0.7 17 1 AR579854
 C 298 13.4 0.7 17 1 AR579854
 C 299 13.4 0.7 17 1 AR579854
 C 300 13.4 0.7 17 1 AR579854
 C 301 13.4 0.7 17 1 AR579854
 C 302 13.4 0.7 17 1 AR579854
 C 303 13.4 0.7 17 1 AR579854
 C 304 13.4 0.7 17 1 AR579854
 C 305 13.4 0.7 17 1 AR579854
 C 306 13.4 0.7 17 1 AR579854
 C 307 13.4 0.7 17 1 AR579854
 C 308 13.4 0.7 17 1 AR579854
 C 309 13.4 0.7 17 1 AR579854
 C 310 13.4 0.7 17 1 AR579854
 C 311 13.4 0.7 17 1 AR579854
 C 312 13.4 0.7 17 1 AR579854
 C 313 13.4 0.7 17 1 AR579854
 C 314 13.4 0.7 17 1 AR579854
 C 315 13.4 0.7 17 1 AR579854
 C 316 13.2 0.7 15 1 AR165194
 C 317 13.3 0.7 15 1 AR056166
 C 318 13.3 0.7 15 1 AR113924
 C 319 13.3 0.7 15 1 AR113924
 C 320 13.3 0.7 15 1 AR113924
 C 321 13.3 0.7 15 1 AR113924
 C 322 13.3 0.7 15 1 AR113924
 C 323 13.3 0.7 15 1 AR113924
 C 324 13.3 0.7 15 1 AR113924
 C 325 13.3 0.7 15 1 AR113924

C 326 13 0.7 17 1 AR168852
 C 327 13 0.7 17 1 BD241318
 C 328 13 0.7 17 1 BD254874
 C 329 13 0.7 17 1 CQ617849
 C 330 13 0.7 17 1 CQ617854
 C 331 13 0.7 17 1 AR200317
 C 332 13 0.7 17 1 AR200321
 C 333 13 0.7 17 1 AR262448
 C 334 13 0.7 17 1 AR262452
 C 335 13 0.7 17 1 AR365612
 C 336 13 0.7 17 1 AR401993
 C 337 13 0.7 17 1 AR458912
 C 338 13 0.7 17 1 AR458917
 C 339 13 0.7 17 1 AR482819
 C 340 13 0.7 17 1 AR482819
 C 341 13 0.7 17 1 AR482819
 C 342 13 0.7 17 1 AR482819
 C 343 13 0.7 17 1 AR482819
 C 344 13 0.7 17 1 AR482819
 C 345 13 0.7 17 1 AR482819
 C 346 13 0.7 17 1 AR482819
 C 347 13 0.7 17 1 AR482819
 C 348 13 0.7 17 1 AR482819
 C 349 13 0.7 17 1 AR482819
 C 350 13 0.7 17 1 AR482819
 C 351 13 0.7 17 1 AR482819
 C 352 13 0.7 17 1 AR482819
 C 353 13 0.7 17 1 AR482819
 C 354 13 0.7 17 1 AR482819
 C 355 13 0.7 17 1 AR482819
 C 356 13 0.7 17 1 AR482819
 C 357 13 0.7 17 1 AR482819
 C 358 13 0.7 17 1 AR482819
 C 359 13 0.7 17 1 AR482819
 C 360 13 0.7 17 1 AR482819
 C 361 13 0.7 17 1 AR482819
 C 362 13 0.7 17 1 AR482819
 C 363 13 0.7 17 1 AR482819
 C 364 13 0.7 17 1 AR482819
 C 365 12.8 0.7 17 1 AR482819
 C 366 12.8 0.7 17 1 AR482819
 C 367 12.8 0.7 17 1 AR482819
 C 368 12.8 0.7 17 1 AR482819
 C 369 12.8 0.7 17 1 AR482819

ALIGNMENTS

RESULT 1

BD106421/c

LOCUS

BD106421

29 bp DNA linear

PAT 18-SEP-2002

DEFINITION

Secreted proteins and polynucleotides encoding them.

ACCESSION

BD106421

VERSION

BD106421.1

KEYWORDS

JP 2002503955-A/12

SOURCE

Chlamydia sp.

ORGANISM

Bacteria; Chlamydiales; Chlamydiales; Chlamydia.

REFERENCE

1 (bases 1 to 29)

AUTHORS

Jacobson, K., McCoy, J.M., Lavallie, E.R., Racine, L.A., Merberg, D.,

Treacy, M., Spaulding, V. and Agostino, M.J.

TITLE

Secreted proteins and polynucleotides encoding them

JOURNAL

Patent: JP 2002503955-A 12 05-FEB-2002;

COMMENT

GENETICS INSTITUTE INC

PN JP 2002503955-A/12

PD 05-FEB-2002

PF 20-MAR-1998 JP 1998545874

PR 21-MAR-1997 US 08/822167, 19-MAR-1998 US 09/044466 PI

KENNETH JACOBS, JOHN M MCCOY, EDWARD R LAVALLIE, LISA A RACIE, PI

DAVID MERBERG,

PI MAURICE TREACY, VIKKI SPAULDING, MICHAEL J AGOSTINO PC

C12N15/12, C07K14/47, A61K38/17

```

CC Strandedness: Single;
CC Topology: Linear;
CC /desc="Oligonucleotide",
FH Key Location/Qualifiers.
FEATURES
    source
        1..29
            Location/Qualifiers
                /organism="Chlamydia sp."
                /mol_type="genomic DNA"
                /db_xref="taxon:35827"

Query Match
Best Local Similarity 1.5%; Score 28; DB 1; Length 29;
Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 295 GATTGGCACTCTCGTTGACTACTGTTGGA 323
Db 29 GATTGGCACTCTCGTTGACTACTGTTGNA 1

RESULT 2
AR562157/c
LOCUS AR562157 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 33 from patent US 6759215.
ACCESSION AR562157
VERSION AR562157.1 GI:53976020
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Method of preparing human stem cell factor polypeptide
JOURNAL Patent: US 6759215-A 33 06-JUL-2004;
FEATURES
    source
        1..20
            Location/Qualifiers
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match
Best Local Similarity 1.0%; Score 18.4; DB 1; Length 20;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1832 CTGAAAAAATAAAAAAAAAA 1851
Db 20 CTAAAAAATAAAAAAAAAA 1

RESULT 3
AR562158/c
LOCUS AR562158 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 34 from patent US 6759215.
ACCESSION AR562158
VERSION AR562158.1 GI:53976021
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Method of preparing human stem cell factor polypeptide
JOURNAL Patent: US 6759215-A 34 06-JUL-2004;
FEATURES
    source
        1..20
            Location/Qualifiers
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match
Best Local Similarity 1.0%; Score 18; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAATAAAAAAAAAA 1851
Db 19 GAAAAAATAAAAAAAAAA 2

RESULT 4
A69549/c
LOCUS A69549 23 bp DNA linear PAT 07-MAY-1999
DEFINITION Sequence 11 from Patent WO9805762.
ACCESSION A69549
VERSION A69549.1 GI:4774190
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 23)
AUTHORS Fischer,S. and Kohnert,U.
TITLE PLASMINOGEN ACTIVATOR CAPABLE OF BEING ACTIVATED BY THROMBIN
JOURNAL Patent: WO 9805762-A 11 12-FEB-1998;
FEATURES
    source
        1..23
            Location/Qualifiers
                /organism="unidentified"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32644"

Query Match
Best Local Similarity 1.0%; Score 17.8; DB 1; Length 23;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1263 ATGAGCCTCTGCGAGCCCTC 1283
Db 22 ATGAGCCTCTGCGAGCGCTC 2

RESULT 5
AR528447/c
LOCUS AR528447 19 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 85 from patent US 6723897.
ACCESSION AR528447
VERSION AR528447.1 GI:53916512
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Brown,S.M., Elich,T.D., Heck,G.R., Kishore,G.M., Logusch,E.W.,
Logusch,S.J., Piller,K.J., Rao,S., Ream,J.E. and Baerson,S.R.
TITLE Methods for controlling gibberellin levels
JOURNAL Patent: US 6723897-A 85 20-APR-2004;
FEATURES
    source
        1..19
            Location/Qualifiers
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.9%; Score 17.2; DB 1; Length 19;
Matches 17; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAATAAAAAAAAAA 1851
Db 19 BAAAAAATAAAAAAAAAA 2

RESULT 6
AR541350/c
LOCUS AR541350 19 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 15 from patent US 6737520.
ACCESSION AR541350
VERSION AR541350.1 GI:53932997
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.

```

TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 15 18-MAY-2004;
FEATURES Location/Qualifiers
source 1. 19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
| | | | | | | | | | | | | | | | | | | | |
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 7
AR541351/c AR541351 19 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 16 from patent US 6737520.
DEFINITION AR541351
ACCESSION AR541351
VERSION AR541351.1 GI:53932998
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 16 18-MAY-2004;
FEATURES Location/Qualifiers
source 1. 19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
| | | | | | | | | | | | | | | | | | | | |
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 8
AR541352/c AR541352 19 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 17 from patent US 6737520.
DEFINITION AR541352
ACCESSION AR541352
VERSION AR541352.1 GI:53932999
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 17 18-MAY-2004;
FEATURES Location/Qualifiers
source 1. 19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
| | | | | | | | | | | | | | | | | | | | |
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 9
AR541353/c AR541353 19 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 18 from patent US 6737520.
DEFINITION AR541353
ACCESSION AR541353
VERSION AR541353.1 GI:53933000
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 18 18-MAY-2004;
FEATURES Location/Qualifiers
source 1. 19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
| | | | | | | | | | | | | | | | | | | | |
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 10
AR541361/c AR541361 19 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 26 from patent US 6737520.
DEFINITION AR541361
ACCESSION AR541361
VERSION AR541361.1 GI:53933008
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 26 18-MAY-2004;
FEATURES Location/Qualifiers
source 1. 19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
| | | | | | | | | | | | | | | | | | | | |
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 11
AR532682 AR532682 20 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 55 from patent US 6730269.
DEFINITION AR532682
ACCESSION AR532682
VERSION AR532682.1 GI:53922053
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J., Elghanian,R. and Taton,T.A.

```

TITLE      Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL    Patent: US 6730269-A 55 04-MAY-2004;
FEATURES   Location/Qualifiers
           source
           1. .20
           /organism="unknown"
           /mol_type="genomic DNA"

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1835 AAAAAAAAAAAAAAAAAA 1851
Db      1 AAAAAAAAAAAAAAAAAA 17

RESULT 12
AR559396
LOCUS      AR559396                20 bp    DNA          linear    PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6750016.
ACCESSION  AR559396
VERSION     AR559396.1 GI:53968812
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Mirkin,C.A., Letsinger,R.L. and Park,S.-J.
TITLE       Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL    Patent: US 6750016-A 55 15-JUN-2004;
FEATURES   Location/Qualifiers
           source
           1. .20
           /organism="unknown"
           /mol_type="genomic DNA"

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1835 AAAAAAAAAAAAAAAAAA 1851
Db      1 AAAAAAAAAAAAAAAAAA 17

RESULT 13
AR559411
LOCUS      AR559411                20 bp    DNA          linear    PAT 08-OCT-2004
DEFINITION Sequence 70 from patent US 6750016.
ACCESSION  AR559411
VERSION     AR559411.1 GI:53968827
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Mirkin,C.A., Letsinger,R.L. and Park,S.-J.
TITLE       Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL    Patent: US 6750016-A 70 15-JUN-2004;
FEATURES   Location/Qualifiers
           source
           1. .20
           /organism="unknown"
           /mol_type="genomic DNA"

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1835 AAAAAAAAAAAAAAAAAA 1851
Db      1 AAAAAAAAAAAAAAAAAA 17

TITLE      Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL    Patent: US 6730269-A 55 04-MAY-2004;
FEATURES   Location/Qualifiers
           source
           1. .20
           /organism="unknown"
           /mol_type="genomic DNA"

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1835 AAAAAAAAAAAAAAAAAA 1851
Db      1 AAAAAAAAAAAAAAAAAA 17

```

```

RESULT 14
AR561993
LOCUS      AR561993                20 bp    DNA          linear    PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6759199.
ACCESSION  AR561993
VERSION     AR561993.1 GI:53975645
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J.,
Elghanian,R. and Taton,T.A.
TITLE       Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL    Patent: US 6759199-A 55 06-JUL-2004;
FEATURES   Location/Qualifiers
           source
           1. .20
           /organism="unknown"
           /mol_type="genomic DNA"

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1835 AAAAAAAAAAAAAAAAAA 1851
Db      1 AAAAAAAAAAAAAAAAAA 17

RESULT 15
AR562156/c
LOCUS      AR562156                20 bp    DNA          linear    PAT 08-OCT-2004
DEFINITION Sequence 32 from patent US 6759215.
ACCESSION  AR562156
VERSION     AR562156.1 GI:53976019
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Zsebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE       Method of preparing human stem cell factor polypeptide
JOURNAL    Patent: US 6759215-A 32 06-JUL-2004;
FEATURES   Location/Qualifiers
           source
           1. .20
           /organism="unknown"
           /mol_type="genomic DNA"

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1835 AAAAAAAAAAAAAAAAAA 1851
Db      18 AAAAAAAAAAAAAAAAAA 2

RESULT 16
AR565165
LOCUS      AR565165                20 bp    DNA          linear    PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6767702.
ACCESSION  AR565165
VERSION     AR565165.1 GI:53981003
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J.,
Elghanian,R., Taton,T.A., Garimella,V. and Li,Z.

```



```

TITLE      Nanoparticles having oligonucleotides attached thereto and uses
JOURNAL    therefor
PATENT     Patent: US 6767702-A 55 27-JUL-2004;
FEATURES   Location/Qualifiers
SOURCE     1..20
           /organism="unknown"
           /mol_type="genomic DNA"

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1851
Db 1 AAAAAAAAAAAAAA 17

RESULT 17
LOCUS   AR292366/c
DEFINITION Sequence 4101 from patent US 6537751.
ACCESSION AR292366
VERSION   AR292366.1 GI:31679650
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS  Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE    Balleic markers for use in constructing a high density
JOURNAL  disequilibrium map of the human genome
PATENT   Patent: US 6537751-A 4101 25-MAR-2003;
FEATURES Location/Qualifiers
SOURCE   1..18
           /organism="unknown"
           /mol_type="genomic DNA"

Query Match      0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 730 CCATCTACAGTCCTCACA 747
Db 18 CCATCTACATTCCTCACA 1

RESULT 18
LOCUS   CQ882062
DEFINITION Sequence 3 from Patent WO2004083232.
ACCESSION CQ882062
VERSION   CQ882062.1 GI:54034772
KEYWORDS
SOURCE   synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS  Pettipher,R.
TITLE    Receptor proteins
JOURNAL  Patent: WO 2004083232-A 3 30-SEP-2004;
          Oxagen Limited (GB)
FEATURES Location/Qualifiers
SOURCE   1..20
           /organism="synthetic construct"
           /mol_type="unassigned DNA"
           /db_xref="taxon:32630"
           /note="PRIMER/OLIGONUCLEOTIDE"

Query Match      0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 62;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1411 ACACCATGACTGTCATGG 1428

```

```

Db 2 ACACCGTGAAGTCATGG 19
||||| ||||| ||||| |||||
AR312535 20 bp DNA linear PAT 12-JUN-2003
LOCUS   Sequence 3072 from patent US 6559294.
DEFINITION AR312535
ACCESSION AR312535
VERSION   AR312535.1 GI:31705961
KEYWORDS
SOURCE   Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS  Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
          Sankaran,B. and Fletcher,L.D.
TITLE    Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL  Patent: US 6559294-A 3072 06-MAY-2003;
FEATURES Location/Qualifiers
SOURCE   1..20
           /organism="unknown"
           /mol_type="genomic DNA"

Query Match      0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 62;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1612 TCATCTTCAAAGCACAC 1629
Db 19 TCATCTTCAAAGCACAC 2

RESULT 20
LOCUS   DOGVWFB/c
DEFINITION Canis familiaris von Willebrand's factor (VWF) STS DNA, 3' primer,
          sequence tagged site.
ACCESSION L77431
VERSION   L77431.1 GI:1261792
KEYWORDS  STS; PCR identification; PCR primer; sequence tagged site;
          universal mammalian STS; von Willebrand factor.
SOURCE   Canis familiaris (dog)
ORGANISM Canis familiaris
REFERENCE 1 (bases 1 to 20)
AUTHORS  Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
TITLE    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Vento,P.J., Brouillette,J.A., Yuzbasiyan-Gurkan,V. and Brewer,G.J.
JOURNAL  Gene-specific universal mammalian sequence-tagged sites:
          application to the canine genome
COMMENT   Unpublished (1996)
          Original source text: Canis familiaris DNA.
          Gene-specific universal mammalian sequence-tagged site for VWF.
          Primer for the 3' end is in exon 47. Human product is 650 bp.
          Canine product is 650 bp.
          PCR conditions: 1 min, 94 C, 2 min, 57 C, 3 min, 72 C, 35 cycles.
FEATURES Location/Qualifiers
SOURCE   1..20
           /organism="Canis familiaris"
           /mol_type="genomic DNA"
           /db_xref="taxon:9615"

primer_bind 1..20
            /note="PCR primer binding site"
            /evidence=experimental

STS 1..20

Query Match      0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 62;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1333 GGATCCAGCTGGAGTGC 1350
Db 20 GGATTCAGCTGGAGTGC 3

```

```
RESULT 21
AR084578
LOCUS
DEFINITION
Sequence 67 from patent US 5981185.
AR084578
ACCESSION
AR084578.1 GI:10011349
VERSION
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 21)
AUTHORS
Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE
Oligonucleotide repeat arrays
JOURNAL
Patent: US 5981185-A 67 09-NOV-1999;
FEATURES
Location/Qualifiers
source
1. .21
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.9%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 28 GCGCCTCCGTCGCGCGGTC 48
Db 21 GCGCGCGCGCGCGCGCGCC 1

RESULT 24
AR526824
LOCUS
DEFINITION
Sequence 32 from patent US 6723506.
AR526824
ACCESSION
AR526824.1 GI:53913647
VERSION
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 21)
AUTHORS
Fletcher,J.A. and Kroll,T.G.
TITLE
Method of identifying PAX8-PPAR gamma-nucleic acid molecules
JOURNAL
Patent: US 6723506-A 32 20-APR-2004;
FEATURES
Location/Qualifiers
source
1. .21
/mol_type="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.9%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 886 ACCGATGACTGATTCCTTCA 906
Db 1 ACCGAGAAAGCGATTCCTTCA 21

RESULT 25
AX922788
LOCUS
DEFINITION
Sequence 1128 from Patent WO02068649.
AX922788
ACCESSION
AX922788.1 GI:40215778
VERSION
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Patent: WO 02068649-A 1128 06-SEP-2002;
JOURNAL
Curagen Corporation (US)
FEATURES
Location/Qualifiers
source
1. .21
/mol_type="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Description of Artificial Sequence: Ag712 Reverse"

Query Match
Best Local Similarity 0.9%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1441 TGAATGTTGCTGCTGCTTT 1461
Db 1 TGAATGTTGCTGCTGCTTCT 21

RESULT 26
AR093142/c
LOCUS
DEFINITION
Sequence 11 from patent US 5998596.
AR093142
ACCESSION
AR093142.1 GI:10019894
VERSION
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 21)
AUTHORS
Bergan,R. and Neckers,L.
TITLE
Inhibition of protein kinase activity by aptameric action of
oligonucleotides
JOURNAL
Patent: US 5998596-A 11 07-DEC-1999;
```

```
FEATURES
source
Location/Qualifiers
1. .21
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.9%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 28 GCGCCTCCGTCGCGCGGTC 48
Db 21 GCGCGCGCGCGCGCGCGCC 1

RESULT 24
AR526824
LOCUS
DEFINITION
Sequence 32 from patent US 6723506.
AR526824
ACCESSION
AR526824.1 GI:53913647
VERSION
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 21)
AUTHORS
Fletcher,J.A. and Kroll,T.G.
TITLE
Method of identifying PAX8-PPAR gamma-nucleic acid molecules
JOURNAL
Patent: US 6723506-A 32 20-APR-2004;
FEATURES
Location/Qualifiers
source
1. .21
/mol_type="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.9%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 886 ACCGATGACTGATTCCTTCA 906
Db 1 ACCGAGAAAGCGATTCCTTCA 21

RESULT 25
AX922788
LOCUS
DEFINITION
Sequence 1128 from Patent WO02068649.
AX922788
ACCESSION
AX922788.1 GI:40215778
VERSION
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Patent: WO 02068649-A 1128 06-SEP-2002;
JOURNAL
Curagen Corporation (US)
FEATURES
Location/Qualifiers
source
1. .21
/mol_type="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Description of Artificial Sequence: Ag712 Reverse"

Query Match
Best Local Similarity 0.9%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1441 TGAATGTTGCTGCTGCTTT 1461
Db 1 TGAATGTTGCTGCTGCTTCT 21

RESULT 26
AR093142/c
LOCUS
DEFINITION
Sequence 11 from patent US 5998596.
AR093142
ACCESSION
AR093142.1 GI:10019894
VERSION
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 21)
AUTHORS
Bergan,R. and Neckers,L.
TITLE
Inhibition of protein kinase activity by aptameric action of
oligonucleotides
JOURNAL
Patent: US 5998596-A 11 07-DEC-1999;
```

AR561628 AR561628 16 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 1 from patent US 6756492.
DEFINITION
ACCESSION AR561628
VERSION AR561628.1 GI:53974736
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Beier, M. and Honeiseil, J.
TITLE Nucleoside derivatives with photo-unstable protective groups
JOURNAL Patent: US 6756492-A 1 29-JUN-2004;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.9%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 48;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1835 AAAAAAAAAAAAAA 1850
Db 1 AAAAAAAAAAAAAA 16
RESULT 27
AR561693/c
LOCUS AR561693 16 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 9 from patent US 6759039.
ACCESSION AR561693
VERSION AR561693.1 GI:53974843
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Tsang, W.-G., Zheng, T. and Huang, C.J.
TITLE Culturing pancreatic stem cells having a specified, intermediate stage of development
JOURNAL Patent: US 6759039-A 9 06-JUL-2004;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.9%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 48;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1835 AAAAAAAAAAAAAA 1850
Db 16 AAAAAAAAAAAAAA 1
RESULT 28
AX129261/c
LOCUS AX129261 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 479 from Patent WO0130362.
ACCESSION AX129261
VERSION AX129261.1 GI:14135566
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Robbins, J.M. and Tritz, R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 479 03-MAY-2001;
FEATURES IMMUSOL, INC. (US)

AR561628 AR561628 16 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 1 from patent US 6756492.
DEFINITION
ACCESSION AR561628
VERSION AR561628.1 GI:53974736
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Beier, M. and Honeiseil, J.
TITLE Nucleoside derivatives with photo-unstable protective groups
JOURNAL Patent: US 6756492-A 1 29-JUN-2004;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.9%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 48;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1835 AAAAAAAAAAAAAA 1850
Db 1 AAAAAAAAAAAAAA 16
RESULT 27
AR561693/c
LOCUS AR561693 16 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 9 from patent US 6759039.
ACCESSION AR561693
VERSION AR561693.1 GI:53974843
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Tsang, W.-G., Zheng, T. and Huang, C.J.
TITLE Culturing pancreatic stem cells having a specified, intermediate stage of development
JOURNAL Patent: US 6759039-A 9 06-JUL-2004;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.9%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 48;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1835 AAAAAAAAAAAAAA 1850
Db 16 AAAAAAAAAAAAAA 1
RESULT 28
AX129261/c
LOCUS AX129261 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 479 from Patent WO0130362.
ACCESSION AX129261
VERSION AX129261.1 GI:14135566
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Robbins, J.M. and Tritz, R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 479 03-MAY-2001;
FEATURES IMMUSOL, INC. (US)

FEATURES source Location/Qualifiers
1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cdk4 ribozyme binding site"
Query Match 0.9%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 66;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1095 TGGACTGCAGAGAAC 1110
Db 19 TGGACTGCAGAGAAC 4
RESULT 29
AR241724/c
LOCUS AR241724 19 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 12 from patent US 6472154.
ACCESSION AR241724
VERSION AR241724.1 GI:27287536
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Garner, H.R., Wren, J.D., Minna, J.D. and Fondon, J.W. III.
TITLE Polymorphic repeats in human genes
JOURNAL Patent: US 6472154-A 12 29-OCT-2002;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1516 AGAAACAGTAAGAAAGAAA 1534
Db 19 AGAAAGAAAGAAAGAAA 1
RESULT 30
AX131832/c
LOCUS AX131832 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 3050 from Patent WO0130362.
ACCESSION AX131832
VERSION AX131832.1 GI:14138137
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Robbins, J.M. and Tritz, R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 3050 03-MAY-2001;
FEATURES IMMUSOL, INC. (US)
source 1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin A1 ribozyme binding site"
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 436 GGGAGAGGGGAGAGAAATC 454

```

Db      19  GCGAGAGGAGATGAATC 1
|||||
AX131833      19 bp  DNA  linear  PAT 15-MAY-2001
LOCUS
DEFINITION Sequence 3051 from Patent WO0130362.
ACCESSION AX131833
VERSION AX131833.1 GI:14138138
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 3051 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
    source
        1..19
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
            /note="Cyclin A1 ribozyme binding site"
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      434  CTGGGAGAGGGGAGAGAA 452
|||||
Db      19  CTGGGAGAGGAGAGATGAA 1

RESULT 32
BD272150      20 bp  DNA  linear  PAT 17-JUL-2003
LOCUS
DEFINITION Nucleic acid sequences to proteins involved in isoprenoid
synthesis.
ACCESSION BD272150
VERSION BD272150.1 GI:33081918
KEYWORDS JP 2002541851-A/7.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Kishore,G.M., Boronat,A. and Campos,N.
TITLE Nucleic acid sequences to proteins involved in isoprenoid synthesis
JOURNAL Patent: JP 2002541851-A 7 10-DEC-2002;
CALGENE LLC
COMMENT OS Artificial Sequence
PN JP 2002541851-A/7
PD 10-DEC-2002
PF 14-APR-2000 JP 2000612468
PR 15-APR-1999 US 60/129899,30-JUL-1999 US 60/146461 PI
GANESH M KISHORE,ALBERT BORONAT,NARSISKO CAMPOS PC
C12N15/09,A01H5/00,C12N5/10//C12N9/90,C12N15/00,C12N5/00 CC
Synthetic Oligonucleotide
FH Key Location/Qualifiers
FT source 1..20
    /organism="Artificial Sequence".
FEATURES
    source
        1..20
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 78;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db      19  GCGAGAGGAGAGATGAATC 1
|||||
AX131833      19 bp  DNA  linear  PAT 15-MAY-2001
LOCUS
DEFINITION Sequence 3051 from Patent WO0130362.
ACCESSION AX131833
VERSION AX131833.1 GI:14138138
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 3051 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
    source
        1..19
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
            /note="Cyclin A1 ribozyme binding site"
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1244  GCGCATCATGGAGGAGGTT 1262
|||||
Db      1  GCGCATGCTGGAGGAGGTT 19
|||||

RESULT 33
I15679      20 bp  DNA  linear  PAT 02-APR-1996
LOCUS
DEFINITION Sequence 16 from patent US 5470719.
ACCESSION I15679
VERSION I15679.1 GI:1250587
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Meng,S.-Y., Morris,C.F. and Tsai,L.B.
TITLE Modified OmpA signal sequence for enhanced secretion of polypeptides
JOURNAL Patent: US 5470719-A 16 28-NOV-1995;
FEATURES
    Location/Qualifiers
        source
            1..20
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 78;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1680  TGATTTCTAGAAAAAGGAAT 1698
|||||
Db      2  TGATTTCTAGAGGAGGAAT 20
|||||

RESULT 34
I36684      20 bp  DNA  linear  PAT 13-MAY-1997
LOCUS
DEFINITION Sequence 16 from patent US 5608036.
ACCESSION I36684
VERSION I36684.1 GI:2086509
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Meng,S.-Y., Morris,C.F. and Tsai,L.B.
TITLE Enhanced secretion of polypeptides
JOURNAL Patent: US 5608036-A 16 04-MAR-1997;
FEATURES
    Location/Qualifiers
        source
            1..20
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 78;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1680  TGATTTCTAGAAAAAGGAAT 1698
|||||
Db      2  TGATTTCTAGAGGAGGAAT 20
|||||

RESULT 35
AR315632/c      20 bp  DNA  linear  PAT 12-JUN-2003
LOCUS
DEFINITION Sequence 6169 from patent US 6559294.
ACCESSION AR315632
VERSION AR315632.1 GI:31709058
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.

```

REFERENCE 1 (bases 1 to 20)
AUTHORS Griffais,R., Hotseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
Sankaran,B. and Fletcher,L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 6169 06-MAY-2003;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 78;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1440 ATGAATGTTGCTGCTGCTG 1458
Db 19 ATGATTGTTGCTGCTGCTG 1

RESULT 36
LOCUS AX040095 20 bp DNA linear PAT 18-NOV-2000
DEFINITION Sequence 8 from Patent WO0063389.
ACCESSION AX040095
VERSION AX040095.1 GI:11230056
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Kishore,G.M., Boronati,A., Bhat,B.G. and Rangwala,S.H.
TITLE Nucleic acid sequences to proteins involved in isoprenoid synthesis
JOURNAL Patent: WO 0063389-A 8 26-OCT-2000;
Calgene LLC (US)
FEATURES Location/Qualifiers
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic Oligonucleotide"

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 78;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1244 GGCCATCATGCGAGGCTT 1262
Db 1 GGCCATGCTGGAGGCTT 19

RESULT 37
LOCUS AX956227/C 20 bp DNA linear PAT 08-JAN-2004
DEFINITION Sequence 134 from Patent WO03093505.
ACCESSION AX956227
VERSION AX956227.1 GI:40784753
KEYWORDS Mus musculus (house mouse).
SOURCE Mus musculus
ORGANISM Mus musculus

REFERENCE 1
AUTHORS Mouthon,F., Nouvel,V. and Deslys,J.P.
TITLE Method for determining the presence of an unconventional transmissible agent responsible for transmissible subacute spongiform encephalopathy
JOURNAL Patent: WO 03093505-A 134 13-NOV-2003;
COMMISSARIAT A L'ENERGIE ATOMIQUE (FR)
FEATURES Location/Qualifiers
source
1..20
/organism="Mus musculus"
/mol_type="unassigned DNA"

REFERENCE 1 (bases 1 to 21)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 52 09-NOV-1999;
FEATURES Location/Qualifiers
source
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCTTCCTCGCGCCGCG 46
Db 3 GCCGCGCGCGCGCGCGCG 21

RESULT 39
LOCUS AR084566 21 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 55 from patent US 5981185.
ACCESSION AR084566
VERSION AR084566.1 GI:10011337
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 55 09-NOV-1999;
FEATURES Location/Qualifiers
source
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCTTCCTCGCGCCGCG 46
Db 2 GCCGCGCGCGCGCGCGCG 20

RESULT 40
LOCUS AR084567/C 21 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 56 from patent US 5981185.
ACCESSION AR084567
VERSION AR084567.1 GI:10011338

/db_xref="taxon:10090"

Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 78;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1240 CCAGGCGCATCATGAGGA 1258
Db 20 CCAGGCGTATCATGAGGA 2

RESULT 38
LOCUS AR084563 21 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 52 from patent US 5981185.
ACCESSION AR084563
VERSION AR084563.1 GI:10011334
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 52 09-NOV-1999;
FEATURES Location/Qualifiers
source
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCTTCCTCGCGCCGCG 46
Db 3 GCCGCGCGCGCGCGCGCG 21

RESULT 39
LOCUS AR084566 21 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 55 from patent US 5981185.
ACCESSION AR084566
VERSION AR084566.1 GI:10011337
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 55 09-NOV-1999;
FEATURES Location/Qualifiers
source
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCTTCCTCGCGCCGCG 46
Db 2 GCCGCGCGCGCGCGCGCG 20

RESULT 40
LOCUS AR084567/C 21 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 56 from patent US 5981185.
ACCESSION AR084567
VERSION AR084567.1 GI:10011338

```
KEYWORDS      .
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 21)
AUTHORS       Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE         Oligonucleotide repeat arrays
JOURNAL       Patent: US 5981185-A 56 09-NOV-1999;
FEATURES      Location/Qualifiers
               source
               1..21
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match   0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTGCGCGCCG 46
Db 19 GCCGCCTCCGTGCGCGCCG 1

RESULT 41
LOCUS         AR084579/c
DEFINITION    Sequence 68 from patent US 5981185.
ACCESSION     AR084579
VERSION       AR084579.1 GI:10011350
KEYWORDS      .
SOURCE        Unknown.
ORGANISM      Unclassified.
REFERENCE     1 (bases 1 to 21)
AUTHORS       Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE         Oligonucleotide repeat arrays
JOURNAL       Patent: US 5981185-A 68 09-NOV-1999;
FEATURES      Location/Qualifiers
               source
               1..21
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match   0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTGCGCGCCG 46
Db 19 GCCGCCTCCGTGCGCGCCG 1

RESULT 42
LOCUS         CQ830490
DEFINITION    Sequence 2 from Patent WO2004055153.
ACCESSION     CQ830490
VERSION       CQ830490.1 GI:50250830
KEYWORDS      .
SOURCE        synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE     1
AUTHORS       Schluesener,H. and Wendel,H.P.
TITLE         Devices coated with substances that mediate the adhesion of
               biological material
JOURNAL       Patent: WO 2004055153-A 2 01-JUL-2004;
               Eberhard-Karls-Universitaet Tuebingen (DE)
FEATURES      Location/Qualifiers
               source
               1..21
               /organism="synthetic construct"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32630"
               /note="Nukleotidsequenz"

Query Match   0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTGCGCGCCG 46
Db 20 GCCGCCTCCGTGCGCGCCG 2

RESULT 43
LOCUS         CQ830491/c
DEFINITION    Sequence 3 from Patent WO2004055153.
ACCESSION     CQ830491
VERSION       CQ830491.1 GI:50250831
KEYWORDS      .
SOURCE        synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE     1
AUTHORS       Schluesener,H. and Wendel,H.P.
TITLE         Devices coated with substances that mediate the adhesion of
               biological material
JOURNAL       Patent: WO 2004055153-A 3 01-JUL-2004;
               Eberhard-Karls-Universitaet Tuebingen (DE)
FEATURES      Location/Qualifiers
               source
               1..21
               /organism="synthetic construct"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32630"
               /note="Nukleotidsequenz"

Query Match   0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTGCGCGCCG 46
Db 20 GCCGCCTCCGTGCGCGCCG 2

RESULT 44
LOCUS         CQ830492/c
DEFINITION    Sequence 4 from Patent WO2004055153.
ACCESSION     CQ830492
VERSION       CQ830492.1 GI:50250832
KEYWORDS      .
SOURCE        synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE     1
AUTHORS       Schluesener,H. and Wendel,H.P.
TITLE         Devices coated with substances that mediate the adhesion of
               biological material
JOURNAL       Patent: WO 2004055153-A 4 01-JUL-2004;
               Eberhard-Karls-Universitaet Tuebingen (DE)
FEATURES      Location/Qualifiers
               source
               1..21
               /organism="synthetic construct"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32630"
               /note="Nukleotidsequenz"

Query Match   0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTGCGCGCCG 46
Db 19 GCCGCCTCCGTGCGCGCCG 1
```

```

RESULT 45
LOCUS AX203496 21 bp DNA linear PAT 30-AUG-2001
DEFINITION Sequence 126 from Patent WO0153520.
ACCESSION AX203496
VERSION AX203496.1 GI:15392907
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
AUTHORS Homo sapiens
TITLE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
JOURNAL Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
FEATURES
source
1. Cullen, P. and Seedorf, U.
2. Gene chip for neonate screening
3. Patent: WO 0153520-A 126 26-JUL-2001;
4. Cullen, Paul (DE) ; Seedorf, Udo (DE)
Location/Qualifiers
1. .21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 197 TGAAGAAATAAAGAGAA 215
Db 3 TGAAGAAATTAACGAGAA 21

RESULT 46
LOCUS BD056667/c 21 bp DNA linear PAT 27-AUG-2002
DEFINITION Method to diagnose and treat pathological conditions resulting from
ACCESSION BD056667
VERSION BD056667.1 GI:22602273
KEYWORDS JP 2001508291-A/124.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS other sequences; artificial sequences.
TITLE 1. (bases 1 to 21)
JOURNAL Lifton, R.P. and Simon, D.B.
COMMENT Method to diagnose and treat pathological conditions resulting from
deficient ion transport
Patent: JP 2001508291-A 124 26-JUN-2001;
YALE UNIVERSITY
OS Artificial Sequence
PN JP 2001508291-A/124
PD 26-JUN-2001
PF 19-DEC-1997 JP 1998530123
PR 31-DEC-1996 US 08/778052
PI RICHARD P LIFTON, DAVID B SIMON
PC C12N15/09, C07K14/435, C07K16/00, C12N1/15, C12N1/19, C12N1/21, PC
C12N5/10,
PC C12P21/02, C12P01/68, G01N33/53, C12N15/00, C12N5/00 CC Primer
for analysis of human ROMK gene
FH Key Location/Qualifiers
source
1. .21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 961 GTGGACATCTGGACGCTG 979
Db 21 GTGGACATCTGGACACGG 3

RESULT 47
LOCUS AX725153 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2840 from Patent WO03025176.
ACCESSION AX725153
VERSION AX725153.1 GI:30504496
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
JOURNAL reversion, apoptosis and/or virus resistance and their use as
FEATURES medicines
source
1. Patent: WO 03025176-A 2840 27-MAR-2003;
2. Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 68;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1428 GATCCAAAGCAGATGAA 1444
Db 1 GATCCAAATCAGATGAA 17

RESULT 48
LOCUS AX727863/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5550 from Patent WO03025176.
ACCESSION AX727863
VERSION AX727863.1 GI:30507206
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
JOURNAL Telerman, A., Amson, R. and Tuijnder, M.
COMMENT Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
Patent: WO 03025176-A 5550 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 68;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1040 CTCACCTATTAAAGATC 1056
Db 17 CTCGCTTATTAAAGATC 1

RESULT 49
LOCUS AX733002/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4636 from Patent WO03025175.
ACCESSION AX733002
VERSION AX733002.1 GI:30512345

```

```
KEYWORDS      Homo sapiens (human)
SOURCE
ORGANISM      Homo sapiens
               Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Telesman,A., Anson,R. and Tuijinder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
               reversion, apoptosis and/or virus resistance and their use as
               medicines
JOURNAL      Patent: WO 03025175-A 4636 27-MAR-2003;
               Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 68;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      832 TGGCTTCTCTCATGGGATC 848
Db      17 TGGCTTCTCTTGGGATC 1

RESULT 50
LOCUS      A67588      18 bp      DNA      linear      PAT 05-MAY-1999
DEFINITION Sequence 8 from Patent WO9744485.
ACCESSION  A67588
VERSION    A67588.1 GI:4756451
KEYWORDS   unidentified
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS    Goodfellow,P.N.
TITLE      METHODS FOR IDENTIFYING A MUTATION IN A GENE OF INTEREST
JOURNAL    Patent: WO 9744485-A 8 27-NOV-1997;
               HEXAGEN TECHNOLOGY LIMITED (GB)
FEATURES
source
1. .18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match      0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      30 CGCCTCCGTCGCGCCG 46
Db      18 CGCGCGCGTCGCGCCG 2

RESULT 51
LOCUS      AR035168      18 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 28 from patent US 5871730.
ACCESSION  AR035168
VERSION    AR035168.1 GI:5951836
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS    Brzezinski,R., Dery,C.V. and Beaulieu,C.
TITLE      Thermostable xylanase DNA, protein and methods of use
JOURNAL    Patent: US 5871730-A 28 16-FEB-1999;
               Location/Qualifiers
FEATURES
source
1. .18

KEYWORDS      Homo sapiens (human)
SOURCE
ORGANISM      Homo sapiens
               Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Telesman,A., Anson,R. and Tuijinder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
               reversion, apoptosis and/or virus resistance and their use as
               medicines
JOURNAL      Patent: WO 03025175-A 4636 27-MAR-2003;
               Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 68;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      832 TGGCTTCTCTCATGGGATC 848
Db      17 TGGCTTCTCTTGGGATC 1

RESULT 52
LOCUS      AR089726/c      18 bp      DNA      linear      PAT 07-SEP-2000
DEFINITION Sequence 8 from patent US 5994075.
ACCESSION  AR089726
VERSION    AR089726.1 GI:10016481
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS    Goodfellow,P.N.
TITLE      Methods for identifying a mutation in a gene of interest without a
               phenotypic guide
JOURNAL    Patent: US 5994075-A 8 30-NOV-1999;
               Location/Qualifiers
FEATURES
source
1. .18
/organism="unassigned DNA"
/mol_type="unassigned DNA"

Query Match      0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      30 CGCCTCCGTCGCGCCG 46
Db      18 CGCGCGCGTCGCGCCG 2

RESULT 53
LOCUS      CQ786327      18 bp      DNA      linear      PAT 24-MAR-2004
DEFINITION Sequence 135 from Patent WO2004020668.
ACCESSION  CQ786327
VERSION    CQ786327.1 GI:45721429
KEYWORDS   synthetic construct
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1
AUTHORS    Nakamura,Y. and Katagiri,T.
TITLE      Method for treating synovial sarcoma
JOURNAL    Patent: WO 2004020668-A 135 11-MAR-2004;
               Oncotherapy Science, Inc. (JP); The University of Tokyo (JP)
FEATURES
source
1. .18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Description of Artificial Sequence: synthetic
        oligonucleotide"

Query Match      0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      336 GGCTCCAAGAACCTAGA 352
Db      1 GGCTCCATGAACCTAGA 17
```


RESULT 54
AR340812
LOCUS AR340812 18 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 8 from patent US 6573069.
ACCESSION AR340812
VERSION AR340812.1 GI:33732655
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Holloway,J.L., Gao,Z. and Whitmore,T.E.
TITLE Crib protein ZMSE1
JOURNAL Patent: US 6573069-A 8 03-JUN-2003;
FEATURES
source
1 .18
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 714 TCCGTGGCCTCCTTCTC 730
|||||
Db 1 TCCGCGGCCTCCTTCTC 17
RESULT 55
AX141245
LOCUS AX141245 18 bp DNA linear PAT 31-MAY-2001
DEFINITION Sequence 8 from Patent WO0134803.
ACCESSION AX141245
VERSION AX141245.1 GI:14281481
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Holloway,J.L., Gao,Z. and Whitmore,T.E.
TITLE Crib protein zmsel
JOURNAL Patent: WO 0134803-A 8 17-MAY-2001;
FEATURES
source
1 .18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide primer ZC18860"
Query Match 0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 714 TCCGTGGCCTCCTTCTC 730
|||||
Db 1 TCCGCGGCCTCCTTCTC 17
RESULT 56
BD142414
LOCUS BD142414 20 bp DNA linear PAT 18-SEP-2002
DEFINITION Method of culturing mesenchymal stem cells.
ACCESSION BD142414
VERSION BD142414.1 GI:23237359
KEYWORDS WO 0222788-A/11.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 20)
AUTHORS Kato,Y., Tsutsumi,S. and Shimazu,A.
TITLE Method of culturing mesenchymal stem cells
JOURNAL Patent: WO 0222788-A 11 21-MAR-2002;

YUKIO KATO,SHINICHI TSUTSUMI,ATSUSHI SHIMAZU
OS Artificial Sequence
PN WO 0222788-A/11
PD 21-MAR-2002
PF 12-SEP-2001 WO 2001JP007914
PR 12-SEP-2000 JP 00P 276971
PI YUKIO KATO,SHINICHI TSUTSUMI,ATSUSHI SHIMAZU
PC C12N5/06,C12N5/02//C12N5/06,C12R1:91),(C12N5/02,C12R1:91) CC
PCR primer
FH Key Location/Qualifiers
FT source 1.20
/organism="Artificial Sequence".
FEATURES
source
1 .20
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 91;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1403 CCACGGAGACCATGA 1419
|||||
Db 1 CCACGGAGACCATGA 17
RESULT 57
AR315566
LOCUS AR315566 20 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 6103 from patent US 6559294.
ACCESSION AR315566
VERSION AR315566.1 GI:31708992
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Griffois,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
Sankaran,B. and Fletcher,L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 6103 06-MAY-2003;
FEATURES
source
1 .20
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 91;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 150 TGCTCTGGGAAGCTAT 166
|||||
Db 2 TGCTCTGGGAAGCTAT 18
RESULT 58
AX149057
LOCUS AX149057 20 bp DNA linear PAT 08-JUN-2001
DEFINITION Sequence 259 from Patent WO0136625.
ACCESSION AX149057
VERSION AX149057.1 GI:14347581
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Wright,J.A., Young,A.H. and Dugourd,D.
TITLE Antisense oligonucleotide sequences derived from groel and groes as
inhibitors of microorganisms
JOURNAL Patent: WO 0136625-A 259 25-MAY-2001;
FEATURES
source
1 .20
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"

```
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Antisense oligonucleotide"

Query Match
Best Local Similarity 0.8%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1445 TGTGTGCTGCTGCTTT 1461
|||||
Db 2 TGTGTGCTGCTGCTTT 18

RESULT 59
AX554362
LOCUS AX554362
DEFINITION Sequence 49 from Patent WO244403.
ACCESSION AX554362
VERSION AX554362.1 GI:25898178
KEYWORDS
ORGANISM
SOURCE
FEATURES
REFERENCE
1
AUTHORS White, J.H.
TITLE Markers for testing analogs of vitamin d and therapeutical uses
JOURNAL MCGILL UNIVERSITY (CA)
LOCATION/Qualifiers
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="primer"

Query Match
Best Local Similarity 0.8%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1272 CTCGAGCCCTCAAT 1288
|||||
Db 3 CTCGAGCCCTCAAT 19

RESULT 60
AR121539/c
LOCUS AR121539
DEFINITION Sequence 75 from patent US 6159734.
ACCESSION AR121539
VERSION AR121539.1 GI:14105115
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS McKay, R., Borchers, A.H. and Baker, B.F.
TITLE Antisense modulation of peroxisome proliferator-activated receptor
JOURNAL gamma expression
JOURNAL Patent: US 6159734-A 75 12-DEC-2000;
FEATURES
LOCATION/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 887 CCCAGATACCTGATCTTCA 906
|||||
Db 20 CCCAGAAAGCGATCTTCA 1

source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Antisense oligonucleotide"

Query Match
Best Local Similarity 0.8%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1445 TGTGTGCTGCTGCTTT 1461
|||||
Db 2 TGTGTGCTGCTGCTTT 18

RESULT 59
AX554362
LOCUS AX554362
DEFINITION Sequence 49 from Patent WO244403.
ACCESSION AX554362
VERSION AX554362.1 GI:25898178
KEYWORDS
ORGANISM
SOURCE
FEATURES
REFERENCE
1
AUTHORS White, J.H.
TITLE Markers for testing analogs of vitamin d and therapeutical uses
JOURNAL MCGILL UNIVERSITY (CA)
LOCATION/Qualifiers
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="primer"

Query Match
Best Local Similarity 0.8%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1272 CTCGAGCCCTCAAT 1288
|||||
Db 3 CTCGAGCCCTCAAT 19

RESULT 60
AR121539/c
LOCUS AR121539
DEFINITION Sequence 75 from patent US 6159734.
ACCESSION AR121539
VERSION AR121539.1 GI:14105115
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS McKay, R., Borchers, A.H. and Baker, B.F.
TITLE Antisense modulation of peroxisome proliferator-activated receptor
JOURNAL gamma expression
JOURNAL Patent: US 6159734-A 75 12-DEC-2000;
FEATURES
LOCATION/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 887 CCCAGATACCTGATCTTCA 906
|||||
Db 20 CCCAGAAAGCGATCTTCA 1

RESULT 61
AR121992
LOCUS AR121992
DEFINITION Sequence 11 from patent US 6160203.
ACCESSION AR121992
VERSION AR121992.1 GI:14105568
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS Ferri, S. and Toguri, T.
TITLE DNA strands coding for glycerol-e-phosphate acyltransferase
JOURNAL Patent: US 6160203-A 11 12-DEC-2000;
FEATURES
LOCATION/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1480 TTGTTGCAGACATGGAAGAA 1499
|||||
Db 1 TTGTTGCAGAAATGGAAGAA 20

RESULT 62
CQ786367
LOCUS CQ786367
DEFINITION Sequence 175 from Patent WO2004020668.
ACCESSION CQ786367
VERSION CQ786367.1 GI:45721468
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Nakamura, Y. and Katagiri, T.
TITLE Method for treating synovial sarcoma
JOURNAL Patent: WO 2004020668-A 175 11-MAR-2004;
JOURNAL Oncotherapy Science, Inc. (JP); The University of Tokyo (JP)
FEATURES
LOCATION/Qualifiers
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Description of Artificial Sequence: synthetic oligonucleotide"

Query Match
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 720 GCCTCCTTCTCCATCTACAG 739
|||||
Db 1 GTCCCTTCTCCATCTCCAG 20

RESULT 63
CQ796907/c
LOCUS CQ796907
DEFINITION Sequence 21 from Patent WO2004026902.
ACCESSION CQ796907
VERSION CQ796907.1 GI:46408533
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
synthetic construct
synthetic construct
other sequences; artificial sequences.
```

AUTHORS Kuernsteiner,H. and Friedlin,E.
TITLE Process for production of cephalosporin c
PATENT: WO 2004026902-A 21 01-APR-2004;
SANDOZ GMBH (AT)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="oligonucleotide primer"
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 381 CTGCAGCAAGATGGCTGGA 400
Db 20 CTGGAGCAGGTGAGCTGGA 1
RESULT 64
183426/c 183426 20 bp DNA linear PAT 10-AUG-1998
LOCUS 183426
DEFINITION Sequence 7 from patent US 5714318.
ACCESSION 183426
VERSION 183426.1 GI:3406956
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sagner,G., Kessler,C., Blum,H. and Domdey,H.
TITLE Simultaneous sequencing of nucleic acids
JOURNAL Patent: US 5714318-A 7 03-FEB-1998;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 620 CCAACCTTACATCACTACT 639
Db 20 CCAACCTTACATCACTTCT 1
RESULT 65
AR182885/c AR182885 20 bp DNA linear PAT 20-APR-2002
LOCUS AR182885
DEFINITION Sequence 57 from patent US 6339068.
ACCESSION AR182885
VERSION AR182885.1 GI:20226092
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Krieg,A.M., Davis,H.L., Wu,T. and Schorr,J.
TITLE Vectors and methods for immunization or therapeutic protocols
JOURNAL Patent: US 6339068-A 57 15-JAN-2002;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 29 CCGCCTCCGTCGCGCGTC 48
||||| ||| |||||||

Db 20 CCGCGCGCGCGCGCGGCC 1
RESULT 66
AR313757 AR313757 20 bp DNA linear PAT 12-JUN-2003
LOCUS AR313757
DEFINITION Sequence 4294 from patent US 6559294.
ACCESSION AR313757
VERSION AR313757.1 GI:31707183
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
Sankaran,B. and Fletcher,L.D.
TITLE Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL Patent: US 6559294-A 4294 06-MAY-2003;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1428 GATCCGAACGATGAATGT 1447
Db 1 GCTCCGAACGATGAATGT 20
RESULT 67
AR429256 AR429256 20 bp DNA linear PAT 18-DEC-2003
LOCUS AR429256
DEFINITION Sequence 10 from patent US 6642370.
ACCESSION AR429256
VERSION AR429256.1 GI:40189415
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Wise,C.A.
TITLE Genetic marker for autoimmune disorder
JOURNAL Patent: US 6642370-A 10 04-NOV-2003;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 989 GCAGGGTGCCATGGATGATG 1008
Db 1 GCAGGTGTCAAGATGATG 20
RESULT 68
AX104051/c AX104051 20 bp DNA linear PAT 30-APR-2001
LOCUS AX104051
DEFINITION Sequence 243 from Patent WO0122972.
ACCESSION AX104051
VERSION AX104051.1 GI:13920248
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 other sequences; artificial sequences.
AUTHORS Krieg,A.M., Schetter,C. and Vollmer,J.C.
TITLE Immunostimulatory nucleic acids

```
JOURNAL Patent: WO 012972-A 243 05-APR-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
GmbH (DE)
FEATURES
  source      Location/Qualifiers
    1..20
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCTCCGTCGCCCGCTC 48
Db 20 CCGCGCGCGCGCGCGGCC 1

RESULT 69
AX298435/c
LOCUS AX298435 20 bp DNA linear PAT 26-NOV-2001
DEFINITION Sequence 69 from Patent WO0183749.
ACCESSION AX298435
VERSION AX298435.1 GI:17128425
KEYWORDS Mus sp.
SOURCE Mus sp.
ORGANISM Mus sp.
REFERENCE 1
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
TITLE Bachmanov,A.A., Beauchamp,G.K., Chatterjee,A., de Jong,P.J., Li,S.,
Li,X., Ohmen,J.D., Reed,D.R., Ross,D. and Tordoff,M.G.
Gene and sequence variation associated with sensing carbohydrate
compounds and other sweeteners
JOURNAL Patent: WO 0183749-A 69 08-NOV-2001;
WARNER-LAMBERT COMPANY (US) ; The Monell Chemical Senses Center
(US)
FEATURES
  source      Location/Qualifiers
    1..20
    /organism="Mus sp."
    /mol_type="unassigned DNA"
    /db_xref="taxon:10095"

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 685 AGGTGGGGCTTGGCATCT 704
Db 20 AGTGAGGGTTTGGCTTCT 1

RESULT 70
AX355382/c
LOCUS AX355382 20 bp DNA linear PAT 06-FEB-2002
DEFINITION Sequence 410 from Patent WO0197843.
ACCESSION AX355382
VERSION AX355382.1 GI:18620050
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Weiner,G. and Hartmann,G.
TITLE Methods for enhancing antibody-induced cell lysis and treating
cancer
JOURNAL Patent: WO 0197843-A 410 27-DEC-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
FEATURES
  source      Location/Qualifiers
    1..20
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"

/note="Synthetic oligonucleotide-phosphodiester backbone"

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCTCCGTCGCCCGCTC 48
Db 20 CCGCGCGCGCGCGCGGCC 1

RESULT 71
AX458688/c
LOCUS AX458688 20 bp DNA linear PAT 08-JUL-2002
DEFINITION Sequence 5 from Patent WO0246462.
ACCESSION AX458688
VERSION AX458688.1 GI:21725352
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Greaves,D., Price,S. and Watkins,H.
TITLE Functional genetic variants
JOURNAL Patent: WO 0246462-A 5 13-JUN-2002;
Isis Innovation Limited (GB)
FEATURES
  source      Location/Qualifiers
    1..20
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"
    /note="Amplification Primer"

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 384 CAGCAGATGGCTGGAGAA 403
Db 20 CAGCAGAGGCGACTGGAGAA 1

RESULT 72
AX547104/c
LOCUS AX547104 20 bp DNA linear PAT 01-MAR-2003
DEFINITION Sequence 243 from Patent WO02053141.
ACCESSION AX547104
VERSION AX547104.1 GI:25812248
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Bratzler,R.L.
TITLE Inhibition of angiogenesis by nucleic acids
JOURNAL Patent: WO 02053141-A 243 11-JUL-2002;
Coley Pharmaceutical Group, Inc. (US)
FEATURES
  source      Location/Qualifiers
    1..20
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"
    /note="Synthetic Sequence"

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCTCCGTCGCCCGCTC 48
Db 20 CCGCGCGCGCGCGCGGCC 1
```

FEATURES

```
source 1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
misc_feature 1..20
/notes="forward primer for human STS sts-SGC34104 at 1p36
sts-SGC34104 obtained from clones B99P18, B345C23, B275J8,
Human BAC library RPCI-11"

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1789 TTCCACTTTAAAGTAAACA 1808
Db 1 TTCCACTTTGCAAGCAACA 20

RESULT 77
AX129260/c AX129260 19 bp DNA linear PAT 15-MAY-2001
LOCUS
DEFINITION Sequence 478 from Patent WO0130362.
ACCESSION AX129260
VERSION AX129260.1 GI:14135565
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
JOURNAL Patent: WO 0130362-A 478 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
source 1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/notes="Cdk4 ribozyme binding site"

Query Match 0.8%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1096 GGACTGCAGAGAAC 1110
Db 19 GGACTGCAGAGAAC 5

RESULT 78
AR107613
LOCUS
DEFINITION Sequence 53 from patent US 6110664.
ACCESSION AR107613
VERSION AR107613.1 GI:12823100
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowser,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 53 29-AUG-2000;
FEATURES
source 1..20
/organism="unassigned DNA"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGTTT 1461
Db 3 TTGCTGCTGCTGTTT 17

RESULT 81
AR107616
LOCUS
DEFINITION Sequence 56 from patent US 6110664.
ACCESSION AR107616
VERSION AR107616.1 GI:12823103
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
```

```
QY 1447 TTGCTGCTGCTGTTT 1461
Db 1 TTGCTGCTGCTGTTT 15

RESULT 79
AR107614
LOCUS
DEFINITION Sequence 54 from patent US 6110664.
ACCESSION AR107614
VERSION AR107614.1 GI:12823101
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowser,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 54 29-AUG-2000;
FEATURES
source 1..20
/organism="unassigned DNA"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGTTT 1461
Db 2 TTGCTGCTGCTGTTT 16

RESULT 80
AR107615
LOCUS
DEFINITION Sequence 55 from patent US 6110664.
ACCESSION AR107615
VERSION AR107615.1 GI:12823102
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowser,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 55 29-AUG-2000;
FEATURES
source 1..20
/organism="unassigned DNA"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGTTT 1461
Db 3 TTGCTGCTGCTGTTT 17

RESULT 81
AR107616
LOCUS
DEFINITION Sequence 56 from patent US 6110664.
ACCESSION AR107616
VERSION AR107616.1 GI:12823103
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
```

```

AUTHORS      Cowsert, L.M.
TITLE        Antisense inhibition of G-alpha-S1 expression
JOURNAL      Patent: US 6110664-A 56 29-AUG-2000;
FEATURES     Location/Qualifiers
source       1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTTT 1461
Db 4 TTGCTGCTGCTGTTT 18

RESULT 82
AR107617      ARI07617      20 bp      DNA      linear      PAT 14-FEB-2001
LOCUS
DEFINITION    Sequence 57 from patent US 6110664.
ACCESSION     ARI07617
VERSION       ARI07617.1 GI:12823104
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unclassified.
REFERENCE     1 (bases 1 to 20)
AUTHORS      Cowsert, L.M.
TITLE        Antisense inhibition of G-alpha-S1 expression
JOURNAL      Patent: US 6110664-A 57 29-AUG-2000;
FEATURES     Location/Qualifiers
source       1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTTT 1461
Db 5 TTGCTGCTGCTGTTT 19

RESULT 83
AR107618      ARI07618      20 bp      DNA      linear      PAT 14-FEB-2001
LOCUS
DEFINITION    Sequence 58 from patent US 6110664.
ACCESSION     ARI07618
VERSION       ARI07618.1 GI:12823105
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unclassified.
REFERENCE     1 (bases 1 to 20)
AUTHORS      Cowsert, L.M.
TITLE        Antisense inhibition of G-alpha-S1 expression
JOURNAL      Patent: US 6110664-A 58 29-AUG-2000;
FEATURES     Location/Qualifiers
source       1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTTT 1461
Db 6 TTGCTGCTGCTGTTT 20

AUTHORS      Cowsert, L.M.
TITLE        Antisense inhibition of G-alpha-S1 expression
JOURNAL      Patent: US 6110664-A 56 29-AUG-2000;
FEATURES     Location/Qualifiers
source       1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTTT 1461
Db 6 TTGCTGCTGCTGTTT 20

```

```

RESULT 84
I15672
LOCUS
DEFINITION    Sequence 9 from patent US 5470719.
ACCESSION     I15672
VERSION       I15672.1 GI:1250580
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unknown.
REFERENCE     1 (bases 1 to 19)
AUTHORS      Meng, S.-Y., Morris, C.F. and Tsai, L.B.
TITLE        Modified OmpA signal sequence for enhanced secretion of
              polypeptides
JOURNAL      Patent: US 5470719-A 9 28-NOV-1995;
FEATURES     Location/Qualifiers
source       1..19
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred.No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1680 TGATTCTAGAAAAGGAA 1697
Db 2 TGATTCTAGAAAGGAGGAA 19

RESULT 85
I36677
LOCUS
DEFINITION    Sequence 9 from patent US 5608036.
ACCESSION     I36677
VERSION       I36677.1 GI:2086502
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unknown.
REFERENCE     1 (bases 1 to 19)
AUTHORS      Meng, S.-Y., Morris, C.F. and Tsai, L.B.
TITLE        Enhanced secretion of polypeptides
JOURNAL      Patent: US 5608036-A 9 04-MAR-1997;
FEATURES     Location/Qualifiers
source       1..19
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred.No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1680 TGATTCTAGAAAAGGAA 1697
Db 2 TGATTCTAGAAAGGAGGAA 19

RESULT 86
AR295153/c
LOCUS
DEFINITION    Sequence 6888 from patent US 6537751.
ACCESSION     AR295153
VERSION       AR295153.1 GI:31682437
KEYWORDS
SOURCE        Unknown.
ORGANISM      Unknown.
REFERENCE     1 (bases 1 to 19)
AUTHORS      Cohen, D., Chumakov, I. and Blumenfeld, M.
TITLE        Biallelic markers for use in constructing a high density
              disequilibrium map of the human genome
JOURNAL      Patent: US 6537751-A 6888 25-MAR-2003;
FEATURES     Location/Qualifiers

```

```
source 1. .19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 GTTGTTCCTATGTTGTT 1484
||| ||||| |||||
Db 19 GTTCCTCTTATGTTGTT 2

RESULT 87
AR295404/c
LOCUS AR295404 19 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 7139 from patent US 6537751.
ACCESSION AR295404
VERSION AR295404.1 GI:31682688
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 19)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 7139 25-MAR-2003;
FEATURES
Location/Qualifiers
1. .19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1629 CTCTATTTCATGCTTCT 1646
||| ||||| |||||
Db 19 CTCTCTTCTTGCTTCT 2

RESULT 88
AR533334/c
LOCUS AR533334 19 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 19 from patent US 6730500.
ACCESSION AR533334
VERSION AR533334.1 GI:53922962
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 19)
AUTHORS Lok,S.
TITLE Methods for generating a continuous nucleotide sequence from
noncontiguous nucleotide sequences
JOURNAL Patent: US 6730500-A 19 04-MAY-2004;
FEATURES
Location/Qualifiers
1. .19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1065 CGTCCAAAGAGACTCTG 1082
||| ||||| |||||
Db 19 CTTCCTATAGAGACTCTG 2

RESULT 89
AX131510/c
LOCUS AX131510 19 bp DNA linear PAT 08-JUN-2001
DEFINITION Sequence 371 from Patent WO0136625.
ACCESSION AX149169
VERSION AX149169.1 GI:14347693
KEYWORDS
SOURCE
ORGANISM
```

```
LOCUS AX131510 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 2728 from Patent WO0130362.
ACCESSION AX131510
VERSION AX131510.1 GI:14137815
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
diseases
JOURNAL Patent: WO 0130362-A 2728 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
Location/Qualifiers
1. .19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin G1 ribozyme binding site"

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1326 AACTTTGGATCCAGCT 1343
||| ||||| |||||
Db 18 AACATTTGGATACAGCT 1

RESULT 90
AX132341/c
LOCUS AX132341 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 3559 from Patent WO0130362.
ACCESSION AX132341
VERSION AX132341.1 GI:14138646
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
diseases
JOURNAL Patent: WO 0130362-A 3559 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
Location/Qualifiers
1. .19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cdc25 hs ribozyme binding site"

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 963 GGACATCTGGACAGCTGG 980
||| ||||| |||||
Db 19 GGACATCTGGACAGACGG 2

RESULT 91
AX149169/c
LOCUS AX149169 19 bp DNA linear PAT 08-JUN-2001
DEFINITION Sequence 371 from Patent WO0136625.
ACCESSION AX149169
VERSION AX149169.1 GI:14347693
KEYWORDS
SOURCE
ORGANISM
synthetic construct
```



```

other sequences; artificial sequences.
1
REFERENCE
AUTHORS Wright,J.A., Young,A.H. and Dugourd,D.
TITLE Antisense oligonucleotide sequences derived from groel and groes as
JOURNAL inhibitors of microorganisms
Patent: WO 0136625-A 371 25-MAY-2001;
GeneSense Technologies Inc. (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisense oligonucleotide"

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 88 TGGAAAAAATAATGAAAT 105
Db 18 TGAATAATAAATAATGAAAT 1

RESULT 92
CQ623624
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8364 from Patent WO0192524.
ACCESSION CQ623624
VERSION CQ623624.1 GI:41673842
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8364 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 395 GCTGGAGAAAGTTCAC 410
Db 2 GCTGGAGAAAGTGCAC 17

RESULT 93
CQ623625
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8365 from Patent WO0192524.
ACCESSION CQ623625
VERSION CQ623625.1 GI:41673843
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8365 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 395 GCTGGAGAAAGTTCAC 410
Db 2 GCTGGAGAAAGTGCAC 17

RESULT 94
CQ625290/c
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10030 from Patent WO0192524.
ACCESSION CQ625290
VERSION CQ625290.1 GI:41675508
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10030 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 395 GCTGGAGAAAGTTCAC 410
Db 1 GCTGGAGAAAGTGCAC 16

RESULT 95
CQ625291/c
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10031 from Patent WO0192524.
ACCESSION CQ625291
VERSION CQ625291.1 GI:41675509
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10031 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1065 CGTCCAAAGAGGACTC 1080
Db 17 CGTCCACAGAGGACTC 2

RESULT 96
CQ625291/c
LOCUS 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10031 from Patent WO0192524.
ACCESSION CQ625291
VERSION CQ625291.1 GI:41675509
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10031 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1065 CGTCCAAAGAGGACTC 1080
Db 17 CGTCCACAGAGGACTC 2

```

```

QY      1065 CGTCAAAGAGGACTC 1080
Db      16  CGTCCACAGAGGACTC 1

RESULT 96
AR327069
LOCUS      AR327069          17 bp  RNA          PAT 17-AUG-2003
DEFINITION Sequence 4471 from patent US 6566127.
ACCESSION  AR327069
VERSION     AR327069.1  GI:33712877
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE     Method and reagent for the treatment of diseases or conditions
          related to levels of vascular endothelial growth factor receptor
JOURNAL   Patent: US 6566127-A 4471 20-MAY-2003;
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="unknown"
                /mol_type="unassigned RNA"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1204 TACCCACTGGCGTCGA 1219
Db      2  TACCCACTGGCGACGA 17

RESULT 97
AR464687
LOCUS      AR464687          17 bp  DNA          PAT 20-FEB-2004
DEFINITION Sequence 8364 from patent US 6686188.
ACCESSION  AR464687
VERSION     AR464687.1  GI:42699744
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
          Shannon,M.E.
TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
          predominantly in heart and muscle
JOURNAL   Patent: US 6686188-A 8364 03-FEB-2004;
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      395 GCTGGAGAAAGTTCAC 410
Db      2  GCTGGAGAAAGTGCAC 17

RESULT 98
AR464688
LOCUS      AR464688          17 bp  DNA          PAT 20-FEB-2004
DEFINITION Sequence 8365 from patent US 6686188.
ACCESSION  AR464688
VERSION     AR464688.1  GI:42699745
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.

```

```

Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
          Shannon,M.E.
TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
          predominantly in heart and muscle
JOURNAL   Patent: US 6686188-A 8365 03-FEB-2004;
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      395 GCTGGAGAAAGTTCAC 410
Db      1  GCTGGAGAAAGTGCAC 16

RESULT 99
AR466353/c
LOCUS      AR466353          17 bp  DNA          PAT 20-FEB-2004
DEFINITION Sequence 10030 from patent US 6686188.
ACCESSION  AR466353
VERSION     AR466353.1  GI:42701410
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
          Shannon,M.E.
TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
          predominantly in heart and muscle
JOURNAL   Patent: US 6686188-A 10030 03-FEB-2004;
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1065 CGTCAAAGAGGACTC 1080
Db      17  CGTCCACAGAGGACTC 2

RESULT 100
AR466354/c
LOCUS      AR466354          17 bp  DNA          PAT 20-FEB-2004
DEFINITION Sequence 10031 from patent US 6686188.
ACCESSION  AR466354
VERSION     AR466354.1  GI:42701411
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
          Shannon,M.E.
TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
          predominantly in heart and muscle
JOURNAL   Patent: US 6686188-A 10031 03-FEB-2004;
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Best Local Similarity 93.8%; Pred. No. 1e+02; Mismatches 0; Indels 1; Gaps 0;

QY 1065 CGTCCAAAGAGGACTC 1080
Db 16 CGTCCACAGAGGACTC 1

RESULT 101

AX218292 17 bp RNA linear PAT 07-SEP-2001
LOCUS Sequence 3734 from Patent WO0159103.

AX218292
ACCESSION
VERSION AX218292.1 GI:15528353

KEYWORDS

SOURCE

ORGANISM

synthetic construct

other sequences; artificial sequences.

REFERENCE

AUTHORS Blatt, L., McSwiggen, J., and Chowrira, B.M.

TITLE Method and reagent for the modulation and diagnosis of cd20 and

JOURNAL nogo gene expression

Patent: WO 0159103-A 3734 16-AUG-2001;

RBOZYMNE PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);

McSwiggen, James (US); Chowrira, Bharat M. (US)

Location/Qualifiers

1. .17

/organism="synthetic construct"

/mol_type="unassigned RNA"

/db_xref="taxon:32630"

/notes="Nucleic Acid"

Query Match

Best Local Similarity 93.8%; Pred. No. 1e+02; Length 17;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 AAATAAAGAGAGAAAT 217

Db 1 AAATAAAGAGAGAGT 16

RESULT 102

AX579784/c 17 bp RNA linear PAT 10-JAN-2003
LOCUS Sequence 1622 from Patent WO0211674.

AX579784

ACCESSION

VERSION AX579784.1 GI:27648986

KEYWORDS

SOURCE

ORGANISM

Homo sapiens (human)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.

Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.

and Grupe, A.

Method and reagent for the inhibition of calcium activated chloride

channel-1 (clca-1)

Patent: WO 0211674-A 1622 14-FEB-2002;

RBOZYMNE PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);

Thompson, James (US)

Location/Qualifiers

1. .17

/organism="Homo sapiens"

/mol_type="unassigned RNA"

/db_xref="taxon:9606"

Query Match

Best Local Similarity 93.8%; Pred. No. 1e+02; Length 17;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1152 GTAATATTTCCAACT 1167

Db 16 GTAATATTTCCATCT 1

RESULT 103

AX722986/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 673 from Patent WO03025176.

AX722986

ACCESSION

VERSION AX722986.1 GI:30423487

KEYWORDS

SOURCE

ORGANISM

Mus musculus (house mouse)

Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1

Teleman, A., Amson, R. and Tuijnder, M.

Sequences involved in phenomena of tumour suppression, tumour

reversion, apoptosis and/or virus resistance and their use as

medicines

Patent: WO 03025176-A 673 27-MAR-2003;

Molecular Engines Laboratories (FR)

Location/Qualifiers

1. .17

/organism="Mus musculus"

/mol_type="unassigned DNA"

/db_xref="taxon:10090"

Query Match

Best Local Similarity 93.8%; Pred. No. 1e+02; Length 17;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 968 TCTGGACAGCTGGAT 983

Db 17 TCTGGATAGCTGGAT 2

RESULT 104

AX723927 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 1614 from Patent WO03025176.

AX723927

ACCESSION

VERSION AX723927.1 GI:30503270

KEYWORDS

SOURCE

ORGANISM

Mus musculus (house mouse)

Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1

Teleman, A., Amson, R. and Tuijnder, M.

Sequences involved in phenomena of tumour suppression, tumour

reversion, apoptosis and/or virus resistance and their use as

medicines

Patent: WO 03025176-A 1614 27-MAR-2003;

Molecular Engines Laboratories (FR)

Location/Qualifiers

1. .17

/organism="Mus musculus"

/mol_type="unassigned DNA"

/db_xref="taxon:10090"

Query Match

Best Local Similarity 93.8%; Pred. No. 1e+02; Length 17;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1558 ATCTGGGTCTGCAAC 1573

Db 2 ATCTGGGTCTGCAAC 17

RESULT 105

AX724619 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 2306 from Patent WO03025176.

AX724619

ACCESSION

AX724619

AX724619.1	GI:30503962
VERSION	Mus musculus (house mouse)
KEYWORDS	Mus musculus
SOURCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
ORGANISM	1
REFERENCE	Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines Patent: WO 03025176-A 2306 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
AUTHORS	1..17
TITLE	/organism="Mus musculus" /mol_type="unassigned DNA" /db_xref="taxon:10090"
JOURNAL	Query Match 0.8%; Score 14.4; DB 1; Length 17; Best Local Similarity 93.8%; Pred. No.1e+02; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
FEATURES	source
QY	492 ATCCTGGGCTTTGGCA 507
DB	2 ATCCTGGGCTTTGGCA 17
RESULT 106	AX725224/c
LOCUS	AX725224 17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 2911 from Patent WO03025176.
ACCESSION	AX725224
VERSION	AX725224.1 GI:30504567
KEYWORDS	Mus musculus (house mouse)
SOURCE	Mus musculus
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE	1
AUTHORS	Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines Patent: WO 03025176-A 2911 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
TITLE	1..17
JOURNAL	Query Match 0.8%; Score 14.4; DB 1; Length 17; Best Local Similarity 93.8%; Pred. No.1e+02; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
FEATURES	source
QY	1041 TCATTATTAAGATC 1056
DB	16 TCATTATTAAGATC 1
RESULT 107	AX726651/c
LOCUS	AX726651 17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 4338 from Patent WO03025176.
ACCESSION	AX726651
VERSION	AX726651.1 GI:30505994
KEYWORDS	Mus musculus (house mouse)
SOURCE	Mus musculus
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE	1
AUTHORS	Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines Patent: WO 03025176-A 4338 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
TITLE	1..17
JOURNAL	Query Match 0.8%; Score 14.4; DB 1; Length 17; Best Local Similarity 93.8%; Pred. No.1e+02; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
FEATURES	source
QY	920 GATCACTGGGAGCAAA 935
DB	1 GATCACTGGGAGCAAA 16
RESULT 109	AX736376
LOCUS	AX736376 17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 1966 from Patent WO03025177.
ACCESSION	AX736376
VERSION	AX736376.1 GI:30515653
KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1
AUTHORS	Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments Patent: WO 03025177-A 1966 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
TITLE	1..17
JOURNAL	Query Match 0.8%; Score 14.4; DB 1; Length 17; Best Local Similarity 93.8%; Pred. No.1e+02; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
FEATURES	source
QY	920 GATCACTGGGAGCAAA 935
DB	1 GATCACTGGGAGCAAA 16
RESULT 108	AX735552
LOCUS	AX735552 17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 1142 from Patent WO03025177.
ACCESSION	AX735552
VERSION	AX735552.1 GI:30514829
KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1
AUTHORS	Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments Patent: WO 03025177-A 1142 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
TITLE	1..17
JOURNAL	Query Match 0.8%; Score 14.4; DB 1; Length 17; Best Local Similarity 93.8%; Pred. No.1e+02; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
FEATURES	source
QY	920 GATCACTGGGAGCAAA 935
DB	1 GATCACTGGGAGCAAA 16
RESULT 109	AX736376
LOCUS	AX736376 17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 1966 from Patent WO03025177.
ACCESSION	AX736376
VERSION	AX736376.1 GI:30515653
KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1
AUTHORS	Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments Patent: WO 03025177-A 1966 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
TITLE	1..17
JOURNAL	Query Match 0.8%; Score 14.4; DB 1; Length 17; Best Local Similarity 93.8%; Pred. No.1e+02; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
FEATURES	source
QY	920 GATCACTGGGAGCAAA 935
DB	1 GATCACTGGGAGCAAA 16
RESULT 106	AX725224/c
LOCUS	AX725224 17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 2911 from Patent WO03025176.
ACCESSION	AX725224
VERSION	AX725224.1 GI:30504567
KEYWORDS	Mus musculus (house mouse)
SOURCE	Mus musculus
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE	1
AUTHORS	Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines Patent: WO 03025176-A 2911 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
TITLE	1..17
JOURNAL	Query Match 0.8%; Score 14.4; DB 1; Length 17; Best Local Similarity 93.8%; Pred. No.1e+02; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
FEATURES	source
QY	1041 TCATTATTAAGATC 1056
DB	16 TCATTATTAAGATC 1
RESULT 107	AX726651/c
LOCUS	AX726651 17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 4338 from Patent WO03025176.
ACCESSION	AX726651
VERSION	AX726651.1 GI:30505994
KEYWORDS	Mus musculus (house mouse)
SOURCE	Mus musculus

Db	Sequence	Accession	Version	Keywords	Organism	Reference	Authors	Title	Journal	Features	Source	Query Match	Best Local Similarity	Matches	Score	DB 1	Length	DB 2	Length	DB 3	Length	DB 4	Length	DB 5	Length	DB 6	Length	DB 7	Length	DB 8	Length	DB 9	Length	DB 10	Length	DB 11	Length	DB 12	Length	DB 13	Length	DB 14	Length	DB 15	Length	DB 16	Length	DB 17	Length	DB 18	Length	DB 19	Length	DB 20	Length	DB 21	Length	DB 22	Length	DB 23	Length	DB 24	Length	DB 25	Length	DB 26	Length	DB 27	Length	DB 28	Length	DB 29	Length	DB 30	Length	DB 31	Length	DB 32	Length	DB 33	Length	DB 34	Length	DB 35	Length	DB 36	Length	DB 37	Length	DB 38	Length	DB 39	Length	DB 40	Length	DB 41	Length	DB 42	Length	DB 43	Length	DB 44	Length	DB 45	Length	DB 46	Length	DB 47	Length	DB 48	Length	DB 49	Length	DB 50	Length	DB 51	Length	DB 52	Length	DB 53	Length	DB 54	Length	DB 55	Length	DB 56	Length	DB 57	Length	DB 58	Length	DB 59	Length	DB 60	Length	DB 61	Length	DB 62	Length	DB 63	Length	DB 64	Length	DB 65	Length	DB 66	Length	DB 67	Length	DB 68	Length	DB 69	Length	DB 70	Length	DB 71	Length	DB 72	Length	DB 73	Length	DB 74	Length	DB 75	Length	DB 76	Length	DB 77	Length	DB 78	Length	DB 79	Length	DB 80	Length	DB 81	Length	DB 82	Length	DB 83	Length	DB 84	Length	DB 85	Length	DB 86	Length	DB 87	Length	DB 88	Length	DB 89	Length	DB 90	Length	DB 91	Length	DB 92	Length	DB 93	Length	DB 94	Length	DB 95	Length	DB 96	Length	DB 97	Length	DB 98	Length	DB 99	Length	DB 100	Length	DB 101	Length	DB 102	Length	DB 103	Length	DB 104	Length	DB 105	Length	DB 106	Length	DB 107	Length	DB 108	Length	DB 109	Length	DB 110	Length	DB 111	Length	DB 112	Length	DB 113	Length	DB 114	Length	DB 115	Length	DB 116	Length	DB 117	Length	DB 118	Length	DB 119	Length	DB 120	Length	DB 121	Length	DB 122	Length	DB 123	Length	DB 124	Length	DB 125	Length	DB 126	Length	DB 127	Length	DB 128	Length	DB 129	Length	DB 130	Length	DB 131	Length	DB 132	Length	DB 133	Length	DB 134	Length	DB 135	Length	DB 136	Length	DB 137	Length	DB 138	Length	DB 139	Length	DB 140	Length	DB 141	Length	DB 142	Length	DB 143	Length	DB 144	Length	DB 145	Length	DB 146	Length	DB 147	Length	DB 148	Length	DB 149	Length	DB 150	Length	DB 151	Length	DB 152	Length	DB 153	Length	DB 154	Length	DB 155	Length	DB 156	Length	DB 157	Length	DB 158	Length	DB 159	Length	DB 160	Length	DB 161	Length	DB 162	Length	DB 163	Length	DB 164	Length	DB 165	Length	DB 166	Length	DB 167	Length	DB 168	Length	DB 169	Length	DB 170	Length	DB 171	Length	DB 172	Length	DB 173	Length	DB 174	Length	DB 175	Length	DB 176	Length	DB 177	Length	DB 178	Length	DB 179	Length	DB 180	Length	DB 181	Length	DB 182	Length	DB 183	Length	DB 184	Length	DB 185	Length	DB 186	Length	DB 187	Length	DB 188	Length	DB 189	Length	DB 190	Length	DB 191	Length	DB 192	Length	DB 193	Length	DB 194	Length	DB 195	Length	DB 196	Length	DB 197	Length	DB 198	Length	DB 199	Length	DB 200	Length	DB 201	Length	DB 202	Length	DB 203	Length	DB 204	Length	DB 205	Length	DB 206	Length	DB 207	Length	DB 208	Length	DB 209	Length	DB 210	Length	DB 211	Length	DB 212	Length	DB 213	Length	DB 214	Length	DB 215	Length	DB 216	Length	DB 217	Length	DB 218	Length	DB 219	Length	DB 220	Length	DB 221	Length	DB 222	Length	DB 223	Length	DB 224	Length	DB 225	Length	DB 226	Length	DB 227	Length	DB 228	Length	DB 229	Length	DB 230	Length	DB 231	Length	DB 232	Length	DB 233	Length	DB 234	Length	DB 235	Length	DB 236	Length	DB 237	Length	DB 238	Length	DB 239	Length	DB 240	Length	DB 241	Length	DB 242	Length	DB 243	Length	DB 244	Length	DB 245	Length	DB 246	Length	DB 247	Length	DB 248	Length	DB 249	Length	DB 250	Length	DB 251	Length	DB 252	Length	DB 253	Length	DB 254	Length	DB 255	Length	DB 256
----	----------	-----------	---------	----------	----------	-----------	---------	-------	---------	----------	--------	-------------	-----------------------	---------	-------	------	--------	------	--------	------	--------	------	--------	------	--------	------	--------	------	--------	------	--------	------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	-------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------	--------

```
KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS      Robbins,J.M. and Tritz,R.
TITLE        Ribozyme therapy for the treatment of proliferative skin and eye
              diseases
JOURNAL      Patent: WO 0130362-A 3052 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES     1..19
source       /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
              /note="Cyclin A1 ribozyme binding site"
Query Match      0.8%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 433 ACTGGAGAGGGGAGA 448
Db 17 ACTGGAGAGGGGAGA 2
      |||||
RESULT 115
LOCUS      I81221 17 bp DNA linear PAT 10-JUN-1998
DEFINITION Sequence 5 from patent US 5710023.
ACCESSION  I81221
VERSION     I81221.1 GI:3209511
KEYWORDS   Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Collins,M., Donaldson,D., Fitz,L., Neben,T., Whitters,M. and
              Wood,C.
TITLE     IL-13 cytokine receptor chain
JOURNAL   Patent: US 5710023-A 5 20-JAN-1998;
FEATURES  Location/Qualifiers
source    1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match      0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTCCTGGAGCCA 1359
Db 17 TGGAGYGMVTGGAGYSM 1
      |||||
RESULT 116
LOCUS      AR438875 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 5 from patent US 6664227.
ACCESSION  AR438875
VERSION     AR438875.1 GI:42663882
KEYWORDS   Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Wynn,T.A., Chiaromonte,M.G., Collins,M., Donaldson,D., Fitz,L.,
              Neben,T., Whitters,M.J. and Wood,C.
TITLE     Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor
              chains
JOURNAL   Patent: US 6664227-A 5 16-DEC-2003;
FEATURES  Location/Qualifiers

KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 2590 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES     1..17
source       /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGGTGCCCATGGA 1003
Db 4 CAGGGTGCCCATGGA 17
      |||||
KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 2590 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES     1..17
source       /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGGTGCCCATGGA 1003
Db 4 CAGGGTGCCCATGGA 17
      |||||
source       1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match      0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 94;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1445 TGTTGCTGCTGCTG 1458
Db 14 TGTTGCTGCTGCTG 1
      |||||
RESULT 118
LOCUS      CQ617850 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2590 from Patent WO0192524.
ACCESSION  CQ617850
VERSION     CQ617850.1 GI:41668068
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 2590 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES  Location/Qualifiers
source    1..17
              /organism="unknown"
              /mol_type="genomic DNA"
Query Match      0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 94;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1445 TGTTGCTGCTGCTG 1458
Db 14 TGTTGCTGCTGCTG 1
      |||||
RESULT 118
LOCUS      CQ617850 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2590 from Patent WO0192524.
ACCESSION  CQ617850
VERSION     CQ617850.1 GI:41668068
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 2590 06-DEC-2001;
              Aeomica, Inc. (US)
FEATURES  Location/Qualifiers
source    1..17
              /organism="unknown"
              /mol_type="genomic DNA"
Query Match      0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 94;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1445 TGTTGCTGCTGCTG 1458
Db 14 TGTTGCTGCTGCTG 1
      |||||
```

RESULT 119
CQ617851 17 bp DNA linear PAT 02-FEB-2004
LOCUS
DEFINITION Sequence 2591 from Patent WO0192524.
ACCESSION CQ617851
VERSION CQ617851.1 GI:41668069
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2591 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 990 CAGGGTGCCATGGA 1003
Db 3 CAGGGTGCCATGGA 16
|||||
RESULT 120
CQ617852 17 bp DNA linear PAT 02-FEB-2004
LOCUS
DEFINITION Sequence 2592 from Patent WO0192524.
ACCESSION CQ617852
VERSION CQ617852.1 GI:41668070
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2592 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 990 CAGGGTGCCATGGA 1003
Db 2 CAGGGTGCCATGGA 15
|||||
RESULT 121
CQ617853 17 bp DNA linear PAT 02-FEB-2004
LOCUS
DEFINITION Sequence 2593 from Patent WO0192524.
ACCESSION CQ617853
VERSION CQ617853.1 GI:41668071
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2593 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 990 CAGGGTGCCATGGA 1003
Db 1 CAGGGTGCCATGGA 14
|||||
RESULT 122
AR458913 17 bp DNA linear PAT 20-FEB-2004
LOCUS
DEFINITION Sequence 2590 from patent US 6686188.
ACCESSION AR458913
VERSION AR458913.1 GI:42693970
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2590 03-FEB-2004;
FEATURES
source
1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 990 CAGGGTGCCATGGA 1003
Db 4 CAGGGTGCCATGGA 17
|||||
RESULT 123
AR458914 17 bp DNA linear PAT 20-FEB-2004
LOCUS
DEFINITION Sequence 2591 from patent US 6686188.
ACCESSION AR458914
VERSION AR458914.1 GI:42693971
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2591 03-FEB-2004;
FEATURES
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

```

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 990 CAGGGTGCCATGGA 1003
|||||
Db 3 CAGGGTGCCATGGA 16

RESULT 124
AR458915
LOCUS AR458915 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2592 from patent US 6686188.
ACCESSION AR458915
VERSION AR458915.1 GI:42693972
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2592 03-FEB-2004;
FEATURES
source
location/Qualifiers
1..17
/mol_type="genomic DNA"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 990 CAGGGTGCCATGGA 1003
|||||
Db 2 CAGGGTGCCATGGA 15

RESULT 125
AR458916
LOCUS AR458916 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2593 from patent US 6686188.
ACCESSION AR458916
VERSION AR458916.1 GI:42693973
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2593 03-FEB-2004;
FEATURES
source
location/Qualifiers
1..17
/mol_type="genomic DNA"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 990 CAGGGTGCCATGGA 1003
|||||
Db 1 CAGGGTGCCATGGA 14

RESULT 126
AX217415
LOCUS AX217415 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 835 from patent EP1281758.
ACCESSION AX688103
VERSION AX688103.1 GI:29410801
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```

```

DEFINITION Sequence 2857 from Patent WO0159103.
ACCESSION AX217415
VERSION AX217415.1 GI:15527476
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 2857 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
location/Qualifiers
1..17
/mol_type="synthetic construct"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 201 GAATTAAGAGAGA 214
|||||
Db 4 GAATTAAGAGAGA 17

RESULT 127
AX688102/c
LOCUS AX688102 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 834 from Patent EP1281758.
ACCESSION AX688102
VERSION AX688102.1 GI:29410800
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL Patent: EP 1281758-A 834 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
location/Qualifiers
1..17
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1236 AAGGCCAGGCCAT 1249
|||||
Db 17 AAGGCCAGGCCAT 4

RESULT 128
AX688103/c
LOCUS AX688103 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 835 from Patent EP1281758.
ACCESSION AX688103
VERSION AX688103.1 GI:29410801
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```



```
REFERENCE
1  Shannon,M., Gu,Y. and Nguyen,C.T.
   TITLE   Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
   mdz12
JOURNAL   Patent: EP 1281758-A 835 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/mol_type="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 AAGGCCAGGGCCAT 1249
Db 16 AAGGCCAGGGCCAT 3

RESULT 129
AX688104/c      17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 836 from Patent EP1281758.
ACCESSION AX688104
VERSION AX688104.1 GI:29410802
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
1  Shannon,M., Gu,Y. and Nguyen,C.T.
   AUTHORS
   TITLE   Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
   mdz12
JOURNAL   Patent: EP 1281758-A 836 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/mol_type="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 AAGGCCAGGGCCAT 1249
Db 15 AAGGCCAGGGCCAT 2

RESULT 130
AX688105/c      17 bp DNA linear PAT 31-MAR-2003
LOCUS
DEFINITION Sequence 837 from Patent EP1281758.
ACCESSION AX688105
VERSION AX688105.1 GI:29410803
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
1  Shannon,M., Gu,Y. and Nguyen,C.T.
   AUTHORS
   TITLE   Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
   mdz12
JOURNAL   Patent: EP 1281758-A 837 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/mol_type="Homo sapiens"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 AAGGCCAGGGCCAT 1249
Db 15 AAGGCCAGGGCCAT 2

RESULT 130
AX753818/c      17 bp DNA linear PAT 23-JUN-2003
LOCUS
DEFINITION Sequence 165 from Patent WO03037931.
ACCESSION AX753818
VERSION AX753818.1 GI:32166515
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
1  Shannon,M. and Phan,T.
   AUTHORS
   TITLE   Human angiotensin-like protein 1
   JOURNAL Patent: WO 03037931-A 165 08-MAY-2003;
Anergham Biosciences SV Corp. (US)
FEATURES
source
1. .17
/mol_type="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1445 TGTTCGTGCTGCTG 1458
Db 1445 TGTTCGTGCTGCTG 1458
```

Db 17 TGTGTCTGCTGCTG 4

RESULT 133
AX753819/c
LOCUS AX753819 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 166 from Patent WO03037931.
ACCESSION AX753819
VERSION AX753819.1 GI:32166516
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiomotin-like protein 1
JOURNAL Patent: WO 03037931-A 166 08-MAY-2003;
Amersham Biosciences SV Corp. (US)

FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGTCTGCTGCTG 1458
|||||
Db 16 TGTGTCTGCTGCTG 3

RESULT 134
AX753820/c
LOCUS AX753820 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 167 from Patent WO03037931.
ACCESSION AX753820
VERSION AX753820.1 GI:32166517
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiomotin-like protein 1
JOURNAL Patent: WO 03037931-A 167 08-MAY-2003;
Amersham Biosciences SV Corp. (US)

FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGTCTGCTGCTG 1458
|||||
Db 16 TGTGTCTGCTGCTG 3

RESULT 135
AX753821/c
LOCUS AX753821 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 168 from Patent WO03037931.
ACCESSION AX753821
VERSION AX753821.1 GI:32166518
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiomotin-like protein 1
JOURNAL Patent: WO 03037931-A 183 08-MAY-2003;
Amersham Biosciences SV Corp. (US)

FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGTCTGCTGCTG 1458
|||||
Db 15 TGTGTCTGCTGCTG 2

RESULT 137
AX753836
LOCUS AX753836 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 183 from Patent WO03037931.
ACCESSION AX753836
VERSION AX753836.1 GI:32166533
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiomotin-like protein 1
JOURNAL Patent: WO 03037931-A 183 08-MAY-2003;
Amersham Biosciences SV Corp. (US)

FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 662 GCAGGGGGCGGTGG 675
|||||
Db 4 GCAGGGGGCGGTGG 17

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiomotin-like protein 1
JOURNAL Patent: WO 03037931-A 182 08-MAY-2003;
Amersham Biosciences SV Corp. (US)

FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGTCTGCTGCTG 1458
|||||
Db 14 TGTGTCTGCTGCTG 1

RESULT 136
AX753835
LOCUS AX753835 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 182 from Patent WO03037931.
ACCESSION AX753835
VERSION AX753835.1 GI:32166532
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiomotin-like protein 1
JOURNAL Patent: WO 03037931-A 182 08-MAY-2003;
Amersham Biosciences SV Corp. (US)

FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGTCTGCTGCTG 1458
|||||
Db 14 TGTGTCTGCTGCTG 1

RESULT 137
AX753836
LOCUS AX753836 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 183 from Patent WO03037931.
ACCESSION AX753836
VERSION AX753836.1 GI:32166533
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Shannon,M. and Phan,T.
TITLE Human angiomotin-like protein 1
JOURNAL Patent: WO 03037931-A 183 08-MAY-2003;
Amersham Biosciences SV Corp. (US)

FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 662 GCAGGGGCGGTGG 675
Db 3 GCAGGGGCGGTGG 16

RESULT 138
LOCUS AX753837
DEFINITION Sequence 184 from Patent WO03037931.
ACCESSION AX753837
VERSION AX753837.1 GI:32166534
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 184 08-MAY-2003;
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 662 GCAGGGGCGGTGG 675
Db 2 GCAGGGGCGGTGG 15

RESULT 139
LOCUS AX753838
DEFINITION Sequence 185 from Patent WO03037931.
ACCESSION AX753838
VERSION AX753838.1 GI:32166535
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 185 08-MAY-2003;
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 662 GCAGGGGCGGTGG 675
Db 1 GCAGGGGCGGTGG 14

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 662 GCAGGGGCGGTGG 675
Db 3 GCAGGGGCGGTGG 16

RESULT 138
LOCUS AX753837
DEFINITION Sequence 184 from Patent WO03037931.
ACCESSION AX753837
VERSION AX753837.1 GI:32166534
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 184 08-MAY-2003;
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 662 GCAGGGGCGGTGG 675
Db 2 GCAGGGGCGGTGG 15

RESULT 139
LOCUS AX753838
DEFINITION Sequence 185 from Patent WO03037931.
ACCESSION AX753838
VERSION AX753838.1 GI:32166535
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 185 08-MAY-2003;
FEATURES Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 662 GCAGGGGCGGTGG 675
Db 1 GCAGGGGCGGTGG 14

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14; DB 1; Length 18;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 272 AGCCGAGACAGAT 285
Db 1 AGCCGAGACAGAT 14

RESULT 140
LOCUS I66351
DEFINITION Sequence 10 from patent US 5670330.
ACCESSION I66351
VERSION I66351.1 GI:2724328
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Sonenberg, N., Katze, M.G., Roy, S., Koromilas, A.E. and Barber, G.H.
TITLE Anti-tumor agent assay using PKR
JOURNAL Patent: US 5670330-A 10 23-SEP-1997;
FEATURES Location/Qualifiers
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 14; DB 1; Length 18;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 272 AGCCGAGACAGAT 285
Db 1 AGCCGAGACAGAT 14

RESULT 141
LOCUS AR564469
DEFINITION Sequence 1 from patent US 6759580.
ACCESSION AR564469
VERSION AR564469.1 GI:53979879
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cunyngnam, C.T.
TITLE Inbred maize line PH87H
JOURNAL Patent: US 6759580-A 1 06-JUL-2004;
FEATURES Location/Qualifiers
source
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 14; DB 1; Length 18;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1084 GGCTGGTCTCTGG 1097
Db 4 GGCTGGTCTCTGG 17

RESULT 142
LOCUS AR168820/c
DEFINITION Sequence 46 from patent US 6288042.
ACCESSION AR168820
VERSION AR168820.1 GI:17904939
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando, R.F., Ojwang, J.O., Hogan, M.E., Wallace, T.L. and Cossum, P.A.
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides
JOURNAL Patent: US 6288042-A 46 11-SEP-2001;
FEATURES Location/Qualifiers
source
1..17
```

```

/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1705 CCCTCCCTCCACCAC 1721
Db 17 CCCACCCACCACCAC 1

RESULT 143
BD198938/c
LOCUS      17 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION  BD198938
VERSION     1 GI:33008708
KEYWORDS   JP 2002509721-A/1964.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
JOURNAL   Patent: JP 2002509721-A 1964 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT   OS Homo sapiens (human)
            PN JP 2002509721-A/1964
            PD 02-APR-2002
            PF 24-MAR-1999 JP 2000541291
            PR 27-MAR-1998 US 60/079678
            PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PJ JAMES A MCSWIGGEN
            PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17 /organism='Homo sapiens (human)'.

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 202 AAATAAAGAGAAATAG 218
Db 17 AAATAAAGAGAAATAG 1

RESULT 145
LOCUS      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 1536 from Patent WO0192524.
ACCESSION  CQ616796
VERSION     CQ616796.1 GI:41667014
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 1536 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
source     1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1081 TCGGGCTGGTCTCTGG 1097
Db 1 TCGGGCTGGTCTCTGG 17

RESULT 144
BD201322/c
LOCUS      17 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION  BD201322
VERSION     1 GI:33011092
KEYWORDS   JP 2002509721-A/4348.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
JOURNAL   Patent: JP 2002509721-A 4348 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT   OS Homo sapiens (human)
            PN JP 2002509721-A/1964
            PD 02-APR-2002
            PF 24-MAR-1999 JP 2000541291
            PR 27-MAR-1998 US 60/079678
            PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PJ JAMES A MCSWIGGEN
            PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17 /organism='Homo sapiens (human)'.

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 203 AAATAAAGAGAAATAG 219
Db 17 AGTAATAGAGAAATAG 1

RESULT 144
BD201322/c
LOCUS      17 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response.
ACCESSION  BD201322
VERSION     1 GI:33011092
KEYWORDS   JP 2002509721-A/4348.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 17)
AUTHORS   Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE     Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
JOURNAL   Patent: JP 2002509721-A 4348 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT   OS Homo sapiens (human)
            PN JP 2002509721-A/1964
            PD 02-APR-2002
            PF 24-MAR-1999 JP 2000541291
            PR 27-MAR-1998 US 60/079678
            PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
            PJ JAMES A MCSWIGGEN
            PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17 /organism='Homo sapiens (human)'.

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

```

RESULT 146
LOCUS CQ616797 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 1537 from Patent WO0192524.
ACCESSION CQ616797
VERSION CQ616797.1 GI:41667015
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 1537 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1082 GCGGCTGGTGCTCTGGA 1098
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GGGGCTGGTGCCCTGGA 17

RESULT 147
LOCUS CQ623620 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8360 from Patent WO0192524.
ACCESSION CQ623620
VERSION CQ623620.1 GI:41673838
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8360 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 390 GATGGCTGGAGAAAGT 406
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GAGGAGCTGGAGAAAGT 17

RESULT 148
LOCUS CQ623623 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8363 from Patent WO0192524.
ACCESSION CQ623623
VERSION CQ623623.1 GI:41673841
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8363 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 393 GGGCTGGAGAAAGTTCA 409
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GAGCTGGAGAAAGTGCA 17

RESULT 149
LOCUS CQ624832/c 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 9572 from Patent WO0192524.
ACCESSION CQ624832
VERSION CQ624832.1 GI:41675050
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 9572 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 CTCGACAGCTGGGATGT 985
| | | | | | | | | | | | | | | | | | | | | |
Db 17 CTCGACAGCGGGATGT 1

RESULT 150
LOCUS AR188676 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4164 from patent US 6346398.
ACCESSION AR188676
VERSION AR188676.1 GI:20234641
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Favco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4164 12-FEB-2002;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"

```
/mol_type="unassigned DNA"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTGCAACTTTGGAAAC 1583
Db 1 CTGCAATTGGAAACC 17

RESULT 151
ARI88677
LOCUS ARI88677 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4165 from patent US 6346398.
ACCESSION ARI88677
VERSION ARI88677.1 GI:20234642
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4165 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned DNA"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCACACTTTGGAAACT 1584
Db 1 TGCACATTGGAAACCT 17

RESULT 152
ARI88762/c
LOCUS ARI88762 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4250 from patent US 6346398.
ACCESSION ARI88762
VERSION ARI88762.1 GI:20234727
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4250 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned DNA"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 AAGGTAATATTTCCAA 1165
Db 17 AAGGAAATATTTCCCA 1

RESULT 153
ARI90246
LOCUS ARI90246 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 5734 from patent US 6346398.
```

```
ACCESSION ARI90246
VERSION ARI90246.1 GI:20236211
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5734 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned DNA"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTGCAACTTTGGAAAC 1583
Db 1 CTGCAAGTTTGGAAACC 17

RESULT 154
ARI90247
LOCUS ARI90247 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 5735 from patent US 6346398.
ACCESSION ARI90247
VERSION ARI90247.1 GI:20236212
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5735 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned DNA"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCACACTTTGGAAACT 1584
Db 1 TGCACATTGGAAACCT 17

RESULT 155
ARI90332/c
LOCUS ARI90332 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 5820 from patent US 6346398.
ACCESSION ARI90332
VERSION ARI90332.1 GI:20236297
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5820 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned DNA"
```

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGTAATATTTCCAA 1165
 ||||| ||||| ||||| |||||
 Db 17 AAGGAAATATTTCCCA 1

RESULT 156
 AR192330/c AR192330 17 bp DNA linear PAT 20-APR-2002
 LOCUS Sequence 7818 from patent US 6346398.
 DEFINITION AR192330.
 ACCESSION AR192330.
 VERSION AR192330.1 GI:20238295
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
 TITLE Method and reagent for the treatment of diseases or conditions
 related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6346398-A 7818 12-FEB-2002;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAA 1851
 ||||| ||||| ||||| |||||
 Db 17 AAAAAAAAAACAAAAA 1

RESULT 157
 AR192331/c AR192331 17 bp DNA linear PAT 20-APR-2002
 LOCUS Sequence 7819 from patent US 6346398.
 DEFINITION AR192331
 ACCESSION AR192331
 VERSION AR192331.1 GI:20238296
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
 TITLE Method and reagent for the treatment of diseases or conditions
 related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6346398-A 7819 12-FEB-2002;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAA 1851
 ||||| ||||| ||||| |||||
 Db 17 AAAAAAAAAACAAAAA 1

RESULT 158
 AR200289/c AR200289 17 bp DNA linear PAT 20-APR-2002
 LOCUS Sequence 46 from patent US 6355785.
 DEFINITION AR200289
 ACCESSION AR200289

VERSION AR200289.1 GI:20250363
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Rando, R.F., Fennewald, S., Zendequi, J.G., Ojwang, J.O., Hogan, M.E.,
 Pommer, Y. and Mazumder, A.
 TITLE Guanosine-rich oligonucleotide integrase inhibitors
 JOURNAL Patent: US 6355785-A 46 12-MAR-2002;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1705 CCCCTCCCTCCACCAC 1721
 ||||| ||||| ||||| |||||
 Db 17 CCCACCACCCACCAC 1

RESULT 159
 AR262421/c AR262421 17 bp DNA linear PAT 29-JAN-2003
 LOCUS Sequence 46 from patent US 6323185.
 DEFINITION AR262421
 ACCESSION AR262421
 VERSION AR262421.1 GI:28073852
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Rando, R.F., Fennewald, S., Zendequi, J.G., Ojwang, J.O. and Hogan, M.E.
 TITLE Anti-viral guanosine-rich oligonucleotides and method of treating
 HIV
 JOURNAL Patent: US 6323185-A 46 27-NOV-2001;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1705 CCCCTCCCTCCACCAC 1721
 ||||| ||||| ||||| |||||
 Db 17 CCCACCACCCACCAC 1

RESULT 160
 AR324529 AR324529 17 bp RNA linear PAT 17-AUG-2003
 LOCUS Sequence 1931 from patent US 6566127.
 DEFINITION AR324529
 ACCESSION AR324529
 VERSION AR324529.1 GI:33710337
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
 TITLE Method and reagent for the treatment of diseases or conditions
 related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6566127-A 1931 20-MAY-2003;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="unassigned RNA"

<hr/>					
Query Match 0.7%; Score 13.8; DB 1; Length 17;					
Best Local Similarity 88.2%; Pred. No. 1.3e+02;					
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
 QY 1567 CTGCAACTTTGGAAAC 1583					
Db 1 CTGCAAAATTGGAAACC 17					
 RESULT 161					
AR324530 AR324530 17 bp RNA PAT 17-AUG-2003					
LOCUS Sequence 1932 from patent US 6566127.					
DEFINITION AR324530					
ACCESSION AR324530.1 GI:33710338					
VERSION AR324530.1					
KEYWORDS Unknown.					
SOURCE Unknown.					
ORGANISM Unclassified.					
REFERENCE 1 (bases 1 to 17)					
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.					
TITLE Method and reagent for the treatment of diseases or conditions					
related to levels of vascular endothelial growth factor receptor					
JOURNAL Patent: US 6566127-A 1932 20-MAY-2003;					
FEATURES Location/Qualifiers					
source 1..17					
/organism="unknown"					
/mol_type="unassigned RNA"					
 Query Match 0.7%; Score 13.8; DB 1; Length 17;					
Best Local Similarity 88.2%; Pred. No. 1.3e+02;					
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
 QY 1567 CTGCAACTTTGGAAAC 1583					
Db 1 CTGCAAGTTTGGAAACC 17					
 RESULT 164					
AR325212 AR325212 17 bp RNA PAT 17-AUG-2003					
LOCUS Sequence 2614 from patent US 6566127.					
DEFINITION AR325212					
ACCESSION AR325212					
VERSION AR325212.1 GI:33711020					
KEYWORDS Unknown.					
SOURCE Unknown.					
ORGANISM Unclassified.					
REFERENCE 1 (bases 1 to 17)					
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.					
TITLE Method and reagent for the treatment of diseases or conditions					
related to levels of vascular endothelial growth factor receptor					
JOURNAL Patent: US 6566127-A 2614 20-MAY-2003;					
FEATURES Location/Qualifiers					
source 1..17					
/organism="unknown"					
/mol_type="unassigned RNA"					
 Query Match 0.7%; Score 13.8; DB 1; Length 17;					
Best Local Similarity 88.2%; Pred. No. 1.3e+02;					
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
 QY 1568 TGCAACTTTGGAAACT 1584					
Db 1 TGCAAAATTTGGAAACCT 17					
 RESULT 162					
AR324615/c AR324615 17 bp RNA PAT 17-AUG-2003					
LOCUS Sequence 2017 from patent US 6566127.					
DEFINITION AR324615					
ACCESSION AR324615					
VERSION AR324615.1 GI:33710423					
KEYWORDS Unknown.					
SOURCE Unknown.					
ORGANISM Unclassified.					
REFERENCE 1 (bases 1 to 17)					
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.					
TITLE Method and reagent for the treatment of diseases or conditions					
related to levels of vascular endothelial growth factor receptor					
JOURNAL Patent: US 6566127-A 2017 20-MAY-2003;					
FEATURES Location/Qualifiers					
source 1..17					
/organism="unknown"					
/mol_type="unassigned RNA"					
 Query Match 0.7%; Score 13.8; DB 1; Length 17;					
Best Local Similarity 88.2%; Pred. No. 1.3e+02;					
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
 QY 1149 AAGTAATAATTCCAA 1165					
Db 17 AAGGAATAATTTCCCA 1					
 RESULT 163					
AR325211 AR325211 17 bp RNA PAT 17-AUG-2003					
LOCUS Sequence 2613 from patent US 6566127.					
DEFINITION AR325211					
ACCESSION AR325211					
VERSION AR325211.1 GI:33711019					
KEYWORDS Unknown.					
SOURCE Unknown.					
ORGANISM Unclassified.					
REFERENCE 1 (bases 1 to 17)					
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.					
TITLE Method and reagent for the treatment of diseases or conditions					
related to levels of vascular endothelial growth factor receptor					
JOURNAL Patent: US 6566127-A 3602 20-MAY-2003;					
FEATURES Location/Qualifiers					
source 1..17					
/organism="unknown"					
/mol_type="unassigned RNA"					
 Query Match 0.7%; Score 13.8; DB 1; Length 17;					
Best Local Similarity 88.2%; Pred. No. 1.3e+02;					
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
 QY 1568 TGCAACTTTGGAAACT 1584					
Db 1 TGCAAGTTTGGAAACCT 17					
 RESULT 165					
AR326200/c AR326200 17 bp RNA PAT 17-AUG-2003					
LOCUS Sequence 3602 from patent US 6566127.					
DEFINITION AR326200					
ACCESSION AR326200					
VERSION AR326200.1 GI:33712008					
KEYWORDS Unknown.					
SOURCE Unknown.					
ORGANISM Unclassified.					
REFERENCE 1 (bases 1 to 17)					
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.					
TITLE Method and reagent for the treatment of diseases or conditions					
related to levels of vascular endothelial growth factor receptor					
JOURNAL Patent: US 6566127-A 3602 20-MAY-2003;					
FEATURES Location/Qualifiers					
source 1..17					
/organism="unknown"					
/mol_type="unassigned RNA"					
 Query Match 0.7%; Score 13.8; DB 1; Length 17;					
Best Local Similarity 88.2%; Pred. No. 1.3e+02;					
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
 QY 1567 CTGCAACTTTGGAAAC 1583					
Db 1 CTGCAAAATTGGAAACC 17					
 RESULT 166					
AR326200/c AR326200 17 bp RNA PAT 17-AUG-2003					
LOCUS Sequence 3602 from patent US 6566127.					
DEFINITION AR326200					
ACCESSION AR326200					
VERSION AR326200.1 GI:33712008					
KEYWORDS Unknown.					
SOURCE Unknown.					
ORGANISM Unclassified.					
REFERENCE 1 (bases 1 to 17)					
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.					
TITLE Method and reagent for the treatment of diseases or conditions					
related to levels of vascular endothelial growth factor receptor					

Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 17 AAACAAACAAACAAAA 1

RESULT 166
AR326201/c
LOCUS AR326201 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3603 from patent US 6566127.
ACCESSION AR326201
VERSION AR326201.1 GI:33712009
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3603 20-MAY-2003;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 17 AAACAAACAAACAAAA 1

RESULT 167
AR328859/c
LOCUS AR328859 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6261 from patent US 6566127.
ACCESSION AR328859
VERSION AR328859.1 GI:33714667
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6261 20-MAY-2003;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 17 AAACAAACAAACAAAA 1

RESULT 168
AR402091
LOCUS AR402091 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 431 from patent US 6623962.
ACCESSION AR402091
VERSION AR402091.1 GI:40149541
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors
JOURNAL Patent: US 6623962-A 431 23-SEP-2003;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 174 AATGGCATCTTAAGAG 190
Db 1 AATGGCATCTTAAGGG 17

RESULT 169
AR457859
LOCUS AR457859 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1536 from patent US 6686188.
ACCESSION AR457859
VERSION AR457859.1 GI:42692916
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1536 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1081 TGGGGCTGTGCTCTGG 1097
Db 1 TGGGGCTGTGCTCTGG 17

RESULT 170
AR457860
LOCUS AR457860 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1537 from patent US 6686188.
ACCESSION AR457860
VERSION AR457860.1 GI:42692917
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1537 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1082 GCGGCTGGTCTCTGGA 1098
| | | | | | | | | | | | | | | | |
Db 1 GGGGCTGGTCCCTGGA 17

RESULT 171
AR464683
LOCUS AR464683 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8360 from patent US 6686188.
ACCESSION AR464683
VERSION AR464683.1 GI:42699740
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8360 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 390 GATGGCTGGAGAAAGT 406
| | | | | | | | | | | | | | | | |
Db 1 GAGGAGCTGGAGAAAGT 17

RESULT 172
AR464686
LOCUS AR464686 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 8363 from patent US 6686188.
ACCESSION AR464686
VERSION AR464686.1 GI:42699743
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8363 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 393 GGGCTGGAGAAAGTTCA 409
| | | | | | | | | | | | | | | | |
Db 1 GAGCTGGAGAAAGTTCA 17

RESULT 173
AR465895/c
LOCUS AR465895/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 9572 from patent US 6686188.

ACCESSION AR465895
VERSION AR465895.1 GI:42700952
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 9572 03-FEB-2004;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 CTGCAGCTGGGATGT 985
| | | | | | | | | | | | | | | | |
Db 17 CTCGACAGCGGGATGT 1

RESULT 174
AX217108
LOCUS AX217108 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2550 from Patent WO0159103.
ACCESSION AX217108
VERSION AX217108.1 GI:15527169
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL Patent: WO 0159103-A 2550 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAAATAAAAGAGAAAT 217
| | | | | | | | | | | | | | | | |
Db 1 GGAATAAGAGAGAAAT 17

RESULT 175
AX226648/c
LOCUS AX226648/c 17 bp RNA linear PAT 10-SEP-2001
DEFINITION Sequence 20 from Patent WO0157206.
ACCESSION AX226648
VERSION AX226648.1 GI:15555789
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Fattaey, A.R., Jarvis, T., McSwiggen, J., Boehr, R.N. and Holman, P.S.
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme

JOURNAL Patent: WO 0157206-A 20 09-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Pattaey, Ali R. (US)

FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1654 TCTTCTTGATCTTC 1670
Db 17 TCTTCTTAATATTTTC 1

RESULT 176
AX255606/c
LOCUS AX255600 17 bp RNA linear PAT 10-OCT-2001
DEFINITION Sequence 21 from Patent WO0170982.
ACCESSION AX255600
VERSION AX255600.1 GI:16074656
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Beger,C., Barber,J. and Wong-Staal,F.
TITLE Brca-1 regulators and methods of use
JOURNAL Patent: WO 0170982-A 21 27-SEP-2001;
Immusol Incorporated (US) ; Beger, Carmela (DE)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1468 TTGTTTCTATGTGTT 1484
Db 17 TTGATTTCAATGTGTT 1

RESULT 177
AX421858/c
LOCUS AX421858 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 194 from Patent WO0188124.
ACCESSION AX421858
VERSION AX421858.1 GI:21525240
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 194 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1120 TTGGTGCCTTCCAGTAT 1136
Db 17 TTGGTGAATTCAGTAT 1

RESULT 180
AX475498

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1118 AGTTGGTGCCTTCCAGT 1134
Db 17 AGTTGGTGAATTCAGT 1

RESULT 178
AX423222/c
LOCUS AX423222 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 1558 from Patent WO0188124.
ACCESSION AX423222
VERSION AX423222.1 GI:21526604
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1558 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 30 CGCTCCGTCGCGCGCG 46
Db 17 CGCGCGCGTCGCGCGCG 1

RESULT 179
AX423319/c
LOCUS AX423319 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 1655 from Patent WO0188124.
ACCESSION AX423319
VERSION AX423319.1 GI:21526701
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1655 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1120 TTGGTGCCTTCCAGTAT 1136
Db 17 TTGGTGAATTCAGTAT 1

RESULT 180
AX475498

```
LOCUS      AX475498                      17 bp    DNA          linear      PAT 12-AUG-2002
DEFINITION Sequence 719 from Patent WO224750.
ACCESSION  AX475498
VERSION     AX475498.1  GI:22214783
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Zhang, J.
TITLE      Human kidney tumor overexpressed membrane protein 1
JOURNAL    Patent: WO 0224750-A 719 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES   source
            1..17
            Location/Qualifiers
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1414 CCATGACTGTCATGGAT 1430
Db      1 CCAGGACTGTCAGGGAT 17

RESULT 181
AX502944/c
LOCUS      AX502944                      17 bp    DNA          linear      PAT 27-SEP-2002
DEFINITION Sequence 4251 from Patent EP1229046.
ACCESSION  AX502944
VERSION     AX502944.1  GI:23385237
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Zhan, J.
TITLE      Human testis expressed patched like protein
JOURNAL    Patent: EP 1229046-A 4251 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES   source
            1..17
            Location/Qualifiers
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      65 ATTATCTTAACAGAAA 81
Db      17 AATATCATACAAGAAA 1

RESULT 182
AX578360/c
LOCUS      AX578360                      17 bp    RNA          linear      PAT 10-JAN-2003
DEFINITION Sequence 198 from Patent WO0211674.
ACCESSION  AX578360
VERSION     AX578360.1  GI:27647562
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.

LOCUS      AX475498                      17 bp    DNA          linear      PAT 12-AUG-2002
DEFINITION Sequence 719 from Patent WO224750.
ACCESSION  AX475498
VERSION     AX475498.1  GI:22214783
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Zhang, J.
TITLE      Human kidney tumor overexpressed membrane protein 1
JOURNAL    Patent: WO 0224750-A 719 28-MAR-2002;
            Aeomica, Inc. (US)
FEATURES   source
            1..17
            Location/Qualifiers
                /organism="Homo sapiens"
                /mol_type="unassigned RNA"
                /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1722 ATAGAATCAACATATGG 1738
Db      17 ATAGAATCAACATGTG 1

RESULT 183
AX578426
LOCUS      AX578426                      17 bp    RNA          linear      PAT 10-JAN-2003
DEFINITION Sequence 264 from Patent WO0211674.
ACCESSION  AX578426
VERSION     AX578426.1  GI:27647628
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
            and Grupe, A.
TITLE      Method and reagent for the inhibition of calcium activated chloride
            channel-1 (clca-1)
JOURNAL    Patent: WO 0211674-A 264 14-FEB-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
            Thompson, James (US)
FEATURES   source
            1..17
            Location/Qualifiers
                /organism="Homo sapiens"
                /mol_type="unassigned RNA"
                /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1722 ATAGAATCAACATATGG 1738
Db      17 ATAGAATCAACATGTG 1

RESULT 184
AX615236
LOCUS      AX615236                      17 bp    DNA          linear      PAT 20-FEB-2003
DEFINITION Sequence 43 from Patent EP1262488.
ACCESSION  AX615236
VERSION     AX615236.1  GI:28446135
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Gu, Y. and Nguyen, C.T.
TITLE      Human lccl-domain containing protein
JOURNAL    Patent: EP 1262488-A 43 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES   source
            1..17
            Location/Qualifiers
                /organism="Homo sapiens"
                /mol_type="unassigned RNA"
                /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      210 GAAGAAATAGCCAGCTG 226
Db      1 GAAGAAATATCCAACTG 17

RESULT 184
AX615236
LOCUS      AX615236                      17 bp    DNA          linear      PAT 20-FEB-2003
DEFINITION Sequence 43 from Patent EP1262488.
ACCESSION  AX615236
VERSION     AX615236.1  GI:28446135
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Gu, Y. and Nguyen, C.T.
TITLE      Human lccl-domain containing protein
JOURNAL    Patent: EP 1262488-A 43 04-DEC-2002;
            Aeomica, Inc. (US)
FEATURES   source
            1..17
            Location/Qualifiers
                /organism="Homo sapiens"
                /mol_type="unassigned RNA"
                /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      210 GAAGAAATAGCCAGCTG 226
Db      1 GAAGAAATATCCAACTG 17
```

```
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1518 AACACAGTAAAGAAAGAA 1534
Db 1 AACACAGAAAGAAAAA 17

RESULT 185
AX615237
LOCUS AX615237 17 bp DNA linear PAT 20-FEB-2003
DEFINITION Sequence 44 from Patent EP1262488.
ACCESSION AX615237
VERSION AX615237.1 GI:28446136
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Gu, Y.
AUTHORS Human sodium-hydrogen exchanger like protein 1
TITLE Patent: EP 1262488-A 44 04-DEC-2002;
JOURNAL Aeomica, Inc. (US)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1519 AACAGTAAAGAAAGAAC 1535
Db 1 AACAGAAAGAAAAAAC 17

RESULT 186
AX648875/c
LOCUS AX648875 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 715 from Patent EP1273660.
ACCESSION AX648875
VERSION AX648875.1 GI:29151693
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Gu, Y.
AUTHORS Human sodium-hydrogen exchanger like protein 1
TITLE Patent: EP 1273660-A 715 08-JAN-2003;
JOURNAL Aeomica, Inc. (US)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 911 TGTAGCAGATCACTG 927
Db 17 TGTAGCAGACATCAGTG 1

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1102 CAGAAGAACCAAGGTGGA 1118
Db 1 CAGCAGAACCAATGTGGA 17

RESULT 189
AX724533/c
LOCUS AX724533 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2220 from Patent WO03025176.
ACCESSION AX724533
VERSION AX724533.1 GI:30503876
KEYWORDS Mus musculus (house mouse)
SOURCE
```

```
RESULT 187
AX648876/c
LOCUS AX648876 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 716 from Patent EP1273660.
ACCESSION AX648876
VERSION AX648876.1 GI:29151694
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Gu, Y.
AUTHORS Human sodium-hydrogen exchanger like protein 1
TITLE Patent: EP 1273660-A 716 08-JAN-2003;
JOURNAL Aeomica, Inc. (US)
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 910 CTGTAGCAGATCACT 926
Db 17 CTGTAGCAGACATCAGT 1

RESULT 188
AX693083
LOCUS AX693083 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5815 from Patent EP1281758.
ACCESSION AX693083
VERSION AX693083.1 GI:29416047
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Shannon, M., Gu, Y. and Nguyen, C.T.
AUTHORS Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
TITLE Patent: EP 1281758-A 5815 05-FEB-2003;
JOURNAL mdz12
FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1102 CAGAAGAACCAAGGTGGA 1118
Db 1 CAGCAGAACCAATGTGGA 17

RESULT 189
AX724533/c
LOCUS AX724533 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2220 from Patent WO03025176.
ACCESSION AX724533
VERSION AX724533.1 GI:30503876
KEYWORDS Mus musculus (house mouse)
SOURCE
```

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 2220 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 438 GAGAGGGGAGAGGATC 454
Db 17 GTGAGGGGAGAGGATC 1
RESULT 190
AX728002/c
LOCUS AX728002
DEFINITION Sequence 5689 from Patent WO03025176.
ACCESSION AX728002
VERSION AX728002.1 GI:30507345
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 5689 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1040 CTCACCTATTAAAGATC 1056
Db 17 CTCCTTTATTAAAGATC 1
RESULT 191
AX730762
LOCUS AX730762
DEFINITION Sequence 2396 from Patent WO03025175.
ACCESSION AX730762
VERSION AX730762.1 GI:30510105
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as

medicines
JOURNAL Patent: WO 03025175-A 2396 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1827 GATCTCTGAAAAA 1843
Db 1 GATCTCTGAAAAAATAA 17
RESULT 192
AX734915
LOCUS AX734915
DEFINITION Sequence 505 from Patent WO03025177.
ACCESSION AX734915
VERSION AX734915.1 GI:30514192
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 505 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 231 GATGTTGCTAAAGCAAT 247
Db 1 GATCTTGCTACAGCAAT 17
RESULT 193
AX736157
LOCUS AX736157
DEFINITION Sequence 1747 from Patent WO03025177.
ACCESSION AX736157
VERSION AX736157.1 GI:30515434
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 1747 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"

```

/db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1827 GATCTCTGAAAAA 1843
      |||||
Db 1 GATCTCTTAAATAAAA 17

RESULT 194
AX736485/c
LOCUS      AX736485      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 2075 from Patent WO03025177.
ACCESSION  AX736485
VERSION     AX736485.1 GI:30515773
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
JOURNAL     Patent: WO 03025177-A 2075 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    source
            Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 129 GGTGTTACCTTTATC 145
      |||||
Db 17 GGTGTTACCTTTGATC 1

RESULT 195
AX737865
LOCUS      AX737865      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 3455 from Patent WO03025177.
ACCESSION  AX737865
VERSION     AX737865.1 GI:30517153
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
JOURNAL     Patent: WO 03025177-A 3455 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    source
            Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 845 GATCAAAATTGTCATTC 861
      |||||
Db 1 GATCAAAATTGTCATTC 17

RESULT 196
AX783722/c
LOCUS      AX783722      17 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Sequence 2053 from Patent WO03050284.
ACCESSION  AX783722
VERSION     AX783722.1 GI:32951571
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Guo,J.
TITLE       Human prostate cancer candidate protein 1
JOURNAL     Patent: WO 03050284-A 2053 19-JUN-2003;
            Amersham Biosciences (SV) Corp. (US)
FEATURES    source
            Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 511 GCATTGGACTCTCTCA 527
      |||||
Db 17 GCATTGGACTCTCTCA 1

RESULT 197
BD067591
LOCUS      BD067591      17 bp      RNA      linear      PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION  BD067591
VERSION     BD067591.1 GI:22613194
KEYWORDS    JP 2001511003-A/431.
SOURCE      unidentified
ORGANISM    unclassified
REFERENCE   1 (bases 1 to 17)
AUTHORS     Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE       Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
JOURNAL     Patent: JP 2001511003-A 431 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT     OS Unidentified
            PN JP 2001511003-A/431
            PD 07-AUG-2001
            PF 14-JAN-1998 JP 1998532913
            PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
            SAGHR, AKHTAR, PATRICIA FELL, JAMES A MCSWIGGEN PC
            C12N/00,C07K14/71
            CC Strandedness: Single;
            CC Topology: Linear;
            CC Enzymatic nucleic acid treatment of diseases or conditions
            related to
            CC levels of epidermal growth factor receptors
            FH Key Location/Qualifiers
            FT source 1..17 /organism="Unidentified".
            FT Location/Qualifiers
            1..17
            /organism="unidentified"
            /mol_type="genomic RNA"
            /db_xref="taxon:32644"

```

```
Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 174 AATGGCATCTCTAAGAG 190
      ||||| ||||| |||||
Db 1 AATGGCATCTTTAAGGG 17

RESULT 198
AL14295/c
LOCUS      A14295      18 bp      DNA      linear      PAT 05-OCT-1994
DEFINITION oligonucleotide.
ACCESSION A14295
VERSION   A14295.1 GI:640787
KEYWORDS  .
SOURCE    synthetic construct
ORGANISM  synthetic construct
          other sequences: artificial sequences.
REFERENCE 1 (bases 1 to 18)
AUTHORS   .
JOURNAL   Patent: GB 2068971-A 40 19-AUG-1981;
          Location/Qualifiers
FEATURES   source
            1..18
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 190 GGACTTTTGAAGAAATA 206
      ||| ||| ||||| |||||
Db 17 GGATTATGAAGAAATA 1

RESULT 199
AL18146
LOCUS      A18146      18 bp      DNA      linear      PAT 22-APR-1994
DEFINITION Probe specific for region corresponding to amino acids 56 to 61 of
          HUA-B*2703 alpha 1 domain seq ID No:12.
ACCESSION A18146
VERSION   A18146.1 GI:513201
KEYWORDS  .
SOURCE    synthetic construct
ORGANISM  synthetic construct
          other sequences: artificial sequences.
REFERENCE 1 (bases 1 to 18)
AUTHORS   .
JOURNAL   PROCESS FOR AMPLIFYING NUCLEIC ACID
          Patent: WO 9207956-A 14 14-MAY-1992;
          Location/Qualifiers
FEATURES   source
            1..18
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 504 GGCAGCAGCATTTGGGAC 520
      ||| ||| ||||| |||||
Db 2 GGCGCGGAGCATTTGGGAC 18

RESULT 200
A65728/c
LOCUS      A65728      18 bp      DNA      linear      PAT 29-MAR-1999
DEFINITION Sequence 9 from Patent WO9735973.
ACCESSION A65728
VERSION   A65728.1 GI:4531347

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCGCGCTCCGTGCGCGC 44
      ||||| ||||| |||||
Db 17 GCGCGCGCGCGCGCGC 1

RESULT 202
AR049397
LOCUS      AR049397      18 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 12 from patent US 5824515.
ACCESSION AR049397
VERSION   AR049397.1 GI:6005436
KEYWORDS  .
SOURCE    Unknown.
ORGANISM  Unclassified.
          1 (bases 1 to 18)
REFERENCE Hill, A. Vivian. Sinton.
          Process for amplifying nucleic acid
          Patent: US 5824515-A 12 20-OCT-1998;
          Location/Qualifiers
FEATURES   source
            1..18
            /organism="unknown"
```

```
KEYWORDS  .
SOURCE     unidentified
ORGANISM   unidentified
REFERENCE 1
AUTHORS    Lenzen, G., Pietri-Rouxel, F., Drumare, Marie-Francoise and
          Strosberg, A. D.
TITLE     CANINE beta 2- AND beta 3-ADRENERGIC RECEPTORS AND USE THEREOF
JOURNAL   Patent: WO 9735973-A 9 02-OCT-1997;
          VETIGEN (FR)
COMMENT   Other publication FR 2746813 19971003.
FEATURES   Location/Qualifiers
            1..18
            /organism="unidentified"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32644"

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 CCTCCTTCTCCATCTAC 737
      ||||| ||||| |||||
Db 18 CCTCGCTCTCCTCTTAC 2

RESULT 201
A67594/c
LOCUS      A67594      18 bp      DNA      linear      PAT 05-MAY-1999
DEFINITION Sequence 14 from Patent WO9744485.
ACCESSION A67594
VERSION   A67594.1 GI:4756457
KEYWORDS  .
SOURCE     unidentified
ORGANISM   unclassified.
          1 (bases 1 to 18)
REFERENCE Goodfellow, P. N.
          METHODS FOR IDENTIFYING A MUTATION IN A GENE OF INTEREST
          Patent: WO 9744485-A 14 27-NOV-1997;
          HEXAGEN TECHNOLOGY LIMITED (GB)
          Location/Qualifiers
FEATURES   source
            1..18
            /organism="unidentified"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32644"

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCGCGCTCCGTGCGCGC 44
      ||||| ||||| |||||
Db 17 GCGCGCGCGCGCGCGC 1

RESULT 202
AR049397
LOCUS      AR049397      18 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 12 from patent US 5824515.
ACCESSION AR049397
VERSION   AR049397.1 GI:6005436
KEYWORDS  .
SOURCE    Unknown.
ORGANISM  Unclassified.
          1 (bases 1 to 18)
REFERENCE Hill, A. Vivian. Sinton.
          Process for amplifying nucleic acid
          Patent: US 5824515-A 12 20-OCT-1998;
          Location/Qualifiers
FEATURES   source
            1..18
            /organism="unknown"
```


SOURCE
ORGANISM synthetic construct
REFERENCE synthetic construct
AUTHORS other sequences; artificial sequences.
1
Rasmussen, P., Frandsen, N.M., Nyborg, M., Rasmussen, F.W., Hamzavi, R.,
Nielsen, P.E. and Kj Ruliff, S.R.
TITLE Modified pna molecules
JOURNAL Patent: WO 2004024757-A 9 25-MAR-2004;
Santaris Pharma A/S (DK)
FEATURES Location/Qualifiers
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Novel sequence"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 332 GAGTGGCTCCAGAAC 348
Db 18 GAGTGGCTCCGAGAGC 2

RESULT 212
CQ807790/c
LOCUS 18 bp DNA linear PAT 10-MAY-2004
DEFINITION Sequence 1240 from Patent WO2004035803.
ACCESSION CQ807790
VERSION CQ807790.1 GI:4713184
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS other sequences; artificial sequences.
1
Foekens, J., Harbeck, N., Koenig, T., Maier, S., Martens, J., Model, F.,
Nimmrich, I., Rujan, T., Schmitt, A., Schmitt, M., Look, M.P. and
Marx, A.
TITLE Method and nucleic acids for the improved treatment of breast cell.
JOURNAL proliferative disorders
Patent: WO 2004035803-A 1240 29-APR-2004;
Epigenomics AG (DE)
FEATURES Location/Qualifiers
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Detection oligonucleotide for ING4"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1617 TTCAAGCACAACCTCTA 1633
Db 18 TTCAAAACACATCTCTA 2

RESULT 213
CQ876358/c
LOCUS 18 bp DNA linear PAT 04-OCT-2004
DEFINITION Sequence 208 from Patent WO2004065583.
ACCESSION CQ876358
VERSION CQ876358.1 GI:53789962
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS other sequences; artificial sequences.
1
Cobleigh, M.A., Shak, S., Baker, J.B. and Cronin, M.T.
TITLE Gene expression markers for breast cancer prognosis
JOURNAL Patent: WO 2004065583-A 208 05-AUG-2004;

Genomic Health, Inc. (US); Rush University Medical Center (US)
FEATURES Location/Qualifiers
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="probe"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 673 TGGAGGCTGCCAAGGTG 689
Db 17 TGGCAGCTGCCCAGGTG 1

RESULT 214
E29787/c
LOCUS 18 bp DNA linear PAT 18-JUN-2001
DEFINITION Method for discriminating and detecting human coagulation factor V
gene polymorphism.
ACCESSION E29787
VERSION E29787.1 GI:13016883
KEYWORDS JP 1999313676-A/34.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 18)
AUTHORS Takashi, F., Shigetoshi, K., Makoto, H. and Keizo, S.
TITLE Method for discriminating and detecting human coagulation factor V
gene polymorphism
JOURNAL Patent: JP 1999313676-A 34 16-NOV-1999;
OTSUKA PHARMACEUT CO LTD
COMMENT OS Unidentified
PN JP 1999313676-A/34
PD 16-NOV-1999
PF 30-APR-1998 JP 1998120217
PR
PI TAKASHI FUKUI, SHIGETOSHI KINOSHITA, MAKOTO HASHIZUME, PI
KEIZO SUGIMACHI
PC C12N15/09, C12Q1/68, C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..18
FT Location/Qualifiers
source
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1685 CTAGAAAAGCAATCAT 1701
Db 18 CTAGAAAAGCAATGAT 2

RESULT 215
I21931
LOCUS 18 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 12 from patent US 5525492.
ACCESSION I21931
VERSION I21931.1 GI:1602285
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)

AUTHORS Griffiths,A.D., Hoogenboom,H.R.J.M., Marks,J.D., McCafferty,J.,
Winter,G.P. and Grigg,G.W.
TITLE Production of anti-self bodies from antibody segment repertoires
and displayed on phage
JOURNAL Patent: US 6582915-A 14 24-JUN-2003;
FEATURES Location/Qualifiers
source
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 TGTATTACGTTGGGAAGA 811
|||||
Db 2 TGTATTACTGTGCAAGA 18
|||||

RESULT 221
AR4353533
LOCUS 18 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 14 from patent US 6593081.
ACCESSION AR353533
VERSION AR353533.1 GI:33759523
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Griffiths,A.D., Hoogenboom,H.R.J.M., Marks,J.D., McCafferty,J.,
Winter,G.P. and Grigg,G.W.
TITLE Production of anti-self antibodies from antibody segment
repertoires and displayed on phage
JOURNAL Patent: US 6593081-A 14 15-JUL-2003;
FEATURES Location/Qualifiers
source
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 TGTATTACGTTGGGAAGA 811
|||||
Db 2 TGTATTACTGTGCAAGA 18
|||||

RESULT 222
AR442110/c
LOCUS 18 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 9 from patent US 6670124.
ACCESSION AR442110
VERSION AR442110.1 GI:42669367
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Chow,R. and Tonai,R.
TITLE High throughput methods of HLA typing
JOURNAL Patent: US 6670124-A 9 30-DEC-2003;
FEATURES Location/Qualifiers
source
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 382 TGCAGCAAGATGGGCTG 398
|||||

Db 17 TGCAGCACGAGGGGCTG 1
|||||

RESULT 223
AR442224/c
LOCUS 18 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 125 from patent US 6670124.
ACCESSION AR442224
VERSION AR442224.1 GI:42669481
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Chow,R. and Tonai,R.
TITLE High throughput methods of HLA typing
JOURNAL Patent: US 6670124-A 125 30-DEC-2003;
FEATURES Location/Qualifiers
source
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 382 TGCAGCAAGATGGGCTG 398
|||||
Db 17 TGCAGCACGAGGGGCTG 1
|||||

RESULT 224
AR493061
LOCUS 18 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 93 from patent US 6720137.
ACCESSION AR493061
VERSION AR493061.1 GI:47264447
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Roder,M., Plaschke,J. and Ganai,M.
TITLE Microsatellite markers for plants of the species Triticum aestivum
and Tribe triticeae and the use of said markers
JOURNAL Patent: US 6720137-A 93 13-APR-2004;
FEATURES Location/Qualifiers
source
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1696 AATCATTCTCCCTCCC 1712
|||||
Db 2 AATCATTCTCCCTCCC 18
|||||

RESULT 225
AX092726/c
LOCUS 18 bp DNA linear PAT 21-MAR-2001
DEFINITION Sequence 138 from Patent WO0115676.
ACCESSION AX092726
VERSION AX092726.1 GI:13444783
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Rutheria; Primates; Catarrhini; Hominidae; Homo.
1

AUTHORS Hayden,M.R., Brooks-Wilson,A.R., Pimstone,S.N. and Clee,S.M.
TITLE Compositions and methods for modulating hdl cholesterol and triglyceride levels
JOURNAL University of British Columbia (CA) ; Xenon Genetics Inc. (CA)
FEATURES Location/Qualifiers
source 1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1641 CTTTCTGTTATTCTT 1657
||||| ||||| |||||
Db 18 CTTTCTGATTCTCTT 2

RESULT 226
AX113887
LOCUS AX113887 18 bp DNA linear PAT 01-MAY-2001
DEFINITION Sequence 35 from Patent WO0127330.
ACCESSION AX113887
VERSION AX113887.1 GI:13940067
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Ahuja,S., Gonzalez,E. and Mummidu,S.
TITLE Screening for disease susceptibility by genotyping the ccr5 and ccr2 genes
JOURNAL Patent: WO 0127330-A 35 19-APR-2001;
Board of Regents, The University of Texas System (US)

FEATURES
source 1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1506 CCTAGGTCCTAGAAACA 1522
||||| ||||| |||||
Db 1 CCTGGGTCCTAGAAATCA 17

RESULT 227
AX326905
LOCUS AX326905 18 bp DNA linear PAT 07-JAN-2002
DEFINITION Sequence 101 from Patent WO0178894.
ACCESSION AX326905
VERSION AX326905.1 GI:18097616
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Keith,T.
TITLE Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
JOURNAL Patent: WO 0178894-A 101 25-OCT-2001;
Genome Therapeutics Corp. (US)

FEATURES
source 1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

/note="Primer"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1101 GCAGAGACCAAGGTGG 1117
||||| ||||| |||||
Db 2 GCAGAGGACCAAGGTGG 18

RESULT 228
AX378472/c
LOCUS AX378472 18 bp DNA linear PAT 18-MAR-2002
DEFINITION Sequence 261 from Patent WO0206525.
ACCESSION AX378472
VERSION AX378472.1 GI:19574325
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens

ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Cohen,D., Blumenfeld,M., Chumakov,I., Abderrahim,H. and Bihain,B.
TITLE Obesity associated biallelic marker maps
JOURNAL Patent: WO 0206525-A 261 24-JAN-2002;
GENSET (FR)

FEATURES
source 1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

primer_bind 1..18
/note="upstream amplification primer 99-32166 for SEQ 90"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 224 CTGTGAGATGTTGCTA 240
||||| ||||| |||||
Db 17 CTGTGAAGATGATGCTA 1

RESULT 229
AX699211
LOCUS AX699211 18 bp DNA linear PAT 29-MAY-2003
DEFINITION Sequence 152 from Patent WO03000727.
ACCESSION AX699211
VERSION AX699211.1 GI:29499861
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Zhang,Y., Moffatt,M., Cookson,W. and Tinsley,J.O.
TITLE Atopy
JOURNAL Patent: WO 03000727-A 152 03-JAN-2003;
ISIS INNOVATION LIMITED (GB)

FEATURES
source 1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 939 CCAGAACAGGTTGTACT 955
||||| ||||| |||||
Db 1 CCTGAACAGGCTGTACT 17

[illegible][illegible]

PR	07-OCT-1998	CA	2246623	JERRY PELLETIER, MANJULA DAS
PI	C12N15/09, C12Q1/68, C12N15/00			Description of Artificial Sequence: synthetic oligonucleotide
PC	Key	Location/Qualifiers		
PH	1..15	/organism='Artificial Sequence'		
FT	source	Location/Qualifiers		
FT	1..15	/organism='synthetic construct'		
FT	/mol_type='genomic DNA'			
FT	/db_xref='taxon:32630'			
FEATURES				
source				
Query Match	1835	AAAAAAAAAAAAA	1849	Score 13.4; DB 1; Length 15;
Best Local Similarity				93.3%; Pred. NO. 1.2e+02;
Matches	14;	Conservative	0;	Mismatches 1; Indels 0; Gaps 0;
QY	1835	AAAAAAAAAAAAA	1849	
DB	1	AAAAAAAAATAAAAAA	15	
RESULT 236				
LOCUS	AR328438	16 bp	RNA	linear
DEFINITION	Sequence 5840 from patent US 6566127.			
ACCESSION	AR328438			
VERSION	AR328438.1	GI:33714246		
KEYWORDS	Unknown.			
SOURCE	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 16)			
AUTHORS	Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.			
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor			
JOURNAL	Patent: US 6566127-A 5840 20-MAY-2003;			
FEATURES				
source				
Query Match	1281	CTCAATATCACTCAG	1295	Score 13.4; DB 1; Length 16;
Best Local Similarity				93.3%; Pred. NO. 1.3e+02;
Matches	14;	Conservative	0;	Mismatches 1; Indels 0; Gaps 0;
QY	1281	CTCAATATCACTCAG	1295	
DB	16	CTCAATATCACTCAG	2	
RESULT 237				
LOCUS	AX928000/C	16 bp	DNA	linear
DEFINITION	Sequence 86 from Patent WO03085110.			
ACCESSION	AX928000			
VERSION	AX928000.1	GI:40251008		
KEYWORDS	synthetic construct			
SOURCE	synthetic construct			
ORGANISM	other sequences; artificial sequences.			
REFERENCE	1			
AUTHORS	True, C.A., h G.A.M. and Kristjansen, P.E.			
TITLE	Oligomeric compounds for the modulation hif-lalpha expression			
JOURNAL	Patent: WO 03085110-A 86 16-OCT-2003;			
FEATURES				
source				
Query Match	633	AACTACTCAAGGACGGT	649	Score 13.8; DB 1; Length 18;
Best Local Similarity				88.2%; Pred. NO. 1.4e+02;
Matches	15;	Conservative	0;	Mismatches 2; Indels 0; Gaps 0;
QY	633	AACTACTCAAGGACGGT	649	
DB	1	AGCTTCTCAAGGACGGT	17	
RESULT 235				
LOCUS	BD244856	15 bp	DNA	linear
DEFINITION	Oligonucleotide primer capable of making the non-specific double strand formation unstable.			
ACCESSION	BD244856			
VERSION	BD244856.1	GI:33054626		
KEYWORDS	JP 2002532063-A/1.			
SOURCE	synthetic construct			
ORGANISM	other sequences; artificial sequences.			
REFERENCE	1 (bases 1 to 15)			
AUTHORS	Pelletier, J. and Das, M.			
TITLE	Oligonucleotide primer capable of making the non-specific double strand formation unstable			
JOURNAL	Patent: JP 2002532063-A 1 02-OCT-2002;			
COMMENT	MCGILL UNIVERSITY			
OS	Artificial Sequence			
PN	JP 2002532063-A/1			
PF	02-OCT-2002			
PF	06-OCT-1999	JP 2000574722		

PR	07-OCT-1998	CA	2246623	JERRY PELLETIER, MANJULA DAS
PI	C12N15/09, C12Q1/68, C12N15/00			Description of Artificial Sequence: synthetic oligonucleotide
PC	Key	Location/Qualifiers		
PH	1..15	/organism='Artificial Sequence'		
FT	source	Location/Qualifiers		
FT	1..15	/organism='synthetic construct'		
FT	/mol_type='genomic DNA'			
FT	/db_xref='taxon:32630'			
FEATURES				
source				
Query Match	1835	AAAAAAAAAAAAA	1849	Score 13.4; DB 1; Length 15;
Best Local Similarity				93.3%; Pred. NO. 1.2e+02;
Matches	14;	Conservative	0;	Mismatches 1; Indels 0; Gaps 0;
QY	1835	AAAAAAAAAAAAA	1849	
DB	1	AAAAAAAAATAAAAAA	15	
RESULT 236				
LOCUS	AR328438	16 bp	RNA	linear
DEFINITION	Sequence 5840 from patent US 6566127.			
ACCESSION	AR328438			
VERSION	AR328438.1	GI:33714246		
KEYWORDS	Unknown.			
SOURCE	Unknown.			
ORGANISM	Unclassified.			
REFERENCE	1 (bases 1 to 16)			
AUTHORS	Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.			
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor			
JOURNAL	Patent: US 6566127-A 5840 20-MAY-2003;			
FEATURES				
source				
Query Match	1281	CTCAATATCACTCAG	1295	Score 13.4; DB 1; Length 16;
Best Local Similarity				93.3%; Pred. NO. 1.3e+02;
Matches	14;	Conservative	0;	Mismatches 1; Indels 0; Gaps 0;
QY	1281	CTCAATATCACTCAG	1295	
DB	16	CTCAATATCACTCAG	2	
RESULT 237				
LOCUS	AX928000/C	16 bp	DNA	linear
DEFINITION	Sequence 86 from Patent WO03085110.			
ACCESSION	AX928000			
VERSION	AX928000.1	GI:40251008		
KEYWORDS	synthetic construct			
SOURCE	synthetic construct			
ORGANISM	other sequences; artificial sequences.			
REFERENCE	1			
AUTHORS	True, C.A., h G.A.M. and Kristjansen, P.E.			
TITLE	Oligomeric compounds for the modulation hif-lalpha expression			
JOURNAL	Patent: WO 03085110-A 86 16-OCT-2003;			
FEATURES				
source				
Query Match	633	AACTACTCAAGGACGGT	649	Score 13.8; DB 1; Length 18;
Best Local Similarity				88.2%; Pred. NO. 1.4e+02;
Matches	15;	Conservative	0;	Mismatches 2; Indels 0; Gaps 0;
QY	633	AACTACTCAAGGACGGT	649	
DB	1	AGCTTCTCAAGGACGGT	17	
RESULT 235				
LOCUS	BD244856	15 bp	DNA	linear
DEFINITION	Oligonucleotide primer capable of making the non-specific double strand formation unstable.			
ACCESSION	BD244856			
VERSION	BD244856.1	GI:33054626		
KEYWORDS	JP 2002532063-A/1.			
SOURCE	synthetic construct			
ORGANISM	other sequences; artificial sequences.			
REFERENCE	1 (bases 1 to 15)			
AUTHORS	Pelletier, J. and Das, M.			
TITLE	Oligonucleotide primer capable of making the non-specific double strand formation unstable			
JOURNAL	Patent: JP 2002532063-A 1 02-OCT-2002;			
COMMENT	MCGILL UNIVERSITY			
OS	Artificial Sequence			
PN	JP 2002532063-A/1			
PD	02-OCT-2002			
PF	06-OCT-1999	JP 2000574722		

Query Match 0.7%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 399 GAGAAAGTTCACCTG 413
||| ||||| ||||| |||||
Db 15 GACAAAGTTCACCTG 1

RESULT 238
AR168840/c
LOCUS AR168840 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 66 from patent US 6288042.
ACCESSION AR168840
VERSION AR168840.1 GI:17904970
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando,R.F., Ojwaug,J.O., Hogan,M.E., Wallace,T.L. and Cossum,P.A.
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides
JOURNAL Patent: US 6288042-A 66 11-SEP-2001;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
||| ||||| ||||| |||||
Db 16 CCNCCACCACCAC 1

RESULT 239
AR168847/c
LOCUS AR168847 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 73 from patent US 6288042.
ACCESSION AR168847
VERSION AR168847.1 GI:17904981
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando,R.F., Ojwaug,J.O., Hogan,M.E., Wallace,T.L. and Cossum,P.A.
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides
JOURNAL Patent: US 6288042-A 73 11-SEP-2001;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
||| ||||| ||||| |||||
Db 16 CCNCCACCACCAC 1

RESULT 240
AR168850/c
LOCUS AR168850 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 76 from patent US 6288042.
ACCESSION AR168850
VERSION AR168850.1 GI:17904985
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando,R.F., Ojwaug,J.O., Hogan,M.E., Wallace,T.L. and Cossum,P.A.
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides
JOURNAL Patent: US 6288042-A 76 11-SEP-2001;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
||| ||||| ||||| |||||
Db 16 CCNCCACCACCAC 1

RESULT 241
AR168851/c
LOCUS AR168851 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 77 from patent US 6288042.
ACCESSION AR168851
VERSION AR168851.1 GI:17904987
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando,R.F., Ojwaug,J.O., Hogan,M.E., Wallace,T.L. and Cossum,P.A.
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides
JOURNAL Patent: US 6288042-A 77 11-SEP-2001;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
||| ||||| ||||| |||||
Db 16 CCNCCACCACCAC 1

RESULT 242
BD198937/c
LOCUS BD198937 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
ACCESSION BD198937
VERSION BD198937.1 GI:33008707
KEYWORDS JP 2002509721-A/1963.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 1963 02-APR-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/1963
PD 02-APR-2002.
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,


```

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAAGACAAGG 1114
|||||
Db 3 TGCAGAAGACAAGG 17

RESULT 250
CQ623848
LOCUS      CQ623848      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8588 from Patent WO0192524.
ACCESSION CQ623848
VERSION   CQ623848.1 GI:41674066
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
           Shannon,M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 8588 06-DEC-2001;
           Aeomica, Inc. (US)
FEATURES  Location/Qualifiers
           source
             1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAAGACAAGG 1114
|||||
Db 2 TGCAGAAGACAAGG 16

RESULT 251
CQ623849
LOCUS      CQ623849      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8589 from Patent WO0192524.
ACCESSION CQ623849
VERSION   CQ623849.1 GI:41674067
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
           Shannon,M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 8589 06-DEC-2001;
           Aeomica, Inc. (US)
FEATURES  Location/Qualifiers
           source
             1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAAGACAAGG 1114
|||||
Db 3 TGCAGAAGACAAGG 17

RESULT 252
CQ625289/c
LOCUS      CQ625289/c    17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 10029 from Patent WO0192524.
ACCESSION CQ625289
VERSION   CQ625289.1 GI:41675507
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
           Shannon,M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 10029 06-DEC-2001;
           Aeomica, Inc. (US)
FEATURES  Location/Qualifiers
           source
             1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1066 GTCCAAAGAGGACTC 1080
|||||
Db 17 GTCCACAGAGGACTC 3

RESULT 253
CQ625292/c
LOCUS      CQ625292/c    17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 10032 from Patent WO0192524.
ACCESSION CQ625292
VERSION   CQ625292.1 GI:41675510
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS   Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
           Shannon,M.E.
TITLE     Myosin-like gene expressed in human heart and muscle
JOURNAL   Patent: WO 0192524-A 10032 06-DEC-2001;
           Aeomica, Inc. (US)
FEATURES  Location/Qualifiers
           source
             1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1065 CGTCCAAAGAGGACT 1079
|||||
Db 15 CGTCCACAGAGGACT 1

RESULT 254
E32474/c
LOCUS      E32474
DEFINITION Novel vascular smooth muscle cell growth factor.
ACCESSION E32474

```



```
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCACCCNCCACCAC 1

RESULT 264
AR262451/c
LOCUS AR262451 Sequence 77 from patent US 6323185. 17 bp DNA linear PAT 29-JAN-2003
DEFINITION AR262451
ACCESSION AR262451
VERSION AR262451.1 GI:28073882
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando,R.F., Fennwald,S., Zendequi,J.G., Ojwang,J.O. and Hogan,M.B.
TITLE Anti-viral guanosine-rich oligonucleotides and method of treating HIV
JOURNAL Patent: US 6323185-A 77 27-NOV-2001;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCNCCACCACCAC 1

RESULT 265
AR324616/c
LOCUS AR324616 Sequence 2018 from patent US 6566127. 17 bp RNA linear PAT 17-AUG-2003
DEFINITION AR324616
ACCESSION AR324616
VERSION AR324616.1 GI:33710424
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwigen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2018 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned RNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1149 AAGTAAATATTTC 1163
Db 15 AAGGAAATATTTC 1

RESULT 266
AR457861
LOCUS AR457861 Sequence 1538 from patent US 6686188. 17 bp DNA linear PAT 20-FEB-2004
DEFINITION AR457861
ACCESSION AR457861
VERSION AR457861.1 GI:42692918
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1538 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"
```

```
DEFINITION Sequence 1538 from patent US 6686188.
ACCESSION AR457861
VERSION AR457861.1 GI:42692918
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1538 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1084 GGCTGGTGCTCTGGA 1098
Db 2 GGCTGGTGCTCTGGA 16

RESULT 267
AR457862
LOCUS AR457862 Sequence 1539 from patent US 6686188. 17 bp DNA linear PAT 20-FEB-2004
DEFINITION AR457862
ACCESSION AR457862
VERSION AR457862.1 GI:42692919
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1539 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1084 GGCTGGTGCTCTGGA 1098
Db 1 GGCTGGTGCTCTGGA 15

RESULT 268
AR464689
LOCUS AR464689 Sequence 8366 from patent US 6686188. 17 bp DNA linear PAT 20-FEB-2004
DEFINITION AR464689
ACCESSION AR464689
VERSION AR464689.1 GI:42699746
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8366 03-FEB-2004;
```

```
FEATURES             Location/Qualifiers
     source           1..17
                        /organism="unknown"
                        /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 396 CTCGAGAAAGTTTCAC 410
Db 1 CTCGAGAAAGTGCAC 15

RESULT 269
LOCUS AR464910
DEFINITION Sequence 8587 from patent US 6686188.
ACCESSION AR464910
VERSION AR464910.1 GI:42699967
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8587 03-FEB-2004;
FEATURES Location/Qualifiers
     source           1..17
                        /organism="unknown"
                        /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAAGACCAAGG 1114
Db 3 TGCAGAAGCAACAGG 17

RESULT 270
LOCUS AR464911
DEFINITION Sequence 8588 from patent US 6686188.
ACCESSION AR464911
VERSION AR464911.1 GI:42699968
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8588 03-FEB-2004;
FEATURES Location/Qualifiers
     source           1..17
                        /organism="unknown"
                        /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAAGACCAAGG 1114
Db 2 TGCAGAAGCAACAGG 16

RESULT 271
LOCUS AR464912
DEFINITION Sequence 8589 from patent US 6686188.
ACCESSION AR464912
VERSION AR464912.1 GI:42699969
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8589 03-FEB-2004;
FEATURES Location/Qualifiers
     source           1..17
                        /organism="unknown"
                        /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAAGACCAAGG 1114
Db 1 TGCAGAAGCAACAGG 15

RESULT 272
LOCUS AR466352/c
DEFINITION Sequence 10029 from patent US 6686188.
ACCESSION AR466352
VERSION AR466352.1 GI:42701409
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10029 03-FEB-2004;
FEATURES Location/Qualifiers
     source           1..17
                        /organism="unknown"
                        /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1066 GTCCAAAGAGGACTC 1080
Db 17 GTCCACAGAGGACTC 3

RESULT 273
LOCUS AR466355/c
DEFINITION Sequence 10032 from patent US 6686188.
ACCESSION AR466355
VERSION AR466355.1 GI:42701412
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
```


Shannon, M.E.
 Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 Patent: US 6686188-A 10032 03-FEB-2004;
 JOURNAL Location/Qualifiers
 FEATURES
 source
 1..17
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 0.7%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1065 CGTCCAAAGAGACT 1079
 Db 15 CGTCCACAGAGACT 1

RESULT 274
 AX475031/c
 LOCUS
 DEFINITION Sequence 418 from patent US 6692917.
 ACCESSION AR475031
 VERSION AR475031.1
 KEYWORDS
 SOURCE
 ORGANISM
 Unknown.
 Unclassified.
 REFERENCE
 1 (bases 1 to 17)
 AUTHORS Neri, B.P., Hall, J.G., Lyamichev, V. and Smith, L.M.
 TITLE Systems and methods for invasive cleavage reaction on dendrimers
 JOURNAL Patent: US 6692917-A 418 17-FEB-2004;
 FEATURES Location/Qualifiers
 source
 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 566 CGATGAAGCTGCAGAG 580
 Db 16 CGATGACCTGCAGAG 2

RESULT 275
 AX183650/c
 LOCUS
 DEFINITION Sequence 1403 from Patent WO0142511.
 ACCESSION AX183650
 VERSION AX183650.1
 KEYWORDS
 SOURCE
 ORGANISM
 Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE
 1
 AUTHORS Daly, M., Hudson, T.J., Lander, E.S., Rioux, J. and Siminovitch, K.
 TITLE Ibd-related polymorphisms
 JOURNAL Patent: WO 0142511-A 1403 14-JUN-2001;
 WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Ellipsis
 Biotherapeutics Corporation (CA)
 FEATURES Location/Qualifiers
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 94 AAAAAATGAAATTCCT 109
 Db 17 AAAAAANGAAATTCAT 2

RESULT 276
 AX217109
 LOCUS
 DEFINITION Sequence 2551 from Patent WO0159103.
 ACCESSION AX217109
 VERSION AX217109.1
 KEYWORDS
 SOURCE
 ORGANISM
 synthetic construct
 synthetic construct
 other sequences; artificial sequences.
 REFERENCE
 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 2551 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
 McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES Location/Qualifiers
 source
 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 203 AATAAAGAGAAAT 217
 Db 2 AATAAAGAGAAAT 16

RESULT 277
 AX264296
 LOCUS
 DEFINITION Sequence 1687 from Patent WO0173002.
 ACCESSION AX264296
 VERSION AX264296.1
 KEYWORDS
 SOURCE
 ORGANISM
 Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE
 1
 AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
 TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
 JOURNAL Patent: WO 0173002-A 1687 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
 FEATURES Location/Qualifiers
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 198 GAAGAAATAAAGAA 212
 Db 2 GCAGAAATAAAGAA 16

RESULT 278
 AX264297/c
 LOCUS
 AX264297

DEFINITION Sequence 1688 from Patent WO0173002.
ACCESSION AX264297
VERSION AX264297.1 GI:16513096
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 1688 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 198 GAAGAAATAAAAGAA 212
Db 16 GCAGAAATAAAAGAA 2
RESULT 279
AX502942/c
LOCUS AX502942 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 4249 from Patent EPI229046.
ACCESSION AX502942
VERSION AX502942.1 GI:23385235
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 4249 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 67 TATCTTAACAAGAA 81
Db 17 TATCATAACAAGAA 3
RESULT 280
AX502943/c
LOCUS AX502943 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 4250 from Patent EPI229046.
ACCESSION AX502943
VERSION AX502943.1 GI:23385236
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.

TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 4250 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 67 TATCTTAACAAGAA 81
Db 16 TATCATAACAAGAA 2
RESULT 281
AX532149/c
LOCUS AX532149 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 1658 from Patent EPI239051.
ACCESSION AX532149
VERSION AX532149.1 GI:25256083
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1658 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1497 GAAATGCTGCTAGG 1511
Db 17 GAAATGCTGCTTGG 3
RESULT 282
AX532150/c
LOCUS AX532150 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 1659 from Patent EPI239051.
ACCESSION AX532150
VERSION AX532150.1 GI:25256085
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Shannon, M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 1659 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1497 GAAATGCTGCTAGG 1511
Db 17 GAAATGCTGCTTGG 3

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1497 GAAATGCTGCCTAGG 1511
 |||||
 Db 16 GAAATGCTGCCTGG 2

RESULT 283

LOCUS AX532151/c
 DEFINITION Sequence 1660 from Patent EP1239051.
 ACCESSION AX532151
 VERSION AX532151.1 GI:25256087
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

17 bp DNA linear PAT 22-NOV-2002

REFERENCE 1
 AUTHORS Shannon, M.
 TITLE Human pox-like protein 1
 JOURNAL Patent: EP 1239051-A 1660 11-SEP-2002;
 Acemica, Inc. (US)

FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1497 GAAATGCTGCCTAGG 1511
 |||||
 Db 15 GAAATGCTGCCTGG 1

RESULT 284

LOCUS AX579422/c
 DEFINITION Sequence 1260 from Patent WO0211674.
 ACCESSION AX579422
 VERSION AX579422.1 GI:27648624
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

17 bp RNA linear PAT 10-JAN-2003

REFERENCE 1
 AUTHORS Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
 TITLE Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)
 JOURNAL Patent: WO 0211674-A 1260 14-FEB-2002;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
 Thompson, James (US)

FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned RNA"
 /db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1722 ATAGATCAACATAT 1736
 |||||
 Db 16 ATAGATCAACATGT 2

RESULT 285

AX579854/c
 LOCUS AX579854
 DEFINITION Sequence 1692 from Patent WO0211674.
 ACCESSION AX579854
 VERSION AX579854.1 GI:27649056
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

17 bp RNA linear PAT 10-JAN-2003

REFERENCE 1
 AUTHORS Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
 TITLE Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)
 JOURNAL Patent: WO 0211674-A 1692 14-FEB-2002;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
 Thompson, James (US)

FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned RNA"
 /db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1722 ATAGATCAACATAT 1736
 |||||
 Db 15 ATAGATCAACATGT 1

RESULT 286

LOCUS AX648877/c
 DEFINITION Sequence 717 from Patent EP1273660.
 ACCESSION AX648877
 VERSION AX648877.1 GI:29151695
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

17 bp DNA linear PAT 22-MAR-2003

REFERENCE 1
 AUTHORS Gu, Y.
 TITLE Human sodium-hydrogen exchanger like protein 1
 JOURNAL Patent: EP 1273660-A 717 08-JAN-2003;
 Aeomica, Inc. (US)

FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 910 CTGTAGCAGATCA 924
 |||||
 Db 16 CTGTAGCAGACATCA 2

RESULT 287

LOCUS AX648878/c
 DEFINITION Sequence 718 from Patent EP1273660.
 ACCESSION AX648878
 VERSION AX648878.1 GI:29151696
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

17 bp DNA linear PAT 22-MAR-2003

REFERENCE 1
 AUTHORS Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
 TITLE Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)
 JOURNAL Patent: WO 0211674-A 1260 14-FEB-2002;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
 Thompson, James (US)

FEATURES
 source
 1..17
 /organism="Homo sapiens"
 /mol_type="unassigned RNA"
 /db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

1
Gu, Y.
Human sodium-hydrogen exchanger like protein 1
Patent: EP 1273660-A 718 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 CTGTAGCAGATCA 924
Db 15 CTGTAGCAGATCA 1
|||||

RESULT 288
AX648913
LOCUS AX648913 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 753 from Patent EPI273660.
ACCESSION AX648913
VERSION AX648913.1 GI:29151731
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

1
Gu, Y.
Human sodium-hydrogen exchanger like protein 1
Patent: EP 1273660-A 753 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 563 TTTCGATGAAGTCA 577
Db 3 TTTCGATGAAGTCA 17
|||||

RESULT 289
AX648914
LOCUS AX648914 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 754 from Patent EPI273660.
ACCESSION AX648914
VERSION AX648914.1 GI:29151732
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

1
Gu, Y.
Human sodium-hydrogen exchanger like protein 1
Patent: EP 1273660-A 754 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 563 TTTCGATGAAGTCA 577
Db 2 TTTCGATGAAGTCA 16
|||||

RESULT 290
AX648915
LOCUS AX648915 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 755 from Patent EPI273660.
ACCESSION AX648915
VERSION AX648915.1 GI:29151733
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

1
Gu, Y.
Human sodium-hydrogen exchanger like protein 1
Patent: EP 1273660-A 755 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 563 TTTCGATGAAGTCA 577
Db 1 TTTCGATGAAGTCA 15
|||||

RESULT 291
AX672337
LOCUS AX672337 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 782 from Patent WO03004526.
ACCESSION AX672337
VERSION AX672337.1 GI:29330685
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

1
Telerman, A., Amson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 782 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1248 ATCATGAGAGGTT 1262
Db 2 ATCATGAGAGGTT 16
|||||

```

RESULT 292
AX672766
LOCUS AX672766 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1211 from Patent WO03004526.
ACCESSION AX672766
VERSION AX672766.1 GI:29331114
KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM Homo sapiens
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1211 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1354 GAGCAGTCTACTTG 1368
Db 1 GATCCAGTCTACTTG 15
RESULT 293
AX722790/c
LOCUS AX722790 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 477 from Patent WO03025176.
ACCESSION AX722790
VERSION AX722790.1 GI:30423291
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM Mus musculus
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 477 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1650 ATTATCTTCTTGAT 1664
Db 16 ATTTCTTCTTGAT 2
RESULT 294
AX723876
LOCUS AX723876 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1563 from Patent WO03025176.
ACCESSION AX723876

```

```

VERSION AX723876.1 GI:30503219
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM Mus musculus
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 1563 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1831 TCTGAAAAA 1845
Db 3 TCTGAAAAA 17
RESULT 295
AX725443/c
LOCUS AX725443 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3130 from Patent WO03025176.
ACCESSION AX725443
VERSION AX725443.1 GI:30504786
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM Mus musculus
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 3130 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 440 GAGGGGAGAGATC 454
Db 15 GAGGGGAGAGATC 1
RESULT 296
AX725734/c
LOCUS AX725734 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3421 from Patent WO03025176.
ACCESSION AX725734
VERSION AX725734.1 GI:30505077
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM Mus musculus
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 3421 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 440 GAGGGGAGAGATC 454
Db 15 GAGGGGAGAGATC 1
RESULT 297
AX725734/c
LOCUS AX725734 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3421 from Patent WO03025176.
ACCESSION AX725734
VERSION AX725734.1 GI:30505077
KEYWORDS Mus musculus (house mouse)
SOURCE
ORGANISM Mus musculus
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 3421 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 440 GAGGGGAGAGATC 454
Db 15 GAGGGGAGAGATC 1

```


Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1831 TCTGAAAAA 1845
Db 3 TCTGAAAAA 17

RESULT 301
AX733113
LOCUS AX733113 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4747 from Patent WO03025175.
ACCESSION AX733113
VERSION AX733113.1 GI:30512456
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 4747 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1704 TCCCTCCCTCCAC 1718
Db 3 TCCCTCCCTCCAC 17

RESULT 302
AX734098
LOCUS AX734098 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5732 from Patent WO03025175.
ACCESSION AX734098
VERSION AX734098.1 GI:30513441
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 5732 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1704 TCCCTCCCTCCAC 1718
Db 3 TCCCTCCCTCCAC 17

RESULT 303
AX734177
LOCUS AX734177 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5811 from Patent WO03025175.
ACCESSION AX734177
VERSION AX734177.1 GI:30513520
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 5811 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1704 TCCCTCCCTCCAC 1718
Db 3 TCCCTCCCTCCAC 17

RESULT 304
AX734975
LOCUS AX734975 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 565 from Patent WO03025177.
ACCESSION AX734975
VERSION AX734975.1 GI:30514252
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 565 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1831 TCTGAAAAA 1845
Db 3 TCTGAAAAA 17

RESULT 305
AX736940
LOCUS AX736940 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2530 from Patent WO03025177.
ACCESSION AX736940
VERSION AX736940.1 GI:30516228
KEYWORDS

<p>apoptosis and/or viral resistance phenomena and their use as medicines</p> <p>Patent: WO 03040369-A 1658 15-MAY-2003;</p> <p>Molecular Engines Laboratories (FR)</p> <p>Location/Qualifiers</p> <p>1. .17</p> <p>/organism="Homo sapiens"</p> <p>/mol_type="unassigned DNA"</p> <p>/db_xref="taxon:9606"</p>	<p>apoptosis and/or viral resistance phenomena and their use as medicines</p> <p>Patent: WO 03040369-A 1658 15-MAY-2003;</p> <p>Molecular Engines Laboratories (FR)</p> <p>Location/Qualifiers</p> <p>1. .17</p> <p>/organism="Homo sapiens"</p> <p>/mol_type="unassigned DNA"</p> <p>/db_xref="taxon:9606"</p>
<p>Query Match</p> <p>Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;</p> <p>Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p>	<p>Query Match</p> <p>Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;</p> <p>Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p>
<p>QY 825 TCAAGAATGGCTTCT 839</p> <p>Db 3 TCAAGAAAGGCTTCT 17</p>	<p>QY 825 TCAAGAATGGCTTCT 839</p> <p>Db 3 TCAAGAAAGGCTTCT 17</p>
<p>RESULT 308</p> <p>AX759487</p> <p>LOCUS AX759487 17 bp DNA linear PAT 25-JUN-2003</p> <p>DEFINITION Sequence 2808 from Patent WO03040369.</p> <p>ACCESSION AX759487</p> <p>VERSION AX759487.1 GI:32254103</p> <p>KEYWORDS</p> <p>SOURCE Homo sapiens (human)</p> <p>ORGANISM</p> <p>Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.</p>	<p>RESULT 308</p> <p>AX759487</p> <p>LOCUS AX759487 17 bp DNA linear PAT 25-JUN-2003</p> <p>DEFINITION Sequence 2808 from Patent WO03040369.</p> <p>ACCESSION AX759487</p> <p>VERSION AX759487.1 GI:32254103</p> <p>KEYWORDS</p> <p>SOURCE Homo sapiens (human)</p> <p>ORGANISM</p> <p>Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.</p>
<p>REFERENCE</p> <p>AUTHORS Telerman,A., Amson,R. and Tuijnder,M.</p> <p>TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines</p>	<p>REFERENCE</p> <p>AUTHORS Telerman,A., Amson,R. and Tuijnder,M.</p> <p>TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines</p>
<p>JOURNAL</p> <p>Patent: WO 03040369-A 2808 15-MAY-2003;</p> <p>Molecular Engines Laboratories (FR)</p> <p>Location/Qualifiers</p> <p>1. .17</p> <p>/organism="Homo sapiens"</p> <p>/mol_type="unassigned DNA"</p> <p>/db_xref="taxon:9606"</p>	<p>JOURNAL</p> <p>Patent: WO 03040369-A 2808 15-MAY-2003;</p> <p>Molecular Engines Laboratories (FR)</p> <p>Location/Qualifiers</p> <p>1. .17</p> <p>/organism="Homo sapiens"</p> <p>/mol_type="unassigned DNA"</p> <p>/db_xref="taxon:9606"</p>
<p>Query Match</p> <p>Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;</p> <p>Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p>	<p>Query Match</p> <p>Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;</p> <p>Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p>
<p>QY 1831 TCTGAAAAAAGAAAA 1845</p> <p>Db 3 TCTGAAAAAAGAAAA 17</p>	<p>QY 1831 TCTGAAAAAAGAAAA 1845</p> <p>Db 3 TCTGAAAAAAGAAAA 17</p>
<p>RESULT 309</p> <p>AX760053/c</p> <p>LOCUS AX760053 17 bp DNA linear PAT 25-JUN-2003</p> <p>DEFINITION Sequence 3374 from Patent WO03040369.</p> <p>ACCESSION AX760053</p> <p>VERSION AX760053.1 GI:32254669</p> <p>KEYWORDS</p> <p>SOURCE Homo sapiens (human)</p> <p>ORGANISM</p> <p>Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.</p>	<p>RESULT 309</p> <p>AX760053/c</p> <p>LOCUS AX760053 17 bp DNA linear PAT 25-JUN-2003</p> <p>DEFINITION Sequence 3374 from Patent WO03040369.</p> <p>ACCESSION AX760053</p> <p>VERSION AX760053.1 GI:32254669</p> <p>KEYWORDS</p> <p>SOURCE Homo sapiens (human)</p> <p>ORGANISM</p> <p>Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.</p>
<p>REFERENCE</p> <p>AUTHORS Telerman,A., Amson,R. and Tuijnder,M.</p> <p>TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines</p>	<p>REFERENCE</p> <p>AUTHORS Telerman,A., Amson,R. and Tuijnder,M.</p> <p>TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines</p>
<p>JOURNAL</p> <p>Patent: WO 03040369-A 3374 15-MAY-2003;</p> <p>Molecular Engines Laboratories (FR)</p> <p>Location/Qualifiers</p> <p>1. .17</p> <p>/organism="Homo sapiens"</p> <p>/mol_type="unassigned DNA"</p> <p>/db_xref="taxon:9606"</p>	<p>JOURNAL</p> <p>Patent: WO 03040369-A 3374 15-MAY-2003;</p> <p>Molecular Engines Laboratories (FR)</p> <p>Location/Qualifiers</p> <p>1. .17</p> <p>/organism="Homo sapiens"</p> <p>/mol_type="unassigned DNA"</p> <p>/db_xref="taxon:9606"</p>
<p>Query Match</p> <p>Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;</p> <p>Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p>	<p>Query Match</p> <p>Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;</p> <p>Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p>
<p>QY 743 TCACACAGGTATCA 757</p> <p>Db 3 TCACACAGGTATCA 17</p>	<p>QY 743 TCACACAGGTATCA 757</p> <p>Db 3 TCACACAGGTATCA 17</p>
<p>RESULT 307</p> <p>AX758337</p> <p>LOCUS AX758337 17 bp DNA linear PAT 25-JUN-2003</p> <p>DEFINITION Sequence 1658 from Patent WO03040369.</p> <p>ACCESSION AX758337</p> <p>VERSION AX758337.1 GI:32252953</p> <p>KEYWORDS</p> <p>SOURCE Homo sapiens (human)</p> <p>ORGANISM</p> <p>Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.</p>	<p>RESULT 307</p> <p>AX758337</p> <p>LOCUS AX758337 17 bp DNA linear PAT 25-JUN-2003</p> <p>DEFINITION Sequence 1658 from Patent WO03040369.</p> <p>ACCESSION AX758337</p> <p>VERSION AX758337.1 GI:32252953</p> <p>KEYWORDS</p> <p>SOURCE Homo sapiens (human)</p> <p>ORGANISM</p> <p>Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.</p>
<p>REFERENCE</p> <p>AUTHORS Telerman,A., Amson,R. and Tuijnder,M.</p> <p>TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines</p>	<p>REFERENCE</p> <p>AUTHORS Telerman,A., Amson,R. and Tuijnder,M.</p> <p>TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines</p>
<p>JOURNAL</p> <p>Patent: WO 03040369-A 384 15-MAY-2003;</p> <p>Molecular Engines Laboratories (FR)</p> <p>Location/Qualifiers</p> <p>1. .17</p> <p>/organism="Homo sapiens"</p> <p>/mol_type="unassigned DNA"</p> <p>/db_xref="taxon:9606"</p>	<p>JOURNAL</p> <p>Patent: WO 03040369-A 384 15-MAY-2003;</p> <p>Molecular Engines Laboratories (FR)</p> <p>Location/Qualifiers</p> <p>1. .17</p> <p>/organism="Homo sapiens"</p> <p>/mol_type="unassigned DNA"</p> <p>/db_xref="taxon:9606"</p>
<p>Query Match</p> <p>Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;</p> <p>Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p>	<p>Query Match</p> <p>Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;</p> <p>Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;</p>
<p>QY 82 ACCAACTGGAAAAA 96</p> <p>Db 2 ATCAACTGGAAAAA 16</p>	<p>QY 82 ACCAACTGGAAAAA 96</p> <p>Db 2 ATCAACTGGAAAAA 16</p>
<p>RESULT 306</p> <p>AX757063</p> <p>LOCUS AX757063 17 bp DNA linear PAT 25-JUN-2003</p> <p>DEFINITION Sequence 384 from Patent WO03040369.</p> <p>ACCESSION AX757063</p> <p>VERSION AX757063.1 GI:32251679</p> <p>KEYWORDS</p> <p>SOURCE Homo sapiens (human)</p> <p>ORGANISM</p> <p>Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.</p>	<p>RESULT 306</p> <p>AX757063</p> <p>LOCUS AX757063 17 bp DNA linear PAT 25-JUN-2003</p> <p>DEFINITION Sequence 384 from Patent WO03040369.</p> <p>ACCESSION AX757063</p> <p>VERSION AX757063.1 GI:32251679</p> <p>KEY</p>

RESULT 314
AX783723/C

LOCUS AX783723 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2054 from Patent WO03050284.
ACCESSION AX783723
VERSION AX783723.1 GI:32951572
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2054 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 511 GCATTGGGACTCTC 525
Db 16 GCATTGGGACTCTC 2
RESULT 315
AX783724/c
LOCUS AX783724 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2055 from Patent WO03050284.
ACCESSION AX783724
VERSION AX783724.1 GI:32951573
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2055 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 511 GCATTGGGACTCTC 525
Db 15 GCATTGGGACTCTC 1
RESULT 316
AR165194/c
LOCUS AR165194 15 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 8 from patent US 6274708.
ACCESSION AR165194
VERSION AR165194.1 GI:16238662
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Hilton,D.James.
TITLE Mouse interleukin-11 receptor

JOURNAL Patent: US 6274708-A 8 14-AUG-2001;
FEATURES
source
1..15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 13.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.3e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1343 TGGAGTGCCTGGAGC 1357
Db 15 TGGAGGCGNTGGAGY 1
RESULT 317
AR056166/c
LOCUS AR056166 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 370 from patent US 5837542.
ACCESSION AR056166
VERSION AR056166.1 GI:5981743
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 370 17-NOV-1998;
FEATURES
source
1..15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1829 TCTCTGAAAAAAA 1841
Db 13 TCTCTGAAAAAAA 1
RESULT 318
AR113924/c
LOCUS AR113924 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 370 from patent US 6132967.
ACCESSION AR113924
VERSION AR113924.1 GI:14094246
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 370 17-OCT-2000;
FEATURES
source
1..15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1829 TCTCTGAAAAAAA 1841
Db 13 TCTCTGAAAAAAA 1

```

RESULT 319
BD268106/c
LOCUS
DEFINITION
  BD268106
  15 bp DNA linear PAT 17-JUL-2003
  Stabilized biologically active peptides, and identification,
  synthesis and utilization methods.
ACCESSION
  BD268106
  1 GI:33077874
VERSION
  JP 2002534059-A/16
KEYWORDS
  synthetic construct
SOURCE
  synthetic construct
  other sequences; artificial sequences.
REFERENCE
  1 (bases 1 to 15)
  Altman,E.
  Stabilized biologically active peptides, and identification,
  synthesis and utilization methods
  Patent: JP 2002534059-A 16 15-OCT-2002;
  THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
COMMENT
  OS Artificial Sequence
  PN JP 2002534059-A/16
  PD 15-OCT-2002
  PF 12-OCT-1999 JP 2000576003
  PR 13-OCT-1998 US 60/104013,14-DEC-1998 US 60/112150 PT
  ELLIOT ALTMAN
  PC C12N15/09,A61K38/00,A61K47/48,A61P31/04,C07K5/075,C07K5/097,
  C07K14/47,
  PC C12N1/11,C12N1/21,C12N5/10,C12Q1/02//(C12N1/21,C12R1:19), PC
  (C12N1/21,C12R1:46), (C12N1/21,C12R1:44), (C12Q1/02,C12R1:19), PC
  (C12Q1/02,C12R1:46), (C12Q1/02,C12R1:44), (C12Q1/02,C12R1:01), PC
  C12N15/00,
  PC C12N5/00,A61K37/02
  CC Description of Artificial Sequence: primer fragment FH Key
  Location/Qualifiers
  FT source 1..15
  FT /organism='Artificial Sequence'.
  FEATURES
  .source
  1..15
  /organism='synthetic construct'
  /mol_type='genomic DNA'
  /db_xref='taxon:32630'
  Query Match 0.7%; Score 13; DB 1; Length 15;
  Best Local Similarity 100.0%; Pred. No. 1.4e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
  Qy 475 GAATTCATAGAT 487
  Db 15 GAATTCATAGAT 3
  RESULT 320
  BD268107/c
  LOCUS
  DEFINITION
    BD268107
    15 bp DNA linear PAT 17-JUL-2003
    Stabilized biologically active peptides, and identification,
    synthesis and utilization methods.
  ACCESSION
    BD268107
    1 GI:33077875
  VERSION
    JP 2002534059-A/17
  KEYWORDS
    synthetic construct
  SOURCE
    synthetic construct
    other sequences; artificial sequences.
  REFERENCE
    1 (bases 1 to 15)
    Altman,E.
    Stabilized biologically active peptides, and identification,
    synthesis and utilization methods
    Patent: JP 2002534059-A 17 15-OCT-2002;
    THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
  COMMENT
    OS Artificial Sequence
    PN JP 2002534059-A/17
    PD 15-OCT-2002
    PF 12-OCT-1999 JP 2000576003
    PR 13-OCT-1998 US 60/104013,14-DEC-1998 US 60/112150 PT
    ELLIOT ALTMAN
  
```

```

PC C12N15/09,A61K38/00,A61K47/48,A61P31/04,C07K5/075,C07K5/097,
PC C07K14/47,
PC C12N1/11,C12N1/21,C12N5/10,C12Q1/02//(C12N1/21,C12R1:19), PC
(C12N1/21,C12R1:46), (C12N1/21,C12R1:44), (C12Q1/02,C12R1:19), PC
(C12Q1/02,C12R1:46), (C12Q1/02,C12R1:44), (C12Q1/02,C12R1:01), PC
C12N15/00,
PC C12N5/00,A61K37/02
CC Description of Artificial Sequence: primer fragment FH Key
Location/Qualifiers
FT source 1..15
FT /organism='Artificial Sequence'.
  FEATURES
  .source
  1..15
  /organism='synthetic construct'
  /mol_type='genomic DNA'
  /db_xref='taxon:32630'
  Query Match 0.7%; Score 13; DB 1; Length 15;
  Best Local Similarity 100.0%; Pred. No. 1.4e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
  Qy 475 GAATTCATAGAT 487
  Db 15 GAATTCATAGAT 3
  RESULT 321
  BD268108/c
  LOCUS
  DEFINITION
    BD268108
    15 bp DNA linear PAT 17-JUL-2003
    Stabilized biologically active peptides, and identification,
    synthesis and utilization methods.
  ACCESSION
    BD268108
    1 GI:33077876
  VERSION
    JP 2002534059-A/18
  KEYWORDS
    synthetic construct
  SOURCE
    synthetic construct
    other sequences; artificial sequences.
  REFERENCE
    1 (bases 1 to 15)
    Altman,E.
    Stabilized biologically active peptides, and identification,
    synthesis and utilization methods
    Patent: JP 2002534059-A 18 15-OCT-2002;
    THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
  COMMENT
    OS Artificial Sequence
    PN JP 2002534059-A/18
    PD 15-OCT-2002
    PF 12-OCT-1999 JP 2000576003
    PR 13-OCT-1998 US 60/104013,14-DEC-1998 US 60/112150 PT
    ELLIOT ALTMAN
  PC C12N15/09,A61K38/00,A61K47/48,A61P31/04,C07K5/075,C07K5/097,
  C07K14/47,
  PC C12N1/11,C12N1/21,C12N5/10,C12Q1/02//(C12N1/21,C12R1:19), PC
  (C12N1/21,C12R1:46), (C12N1/21,C12R1:44), (C12Q1/02,C12R1:19), PC
  (C12Q1/02,C12R1:46), (C12Q1/02,C12R1:44), (C12Q1/02,C12R1:01), PC
  C12N15/00,
  PC C12N5/00,A61K37/02
  CC Description of Artificial Sequence: primer fragment FH Key
  Location/Qualifiers
  FT source 1..15
  FT /organism='Artificial Sequence'.
  FEATURES
  .source
  1..15
  /organism='synthetic construct'
  /mol_type='genomic DNA'
  /db_xref='taxon:32630'
  Query Match 0.7%; Score 13; DB 1; Length 15;
  Best Local Similarity 100.0%; Pred. No. 1.4e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
  Qy 475 GAATTCATAGAT 487
  Db 15 GAATTCATAGAT 3
  RESULT 322
  BD268109/c
  LOCUS
  DEFINITION
    BD268109
    15 bp DNA linear PAT 17-JUL-2003
    Stabilized biologically active peptides, and identification,
    synthesis and utilization methods.
  ACCESSION
    BD268109
    1 GI:33077877
  VERSION
    JP 2002534059-A/19
  KEYWORDS
    synthetic construct
  SOURCE
    synthetic construct
    other sequences; artificial sequences.
  REFERENCE
    1 (bases 1 to 15)
    Altman,E.
    Stabilized biologically active peptides, and identification,
    synthesis and utilization methods
    Patent: JP 2002534059-A 19 15-OCT-2002;
    THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
  COMMENT
    OS Artificial Sequence
    PN JP 2002534059-A/19
    PD 15-OCT-2002
    PF 12-OCT-1999 JP 2000576003
    PR 13-OCT-1998 US 60/104013,14-DEC-1998 US 60/112150 PT
    ELLIOT ALTMAN
  
```

```

RESULT 322
AX633215/c
LOCUS AX633215 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 354 from Patent EP1260586.
ACCESSION AX633215
VERSION AX633215.1 GI:28468829
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
Mewiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweeder,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Wolff,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 354 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1. .15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1829 TCCTCGAAAAAA 1841
Db 13 TCCTCGAAAAAA 1
RESULT 323
A11765
LOCUS A11765 16 bp DNA linear PAT 27-NOV-1993
DEFINITION Nucleotide sequence 4 from patent number EP0228018.
ACCESSION A11765
VERSION A11765.1 GI:489383
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS other sequences; artificial sequences.
TITLE Habermann,P. and Muellner,H.
JOURNAL GM-CSF protein, its derivatives, preparation of such proteins and
their use
JOURNAL Patent: EP 0228018-A 4 08-JUL-1987;
HOECHST AKTIENGESELLSCHAFT
FEATURES
source
1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
Query Match 0.7%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 992 GGGTGCCATGGAT 1004
Db 1 GGGTGCCATGGAT 13
RESULT 324
AX252970
LOCUS AX252970 16 bp DNA linear PAT 05-OCT-2001
DEFINITION Sequence 13 from Patent WO0168900.
ACCESSION AX252970

```

```

VERSION AX252970.1 GI:15986224
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Walcher,M., Wagner,M. and Snaidr,J.
TITLE Method for specifically detecting microorganisms by polymerase
chain reaction
JOURNAL Patent: WO 0168900-A 13 20-SEP-2001;
Vermicon AG (DE)
FEATURES
source
1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Beschreibung der kunstlichen Sequenz:
Oligonukleotidprimer"
Query Match 0.7%; Score 13; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 1.5e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 1444 ATGTTGCTGCTGCTG 1458
Db 2 AGGTGCTGCTGCTG 16
RESULT 325
A168848/c
LOCUS A168848 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 74 from patent US 6288042.
ACCESSION A168848
VERSION A168848.1 GI:17904982
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Rando,R.F., Ojwaug,J.O., Hogan,M.E., Wallace,T.L. and Cossum,P.A.
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides
JOURNAL Patent: US 6288042-A 74 11-SEP-2001;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1706 CCTCTCCTCCACCAC 1721
Db 16 CCCNCCNCCNCCAC 1
RESULT 326
A168852/c
LOCUS A168852 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 78 from patent US 6288042.
ACCESSION A168852
VERSION A168852.1 GI:17904988
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Rando,R.F., Ojwaug,J.O., Hogan,M.E., Wallace,T.L. and Cossum,P.A.
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides
JOURNAL Patent: US 6288042-A 78 11-SEP-2001;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

```

Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

Unclassified.
1 (bases 1 to 17)
AUTHORS Fiddes,J.C. and Abraham,J.A.
TITLE Methods of producing recombinant fibroblast growth factors
JOURNAL Patent: US 5514566-A 19 07-MAY-1996;
FEATURES Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1329 TTTTGGATCCCAAG 1341
Db 14 TTTTGGATCCCAAG 2

RESULT 336
AR401993
LOCUS AR401993 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 333 from patent US 6623962.
ACCESSION AR401993
VERSION AR401993.1 GI:40149443
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors
JOURNAL Patent: US 6623962-A 333 23-SEP-2003;
FEATURES Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1330 TTTTGGATCCCAAGC 1342
Db 2 TTTTGGATCCCAAGC 14

RESULT 337
AR458912
LOCUS AR458912 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2589 from patent US 6686188.
ACCESSION AR458912
VERSION AR458912.1 GI:42693969
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2589 03-FEB-2004;
FEATURES Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGTGCCCATGG 1002
Db 5 CAGGTGCCCATGG 17

RESULT 338
AR458917
LOCUS AR458917 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2594 from patent US 6686188.
ACCESSION AR458917
VERSION AR458917.1 GI:42693974
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2594 03-FEB-2004;
FEATURES Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 991 AGGTGCCCATGGA 1003
Db 1 AGGTGCCCATGGA 13

RESULT 339
AR482819
LOCUS AR482819 17 bp DNA linear PAT 14-MAY-2004
DEFINITION Sequence 265 from patent US 6703228.
ACCESSION AR482819
VERSION AR482819.1 GI:47245342
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Landers,J., Jordan,B., Housman,D.E. and Charest,A.
TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: US 6703228-A 265 09-MAR-2004;
FEATURES Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1594 ATAACAATTCAT 1606
Db 5 ATAACAATTCAT 17

RESULT 340
AX422454/c
LOCUS AX422454 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 790 from Patent WO0188124.
ACCESSION AX422454
VERSION AX422454.1 GI:21525836
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 790 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1119 GTTGGTGCCTTCC 1131
Db 14 GTTGGTGCCTTCC 2

RESULT 341
AX423117/c
LOCUS AX423117 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 1453 from Patent WO0188124.
ACCESSION AX423117
VERSION AX423117.1 GI:21526499
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 1453 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1119 GTTGGTGCCTTCC 1131
Db 16 GTTGGTGCCTTCC 4

RESULT 342
AX423564/c
LOCUS AX423564 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 1900 from Patent WO0188124.
ACCESSION AX423564
VERSION AX423564.1 GI:21526946
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 1900 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 790 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1119 GTTGGTGCCTTCC 1131
Db 14 GTTGGTGCCTTCC 2

RESULT 343
AX578184/c
LOCUS AX578184 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 22 from Patent WO0211674.
ACCESSION AX578184
VERSION AX578184.1 GI:27647386
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
Thompson,J., Mcswiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
TITLE
Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL
Patent: WO 0211674-A 22 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1152 GTAAATATTTCCTCA 1164
Db 14 GTAAATATTTCCTCA 2

RESULT 344
AX578361/c
LOCUS AX578361 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 199 from Patent WO0211674.
ACCESSION AX578361
VERSION AX578361.1 GI:27647563
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
Thompson,J., Mcswiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
TITLE
Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL
Patent: WO 0211674-A 199 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;

```


Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1722 ATAGAATCAACAT 1734
Db 13 ATAGAATCAACAT 1

RESULT 345
AX688101/c
LOCUS AX688101 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 833 from Patent EP1281758.

ACCESSION AX688101
VERSION AX688101.1 GI:29410799

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM

REFERENCE
AUTHORS
TITLE
Shannon, M., Gu, Y., and Nguyen, C.T.
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12

JOURNAL
Patent: EP 1281758-A 833 05-FEB-2003;
Aecomica, Inc. (US)

FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1237 AGGCCAGGGCCAT 1249
Db 17 AGGCCAGGGCCAT 5

RESULT 346
AX688106/c
LOCUS AX688106 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 838 from Patent EP1281758.

ACCESSION AX688106
VERSION AX688106.1 GI:29410804

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM

REFERENCE
AUTHORS
TITLE
Shannon, M., Gu, Y., and Nguyen, C.T.
Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12

JOURNAL
Patent: EP 1281758-A 838 05-FEB-2003;
Aecomica, Inc. (US)

FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 AAGGCCAGGGCCA 1248
Db 13 AAGGCCAGGGCCA 1

RESULT 347
AX723059
LOCUS AX723059 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 746 from Patent WO03025176.

ACCESSION AX723059
VERSION AX723059.1 GI:30423560

KEYWORDS

SOURCE Mus musculus (house mouse)

ORGANISM

REFERENCE
AUTHORS
TITLE
Telerman, A., Anson, R., and Tuijinder, M.
Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL
Patent: WO 03025176-A 746 27-MAR-2003;
Molecular Engines Laboratories (FR)

FEATURES
source
1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 845 GATCAAAATGTC 857
Db 1 GATCAAAATGTC 13

RESULT 349
AX726794/c
LOCUS AX726794 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4481 from Patent WO03025176.

ACCESSION AX726794
VERSION AX726794.1 GI:30506137

KEYWORDS

SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 4481 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 466 TGGAGCCCAAGAT 478
Db 17 TGGAGCCCAAGAT 5
RESULT 350
LOCUS AX729200 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 834 from Patent WO03025175.
ACCESSION AX729200
VERSION AX729200.1 GI:30508543
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 834 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 630 ATCAACTACTCAA 642
Db 2 ATCAACTACTCAA 14
RESULT 351
LOCUS AX731823/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3457 from Patent WO03025175.
ACCESSION AX731823
VERSION AX731823.1 GI:30511166
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 3964 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1677 CTCTGATTCTAGA 1689
Db 15 CTCTGATTCTAGA 3
RESULT 353
LOCUS AX732330 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3964 from Patent WO03025175.
ACCESSION AX732330
VERSION AX732330.1 GI:30511673
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 3964 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1429 ATCCAAAGCAGAT 1441
Db 14 ATCCAAAGCAGAT 2
RESULT 352
LOCUS AX732282/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3916 from Patent WO03025175.
ACCESSION AX732282
VERSION AX732282.1 GI:30511625
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 3916 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1677 CTCTGATTCTAGA 1689
Db 15 CTCTGATTCTAGA 3
RESULT 353
LOCUS AX732330 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3964 from Patent WO03025175.
ACCESSION AX732330
VERSION AX732330.1 GI:30511673
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 3964 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

```

/db_xref="taxon:9606"

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY    845 GATCAAAATTGTC 857
Db     1 GATCAAAATTGTC 13
|||||
RESULT 354
AX732492          AX732492          17 bp DNA linear PAT 08-MAY-2003
LOCUS              Sequence 4126 from Patent WO03025175.
DEFINITION          ACCESSION
VERSION             AX732492.1 GI:30511835
KEYWORDS
SOURCE              Homo sapiens (human)
ORGANISM            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE           1
AUTHORS             Telerman,A., Amson,R. and Tuijinder,M.
TITLE               Sequences involved in phenomena of tumour suppression, tumour
JOURNAL             reversion, apoptosis and/or virus resistance and their use as
                    medicines
PATENT              WO 03025175-A 4126 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source              1..17
                    /organism="Homo sapiens"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9606"

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY    967 ATCTGGACAGCTG 979
Db     2 ATCTGGACAGCTG 14
|||||
RESULT 355
AX739518          AX739518          17 bp DNA linear PAT 08-MAY-2003
LOCUS              Sequence 5108 from Patent WO03025177.
DEFINITION          ACCESSION
VERSION             AX739518.1 GI:30518815
KEYWORDS
SOURCE              Homo sapiens (human)
ORGANISM            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE           1
AUTHORS             Telerman,A., Amson,R. and Tuijinder,M.
TITLE               Sequences involved in phenomena of tumour suppression, tumour
JOURNAL             reversion, apoptosis and/or resistance to viruses and the use
                    thereof as medicaments
PATENT              WO 03025177-A 5108 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source              1..17
                    /organism="Homo sapiens"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9606"

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY    203 AATAAAGAAGAA 215

```

```

SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M. and Phan,T.
TITLE       Human angiotensin-like protein 1
JOURNAL     Patent: WO 03037931-A 181 08-MAY-2003;
            Amer sham Biosciences SV Corp. (US)
FEATURES   Location/Qualifiers
            source          1..17
                        0.7%; Score 13; DB 1; Length 17;
                        Best Local Similarity 100.0%; Pred. No. 1.7e+02;
                        Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          662 GCAGGGGGCGGTG 674
            1. .17
            |||||
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Db          5 GCAGGGGGCGGTG 17

RESULT 359
AX753839
LOCUS       AX753839                17 bp    DNA    linear    PAT 23-JUN-2003
DEFINITION Sequence 186 from Patent WO03037931.
ACCESSION  AX753839
VERSION    AX753839.1 GI:32166536
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M. and Phan,T.
TITLE       Human angiotensin-like protein 1
JOURNAL     Patent: WO 03037931-A 186 08-MAY-2003;
            Amer sham Biosciences SV Corp. (US)
FEATURES   Location/Qualifiers
            source          1..17
                        0.7%; Score 13; DB 1; Length 17;
                        Best Local Similarity 100.0%; Pred. No. 1.7e+02;
                        Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          663 CAGGGGGCGGTG 675
            1. .17
            |||||
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Db          1 CAGGGGGCGGTG 13

RESULT 360
AX757635
LOCUS       AX757635                17 bp    DNA    linear    PAT 25-JUN-2003
DEFINITION Sequence 956 from Patent WO03040369.
ACCESSION  AX757635
VERSION    AX757635.1 GI:32252251
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Telerman,A., Anson,R. and Tuijnder,M.
TITLE       Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
JOURNAL     Patent: WO 03040369-A 956 15-MAY-2003;
            Molecular Engines Laboratories (FR)

SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Shannon,M. and Phan,T.
TITLE       Human angiotensin-like protein 1
JOURNAL     Patent: WO 03037931-A 181 08-MAY-2003;
            Amer sham Biosciences SV Corp. (US)
FEATURES   Location/Qualifiers
            source          1..17
                        0.7%; Score 13; DB 1; Length 17;
                        Best Local Similarity 100.0%; Pred. No. 1.7e+02;
                        Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          663 CAGGGGGCGGTG 675
            1. .17
            |||||
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Db          1 CAGGGGGCGGTG 13

RESULT 361
AX757635
LOCUS       AX757635                17 bp    DNA    linear    PAT 27-AUG-2002
DEFINITION Sequence 956 from Patent WO03040369.
ACCESSION  AX757635
VERSION    AX757635.1 GI:32252251
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Telerman,A., Anson,R. and Tuijnder,M.
TITLE       Sequences involved in tumoral suppression, tumoral reversion,
            apoptosis and/or viral resistance phenomena and their use as
            medicines
JOURNAL     Patent: WO 03040369-A 956 15-MAY-2003;
            Molecular Engines Laboratories (FR)

SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Thompson,S.A. and Abraham,J.A.
TITLE       High-level expression of basic fibroblast growth factors having the
            same N-terminals
JOURNAL     Patent: JP 2001169793-A 9 26-JUN-2001;
            SCIOS INC
COMMENT     OS Unidentified
            PN JP 2001169793-A/9
            PD 26-JUN-2001
            PF 20-NOV-2000 JP 2000353649
            PR 29-MAR-1990 US 501206
            PI STEWART A THOMPSON JUDITH A ABRAHAM
            PC C12N15/09,C07K14/50,C12N15/00
            CC Strandedness: Single;
            CC Topology: Linear;
            CC High-level expression of basic fibroblast growth factors CC
            having the same
            CC N-terminals
            FH Key Location/Qualifiers
            FT source          1..17
                        0.7%; Score 13; DB 1; Length 17;
                        Best Local Similarity 100.0%; Pred. No. 1.7e+02;
                        Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          1329 TTTTGGATCCAAG 1341
            1. .17
            |||||
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
Db          14 TTTTGGATCCAAG 2

RESULT 362
BD067493
LOCUS       BD067493                17 bp    RNA    linear    PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION  BD067493
VERSION    BD067493.1 GI:22613096
KEYWORDS   JP 2001511003-A/333.
            unclassified
            ORGANISM unclassified.

```

```

REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
        to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 333 07-AUG-2001,
        RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
        PN JP 2001511003-A/333
        PD 07-AUG-2001
        PR 31-JAN-1997 US 60/036476 04-DEC-1997 US 08/985162 PI
        SAGHIR,AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
        C12N9/00,C07K14/71
        CC Strandedness: Single;
        CC Topology: Linear;
        CC Enzymatic nucleic acid treatment of diseases or conditions CC
        CC levels of epidermal growth factor receptors
        FH Key Location/Qualifiers
        FT source 1..17
        FT /organism='Unidentified'
FEATURES source
        Location/Qualifiers
        1..17
        /organism='unidentified'
        /mol_type='genomic RNA'
        /db_xref='taxon:32644'
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1330 TTTGGATCCCAAGC 1342
Db 2 TTTGGATCCCAAGC 14

RESULT 363
LOCUS BD104092 17 bp DNA linear PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104092.1 GI:22649666
KEYWORDS WO 0192572-A/196.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
        Nishida,M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 196 06-DEC-2001;
        NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
        KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
        NISHIDA
COMMENT OS Artificial Sequence
        PN WO 0192572-A/196
        PD 06-DEC-2001
        PR 01-JUN-2001 WO 2001JP004662
        PR 01-JUN-2000 JP ODP 164798
        PI HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
        MATSUMURA,
        PI SHOGO MORIYA,MICHIO NISHIDA
        PC C1201/68,C12M1/00,C12N15/09,G01N33/53
        CC Description of Artificial Sequence:capture
        FH Key Location/Qualifiers
        FT source 1..17
        FT /organism='Artificial Sequence'
FEATURES source
        Location/Qualifiers
        1..17
        /organism='synthetic construct'
        /mol_type='genomic DNA'
        /db_xref='taxon:32630'
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 33 CTCGGTCGCGGCC 45
Db 16 CTCGGTCGCGGCC 4

RESULT 365
LOCUS AX724533 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2220 from Patent WO03025176.
ACCESSION AX724533
KEYWORDS AX724533.1 GI:30503876
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
        Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
        reversion, apoptosis and/or virus resistance and their use as
        medicines
JOURNAL Patent: WO 03025176-A 2220 27-MAR-2003;
        Molecular Engines Laboratories (FR)

```

```

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 33 CTCGGTCGCGGCC 45
Db 15 CTCGGTCGCGGCC 3

RESULT 364
LOCUS BD104594/c 17 bp DNA linear PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104594
KEYWORDS BD104594.1 GI:22650168
        WO 0192572-A/698.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
        Nishida,M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 698 06-DEC-2001;
        NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
        KAGIYA, TATSUO ICHIHARA,YOSHIYUKI MATSUMURA,SHOGO MORIYA,MICHIO
        NISHIDA
COMMENT OS Artificial Sequence
        PN WO 0192572-A/698
        PD 06-DEC-2001
        PR 01-JUN-2001 WO 2001JP004662
        PR 01-JUN-2000 JP ODP 164798
        PI HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
        MATSUMURA,
        PI SHOGO MORIYA,MICHIO NISHIDA
        PC C1201/68,C12M1/00,C12N15/09,G01N33/53
        CC Description of Artificial Sequence:capture
        FH Key Location/Qualifiers
        FT source 1..17
        FT /organism='Artificial Sequence'
FEATURES source
        Location/Qualifiers
        1..17
        /organism='synthetic construct'
        /mol_type='genomic DNA'
        /db_xref='taxon:32630'
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 33 CTCGGTCGCGGCC 45
Db 16 CTCGGTCGCGGCC 4

RESULT 365
LOCUS AX724533 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2220 from Patent WO03025176.
ACCESSION AX724533
KEYWORDS AX724533.1 GI:30503876
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
        Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
        reversion, apoptosis and/or virus resistance and their use as
        medicines
JOURNAL Patent: WO 03025176-A 2220 27-MAR-2003;
        Molecular Engines Laboratories (FR)

```

```

FEATURES
  source      Location/Qualifiers
    1..17     /organism="Mus musculus"
              /mol_type="unassigned DNA"
              /db_xref="taxon:10090"

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1697 ATCATTCTCCCTCC 1712
Db 2 ATCTTCTCCCTCAC 17

RESULT 366
LOCUS AR365612 17 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 19 from patent US 5514566.
ACCESSION AR365612
VERSION AR365612.1 GI:34429443
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Fiddes,J.C. and Abraham,J.A.
TITLE Methods of producing recombinant fibroblast growth factors
JOURNAL Patent: US 5514566-A 19 07-MAY-1996;
FEATURES
  source      Location/Qualifiers
    1..17     /organism="unknown"
              /mol_type="genomic DNA"

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1424 CATGGATCCAAAGCAG 1439
Db 2 CTTGGATCCAAACAG 17

RESULT 367
AR401993/c
LOCUS AR401993 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 333 from patent US 6623962.
ACCESSION AR401993
VERSION AR401993.1 GI:40149443
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: US 6623962-A 333 23-SEP-2003;
FEATURES
  source      Location/Qualifiers
    1..17     /organism="unknown"
              /mol_type="genomic DNA"

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1421 TGTCTGGATCCAAAG 1436
Db 16 TGGCTGGATCCAAAG 1

RESULT 368

```

```

BD015242
LOCUS BD015242 17 bp DNA linear PAT 27-AUG-2002
DEFINITION High-level expression of basic fibroblast growth factors having the
same N-terminals.
ACCESSION BD015242
VERSION BD015242.1 GI:22556049
KEYWORDS JP 2001169793-A/9.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Thompson,S.A. and Abraham,J.A.
TITLE High-level expression of basic fibroblast growth factors having the
same N-terminals
JOURNAL Patent: JP 2001169793-A 9 26-JUN-2001;
COMMENT SCIOS INC
OS Unidentified
PN JP 2001169793-A/9
PD 26-JUN-2001
PF 20-NOV-2000 JP 2000353649
PR 29-MAR-1990 US 501206
PI STEWART A THOMPSON,JUDITH A ABRAHAM
PC C12N15/09,C07K14/50,C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC High-level expression of basic fibroblast growth factors CC
CC N-terminals having the same
FH Key Location/Qualifiers
FT source 1..17 /organism='Unidentified'.
FEATURES
  source      Location/Qualifiers
    1..17     /organism="unidentified"
              /mol_type="genomic DNA"
              /db_xref="taxon:32644"

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1424 CATGGATCCAAAGCAG 1439
Db 2 CTTGGATCCAAACAG 17

RESULT 369
BD067493/c
LOCUS BD067493 17 bp RNA linear PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION BD067493
VERSION BD067493.1 GI:22613096
KEYWORDS JP 2001511003-A/333.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 333 07-AUG-2001;
COMMENT RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
OS Unidentified
PN JP 2001511003-A/333
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC

```

related to
CC levels of epidermal growth factor receptors
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Unidentified'
FEATURES
source Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic RNA'
/db_xref='taxon:32644'
Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1421 TGTCTGGATCCAAAG 1436
|||
Db 16 TGGCTTGGATCCAAAG 1

Search completed: July 12, 2005, 10:37:31
Job time : 8 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 12, 2005, 10:40:04 ; Search time 9 Seconds
(without alignments)
3.379 Million cell updates/sec

Title: US-09-745-763-35
Perfect score: 1851
Sequence: 1 GGCTAGCCGCGAGCTTAGT.....CTGCAAAAAAAAAAAAAAAAAA 1851

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 448 seqs, 8214 residues

Total number of hits satisfying chosen parameters: 896

Minimum DB seq length: 0
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 448 summaries

Database : rng35.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	28	1.5	29	1 AAV82789	Probe used to isol
C 2	28	1.5	29	1 ABQ92088	Human polynucleoti
C 3	26	1.4	26	1 AAZ58336	Human peptidase NA
C 4	26	1.4	26	1 AAZ58335	Human peptidase NA
C 5	25	1.4	25	1 AAZ58343	Human peptidase NA
C 6	24	1.3	24	1 AAZ58344	Human peptidase NA
C 7	19.2	1.0	24	1 ABA01588	Human neuroprotein
C 8	19.2	1.0	24	1 ABL55122	Human Myb protein
C 9	18	1.0	24	1 ADR44221	Caenorhabditis ele
C 10	17.4	0.9	21	1 ADD14311	Human src biomarke
C 11	17.2	0.9	22	1 ADS13095	Oligo dt PCR prime
C 12	17	0.9	18	1 ADR32355	Rat KDR cytosolic
C 13	17	0.9	18	1 ADR57967	Nucleotide #4 for
C 14	17	0.9	19	1 ADR82260	Hepatitis C virus
C 15	17	0.9	19	1 ADR82257	Hepatitis C virus
C 16	17	0.9	19	1 ADR82261	Hepatitis C virus
C 17	17	0.9	19	1 ADR82258	Hepatitis C virus
C 18	17	0.9	19	1 ADR82256	Hepatitis C virus
C 19	17	0.9	19	1 ADR82259	Hepatitis C virus
C 20	17	0.9	20	1 ADR59805	Micro-channel mole
C 21	16.8	0.9	20	1 ADK23158	Acyl-coenzyme A sy
C 22	16.8	0.9	21	1 AAZ55611	Primer for PTI-1 b
C 23	16.4	0.9	18	1 AAZ69745	Human biallelic ma
C 24	16.4	0.9	20	1 AAV01232	Von Willebrand's f
C 25	16.4	0.9	20	1 AAX93746	PCR primer used to
C 26	16.4	0.9	20	1 ADS75311	PCR primer CCRL2 P
C 27	16.2	0.9	21	1 AAZ44349	Protein kinase inh
C 28	16.2	0.9	21	1 AAH76301	Human PPARgamma cD
C 29	16.2	0.9	21	1 ABK99279	Hepatitis C virus
C 30	16.2	0.9	21	1 ADI17592	Reverse PCR primer
C 31	16.2	0.9	21	1 ADN42680	Human NOV37 RTQ-PC
C 32	16.2	0.9	21	1 ADS82520	RT-PCR primer for
C 33	16	0.9	19	1 AAA82893	cdk4 ribozyme bind

Cell-cycle depende
Hepatitis C virus
Primer BRL367. SY
Cyclin A1 ribozyme
Cyclin A1 ribozyme
Cyclin A1 ribozyme
Cyclin A1 ribozyme
Caenorhabditis ele
EST polymorphic DN
Human TGFb-R sRNA
Human TGFb-R trans
Plant gene polymor
Human glucose-6-ph
PCR primer used in
PCR primer used to
PCR primer for nuc
D-1-deoxyxylulose
Human endometrium
Arabidopsis dmr RA
Mouse interferon B
Human OKL38 3' spl
Murine plasma glut
Chimeric phosphoro
Chimeric phosphoro
PCR primer used to
Human brain natriu
Acyl-coenzyme A sy
Acyl-coenzyme A sy
Human ROMK gene ex
Human CFTR gene as
Human G-protein co
Device with substa
Device with substa
Device with substa
Aromatase siRNA se
Oestrogen receptor
WNV inozyme subatr
WNV inozyme subatr
WNV minus strand A
Tumour suppression
HBV hammerhead rib
Murine oligonucleo
Murine oligonucleo
Hepatitis B virus
Silkworm juvenile
Human single nucle
Streptomyces sp. d
PCR primer D-R use
Murine Sox3 gene P
PCR primer D-R use
Human zmsel mappin
Human zmsel PCR pr
Endothelin 3 (SYX
Allele A oligo #2,
Allele A oligo #1,
Rat Atrial naturer
Rat Atrial naturer
Rat gene specific
Rat RT-PCR primer
Mitogen activated
Mitogen activated
Protein tyrosine p
Rat ANP gene speci
Hv 18-specific ol
PCR primer used to
Streptococcus pyog
VRP gene specific
Fibroblast growth
Vpr-driven constru
rpoB gene oligomer
Human HIF-1 antise
Acyl-coenzyme A sy
Acyl-coenzyme A sy
Multiplex vector 1

107	15.2	0.8	20	1	AAQ92495	Spinach glycerol-3	180	15	0.8	20	1	AAA94503	Antisense oligonuc
108	15.2	0.8	20	1	AAT61766	Primer for Atase c	181	15	0.8	20	1	AAA94505	Antisense oligonuc
109	15.2	0.8	20	1	AAV47686	Unmethylated CpG d	182	15	0.8	20	1	AAA94506	Antisense oligonuc
110	15.2	0.8	20	1	AAV74243	CpG-N motif O-ODN	183	15	0.8	20	1	AAA94508	Antisense oligonuc
111	15.2	0.8	20	1	AAZ02802	PCR primer used to	184	15	0.8	20	1	AB285199	Human oligonucleot
112	15.2	0.8	20	1	AAZ04579	PCR primer used to	185	15	0.8	20	1	AB285565	Human oligonucleot
113	15.2	0.8	20	1	AAZ94968	PCR primer used to	186	15	0.8	20	1	ABD21429	Human transglutami
114	15.2	0.8	20	1	AAZ60081	Forward PCR primer	187	15	0.8	20	1	ABD21795	Human stanniocalci
115	15.2	0.8	20	1	AAZ60557	Human fra-1 mRNA a	188	15	0.8	20	1	ADF11714	Set 2 left PCR pri
116	15.2	0.8	20	1	AAH75307	Mouse inducible NO	189	14.8	0.8	18	1	AAF85699	Multiple repeated
117	15.2	0.8	20	1	AAF99116	Immunostimulatory	190	14.8	0.8	18	1	ADQ26654	Synthetic leader s
118	15.2	0.8	20	1	AAZ08746	Human PD-ABC form	191	14.8	0.8	18	1	ADQ26616	Synthetic leader s
119	15.2	0.8	20	1	AAZ08837	Human PD-ABC form	192	14.8	0.8	18	1	ADQ26622	Synthetic leader s
120	15.2	0.8	20	1	AAF23716	Human PPARgamma an	193	14.8	0.8	18	1	ADQ26692	Synthetic leader s
121	15.2	0.8	20	1	AS974759	Murine SAC1 Gene-s	194	14.8	0.8	19	1	AAA85973	Cdc25 hs ribozyme
122	15.2	0.8	20	1	ABS77759	Angiogenesis inhib	195	14.8	0.8	19	1	AAA85142	Cyclin G1 ribozyme
123	15.2	0.8	20	1	ABL39008	Immunostimulatory	196	14.8	0.8	19	1	AAZ72532	Human biallelic ma
124	15.2	0.8	20	1	ABN86471	Human MMP-2 1306T	197	14.8	0.8	19	1	AAZ72783	Human biallelic ma
125	15.2	0.8	20	1	ABL43517	Human chromosome 1	198	14.8	0.8	19	1	AH56723	S. aureus groE ope
126	15.2	0.8	20	1	ABT13053	Human apolipoprote	199	14.8	0.8	19	1	AH60304	Cyclin G1 ribozyme
127	15.2	0.8	20	1	ABN80988	Mouse caspase 7 ph	200	14.8	0.8	19	1	AH61135	Cdc25 hs ribozyme
128	15.2	0.8	20	1	ABK47992	Human MIP-3 beta R	201	14.8	0.8	19	1	ADJ94210	Human MYOC gene mu
129	15.2	0.8	20	1	ACD99549	Immunostimulatory	202	14.8	0.8	19	1	ADM70255	Plant gene polymor
130	15.2	0.8	20	1	ADB36618	Immunostimulatory	203	14.8	0.8	19	1	ADM86693	Example nucleotide
131	15.2	0.8	20	1	ADD24338	CD2 binding protei	204	14.8	0.8	19	1	ADR80686	Human apolipoprote
132	15.2	0.8	20	1	AAD63540	Human CD2BF1 cDNA	205	14.8	0.8	19	1	ADR81197	Hepatitis C virus
133	15.2	0.8	20	1	AB290044	Human oligonucleot	206	14.8	0.8	19	1	ADR78028	Human apolipoprote
134	15.2	0.8	20	1	ABZ89607	Human oligonucleot	207	14.4	0.8	16	1	ABL57076	Molecular beacon t
135	15.2	0.8	20	1	ABZ90469	Human oligonucleot	208	14.4	0.8	16	1	AAD57846	Target oligonucleo
136	15.2	0.8	20	1	ABZ82795	Mouse HSL chimeric	209	14.4	0.8	16	1	ADF23332	Binding partner sc
137	15.2	0.8	20	1	ABD26699	N35316-derived oli	210	14.4	0.8	16	1	ADS15827	Control probe targ
138	15.2	0.8	20	1	ABD26274	AA398883-derived o	211	14.4	0.8	17	1	AAZ25490	Oestrogen receptor
139	15.2	0.8	20	1	ABD25837	AI085559-derived o	212	14.4	0.8	17	1	AAZ25488	Oestrogen receptor
140	15.2	0.8	20	1	ADH41329	Human ovarian spec	213	14.4	0.8	17	1	AAZ25596	Oestrogen receptor
141	15.2	0.8	20	1	ADH18272	2'-MOE gapmer anti	214	14.4	0.8	17	1	ABK03734	Human CD20 Amberzy
142	15.2	0.8	20	1	ADH18846	2'-MOE gapmer anti	215	14.4	0.8	17	1	ABN00373	Human GDMPLP-1 17-m
143	15.2	0.8	20	1	ADH18638	Human apolipoprote	216	14.4	0.8	17	1	ABN08373	Human GDMPLP-1 17-m
144	15.2	0.8	20	1	ADJ31845	Human splicing fac	217	14.4	0.8	17	1	ABN10038	Human GDMPLP-1 17-m
145	15.2	0.8	20	1	ADK43321	Antisense 2'-MOE g	218	14.4	0.8	17	1	ABN08372	Human GDMPLP-1 17-m
146	15.2	0.8	20	1	ADK43334	Human PTPRA DNA ta	219	14.4	0.8	17	1	ABK57251	Human CUCAL Gene e
147	15.2	0.8	20	1	ADJ24885	Human endothelial	220	14.4	0.8	17	1	ACN01676	WNV inozyme substr
148	15.2	0.8	20	1	ADJ24174	Human endothelial	221	14.4	0.8	17	1	ACN13699	WNV inozyme strand D
149	15.2	0.8	20	1	ADK79679	Chimeric phosphoro	222	14.4	0.8	17	1	ACN12456	WNV minus strand Z
150	15.2	0.8	20	1	ADK75648	Chimeric phosphoro	223	14.4	0.8	17	1	ACN01677	WNV inozyme substr
151	15.2	0.8	20	1	ADK75704	Chimeric phosphoro	224	14.4	0.8	17	1	ACN15154	WNV minus strand A
152	15.2	0.8	20	1	ADK70098	Plant gene polymor	225	14.4	0.8	17	1	ABZ61174	Human K-Ras DNazym
153	15.2	0.8	20	1	ADL91774	Sequencing primer	226	14.4	0.8	17	1	ACD50766	HBV hammerhead rib
154	15.2	0.8	20	1	ADM41705	Cephalosporin C bi	227	14.4	0.8	17	1	ACD63373	HCV minus strand D
155	15.2	0.8	20	1	ADM15799	Murine SAC1 DNA PC	228	14.4	0.8	17	1	ACD59296	HCV DNazyme substr
156	15.2	0.8	20	1	ADO01532	Human IGFBP-1 reve	229	14.4	0.8	17	1	ACD59612	HCV DNazyme substr
157	15.2	0.8	20	1	ADP79070	Chimeric phosphoro	230	14.4	0.8	17	1	ACD50768	HBV hammerhead rib
158	15.2	0.8	20	1	ADN40102	Human selenoprotei	231	14.4	0.8	17	1	ACC65059	Murine oligonucleo
159	15.2	0.8	20	1	ADN40132	Human selenoprotei	232	14.4	0.8	17	1	ACC63426	Murine oligonucleo
160	15.2	0.8	20	1	ADN30177	Hepatocyte growth	233	14.4	0.8	17	1	ACC64367	Murine oligonucleo
161	15.2	0.8	20	1	ADN30248	Hepatocyte growth	234	14.4	0.8	17	1	ACC65664	Murine oligonucleo
162	15.2	0.8	20	1	ADN31637	Human equaiene syn	235	14.4	0.8	17	1	ACC67091	Murine oligonucleo
163	15.2	0.8	20	1	ADO33179	Human apolipoprote	236	14.4	0.8	17	1	ADJ48639	Human tumour suppr
164	15.2	0.8	20	1	ADO33387	Antisense 2'-MOE g	237	14.4	0.8	17	1	ADJ49463	Hepatitis B virus
165	15.2	0.8	20	1	ADO33432	Phosphodiester dou	238	14.4	0.8	17	1	ADM58131	Hepatitis B virus
166	15.2	0.8	20	1	ADO32813	Antisense 2'-MOE g	239	14.4	0.8	17	1	ADM58133	HCV DNazyme substr
167	15.2	0.8	20	1	ADP68918	Human DRK2 antise	240	14.4	0.8	17	1	ADJ84168	HCV DNazyme substr
168	15.2	0.8	20	1	ADP68974	Human DRK2 antise	241	14.4	0.8	17	1	ADJ86043	HCV DNazyme substr
169	15.2	0.8	20	1	ADQ13711	DMD region PCR pri	242	14.4	0.8	17	1	ADR27062	Human single nucle
170	15.2	0.8	20	1	ADJ32216	Human nestin rever	243	14.4	0.8	17	1	ACN73128	Human GDMPLP-1 prob
171	15.2	0.8	20	1	ADT79911	Human squalene syn	244	14.4	0.8	17	1	ACN71463	Human GDMPLP-1 prob
172	15	0.8	15	1	AAZ59263	Human NR8 gene pro	245	14.4	0.8	17	1	ACN73129	Human GDMPLP-1 prob
173	15	0.8	15	1	ADQ81798	Oligonucleotide sy	246	14.4	0.8	17	1	ACN71462	Human GDMPLP-1 prob
174	15	0.8	17	1	ABZ61173	Human K-Ras DNazym	247	14.4	0.8	18	1	AAZ25403	Infectious pancrea
175	15	0.8	18	1	ADF13436	Cdc42-interactng	248	14.4	0.8	18	1	AAA10847	G-alpha-i1 antisen
176	15	0.8	19	1	AAA82892	cdk4 ribozyme bind	249	14.4	0.8	18	1	AAA86639	Cdc 2 kinase hamme
177	15	0.8	19	1	AAA58054	Cell-cycle depende	250	14.4	0.8	18	1	AAA58514	PCR primer used to
178	15	0.8	20	1	AAA94507	Antisense oligonuc	251	14.4	0.8	18	1	AH61805	Cdc 2 kinase hamme
179	15	0.8	20	1	AAA94504	Antisense oligonuc	252	14.4	0.8	18	1	ABZ72355	Gene 216 polymorph

C 253 14.4 0.8 18 1 AAD40167 Cauliflower mosaic
C 254 14.4 0.8 18 1 AAD40589 HIV-1 LTR lucifera
C 255 14.4 0.8 18 1 ABX75208 Human 216 gene all
C 256 14.4 0.8 18 1 ABZ81757 Huntington's disea
C 257 14.4 0.8 18 1 ACC70479 HIV DNA gp41 seque
C 258 14.4 0.8 18 1 ADH71082 Human Vbeta micros
C 259 14.4 0.8 18 1 ADH71082 Gene 216 related a
C 260 14.4 0.8 18 1 ADH71082 Gene 216 ASO prime
C 261 14.4 0.8 18 1 ADH71082 Cyclin A1 ribozyme
C 262 14.4 0.8 18 1 ADH71082 Cyclin A1 ribozyme
C 263 14.4 0.8 18 1 ADH71082 Human GAS2 short i
C 264 14.4 0.8 18 1 ADH71082 Human GAS2 short i
C 265 14.4 0.8 18 1 ADH71082 Extend primer 78 u
C 266 14.4 0.8 18 1 ADH71082 Probe used to isol
C 267 14.4 0.8 18 1 ADH71082 Mouse interleukin-
C 268 14.2 0.8 17 1 AAT95215 Degenerate 17mer p
C 269 14.2 0.8 17 1 AAT95215 Degenerate hybrid
C 270 14.2 0.8 17 1 AAT95215 Human IL4 recepto
C 271 14.2 0.8 17 1 AAT95215 Human IL4 recepto
C 272 14.2 0.8 17 1 AAT95215 Human NR8 gene pro
C 273 14.2 0.8 17 1 AAT95215 Human NR8 gene pro
C 274 14.2 0.8 17 1 AAT95215 Human NR8 gene pro
C 275 14.2 0.8 17 1 AAT95215 Human NR8 gene pro
C 276 14.2 0.8 17 1 AAT95215 Triple helix formi
C 277 14.2 0.8 17 1 AAT95215 Triple helix formi
C 278 14.2 0.8 17 1 AAT95215 Triple helix formi
C 279 14.2 0.8 17 1 AAT95215 Triple helix formi
C 280 14.2 0.8 17 1 AAT95215 Triple helix formi
C 281 14.2 0.8 17 1 AAT95215 Human nicking agen
C 282 14.2 0.8 17 1 AAT95215 Human nicking agen
C 283 14.2 0.8 17 1 AAT95215 Human nicking agen
C 284 14.2 0.8 17 1 AAT95215 Human nicking agen
C 285 14.2 0.8 17 1 AAT95215 Human CD20 Hamme
C 286 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 287 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 288 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 289 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 290 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 291 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 292 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 293 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 294 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 295 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 296 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 297 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 298 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 299 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 300 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 301 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 302 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 303 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 304 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 305 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 306 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 307 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 308 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 309 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 310 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 311 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 312 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 313 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 314 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 315 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 316 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 317 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 318 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 319 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 320 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 321 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 322 14.2 0.8 17 1 AAT95215 Human GMMLP-1 17-m
C 323 13.8 0.7 18 1 AAT95215 Human GMMLP-1 17-m
C 324 13.8 0.7 18 1 AAT95215 Human GMMLP-1 17-m
C 325 13.8 0.7 18 1 AAT95215 Human GMMLP-1 17-m

C 326 13.8 0.7 17 1 AAX71500 Human KDR VEGF rec
C 327 13.8 0.7 17 1 AAX75068 Mouse flt-1 VEGF r
C 328 13.8 0.7 17 1 AAX71415 Human KDR VEGF rec
C 329 13.8 0.7 17 1 AAX72984 Mouse flk-1 VEGF r
C 330 13.8 0.7 17 1 AAX73070 Mouse flk-1 VEGF r
C 331 13.8 0.7 17 1 AAX72985 Mouse flt-1 VEGF r
C 332 13.8 0.7 17 1 AAX75069 Mouse flt-1 VEGF r
C 333 13.8 0.7 17 1 AAX71414 Human KDR VEGF rec
C 334 13.8 0.7 17 1 AAX71414 Human EGF-R target
C 335 13.8 0.7 17 1 AAX79245 Oligonucleotide #3
C 336 13.8 0.7 17 1 AAX79245 Integrin alpha 6 s
C 337 13.8 0.7 17 1 AAX79245 Human TIE-2 substra
C 338 13.8 0.7 17 1 AAX79245 Oestrogen receptor
C 339 13.8 0.7 17 1 AAX79245 Oestrogen receptor
C 340 13.8 0.7 17 1 AAX79245 Human Chk1 ribozym
C 341 13.8 0.7 17 1 AAX79245 Human NOGO Amberzy
C 342 13.8 0.7 17 1 AAX79245 BRL ribozyme seque
C 343 13.8 0.7 17 1 AAX79245 Probe PN(n)T used
C 344 13.8 0.7 17 1 AAX79245 Human GMMLP-1 17-m
C 345 13.8 0.7 17 1 AAX79245 Human GMMLP-1 17-m
C 346 13.8 0.7 17 1 AAX79245 Human GMMLP-1 17-m
C 347 13.8 0.7 17 1 AAX79245 Human GMMLP-1 17-m
C 348 13.8 0.7 17 1 AAX79245 Human GMMLP-1 17-m
C 349 13.8 0.7 17 1 AAX79245 Human KTM1a portin
C 350 13.8 0.7 17 1 AAX79245 Human HTP1 scannin
C 351 13.8 0.7 17 1 AAX79245 Human ERG hamethe
C 352 13.8 0.7 17 1 AAX79245 Human ERG DNazyme
C 353 13.8 0.7 17 1 AAX79245 Human ERG DNazyme
C 354 13.8 0.7 17 1 AAX79245 ON-21 oligonucleot
C 355 13.8 0.7 17 1 AAX79245 Human CLCA1 gene e
C 356 13.8 0.7 17 1 AAX79245 Human CLCA1 gene e
C 357 13.8 0.7 17 1 AAX79245 Human Inozyme substra
C 358 13.8 0.7 17 1 AAX79245 WNV minus strand Z
C 359 13.8 0.7 17 1 AAX79245 WNV Inozyme substra
C 360 13.8 0.7 17 1 AAX79245 WNV Zinzyme substra
C 361 13.8 0.7 17 1 AAX79245 WNV Zinzyme substra
C 362 13.8 0.7 17 1 AAX79245 WNV minus strand A
C 363 13.8 0.7 17 1 AAX79245 WNV Hammerhead Rib
C 364 13.8 0.7 17 1 AAX79245 Tumour suppression
C 365 13.8 0.7 17 1 AAX79245 Human MD212 scanni
C 366 13.8 0.7 17 1 AAX79245 Human H-Ras DNazym
C 367 13.8 0.7 17 1 AAX79245 HCV minus strand D
C 368 13.8 0.7 17 1 AAX79245 HCV DNazyme substra
C 369 13.8 0.7 17 1 AAX79245 Murine oligonucleo
C 370 13.8 0.7 17 1 AAX79245 Murine oligonucleo
C 371 13.8 0.7 17 1 AAX79245 Human Na/H exchang
C 372 13.8 0.7 17 1 AAX79245 Human Na/H exchang
C 373 13.8 0.7 17 1 AAX79245 Anti-HIV L-DNA #48
C 374 13.8 0.7 17 1 AAX79245 Human PCCP1 DNA fr
C 375 13.8 0.7 17 1 AAX79245 Human tumour suppr
C 376 13.8 0.7 17 1 AAX79245 Human tumour suppr
C 377 13.8 0.7 17 1 AAX79245 Human tumour suppr
C 378 13.8 0.7 17 1 AAX79245 Human IL4-R oligon
C 379 13.8 0.7 17 1 AAX79245 Human PKR substra
C 380 13.8 0.7 17 1 AAX79245 Human ADG4673
C 381 13.8 0.7 17 1 AAX79245 Human ADG4673
C 382 13.8 0.7 17 1 AAX79245 Human NOGO recepto
C 383 13.8 0.7 17 1 AAX79245 Human PKR substra
C 384 13.8 0.7 17 1 AAX79245 Human IL4-R derive
C 385 13.8 0.7 17 1 AAX79245 Oligonucleotide as
C 386 13.8 0.7 17 1 AAX79245 HCV DNazyme substra
C 387 13.8 0.7 17 1 AAX79245 HCV DNazyme substra
C 388 13.8 0.7 17 1 AAX79245 Human oligonucleot
C 389 13.8 0.7 17 1 AAX79245 Human GMMLP-1 prob
C 390 13.8 0.7 17 1 AAX79245 Human GMMLP-1 prob
C 391 13.8 0.7 17 1 AAX79245 Human GMMLP-1 prob
C 392 13.8 0.7 17 1 AAX79245 Human GMMLP-1 prob
C 393 13.8 0.7 17 1 AAX79245 Human GMMLP-1 prob
C 394 13.8 0.7 18 1 AAX79245 Oligonucleotide #3
C 395 13.8 0.7 18 1 AAX79245 Human leukocyte an
C 396 13.8 0.7 18 1 AAX79245 Primer CDRBACK. S
C 397 13.8 0.7 18 1 AAX79245 Antisense oligonuc
C 398 13.8 0.7 18 1 AAX79245 Triple helix formi

399 13.8 0.7 18 1 AAT77597 Wheat microsatelli
 C 400 13.8 0.7 18 1 AAV30476 Canine beta-3 adre
 C 401 13.8 0.7 18 1 AAV16014 PCR primer G-R use
 C 402 13.8 0.7 18 1 AAV33800 Human growth hormo
 C 403 13.8 0.7 18 1 AAZ31824 Human G-alpha-13 a
 C 404 13.8 0.7 18 1 AAZ39664 Human Vch aggregat
 C 405 13.8 0.7 18 1 AAZ43273 Murine Sox3 gene p
 C 406 13.8 0.7 18 1 AAZ05258 PCR primer G-R use
 C 407 13.8 0.7 18 1 AAF26702 Human Smad7 phosph
 C 408 13.8 0.7 18 1 AAF92967 Wild type sequence
 C 409 13.8 0.7 18 1 ABZ72129 Gene 216 SSCP dete
 C 410 13.8 0.7 18 1 ABK41013 Human obesity-asso
 C 411 13.8 0.7 18 1 ABS97456 Human diazepam bin
 C 412 13.8 0.7 18 1 ABS66015 Mycobacterium dete
 C 413 13.8 0.7 18 1 ABS66019 Mycobacterium intr
 C 414 13.8 0.7 18 1 AAD34959 Human SDF1 gene am
 C 415 13.8 0.7 18 1 ABK98126 Triple helix formi
 C 416 13.8 0.7 18 1 ABX74982 Human gene 216 pol
 C 417 13.8 0.7 18 1 ADA27361 Human microsatelli
 C 418 13.8 0.7 18 1 AAL60043 Human GH-1 gene am
 C 419 13.8 0.7 18 1 AAL60014 Human GH-1 gene am
 C 420 13.8 0.7 18 1 ADEI3507 HLA class I allele
 C 421 13.8 0.7 18 1 ADEI3393 HLA class I allele
 C 422 13.8 0.7 18 1 ADF13036 Human PCM1 exon 33
 C 423 13.8 0.7 18 1 ADF78408 Chromosomal abnorm
 C 424 13.8 0.7 18 1 ADG70285 CILDB exon 12 and
 C 425 13.8 0.7 18 1 ADG73179 Pseudomonas syring
 C 426 13.8 0.7 18 1 ADH42989 Lower PCR primer u
 C 427 13.8 0.7 18 1 ADH53213 Human APC (adenoma
 C 428 13.8 0.7 18 1 ADL12235 Pseudomonas syring
 C 429 13.8 0.7 18 1 ADM07244 PCR primer 2 used
 C 430 13.8 0.7 18 1 ADM07236 PCR primer 2 used
 C 431 13.8 0.7 18 1 ADJ36710 Human gene 216 SNP
 C 432 13.8 0.7 18 1 ADL09243 HLA locus-specific
 C 433 13.8 0.7 18 1 ADL09357 HLA locus-specific
 C 434 13.8 0.7 18 1 ADL61289 Gene 216 SSCP prim
 C 435 13.8 0.7 18 1 ADM76352 NEPHA gene transcr
 C 436 13.8 0.7 18 1 ADM76353 NEPHA gene transcr
 C 437 13.8 0.7 18 1 ADM06884 Mouse Hnf4 exon 8/
 C 438 13.8 0.7 18 1 ADO26612 Synthetic leader s
 C 439 13.8 0.7 18 1 ADO26628 Synthetic leader s
 C 440 13.8 0.7 18 1 ADP27776 PCR primer to ampl
 C 441 13.8 0.7 18 1 ADP08680 Extend primer 17 u
 C 442 13.8 0.7 18 1 ADQ78196 PCR primer used to
 C 443 13.8 0.7 18 1 ADP84638 Human breast-speci
 C 444 13.8 0.7 18 1 ADR00170 EGFR PCR reverse p
 C 445 13.8 0.7 18 1 ADS0224 Oligonucleotide of
 C 446 13.8 0.7 18 1 ADR97984 Human APC DNA frag
 C 447 13.8 0.7 18 1 ADS08668 Human DNA oligonuc
 C 448 13.6 0.7 15 1 AAS95939 Human CALM1 gene a

ALIGNMENTS

RESULT 1
 AAV82789/c
 ID AAV82789 standard; DNA; 29 BP.
 XX
 AC AAV82789;
 XX
 AC
 XX
 DT 25-FEB-1999 (first entry)
 XX
 XX
 DE Probe used to isolate clone bu45_2 (V82779).
 XX
 XX Secreted protein; nutritional activity; immune stimulating; vaccine;
 KW suppressing activity; haematopoiesis regulating activity;
 KW tissue growth activity; activin; inhibin activity; chemotaxis;
 KW chemokinetic activity; haemostasis; thrombolytic activity; receptor;
 KW ligand; anti-inflammatory; cadherin; tumour invasion suppressor;
 KW tumour inhibition; gene therapy; probe; ss.
 XX
 XX Synthetic.

OS Homo sapiens.
 XX
 PN WO9842739-A2.
 XX
 PD 01-OCT-1998.
 XX
 PF 20-MAR-1998; 98WO-US005653.
 XX
 PR 21-MAR-1997; 97US-00822167.
 PR 19-MAR-1998; 98US-00044466.
 XX
 PA (GEM) GENETICS INST INC.
 XX
 PI Jacobs K, McCoy JM, Lavallie ER, Racie LA, Merberg D, Treacy M;
 PI Spaulding V, Agostino MJ;
 XX
 DR WPI; 1998-609890/51.
 XX
 PT New polynucleotides encoding secreted human proteins - derived from human
 PT foetal brain, adult brain, foetal kidney, placenta or adult pineal gland
 PT cDNA libraries.
 XX
 PS Disclosure; Page 90; 113pp; English.
 XX
 CC Probes AAV82788-97 were used to isolate clones encoding secreted
 CC proteins. The polynucleotides and their secreted proteins are predicted
 CC to have biological activities which would make them suitable for
 CC treating, preventing or ameliorating medical conditions in humans and
 CC animals, although no supporting data is given. Suggested activities
 CC include nutritional activity, immune stimulating (e.g. as vaccines) or
 CC suppressing activity, haematopoiesis regulating activity, tissue growth
 CC activity, activin/inhibin activity, chemotactic/chemokinetic activity,
 CC haemostatic and thrombolytic activity, receptor/ligand activity, anti-
 CC inflammatory activity, cadherin/tumour invasion suppressor activity, and
 CC tumour inhibition activity (no data is given in the specification to
 CC support these activities). The polynucleotide is also stated to be useful
 CC for gene therapy
 XX
 SQ Sequence 29 BP; 11 A; 8 C; 4 G; 5 T; 0 U; 1 Other;
 Query Match 1.5%; Score 28; DB 1; Length 29;
 Best Local Similarity 96.6%; Pred. No. 0.91;
 Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 295 GATTGGCACTTCTGTTGATCTACTGTGGA 323
 DB 29 GATTGGCACTTCTGTTGATCTACTGTGNA 1
 RESULT 2
 ABQ92088/c
 ID ABQ92088 standard; DNA; 29 BP.
 XX
 AC ABQ92088;
 XX
 AC
 XX
 DT 04-OCT-2002 (first entry)
 XX
 DE Human polynucleotide related probe SEQ ID NO 85.
 XX
 XX Human; cytostatic; antirheumatic; antiarthritic; vulnery; analgesic;
 KW antiinflammatory; antibacterial; immunosuppressive; antiparkinsonian;
 KW neuroprotective; nootropic; osteopathic; haemostatic; vasotropic;
 KW antitumor; fungicide; antidiabetic; antisthmatic; antiallergic;
 KW immunostimulant; antiparasitic; secreted protein; transmembrane protein;
 KW cytokine; cell proliferation; cell differentiation; autoimmune disease;
 KW stem cell; growth factor; nervous system disease; neuropathy;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
 KW osteoporosis; severe combined immunodeficiency; SCID; infection;
 KW multiple sclerosis; rheumatoid arthritis; gene therapy; probe; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002065394-A1.

XX 30-MAY-2002.
 XX 22-DEC-2000; 2000US-00745763.
 XX 18-MAR-1998; 98US-00040963.
 XX (JACO/) JACOBS K.
 XX (MCCO/) MCCOY J M.
 XX (LAVA/) LAVALLIE E R.
 XX (COLL/) COLLINS-RACIE L A.
 XX (EVAN/) EVANS C.
 XX (MERB/) MERBERG D.
 XX (TREA/) TREACY M.
 XX (SPAU/) SPAULDING V.
 XX Jacobs K, McCoy JM, Lavallie ER, Collins-Racie LA, Evans C;
 XX Merberg D, Treacy M, Spaulding V;
 XX WPI; 2002-582343/62.
 XX Novel secreted or transmembrane protein and polynucleotide encoding the
 XX protein, useful for diagnosis and treatment of neurological disorders,
 XX cancer, autoimmune diseases, bone disorders and lung or liver fibrosis.
 XX Disclosure; Page 128; 284pp; English.
 XX The invention relates to human secreted or transmembrane protein (I),
 XX their fragments and is encoded by specific complementary deoxyribonucleic
 XX acid (cDNA) inserts (II), where the protein is substantially free from
 XX other mammalian proteins. (I) are useful for preventing, treating or
 XX ameliorating a medical condition, especially immunological treatment or
 XX prevention of tumours. (I) exhibits activity relating to angiogenesis,
 XX cytokine, cell proliferation, cell differentiation, antiinflammatory,
 XX stem cell growth factor activity and activin or inhibin-related
 XX activities. (I) can be used to manipulate stem cells in culture to give
 XX rise to neuroepithelial cells that can be used to augment or replace
 XX cells damaged by illness, autoimmune disease, accidental damage or
 XX genetic disorders. (I) induces the proliferation of neural cells and
 XX regeneration of nerve and brain tissue and is useful for the treatment of
 XX central and peripheral nervous system diseases and neuropathies, such as
 XX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 XX lateral sclerosis. (I) is involved in chemotactic or chemokinetic
 XX activity, regulation of haematopoiesis and is useful for treating myeloid
 XX or lymphoid cell disorders, platelet disorders such as thrombocytopaenia
 XX and for regeneration of bone, cartilage, tendon, ligament and/or nerve
 XX tissue growth and in tissue repair, healing of burns, incisions, ulcers,
 XX for treating osteoporosis, osteoarthritis, bone degenerative disorders or
 XX periodontal disease. (I) is also useful for gut protection or
 XX regeneration and treatment of lung or liver fibrosis, and disorders including
 XX in various tissues, various immune deficiencies and disorders including
 XX severe combined immunodeficiency (SCID), bacterial or fungal infections,
 XX autoimmune disorders e.g. multiple sclerosis, rheumatoid arthritis,
 XX diabetes mellitus, myasthenia gravis, allergic reactions and conditions,
 XX such as asthma or other respiratory problems. (II) is useful to express
 XX recombinant protein, as markers for tissues in which the corresponding
 XX protein is preferentially expressed and in gene therapy. The present
 XX sequence is that of a probe used in the isolation of polynucleotides of
 XX the invention
 XX SQ Sequence 29 BP; 11 A; 8 C; 4 G; 5 T; 0 U; 1 Other;
 Query Match 1.5%; Score 28; DB 1; Length 29;
 Best Local Similarity 96.6%; Pred. No. 0.91;
 Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 295 GATTGGCACTTCTGGTTGATCTGTGGA 323
 Db 29 GATTGGCACTTCTGGTTGATCTGTGNA 1
 RESULT 3
 AAZ58336/c

ID AAZ58336 standard; cDNA; 26 BP.
 XX AAZ58336;
 XX 08-MAY-2000 (first entry)
 XX Human peptidase NAALAD-ase IV PCR primer NAALD4AP4.
 XX NAALAD-ase IV; N-acetylated alpha-linked acidic dipeptidase; human;
 XX prostate cancer; neurodegenerative disease; Alzheimer's disease;
 XX schizophrenia; ALS; Parkinson's disease; peripheral neuropathy;
 XX Huntington's disease; acute brain injury; multiple sclerosis;
 XX peripheral nerve trauma; ischaemia; dementia; gene therapy; diagnosis;
 XX neurotropic; neuroprotective; neuroleptic; antiparkinsonian;
 XX anticonvulsant; vasotropic; PCR primer; ss.
 XX Homo sapiens.
 XX WO200004157-A2.
 XX 27-JAN-2000.
 XX 14-JUL-1999; 99WO-GB002241.
 XX 14-JUL-1998; 98GB-00015284.
 XX (JANC) JANSSEN PHARM NV.
 XX Pangalos M, Neefs JEFM, Peeters DCG;
 XX WPI; 2000-182424/16.
 XX New human N-acetylated alpha-linked acidic dipeptidases for treating
 XX neural disorders e.g. Alzheimer's disease, schizophrenia and Parkinson's
 XX disease.
 XX Disclosure; Page 27; 95pp; English.
 XX The present sequence is that of primer NAALD4AP4 used in the PCR
 XX amplification of full-length human N-acetylated alpha-linked acidic
 XX dipeptidase IV (NAALAD-ase IV) cDNA (see AAZ58333). cDNA from human
 XX hippocampus was as template. The invention provides human NAALAD-ase L,
 XX II and IV polypeptides, cDNAs, antisense nucleic acids, vectors, host
 XX cells, transgenic organisms, antagonists and agonists. These are useful
 XX for treating neural disorders such as Alzheimer's disease, schizophrenia,
 XX ALS, Parkinson's disease, peripheral neuropathy, Huntington's disease,
 XX acute brain injury, multiple sclerosis, exposure to neurotoxins,
 XX peripheral nerve trauma, ischaemia or dementia (claimed). Nucleic acids
 XX can also be used for gene therapy and for genetic screening of
 XX predisposition to disorders associated with NAALAD-ase
 XX SQ Sequence 26 BP; 7 A; 6 C; 7 G; 6 T; 0 U; 0 Other;
 Query Match 1.4%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 1.9;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1563 GGGTCTGCACTTTGGAAACTCTC 1588
 Db 26 GGGTCTGCACTTTGGAAACTCTC 1
 RESULT 4
 AAZ58335
 ID AAZ58335 standard; cDNA; 26 BP.
 XX AAZ58335;
 XX 08-MAY-2000 (first entry)
 XX Human peptidase NAALAD-ase IV PCR primer NAALD4SP2.
 XX NAALAD-ase IV; N-acetylated alpha-linked acidic dipeptidase; human;

KW prostate cancer; neurodegenerative disease; Alzheimer's disease;
 KW schizophrenia; ALS; Parkinson's disease; peripheral neuropathy;
 KW Huntington's disease; acute brain injury; multiple sclerosis;
 KW peripheral nerve trauma; ischaemia; dementia; gene therapy; diagnosis;
 KW neurotropic; neuroprotective; neuroleptic; antiparkinsonian;
 KW anticonvulsant; vasotropic; PCR primer; ss.
 OS Homo sapiens.
 XX WO200004157-A2.
 PN 27-JAN-2000.
 XX 14-JUL-1999; 99WO-GB002241.
 XX 14-JUL-1998; 98GB-00015284.
 XX (JANC) JANSSEN PHARM NV.
 PI Pangalos M, Neefs JEFM, Peeters DCG;
 XX WPI; 2000-182424/16.
 XX New human N-acetylated alpha-linked acidic dipeptidases for treating
 PT neural disorders e.g. Alzheimer's disease, schizophrenia and Parkinson's
 PT disease.
 XX Disclosure; Page 27; 95pp; English.
 XX The present sequence is that of primer NAALD4SP2 used in the PCR
 CC amplification of full-length human N-acetylated alpha-linked acidic
 CC dipeptidase IV (NAALAD-ase IV) cDNA (see AAZ58313). cDNA from human
 CC hippocampus was as template. The invention provides human NAALAD-ase L,
 CC II and IV polypeptides, cDNAs, antisense nucleic acids, vectors, host
 CC cells, transgenic organisms, antagonists and agonists. These are useful
 CC for treating neural disorders such as Alzheimer's disease, schizophrenia,
 CC ALS, Parkinson's disease, peripheral neuropathy, Huntington's disease,
 CC acute brain injury, multiple sclerosis, exposure to neurotoxins,
 CC peripheral nerve trauma, ischaemia or dementia (claimed). Nucleic acids
 CC can also be used for gene therapy and for genetic screening of
 CC predisposition to disorders associated with NAALAD-ase
 XX
 SQ Sequence 26 BP; 6 A; 9 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 1.4%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 1.9;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 45 CGTCAGAGCGCCCTATCAGATTATC 70
 DB 1 CGTCAGAGCGCCCTATCAGATTATC 26
 RESULT 5
 AAZ58343
 ID AAZ58343 standard; cDNA; 25 BP.
 XX AAZ58343;
 XX 08-MAY-2000 (first entry)
 DT Human peptidase NAALAD-ase IV PCR primer NAALD4SI.
 DE NAALAD-ase IV; N-acetylated alpha-linked acidic dipeptidase; human;
 XX prostate cancer; neurodegenerative disease; Alzheimer's disease;
 KW schizophrenia; ALS; Parkinson's disease; peripheral neuropathy;
 KW Huntington's disease; acute brain injury; multiple sclerosis;
 KW peripheral nerve trauma; ischaemia; dementia; gene therapy; diagnosis;
 KW neurotropic; neuroprotective; neuroleptic; antiparkinsonian;
 KW anticonvulsant; vasotropic; PCR primer; ss.
 XX Homo sapiens.
 OS

PN WO200004157-A2.
 XX 27-JAN-2000.
 XX 14-JUL-1999; 99WO-GB002241.
 XX 14-JUL-1998; 98GB-00015284.
 XX (JANC) JANSSEN PHARM NV.
 PI Pangalos M, Neefs JEFM, Peeters DCG;
 XX WPI; 2000-182424/16.
 XX New human N-acetylated alpha-linked acidic dipeptidases for treating
 PT neural disorders e.g. Alzheimer's disease, schizophrenia and Parkinson's
 PT disease.
 XX Disclosure; Page 33; 95pp; English.
 XX The present sequence is that of primer NAALD4SI used in the RT-PCR
 CC amplification of human N-acetylated alpha-linked acidic dipeptidase IV
 CC (NAALAD-ase IV) cDNA (see AAZ58313) for use in gene expression studies.
 CC The invention provides human NAALAD-ase L, II and IV polypeptides, cDNAs,
 CC antisense nucleic acids, vectors, host cells, transgenic organisms,
 CC antagonists and agonists. These are useful for treating neural disorders
 CC such as Alzheimer's disease, schizophrenia, ALS, Parkinson's disease,
 CC peripheral neuropathy, Huntington's disease, acute brain injury, multiple
 CC sclerosis, exposure to neurotoxins, peripheral nerve trauma, ischaemia or
 CC dementia
 XX
 SQ Sequence 25 BP; 8 A; 2 C; 11 G; 4 T; 0 U; 0 Other;
 Query Match 1.4%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 2.7;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1101 GCAGAGAACACAGGTGGAGTTGGTG 1125
 DB 1 GCAGAGAACACAGGTGGAGTTGGTG 25
 RESULT 6
 AAZ58344/C
 ID AAZ58344 standard; cDNA; 24 BP.
 XX AAZ58344;
 XX 08-MAY-2000 (first entry)
 DT Human peptidase NAALAD-ase IV PCR primer NAALD4SI.
 DE NAALAD-ase IV; N-acetylated alpha-linked acidic dipeptidase; human;
 KW prostate cancer; neurodegenerative disease; Alzheimer's disease;
 KW schizophrenia; ALS; Parkinson's disease; peripheral neuropathy;
 KW Huntington's disease; acute brain injury; multiple sclerosis;
 KW peripheral nerve trauma; ischaemia; dementia; gene therapy; diagnosis;
 KW neurotropic; neuroprotective; neuroleptic; antiparkinsonian;
 KW anticonvulsant; vasotropic; PCR primer; ss.
 XX Homo sapiens.
 OS
 XX WO200004157-A2.
 PN 27-JAN-2000.
 XX 14-JUL-1999; 99WO-GB002241.
 XX 14-JUL-1998; 98GB-00015284.
 XX (JANC) JANSSEN PHARM NV.
 PI Pangalos M, Neefs JEFM, Peeters DCG;
 XX WPI; 2000-182424/16.
 XX New human N-acetylated alpha-linked acidic dipeptidases for treating
 PT neural disorders e.g. Alzheimer's disease, schizophrenia and Parkinson's
 PT disease.
 XX Disclosure; Page 33; 95pp; English.
 XX The present sequence is that of primer NAALD4SI used in the RT-PCR
 CC amplification of human N-acetylated alpha-linked acidic dipeptidase IV
 CC (NAALAD-ase IV) cDNA (see AAZ58313) for use in gene expression studies.
 CC The invention provides human NAALAD-ase L, II and IV polypeptides, cDNAs,
 CC antisense nucleic acids, vectors, host cells, transgenic organisms,
 CC antagonists and agonists. These are useful for treating neural disorders
 CC such as Alzheimer's disease, schizophrenia, ALS, Parkinson's disease,
 CC peripheral neuropathy, Huntington's disease, acute brain injury, multiple
 CC sclerosis, exposure to neurotoxins, peripheral nerve trauma, ischaemia or
 CC dementia
 XX

XX WPI; 2000-182424/16.
 XX New human N-acetylated alpha-linked dipeptidases for treating
 PT neural disorders e.g. Alzheimer's disease, schizophrenia and Parkinson's
 PT disease.
 XX Disclosure; Page 33; 95pp; English.
 XX
 XX The present sequence is that of primer NAALD4AS1 used in the RT-PCR
 CC amplification of human N-acetylated alpha-linked acidic dipeptidase IV
 CC (NAALAD-ase IV) cDNA (see A258313) for use in gene expression studies.
 CC The invention provides human NAALAD-ase L, II and IV polypeptides, cDNAs,
 CC antisense nucleic acids, vectors, host cells, transgenic organisms,
 CC antagonists and agonists. These are useful for treating neural disorders
 CC such as Alzheimer's disease, schizophrenia, ALS, Parkinson's disease,
 CC peripheral neuropathy, Huntington's disease, acute brain injury, multiple
 CC sclerosis, exposure to neurotoxins, peripheral nerve trauma, ischaemia or
 CC dementia
 XX
 XX Sequence 24 BP; 5 A; 5 C; 7 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 1.3%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 4;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1414 CCATGACTGTCATGATCCAAAGC 1437
 Db 24 CCATGACTGTCATGATCCAAAGC 1
 RESULT 7
 ABA01588
 ID ABA01588 standard; DNA; 24 BP.
 XX
 XX ABA01588;
 AC
 XX
 XX 31-JAN-2002 (first entry)
 DT
 XX Human neuroproteins Y 11 PCR primer 2 SEQ ID NO:4.
 DE
 XX Human; neuroproteins Y 11; cytostatic; virucidal; immunomodulatory;
 KW antiinflammatory; haemostatic; cardiant; gene therapy; diagnosis;
 KW malignant tumour; haemopathy; human immunodeficiency virus;
 KW HIV infection; immunological disease; inflammation; angiocardopathy;
 KW developmental disorder; PCR primer; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200175020-A2.
 PN
 XX
 XX 11-OCT-2001.
 PD
 XX 19-MAR-2001; 2001WO-CN000358.
 PF
 XX 22-MAR-2000; 2000CN-00115045.
 PR
 XX (BIOW-) BLOWDOWN GENE DEV INC SHANGHAI.
 PA
 XX Mao Y, Xie Y;
 PI
 XX WPI; 2002-025842/03.
 DR
 XX Human neuroproteins Y 11 and encoded polynucleotide, used in diagnosis and
 PT treatment of malignant tumors, hemopathy, human immunodeficiency virus
 PT infection, immunological diseases and inflammation.
 PT
 XX Example 2; Page 12; 33pp; Chinese.
 PS
 XX The present invention describes the human neuroproteins Y 11 protein.
 CC Human neuroproteins Y 11 has cytostatic, virucidal, immunomodulatory,
 CC antiinflammatory, haemostatic and cardiant activities and can be used in
 CC gene therapy. The human neuroproteins Y 11 protein and its encoding

CC polynucleotide can be used in the diagnosis and treatment of malignant
 CC tumour, haemopathy, human immunodeficiency virus (HIV) infection,
 CC immunological diseases, various inflammations, angiocardopathy and
 CC developmental disorders. The present sequence represents a PCR primer for
 CC human neuroprotein Y 11 which is used in an example from the present
 CC invention
 XX
 XX Sequence 24 BP; 0 A; 4 C; 9 G; 11 T; 0 U; 0 Other;
 SQ
 Query Match 1.0%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 30;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 1446 GTTGCTGCTGCTGTTGGGCTGTT 1469
 Db 1 GTTGCTGCTGCTGTTGGGCTGTT 24
 RESULT 8
 ABL55122
 ID ABL55122 standard; DNA; 24 BP.
 XX
 XX ABL55122;
 AC
 XX 31-MAY-2002 (first entry)
 DT
 XX Human Myb protein 32 RT-PCR primer, SEQ ID NO:3.
 DE
 XX Human; Myb protein 32; recombinant production; cancer; HIV infection;
 KW human immunodeficiency virus; gene therapy; cytostatic; anti-HIV;
 KW reverse transcription-PCR; RT-PCR; primer; ss.
 XX
 XX Homo sapiens.
 OS
 XX CN1325886-A.
 PN
 XX 12-DEC-2001.
 PD
 XX 26-MAY-2000; 2000CN-00115890.
 PF
 XX 26-MAY-2000; 2000CN-00115890.
 PR
 XX (BODE-) BODE GENE DEV CO LTD SHANGHAI.
 PA
 XX Mao Y, Xie Y;
 PI
 XX WPI; 2002-196654/26.
 DR
 XX Polypeptide-human Myb protein 32 and polynucleotide for coding it, useful
 PT for treating cancer, and HIV infection.
 PT
 XX Example 2; Page 17 (Disclosure); 33pp; Chinese.
 PS
 XX The invention relates to human Myb protein 32 (AAM49156) and to nucleic
 CC acids encoding it (ABL55121). The protein has a molecular weight of 32
 CC kD. The invention also relates to a method for the recombinant production
 CC of the protein, an antagonist of the protein, and the use of the protein,
 CC gene and antagonist in therapeutic applications. Myb protein 32 can be
 CC used in the treatment of a variety of diseases such as cancer and HIV
 CC (human immunodeficiency virus) infection. Sequences ABL55122-ABL55123
 CC represent reverse transcription-PCR (RT-PCR) primers used in an
 CC exemplification of the invention to isolate human Myb protein 32 cDNA
 XX
 XX Sequence 24 BP; 2 A; 12 C; 9 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 1.0%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 30;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 25 GGAGCGCGCTCCGTCGCCCGCGTC 48
 Db 1 GGAGCGCGCGCTCCGTCGCCCGCGTC 24


```

OS Unidentified.
XX WO2004072302-A1.
XX
XX
XX PD 26-AUG-2004.
XX
XX PF 13-FEB-2004; 2004WO-JP001588.
XX
XX PR 14-FEB-2003; 2003JP-00037212.
XX
XX (PALM-) PALMA BEEZ RES INST CO LTD.
XX
XX PI Usui M, Fujikawa T;
XX
XX DR WPI; 2004-642306/62.
XX
XX PT Signal amplification method for detecting expressed gene, by using
XX reverse transcription reaction and self-assembly reaction of
XX oligonucleotide probes.
XX
XX PS Disclosure; SEQ ID NO 4; 27pp; Japanese.
XX
XX CC The invention relates to a signal amplification method (M1) for detecting
XX expressed gene using reverse transcription reaction and a self-assembly
XX reaction of forming a self assembly of oligonucleotide probes, thus
XX improving detection sensitivity of the expressed gene in a DNA chip. (M1)
XX is useful for signal amplification method (M1) for detecting expressed
XX gene (claimed). (M1) improves detection sensitivity of the expressed gene
XX in a DNA chip (claimed). (M1) does not require use of expensive enzymes
XX and enables detection corresponding to the original RNA length or
XX expression amount because of using neither linear amplification nor PCR.
XX This sequence corresponds to a nucleotide used in the method of the
XX invention.
XX
XX SQ Sequence 18 BP; 0 A; 0 C; 0 G; 18 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 17; DB 1; Length 18;
XX Best Local Similarity 100.0%; Pred. No. 53;
XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2
XX
RESULT 14
ID ADR82260/c
XX ADR82260 standard; DNA; 19 BP.
XX
XX AC ADR82260;
XX
XX DT 16-DEC-2004 (first entry)
XX
XX DE Hepatitis C virus (HCV) oligonucleotide seqid 6759.
XX
XX KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
XX cyostatic; anticonvulsant; nootropic; muscula; anti-HIV;
XX RNA interference; iRNA; antisense technology; lipid metabolism;
XX cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
XX coronary artery disease; CAD; coronary heart disease; CHD;
XX atherosclerosis; hepatic glucose production;
XX glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
XX colon cancer; lung cancer; neurological disease; Huntington disease;
XX spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX
XX OS Hepatitis C virus.
XX
XX PN WO2004080406-A2.
XX
XX PD 23-SEP-2004.
XX
XX PF 08-MAR-2004; 2004WO-US007070.
XX

```

```

PR 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 14-APR-2003; 2003US-0455050P.
PR 17-APR-2003; 2003US-0462894P.
PR 25-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
XX (ALNY-) ALNYLAM PHARM.
XX
XX PI Manoharan M, Bumcrot D;
XX
XX DR WPI; 2004-677362/66.
XX
XX PT Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX sequence and antisense sequence which has specific modifications.
XX
XX PS Example 5; SEQ ID NO 6759; 378pp; English.
XX
XX CC The invention describes a RNA interference (iRNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are a pharmaceutical preparation comprising (I); reducing (M1) apob-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instruction for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apob-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidaemias, hypercholesterolaemia, statin-resistant
XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX inhibit hepatic glucose production or for treating glucose-metabolism-
XX related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX lung cancer), neurological disease (e.g., Huntington disease or
XX spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX represents a hepatitis C virus (HCV) antisense oligonucleotide that can
XX be used to control HCV gene expression.
XX
XX SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 17; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 57;
XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 19 AAAAAAAAAAAAAAAAAA 3
XX
RESULT 15
ID ADR82257/c
XX ADR82257 standard; DNA; 19 BP.
XX
XX XX
XX AC ADR82257;
XX

```

XX 16-DEC-2004 (first entry)
XX Hepatitis C virus (HCV) oligonucleotide seqid 6756.
XX
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytosatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX
OS Hepatitis C virus.
XX
PN WO2004080406-A2.
XX
PD 23-SEP-2004.
XX
PF 08-MAR-2004; 2004WO-US007070.
XX
PR 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 13-MAR-2003; 2003US-0455050P.
PR 14-MAR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 10-OCT-2003; 2003US-0510246P.
PR 09-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALNY-) ALNYLAM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX
DR Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
PS Example 5; SEQ ID NO 6756; 378pp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-

CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
CC be used to control HCV gene expression.
XX
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1835 AAAAAAAAAAAAAA 1851
Db 19 AAAAAAAAAAAAAA 3
RESULT 16
ADR82261/C
ID ADR82261 standard; DNA; 19 BP.
XX
XX AC ADR82261;
XX
XX 16-DEC-2004 (first entry)
XX
DE Hepatitis C virus (HCV) oligonucleotide seqid 6760.
XX
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytosatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX
OS Hepatitis C virus.
XX
PN WO2004080406-A2.
XX
PD 23-SEP-2004.
XX
PF 08-MAR-2004; 2004WO-US007070.
XX
PR 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 13-MAR-2003; 2003US-0455050P.
PR 14-MAR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 10-OCT-2003; 2003US-0510246P.
PR 09-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALNY-) ALNYLAM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX
DR Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
PS Example 5; SEQ ID NO 6760; 378pp; English.
XX

```

XX CC The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
CC be used to control HCV gene expression.
XX SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;

Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 17
AD82258/c
ID AD82258 standard; DNA; 19 BP.
XX AC AD82258;
XX DT 16-DEC-2004 (first entry)
XX DE Hepatitis C virus (HCV) oligonucleotide seqid 6757.
XX KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
XX KW cytosstatic; anticonvulsant; nootropic; muscula; anti-HIV;
XX KW RNA interference; iRNA; antisense technology; lipid metabolism;
XX KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
XX KW coronary artery disease; CAD; coronary heart disease; CHD;
XX KW atherosclerosis; hepatic glucose production;
XX KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
XX KW colon cancer; lung cancer; neurological disease; Huntington disease;
XX KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX OS Hepatitis C virus.
XX PN WO2004080406-A2.
XX PD 23-SEP-2004.
XX PF 08-MAR-2004; 2004WO-US007070.
XX PR 07-MAR-2003; 2003US-0452682P.
XX PR 12-MAR-2003; 2003US-0454265P.
XX PR 13-MAR-2003; 2003US-0454962P.
XX PR 13-MAR-2003; 2003US-0455050P.

```

```

PR 14-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX (ALNY-) ALNYLAM PHARM.
XX PA Manoharan M, Bumcrot D;
XX PI WPI; 2004-677362/66.
XX DR
XX PT Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX sequence and antisense sequence which has specific modifications.
XX PS Example 5; SEQ ID NO 6757; 378pp; English.
XX CC The invention describes a RNA interference (iRNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX introducing one or more asymmetrical modification in the sequence, where
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instruction for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidaemias, hypercholesterolaemia, statin-resistant
XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX inhibit hepatic glucose production or for treating glucose-metabolism-
XX related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX lung cancer), neurological disease (e.g., Huntington disease or
XX spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX represents a hepatitis C virus (HCV) antisense oligonucleotide that can
XX be used to control HCV gene expression.
XX SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;

Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 18
AD82256/c
ID AD82256 standard; DNA; 19 BP.
XX AC AD82256;
XX DT 16-DEC-2004 (first entry)
XX DE Hepatitis C virus (HCV) oligonucleotide seqid 6755.

```

XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX
OS Hepatitis C virus.
XX
XX WO2004080406-A2.
XX
XX 23-SEP-2004.
XX
XX 08-MAR-2004; 2004WO-US007070.
XX
XX 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 14-MAR-2003; 2003US-0455050P.
PR 17-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALNY-) ALNYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 6755; 378pp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequence
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are a pharmaceutical preparation comprising (I); reducing (MI) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (MI)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence

CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
CC be used to control HCV gene expression.
XX
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1835 AAAAAAAAAAAAAA 1851
Db 19 AAAAAAAAAAAAAA 3
RESULT 19
ADR82259/c
ID ADR82259 standard; DNA; 19 BP.
XX
XX ADR82259;
AC
XX
DT 16-DEC-2004 (first entry)
XX
DE Hepatitis C virus (HCV) oligonucleotide seqid 6758.
XX
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX
OS Hepatitis C virus.
XX
XX WO2004080406-A2.
XX
XX 23-SEP-2004.
XX
XX 08-MAR-2004; 2004WO-US007070.
XX
XX 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 14-MAR-2003; 2003US-0455050P.
PR 17-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALNY-) ALNYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 6758; 378pp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequence
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are a pharmaceutical preparation comprising (I); reducing (MI) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (MI)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence

CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (MI) apoB-100
 CC levels or glucose-6-phosphate levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphate levels. (MI)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphate levels. (MI)
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful, for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
 CC be used to control HCV gene expression.

XX SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
 Query Match 0.9%; Score 17; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 57;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
 |||||
 DB 19 AAAAAAAAAAAAAAAAAA 3

RESULT 20
 ADK23158
 ID ADK23158 standard; DNA; 20 BP.
 AC ADK23158;
 XX ADK23158;
 DT 02-DEC-2004 (first entry)
 XX Micro-channel molecule isolation related Adenine oligo.
 DE molecule isolation; micro-channel; molecular weight; micro flow path;
 KW polymer compound; flow behaviour; non turbulent flow; ss.
 XX Unidentified.
 OS WO2004076038-A1.
 XX 10-SEP-2004.
 XX 18-FEB-2004; 2004WO-JP001814.
 PF 18-FEB-2003; 2003JP-00039870.
 XX (NAAD-) NAT INST ADVANCED IND SCI & TECHNOLOGY.
 PA Yamashita K, Maeda H, Shimizu H, Miyazaki M, Nakamura H;
 PI Yamaguchi Y;
 XX WPI; 2004-661906/64.
 XX Isolating molecules e.g., DNA, by introducing solution with two types of
 PT solute molecules into micro flow path to form non turbulent flow,
 PT providing physical action to molecule causing difference in flow
 PT behavior, separating molecules.
 XX Example 3; Page 7; 19pp; Japanese.

XX The invention relates to a novel method for isolating molecules using a
 CC micro-channel. The molecules are isolated by introducing a mixed solution
 CC having two types of solute molecules differing in molecular weight into a
 CC micro flow path, to form a non turbulent flow, and providing physical
 CC action to the molecules by changing the flow state, thus causing
 CC different behaviours among different solute molecules, where the
 CC different behaviour enables uneven distribution of specific kinds of
 CC molecules in the flow path, causing separation of the molecules. The
 CC invention further comprises: molecule separation apparatus, comprising a
 CC substrate with a micro flow path, having one or more curved portions, a
 CC sample intake unit at one side and a sample removal opening at the other
 CC side, and a physical property detection sensor arranged inside the curved
 CC portion or outside the curved portion. The method is useful for isolating
 CC molecules, e.g. polymer compounds, DNA or proteins. The method enables
 CC simple and efficient separation of molecules by utilising specific flow
 CC behaviour in a non turbulent flow, in a micro flow path, where a large
 CC number of samples can be processed. This polynucleotide sequence
 CC represents an oligo used in the exemplification of the invention.

XX SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.9%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 60;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
 |||||
 DB 1 AAAAAAAAAAAAAAAAAA 17

RESULT 21
 ADK23158
 ID ADK23158 standard; DNA; 20 BP.
 AC ADK23158;
 XX ADK23158;
 DT 18-NOV-2004 (first entry)
 XX Acyl-coenzyme A synthetase 1, ACS1, antisense oligonucleotide #3235.
 DE acyl-coenzyme A synthetase 1; ACS1; diabetes; obesity;
 KW metabolic syndrome X; cardiovascular disorder; cancer; infection;
 KM inflammation; tumour; antisense; ss.
 XX Synthetic.
 OS WO2004016749-A2.
 XX 26-FEB-2004.
 XX 14-AUG-2003; 2003WO-US025389.
 PF 14-AUG-2002; 2002US-0403591P.
 XX (PHAA) PHARMACIA CORP.
 PA Ross SA;
 PI WPI; 2004-203782/19.
 XX New antisense compounds targeted to nucleic acid molecules encoding acyl-
 PT coenzyme A synthetase 1 (ACS1), useful for treating diseases or
 PT conditions associated with aberrant expression of ACS1, e.g. diabetes,
 PT obesity or cancer.
 XX Claim 3; SEQ ID NO 3235; 940pp; English.
 XX The invention relates to an antisense compound targeted to a nucleic acid
 CC molecule encoding acyl-coenzyme A synthetase 1 (ACS1). The antisense
 CC compound specifically hybridises with and inhibits the expression of
 CC ACS1. The antisense oligonucleotides or compounds are useful for
 CC inhibiting the expression of acyl-coenzyme A synthetase 1 (ACS1), and for

CC treating diseases or conditions associated with aberrant expression of
CC ACS1, e.g. diabetes, obesity, metabolic syndrome X, cardiovascular
CC disorder or cancer. The antisense compounds are also useful as research
CC reagents and kits, or in diagnostic, therapeutic and prophylactic
CC applications, e.g. to prevent or delay infection, inflammation or tumour
CC formation. The present sequence represents an acyl-coenzyme A synthetase
CC 1, ACS1, antisense oligonucleotide.

XX Sequence 20 BP; 2 A; 2 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 85;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1463 GGCTGTTGTTCTTATGTTG 1482

Db 1 GGCTGTTGTTCTGATGATG 20

RESULT 22

AAV25611/c
ID AAV25611 standard; DNA; 21 BP.

XX AC AAV25611;

XX DT 16-JUL-1998 (first entry)

XX DE Primer for PTI-1 bridge region.

XX KW PCR primer; bridge region; prostate tumour inducing gene; PCI-1;
XX KW detection; cancer cell; carcinoma cell; metastatic prostate cancer;
XX KW late stage prostate cancer; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN WO9810098-A1.

XX PD 12-MAR-1998.

XX PF 05-SEP-1997; 97WO-US015645.

XX PR 06-SEP-1996; 96US-00708208.

XX PA (UYCO) UNIV COLUMBIA NEW YORK.

XX PI Fisher PB;

XX DR WPI; 1998-193641/17.

XX PT Detection of prostate tumour inducing gene using specific primers -
XX PT useful for detection of cancer cells.

XX PS Claim 11; Page 32; 43pp; English.

XX CC The present sequence is a primer for the bridge region of the prostate
XX CC tumour inducing gene, PCI-1. The primer was used in the development of a
XX CC novel method for the detection of cancer cells, comprising the detection
XX CC of PCI-1 expression. The method can be used to detect carcinoma cells or
XX CC prostate, breast, colon or lung cancer cells, and determine whether a
XX CC subject has metastatic or late stage prostate cancer

XX SQ Sequence 21 BP; 10 A; 7 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 89;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1441 TGAATGTTGCTGCTGCTGT 1460

Db 20 TGATGTTGCTGCTGCTGT 1

RESULT 23

AAZ69745/c

ID AAZ69745 standard; DNA; 18 BP.

XX AC AAZ69745;

XX DT 10-SEP-2001 (first entry)

XX DE Human biallelic marker upstream amplification primer SEQ ID NO:4101.

XX KW Human genome; biallelic marker; high density disequilibrium map;
XX KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
XX KW haplotyping; hybridisation; identification; characterisation;
XX KW amplification; single nucleotide polymorphism; SNP; PCR primer;
XX KW diagnosis; ss.

XX OS Homo sapiens.

XX PN WO9954500-A2.

XX PD 28-OCT-1999.

XX PF 21-APR-1999; 99WO-IB000822.

XX PR 21-APR-1998; 98US-0082614P.

XX PR 23-NOV-1998; 98US-0109732P.

XX PA (CBST) GENSET.

XX PI Cohen D, Blumenfeld M, Chumakov I;

XX DR WPI; 2000-013267/01.

XX PT Novel biallelic markers used to construct a high density disequilibrium
XX PT map of the human genome.

XX PS Claim 8; Page 1105; 2745pp; English.

XX CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
XX CC invention, which contain a polymorphic base at position 24 of their
XX CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
XX CC primers for the biallelic markers. The biallelic markers of the invention
XX CC have a variety of uses: they can be used for high density mapping of the
XX CC human genome, and in complex association studies and haplotyping studies
XX CC which are useful in determining the genetic basis for disease states.
XX CC Compositions and methods of the invention can also be useful for the
XX CC identification of the targets for the development of pharmaceutical
XX CC agents and diagnostic methods, as well as the characterisation of the
XX CC differential efficacious responses to and side effects from
XX CC pharmaceutical agents acting on a disease as well as other treatment.
XX CC N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
XX CC 3367, are not actually given a sequence in the Sequence Listing from the
XX CC present invention

XX SQ Sequence 18 BP; 5 A; 0 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 18;

Best Local Similarity 94.4%; Pred. No. 68;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 730 CCATCTACAGTCTCTCACA 747

Db 18 CCATCTACATTCCTCACA 1

RESULT 24

AAV01232/c

ID AAV01232 standard; DNA; 20 BP.

XX AC AAV01232;

XX DT 23-MAR-1998 (first entry)

XX XX

```

DE Von Willebrand's factor PCR primer for univereal mammalian STS's.
XX
KW PCR primer; polymerase chain reaction; amplification; UM-STS;
KW universal mammalian sequence tagged site; genomic map; clone; ss.
XX
OS Synthetic.
XX
XX WO9731012-A1.
XX
XX 28-AUG-1997.
XX
XX 18-FEB-1997; 97WO-US002403.
XX
XX 22-FEB-1996; 96US-0012061P.
XX
XX (UNMI ) UNIV MICHIGAN.
XX (UNMS ) UNIV MICHIGAN STATE.
XX
XX Brewer GJ, Venta PJ, Yuzbasiyan-Gurkan V;
XX WPI; 1997-435083/40.
XX
XX New oligonucleotide primers amplifying gene regions conserved among
XX mammals - useful for developing genomic maps, isolating clones and making
XX cross-species comparisons.
XX
XX Claim 1; Page 11; 26pp; English.
XX
XX The present sequence represents a specifically claimed oligonucleotide
XX PCR primer. The oligonucleotide can be used for polymerase chain reaction
XX (PCR) amplification of DNA, specifically regions of specific genes that
XX are conserved among mammalian species, i.e. pairs of oligonucleotides
XX from the present specification represent universal mammalian sequences-
XX tagged site (UM-STS) primers. The primers are used to develop genomic
XX maps, to isolate clones from libraries, to make cross-species comparisons
XX and to develop additional genetic markers. UM-STS allow genomic
XX comparisons to be made between more species
XX
XX Sequence 20 BP; 4 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 16.4; DB 1; Length 20;
XX Best Local Similarity 94.4%; Pred. No. 77;
XX Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1333 GGATCCAAAGCTGGAGTGC 1350
DB |||||
20 GGATTCGAAGCTGGAGTGC 3

RESULT 25
AA93746/c
ID AAX93746 standard; DNA; 20 BP.
XX
XX AAX93746;
XX
XX 13-SEP-1999 (first entry)
XX
XX PCR primer used to amplify an ORF of Chlamydia pneumoniae.
XX
XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
XX sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
XX neutralising epitope; PCR primer; ss.
XX
XX Synthetic.
XX Chlamydophila pneumoniae.
XX
XX WO9927105-A2.
XX
XX 03-JUN-1999.
XX
XX 20-NOV-1998; 98WO-IB001890.
XX
XX 21-NOV-1997; 97FR-00014673.
XX
PR 04-NOV-1998; 98US-0107078P.
XX
XX (GEST ) GENSET.
XX
XX Griffais R;
XX
XX WPI; 1999-357842/30.
XX
XX Genome sequence of Chlamydia pneumoniae.
XX
XX Page 1615; Disclosure; 1912pp; English.
XX
XX AAX91991-X97517 represent PCR primers used to amplify open reading frames
XX and other nucleic acid sequences from the genome of Chlamydia pneumoniae
XX (see AAX91990). C. pneumoniae causes respiratory disease such as
XX pneumonia and bronchitis and is thought to be a contributing factor in
XX heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
XX nodosum or pharyngitis. The polypeptides encoded by the open reading
XX frames of the C. pneumoniae genome (see AAY34584- AAY35875) can be used
XX in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
XX nucleotides sequences can also be used as immunogenic compositions,
XX especially where the vector directs the expression of a neutralising
XX epitope of C. pneumoniae
XX
XX Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 16.4; DB 1; Length 20;
XX Best Local Similarity 94.4%; Pred. No. 77;
XX Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1612 TCATCTTCAAGCACAAC 1629
DB |||||
19 TCATCTTCAAGCAGCAGC 2

RESULT 26
AD575311
ID ADS75311 standard; DNA; 20 BP.
XX
XX ADS75311;
XX
XX 16-DEC-2004 (first entry)
XX
XX PCR primer CCRL2 P1v2 F used to amplify a human CCRL2 DNA SNP region.
XX
XX PCR; ss; inflammatory bowel disease; IBD; ulcerative colitis; CCRL2;
XX GPCR receptor; chemokine (C-C motif) receptor-like 2; HCR; gene therapy;
XX antiinflammatory; primer.
XX
XX Homo sapiens.
XX
XX WO2004083232-A2.
XX
XX 30-SEP-2004.
XX
XX 18-MAR-2004; 2004WO-GB001159.
XX
XX 20-MAR-2003; 2003GB-00006428.
XX
XX (OXAG-) OXAGEN LTD.
XX
XX Pettipher R;
XX
XX WPI; 2004-728453/71.
XX
XX Determining whether an individual is predisposed to inflammatory bowel
XX disease (i.e. ulcerative colitis) comprises identifying whether the
XX individual has a polymorphism in the CCRL2 polynucleotide or protein.
XX
XX Example 2; Page 28; 60pp; English.
XX
XX This invention relates to a novel method for determining whether an
XX individual is predisposed to inflammatory bowel disease (IBD), preferably

```


CC to ulcerative colitis. Specifically, it refers to the identification of
 CC single nucleotide polymorphisms (SNPs) in the CCR12 polynucleotide or
 CC encoded protein thereof, where CCR12 refers to the GPCR receptor
 CC chemokine (C-C motif) receptor-like 2 protein that is also known as HCR.
 CC The present invention describes methods for preventing or treating IBD,
 CC as well as diagnosing a predisposition to the disease by use of probes,
 CC primers and antibodies that can detect and amplify the CCR12 SNP regions.
 CC Furthermore, it provides a screening assay for agents that can be used to
 CC identify individuals with a genetic predisposition and in turn be used
 CC for gene therapy purposes. The pharmaceutical compositions derived
 CC thereof exhibit an antiinflammatory activity. This oligonucleotide
 CC sequence is a PCR primer used to amplify a human CCR12 DNA SNP region of
 CC the invention.

XX Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 77;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1411 ACACCATGACTGTCATGG 1428
 Db 2 ACACCGTACTGTCATGG 19

RESULT 27
 AAZ44349/C
 ID AAZ44349 standard; DNA; 21 BP.

XX AAZ44349;

DT 04-APR-2000 (first entry)

DE Protein kinase inhibiting primer #11.

XX Antimicrobial; cytostatic; immunosuppressive; protein kinase;
 KW prophylactic; therapy; treatment; cancer; autoimmune disease;
 KW pathogenic microorganism; primer; ss.

OS Unidentified.

PN US5998596-A.

PD 07-DEC-1999.

FF 04-APR-1995; 95US-00416214.

PR 04-APR-1995; 95US-00416214.

PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

PI Bergan R, Neckers L;

DR WPI; 2000-104623/09.

XX Oligonucleotides inhibiting protein kinase, useful for treating diseases
 PT such as cancer and autoimmune disease.

PS Example 3; Col 27-28; 26pp; English.

XX This invention describes novel purified aptameric oligonucleotides which
 CC have antimicrobial, cytostatic and immunosuppressive activity. The
 CC oligonucleotides are useful for binding to and preventing or inhibiting
 CC the biological function of a protein kinase or a target molecule and for
 CC detecting the presence or absence of a target molecule in biological
 CC samples. The oligonucleotides are also useful for prophylactic and
 CC therapeutic treatment of diseases such as cancer, autoimmune diseases and
 CC diseases caused by pathogenic microorganisms. This sequence represents a
 CC primer used in the method of the invention

XX Sequence 21 BP; 0 A; 7 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.2; DB 1; Length 21;

Best Local Similarity 85.7%; Pred. No. 88;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 28 GCGCCCTCCGTCGCGCGGTC 48
 Db 21 GCGCCGCGCGCGCGCGGTC 1

RESULT 28

AAH76301

ID AAH76301 standard; DNA; 21 BP.

XX AAH76301;

DT 29-OCT-2001 (first entry)

DE Human PPARGamma cDNA amplifying 5' primer.

XX PAX8-PPARGamma; oncogene; cytostatic; PAX8; PPARGamma; cancer;
 KW follicular carcinoma; PAX8e7-PPARGammae1; human; PCR primer; ss.

OS Homo sapiens.

PN WO200152789-A2.

PD 26-JUL-2001.

FF 18-JAN-2001; 2001WO-US001664.

PR 20-JAN-2000; 2000US-0177109P.

PR 14-AUG-2000; 2000US-0225079P.

PA (BGHM) BRIGHAM & WOMENS HOSPITAL INC.

PI Kroll TG, Fletcher JA;

DR WPI; 2001-514487/56.

XX New PAX8-PPARc1 oncogene and oncoprotein, useful for detecting and
 PT treating certain tumors or cancers, e.g. follicular carcinoma.

PS Example; Page 141; 145pp; English.

XX The invention relates to an oncogene designated PAX8-PPARGamma that
 CC contains a PAX8 coding region fused to PPARGamma coding region. The PAX8
 CC -PPARGamma polypeptides can be expressed by standard recombinant
 CC methodology. A PPARGamma ligand or agent is useful for treating a subject
 CC having a disorder characterized by the presence of a PAX8-PPARGamma,
 CC where the disorder is cancer, e.g. follicular carcinoma. The PAX8-
 CC PPARGamma molecules are also useful for providing nucleotide and amino
 CC acid sequences useful for detecting the above disease. The present
 CC sequence represents a PCR primer for amplifying PPARGamma cDNA

XX Sequence 21 BP; 7 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.2; DB 1; Length 21;

Best Local Similarity 85.7%; Pred. No. 88;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 886 ACCCAGATCTGATTCCTTCA 906
 Db 1 ACCCAGAAAGCGATTCCTTCA 21

RESULT 29

ABK99279

ID ABK99279 standard; RNA; 21 BP.

XX ABK99279;

DT 21-OCT-2002 (first entry)

XX Hepatitis C virus (HCV) NS5B replicase RNA synthesis template #9.

XX Hepatitis C virus; HCV; NS5B replicase; ss; RNA polymerase.
KW Synthetic.
XX
OS
XX US2002064771-A1.
XX
XX 30-MAY-2002.
XX
XX 06-APR-2001; 2001US-00828034.
XX
XX 07-APR-2000; 2000US-0195852P.
XX
XX (ZHON/) ZHONG W.
PA (HONG/) HONG Z.
PA (FERRI/) FERRARI E.
XX
XX Zhong W, Hong Z, Ferrari E;
XX WPI; 2002-582330/62.
XX
XX Novel replicase complex comprising hepatitis C virus NS5B replicase, a 3
PT nucleotide-long template to which a 2 nucleotide-long primer is annealed,
PT and template and primer which do not form a stable duplex in the absence
PT of HCV NS5B.
XX
XX Example; Page 6; 17pp; English.
XX
XX The invention relates to a replicase complex comprising a hepatitis C
CC virus (HCV) NS5B replicase protein, a linear nucleic acid template and a
CC complementary nucleic acid primer which is annealed to the 3' terminus of
CC the template, where the template is at least three nucleotides and the
CC primer is two or three nucleotides, and the template and primer do not
CC form a stable duplex in solution in the absence of the HCV NS5B protein.
CC The complex is useful for detecting HCV replicase activity and permits
CC establishment of sensitive RNA-dependent RNA polymerase assays to screen
CC and evaluate antiviral inhibitors and to improve the specificity and
CC efficacy of the inhibitors. The complex is also useful in the development
CC of a reliable system for determining kinetic and thermodynamic constants
CC of HCV NS5B-catalysed nucleotide incorporation and investigation of
CC mechanistic inhibitors for mis-incorporation or chain termination.
CC Specifically, the short RNA template and primer pairs are useful in
CC screening assays which are used for determining kinetic, thermodynamic
CC and mechanistic properties of NS5B replication and ultimately in the
CC development of inhibitors of NS5B. Newly identified inhibitors of
CC replicase activity may be used for developing anti-HCV pharmaceuticals.
CC Sequences ABK99271-ABK99296 represent HCV NS5B replicase RNA synthesis
CC templates
XX
XX Sequence 21 BP; 0 A; 14 C; 7 G; 0 T; 0 U; 0 Other;
SQ

Query Match 0.94; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.74; Pred. No. 88;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 28 GCGGCTTCCTCGCGCGCTC 48
Db 1 GCGGCGCGCGCGCGCGCTC 21
||||| ||| ||||| |||
RESULT 30
AD117592
ID AD117592 standard; DNA; 21 BP.
XX
XX AD117592;
XX
XX 15-APR-2004 (first entry)
DT
XX Reverse PCR primer used to amplify human NOVX DNA SeqID1128.
DE
XX PCR; ss; NOVX; metabolic disorder; diabetes; anorexia; cancer;
KW cardiovascular; infectious; neurodegenerative; immune;
KW haematopoietic disease; dyslipidaemia; anorectic; virucide; nootropic;

antiinflammatory; neuroprotective; antilipaeamic; anabolic; cardiant;
neurogenesis; wound healing; angiogenesis; chromosome mapping;
tissue typing; preventive medicine; pharmacogenomic; primer; human.
Homo sapiens.
WO200268649-A2.
XX
XX 06-SEP-2002.
XX
XX 31-JAN-2002; 2002WO-US002785.
XX
XX 31-JAN-2001; 2001US-0265395P.
XX 31-JAN-2001; 2001US-0265412P.
XX 31-JAN-2001; 2001US-0265517P.
XX 31-JAN-2001; 2001US-0265517P.
XX 02-FEB-2001; 2001US-0266406P.
XX 05-FEB-2001; 2001US-0266767P.
XX 07-FEB-2001; 2001US-0266975P.
XX 07-FEB-2001; 2001US-0267057P.
XX 08-FEB-2001; 2001US-0267459P.
XX 09-FEB-2001; 2001US-0267823P.
XX 15-FEB-2001; 2001US-0268974P.
XX 26-FEB-2001; 2001US-0271664P.
XX 27-FEB-2001; 2001US-0271839P.
XX 27-FEB-2001; 2001US-0271855P.
XX 02-MAR-2001; 2001US-0272788P.
XX 02-MAR-2001; 2001US-0273046P.
XX 14-MAR-2001; 2001US-0275925P.
XX 14-MAR-2001; 2001US-0275947P.
XX 14-MAR-2001; 2001US-0275950P.
XX 14-MAR-2001; 2001US-0275989P.
XX 15-MAR-2001; 2001US-0276448P.
XX 16-MAR-2001; 2001US-0276450P.
XX 16-MAR-2001; 2001US-0276397P.
XX 16-MAR-2001; 2001US-0276768P.
XX 20-MAR-2001; 2001US-0278652P.
XX 26-MAR-2001; 2001US-0278775P.
XX 26-MAR-2001; 2001US-0278778P.
XX 29-MAR-2001; 2001US-0279882P.
XX 29-MAR-2001; 2001US-0279884P.
XX 30-MAR-2001; 2001US-0280147P.
XX 11-APR-2001; 2001US-0282992P.
XX 11-APR-2001; 2001US-0283083P.
XX 20-APR-2001; 2001US-0285133P.
XX 23-APR-2001; 2001US-0285749P.
XX 03-MAY-2001; 2001US-0288327P.
XX 03-MAY-2001; 2001US-0288504P.
XX 29-MAY-2001; 2001US-0294047P.
XX 30-MAY-2001; 2001US-0294473P.
XX 08-JUN-2001; 2001US-0296964P.
XX 18-JUN-2001; 2001US-0298959P.
XX 19-JUN-2001; 2001US-0299324P.
XX 13-AUG-2001; 2001US-0312020P.
XX 16-AUG-2001; 2001US-0312889P.
XX 16-AUG-2001; 2001US-0312908P.
XX 21-AUG-2001; 2001US-0313390P.
XX 28-AUG-2001; 2001US-0315470P.
XX 31-AUG-2001; 2001US-0316477P.
XX 07-SEP-2001; 2001US-0318115P.
XX 07-SEP-2001; 2001US-0318118P.
XX 12-SEP-2001; 2001US-0318740P.
XX 19-SEP-2001; 2001US-0323379P.
XX 18-OCT-2001; 2001US-0330245P.
XX 18-OCT-2001; 2001US-0330308P.
XX 14-NOV-2001; 2001US-0332701P.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Tchernev VT, Spytek KA, Zerhusen BD, Patturajan M, Shimkets RA;
PI Li L, Gangolli EA, Padigaru M, Anderson DM, Rastelli L, Miller CE;
PI Gerlach VL, Taupier RJ, Gusev VY, Colman SD, Wolenc AR, Pena CEA;
PI Furtak K, Grosse WM, Alsobrook JP, Lepley DM, Rieger DK, Burgess CE;

XX WPI; 2002-706998/76.
 XX New NOVX polypeptides and nucleic acids, useful for preventing or
 PT treating NOVX-associated disorders, e.g. cancer, cardiomyopathy, or
 PT atherosclerosis, or diabetes, and in chromosome mapping, tissue typing or
 PT pharmacogenomics.
 XX
 PS Example 2; SEQ ID NO 1128; 1498pp; English.
 XX
 CC This invention relates to a novel nucleic acids, and encoded polypeptides
 CC thereof, which have properties related to the stimulation of biochemical
 CC or physiological responses in a cell, tissue, organ or organism.
 CC Specifically, it refers to the use of biologically active fragments for
 CC diagnostic and prognostic assays and furthermore in the treatment of
 CC diverse pathological conditions. The present invention describes novel
 CC human and murine NOVX proteins, as well as methods to modulate their
 CC expression using antisense oligos, ribozymes and peptide nucleic acids.
 CC The polypeptides, nucleic acid molecules and antibodies are useful in the
 CC manufacture of a medicament for treating metabolic disorders, diabetes,
 CC anorexia, cancer, cardiovascular, infectious, neurodegenerative, immune
 CC and haematopoietic diseases as well as various dyslipidaemias.
 CC Accordingly, these molecules have many activities including anorectic,
 CC virucide, nootropic, antiinflammatory, neuroprotective, antilipaeamic,
 CC anabolic and cardiatic. Furthermore, they are useful in screening assays
 CC to identify small molecules that modulate or inhibit, for example,
 CC neurogenesis, wound healing and angiogenesis. The nucleic acids are also
 CC used as in chromosome mapping, tissue typing, preventive medicine and
 CC pharmacogenomics. This oligonucleotide is a PCR primer used to amplify
 CC human NOVX DNA of the invention.
 XX
 SQ Sequence 21 BP; 2 A; 4 C; 6 G; 9 T; 0 U; 0 Other;
 Query Match 0.9%; Score 16.2; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 88;
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 1441 TGAATGTTGCTGCTGCTGTTT 1461
 |||||
 Db 1 TGGATGTTGCTGCTACTGCT 21
 |||||
 RESULT 31
 ADN42680
 ID ADN42680 standard; DNA; 21 BP.
 XX
 AC ADN42680;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE Human NOV37 RTQ-PCR reverse primer #6.
 XX
 KW Human; sg; NOVX; cancer; diabetes; cardiomyopathy; atherosclerosis; PCR;
 KW primer; RTQ PCR; real time quantitative PCR.
 XX
 OS Homo sapiens.
 XX
 XN US2004033493-A1.
 XX
 PD 19-FEB-2004.
 XX
 XX 31-JAN-2002; 2002US-00072012.
 XX
 XX 31-JAN-2001; 2001US-0265395P.
 PR 31-JAN-2001; 2001US-0265412P.
 PR 31-JAN-2001; 2001US-0265514P.
 PR 31-JAN-2001; 2001US-0265517P.
 PR 02-FEB-2001; 2001US-0266406P.
 PR 05-FEB-2001; 2001US-0266767P.
 PR 07-FEB-2001; 2001US-0266975P.
 PR 07-FEB-2001; 2001US-0267057P.
 PR 08-FEB-2001; 2001US-0267459P.
 PR 09-FEB-2001; 2001US-0267823P.

PR 15-FEB-2001; 2001US-0268974P.
 PR 26-FEB-2001; 2001US-0271664P.
 PR 27-FEB-2001; 2001US-0271839P.
 PR 27-FEB-2001; 2001US-0271855P.
 PR 02-MAR-2001; 2001US-0272788P.
 PR 02-MAR-2001; 2001US-0273046P.
 PR 14-MAR-2001; 2001US-0275925P.
 PR 14-MAR-2001; 2001US-0275947P.
 PR 14-MAR-2001; 2001US-0275950P.
 PR 14-MAR-2001; 2001US-0275989P.
 PR 15-MAR-2001; 2001US-0276448P.
 PR 15-MAR-2001; 2001US-0276450P.
 PR 16-MAR-2001; 2001US-0276397P.
 PR 16-MAR-2001; 2001US-0276768P.
 PR 20-MAR-2001; 2001US-0278652P.
 PR 26-MAR-2001; 2001US-0278775P.
 PR 26-MAR-2001; 2001US-0278778P.
 PR 29-MAR-2001; 2001US-0279882P.
 PR 29-MAR-2001; 2001US-0279884P.
 PR 30-MAR-2001; 2001US-0280147P.
 PR 11-APR-2001; 2001US-0282992P.
 PR 11-APR-2001; 2001US-0283083P.
 PR 20-APR-2001; 2001US-0285133P.
 PR 23-APR-2001; 2001US-0285749P.
 PR 03-MAY-2001; 2001US-0288327P.
 PR 03-MAY-2001; 2001US-0288504P.
 PR 29-MAY-2001; 2001US-0294047P.
 PR 30-MAY-2001; 2001US-0294473P.
 PR 08-JUN-2001; 2001US-0296964P.
 PR 18-JUN-2001; 2001US-0298959P.
 PR 19-JUN-2001; 2001US-0299324P.
 PR 13-AUG-2001; 2001US-0312020P.
 PR 16-AUG-2001; 2001US-0312889P.
 PR 16-AUG-2001; 2001US-0312908P.
 PR 21-AUG-2001; 2001US-0313930P.
 PR 28-AUG-2001; 2001US-0315470P.
 PR 31-AUG-2001; 2001US-0316447P.
 PR 07-SEP-2001; 2001US-0318115P.
 PR 07-SEP-2001; 2001US-0318118P.
 PR 12-SEP-2001; 2001US-0318740P.
 PR 18-SEP-2001; 2001US-0323379P.
 PR 18-OCT-2001; 2001US-0330245P.
 PR 18-OCT-2001; 2001US-0330308P.
 PR 14-NOV-2001; 2001US-0332701P.
 XX
 XX (TCHE/) TCHERNEV V T.
 PA (SPY/) SPYTEK K A.
 PA (ZERH/) ZERHUSEN B D.
 PA (PATT/) PATTURAJAN M.
 PA (SHIM/) SHINKETS R A.
 PA (LILL/) LI L.
 PA (GANG/) GANGOLLI E A.
 PA (PADI/) PADIGARU M.
 PA (ANDE/) ANDERSON D W.
 PA (RAST/) RASTELLI L.
 PA (MILL/) MILLER C E.
 PA (GERL/) GERLACH V.
 PA (TAUP/) TAUPIER R J.
 PA (GUSE/) GUSEV V Y.
 PA (COLM/) COLMAN S D.
 PA (WOLE/) WOLENC A R.
 PA (PENA/) PENNA C E A.
 PA (FURT/) FURTAK K.
 PA (GROS/) GROSSE W M.
 PA (ALSO/) ALSOBROOK J P.
 PA (LEPL/) LEPLY D M.
 PA (RIEG/) RIEGER D K.
 PA (BURG/) BURGESS C E.
 XX
 PI Tchernev VT, Spytek KA, Zerhusen BD, Patturajan M, Shinkets RA;
 PI Li L, Gangolli EA, Padigar M, Anderson DW, Rastelli L, Miller CE;
 PI Gerlach V, Taupier RJ, Colman SD, Wolenc AR, Pena CEA;
 PI Furtak K, Grosse WM, Alsobrook JP, Lepley DM, Rieger DK, Burgess CE;

```

XX DR WPI; 2004-180039/17.
XX
XX PT Isolated NOVX polypeptides and polynucleotides, useful for preventing
XX PT diagnosing and/or treating cancer, diabetes, cardiomyopathy and
XX PT atherosclerosis.
XX
XX PS Example 2; SEQ ID NO 1128; 1309pp; English.
XX
XX CC The invention relates isolated 162 NOVX polypeptides (NOV1-NOV99,
XX CC including splice variants) and the nucleic acids (NA) that encode them.
XX CC Also included are the mature NOVX proteins (NA) and their encoding
XX CC polynucleotides), a vector comprising NOVX NA, a cell comprising the
XX CC vector, an antibody that binds immunospecifically to NOVX, determining
XX CC the presence or amount of NOVX in a sample, determining the presence or
XX CC amount of NOVX NA in a sample, identifying an agent that binds to NOVX,
XX CC modulating the activity of NOVX, treating or preventing a NOVX-associated
XX CC disorder, determining the presence of or predisposition to a disease
XX CC associated with altered levels of NOVX and treating a pathological state
XX CC in a mammal comprising administering a polypeptide which is at least 95%
XX CC identical to NOVX (or fragment). NOVX and NA may be used in the
XX CC prevention, treatment and diagnosis of diseases associated with
XX CC inappropriate expression and activity of NOVX (e.g. cancer, diabetes,
XX CC cardiomyopathy and/or atherosclerosis). The anti-NOVX antibodies and
XX CC antagonists may also be used to down regulate expression and activity of
XX CC NOVX. The anti-NOVX antibodies may also be used as diagnostic agents for
XX CC detecting the presence of NOVX in samples (e.g. by enzyme linked
XX CC immunosorbent assay (ELISA). The agents and methods may be used in this
XX CC way to prevent, diagnose and treat cancer, diabetes, cardiomyopathy
XX CC and/or atherosclerosis. The present sequence is a real time quantitative
XX CC PCR (RTQ PCR) primer for tissue specific expression studies for a NOVX
XX CC gene.
XX
XX SQ Sequence 21 BP; 2 A; 4 C; 6 G; 9 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 88;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1441 TGAATGTTGCTGCTGCTGTTT 1461
Db 1 TGGATGTTGCTGCTACTGCTCT 21
|||||
|||||

RESULT 32
ADS82520/c
ID ADS82520 standard; DNA; 21 BP.
XX
XX AC ADS82520;
XX
XX DT 16-DEC-2004 (first entry)
XX
XX DE RT-PCR primer for detection of human MLC-2v expression.
XX
XX KW Cardiomyocyte; embryonic stem cell; differentiation; cell therapy;
XX KW gene therapy; myocardial infarction model; cardiant; human; MLC-2v;
XX KW reverse transcription-PCR; RT-PCR; primer; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO2004081205-A1.
XX
XX PD 23-SEP-2004.
XX
XX PF 11-MAR-2004; 2004WO-AU000302.
XX
XX PR 11-MAR-2003; 2003AU-00901099.
XX
XX PA (ESCE-) ES CELL INT PTE LTD.
XX PA (NEON-) NETHERLANDS INST ONTWIKKELINGSBIOLOGIE.
XX PA (IPOR-) IP ORGANISERS PTY LTD.
XX
XX PI Mummery CL, Doeveandans PAFM, Tertoolen LGJ;

```

```

XX DR WPI; 2004-677542/66.
XX
XX PT Inducing cardiomyocyte differentiation of a human embryonic stem (hES)
XX PT cell, useful for restoring cardiac function, comprises co-culturing the
XX PT hES cell with a cell excreting cardiomyocyte differentiation inducing
XX PT factor.
XX
XX PS Disclosure; SEQ ID NO 7; 46pp; English.
XX
XX CC The invention provides a method for inducing the differentiation of human
XX CC embryonic stem (hES) cells to cardiomyocytes. It involves co-culturing
XX CC the hES cells with a cell excreting at least one cardiomyocyte
XX CC differentiation-inducing factor, or with an extracellular medium, under
XX CC conditions that induce differentiation. A suitable cell line for the co-
XX CC culture is the mouse visceral-endoderm-like END-2 cell line or the HepG2
XX CC liver parenchymal cell line. Treating or preventing a cardiac disease or
XX CC condition comprises introducing an isolated differentiated cardiomyocyte
XX CC and/or a cell capable of differentiating into a cardiomyocyte cell when
XX CC treated, into a cardiac tissue of a subject. The isolated cardiomyocyte
XX CC is transplanted into damaged cardiac tissue of a subject for restoration
XX CC of cardiac function. The differentiated cardiomyocyte resembles a human
XX CC foetal ventricular, atrial cell or pacemaker cell in culture. The
XX CC cardiomyocytes provide a myocardial infarction model for the study of
XX CC human cardiac disease and for testing the ability to restore cardiac
XX CC function. They can also be used for testing drugs, for transplantation,
XX CC cell therapy or gene therapy. The method was demonstrated by determining
XX CC the expression of cardiac-specific ion channels and stem cell or
XX CC sarcomere markers in undifferentiated hES cells and in differentiating
XX CC cells 8 and 15 days after initiation of co-culture with END-2 cells. The
XX CC present sequence is that of an RT-PCR (reverse transcription-PCR) primer
XX CC for MLC-2v. MLC-2v expression became detectable by RT-PCR during the
XX CC course of the co-culture. Transcripts for MLC-2v were also detected in
XX CC non-beating, myocyte-like areas.
XX
XX SQ Sequence 21 BP; 4 A; 8 C; 4 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 88;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1106 AGAACAAAGGTGGAGTTGGTGC 1126
Db 21 AGAACACGTTGGAGTTGGCGC 1
|||||
|||||

RESULT 33
AAA82893/c
ID AAA82893 standard; DNA; 19 BP.
XX
XX AC AAA82893;
XX
XX DT 04-DEC-2000 (first entry)
XX
XX DE cdk4 ribozyme binding site #74.
XX
XX KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
XX OS Mammalia.
XX
XX PN WO200032765-A2.
XX
XX PD 08-JUN-2000.
XX
XX PF 06-DEC-1999; 99WO-US028772.
XX
XX PR 04-DEC-1998; 98US-0110954P.
XX
XX PA (IMMU-) IMMUSOL INC.
XX
XX PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
XX WPI; 2000-412314/35.

```

XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 53; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AA02415 to AA08787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 4 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.9%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1095 TGGACTGCAGAGAAC 1110
Db 19 TGGACTGCAGAGAAC 4
RESULT 34
AAH58055/c
ID AAH58055 standard; DNA; 19 BP.
XX
AC AAH58055;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cell-cycle dependent kinase cdk4 ribozyme binding site SEQ ID NO:479.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antiproliferative; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisticking; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX WO200130362-A2.
XX
PD 03-MAY-2001.
XX
XX 26-OCT-2000; 2000WO-US029500.
XX
XX 26-OCT-1999; 99US-0161532P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Robbins JM, Tritz R;
XX
XX WPI; 2001-300427/31.
XX
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 106; 408pp; English.
XX
XX The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a

CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antiseborrheic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisticking,
CC ophthalmological, vulnary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 4 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.9%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1095 TGGACTGCAGAGAAC 1110
Db 19 TGGACTGCAGAGAAC 4
RESULT 35
ADR81681/c
ID ADR81681 standard; DNA; 19 BP.
XX
AC ADR81681;
XX
DT 16-DEC-2004 (first entry)
XX
DE Hepatitis C virus (HCV) oligonucleotide seqid 6180.
XX
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytosolic; anticonvulsant; nootropic; muscular; anti-HIV;
KW RNA interference; RNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX
OS Hepatitis C virus.
XX
XX WO2004080406-A2.
XX
XX 23-SEP-2004.
XX
XX 08-MAR-2004; 2004WO-US007070.
XX
XX 07-MAR-2003; 2003US-0452682P.
XX
XX 12-MAR-2003; 2003US-0454265P.
XX
XX 13-MAR-2003; 2003US-0454962P.
XX
XX 14-APR-2003; 2003US-0455050P.
XX
XX 17-APR-2003; 2003US-0462894P.
XX
XX 25-APR-2003; 2003US-0463772P.
XX
XX 25-APR-2003; 2003US-0465665P.
XX
XX 29-MAY-2003; 2003US-0465802P.
XX
XX 08-AUG-2003; 2003US-0469612P.
XX
XX 11-AUG-2003; 2003US-0494597P.
XX
XX 26-SEP-2003; 2003US-0506341P.
XX
XX 09-OCT-2003; 2003US-0510246P.
XX
XX 10-OCT-2003; 2003US-0510318P.
XX
XX 07-NOV-2003; 2003US-0518453P.
XX

```

PA (ALNY-) ALNYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX PT sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 6180; 378bp; English.
XX
XX The invention describes a RNA interference (RNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX introducing one or more asymmetrical modification in the sequence, where
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instruction for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidaemias, hypercholesterolaemia, statin-resistant
XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX inhibit hepatic glucose production or for treating glucose-metabolism-
XX related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX lung cancer), neurological disease (e.g., Huntington disease or
XX spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX represents a hepatitis C virus (HCV) antisense oligonucleotide that can
XX be used to control HCV gene expression.
XX
XX Sequence 19 BP; 0 A; 0 C; 2 G; 17 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 16; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 85;
XX Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1835 AAAAAAAAAAAAAA 1850
XX DB 19 AAAAAAAAAAAAAA 4
XX
XX RESULT 36
XX AAZ22510
XX ID AAZ22510 standard; DNA; 19 BP.
XX AC AAZ22510;
XX
XX 02-DEC-1999 (first entry)
XX
XX Primer BRL367.
XX
XX Internal Transcribed Spacer; ITS; fungus; yeast; fermentation; assay;
XX PCR; microorganism; wine-making; commercial; primer; ss.
XX
XX Synthetic.
XX OS Dekkera sp.
XX
XX WO9946405-A1.
XX
XX 16-SEP-1999.
XX
XX 11-MAR-1999; 99WO-US004251.
XX
XX 11-MAR-1998; 98US-00037990.
XX (GALL-) GALLO WINERY E & J.
XX
XX Engel SR, Descenzo RA, Morenzoni RA, Ireland NA;
XX WPI; 1999-551425/46.
XX
XX New isolated fungal and yeast nucleic acids, used for identifying
XX PT different fermentation-related microorganisms, particularly in wine
XX fermentation cultures.
XX
XX Claim 5; Page 46; 52pp; English.
XX
XX This is one of the primers, used to identify Dekkera sp. This invention
XX is directed to the identification of different fermentation-related
XX microorganisms, particularly those involved in the production of wine.
XX The invention utilizes a polymerase chain reaction (PCR) based diagnostic
XX assay of DNA sequences located in the Internal Transcribed Spacer (ITS)
XX region of the ribosomal RNA gene. Ribosomal genes are suitable for use as
XX molecular probe targets because of their high copy number. Non
XX transcribed and transcribed spacer sequences associated with ribosomal
XX genes are usually poorly conserved and, thus, are advantageously used as
XX target sequences for the detection of recent evolutionary divergence.
XX Fungal rRNA genes are organized in units. Each unit encodes mature
XX subunits of 18S, 5.8S and 28S rRNA. The ITS region lies between the 18S
XX and 28S rRNA genes and contains two variable non-coding spacers (ITS1 and
XX ITS2) and the 5.8S rRNA gene
XX
XX Sequence 19 BP; 5 A; 8 C; 0 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 15.8; DB 1; Length 19;
XX Best Local Similarity 89.5%; Pred. No. 92;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1696 AATCATTTCCCTCCCTC 1714
XX DB 1 AATCATTTCCCTCCCTC 19
XX
XX RESULT 37
XX AAA85465/c
XX ID AAA85465 standard; DNA; 19 BP.
XX
XX AAA85465;
XX
XX 04-DEC-2000 (first entry)
XX
XX Cyclin A1 ribozyme binding site #87.
XX
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX OS Mammalia.
XX
XX WO200032765-A2.
XX
XX 08-JUN-2000.
XX
XX 06-DEC-1999; 99WO-US028772.
XX
XX 04-DEC-1998; 98US-0110954P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
XX WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PCNA and Cyclin B1.
XX

```

PS Disclosure; Page 92; 109pp; English.

XX The present invention relates to a hairpin or hammerhead ribozyme, designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.

CC Representative examples of ribozyme recognition sites are given in AAA82415 to AAA86787. The ribozyme of the invention is useful for inhibiting restenosis by introduction of the ribozyme into cells. The ribozyme is resistant to endonuclease activity and hence is efficient in restenosis treatment

XX Sequence 19 BP; 2 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

SQ Query Match 0.9%; Score 15.8; DB 1; Length 19; Best Local Similarity 89.5%; Pred. No. 92; Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 434 CTGGGAGGGGAGAGAA 452
|||||
Dy 19 CTGGGAGGGGAGAGATGAA 1

RESULT 38
AAA85464/C
ID AAA85464 standard; DNA; 19 BP.
XX
AC AAA85464;
XX
XX 04-DEC-2000 (first entry)
XX
DE Cyclin A1 ribozyme binding site #86.
XX
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX Mammalia.
XX
XX WO200032765-A2.
XX
XX 08-JUN-2000.
XX
XX 06-DEC-1999; 99WO-US028772.
XX
XX 04-DEC-1998; 98US-0110954P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
XX WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1, PCNA and Cyclin B1.

PS Disclosure; Page 92; 109pp; English.

XX The present invention relates to a hairpin or hammerhead ribozyme, designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.

CC Representative examples of ribozyme recognition sites are given in AAA82415 to AAA86787. The ribozyme of the invention is useful for inhibiting restenosis by introduction of the ribozyme into cells. The ribozyme is resistant to endonuclease activity and hence is efficient in restenosis treatment

XX Sequence 19 BP; 2 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

SQ Query Match 0.9%; Score 15.8; DB 1; Length 19; Best Local Similarity 89.5%; Pred. No. 92; Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 436 GGGAGAGGGGAGAGAAATC 454
|||||
|||||

Db 19 GGGAGAGGAGAGATGAATC 1

RESULT 39
AAH60627/C
ID AAH60627 standard; DNA; 19 BP.
XX
AC AAH60627;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cyclin A1 ribozyme binding site SEQ ID NO:3051.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme; recognition site; target; ribozyme binding site; eye disease; vulvar; proliferative disease; skin disease; psoriasis; diabetic retinopathy; cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP; matrix metalloproteinase; growth factor; reductase; scarring; cytostatic; antipsoriatic; dermatological; keratolytic; antidiabetic; virucide; antisickling; ophthalmological; keratolytic; gene therapy; viral wart; atopic dermatitis; actinic keratosis; squamous cell carcinoma; basal cell carcinoma; seboreic wart; vitreoretinopathy; scar; sickle cell retinopathy; ss.
XX Homo sapiens.
OS
OS Synthetic.
XX
XX WO200130362-A2.
XX
XX 03-MAY-2001.
XX
XX 26-OCT-2000; 2000WO-US029500.
XX
XX 26-OCT-1999; 99US-0161532P.
XX (IMMU-) IMMUSOL INC.
XX
XX Robbins JM, Tritz R;
XX
XX WPI; 2001-300427/31.
XX
XX Treating proliferative skin or eye diseases and scarring, using ribozymes that cleave RNA encoding cytokines involved in inflammation, matrix metalloproteinases, growth factors and cell-cycle dependent kinases.

Example 1; Page 293; 408pp; English.

XX The present invention describes a method for treating a proliferative skin or eye disease and scarring. The method involves administering a ribozyme (I) which cleaves RNA encoding a cytokine involved in inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle dependent kinase, growth factor or a reductase, or administering a nucleic acid molecule (II) comprising a promoter operably linked to a dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling, ophthalmological, vulvar, keratolytic and virucide activities, and cleaves RNA encoding cytokine involved in inflammation. (I) can be used in gene therapy. (I) and (II) are useful for treating proliferative skin diseases such as psoriasis, atopic dermatitis, actinic keratosis, squamous or basal cell carcinoma and viral or seboreic wart. They can also be used for treating proliferative eye diseases such as diabetic retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of prematurity and retinal detachment, and for treating and preventing scarring such as keloid, adhesion and hypertrophic or hypertrophic burn scar. AAH57577 to AAH62099 represent sequences used in the exemplification of the present invention

XX
XX
SQ Sequence 19 BP; 2 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 92;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY	434	CTGGAGAGGGGAGAGAA	452	Matches	17;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
Db	19	CTGGAGAGGAGAGATGAA	1										
RESULT 40													
AAH60626/c													
ID	AAH60626	standard;	DNA; 19 BP.										
XX	AC	AAH60626;											
XX	DT	10-SEP-2001	(first entry)										
XX	DE	Cyclin A1 ribozyme binding site	SEQ ID NO:3050.										
XX	KW	Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;											
XX	KW	recognition site; target; ribozyme binding site; eye disease; vulnery;											
XX	KW	proliferative disease; skin disease; psoriasis; diabetic retinopathy;											
XX	KW	cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;											
XX	KW	matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;											
XX	KW	antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;											
XX	KW	antisickling; ophthalmological; keratolytic; gene therapy; viral wart;											
XX	KW	atopic dermatitis; actinic keratosis; squamous cell carcinoma;											
XX	KW	basal cell carcinoma; seboreic wart; vitreoretinopathy; scar;											
XX	KW	sickle cell retinopathy; ss.											
XX	OS	Homo sapiens.											
XX	OS	Synthetic.											
XX	PN	WO200130362-A2.											
XX	XX	03-MAY-2001.											
XX	XX	26-OCT-2000; 2000WO-US029500.											
XX	PR	26-OCT-1999; 99US-0161532P.											
XX	PA	(IMMU-) IMMUSOL INC.											
XX	PI	Robbins JM, Tritz R;											
XX	DR	WPI; 2001-300427/31.											
XX	PT	Treating proliferative skin or eye diseases and scarring, using ribozymes											
XX	PT	that cleave RNA encoding cytokines involved in inflammation, matrix											
XX	PT	metalloproteinases, growth factors and cell-cycle dependent kinases.											
XX	PS	Example 1; Page 293; 408pp; English.											
XX	CC	The present invention describes a method for treating a proliferative											
XX	CC	skin or eye disease and scarring. The method involves administering a											
XX	CC	ribozyme (I) which cleaves RNA encoding a cytokine involved in											
XX	CC	inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle											
XX	CC	dependent kinase, growth factor or a reductase, or administering a											
XX	CC	nucleic acid molecule (II) comprising a promoter operably linked to a											
XX	CC	nucleic acid segment encoding (I). (I) can have antipsoriatic,											
XX	CC	dermatological, cycostatic, antiseborrheic, antidiabetic, antisickling,											
XX	CC	ophthalmological, vulnery, keratolytic and virucide activities, and											
XX	CC	cleaves RNA encoding cytokine involved in inflammation. (I) can be used											
XX	CC	in gene therapy. (I) and (II) are useful for treating proliferative skin											
XX	CC	diseases such as psoriasis, atopic dermatitis, actinic keratosis,											
XX	CC	squamous or basal cell carcinoma and viral or seboreic wart. They can											
XX	CC	also be used for treating proliferative eye diseases such as diabetic											
XX	CC	retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of											
XX	CC	prematurity and retinal detachment, and for treating and preventing											
XX	CC	scarring such as keloid, adhesion and hypertrophic or hypertrophic burn											
XX	CC	scar. AAH57577 to AAH62099 represent sequences used in the											
XX	CC	exemplification of the present invention											
XX	XX	Sequence 19 BP; 2 A; 9 C; 1 G; 7 T; 0 U; 0 Other;											
Query Match		0.9%;	Score 15.8;	DB 1;	Length 19;								
Best Local Similarity		89.5%;	Pred. No. 92;										

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 92;


```
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1517 GAACAGCTAAGAAAGAAC 1535
    ||||| ||||| |||||
Db 19 GAACAGCTAAGAAAGAAC 1

RESULT 42
ID ABX79687/c
ID ABX79687 standard; cDNA; 19 BP.
XX
AC ABX79687;
XX
XX 17-APR-2003 (first entry)
XX
DE EST polymorphic DNA repeat polynucleotide #12.
XX
XX EST; expressed sequence tag; ss; polymorphic repeat; tandem repeat;
KW Rep-X; human; genetic disease; drug-treatment; Machado-Joseph;
KW Haw River syndrome; Huntington's disease; fragile-X syndrome;
KW Friedrich's ataxia; myotonic dystrophy; hyperandrogenaemia;
KW spinal atrophy; bulbar atrophy; spinocerebellar ataxia.
XX
XX Homo sapiens.
OS
XX US6472154-B1.
XX
XX 29-OCT-2002.
XX
XX 31-DEC-1999; 99US-00475947.
XX
XX 31-DEC-1999; 99US-00475947.
XX
XX (TEXA ) UNIV TEXAS SYSTEM.
XX
XX Garner HR, Wren JD, Minna JD, Fondon JW;
XX WPI; 2003-208818/20.
XX
XX Identifying a candidate polymorphic repeat within a coding sequence, for
XX understanding or treating genetic disease, comprises detecting tandem
XX repeats in a target coding sequence and scoring the repeats for
XX polymorphic probability.
XX
XX Example; Col 175; 588pp; English.
XX
XX The invention discloses a method for identifying a candidate polymorphic
XX repeat within a coding sequence (expressed sequence tag, EST), which
XX comprises detecting tandem repeats in a target coding sequence, scoring
XX the repeats for polymorphic probability and generating a dataset
XX correlating the repeats with polymorphic probability to identify a
XX candidate polymorphic repeat. The computational methods (polymorphic
XX marker prediction of ubiquitous simple sequences, POMPOUS, and Rep-X) are
XX useful for identifying and detecting candidate polymorphic repeats in
XX human genes, which can be used to understand, treat or eliminate genetic
XX diseases, predispositions or adverse drug-treatment reactions. Examples
XX of diseases linked to nucleotide repeats are Machado-Joseph, Haw River
XX syndrome, Huntington's disease, fragile-X syndrome, Friedrich's ataxia,
XX myotonic dystrophy, hyperandrogenaemia, spinal and bulbar atrophy and
XX spinocerebellar ataxia. The sequences presented in ABX79676-ABX80022 are
XX the polymorphic repeats identified for a search of human ESTs
XX
XX Sequence 19 BP; 0 A; 4 C; 0 G; 15 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 15.8; DB 1; Length 19;
XX Best Local Similarity 89.5%; Pred. No. 92;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1516 AGAACACTAAGAAAGAA 1534
    ||||| ||||| |||||
Db 19 AGAACACTAAGAAAGAA 1
```

```
RESULT 43
ID ADJ66298
ID ADJ66298 standard; RNA; 19 BP.
XX
AC ADJ66298;
XX
XX 06-MAY-2004 (first entry)
XX
DE Human TGFb-R siNA lower strand, SEQ ID NO:136.
XX
XX RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; human;
KW anti-diabetic; nephrotropic; hepatotropic; cytostatic;
KW transforming growth factor beta receptor; TGFb; TGFb-R;
KW diabetic nephropathy; chronic liver disease; pulmonary fibrosis; ss.
XX
XX Homo sapiens.
OS
XX WO2003070197-A2.
XX
XX 28-AUG-2003.
XX
XX 11-FEB-2003; 2003WO-US007273.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX
XX 11-MAR-2002; 2002US-0363124P.
XX
XX 06-JUN-2002; 2002US-0386782P.
XX
XX 29-AUG-2002; 2002US-0406784P.
XX
XX 05-SEP-2002; 2002US-0408378P.
XX
XX 09-SEP-2002; 2002US-0409293P.
XX
XX 12-NOV-2002; 2002US-0425559P.
XX
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L;
XX WPI; 2003-697557/66.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
XX diagnosis of diabetic nephropathy, which downregulates expression of the
XX transforming growth factor-beta receptor gene.
XX
XX Example 3; SEQ ID NO 136; 137pp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
XX downregulate expression of the human transforming growth factor beta
XX (TGFb) receptor (TGFb-R) gene by RNA interference. The siNAs may or may
XX not comprise ribonucleotides and may be double or single stranded. They
XX further comprise sense and antisense regions, or alternatively are
XX assembled from a sense oligonucleotide and an antisense oligonucleotide.
XX Specifically, the siNAs include short interfering RNA (siRNA), double-
XX stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
XX can be unmodified or chemically modified, can contain
XX deoxyribonucleotides, and can be chemically synthesised, expressed from a
XX vector or enzymatically synthesised. The invention also relates to kits
XX for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
XX of siNA; and vectors that express siNA. The siNAs are used to modulate
XX expression of the TGFb-R gene in cells, tissue explants or organisms
XX (e.g., by ex vivo gene therapy), or in grafts and transplants for the
XX treatment of a variety of conditions. They may be used for treating
XX diabetic nephropathy, chronic liver disease or pulmonary fibrosis. The
XX siNAs are also useful for drug screening, diagnosis, therapeutic target
XX identification and validation, genetic engineering, pharmacogenomics,
XX studying gene function, and gene mapping (e.g., of single nucleotide
XX polymorphisms). The present sequence represents the lower strand of a
XX human TGFb-R-targeted double-stranded siNA.
XX
XX Sequence 19 BP; 0 A; 12 C; 7 G; 0 T; 0 U; 0 Other;
```

Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 92;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCTCGTCGCCGCCG 46
||||| ||| |||||
Db 1 GCCGCTCTCGTCGCCGCCG 19

RESULT 44
ADJ66170/c
ID ADJ66170 standard; RNA; 19 BP.
XX
AC ADJ66170;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human TGFb-R transcript target sequence/siNA upper strand, SEQ ID NO.8.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; Double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping; human;
KW antidiabetic; nephrotropic; hepatotropic; cytostatic;
KW transforming growth factor beta receptor; TGFb; TGFb-R;
KW diabetic nephropathy; chronic liver disease; pulmonary fibrosis;
KW target sequence; ss.
XX
OS Homo sapiens.
XX
PN W02003070197-A2.
XX
PD 28-AUG-2003.
XX
PF 11-FEB-2003; 2003WO-US007273.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 03-SEP-2002; 2002US-0409293P.
PR 12-NOV-2002; 2002US-0425559P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L;
XX
WPI; 2003-697557/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of diabetic nephropathy, which downregulates expression of the
PT transforming growth factor-beta receptor gene.
XX
XX Example 3; SEQ ID NO 8; 137bp; English.
XX
PS The invention relates to short interfering nucleic acids (siNA) which
PS downregulate expression of the human transforming growth factor beta
CC (TGFb) receptor (TGFb-R) gene by RNA interference. The siNAs may or may
CC not comprise ribonucleotides and may be double or single stranded. They
CC further comprise sense and antisense regions, or alternatively are
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC Specifically, the siNAs include short interfering RNA (siRNA), double-
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC of siNA; and vectors that express siNA. The siNAs are used to modulate
CC expression of the TGFb-R gene in cells, tissue explants or organisms

CC (e.g., by ex vivo gene therapy), or in grafts and transplants for the
CC treatment of a variety of conditions. They may be used for treating
CC diabetic nephropathy, chronic liver disease or pulmonary fibrosis. The
CC siNAs are also useful for drug screening, diagnosis, therapeutic target
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the upper strand of a
CC human TGFb-R targeted double-stranded siNA, which is identical to the
CC TGFb-R transcript target sequence.
XX
XX Sequence 19 BP; 0 A; 7 C; 12 G; 0 T; 0 U; 0 Other;
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 92;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCTCGTCGCCGCCG 46
||||| ||| |||||
Db 19 GCCGCTCTCGTCGCCGCCG 1

RESULT 45
ADM70256/c
ID ADM70256 standard; DNA; 19 BP.
XX
AC ADM70256;
XX
DT 03-JUN-2004 (first entry)
XX
DE Plant gene polymorphism marker related primer, SEQ ID 1135.
XX
KW Primer; variation mapping; mutation mapping; plant;
KW gene polymorphism marker; ss.
XX
OS Synthetic.
XX
PN JP2003289885-A.
XX
PD 14-OCT-2003.
XX
PF 31-JAN-2003; 2003JP-00024620.
XX
PR 01-FEB-2002; 2002JP-00025338.
XX
PR (RIKA) RIKAGAKU KENKYUSHO.
PA (SAIM-) SAI MEDIA KK.
PA (MATS/) MATSUI M.
PA (NAKA/) NAKAZAWA M.
XX
WPI; 2004-126231/13.
XX
PT A primer set and method useful for mapping at least the
PT variation/mutation part of a plant gene using a gene polymorphism marker.
XX
XX Claim 7; SEQ ID NO 1135; 120pp; Japanese.
XX
XX The present invention relates to a primer set and method for mapping at
XX least the variation/mutation part of a plant gene using a gene
CC polymorphism marker. A mutation site of the plant gene is mapped by
CC utilizing a genetic polymorphism marker as follows: (a) genomic DNA is
CC prepared from a plant homozygously having a mutation to be an object of
CC the mapping; (b) A forward primer 1 containing a base corresponding to
CC the gene polymorphic maker of one ecotype plant, a forward primer 2
CC containing a base corresponding to the genetic polymorphism of the other
CC ecotype plant and a reverse primer 3 based on the base sequence common
CC with both the ecotype plants are prepared; (c) two kinds of
CC oligonucleotides emitting fluorescence of different colors when the
CC genetic polymorphism marker is detected are prepared; (d) an
CC amplification reaction of the genomic DNA is carried out in the presence
CC of the primers 1, 2 and 3 and the two kinds of the oligonucleotides; (e)
CC the fluorescence intensity emitted from the resultant reactional product
CC is detected and (f) the position on the genome of the mutation site is
CC determined from the results of detection. The present sequence is a

CC primer, used to illustrate the invention.
 XX Sequence 19 BP; 3 A; 8 C; 2 G; 6 T; 0 U; 0 Other;
 SQ

Query Match 0.9%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 92;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 594 GCAAGAGGGAAGATTGTTG 612
 |||||
 DB 19 GCAGAGGGAACATTGGTG 1

RESULT 46
 ADR80868/c
 ID ADR80868 standard; DNA; 19 BP.
 XX
 AC ADR80868;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human glucose-6-phosphatase oligonucleotide seqid 5367.
 XX
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cyostatic; anticonvulsant; nootropic; muscular; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; glucose-6-phosphatase; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 XX 08-MAR-2004; 2004WO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0483772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0491986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 PA (ALNY-) ALNYLAM PHARM.
 XX
 FI Manoharan M, Bumcrot D;
 XX
 XX WPI; 2004-677362/66.
 XX
 DR Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sense and antisense sequence which has specific modifications.
 XX
 PS Example 5; SEQ ID NO 5367; 378pp; English.
 XX
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications

and the antisense sequence targets a human gene sequence. Also described
 are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 levels or glucose-6-phosphatase levels in a subject; producing (I);
 stabilising (I), involves selecting a sequence with activity and
 introducing one or more asymmetrical modification in the sequence, where
 the modification decreases nuclease sensitivity while not decreasing its
 activity; a kit comprising (I) and instruction for its use; and a device
 that can be dispense or administer a composition comprising (I). (I) is
 useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 The subject is suffering from a disorder characterised by elevated or
 otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 levels of cholesterol, and/or dysregulation of lipid metabolism. The
 disorder is chosen from the HDL/LDL cholesterol imbalance,
 dyslipidaemias, hypercholesterolaemia, statin-resistant
 hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 disease (CHD) and atherosclerosis. (I) is administered to a subject to
 inhibit hepatic glucose production or for treating glucose-metabolism-
 related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 treating the diseases as mentioned above, cancer (e.g. breast, colon or
 lung cancer), neurological disease (e.g., Huntington disease or
 spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 represents a human glucose-6-phosphatase antisense oligonucleotide that
 can be used to control glucose-6-phosphatase gene expression.

Sequence 19 BP; 1 A; 1 C; 2 G; 15 T; 0 U; 0 Other;
 Query Match 0.9%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 92;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1832 CTGAAAAAAGAAAAA 1850
 |||||
 DB 19 CTCAAAAAAGAAAAA 1

RESULT 47
 AAT05353
 ID AAT05353 standard; CDNA; 20 BP.
 XX
 AC AAT05353;
 XX
 DT 09-MAY-1996 (first entry)
 XX
 DE PCR primer used in the construction of vector pCFW1656/BDNFopt3.
 XX
 KW BDNF; neurotrophic factor; neurotrophin; NT-3; NT-4; nerve growth;
 KW signal peptide; NGF peptide; methionine; ss.
 XX
 OS Homo sapiens.
 XX
 PN W09525743-A1.
 XX
 PD 28-SEP-1995.
 XX
 XX 16-MAR-1995; 95WO-US003175.
 XX
 PR 18-MAR-1994; 94US-00215138.
 XX
 PA (AMGE-) AMGEN INC.
 XX
 PI Meng S, Morris CF, Tsai LB;
 XX
 XX WPI; 1995-344586/44.
 XX
 PT Signal peptide sequences - useful for improving secretion efficacy of
 PT nerve growth factor peptide(s).
 XX
 PS Example 2; Page 32; 59pp; English.
 XX
 XX Human nerve growth factor signal peptide-encoding cDNAs can be used to
 CC enhance the amount of peptides secreted from host cells. By using
 CC indirect expression techniques host cells can be made to express NGF

CC peptides without an amino terminal methionine (Met-less NGF peptides),
 CC vectors used in these techniques include pCFM1656/BDNFopt3 and
 CC pCFM1656/NT-3opt3. AAT05350-54 are PCR primers used in the construction
 CC of these vectors. Signal peptides useful in this invention include those
 CC of neurotrophin-3, neurotrophin-4, BDNF and NGF
 XX
 SQ Sequence 20 BP; 7 A; 1 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 98;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1680 TGATTCTAGAAAAGGNAAT 1698
 |||||
 2 TGATTCTAGAAAGGGAAT 20

RESULT 48
 AAX96843/C
 ID AAX96843 standard; DNA; 20 BP.
 XX AC
 XX AAX96843;
 XX
 DT 13-SEP-1999 (first entry)
 XX
 DE PCR primer used to amplify an ORF of Chlamydia pneumoniae.
 XX
 KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
 KW neutralising epitope; PCR primer; ss.
 XX
 XX Synthetic.
 OS Chlamydia pneumoniae.
 XX
 XX WO9927105-A2.
 XX
 PD 03-JUN-1999.
 XX
 XX 20-NOV-1998; 98WO-IB001890.
 XX
 PF 21-NOV-1997; 97FR-00014673.
 PR 04-NOV-1998; 98US-0107078P.
 XX
 XX (BEST) GENSET.
 PA Griffais R;
 XX
 XX WPI; 1999-357842/30.
 XX
 XX Genome sequence of Chlamydia pneumoniae.
 PT
 PS Page 1857; Disclosure; 1912pp; English.

CC AAX91991-X97517 represent PCR primers used to amplify open reading frames
 CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
 CC (see AAX1990). C. pneumoniae causes respiratory disease such as
 CC pneumonia and bronchitis and is thought to be a contributing factor in
 CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading
 CC frames of the C. pneumoniae genome (see AAX34584-AAX35879) can be used
 CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
 CC nucleotides sequences can also be used as immunogenic compositions,
 CC especially where the vector directs the expression of a neutralising
 CC epitope of C. pneumoniae
 XX
 SQ Sequence 20 BP; 8 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 98;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1440 ATGAATGTTGCTGCTGCTG 1458
 |||||

Db 19 ATGATTGTTGCTGCTGCCG 1

RESULT 49
 AAX15575

ID AAX15575 standard; DNA; 20 BP.

XX AC

AAX15575;

XX DT

06-MAY-1999 (first entry)

XX DE

PCR primer for nucleic acid encoding IFN-beta.

XX KW

Origin binding protein Binding site III sequence; HSV-1; HSV-2;

KW viral infection; viral reactivation; interferon regulatory factor-1;
 KW IRF-1; TIS7; interferon-alpha; IFN-alpha; IFN-beta; PCR primer; ss.

XX OS

Synthetic.

XX PN

WO9901464-A1.

XX PD

14-JAN-1999.

XX PF

01-JUL-1998; 98WO-US013733.

XX PR

03-JUL-1997; 97US-0051633P.

XX PR

01-AUG-1997; 97US-0054515P.

XX PR

01-APR-1998; 98US-0080352P.

XX PA

(SMIK) SMITHKLINE BEECHAM CORP.

XX PA

(WIST-) WISTAR INST.

XX PI

Berger SL, Fraser NW, Leary JJ, Tal-Singer R;

XX DR

WPI; 1999-105992/09.

XX PT

Treating viral infection or reactivation, particularly Herpesvirus -

XX PT

using compounds which modulate interferon pathways.

XX PS

Example 6; Page 41; 40pp; English.

XX CC

PCR primers AAX15571-90 were used to amplify TIS7A, TIS7B, interferon-

XX CC

beta (IFN-beta), IFN-alpha, IFN-alpha/beta, interferon regulatory factor

XX CC

-1 (IRF-1), IRF-2, tumour necrosis factor (TNF)-alpha, beta-actin or

XX CC

cyclophilin, in the course of the invention. The specification describes

XX CC

a method for treating viral infection or reactivation. The method

XX CC

comprises contacting an individual with a compound which is an antagonist

XX CC

of the reaction between the origin binding protein Binding site III

XX CC

sequence from Herpes simplex virus (HSV)-1 and HSV-2 and IRF-1.

XX CC

Alternatively, the compound lowers the level of IRF-1, TIS7, IFN-alpha,

XX CC

or IFN-beta. The method can be used to treat viral reactivation in HSV

XX SQ

Sequence 20 BP; 11 A; 1 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;

Best Local Similarity 89.5%; Pred. No. 98;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 590 AGAAGCAAGGAGGAGATT 608

|||||

2 AAAAGCAAGGAGGAGATT 20

Db

RESULT 50
 AAC65462

ID AAC65462 standard; DNA; 20 BP.

XX AC

AAC65462;

XX DT

12-FEB-2001 (first entry)

XX DE

D-1-deoxyxylulose 5-phosphate reductoisomerase PCR primer DXR-GSP3.

XX

KW D-1-deoxyxylulose 5-phosphate reductoisomerase; dxr;
 KW secondary metabolite; tocopherol; nutrition; cancer; cardiac disease;
 KW cataract; neurodegeneration; PCR primer; ss.
 XX Arabidopsis sp.
 XX WO2000063389-A1.
 FN 26-OCT-2000.
 XX 14-APR-2000; 2000WO-US010367.
 PF 15-APR-1999; 99US-0129899P.
 XX 30-JUL-1999; 99US-0146461P.
 PR (CALJ) CALGENE LLC.
 XX Kishore GM, Boronot A, Bhat BG, Rangwala SH;
 FI WPI; 2000-672739/65.
 DR New nucleic acid encoding 1-deoxy-D-xylulose-5-phosphate reductoisomerase, useful for altering production of isoprenoid compounds in plants.
 PT Example 3; Page 25; 45pp; English.
 XX The present invention describes the D-1-deoxyxylulose 5-phosphate reductoisomerase (dxr) enzyme and its coding sequence from Arabidopsis. This protein is involved in the production of isoprenoids in the cell, which in turn affects the production of secondary metabolites such as tocopherols. These are important in mammalian nutrition, and are known antioxidants, protecting against cardiac disease, cancer, cataracts, retinopathy, Alzheimer's disease and neurodegeneration, and having beneficial effects on the symptoms of arthritis. The gene and protein of the invention can be used to increase the production of dxr in plants and thus increase the amount of tocopherols they produce
 XX Sequence 20 BP; 3 A; 3 C; 10 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.9%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 98;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1244 GCCATCATGCGAGGAGTT 1262
 DB 1 GCCATGCTGGAGGAGTT 19
 RESULT 51
 AAH24585
 ID AAH24585 standard; DNA; 20 BP.
 XX AAH24585;
 AC 07-AUG-2001 (first entry)
 DT Human endometrium cDNA clone 1-9-SP6 PCR primer #1.
 DE Human; endometrium; gynaecological; cytostatic; gene therapy;
 XX peptide therapy; endometriosis; gene expression; drug screening;
 KW PCR primer; ss.
 KW Homo sapiens.
 OS WO200132920-A2.
 FN 10-MAY-2001.
 XX 03-NOV-2000; 2000WO-GB004228.
 PF 03-NOV-1999; 99GB-00026074.
 XX 03-NOV-1999; 99GB-00026076.
 PR

PR 03-NOV-1999; 99GB-00026079.
 PR 03-NOV-1999; 99GB-00026081.
 XX (METR-) METRIS THERAPEUTICS LTD.
 PA Pappa H, Lnenicek M;
 PI WPI; 2001-328804/34.
 DR Screening for a gene or gene product associated with endometriosis, for diagnosing or treating endometriosis, comprises selecting a gene whose level of expression differs between healthy and diseased endometrium tissues.
 PT Example; Fig 3; 106pp; English.
 XX The invention relates to a method for screening for a gene or gene product associated with endometriosis. The method comprises comparing the pattern of gene expression in a diseased endometrium tissue from a patient suffering from endometriosis to the pattern of gene expression in healthy endometrium tissue from the same patient, and selecting a gene whose level of expression differs between healthy and diseased tissues. The gene, gene product and their antagonists and agonists are useful in the manufacture of a medicament for diagnosing or treating endometriosis. The method is useful for screening genes or gene products that are implicated in endometriosis. It is particularly useful in diagnosing endometriosis, as well as for screening agents for treating endometriosis. Prior methods of diagnosing endometriosis are more difficult to perform and are more expensive, normally involving surgery. The present method allows the disease to be diagnosed and treated at earlier stage. The present sequence was used in a reverse transcription polymerase chain reaction (RT-PCR) procedure to validate the results of differential gene expression studies. It was used to amplify human endometrium cDNA encoding elongation factor-1
 XX Sequence 20 BP; 1 A; 3 C; 7 G; 9 T; 0 U; 0 Other;
 SQ Query Match 0.9%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 98;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1441 TGAATGTTGCTGCTGCTGT 1459
 DB 2 TGATTGTTGCTGCTGCTGT 20
 RESULT 52
 ABX14278
 ID ABX14278 standard; DNA; 20 BP.
 XX ABX14278;
 AC 26-FEB-2003 (first entry)
 DT Arabidopsis dxr RACE PCR primer DXR-GSP3.
 DE Plant; ss; 1-deoxy-D-xylulose 5-phosphate reductoisomerase; dxr;
 KW isoprenoid; disease resistance; tocopherol; antioxidant; PCR; primer;
 KW free radical damage; cardiac disease; cancer; cataract; retinopathy;
 KW Alzheimer's disease; arthritis; neurodegeneration; anti-aging;
 KW carotenoid; monoterpene; diterpene; plastoquinone; RACE;
 KW rapid amplification of cDNA ends.
 XX Arabidopsis thaliana.
 OS US2002108148-A1.
 FN 08-AUG-2002.
 XX 13-NOV-2001; 2001US-00987025.
 PF 15-APR-1999; 99US-0129899P.
 XX 30-JUL-1999; 99US-0146461P.
 PR

```

PR 14-APR-2000; 2000US-00549787.
XX (BORO/) BORONAT A.
PA (CAMP/) CAMPOS N.
PA (KISH/) KISHORE G M.
XX
PI Boronat A, Campos N, Kishore GM;
XX WPI; 2003-066660/06.
DR
XX New nucleic acid sequence encoding 1-deoxy-D-xylosylase 5-phosphate
PT reductoisomerase from an eukaryotic source, useful for altering
PT isoprenoid content and composition, and modulating disease resistance in
PT plants.
XX
XX Example 3; Page 9; 19pp; English.
XX
XX The invention relates to an isolated nucleic acid sequence encoding 1-
CC deoxy-D-xylosylase 5-phosphate reductoisomerase (DXR) from a eukaryotic
CC source, or the Arabidopsis (At) dxr gene sequence appearing as AX14272
CC encoding the DXR protein appearing as ABG72671, a polynucleotide
CC comprising a sequence which is 70-95% identical to Arabidopsis dxr, a
CC polynucleotide which hybridizes to dxr or its fragment, or a complement
CC of dxr. Also include are: (1) a DNA construct comprising as operably
CC associated components in the 5'-3' direction of transcription, a promoter
CC functional in a plant cell, At dxr and a transcriptional termination
CC sequence; (2) a host cell comprising the construct; (3) a plant
CC comprising the host cell; and (4) producing an isoprenoid compound of
CC interest in a plant, by obtaining a transformed plant, the plant having
CC and expressing in its genome, a primary construct comprising At dxr
CC operably linked to a transcriptional initiation region functional in a
CC plant cell, and at least one secondary construct comprising a DNA
CC sequence encoding a protein involved in the production of a particular
CC isoprenoid operably linked to a transcriptional initiation region
CC functional in a plant cell. The DNA construct is useful for altering
CC (increasing or decreasing) the isoprenoid content in a plant, where dxr
CC is in sense or antisense orientation, and also for increasing the non-
CC mevalonate isoprenoid biosynthetic flux in cell from a host plant. The
CC DNA construct is also useful for modulating disease resistance in a
CC plant. The modified plant is useful for producing isoprenoids such as
CC tocopherol (useful as an antioxidant and protecting mammalian cells from
CC free radical damage and therefore useful in treatment of cardiac disease,
CC cancer, cataracts, retinopathy, Alzheimer's disease, arthritis,
CC neurodegeneration and in anti-aging treatments), carotenoid, monoterpene,
CC diterpene, or plastoquinone. Dxr is useful for producing plants or plant
CC parts including leaves, stems, roots, reproductive and seed with a
CC modified content of tocopherols. The present sequence is a RACE (rapid
CC amplification of cDNA ends) PCR primer used to isolate At dxr cDNA
XX
SQ Sequence 20 BP; 3 A; 3 C; 10 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1244 GCCCATCGAGAGGTT 1262
DB 1 GCCCATCGAGAGGTT 19
RESULT 53
ADD07277
ID ADD07277 standard; DNA; 20 BP.
XX
XX ADD07277;
XX
XX 01-JAN-2004 (first entry)
DT
XX Mouse interferon Beta RT-PCR primer #1.
DE
XX PCR; ss; interferon regulatory factor; IRF-1; IRF-2; herpes; antiviral;
KW transcription factor; virucide; vaccine; interferon; mouse; primer;
KW differential display; RT-PCR; reverse transcriptase PCR.
XX

```

```

XX OS
XX Mus musculus.
XX US2003104356-A1.
XX
XX 05-JUN-2003.
XX
XX 26-MAR-2002; 2002US-00108164.
XX
XX 22-NOV-1999; 99US-00424348.
XX (SMIK ) SMITHKLINE BEECHAM CORP.
XX
XX Berger SL;
XX
XX WPI; 2003-801223/75.
XX
XX Treating infection or reactivation caused by Herpes virus comprises using
XX antagonist of Herpes Simplex virus polynucleotide sequence and interferon
XX regulatory factor-1.
XX
XX Claim 5; SEQ ID NO 125; 53pp; English.
XX
XX The invention relates to treating viral infection or reactivation
XX comprising contacting an individual with an antagonist of the interaction
XX between a Herpes Simplex virus (HSV) polynucleotide sequence appearing as
XX ADD07153 and interferon regulatory factor-1 (IRF-1, a transcription
XX factor of the interferon regulatory pathway). Also included are an
XX isolated HSV polynucleotide comprising ADD07153, a composition comprising
XX a HSV polypeptide involved in viral infection or reactivation, screening
XX for compounds capable of inhibiting specific binding of IRF-1 to a
XX polynucleotide, screening for compounds capable of inhibiting specific
XX binding of IRF-1 to IRF-1:IRF-BP (undefined) complex, a compound capable
XX of agonising or antagonising any compound in IRF-1 and/or interferon
XX genetic regulatory pathway and a composition for comprising an HSV IRF-1
XX binding site consensus sequence. The method is useful for treating
XX infection or reactivation caused by Herpes virus, e.g., HSV-1 or HSV-2
XX infections and for cytomegalovirus, Epstein Barr virus and zoster virus
XX antiviral vaccines. An experiment was performed where cDNA from the
XX transgenimal ganglia of mice infected with HSV was isolated by
XX differential display reverse transcriptase PCR (DDRT-PCR). The present
XX sequence is an RT-PCR primer from an interferon pathway protein (or
XX control) used to amplify specific cDNA from the DDRT-PCR isolated
XX products.
XX
SQ Sequence 20 BP; 11 A; 1 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 590 AGAAGCAAGAGGAGATT 608
DB 2 AAAAGCAAGAGGAGATT 20
RESULT 54
ADL88498/c
ID ADL88498 standard; DNA; 20 BP.
XX
XX ADL88498;
XX
XX 20-MAY-2004 (first entry)
DT
XX Human OKL38 3' splice acceptor region #2.
DE
XX human; ds; OKL38; cell differentiation; cell proliferation;
KW tumorigenesis; cancer; tumour; liver cancer; kidney cancer;
KW prostate cancer; testis cancer; bladder cancer; lung cancer;
XX breast cancer.
XX
XX Homo sapiens.
XX

```

XX PN US2003166519-A1.
 XX PD 04-SEP-2003.
 XX PF 22-MAR-2001; 2001US-00815453.
 XX PR 24-MAY-2000; 2000AU-00007732.
 XX PR 25-MAY-2000; 2000GB-00012820.
 XX PR 15-AUG-2000; 2000AU-00009470.
 XX PA (NACA-) NAT CANCER CENT SINGAPORE PTE LTD.
 XX PI Huynh TH;
 XX DR WPI; 2003-898095/82.
 XX PT New polypeptide designated OKL38 useful to modulate cell differentiation and proliferation and to diagnose, prevent or treat cancer particularly of the breast, or of the liver, kidney, prostate, testis, bladder or lung.
 XX PS Disclosure; Fig 11; 64pp; English.
 XX CC The invention relates to a biologically active fragment of a polypeptide designated OKL38. The invention is used to modulate cell differentiation, cell proliferation or tumourigenesis and to diagnose, prevent or treat cancer or tumour, particularly of the liver, kidney, prostate, testis, bladder, lung, or more specifically of the breast. The present sequence represents a human OKL38 3' splice acceptor region.
 XX SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.9%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 98;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 564 TTCGATGAACCTGCAGAGAA 582
 DB 19 TTCGATGGACTGCAGGGAA 1
 RESULT 55
 ADF08405/C
 ID ADF08405 standard; DNA; 20 BP.
 AC ADF08405;
 XX 12-FEB-2004 (first entry)
 DT Murine plasma glutamate carboxypeptidase PCR primer, SEQ ID 134.
 DE Murine; subacute transmissible spongiform encephalopathy; ESST; PCR; primer; ss; plasma glutamate carboxypeptidase.
 KW Mus musculus.
 XX FR2839081-A1.
 XX 31-OCT-2003.
 XX 29-APR-2002; 2002FR-00005392.
 XX 29-APR-2002; 2002FR-00005392.
 XX (COMS) COMMISSARIAT ENERGIE ATOMIQUE.
 XX Mouthon F, Nouvel V, Deslys JP;
 XX WPI; 2004-045747/05.
 XX Identifying genes having altered expression level in presence of non-conventional transmissible agent, e.g. prion, useful for diagnosis and

PT drug screening.
 XX Claim 15; SEQ ID NO 134; 100pp; French.
 XX CC The present invention relates to a method for identifying genes (I) the expression level of which, in cells or tissues, is correlated with presence/absence of a non-conventional transmissible agent (A), particularly the normal or pathological form of a prion protein (PrP). The method comprises: applying the RDA (representational difference analysis) method to total and/or messenger RNA from cells or tissues infected by (A) and/or PrP; identifying partial mRNA sequences (Y) for which expression is increased or reduced, relative to non-infected cells or tissues; screening databases of genes and/or cDNA, obtained from the same cells or tissues to identify genes that correspond to Y; optionally, confirming under- or over-expression of the identified genes, e.g. by reverse transcription PCR, using primers having sequences deduced from step (c); and optionally, identifying, from the selected sequences, those for which expression levels are returned to normal after treatment with an agent able to reverse the phenotype of infected cells to normal. The method is useful for measuring gene expression and to detect agents that cause subacute transmissible spongiform encephalopathy (ESST) in humans or animals and to screen for agents that can delay, stop or inhibit development of ESST. The present sequence was used to illustrate the invention.
 XX SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 0.9%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 98;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1240 CCAGGGCCATCATCGAGGA 1258
 DB 20 CCAGGGCTATCATCGAGGA 2
 RESULT 56
 ADK75647
 ID ADK75647 standard; DNA; 20 BP.
 XX AC ADK75647;
 XX 20-MAY-2004 (first entry)
 DT Chimeric phosphorothioate oligonucleotide to target Nav1.3 #2981.
 DE Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia; diabetic neuropathy; arthritic pain; migraine headache;
 KW infantile epilepsy; ataxia; ss.
 XX Synthetic.
 XX WO2004016754-A2.
 XX 26-FEB-2004.
 XX 14-AUG-2003; 2003WO-US025465.
 XX 14-AUG-2002; 2002US-0403416P.
 XX (PHAA) PHARMACIA CORP.
 XX Roberts SL;
 XX WPI; 2004-203785/19.
 XX New antisense compound targeted to a nucleic acid molecule encoding Nav1.3, useful for treating a disease or condition associated with Nav1.3, e.g. pain, seizure disorder such as childhood seizure disorder, or ataxia.
 XX Claim 4; SEQ ID NO 2981; 417pp; English.
 XX PS

CC The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.

XX SQ Sequence 20 BP; 12 A; 1 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 88 TGGAAAAAAAATGAAATT 106
DB 2 TGGCAATAAAAAATGAAATT 20

RESULT 57
ADK76677
ID ADK76677 standard; DNA; 20 BP.
AC ADK76677;
XX 20-MAY-2004 (first entry)
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #4011.
XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
XX diabetic neuropathy; arthritic pain; migraine headache;
XX infantile epilepsy; ataxia; ss.
XX Synthetic.
XX WO2004016754-A2.
XX 26-FEB-2004.
XX 14-AUG-2003; 2003WO-US025465.
XX 14-AUG-2002; 2002US-0403416P.
XX (PHAA) PHARMACIA CORP.
XX Roberds SL;
XX WPI; 2004-203785/19.
XX New antisense compound targeted to a nucleic acid molecule encoding
XX Nav1.3, useful for treating a disease or condition associated
XX with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
XX disorder, or ataxia.
XX Claim 4; SEQ ID NO 4011; 417pp; English.

CC The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present

CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.

XX SQ Sequence 20 BP; 11 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 88 TGGAAAAAAAATGAAATT 106
DB 1 TGGCAATAAAAAATGAAATT 19

RESULT 58
ADO43677
ID ADO43677 standard; DNA; 20 BP.
XX ADO43677;
AC ADO43677;
XX 29-JUL-2004 (first entry)
DE PCR primer used to amplify cDNA encoding Id2.
XX antibody; tissue factor; TF; coagulation factor VIIa; FVIIa;
XX FVIIa/TF-related disorder; deep vein thrombosis;
XX disseminated intravascular coagulation; coronary artery disease; sepsis;
XX inflammation; atherosclerosis; cancer; PCR; primer; Fra-1; Id2; Cyr61;
XX ss.
XX Synthetic.
XX WO2004039842-A2.
XX 13-MAY-2004.
XX 31-OCT-2003; 2003WO-DK000741.
XX 31-OCT-2002; 2002DK-00001661.
XX (NOVO) NOVO NORDISK AS.
XX Svendsen I, Kjaergaard K, Zahn S;
XX WPI; 2004-376165/35.
XX New isolated humanized antibodies that immunoreact with human tissue
XX factor (TF) to inhibit the binding of coagulation factor VIIa, useful for
XX treating factor VIIa/TF-related disorders e.g. deep vein thrombosis,
XX sepsis and cancer.
XX Example 5; Page 36; 58pp; English.

CC The specification describes a humanized antibody that immunoreacts with
CC an epitope present on human tissue factor (TF) and inhibits the binding
CC of human coagulation factor VIIa (FVIIa) to human TF. The antibody is
CC useful for treating FVIIa/TF-related disorders, such as deep vein
CC thrombosis, disseminated intravascular coagulation, coronary artery
CC disease, sepsis, inflammation, atherosclerosis or cancer. PCR primers
CC ADO43676-ADO43677 were used to amplify an Id2 cDNA fragment for Northern
CC blot analysis. Fra-1, Id2 and Cyr61 are up-regulated in BHK-TF cells
CC treated with FVIIa.

XX SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1172 TCTGTGATGGAGCTCTGAC 1190
||||||| |||||


```

Dh      2 TCTGGTGATGCGAGGCTGAC 20
RESULT 59
ADQ82155/c
ID      ADQ82155 standard; DNA; 20 BP.
XX
AC      ADQ82155;
XX
DT      21-OCT-2004 (first entry)
XX
DE      Human brain natriuretic peptide gene PCR primer #1.
XX
KW      cardiovascular; endocrine; SHOX; PCR; primer; ss; natriuretic peptide;
KW      short stature; growth protein; cardiovascular disease;
KW      short stature homeobox-containing gene.
XX
OS      Homo sapiens.
XX
FN      WO2004062555-A2.
XX
PD      29-JUL-2004.
XX
PF      12-JAN-2004; 2004WO-EP000134.
XX
PR      13-JAN-2003; 2003EP-00000728.
XX
PA      (RAPP/) RAPPOLD-HOERBRAND G.
XX
PI      Rappold-Hoerbrand G, Haacker B;
XX
DR      WPI; 2004-544028/52.
XX
PT      Use of natriuretic peptide in combination with a growth protein, e.g.
PT      Short Stature Homeobox-containing gene (SHOX) protein for preparing
PT      pharmaceutical compositions for treating short stature in a subject or
PT      cardiovascular diseases.
XX
PS      Example 5; Page 19; 36pp; English.
XX
CC      The present invention relates to the use of a natriuretic peptide (atrial
CC      natriuretic peptide, ANP or brain natriuretic peptide, BNP) in
CC      combination with a growth protein, e.g. Short Stature Homeobox-containing
CC      gene (SHOX) protein for the preparation of pharmaceutical compositions
CC      for the treatment of short stature in a subject being suspected of having
CC      a genetic defect in the SHOX gene or for treatment of patients with
CC      cardiovascular diseases. The natriuretic peptide (ANP or BNP) in
CC      combination with a growth protein, e.g. SHOX protein is useful for the
CC      preparation of pharmaceutical compositions for the treatment of short
CC      stature in a subject being suspected of having a genetic defect in the
CC      SHOX gene or for treatment of patients with cardiovascular diseases. It
CC      is also useful for the preparation of pharmaceutical compositions for
CC      stimulating or increasing human growth or for treating patients with
CC      idiopathic short stature, patients with Turner syndrome, or patients with
CC      Leri-Weill syndrome. The present sequence is a PCR primer used in the
CC      exemplification of the invention.
XX
SQ      Sequence 20 BP; 1 A; 6 C; 3 G; 10 T; 0 U; 0 Other;

Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      157 GGAAGCTATATGCAAGAA 175
Dh      19 GGAAGCCAGATGCAAGAA 1
XX
RESULT 60
ADK23151
ID      ADK23151 standard; DNA; 20 BP.
XX
AC      ADK23151;
XX

```

```

XX      18-NOV-2004 (first entry)
DT
XX
DE      Acyl-coenzyme A synthetase 1, ACS1, antisense oligonucleotide #3228.
XX
KW      acyl-coenzyme A synthetase 1; ACS1; diabetes; obesity;
KW      metabolic syndrome X; cardiovascular disorder; cancer; infection;
KW      inflammation; tumour; antisense; ss.
XX
OS      Synthetic.
XX
FN      WO2004016749-A2.
XX
PD      26-FEB-2004.
XX
PF      14-AUG-2003; 2003WO-US025389.
XX
PR      14-AUG-2002; 2002US-0403591P.
XX
PA      (PHAA ) PHARMACIA CORP.
XX
PI      Ross SA;
XX
DR      WPI; 2004-203782/19.
XX
PT      New antisense compounds targeted to nucleic acid molecules encoding acyl-
PT      coenzyme A synthetase 1 (ACS1), useful for treating diseases or
PT      conditions associated with aberrant expression of ACS1, e.g. diabetes,
PT      obesity or cancer.
XX
PS      Claim 3; SEQ ID NO 3228; 940pp; English.
XX
CC      The invention relates to an antisense compound targeted to a nucleic acid
CC      molecule encoding acyl-coenzyme A synthetase 1 (ACS1). The antisense
CC      compound specifically hybridises with and inhibits the expression of
CC      ACS1. The antisense oligonucleotides or compounds are useful for
CC      inhibiting the expression of acyl-coenzyme A synthetase 1 (ACS1), and for
CC      treating diseases or conditions associated with aberrant expression of
CC      ACS1, e.g. diabetes, obesity, metabolic syndrome X, cardiovascular
CC      disorder or cancer. The antisense compounds are also useful as research
CC      reagents and kits, or in diagnostic, therapeutic and prophylactic
CC      applications, e.g. to prevent or delay infection, inflammation or tumour
CC      formation. The present sequence represents an acyl-coenzyme A synthetase
CC      1, ACS1, antisense oligonucleotide.
XX
SQ      Sequence 20 BP; 2 A; 3 C; 6 G; 9 T; 0 U; 0 Other;

Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1464 GCTGTTGTTTCTTATGTTG 1482
Dh      1 GCTGTTGTTTCTGATG 19
XX
RESULT 61
ADK22897
ID      ADK22897 standard; DNA; 20 BP.
XX
AC      ADK22897;
XX
DT      18-NOV-2004 (first entry)
XX
DE      Acyl-coenzyme A synthetase 1, ACS1, antisense oligonucleotide #2974.
XX
KW      acyl-coenzyme A synthetase 1; ACS1; diabetes; obesity;
KW      metabolic syndrome X; cardiovascular disorder; cancer; infection;
KW      inflammation; tumour; antisense; ss.
XX
OS      Synthetic.
XX
FN      WO2004016749-A2.

```

```

XX PD 26-FEB-2004.
XX
XX PF 14-AUG-2003; 2003WO-US025389.
XX PR 14-AUG-2002; 2002US-0403591P.
XX PA (PHAA ) PHARMACIA CORP.
XX
XX PI Ross SA;
XX
XX XX WPI; 2004-203782/19.
XX
XX PT New antisense compounds targeted to nucleic acid molecules encoding acyl-
XX PT coenzyme A synthetase 1 (ACSL1), useful for treating diseases or
XX PT conditions associated with aberrant expression of ACS1, e.g. diabetes,
XX PT obesity or cancer.
XX
XX PS Claim 3; SEQ ID NO 2974; 940pp; English.
XX
XX CC The invention relates to an antisense compound targeted to a nucleic acid
XX CC molecule encoding acyl-coenzyme A synthetase 1 (ACSL1). The antisense
XX CC compound specifically hybridises with and inhibits the expression of
XX CC ACS1. The antisense oligonucleotides or compounds are useful for
XX CC inhibiting the expression of acyl-coenzyme A synthetase 1 (ACSL1), and for
XX CC treating diseases or conditions associated with aberrant expression of
XX CC ACS1, e.g. diabetes, obesity, metabolic syndrome X, cardiovascular
XX CC disorder or cancer. The antisense compounds are also useful as research
XX CC reagents and kits, or in diagnostic, therapeutic and prophylactic
XX CC applications, e.g. to prevent or delay infection, inflammation or tumour
XX CC formation. The present sequence represents an acyl-coenzyme A synthetase
XX CC 1, ACS1, antisense oligonucleotide.
XX
XX SQ Sequence 20 BP; 3 A; 2 C; 6 G; 9 T; 0 U; 0 Other;
      Query Match 0.9%; Score 15.8; DB 1; Length 20;
      Best Local Similarity 89.5%; Pred. No. 98;
      Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1463 GGCTGTGTTCTTCTATGTT 1481
Db 2 GGCTGTGTTCTCTGATGAT 20

RESULT 62
AAV45742/c
ID AAV45742 standard; DNA; 21 BP.
XX
XX AC AAV45742;
XX
XX DT 21-DEC-1998 (first entry)
XX
XX DE Human ROMK gene exon 5 reverse primer hROMKex5A.
XX
XX KW ATP-sensitive K+ channel; ROMK; human; Bartter's syndrome; ion transport;
XX KW hypokalaemic alkalosis; hypercalciuria; nephrocalcinosis; diagnosis;
XX KW therapy; SSCP; primer; ss.
XX
XX OS Synthetic.
XX OS Homo sapiens.
XX
XX PN WO9829431-A1.
XX
XX PD 09-JUL-1998.
XX
XX PF 19-DEC-1997; 97WO-US023553.
XX
XX PR 31-DEC-1996; 96US-00778052.
XX
XX PA (UYA ) UNIV YALE.
XX
XX PI Lifton RP, Simon DB;
XX
XX CC This invention describes a novel nucleotide support (A; gene chip) which

```

```

DR XX WPI; 1998-388029/33.
PT
PT PT Thiazide sensitive cotransporter and ATP sensitive potassium channel
PT PT genes - useful for developing products for the diagnosis and treatment of
PT PT ion transport disorders, e.g. Gitelman's Syndrome or Bartter's Syndrome.
XX
XX PS Example 3; Page 76; 105pp; English.
XX
XX CC Primers hROMKex5A forward and reverse (see AAV45741 and AAV45742,
XX CC respectively) are designed to amplify exon 5 of the human ROMK gene that
XX CC codes for ATP-sensitive potassium channel protein ROMK. The forward
XX CC primer is located within an intron of the gene, and the reverse primer
XX CC within exon 5. 8. 11 Sets of specific primers (see AAV45733-54) were used
XX CC for SSCP analysis of ROMK. Amplified products were analysed for molecular
XX CC variants by electrophoresis, and identified variants were sequenced.
XX CC Mutations in ROMK were demonstrated to cause Bartter's syndrome.
XX CC Identification of the molecular basis of Bartter's syndrome allows for
XX CC the genetic diagnosis of this disorder. The invention provides products
XX CC and methods useful for diagnosis and treatment of Bartter's syndrome and
XX CC other ion transport disorders
XX
XX SQ Sequence 21 BP; 4 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
      Query Match 0.9%; Score 15.8; DB 1; Length 21;
      Best Local Similarity 89.5%; Pred. No. 1e+02;
      Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 961 GTGGACATCTGGACAGCTG 979
Db 21 GTGGACATCTGGACACGG 3

RESULT 63
AAH48999
ID AAH48999 standard; DNA; 21 BP.
XX
XX AC AAH48999;
XX
XX DT 12-NOV-2001 (first entry)
XX
XX DE Human CFTR gene associated primer #54.
XX
XX KW Neonate screening; prenatal screening; gene chip; diagnosis;
XX KW phenylketonuria; maple syrup disease; galactosemia; homocysteinuria;
XX KW medium-chain acyl-CoA-dehydrogenase deficiency; biotinidase deficiency;
XX KW familial hypercholesterolemia; familial defective apolipoprotein-B;
XX KW cystic fibrosis; Marfan syndrome; Smith-Lemli-Opitz syndrome;
XX KW androgenital syndrome; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200153520-A2.
XX
XX PD 26-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-EP000139.
XX
XX PR 21-JAN-2000; 2000DE-01002446.
XX
XX (CULL/) CULLEN P.
XX (SEED/) SEEDORF U.
XX
XX PI Cullen P, Seedorf U;
XX
XX DR WPI; 2001-457616/49.
XX
XX DNA chip, useful for neonatal or prenatal screening for many genetic
XX PT diseases simultaneously, carries oligonucleotides complementary to
XX PT phenotypically relevant reference sequences.
XX
XX PS Claim 4; Page 49; 101pp; German.
XX
XX CC This invention describes a novel nucleotide support (A; gene chip) which

```

CC carries a selection of oligonucleotides (I) that are identical, or
 CC complementary, to segments of reference sequences relevant to at least
 CC two genetically determined phenotypes. (A) are used for simultaneous
 CC diagnosis of at least two of the following diseases: phenylketonuria
 CC (maple syrup disease), galactosemia, homocysteinuria, biotinidase
 CC deficiency, medium-chain acyl-CoA-dehydrogenase deficiency, familial
 CC hypercholesterolemia, familial defective apolipoprotein-B, cystic
 CC fibrosis, Marfan syndrome, Smith-Lemli-Opitz syndrome and androgenital
 CC syndrome. Specifically they are used in neonatal or prenatal diagnosis.
 CC (A) require a relatively small number of separate hybridization regions
 CC (about 500 for testing for 21 specified disorders), so can be used for
 CC simultaneous testing for many diseases. Testing is quick, inexpensive,
 CC reliable and more sensitive than current physiological methods. AHA48868-
 CC AHA489166 represent oligonucleotides used to illustrate the method of the
 CC invention

XX SQ Sequence 21 BP; 12 A; 1 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.9%; Score 15.8; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 197 TGAAGAAATAAAGAGAA 215
 Db 3 TGAAGAAATAAAGAGAA 21

RESULT 64

ADE34513

ID ADE34513 standard; DNA; 21 BP.

AC ADE34513;

XX 29-JAN-2004 (first entry)

XX Human G-protein coupled receptor related primer #SEQ ID 133.

XX Cytostatic; antiinflammatory; hepatotropic; nephrotropic; dermatological;

XX antiarthritic; antiasthmatic; antidiabetic; hypotensive; antiulcer;

XX antilipemic; antiarteriosclerotic; nootropic; neuroprotective; anorectic;

XX immunomodulator; uropathic; antiinfertility; G-protein coupled receptor;

XX GPCR; GPCR185; GPCR187; GPCR189; GPCR189; GPCR222; GPCR223;

XX hepatitis; nephritis; dermatitis; pancreatitis; rheumatoid arthritis;

XX osteoarthritis; atopic dermatitis; asthma; diabetes; hypertension;

XX inflammatory bowel disease; gastric ulcer; arteriosclerosis;

XX hyperlipemia; Alzheimer's disease; dementia; obesity; pulmonary fibrosis;

XX renal fibrosis; immune deficiency; infertility; urinary blockage; cancer;

XX PCR; primer; ss.

XX Homo sapiens.

XX WO2003078632-A1.

XX 25-SEP-2003.

XX 14-MAR-2003; 2003WO-JP003050.

XX 15-MAR-2002; 2002JP-00071567.

XX 14-MAY-2002; 2002JP-00138013.

XX 28-FEB-2003; 2003JP-00054663.

XX (NISB) JAPAN TOBACCO INC.

XX Watanabe H, Nozaki Y;

XX WPI; 2003-722435/68.

XX G-protein coupled receptor proteins, genes encoding them and antibodies

XX recognizing them for treatment and diagnosis of cancer, inflammatory and

XX gastrointestinal disorders.

XX Example; SEQ ID NO 133; 274pp; Japanese.

XX

CC The invention relates to G-protein coupled receptor proteins of human
 CC origin. These proteins include GPCR185, GPCR186, GPCR187, GPCR188,
 CC GPCR189, GPCR222 and GPCR223. Proteins of the invention are used in the
 CC treatment and prevention of diseases associated with inflammation,
 CC angiogenesis and tissue neogenesis, including hepatitis, nephritis,
 CC dermatitis, pancreatitis, rheumatoid arthritis, osteoarthritis, atopic
 CC dermatitis, asthma, diabetes, hypertension, inflammatory bowel disease,
 CC gastric ulcer, arteriosclerosis, hyperlipemia, Alzheimer's disease,
 CC dementia, obesity, pulmonary fibrosis, renal fibrosis, immune deficiency,
 CC infertility, urinary blockage and cancer (such as cancer of the brain,
 CC neck, tongue, lung, breast, pancreas, stomach, colon, duodenum, prostate,
 CC bladder, ovary, womb or rectum). Primers of the invention are devised and
 CC synthesised based on G-protein coupled receptor consensus sequences and
 CC used for 5'-RACE (rapid amplification of cDNA ends) and 3'-RACE
 CC amplification of human cDNA derived from adrenal and visual cortex RNA.
 CC Sequences given in ADE34534-ADE34533 represent human G-protein coupled
 CC receptor proteins, genes encoding them, and primers for the amplification
 CC of these sequences.

XX SQ Sequence 21 BP; 8 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 21;

Best Local Similarity 89.5%; Pred. No. 1e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1355 AGCCAGTCTACTTGATGAC 1373

Db 2 AGCCAGTACTTGATGAC 20

RESULT 65

ADQ30709/c

ID ADQ30709 standard; DNA; 21 BP.

XX ADQ30709;

XX 23-SEP-2004 (first entry)

XX Device with substance to aid adhesion of biological material aptamer #3.

XX aptamer; ss; implant; biological material adhesion; bioreactor.

XX Synthetic.

XX WO2004055153-A2.

XX 01-JUL-2004.

XX 10-DEC-2003; 2003WO-EP013989.

XX 17-DEC-2002; 2002DB-01058924.

XX (UYTU-) UNIV TUEBINGEN EBERHARD-KARLS.

XX Schluesener H, Wendel H;

XX WPI; 2004-517421/49.

XX Device coated with aptamers for binding specific biological materials,

XX useful e.g. as stent or component of extracorporeal circulation system,

XX also new aptamers specific for endothelial precursor cells.

XX Claim 15; SEQ ID NO 3; 31pp; German.

XX The present invention relates to a device that has at least one surface

XX that contacts tissue and/or liquids of the human or animal body and is at

XX least partly coated with a substance that mediates binding of biological

XX materials. The new feature is that this substance is an aptamer. The

XX device is particularly an implant, e.g. a stent, vascular prosthesis,

XX heart valve, joint etc., but may also be a component of an extracorporeal

XX circulation system, a nanomaterial for tissue engineering and vascular

XX surgery, a catheter, contact lens, storage device for blood etc., also a

XX bioreactor for isolation and culture of selected cell types, for

```
CC production of substances or for growing organ replacements. The present
CC sequence is an aptamer suitable for use in the device of the invention.
XX
SQ Sequence 21 BP; 0 A; 7 C; 14 G; 0 T; 0 U; 0 Other;

Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCCGTCGCCGCCG 46
Db 20 GCCGCGCGCGCGCGCGCG 2

RESULT 66
ADQ30710/c
ID ADQ30710 standard; DNA; 21 BP.
XX
AC ADQ30710;
XX
DT 23-SEP-2004 (first entry)
XX
DE Device with substance to aid adhesion of biological material aptamer #4.
XX
KW aptamer; ss; implant; biological material adhesion; bioreactor.
XX
OS Synthetic.
XX
PN WO2004055153-A2.
XX
PD 01-JUL-2004.
XX
PF 10-DEC-2003; 2003WO-EP013989.
XX
PR 17-DEC-2002; 2002DE-01058924.
XX
PA (UYTU-) UNIV TUEBINGEN EBERHARD-KARLS.
XX
PI Schluesener H, Wendel H;
XX
DR WPI; 2004-517421/49.
XX
CC Device coated with aptamers for binding specific biological materials,
CC useful e.g. as stent or component of extracorporeal circulation system,
CC also new aptamers specific for endothelial precursor cells.
XX
PS Claim 15; SEQ ID NO 4; 31pp; German.
XX
CC The present invention relates to a device that has at least one surface
CC that contacts tissue and/or liquids of the human or animal body and is at
CC least partly coated with a substance that mediates binding of biological
CC materials. The new feature is that this substance is an aptamer. The
CC device is particularly an implant, e.g. a stent, vascular prosthesis,
CC heart valve, joint etc., but may also be a component of an extracorporeal
CC circulation system, a nanomaterial for tissue engineering and vascular
CC surgery, a catheter, contact lens, storage device for blood etc., also a
CC bioreactor for isolation and culture of selected cell types, for
CC production of substances or for growing organ replacements. The present
CC sequence is an aptamer suitable for use in the device of the invention.
XX
SQ Sequence 21 BP; 0 A; 7 C; 14 G; 0 T; 0 U; 0 Other;

Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCCGTCGCCGCCG 46
Db 19 GCCGCGCGCGCGCGCGCG 1

RESULT 67
ADQ30708
```

```
ID ADQ30708 standard; DNA; 21 BP.
XX
AC ADQ30708;
XX
DT 23-SEP-2004 (first entry)
XX
DE Device with substance to aid adhesion of biological material aptamer #2.
XX
KW aptamer; ss; implant; biological material adhesion; bioreactor.
XX
OS Synthetic.
XX
PN WO2004055153-A2.
XX
PD 01-JUL-2004.
XX
PF 10-DEC-2003; 2003WO-EP013989.
XX
PR 17-DEC-2002; 2002DE-01058924.
XX
PA (UYTU-) UNIV TUEBINGEN EBERHARD-KARLS.
XX
PI Schluesener H, Wendel H;
XX
DR WPI; 2004-517421/49.
XX
CC Device coated with aptamers for binding specific biological materials,
CC useful e.g. as stent or component of extracorporeal circulation system,
CC also new aptamers specific for endothelial precursor cells.
XX
PS Claim 15; SEQ ID NO 2; 31pp; German.
XX
CC The present invention relates to a device that has at least one surface
CC that contacts tissue and/or liquids of the human or animal body and is at
CC least partly coated with a substance that mediates binding of biological
CC materials. The new feature is that this substance is an aptamer. The
CC device is particularly an implant, e.g. a stent, vascular prosthesis,
CC heart valve, joint etc., but may also be a component of an extracorporeal
CC circulation system, a nanomaterial for tissue engineering and vascular
CC surgery, a catheter, contact lens, storage device for blood etc., also a
CC bioreactor for isolation and culture of selected cell types, for
CC production of substances or for growing organ replacements. The present
CC sequence is an aptamer suitable for use in the device of the invention.
XX
SQ Sequence 21 BP; 0 A; 14 C; 7 G; 0 T; 0 U; 0 Other;

Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCCGTCGCCGCCG 46
Db 3 GCCGCGCGCGCGCGCGCG 21

RESULT 68
ADQ92979
ID ADQ92979 standard; RNA; 21 BP.
XX
AC ADQ92979;
XX
DT 21-OCT-2004 (first entry)
XX
DE Aromatase siRNA sense strand, SEQ ID 555.
XX
KW Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;
KW small interfering RNA; siRNA;
KW androgen signal transduction pathway protein;
KW androgen signal transduction; aromatase; hair loss;
KW hyperandrogenic condition; androgenic alopecia; male pattern alopecia;
KW acne vulgaris; seborrhea; female hirsutism; prostatic hypertrophy; ds.
XX
OS Synthetic.
```

```
XX FH Key Location/Qualifiers
XX FT misc_feature /tag= a
XX FT PT /note= "2 deoxynucleotide overhang"
XX PN WO2004063331-A2.
XX PD 29-JUL-2004.
XX PF 05-JAN-2004; 2004WO-US000128.
XX PR 03-JAN-2003; 2003US-0437842P.
XX PA (GENC-) GENCIA CORP.
XX PI Kahn S;
XX DR WPI; 2004-561892/54.
XX PT Inhibitory nucleic acid that inhibits expression of an androgen signal
XX FT transduction pathway protein useful for treating hair loss, comprises a
XX FT double stranded RNA having a partial sequence encoding a pathway protein
XX FT in one strand.
XX PS Claim 11; Page 50; 92pp; English.
XX CC The present invention relates to novel small interfering RNAs (siRNAs),
XX CC comprising a double stranded RNA, where one strand comprises a partial
XX CC nucleic acid sequence of an androgen signal transduction pathway protein,
XX CC and where the double-stranded RNA inhibits translation of mRNA encoding
XX CC the nucleic acid sequence of the androgen signal transduction pathway
XX CC protein thereby blocking the androgen signal transduction pathway. The
XX CC androgen signal transduction pathway protein is chosen from isozymes I
XX CC and II of 5-alpha reductase (ADQ92435 and ADQ92516), the androgen
XX CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-
XX CC hydroxysteroiddehydrogenase (ADQ93182), 3-beta-
XX CC hydroxysteroiddehydrogenase (ADQ93360), 3-beta-
XX CC hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-
XX CC hydroxysteroiddehydrogenase (ADQ93722), and steroid sulfatase
XX CC (ADQ93770). The siRNAs of the invention are useful for reducing hair loss
XX CC in a mammal which involves contacting several mammal's hair cells with
XX CC the siRNA, where the siRNA interferes with the translation of mRNA of the
XX CC androgen signal transduction protein. The siRNAs are useful for treating
XX CC hyperandrogenic conditions of androgenic alopecia, including male pattern
XX CC alopecia, acne vulgaris, seborrhea, and female hirsutism and prostatic
XX CC hypertrophy. The present sequence is the sense strand for one such siRNA
XX CC of the invention.
XX SQ Sequence 21 BP; 5 A; 4 C; 6 G; 2 T; 4 U; 0 Other;
Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1e+02; Indels 0; Gaps 0;
Matches 14; Conservative 3; Mismatches 2;
Qy 965 ACATCTGGACAGCTGGCAT 983
|||:|||||:||||
Db 2 ACAUCUGGACAGGUUGAT 20
RESULT 69
AAA25489
ID AAA25489 standard; DNA; 17 BP.
XX AC AAA25489;
XX DT 19-JUL-2000 (first entry)
XX DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1987.
XX KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
XX KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
XX KW gene expression modification; cancer; phosphorothioate; endonuclease;
XX KW
```

```
antitumor; breast cancer; endometrium cancer; ss.
Homo sapiens.
WO9954459-A2.
28-OCT-1999.
19-APR-1999; 99WO-US008547.
20-APR-1998; 98US-0082404P.
23-JUN-1998; 98US-00103636.
(RIBO-) RIBOZYME PHARM INC.
Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;
Matulic-Adamic J;
WPI; 2000-013248/01.
New nucleic acids that interact, and optionally cleave, target sequences,
used to treat cancer.
Claim 77; Page 81; 148pp; English.
The present invention describes nucleic acids (A) that interact stably
with a target sequence and contain at least one phosphorodithioate
link, having endonuclease activity. (A), and more generally any catalytic
nucleic acid (A') that modulates expression of the oestrogen receptor
gene, are used to treat cancer (particularly of breast or endometrium), or
in vivo or by transforming cells ex vivo and implanting treated cells, or
for other conditions associated with levels of oestrogen receptor.
Because of the high selectivity for targeted RNA (A) can also be used to
correlate inhibition of gene expression with alterations in phenotype,
particularly for identification of therapeutic targets, and as research
reagents (for RNA, in the same way that restriction endonucleases are
used with DNA). The combination of modifications in (A) improves
resistance to nucleases, binding affinity and/or activity. AAA23503 to
AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
sequences, and AAA26107 to AAA26218 represent other corresponding target
sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
antisense oligonucleotides used in the exemplification of the present
invention
XX SQ Sequence 17 BP; 5 A; 4 C; 1 G; 7 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 96;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1323 ATCAACTTTTGGATCCA 1339
|||||:|||||:|||||
Db 1 ATCAACTTTTGGATCCA 17
RESULT 70
ACN03148
ID ACN03148 standard; RNA; 17 BP.
XX AC ACN03148;
XX DT 22-APR-2004 (first entry)
XX DE WNV Inozyme substrate SEQ ID NO 3151.
XX KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX KW encephalitis; myocarditis; meningitis; infection; hepatitis;
XX KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
XX KW Amberzyme; Zinzyme; ss.
```

```

XX OS West Nile Virus.
XX PN WO200268637-A2.
XX PD 06-SEP-2002.
XX PF 19-OCT-2001; 2001WO-US048350.
XX PR 20-OCT-2000; 2000US-0242411P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX PI Blatt L, Mcswiggen JA;
XX PS WPI; 2002-706994/76.
XX DR
XX XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX PS Claim 23; SEQ ID NO 3151; 495pp; English.
XX CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
XX Query Match 0.8%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 82.4%; Pred. No. 96;
XX Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1239 GCCAGGGCCCATCTGGA 1255
DB 1 GCCAGGGCCCAUCAUGA 17
|||||||:|:|

RESULT 71
ACN03149
ID ACN03149 standard; RNA; 17 BP.
XX ACN03149;
XX 22-APR-2004 (first entry)
XX WNV Inozyme substrate SEQ ID NO 3152.
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
XX Amberzyme; Zinzyme; ss.
XX West Nile Virus.
XX WO200268637-A2.
XX 06-SEP-2002.

QY 1240 CCAGGGCCATCATGGAG 1256
DB 1 CCAGGGCCCAUCAUGAG 17
|||||||:|:|

RESULT 72
ACN14350/c
ID ACN14350 standard; RNA; 17 BP.
XX ACN14350;
XX 22-APR-2004 (first entry)
XX WNV minus strand Amberzyme substrate SEQ ID NO 14353.
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
XX Amberzyme; Zinzyme; ss.
XX West Nile Virus.
XX WO200268637-A2.
XX 06-SEP-2002.
XX 19-OCT-2001; 2001WO-US048350.
XX 20-OCT-2000; 2000US-0242411P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.

```

XX PI Blatt L, Mcswiggen JA;
 XX DR WPI; 2002-706994/76.
 XX PT New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX PS Claim 23; SEQ ID NO 14353; 495pp; English.
 XX CC The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Ambzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX SQ
 XX Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 0.8%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 96;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1239 GCCAGGGCCATCATGGA 1255
 DB 17 GCCAGGGCCATCATGGA 1
 RESULT 73
 ABT38999/c
 ID ABT38999 standard; DNA; 17 BP.
 XX AC ABT38999;
 XX DT 12-JUN-2003 (first entry)
 XX DE Tumour suppression related human fukutin oligo SEQ ID No 4636.
 XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX OS Homo sapiens.
 XX FN WO2003025175-A2.
 XX PD 27-MAR-2003.
 XX PF 17-SEP-2002; 2002WO-IB004208.
 XX PR 17-SEP-2001; 2001FR-00011978.
 XX PA (MOLE-) MOLECULAR ENGINES LAB.
 XX PI Telerman A, Anson R, Tuijnder M;
 XX DR WPI; 2003-313353/30.
 XX PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX PS Disclosure; Page 576; 720pp; French.

XX CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX SQ
 XX Sequence 17 BP; 7 A; 5 C; 4 G; 1 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 96;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 832 TGGCTTCTCATGGGATC 848
 DB 17 TGGCTTCTCATGGGATC 1
 RESULT 74
 ACD50767/c
 ID ACD50767 standard; RNA; 17 BP.
 XX AC ACD50767;
 XX DT 23-SEP-2003 (first entry)
 XX DE HBV hammerhead ribozyme substrate sequence #233.
 XX KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
 KW ambzyme; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX OS Hepatitis B virus.
 XX FN WO200281494-A1.
 XX PD 17-OCT-2002.
 XX PF 26-MAR-2002; 2002WO-US009187.
 XX PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLATY) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.

PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX
 XX WPI; 2003-229207/22.
 XX
 XX Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 PS Example 1; Page 140; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HBV
 CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberyzyme sequences
 CC disclosed in the present invention
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 2 G; 0 T; 9 U; 0 Other;
 Query Match 0.8%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 96;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 529 AAGGCATTACAGCAGAA 545
 DB 17 AAGGCATTAAAGCAGAA 1
 |||||
 RESULT 75
 ACC68303/c
 ID ACC68303 standard; DNA; 17 BP.
 XX
 AC ACC68303;
 XX
 XX 01-JUL-2003 (first entry)
 DT
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 5550.
 XX
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; ss.
 XX
 OS Mus musculus.
 XX
 PN WO2003025176-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004210.
 XX
 PR 17-SEP-2001; 2001FR-00011979.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 XX WPI; 2003-333167/31.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 363; 738pp; French.
 XX
 CC The present invention relates to murine oligonucleotides (ACC62754-
 CC ACC6806), which are associated with tumour suppression, tumour
 CC reversion, apoptosis and virus resistance. The oligonucleotides are
 CC useful as (1) as probes and primers for detecting, identifying,
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 96;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1040 CTCACCTTATTAAGATC 1056
 DB 17 CTCGCTTATTAAGATC 1
 |||||
 RESULT 76
 ACC65593
 ID ACC65593 standard; DNA; 17 BP.
 XX
 AC ACC65593;
 XX
 XX 01-JUL-2003 (first entry)
 DT
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2840.
 XX
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; ss.
 XX
 OS Mus musculus.
 XX
 PN WO2003025176-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004210.
 XX
 PR 17-SEP-2001; 2001FR-00011979.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 XX WPI; 2003-333167/31.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 363; 738pp; French.
 XX
 CC The present invention relates to murine oligonucleotides (ACC62754-
 CC ACC6806), which are associated with tumour suppression, tumour
 CC reversion, apoptosis and virus resistance. The oligonucleotides are
 CC useful as (1) as probes and primers for detecting, identifying,

PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-333167/31.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 679; 738pp; French.
 XX
 CC The present invention relates to murine oligonucleotides (ACC62754-
 CC ACC6806), which are associated with tumour suppression, tumour
 CC reversion, apoptosis and virus resistance. The oligonucleotides are
 CC useful as (1) as probes and primers for detecting, identifying,
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 96;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 1040 CTCACCTTATTAAGATC 1056
 DB 17 CTCGCTTATTAAGATC 1
 |||||
 RESULT 76
 ACC65593
 ID ACC65593 standard; DNA; 17 BP.
 XX
 AC ACC65593;
 XX
 XX 01-JUL-2003 (first entry)
 DT
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2840.
 XX
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; ss.
 XX
 OS Mus musculus.
 XX
 PN WO2003025176-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004210.
 XX
 PR 17-SEP-2001; 2001FR-00011979.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 XX WPI; 2003-333167/31.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 363; 738pp; French.
 XX
 CC The present invention relates to murine oligonucleotides (ACC62754-
 CC ACC6806), which are associated with tumour suppression, tumour
 CC reversion, apoptosis and virus resistance. The oligonucleotides are
 CC useful as (1) as probes and primers for detecting, identifying,

CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizoprenia

XX Sequence 17 BP; 8 A; 3 C; 3 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 96;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1428 GATCCAAAGCAGATGAA 1444
 |||||
 Db 1 GATCCAAATCAGATGAA 17

RESULT 77
 ADM58132/c
 ID ADM58132 standard; RNA; 17 BP.

XX AC ADM58132;

XX DT 03-JUN-2004 (first entry)

XX DE Hepatitis B virus (HBV) RNA target sequence #266.

XX KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
 KW hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
 KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
 KW virucide; hepatotropic; antiinflammatory; cytostatic.

XX OS Hepatitis B virus.

XX PN US2004054156-A1.

XX PD 18-MAR-2004.

XX PF 15-JAN-2003; 2003US-00342902.

XX PR 14-MAY-1992; 92US-00882712.

XX PR 07-FEB-1994; 94US-00193627.

XX PR 08-NOV-1999; 99US-00436430.

XX PR 20-MAR-2000; 2000US-00531025.

XX PR 09-AUG-2000; 2000US-00636385.

XX PR 24-OCT-2000; 2000US-00696347.

XX PR 08-JUN-2001; 2001US-00877478.

XX (DRAP/) DRAPER K.

XX PA (BLAT/) BLATT L.

XX PA (MCSW/) MCSWIGGEN J A.

XX PA (MORR/) MORRISSEY D.

XX PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;

XX WPI; 2004-247781/23.

XX PT Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
 PT specifically cleaving RNA derived from Hepatitis B virus and comprising
 PT one or more binding arms, useful for treating hepatitis and cirrhosis.

XX PS Disclosure; SEQ ID NO 266; 122pp; English.

XX CC The invention relates to an enzymatic nucleic acid molecule that
 CC specifically cleaves RNA derived from Hepatitis B virus (HBV) and
 CC comprising one or more binding arms, without requiring the presence of a
 CC 2'-OH group within the molecule for activity. The nucleic acids are
 CC useful for treating hepatitis B virus infection, hepatitis,
 CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
 CC combination with other therapies such as lamivudine and interferons. The
 CC nucleic acids are useful as diagnostic tools to examine genetic drift and
 CC mutations within diseased cells, for detecting the presence of HBV RNA in

CC a cell, for the study of RNA and for down-regulating gene expression of
 CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
 CC sequence represents an HBV RNA target sequence, used in the scope of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 17 BP; 2 A; 4 C; 2 G; 0 T; 9 U; 0 Other;

XX Query Match 0.8%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 96;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 529 AAGCATTACAGCAGAA 545
 |||||
 Db 17 AAGCATTAAAGCAGAA 1

RESULT 78
 ADR05333/c

XX ID ADR05333 standard; DNA; 17 BP.

XX AC ADR05333;

XX DT 21-OCT-2004 (first entry)

XX DE Silkorm juvenile hormone acid transmethylase cDNA PCR primer FP1.

XX KW ss; primer; insect repellent; insect attractant;
 KW reproductive maturation regulator; imago; diapause inducer;
 KW diapause inhibitor; larva; transformation regulator; pupa;
 KW juvenile hormone acid transmethylase; silkorm; Bombyx mori;
 KW Drosophila melanogaster; mosquito; Anopheles gambia; Spodoptera litura;
 KW Helicoverpa armigera; molting; transformation; diapause; blastogenesis;
 KW polymorphism; arthropod; cotton bollworm; PCR primer.

XX OS Bombyx mori.

XX PN WO2004065604-A1.

XX PD 05-AUG-2004.

XX PF 20-JAN-2003; 2003WO-JP000415.

XX PR 20-JAN-2003; 2003WO-JP000415.

XX PA (NAAG-) NAT AGRIC RES ORG JAPAN.

XX PI Shinoda T, Itoyama K, Hamamura T;

XX WPI; 2004-580727/56.

XX PT New DNA encoding protein having juvenile-hormone acid transmethylase
 PT activity, useful for screening for a compound controlling the expression
 PT level of juvenile-hormone acid transmethylase DNA.

XX PS Example 1; SEQ ID NO 11; 118pp; Japanese.

XX CC The invention relates to a DNA (I) encoding a protein (II) having
 CC juvenile-hormone acid transmethylase activity selected from the DNA from
 CC silkorm (Bombyx mori), Drosophila melanogaster, mosquito (Anopheles
 CC gambiae), Spodoptera litura and Helicoverpa armigera, their encoded
 CC proteins (S2), DNAs (D2) that hybridize under stringent conditions with
 CC the nucleic acids or an amino acid sequence (S3) comprising any one of
 CC (S2) in which one or more amino acids are substituted, deleted, inserted
 CC and/or added. (I) is useful for screening a compound that controls the
 CC expression level of (I), and as a controlling agent of molting and
 CC transformation, reproductive, diapause, blastogenesis, action,
 CC polymorphism or lifetime of arthropod. (II) is useful for screening a
 CC compound having binding affinity with respect to (II), which involves
 CC contacting test compound with (II), detecting the binding of (II) with
 CC test compound, and selecting the compound that binds with (II). (II) is
 CC useful for screening a compound that controls the activity of (II), which
 CC involves contacting test compound with (II), measuring the activity of

CC large group of hemicellulase enzymes and function by cutting the beta-1,4
 CC bonds within the xylosic chain of xylan (a polymer of D-xylose residues
 CC that is a major constituent of hemicellulose). This means that they may
 CC be used in the paper and pulp industry to improve the efficiency of the
 CC bleaching process by degrading the structure of the material. XYL I and
 CC XYL II may also be used to treat feed, by degrading a substrate with a
 CC high beta-glucan or cellulose content. XYL I and XYL II retain their
 CC activity at high temperatures (e.g. 70 deg. C) and at low pHs (e.g. 4.0).
 CC conditions which tend to denature most known xylanases. Enzymes that
 CC remain active in these conditions may be used in industrial processes
 CC that are carried out at high temperature and low pH to speed up other,
 CC non-enzymatic reactions, minimising costs, energy requirements, and the
 CC risk of pollution, (e.g. enzymes XYL I and XYL II can be used to
 CC facilitate chlorine bleaching of paper pulp which is carried out in hot,
 CC acidic conditions). Pretreatment with XYL I and XYL II, allows the
 CC bleaching agents to penetrate better, to remove lignin from the pulp and
 CC 'bleach' the colouration from it. This means smaller quantities of the
 CC agents can be used to produce the same or a better result. Also,
 CC disrupting the structure aids water drainage. NOTE: This patent is an
 CC equivalent to FI9503640. (Updated on 25-MAR-2003 to correct DR field.)
 CC
 SQ Sequence 18 BP; 7 A; 2 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 82.4%; Pred. No. 1e+02;
 Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 443 GGGAGAGAAATCAGCTG 459
 Db 2 GGGAGAGAAUACAGAUG 18
 |||||

RESULT 81
 AA16008/C
 ID AA16008 standard; DNA; 18 BP.
 AC AA16008;
 XX
 XX
 DT 21-MAY-1998 (first entry)
 DE PCR primer D-R used to identify Sox-3 gene mutations in mice.

XX Mutation; Sox-3; ENU mutagenesis; mutational screening; recessive;
 KW single strand conformation polymorphism; SSCP; phenotypic alteration;
 KW PCR primer; amplify; ss.
 XX

OS Synthetic.
 OS Mus sp.
 XX

PN WO9744485-A1.
 XX
 PD 27-NOV-1997.
 XX

PF 16-MAY-1997; 97WO-GB001354.
 XX

PR 17-MAY-1996; 96GB-00010355.
 XX

PA (HEXA-) HEXAGEN TECHNOLOGY LTD.
 XX
 PI Goodfellow PN;
 XX

WPI; 1998-018536/02.
 XX

PT Identification of mutation(s) in genes of interest - without prior
 PT observation of phenotypic alteration in the mutated organism or cell.
 XX

PS Example 4; Page 41; 66pp; English.
 XX

XX PCR primers AA16001-18 were used to identify mutations in Sox-3 using
 CC the method of the invention. The primers are located throughout the gene
 CC and are unique to Sox-3. The method comprises testing a nucleic acid
 CC sample from a mutated organism for a mutation in a gene of interest
 CC without the prior observation of a phenotypic alteration in the mutated

CC organism resulting from the mutation. Sox-3 is a member of the Sox gene
 CC family, a family of about 20 genes which all encode a "HMG" box, which is
 CC a DNA-binding domain. Mice were mutagenised using ENU mutagenesis. The
 CC mutagenised mice were tested by PCR with each primer set and fluorescent
 CC single strand conformation polymorphism (SSCP), which identifies mice
 CC carrying mutations in Sox-3. The method provides mutational screening
 CC based on genomic and genetic techniques rather than on phenotypic
 CC observation. The method identifies and characterises genes via
 CC mutagenesis to identify genes encoding products which may have
 CC therapeutic benefit. The method also identifies the presence of mutations
 CC in a gene which do not rely solely upon prior matching of a gene with a
 CC disease. Heterozygotic organisms can also be screened to identify those
 CC carrying a mutation in a copy of a gene of interest even though the gene
 CC may be recessive and therefore causes no phenotypic alteration
 XX
 SQ Sequence 18 BP; 1 A; 6 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 CGCCTCCGTCGCGCGCG 46
 Db 18 CGCGCGCGTCGCGCGCG 2
 |||||

RESULT 82
 AA43267/C
 ID AA43267 standard; DNA; 18 BP.
 XX
 AC AA43267;
 XX

DT 11-FEB-2000 (first entry)
 DE Murine Sox3 gene PCR primer 8.
 XX

XX Screening; mutation; treatment; disease; drug discovery; PCR primer; ss.
 XX Mus musculus.

PN US5994075-A.
 XX

PD 30-NOV-1999.
 XX

PF 16-MAY-1997; 97US-00857946.
 XX

PR 17-MAY-1996; 96US-0017824P.
 XX

PA (HEXA-) HEXAGEN TECHNOLOGY LTD.
 XX

PI Goodfellow PN;
 XX

WPI; 2000-038255/03.
 XX

PT Identifying a mutation in a gene of interest in an organism useful for
 PT identifying genes encoding products which may have therapeutic benefits.
 XX

PS Example 5; Col 63-64; 70pp; English.
 XX

XX This invention describes a novel mutational screening method based on
 CC genomic and genetic techniques to identify and characterize a mutation in
 CC a gene of interest without first selecting a phenotypic characteristic.

CC The screening methods are useful for identifying genes encoding products
 CC which may have therapeutic benefit for treating human or animal diseases.

CC The method can be used for the DNA mutation screening of a class or a
 CC family of genes providing a rapid assay for identifying mutant genes. The
 CC methods produce organisms which can be used for drug discovery e.g.

CC providing a model for the study and treatment of a disease state, allow
 CC in vitro assessment of drug activity and interbreeding of mutants which
 CC allow investigation of gene interactions in the overall phenotype. A
 CC range of phenotypes associated with different mutations, and specified
 CC mutations in a gene of interest can be determined. The method can be
 CC adapted to screen for a mutation in two or more genes of interest in an

CC organism. The methods allow mutations in a gene of interest to be
 CC identified without having to rely on matching a gene with a disease.
 CC AAZ43260-Z43421 represent PCR primers used in the method of the invention

XX SQ Sequence 18 BP; 1 A; 6 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 30 CGCCTCGTCGCGCGCG 46
 ||||| ||||| ||||| |||||
 Db 18 CGCGCGCGTCGCGCGCG 2

RESULT 83
 AAA05252/c
 ID AAA05252 standard; DNA; 18 BP.
 XX AC AAA05252;
 XX DT 19-MAY-2000 (first entry)
 XX DE PCR primer D-R used in Sox-3 amplicon generation.
 XX KW PCR primer; Sox-2; Sox-3; T gene; Tyrosinase; MGF; Sry; c-kit; Tryp-1;
 KW Pax-6; mutation detection; therapeutic target identification; mouse;
 KW mast cell growth factor; ss.
 XX OS Mus sp.
 XX PN US6015670-A.
 XX PD 18-JAN-2000.
 XX PF 14-NOV-1997; 97US-00970740.
 XX PR 17-MAY-1996; 96US-0017824P.
 PR 16-MAY-1997; 97US-00857946.
 XX (HEXA-) HEXAGEN TECHNOLOGY LTD.
 XX Goodfellow PN;
 XX WPI; 2000-181139/16.
 XX Detecting mutations in selected genes, useful e.g. for identifying
 PT therapeutic targets or products, by analyzing DNA in mutated embryonic
 PT stem cells without phenotypic characterization.
 XX Example 5; Col 31; 66pp; English.

XX PCR primers AAA05245-A05406 are used to generate amplicons from the mouse
 CC Sox-3 gene, Sox-2 gene, T gene, tyrosinase gene, Tryp-1 gene, Sry gene,
 CC MGF (mast cell growth factor) gene, c-kit gene, and the Pax-6 gene. The
 CC primers are used in a method for the identification of a mutation in a
 CC selected gene in a tissue without the prior observation of a phenotypic
 CC alteration in the mutated organism or cell. The method is used to
 CC identify mutations in a selected gene that encode products of potential
 CC therapeutic activity or that are potential targets, particularly where
 CC the gene of interest has been identified as a candidate gene by
 CC positional cloning. Other applications are determining functions of genes
 CC ; detecting the range of phenotypes associated with different mutations
 CC in a particular gene and identification of particular mutations. Animals
 CC containing an identified mutation are used as models for studying
 CC diseases or their treatment, and cells from them for in vitro assessment
 CC of drug action. Interbreeding of mutant mice is used to investigate
 CC genetic interaction in the overall phenotype

XX SQ Sequence 18 BP; 1 A; 6 C; 11 G; 0 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 1e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 30 CGCCTCGTCGCGCGCG 46
 ||||| ||||| ||||| |||||
 Db 18 CGCGCGCGTCGCGCGCG 2

RESULT 84
 AAA05675
 ID AAD05675 standard; DNA; 18 BP.

XX AC AAD05675;
 XX DT 31-JUL-2001 (first entry)
 XX DE Human zmsel mapping antisense PCR primer.

XX KW Human; zmsel protein; Cdc42/Rac interactive binding protein; CRIB;
 KW Wiskott-Aldrich Syndrome; cancer; tumour; invasion; metastasis; asthma;
 KW digestion; actin polymerisation; cytoskeletal reorganisation; arthritis;
 KW testicular function; muscle inflammation; inflammatory bowel disease;
 KW diverticulitis; male infertility; male contraceptive agent; myocarditis;
 KW spermatogenesis; sperm capacitation; reperfusion ischaemia; psoriasis;
 KW melanoma; atherosclerosis; pelvic inflammatory disease; PID; eczema;
 KW scleroderma; cytostatic; vasotropic; dermatological; gene therapy;
 KW PCR primer; ss.

XX OS Homo sapiens.
 XX PN WO200134803-A2.
 XX PD 17-MAY-2001.
 XX PF 09-NOV-2000; 2000WO-US030945.
 XX PR 10-NOV-1999; 99US-00438564.
 XX (ZYMO) ZYMOGENETICS INC.
 XX PI Holloway JL, Gao Z, Whitmore TE;
 XX WPI; 2001-335928/35.

XX Novel human CRIB protein, zmsel and polynucleotide encoding the protein,
 PT for detecting human chromosomal abnormalities and for treating cancer,
 PT cardiovascular and inflammatory conditions.

XX Example 3; Page 126; 132pp; English.

XX The present invention relates to DNA and protein for zmsel, a novel human
 CC Cdc42/Rac interactive binding (CRIB) protein. CRIB proteins are
 CC implicated in human disease such as Wiskott-Aldrich Syndrome. Zmsel
 CC metastasis, gene transcription, contractility of various tissues, actin
 CC polymerisation and cytoskeletal reorganisation, digestion, testicular
 CC function and fertility. Zmsel sequence and its modulators are useful for
 CC treating cancer, inflammatory heart or cardiovascular conditions, muscle
 CC inflammation, inflammation during and after surgery, arthritis, asthma,
 CC inflammatory bowel diseases or diverticulitis, myocarditis, scleroderma,
 CC atherosclerosis, pelvic inflammatory disease (PID), eczema and other
 CC inflammatory diseases, male infertility or as male contraceptive agents
 CC and for modulating spermatogenesis and sperm capacitation. zmsel and anti
 CC -zmsel antibodies are useful in diagnosing inflammatory diseases, such as
 CC reperfusion ischaemia, psoriasis, arthritis, melanoma and other
 CC inflammatory diseases, male reproductive cancers such as prostate and
 CC testicular cancers. Zmsel polynucleotide sequences are useful as probes
 CC or primers for detecting human chromosomal abnormalities. zmsel sequence
 CC is used in gene therapy. The present sequence is an antisense PCR primer
 CC used for mapping human zmsel sequence

XX SQ Sequence 18 BP; 1 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.4; DB 1; Length 18;

```
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 714 TCCGTGGCTCCTTCTC 730
DB 1 TCCGGGGCTCTTCTC 17

RESULT 85
ADB49435
ID ADB49435 standard; DNA; 18 BP.
XX
AC ADB49435;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human Zmsel PCR primer ZC18860.
XX
KW primer; human; ss; PCR; Zmsel; wound healing; anti-bacterial; anti-viral;
KW inflammation; asthma; arthritis; diverticulitis; cancer;
KW vasoconstriction; heart inflammation; immunogenic.
XX
OS Homo sapiens.
XX
PN US6573069-B1.
XX
PD 03-JUN-2003.
XX
PF 09-NOV-2000; 2000US-00710794.
XX
PR 10-NOV-1999; 99US-0164685P.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Holloway JL, Gao Z, Whitmore TE;
XX
DR WPI; 2003-764570/72.
XX
XX
XX New isolated polynucleotide encoding Zmsel polypeptide having a Cdc42/Rac
XX interactive binding (CRIB) motif, useful for diagnosing and treating
XX cancer and inflammatory conditions.
XX
XX Example 3; Col 77-78; 55pp; English.
XX
XX The invention relates to an isolated polynucleotide encoding a Zmsel
XX polypeptide. Cells expressing the nucleic acid are useful for producing
XX polypeptides. The nucleic acid is useful as probes or primers to clone 5'
XX non-coding regions of Zmsel gene. The nucleic acid is also useful for
XX detecting allelic differences between diseased or non-diseased
XX individuals at the Zmsel chromosomal locus. The Zmsel polypeptides are
XX useful as research reagents and as an amino acid source for cell culture.
XX The Zmsel present in heart and skeletal muscle are useful in promoting
XX wound healing effects and exhibits anti-bacterial or anti-viral effects.
XX The Zmsel polypeptides are useful for treating inflammatory conditions
XX such as asthma, arthritis, diverticulitis. The Zmsel polypeptide is
XX useful for treating cancer, vasoconstriction, heart inflammation. The
XX Zmsel polypeptide is useful as an immunogen to elicit an immune response
XX in an animal. The Zmsel polypeptide is useful for diagnosing cancer. The
XX present sequence represents a human Zmsel PCR primer.
XX
SQ Sequence 18 BP; 1 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 714 TCCGTGGCTCCTTCTC 730
DB 1 TCCGGGGCTCTTCTC 17

RESULT 86
ADB49435
ID ADB49435 standard; DNA; 18 BP.
XX
AC ADB49435;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human Zmsel PCR primer ZC18860.
XX
KW primer; human; ss; PCR; Zmsel; wound healing; anti-bacterial; anti-viral;
KW inflammation; asthma; arthritis; diverticulitis; cancer;
KW vasoconstriction; heart inflammation; immunogenic.
XX
OS Homo sapiens.
XX
PN US6573069-B1.
XX
PD 03-JUN-2003.
XX
PF 09-NOV-2000; 2000US-00710794.
XX
PR 10-NOV-1999; 99US-0164685P.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
PI Holloway JL, Gao Z, Whitmore TE;
XX
DR WPI; 2003-764570/72.
XX
XX
XX New isolated polynucleotide encoding Zmsel polypeptide having a Cdc42/Rac
XX interactive binding (CRIB) motif, useful for diagnosing and treating
XX cancer and inflammatory conditions.
XX
XX Example 3; Col 77-78; 55pp; English.
XX
XX The invention relates to an isolated polynucleotide encoding a Zmsel
XX polypeptide. Cells expressing the nucleic acid are useful for producing
XX polypeptides. The nucleic acid is useful as probes or primers to clone 5'
XX non-coding regions of Zmsel gene. The nucleic acid is also useful for
XX detecting allelic differences between diseased or non-diseased
XX individuals at the Zmsel chromosomal locus. The Zmsel polypeptides are
XX useful as research reagents and as an amino acid source for cell culture.
XX The Zmsel present in heart and skeletal muscle are useful in promoting
XX wound healing effects and exhibits anti-bacterial or anti-viral effects.
XX The Zmsel polypeptides are useful for treating inflammatory conditions
XX such as asthma, arthritis, diverticulitis. The Zmsel polypeptide is
XX useful for treating cancer, vasoconstriction, heart inflammation. The
XX Zmsel polypeptide is useful as an immunogen to elicit an immune response
XX in an animal. The Zmsel polypeptide is useful for diagnosing cancer. The
XX present sequence represents a human Zmsel PCR primer.
XX
SQ Sequence 18 BP; 1 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 714 TCCGTGGCTCCTTCTC 730
DB 1 TCCGGGGCTCTTCTC 17

RESULT 87
ADS16437
ID ADS16437 standard; DNA; 18 BP.
XX
AC ADS16437;
XX
DT 02-DEC-2004 (first entry)
```

```
ID ADL91734 standard; DNA; 18 BP.
XX
AC ADL91734;
XX
DT 03-JUN-2004 (first entry)
XX
DE Endothelin 3 (SYX 3) antisense S-oligonucleotide, SEQ ID NO:135.
XX
KW Synovial sarcoma; SYX; sarcoma-associated gene; drug screening;
KW Frizzled homologue 10; FZD10-associated disease; colorectal cancer;
KW gastric cancer; chronic myeloid leukaemia; acute myeloid leukaemia;
KW FZD10 antibody; diagnosis; prognosis; prevention; cytostatic;
KW gene therapy; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004020668-A2.
XX
PD 11-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-JP010591.
XX
PR 30-AUG-2002; 2002US-0407506P.
XX
PR 11-JUL-2003; 2003US-0486195P.
XX
PA (ONCO-) ONCOTHERAPY SCI INC.
XX
PA (UVTY) UNIV TOKYO.
XX
PI Nakamura Y, Katagiri T;
XX
DR WPI; 2004-239208/22.
XX
XX
XX Use of a compound or composition for diagnosing, treating or preventing
XX synovial sarcoma or a disease associated with Frizzled homologue 10, e.g.
XX colorectal cancer, gastric cancer, chronic myeloid leukemia or acute
XX myeloid leukemia.
XX
XX Example 4; SEQ ID NO 135; 143pp; English.
XX
XX The invention relates to the use of a compound or composition for
XX diagnosing, prognosing, treating or preventing synovial sarcoma or a
XX Frizzled homologue 10 (FZD10)-associated disease in a patient. The
XX invention encompasses the use of sarcoma-associated genes designated SYX
XX 1-26 or their encoded proteins in diagnosing of synovial sarcoma and in
XX screening for compounds for treating or preventing this condition; and
XX the use of antibodies specific for FZD10 (FZD10 is also referred to as
XX SYX 1 in the specification) for diagnosing, treating or preventing FZD10-
XX associated diseases. The compound, composition and methods of the
XX invention are useful for diagnosing, treating or preventing synovial
XX sarcoma or FZD10-associated diseases, such as colorectal cancer, gastric
XX cancer, chronic myeloid leukaemia or acute myeloid leukaemia. Sequences
XX ADL91688-ADL91751 represent antisense and control S-oligonucleotides used
XX in a study of antisense-mediated inhibition of the expression of synovial
XX sarcoma-associated genes.
XX
SQ Sequence 18 BP; 5 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 336 GGCTCCCAAGAACCTAGA 352
DB 1 GGCTCCATGAACTAGA 17

RESULT 87
ADS16437
ID ADS16437 standard; DNA; 18 BP.
XX
AC ADS16437;
XX
DT 02-DEC-2004 (first entry)
```

XX DE Allele A oligo #2, used in polynucleotide sequence detection.

XX KW Single nucleotide polymorphism; SNP; genotyping; ss.

XX OS Synthetic.

XX PN US2004175704-A1.

XX PD 09-SEP-2004.

XX XX 12-MAY-2003; 2003US-00436231.

XX PF 06-MAR-2003; 2003US-0452481P.

XX PR (STRA-) STRATAGENE.

XX PA Sorge JA, Firmin A;

XX PI WPI; 2004-642120/62.

XX DR Determining polynucleotide sequence differences by amplifying polynucleotide in presence of labeled nucleotide and detecting variation based on incorporation frequency of labeled nucleotide compared to known reference frequency.

XX PS Disclosure; SEQ ID NO 2; 52pp; English.

XX CC The invention relates to compositions, kits and methods for detecting polynucleotide sequence differences. The method involves amplifying the polynucleotide of interest in the presence of a labelled nucleotide and detecting variation based on incorporation frequency of labelled nucleotide compared to known reference frequency. The method is useful for determining a sequence difference such as a single nucleotide polymorphism (SNP) or a tandem repeat, between a region of interest in a polynucleotide and a reference sequence. It is useful for determining the presence of a mutation in a region of interest in a polynucleotide and is also useful for genotyping. The present sequence is an allelic oligonucleotide used in polynucleotide sequence detection.

XX SQ Sequence 18 BP; 0 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

XX Query Match 0.8%; Score 15.4; DB 1; Length 18;

XX Best Local Similarity 94.1%; Pred. No. 1e+02;

XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1445 TGTTCGTCTGCTGTTT 1461

DB 2 TGTTCGTCTGCTGTTT 18

RESULT 88

ADSL6436/c

ID ADS16436 standard; DNA; 18 BP.

XX AC ADS16436;

XX XX 02-DEC-2004 (first entry)

XX DE Allele A oligo #1, used in polynucleotide sequence detection.

XX KW Single nucleotide polymorphism ; SNP; genotyping; ss.

XX OS Unidentified.

XX PN US2004175704-A1.

XX XX 09-SEP-2004.

XX PF 12-MAY-2003; 2003US-00436231.

XX PR 06-MAR-2003; 2003US-0452481P.

XX DR

PA (STRA-) STRATAGENE.

XX Sorge JA, Firmin A;

XX WPI; 2004-642120/62.

XX DR Determining polynucleotide sequence differences by amplifying polynucleotide in presence of labeled nucleotide and detecting variation based on incorporation frequency of labeled nucleotide compared to known reference frequency.

XX PS Disclosure; SEQ ID NO 1; 52pp; English.

XX CC The invention relates to compositions, kits and methods for detecting polynucleotide sequence differences. The method involves amplifying the polynucleotide of interest in the presence of a labelled nucleotide and detecting variation based on incorporation frequency of labelled nucleotide compared to known reference frequency. The method is useful for determining a sequence difference such as a single nucleotide polymorphism (SNP) or a tandem repeat, between a region of interest in a polynucleotide and a reference sequence. It is useful for determining the presence of a mutation in a region of interest in a polynucleotide and is also useful for genotyping. The present sequence is an allelic oligonucleotide used in polynucleotide sequence detection.

XX SQ Sequence 18 BP; 8 A; 5 C; 5 G; 0 T; 0 U; 0 Other;

XX Query Match 0.8%; Score 15.4; DB 1; Length 18;

XX Best Local Similarity 94.1%; Pred. No. 1e+02;

XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1445 TGTTCGTCTGCTGTTT 1461

DB 17 TGTTCGTCTGCTGTTT 1

RESULT 89

ABK10366

ID ABK10366 standard; DNA; 19 BP.

XX AC ABK10366;

XX XX 21-MAY-2002 (first entry)

XX DT Rat Atrial naturetic factor RT-PCR primer #1.

XX DE

XX KW Vascular inflammation; cardiac tissue damage; inflammatory response; inflammation-related disorder; trauma induced inflammation; surgically induced inflammation; bacterial induced inflammation; viral induced inflammation; cardiovascular disorder; arteriosclerosis; coronary artery disease; aneurysm; arteriosclerosis; angina; myocardial infarction; embolism; stroke; thrombosis; Kawasaki disease; vascular plaque inflammation; vascular plaque rupture; calcification; vascular calcification; valvar calcification; PCR; primer; ss; aldosterone blocker.

XX OS Rattus sp.

XX XX WO200209683-A2.

XX PN 07-FEB-2002.

XX PD

XX PF 26-JUL-2001; 2001WO-US023520.

XX XX 27-JUL-2000; 2000US-0221358P.

XX PR 12-JAN-2001; 2001US-0261352P.

XX XX (PHAA) PHARMACIA CORP.

XX PA Rocha R, Zack MD, McMahon EG;

XX PI WPI; 2002-195909/25.

XX DR

PT Treating or preventing an inflammation-related disorder e.g. coronary
PT artery disease, aneurysm, arteriosclerosis and myocardial infarction,
PT comprises treatment with an aldosterone blocker.
PS
XX Example 18; Page 111; 210pp; English.
XX
CC The invention relates to treating or preventing an inflammation-related
CC disorder comprises treatment with an aldosterone blocker or its salts.
CC Rats were treated with aldosterone in the presence of salt to induce
CC vascular inflammation and cardiac tissue damage. The damage induced by
CC the treatment was preceded by an inflammatory response characterised by
CC upregulation of proinflammatory molecules. Administration of eplerenone
CC markedly attenuated this initial vascular inflammatory response and
CC subsequent myocardial infarction. The aldosterone blocker is used for
CC treating or preventing inflammation-related disorders (occurring in
CC tissue or organs), such as trauma induced inflammation, surgically
CC induced inflammation, bacterial induced inflammation or viral induced
CC inflammation, e.g. cardiovascular disorders (e.g. coronary artery
CC disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial
CC infarction, embolism, stroke, thrombosis, angina, vascular plaque
CC inflammation, vascular plaque rupture, Kawasaki disease, calcification
CC (e.g. vascular calcification and valvar calcification) and inflammation
CC or cardiovascular disorder which occurs in whole or in part in the
CC kidney, brain or heart. The present sequence is an RT-PCR (reverse
CC transcriptase PCR) primer for a rat gene encoding a molecule involved in
CC regulation of inflammation whose expression may be altered by
CC administration of an aldosterone blocker
XX
SQ Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY . 718 TGGCTCTCTTCTCCATC 734
DB ||| ||||| ||||| |||||
1 TGGGCTCTTCTCCATC 17
RESULT 90
ABA95109
ID ABA95109 standard; DNA; 19 BP.
XX
AC ABA95109;
XX
DT 20-MAY-2002 (first entry)
XX
DE ANP gene specific forward primer.
XX
KW Aldosterone; cyclooxygenase-2; cardiovascular; eplerenone; cardiant;
KW vasotrophic; antiarteriosclerotic; cerebroprotective; thrombolytic; rat;
KW antianginal; antiinflammatory; vulnerable; antibacterial; virucide; ss;
KW nephrotropic; atrial natriuretic factor; ANP; PCR primer.
XX
OS Rattus sp.
XX
FN WO200209759-A2.
XX
PD 07-FEB-2002.
XX
XX 26-JUL-2001; 2001WO-US023601.
XX
XX 27-JUL-2000; 2000US-0221364P.
XX
XX 12-JAN-2001; 2001US-0261497P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Rocha R, Zack MD, McMahon EG;
XX
XX WPI; 2002-227077/28.
XX
XX Method for treating or preventing inflammation-related cardiovascular
XX disorders comprises administration of an aldosterone antagonist and

PT cyclooxygenase-2 inhibitor combination.
PS
XX Example 18; Page 160; 273pp; English.
XX
CC The invention provides a method for treating or preventing an
CC inflammation-related cardiovascular disorder. The method involves
CC administration of an aldosterone antagonist and cyclooxygenase-2
CC inhibitor combination or their salts. The method is used to treat or
CC prevent inflammation-related cardiovascular disorders in the heart
CC kidney and/or brain, e.g. coronary artery disease, aneurysm, embolism,
CC arteriosclerosis, atherosclerosis, myocardial infarction, thrombosis,
CC stroke, angina, vascular plaque inflammation, vascular plaque rupture,
CC Kawasaki disease, vascular or valvar calcification, trauma-, surgically-,
CC bacterial- or viral-induced inflammation. The use of eplerenone in
CC conjunction with the aldosterone receptor antagonist markedly attenuates
CC the initial vascular inflammatory response and subsequent myocardial
CC injury. Sequences ABA95108-138 represent ratMan primers and probes
CC designed from known sequences of rat genes such as transforming growth
CC factor beta 1 (TGFbeta1), atrial natriuretic factor (ANP), collagen I and
CC III, cyclooxygenase-2 (COX-2), osteopontin, monocyte chemoattractant
CC protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), vascular
CC adhesion molecule-1 (VCAM-1) and a reference cyclophilin, used in the
CC course of the invention
XX
SQ Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 718 TGGCTCTCTTCTCCATC 734
DB ||| ||||| ||||| |||||
1 TGGGCTCTTCTCCATC 17
RESULT 91
ADC18700
ID ADC18700 standard; DNA; 19 BP.
XX
AC ADC18700;
XX
DT 18-DEC-2003 (first entry)
XX
DE Rat RT-PCR primer 2 used for amplification of ANP gene.
XX
KW aldosterone receptor antagonist; non-steroidal anti-inflammatory drug;
KW NSAID; cardiovascular disorder; inflammation; prostaglandin production;
KW anti-inflammatory drug; ulcer;
KW human arachidonic acid/prostaglandin pathway; cyclooxygenase; COX; COX-2;
KW prostaglandin G/H synthase II; combination therapy; cardiovascular-gen;
KW hypotensive; cardiant; antiarteriosclerotic; thrombolytic;
KW cerebroprotective; antianginal; vasotropic; antiinflammatory;
KW immunomodulator; dermatological; hypertension; heart failure;
KW coronary artery disease; aneurysm; arteriosclerosis; atherosclerosis;
KW myocardial infarction; embolism; stroke; thrombosis; angina;
KW vascular plaque inflammation; vascular plaque rupture; Kawasaki disease;
KW calcification; inflammation-related disorder; ss; rat;
KW atrial natriuretic factor; ANP; RT-PCR; reverse transcription PCR; PCR;
KW primer.
XX
OS Rattus sp.
XX
XX WO2003063908-A1.
XX
XX 07-AUG-2003.
XX
XX 30-JAN-2003; 2003WO-US002923.
XX
XX 30-JAN-2002; 2002US-0353008P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX McMahon EG, Rocha R;
XX

XX OS Synthetic.
 XX WO2003072590-A1.
 XX PD 04-SEP-2003.
 XX PF 28-JAN-2003; 2003WO-US002510.
 XX PR 20-FEB-2002; 2002US-0358580P.
 XX PR 11-MAR-2002; 2002US-0363124P.
 XX PR 06-JUN-2002; 2002US-0385782P.
 XX PR 29-AUG-2002; 2002US-0406784P.
 XX PR 05-SEP-2002; 2002US-0408378P.
 XX PR 09-SEP-2002; 2002US-0409293P.
 XX PR 15-JAN-2003; 2003US-0440129P.
 XX PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX PI Mcawiggen J, Beigelman L, Usman N, Haerberli P, Chowrira B;
 XX WPI; 2003-689980/65.
 XX DR New short interfering nucleic acid, useful e.g. for treatment and
 XX PT diagnosis of cancer, downregulates expression of mitogen-activated
 XX PT protein kinase genes.
 XX Example 3; SEQ ID NO 998; 164pp; English.
 XX PS The present invention describes a short interfering nucleic acid (siRNA)
 XX CC that downregulates expression of a mitogen-activated protein kinase
 XX CC (MAPK) genes by RNA interference. Also described: (1) a method for
 XX CC modulating expression of MAPK genes in cells, tissue explants or
 XX CC organisms by introduction of siRNA; (2) kits for in vitro or in vivo
 XX CC delivery of siRNA; (3) conjugates and/or complexes of siRNA; and (4)
 XX CC vectors that express siRNA and cells containing these vectors. MAPK siRNAs
 XX CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
 XX CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
 XX CC antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
 XX CC siRNAs can be used to modulate the expression of MAPK genes, in cells,
 XX CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
 XX CC and II; a wide range of tumors, and inflammatory diseases (asthma,
 XX CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
 XX CC disease). They can also be used for drug screening; diagnosis; target
 XX CC identification and validation; genetic engineering; pharmacogenomics;
 XX CC studying gene function and gene mapping (e.g. of single-nucleotide
 XX CC polymorphisms). The present sequence represents a MAPK siRNA which is used
 XX CC in the exemplification of the present invention.
 XX SQ Sequence 19 BP; 9 A; 1 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 0.8%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 1103 AGAAGACACAGGTGGAG 1119
 ||||| ||||| |||||
 Db 3 AGAAGACACAGGTGGAG 19
 RESULT 94
 ADH01808/c
 ID ADH01808 standard; RNA; 19 BP.
 XX AC ADH01808;
 XX DT 11-MAR-2004 (first entry)
 XX DE Protein tyrosine phosphatase siRNA sequence, SEQ ID No 420.
 XX small interfering RNA; siRNA; protein tyrosine phosphatase; PTP; PTP1B;
 KW insulin receptor protein phosphorylation; Jak2; antidiabetic; anorectic;
 KW antiinflammatory; neuroprotective; cytostatic; immunosuppressive;

KW antimicrobial; gene therapy; ss; siRNA.
 XX Unidentified.
 XX WO2003099227-A2.
 XX PD 04-DEC-2003.
 XX PF 23-MAY-2003; 2003WO-US016651.
 XX PR 23-MAY-2002; 2002US-0383249P.
 XX PR 14-APR-2003; 2003US-0462942P.
 XX PA (CEPT-) CEPTYR INC.
 XX PI Lewis SP, Klinghoffer R, Wilson LK;
 XX WPI; 2004-035036/03.
 XX DR New small interfering polynucleotide that modulates protein tyrosine
 XX PT phosphatase (PTP)1B polypeptide signal transduction, useful for treating
 XX PT disorders associated with altered PTP1B signal transduction, e.g.
 XX PT diabetes or cancer.
 XX Example 3; SEQ ID NO 420; 234pp; English.
 XX PS The invention relates to a novel isolated small interfering RNA (siRNA)
 XX CC polynucleotide, comprising at least one nucleotide sequence from any of
 XX CC the 20 fully defined sequences given in the specification. The invention
 XX CC further relates to: a pharmaceutical composition comprising a new siRNA
 XX CC polynucleotide and a physiological carrier; a recombinant nucleic acid
 XX CC construct, comprising a polynucleotide that is capable of directing
 XX CC transcription of an siRNA; a host cell transformed or transfected with
 XX CC the above recombinant nucleic acid construct; a method for interfering
 XX CC with expression of a protein tyrosine phosphatase (PTP)1B polypeptide, or
 XX CC its variant; a method for identifying a component of a PTP1B signal
 XX CC transduction pathway; a method for modulating an insulin receptor protein
 XX CC phosphorylation state in a cell; a method for altering a Jak2 protein
 XX CC associated disorder. The siRNA has the following activities:
 XX CC antidiabetic, anorectic, antiinflammatory, neuroprotective, cytostatic,
 XX CC immunosuppressive, and antimicrobial. The novel siRNA polynucleotides can
 XX CC be used in gene therapy to treat disorders. The composition and methods
 XX CC are useful in treating disorders associated with PTP1B-mediated signal
 XX CC transduction, such as diabetes, obesity, hyperglycaemia-induced
 XX CC apoptosis, inflammation, neurodegenerative disorders, cancer, autoimmune
 XX CC diseases or infection. This polynucleotide sequence represents an siRNA
 XX CC used for modulating the signal transduction of a protein tyrosine
 XX CC phosphatase of the invention.
 XX SQ Sequence 19 BP; 6 A; 0 C; 9 G; 0 T; 4 U; 0 Other;
 Query Match 0.8%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 722 CTCCTTCTCCATCTACA 738
 ||||| ||||| |||||
 Db 17 CTCCTTCTCCATCTCCA 1
 RESULT 95
 ADO52023
 ID ADO52023 standard; DNA; 19 BP.
 XX AC ADO52023;
 XX DT 15-JUL-2004 (first entry)
 XX DE Rat ANP gene specific forward RT-PCR primer.
 XX Inflammation-related disorder; aldosterone blocker; inflammation;
 KW cardiac remodeling; myocarditis; cardiomyopathy; vasculitis;

KW Behcet's disease; PCR; primer; rat; atrial natriuretic factor; ANP; ss.
 XX Rattus sp.
 XX US2004037806-A1.
 XX 26-FEB-2004.
 XX 24-JAN-2003; 2003US-00350964.
 XX 25-JAN-2002; 2002US-0351851P.
 XX (PHAA) PHARMACIA CORP.
 XX Rocha R, Zack MD;
 XX WPI; 2004-280243/26.
 XX Preventing or treating an inflammation-related disorder such as
 PT cardiomyopathy, comprises using an aldosterone blocker to alter
 PT expression products, e.g., IL-8, involved in the regulation of
 PT inflammation or cardiac remodeling.
 XX Example 18; Page 36; 109pp; English.
 XX The invention relates to a method for preventing or treating an
 CC inflammation-related disorder which involves administering a
 CC therapeutically-effective amount of an aldosterone blocker to alter the
 CC expression of one or more expression products involved, directly or
 CC indirectly, in the regulation of inflammation or cardiac remodeling in
 CC the subject. The method is useful to treat an inflammation-related
 CC disorder such as myocarditis, cardiomyopathy, vasculitis and Behcet's
 CC disease. The present sequence is a TagMan RT-PCR primer specific for rat
 CC atrial natriuretic factor (ANP) gene. This sequence is used to illustrate
 CC the method of the invention.
 XX Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 718 TGGCTCTCTTCTCCATC 734
 Db |||||
 1 TGGGCTCTTCTCCATC 17
 RESULT 96
 AAQ87040/C
 ID AAQ87040 standard; DNA; 20 BP.
 XX AAQ87040;
 AC
 XX 12-JAN-1996 (first entry)
 DT
 XX HPV 18-specific oligonucleotide 96-19.
 DE probe; hybridisation; human papilloma virus; HPV; detection; riboprobe;
 XX diagnosis; ss.
 KW Synthetic.
 XX WO9511316-A1.
 XX 27-APR-1995.
 XX 19-OCT-1994; 94WO-US012044.
 XX 22-OCT-1993; 93US-00141711.
 XX (AMGE-) AMGEN INC.
 XX Martin FH, Jacobsen FW, Green CL;
 PI

XX WPI; 1995-193795/25.
 DR Detection of target nucleic acid sequence in biological samples - using a
 XX labelled riboprobe which hybridises to target nucleic acid for use in
 PT medical diagnostics, forensics, and research.
 PT Example 1; Page 59; 75pp; English.
 PS
 XX HPV 18 often integrates into the human genome, as opposed to remaining in
 CC episomal form. DNA was isolated from HeLa cells known to contain
 CC integrated subgenomic HPV 18 HindIII fragments. HPV 18-specific
 CC oligonucleotides AAQ87038-9 were added to filters contg. the HPV 18 DNA.
 CC Duplicate filters were probed also with AAQ87040-41. Plaques giving
 CC clearly duplicated signals were pulled, purified and grown up. Clones
 CC contg. portions of the HPV 18 genome were obt'd. and verified. DNA was
 CC prep'd. for the prodn. of riboprobes to be used in the methods of the
 CC invention. Riboprobes improve the detection limits of nucleic acid
 CC hybridisation. The detection methods using riboprobes can be used in
 CC medical diagnostics, forensics and molecular biology research
 XX Sequence 20 BP; 9 A; 1 C; 4 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1673 AATTCTCTGATTCTAGA 1689
 Db |||||
 17 AATTCTCTGATTCTAGA 1
 RESULT 97
 AAX96777
 ID AAX96777 standard; DNA; 20 BP.
 XX AAX96777;
 AC
 XX 13-SEP-1999 (first entry)
 DT
 XX PCR primer used to amplify an ORF of Chlamydia pneumoniae.
 DE
 XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
 KW neutralising epitope; PCR primer; ss.
 XX Synthetic.
 OS Chlamydoiphila pneumoniae.
 OS WO9927105-A2.
 PN
 XX 03-JUN-1999.
 PD
 XX 20-NOV-1998; 98WO-IB001890.
 PF
 XX 21-NOV-1997; 97FR-00014673.
 PR
 PR 04-NOV-1998; 98US-0107078P.
 XX (GEST) GENSET.
 XX Griffais R;
 PI
 XX WPI; 1999-357842/30.
 DR Genome sequence of Chlamydia pneumoniae.
 XX Page 1852; Disclosure; 1912pp; English.
 PS
 XX AAX91991-X97517 represent PCR primers used to amplify open reading frames
 CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
 CC (see AAX91990). C. pneumoniae causes respiratory disease such as
 CC pneumonia and bronchitis and is thought to be a contributing factor in
 CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema

CC nodum or pharyngitis. The polypeptides encoded by the open reading
 CC frames of the C. pneumoniae genome (see AAY34584- AAY35879) can be used
 CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
 CC nucleotide sequences can also be used as immunogenic compositions.
 CC especially where the vector directs the expression of a neutralising
 CC epitope of C. pneumoniae
 XX
 SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 150 TGCTCTGGGAAGCTAT 166
 |||||
 Db 2 TGCTCTGGGAACCTAT 18
 RESULT 98
 AAH56611
 ID AAH56611 standard; DNA; 20 BP.
 XX
 AC AAH56611;
 XX
 DT 06-SEP-2001 (first entry)
 XX
 DE Streptococcus pyogenes groEL antisense oligonucleotide SEQ ID NO:259.
 XX
 KW Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;
 KW microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;
 KW Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;
 KW antibacterial; antiviral; antiproliferative; antisense therapy;
 KW microbial infection; ss.
 XX
 XX Streptococcus pyogenes.
 OS
 OS WO200136625-A2.
 PN
 XX
 XX 25-MAY-2001.
 PD
 XX
 XX 20-NOV-2000; 2000WO-CA001347.
 PF
 XX
 PR 18-NOV-1999; 99US-0166249P.
 XX
 PA (GENE-) GENESENSE TECHNOLOGIES INC.
 XX
 XX Wright JA, Young AH, Dugourd D;
 PI
 XX WPI; 2001-355633/37.
 DR
 XX
 XX Novel antisense compounds targeting nucleic acid encoding groEL or groES
 XX gene of microorganism, which hybridize with and inhibit expression of the
 XX genes, useful to inhibit growth of microorganism having the genes.
 PT
 XX
 PS Claim 3; Page 48; 110pp; English.
 XX
 XX The present invention specifically claims AAH56368 to AAH56832 which are
 CC antisense oligonucleotides to nucleotide sequences encoding groE. More
 CC generally, antisense compounds (I) comprising antisense oligonucleotides
 CC of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
 CC shock protein (HSP) 60) (GL) and groES (HSP10) (GS) gene from a
 CC microorganism, where the antisense compound is complementary to GL or GS
 CC of a microorganism and specifically hybridises with and inhibits the
 CC expression of GL or GS, is claimed. (I) have antibacterial, antiviral and
 CC antiproliferative activities, and can be used in antisense therapy and
 CC for inhibition of expression of groES or groEL. (I) are useful for
 CC inhibiting expression of GL or GS in cells or tissues in vitro. (I) are
 CC also useful for inhibiting the growth of a microorganism, or inhibiting
 CC the expression of GL or GS gene in a microorganism (a bacterial cell or a
 CC virus) having a GL or GS gene which involves administering to the
 CC microorganism or to a cell infected with the microorganism, (I). (I) are
 CC also useful for treating a mammalian pathological condition mediated by
 CC the microorganisms which involves identifying a eukaryotic organism

CC having a pathological condition mediated by microorganisms having a GL or
 CC GS gene and administering (I) such that the growth of microorganism is
 CC inhibited. The antisense compounds are utilised for diagnostics,
 CC therapeutics, prophylaxis and as research reagents and kits, e.g., to
 CC prevent or delay microbial infections in humans. They are also useful as
 CC molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854
 CC represent PCR primers for groE sequences which are used in the
 CC exemplification of the present invention. AAH56855 to AAH56870 represent
 CC groE nucleotide sequence given in the present invention
 XX
 SQ Sequence 20 BP; 1 A; 4 C; 5 G; 10 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1445 TGTTGCTGCTGCTGTTT 1461
 |||||
 Db 2 TGTTGCTGCTGCTGTTT 18
 RESULT 99
 AAD41550
 ID AAD41550 standard; DNA; 20 BP.
 XX
 AC AAD41550;
 XX
 DT 30-OCT-2002 (first entry)
 XX
 DE VRP gene specific reverse RT-PCR primer.
 DE Marker; vitamin D analogue; antiproliferative; cancer; osteodystrophy;
 DE multiple sclerosis; osteoporosis; osteomalacia; hyperparathyroidism;
 DE genoprotective; epidermal wound; chemoprotective; DNA repair mechanism;
 KW cystostatic; psoriasis; neuroprotective; vulnerary; RT-PCR; primer; ss.
 KW
 XX Unidentified.
 OS
 OS WO200244403-A2.
 PN
 XX
 XX 06-JUN-2002.
 PD
 XX
 XX 28-NOV-2001; 2001WO-CA001689.
 PF
 XX
 PR 02-NOV-2000; 2000US-0253746P.
 PR
 XX 02-MAY-2001; 2001US-0287729P.
 XX
 XX (UYMC-) UNIV MCGILL.
 PA
 XX White JH;
 PI
 XX WPI; 2002-537458/57.
 DR
 XX
 XX Novel marker for testing analogs of vitamin D expected to be effective in
 XX reducing aberrant activity of vitamin D-responsive cell, comprises gene
 XX pertinent to action of vitamin D for testing the analogs.
 PT
 XX
 PS Example 2; Page 48; 89pp; English.
 XX
 XX The invention relates to a marker for testing analogues of vitamin D
 CC expected to be effective in reducing aberrant activity of vitamin D-
 CC responsive cell, comprises at least one gene pertinent to the action of
 CC vitamin D for testing the analogues and determining analogues capable of
 CC regulating the gene, and is indicative of a chemopreventive or
 CC chemotherapeutic agent. The invention is useful for testing analogues of
 CC vitamin D expected to be effective in reducing aberrant activity of
 CC vitamin D-responsive cell or for testing analogues of vitamin D suspected
 CC to have antiproliferative activity. The invention is useful for reducing
 CC aberrant activity of vitamin D-responsive cell, and for treating a
 CC disorder characterised by an aberrant activity of vitamin D-responsive
 CC cell, where the disorder is selected from cancer, psoriasis, multiple
 CC sclerosis, osteoporosis, osteodystrophy, osteomalacia and
 CC hyperparathyroidism. The invention is useful for identifying regulated

CC target genes correlated with the antiproliferative effect of vitamin D
 CC and its analogues. The invention is useful for protecting against in vivo
 CC DNA damage, for inducing in vivo DNA repair mechanisms in a mammal, or
 CC for reducing or preventing DNA damage to the skin of a mammal, preferably
 CC human. The invention is useful as a genoprotective or chemoprotective
 CC agent. The invention is useful as a marker for the activity of DNA repair
 CC mechanisms. The invention is useful for testing compounds susceptible of
 CC inhibiting an enzyme which metabolises 1,25-dihydroxyvitamin D3. The
 CC invention is useful for treating epidermal wounds. The present sequence
 CC is VPR gene specific RT-PCR primer
 XX
 SQ Sequence 20 BP; 4 A; 9 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1272 CTGCAGCCCTCAATAT 1288
 DB 3 CTGCAGCCCTCACTAT 19

RESULT 100
 ABK49323
 ID ABK49323 standard; DNA; 20 BP.

XX AC ABK49323;

DT 15-JUL-2002 (first entry)

DE Fibroblast growth factor-related RT-PCR primer #11.

KW Mesenchymal stem cell; proliferation potency; fibroblast growth factor;
 KW FGF; pluripotency; transplantation; cartilage; bone tissue; primer; ss;
 KW RT-PCR; reverse transcriptase; osteopathic.

OS Mammalia.

XX W020022798-Al.

XX 21-MAR-2002.

XX 12-SEP-2001; 2001WO-JP007914.

XX 12-SEP-2000; 2000JP-00276971.

XX (KATO/) KATO Y.

XX Kato Y, Teutsumi S, Shimazu A;

XX WPI; 2002-362342/39.

XX Culturing mesenchymal stem cells in large quantity by adding fibroblast
 PT growth factor to medium to stimulate their proliferation potency while
 PT maintaining pluripotency to prolong life, application in transplantation.

PS Example 6; Page 13; 34pp; Japanese.

XX The invention relates to a method of culturing mammalian mesenchymal stem
 CC cells by adding to a medium, a substance that can stimulate proliferation
 CC potency of these cells (such as fibroblast growth factor (FGF)) while
 CC maintaining pluripotency. With this method, large quantities of
 CC mesenchymal stem cells can be cultured over at least 30 generations. The
 CC method is useful for culturing mesenchymal stem cells for transplantation
 CC into cartilage and bone tissues. This sequence represents a reverse
 CC transcriptase PCR (RT-PCR) primer used in the scope of the invention

XX Sequence 20 BP; 7 A; 7 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1403 CCACGGAGACCATGA 1419
 DB 1 CCACGGAGACCATGA 17

RESULT 101

ACA97216

ID ACA97216 standard; DNA; 20 BP.

XX AC ACA97216;

XX 11-AUG-2003 (first entry)

XX Vpr-driven construct associated primer #49.

DE PCR; primer; Vpr; ss; immune response; immunocompromise; HIV; cancer;
 KW gene therapy.

XX Unidentified.

XX US2003017137-A1.

XX 23-JAN-2003.

XX 22-JUL-1998; 98US-00120286.

XX 22-JUL-1998; 98US-00120286.

XX (ALFI/) ALFIERI C.

XX (TANN/) TANNER J.

XX (ROUX/) ROUX P.

XX Alfieri C, Tanner J, Roux P;

XX WPI; 2003-438926/41.

XX Novel DNA or RNA construct for increasing immune response of warm-blooded
 PT animal, has Vpr activated promoter, DNA segment encoding interleukin 2
 PT and secretory DNA encoding signal peptide functional in mammary cells.

XX Disclosure; Page 17; 28pp; English.

XX The invention relates to a DNA or RNA construct capable of expressing
 CC interleukin (IL)-2 in a warm-blooded animal or biological preparation,
 CC comprising a Vpr activated promoter, a transcribable DNA segment coding
 CC for IL-2 and a secretory DNA encoding for a signal peptide functional in
 CC mammary cells and operably linked between the promoter and the DNA
 CC segment to facilitate secretion of IL-2. The construct is useful for
 CC increasing the immune response of a warm-blooded animal or biological
 CC preparation, by introducing the construct in stem cells, antigen
 CC presenting cells or immune cell leukocytes, fibroblasts and epithelial
 CC cells, of the warm-blooded animal or biological preparation to obtain a
 CC transfected cell populations and administering a pharmaceutically
 CC effective amount of the transfected cell populations to the warm-blooded
 CC animal or biological preparation. The warm-blooded animal is an
 CC immunocompromised patient. The method is useful for stimulating immune
 CC response in immunocompromised patients affected with HIV, cancer and
 CC other immunocompromised patients. The present sequence represents a Vpr-
 CC driven construct associated primer. Note: The present sequence is
 CC displayed in the sequence listing but no further reference is made to it
 CC in the specification

XX Sequence 20 BP; 4 A; 9 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1272 CTGCAGCCCTCAATAT 1288

DB 3 CTGCAGCCCTCACTAT 19

```

RESULT 102
AAL54397/c
ID AAL54397 standard; DNA; 20 BP.
XX
XX
AC AAL54397;
XX
DT 03-APR-2003 (first entry)
XX
DE rpoB gene oligomer probe SEQ ID No 14.
XX
XX Mycobacterium tuberculosis; non-tuberculosis Mycobacterium; MOTT;
KW anti-tuberculosis drug; rpoB gene; probe; ss.
XX
XX Mycobacterium abscessus.
OS
XX
XX WO2003008645-A1.
XX
XX 30-JAN-2003.
XX
XX 23-JUL-2001; 2001WO-KR001253.
XX
XX 19-JUL-2001; 2001KR-00043450.
XX
XX (XENI-) XENISS LIFE SCI CO LTD.
XX
XX Lee H, Bang HE, Cho S, Bai G, Kim S;
XX
XX WPI; 2003-221853/21.
XX
XX Identifying Mycobacterium tuberculosis and non-tuberculosis Mycobacterium
PT (MOTT) and detecting resistance or susceptibility to an anti-tuberculosis
PT drug, comprises amplifying a fragment in the rpoB gene.
XX
XX Claim 4; Page 7; 45pp; English.
XX
XX The invention relates to a novel method for identifying Mycobacterium
CC tuberculosis and non-tuberculosis Mycobacterium (MOTT) and detecting the
CC resistance or susceptibility of M. tuberculosis, obtained by mutation of
CC the rpoB gene to an anti-tuberculosis drug by amplifying a 531 base pair
CC fragment in the rpoB gene by a polymerase chain reaction. The method, a
CC kit and oligomer probes are useful for identifying M. tuberculosis and
CC MOTTs and for detecting their resistance or susceptibility obtained by
CC mutation of the rpoB gene. New primers are useful for amplifying a 531 bp
CC fragment in the rpoB gene by PCR. This polynucleotide sequence represents
CC an oligomer probe used for targeting Mycobacterium of the invention
XX
XX Sequence 20 BP; 8 A; 8 C; 3 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 126 GGTGGTGTTCACCTTTT 142
Db |||||||
17 GGTGGTGTTCACCTTTT 1

RESULT 103
ADQ88767
ID ADQ88767 standard; DNA; 20 BP.
XX
XX ADQ88767;
AC
XX
DT 21-OCT-2004 (first entry)
XX
DE Human HIF-1 antisense oligonucleotide RX-0063.
XX
XX RX-0047; RX-0149; human; hypoxia inducible factor; HIF-1; cytotoxicity;
KW cancer; infection; inflammation; tumour formation; ss;
KW antisense oligonucleotide; antisense technology; RX-0158; RX-0063.
XX
XX Homo sapiens.
OS
XX

PN US2004152655-A1.
XX
XX 05-AUG-2004.
XX
XX 28-JAN-2004; 2004US-00766185.
XX
XX 31-JAN-2003; 2003US-0444367P.
XX
XX (YOON/) YOON H.
XX (MAOL/) MAO L.
XX (LEEY/) LEE Y B.
XX (AHNC/) AHN C.
XX (JIAN/) JIANG X.
XX
XX Yoon H, Mao L, Lee YB, Ahn C, Jiang X;
PI
XX
XX WPI; 2004-561492/54.
XX
XX New RX-0047 and RX-0149 antisense oligonucleotide compounds targeted to a
PT nucleic acid molecule encoding human hypoxia inducible factor (HIF-1),
PT useful for inhibiting expression of HIF-1 and inducing cytotoxicity in
PT several cancer cells.
XX
XX Example 4; SEQ ID NO 47; 35pp; English.
XX
XX The invention describes a compound, RX-0047 or RX-0149 targeted to a
CC nucleic acid molecule encoding human hypoxia inducible factor (HIF-1),
CC where the oligonucleotide compound inhibits the expression of human HIF-
CC 1. Also described are: a method of inhibiting the expression of HIF-1 in
CC human cells or tissues; and a method of inducing cytotoxicity in a cancer
CC cell. Specifically claimed are RX-0047 and RX-0149 compounds having a
CC fully defined sequence comprising 20 bp (SEQ ID NO. 2, 5',
CC aatgacccaccagtgcacaa 3' and SEQ ID NO. 4, 5' ggagctaacatctccaagtc 3',
CC respectively). The compounds are useful for inhibiting the expression of
CC HIF-1 and inducing the cytotoxicity in several cancer cells. The
CC antisense compounds are also useful for preventing or delaying infection,
CC inflammation, or tumour formation. This sequence represents a human HIF-1
CC antisense oligonucleotide.
XX
XX Sequence 20 BP; 8 A; 3 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1134 TATTATCAGTTACACAA 1150
Db |||||||
4 TAATATCAGTTACACAA 20

RESULT 104
ADK23065
ID ADK23065 standard; DNA; 20 BP.
XX
XX ADK23065;
AC
XX
DT 18-NOV-2004 (first entry)
XX
DE Acyl-coenzyme A synthetase 1, ACS1, antisense oligonucleotide #3142.
XX
XX acyl-coenzyme A synthetase 1; ACS1; diabetes; obesity;
KW metabolic syndrome X; cardiovascular disorder; cancer; infection;
KW inflammation; tumour; antisense; ss.
XX
XX Synthetic.
OS
XX
XX WO2004016749-A2.
XX
XX 26-FEB-2004.
XX
XX 14-AUG-2003; 2003WO-US025389.
XX
XX 14-AUG-2002; 2002US-0403591P.
XX

```

```

XX PA (PHAA ) PHARMACIA CORP.
XX PI Ross SA;
XX DR WPI; 2004-203782/19.
XX PT New antisense compounds targeted to nucleic acid molecules encoding acyl-
PT coenzyme A synthetase 1 (ACSL1), useful for treating diseases or
PT conditions associated with aberrant expression of ACS1, e.g. diabetes,
PT obesity or cancer.
XX PS Claim 3; SEQ ID NO 3142; 940pp; English.
XX CC The invention relates to an antisense compound targeted to a nucleic acid
CC molecule encoding acyl-coenzyme A synthetase 1 (ACSL1). The antisense
CC compound specifically hybridises with and inhibits the expression of
CC ACS1. The antisense oligonucleotides or compounds are useful for
CC inhibiting the expression of acyl-coenzyme A synthetase 1 (ACSL1), and for
CC treating diseases or conditions associated with aberrant expression of
CC ACS1, e.g. diabetes, obesity, metabolic syndrome X, cardiovascular
CC disorder or cancer. The antisense compounds are also useful as research
CC reagents and kits, or in diagnostic, therapeutic and prophylactic
CC applications, e.g. to prevent or delay infection, inflammation or tumour
CC formation. The present sequence represents an acyl-coenzyme A synthetase
CC 1, ACS1, antisense oligonucleotide.
XX SQ Sequence 20 BP; 3 A; 3 C; 6 G; 8 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1463 GGCTGTGTTCTTATG 1479
Db 4 GGCTGTGTTCTGATG 20
|||||
RESULT 105
AAQ54138/c
XX ID AAQ54138 standard; DNA; 20 BP.
XX AC AAQ54138;
XX DT 25-MAR-2003 (revised)
XX DT 15-JUN-1994 (first entry)
XX DE Multiplex vector 19 primer Plex 19E.
XX KW Simultaneous sequencing; ss.
XX OS Synthetic.
XX PN WO9324654-A1.
XX PD 09-DEC-1993.
XX PF 01-JUN-1993; 93WO-BP001376.
XX PR 02-JUN-1992; 92DE-04218152.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Sagner G, Blum H, Domdey H;
XX DR WPI; 1993-405842/50.
XX PT Simultaneously sequencing many nucleic acid fragments - by cloning in
PT vector after attachment of double strands adaptors, and sequencing
PT selected clones, for high cloning efficiency with only one vector.
XX PS Example 3; Page 23; 47pp; German.
XX CC The sequence is that of a primer, plex 19E, which was used in the
CC sequencing of Multiplex vector 19 as part of a method of simultaneously
CC sequencing nucleic acids. (Updated on 25-MAR-2003 to correct PN field.)
XX SQ Sequence 20 BP; 6 A; 0 C; 8 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 620 CCAACCTTACATCACTACT 639
|||||

```

```

Db      20 CCAACCCCTACATTAACTTCT 1
RESULT 107
AAQ92495
ID AAQ92495 standard; DNA; 20 BP.
XX
AC AAQ92495;
XX
DT 12-JAN-1996 (first entry)
XX
DE Spinach glycerol-3-phosphate acyltransferase gene PCR primer.
XX
KW Glycerol-3-phosphate acyltransferase; cold resistance; transgenic; plant;
KW spinach; ss.
XX
OS Synthetic.
XX
PN WO9514094-A1.
XX
PD 26-MAY-1995.
XX
PF 18-NOV-1994; 94WO-JP001956.
XX
PR 19-NOV-1993; 93JP-00314212.
XX
PA (KIRI ) KIRIN BEER KK.
XX
PI Nishizawa O, Toguri T;
XX
WPI; 1995-200384/26.
XX
Glycerol-3-phosphate acyltransferase gene from spinach - useful for
PT generating cold-resistant transgenic plants.
XX
PS Example 2; Page 18; 49pp; Japanese.
XX
AAQ92495-Q92499 and AAQ93859 are PCR primers used for the isolation and
CC amplification of DNA coding for spinach glycerol-3-phosphate
CC acyltransferase (AAQ92494). This DNA can be incorporated into cold-
CC sensitive transgenic plants to increase their resistance to low
CC temperatures
XX
SQ Sequence 20 BP; 7 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy      1480 TTGTTGCAGACATGGAAGAA 1499
Db      1 TTGCTGCAGGAATGGAAGAA 20

RESULT 108
AAAT61766
ID AAAT61766 standard; DNA; 20 BP.
XX
AC AAAT61766;
XX
DT 08-OCT-1997 (first entry)
XX
DE Primer for Atase coding sequence amplification.
XX
KW primer; PCR; polymerase chain reaction; glycerol-3-phosphate; Atase;
KW acyltransferase; chimera; Atase; pumpkin; spinach; Spinacia oleracea;
KW Cucurbita moschata; enhanced substrate specificity; unsaturated;
KW fatty acid; transgenic plant; membrane lipid; phosphatidylglycerol;
KW cold resistance; ss.
XX
OS Synthetic.
XX
PN WO9705246-A1.

XX 13-FEB-1997.
XX PD
XX PF 03-JUL-1996; 96WO-JP001844.
XX PR
XX PA (KIRI ) KIRIN BEER KK.
XX PI Ferri S, Toguri T;
XX DR WPI; 1997-145684/13.
XX
PT Chimeric gene coding for glycerol-3-phosphate acyltransferase - combines
PT parts of spinach and pumpkin genes, and imparts greater cold resistance
PT to plants transformed with it.
XX
PS Disclosure; Page 14; 53pp; Japanese.
XX
AAAT61766-71 are primers used to amplify glycerol-3-phosphate acyl-
CC transferase (Atase) gene sequences from spinach (Spinacea oleracea) and
CC pumpkin (Cucurbita moschata). New chimeric Atase genes, are based on the
CC pumpkin Atase gene, where part of the sequence (between defined
CC restriction points) is replaced with the corresponding sequence from the
CC spinach Atase gene. The encoded chimeric enzyme has enhanced substrate
CC specificity for unsaturated fatty acids. The DNA can be inserted into a
CC suitable vector, which can be used to transform plants, enabling them to
CC produce membrane lipid phosphatidylglycerol with a higher unsaturated
CC content. Plants, e.g. tobacco, tomato, rice, maize, potato, banana,
CC melon, barley, etc., transformed with the chimeric DNA have improved cold
CC resistance
XX
SQ Sequence 20 BP; 7 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy      1480 TTGTTGCAGACATGGAAGAA 1499
Db      1 TTGCTGCAGGAATGGAAGAA 20

RESULT 109
AAV47686/C
ID AAV47686 standard; DNA; 20 BP.
XX
AC AAV47686;
XX
DT 20-NOV-1998 (first entry)
XX
DE Unmethylated CpG dinucleotide.2001.
XX
KW Unmethylated CpG dinucleotide; immune response; bacterial meningitis;
KW natural killer cell activation; NK cell; Th2 response; neonatal sepsis;
KW pulmonary disorder; asthma; environmentally induced airway disease;
KW bacterial infection; endotoxaemia; therapy; cystic fibrosis;
KW inflammatory bowel disease; ss.
XX
OS Synthetic.
XX
PN WO9837919-A1.
XX
PD 03-SEP-1998.
XX
PF 25-FEB-1998; 98WO-US003678.
XX
PR 28-FEB-1997; 97US-0039405P.
XX
PA (IOWA ) UNIV IOWA RES FOUND.
XX
PI Schwartz DA, Krieg AM;
XX

```

```

DR  WPI; 1998-480941/41.
XX
PT  Use of nucleic acids containing an unmethylated CpG - for treating a
PT  subject having or at risk of having an acute decrement in air flow or
PT  inhibiting an inflammatory response.
XX
PS  Claim 35; Page 27; 65pp; English.
XX
CC  This sequence represents an unmethylated CpG dinucleotide, and can be
CC  used in the method of the invention. The method is for treating a subject
CC  having, or at risk of having an acute decrement in air flow, comprising
CC  administering a nucleic acid sequence containing at least one
CC  unmethylated CpG. The nucleic acids containing an unmethylated CpG
CC  dinucleotide affect an immune response in a subject by activating natural
CC  killer cells (NK) or redirecting a subject's immune response from a Th2
CC  to a Th1 response by inducing monocytic and other cells to produce Th1
CC  cytokines. They can be used to treat pulmonary disorders having an
CC  immunologic component, such as asthma or environmentally induced airway
CC  disease. They can also be used to treat diseases associated with Gram-
CC  positive bacterial infections or endotoxaemia including bacterial
CC  meningitis, neonatal sepsis, cystic fibrosis, inflammatory bowel disease
CC  and liver cirrhosis, Gram-negative pneumonia, Gram-negative abdominal
CC  abscess, haemorrhagic shock, disseminated intravascular coagulation, or
CC  an inflammatory response to lipopolysaccharide
XX
SQ  Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY  29  CCGCCTCCGTCGCGCGGTC 48
DB  20  CCGCGCGCGCGCGCGCGCC 1

RESULT 110
AAV74243/c
ID  AAV74243 standard; DNA; 20 BP.
AC  AAV74243;
XX
DT  20-MAR-2003 (revised)
DT  15-MAR-1999 (first entry)
XX
XX  CpG-N motif O-ODN 2001 DNA.
XX
XX  CpG-N motif; immunostimulation; antigen; CpG-S motif; immunisation; ODN;
XX  viral antigen; bacterial antigen; parasite; therapeutic; growth factor;
XX  toxin; tumour suppressor; cytokine; apoptotic protein; interferon;
XX  hormone; clotting factor; ligand; receptor; oligodeoxynucleotide; ss.
XX
OS  Synthetic.
XX
XX  W09852581-A1.
XX
XX  26-NOV-1998.
XX
XX  20-MAY-1998; 98WO-US010408.
XX
XX  20-MAY-1997; 97US-0047209P.
XX  20-MAY-1997; 97US-0047233P.
XX
XX  (OTTA-) OTTAWA CIVIC HOSPITAL LOEB RES INST.
PA  (IOWA) UNIV IOWA RES FOUND.
PA  (QIAG-) QIAGEN GMBH.
XX
PI  Davis HL, Krieg AM, Schorr J, Wu T;
XX
XX  WPI; 1999-059712/05.
XX
XX  Use of neutralising CpG and stimulating CpG motifs in DNA vectors - for
PT  enhancing the immunostimulatory effect of an antigen or enhancing the
expression of a therapeutic polypeptide.
XX
XX  Example 1; Page 64; 109pp; English.
XX
AAV74237-V74253 are oligodeoxynucleotide (ODN) primers used to describe a
method for enhancing the immunostimulatory effect of an antigen encoded
by nucleic acid contained in a nucleic acid construct. The method
involves determining the CpG-N and CpG-S motifs present in the construct,
removing neutralising CpG (CpG-N) motifs and optionally inserting a
stimulatory CpG (CpG-S) motifs in the construct, thereby producing a
nucleic acid construct having enhanced immunostimulatory efficacy. The
method can be used for immunisation against viral antigens, e.g. from
hepatitis B virus (HBV), bacterial antigens or an antigen derived from a
parasite. They can also be used for expression of a therapeutic
polypeptide, e.g. growth factors, toxins, tumour suppressors, cytokines,
apoptotic proteins, interferons, hormones, clotting factors, ligands and
receptors. (Updated on 20-MAR-2003 to correct PA field.)
XX
SQ  Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY  29  CCGCCTCCGTCGCGCGGTC 48
DB  20  CCGCGCGCGCGCGCGCGCC 1

RESULT 111
AAZ02802
ID  AAZ02802 standard; DNA; 20 BP.
XX
XX  AAZ02802;
XX
DT  07-OCT-1999 (first entry)
XX
XX  PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
XX  Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
XX  paratrachoma; inclusion conjunctivitis; genital disease; peritheatitis;
XX  nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
XX  bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS  Synthetic.
XX
XX  Chlamydia trachomatis.
XX
XX  W09928475-A2.
XX
XX  10-JUN-1999.
XX
XX  27-NOV-1998; 98WO-IB001939.
XX
XX  28-NOV-1997; 97FR-00015041.
XX  17-DEC-1997; 97FR-00016034.
XX  04-NOV-1998; 98US-0107077P.
XX
XX  (GEST) GENSET.
XX
XX  Griffais R;
XX
XX  WPI; 1999-371125/31.
XX
XX  Genome sequence of Chlamydia trachomatis.
PT
XX  Disclosure; Page 1554; 1755pp; English.
XX
XX  PCR primers AAZ01426-Z06209 were used to amplify open reading frames
XX  (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
XX  encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
XX  against Chlamydia trachomatis. Antisense and ribozyme sequences can also
XX  be used to control growth of the microorganism. Chlamydia trachomatis is
XX  responsible for a large number of diseases, e.g. eye diseases such as

```


CC conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
 CC conjunctivitis; genital diseases such as nongonococcal urethritis,
 CC epididymitis, cervicitis, salpingitis, perihepatitis, Bartholinitis;
 CC pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.
 CC The polypeptides of the invention may be of use in treating these
 CC diseases
 XX
 SQ Sequence 20 BP; 1 A; 9 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1756 GCATTTCTTTATATACACCTC 1775
 |||||
 DB 1 GCATTTCTTTCTCTCCCTC 20

RESULT 112
 AAZ04579
 ID AAZ04579 standard; DNA; 20 BP.
 AC AAZ04579;
 XX
 DT 07-OCT-1999 (first entry)
 XX
 DE PCR primer used to amplify an ORF of Chlamydia trachomatis.
 XX
 KW Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
 KW paratrachoma; inclusion conjunctivitis; genital disease; perihepatitis;
 KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
 KW Bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
 XX
 OS Synthetic.
 OS Chlamydia trachomatis.
 XX
 FN WO9928475-A2.
 XX
 PD 10-JUN-1999.
 XX
 PF 27-NOV-1998; 98WO-IB001939.
 XX
 PR 28-NOV-1997; 97FR-00015041.
 PR 17-DEC-1997; 97FR-00016034.
 PR 04-NOV-1998; 98US-0107077P.
 XX
 PA (GEST) GENSET.
 XX
 PI Griffiths R;
 XX
 DR WPI; 1999-371125/31.
 XX
 PT Genome sequence of Chlamydia trachomatis.
 XX
 PS Disclosure; Page 1700; 1755pp; English.

PCR primers AAZ01426-206209 were used to amplify open reading frames (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs encode polypeptides (see AAY36754-Y37949) which can be used as vaccines against Chlamydia trachomatis. Antisense and ribozyme sequences can also be used to control growth of the microorganism. Chlamydia trachomatis is responsible for a large number of diseases, e.g. eye diseases such as conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion conjunctivitis; genital diseases such as nongonococcal urethritis, epididymitis, cervicitis, salpingitis, perihepatitis, Bartholinitis; pneumopathy in breast feeding infants; and venereal lymphogranulomatosis. The polypeptides of the invention may be of use in treating these diseases

SQ Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1414 CCATGACTGTCTATGATCCA 1433
 |||||
 DB 1 CCACGACTGTCTATGATCCA 20

RESULT 113
 AAX94968
 ID AAX94968 standard; DNA; 20 BP.
 XX
 AC AAX94968;
 XX
 DT 13-SEP-1999 (first entry)
 XX
 DE PCR primer used to amplify an ORF of Chlamydia pneumoniae.

XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
 KW neutralising epitope; PCR primer; ss.
 XX
 OS Synthetic.
 OS Chlamydia pneumoniae.

XX WO9927105-A2.
 XX
 PD 03-JUN-1999.
 XX
 PF 20-NOV-1998; 98WO-IB001890.
 XX
 PR 21-NOV-1997; 97FR-00014673.
 PR 04-NOV-1998; 98US-0107078P.
 XX
 PA (GEST) GENSET.
 XX
 PI Griffiths R;
 XX
 DR WPI; 1999-357842/30.
 XX
 PT Genome sequence of Chlamydia pneumoniae.

PS Page 1711; Disclosure; 1912pp; English.
 XX
 CC AAX91991-X97517 represent PCR primers used to amplify open reading frames and other nucleic acid sequences from the genome of Chlamydia pneumoniae (see AAX91990). C. pneumoniae causes respiratory disease such as pneumonia and bronchitis and is thought to be a contributing factor in heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema nodosum or pharyngitis. The polypeptides encoded by the open reading frames of the C. pneumoniae genome (see AAY34584-AAY35879) can be used in immunogenic compositions as vaccines. Vectors containing C. pneumoniae nucleotides sequences can also be used as immunogenic compositions, especially where the vector directs the expression of a neutralising epitope of C. pneumoniae

SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1428 GATCCAAAGCAGATGAATGT 1447
 |||||
 DB 1 GCTCCGACCAGATGAATGT 20

RESULT 114
 AAZ60081
 ID AAZ60081 standard; DNA; 20 BP.
 XX
 AC AAZ60081;
 XX
 DT 25-APR-2000 (first entry)

```

XX Forward PCR primer +25/MIP-3beta used to amplify MIP-3beta ORF.
DE
XX
XX Chemokine; PCR primer; macrophage inflammation protein 3beta;
KW dendritic cell; disease treatment; MIP-3beta; infection; cancer; allergy;
KW immune response initiation; autoimmune disease; tissue rejection; ss.
XX
OS Homo sapiens.
XX
XX EP974357-A1.
PN
XX
XX 26-JAN-2000.
PD
XX
XX 16-JUL-1998; 98EP-00401799.
PF
XX
XX 16-JUL-1998; 98EP-00401799.
PR
XX
XX (SCHE ) SCHERING-PLOUGH.
PA
XX
XX Caux C, Vanbervliet B, Lebecque S, Vicari A, Dieu M;
PI WPI; 2000-118300/11.
XX
XX Use of chemokines capable of directing migration of dendritic cells,
DR useful for treating microbial infections, cancer and autoimmune diseases.
XX
XX Disclosure; Col 13; 16pp; English.
PS
XX
XX This sequence represents a PCR primer used to amplify the chemokine
CC macrophage inflammation protein 3 beta (MIP 3beta) coding sequence. The
CC PCR product is used in the analysis of dendritic cell response to
CC different chemokines. The invention relates to the use of chemokines
CC which are capable of directing dendritic cells, in the manufacture of a
CC medicament for the treatment of a disease state. Methods are included for
CC treating diseases by facilitating or inhibiting the migration or
CC activation of antigen-presenting dendritic cells. The chemokines can be
CC used to initiate, amplify or modulate an immune response. The chemokines
CC are useful for the treatment of disease states e.g. a bacterial, viral,
CC fungal or parasitic infection, cancer (especially melanoma, breast,
CC pancreatic, colon, lung, glioma, hepatocellular, endometrial, gastric,
CC intestinal, renal, prostate, thyroid, ovarian, testicular, liver, head
CC and neck, colorectal, oesophagus, stomach, eye, bladder, glioblastoma and
CC metastatic carcinomas), autoimmune disease, tissue rejection or an
CC allergy
XX
XX Sequence 20 BP; 1 A; 6 C; 5 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1083 CGGCTGGTGTCTGGACTGC 1102
Db 1 CTGCTGGTCTCTGGACTTC 20

RESULT 115
AAC60557
ID AAC60557 standard; DNA; 20 BP.
AC
XX
XX AAC60557;
XX
XX 31-JAN-2001 (first entry)
XX
XX Human fra-1 mRNA antisense oligonucleotide ISIS 109048.
DE
XX
XX Human; fra-1; antisense oligonucleotide; phosphorothioate; cytostatic;
KW antiinflammatory; 2'-methoxyethyl wing; 2'-MOE wing; infection; cancer;
KW ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX

US6124133-A.
PN
XX
XX 26-SEP-2000.
PD
XX
XX 15-OCT-1999; 99US-00418641.
PF
XX
XX 15-OCT-1999; 99US-00418641.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Taylor JK, Cowsett LM;
PI WPI; 2000-601552/57.
XX
XX Novel antisense compound 8-30 nucleobases in length targeted to human fra
PT -1 and which specifically hybridizes with and inhibits the expression of
PT human fra-1, useful for modulating the expression of fra-1 in cells.
XX
XX Claim 3; Col 41; 38pp; English.
PS
XX
XX The present sequence is one of a large number of antisense
CC oligonucleotides which are targeted to nucleic acids encoding fra-1. The
CC sequences may be oligodeoxyribonucleotides or chimeric oligonucleotides
CC containing a central gap region consisting of ten 2'-deoxynucleotides,
CC which is flanked on both sides by 2'-methoxyethyl (2'-MOE) wings. The
CC oligonucleotides have a phosphorothioate backbone and the cytidine
CC residues in the 2'-MOE wings are 5-methylcytidines. The fra-1 antisense
CC oligonucleotides are useful for inhibiting the expression of fra-1 in
CC human cells or tissues. They can be used for diagnostics, therapeutics,
CC prophylaxis and as research reagents and in kits. Use of the antisense
CC compounds may also be useful prophylactically, e.g. to prevent or delay
CC infection, inflammation or tumour formation
XX
XX Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1270 TGTGTGAGCCCTCAATATC 1289
Db 1 TTCTGCAGCTCTCAATATC 20

RESULT 116
AAH75307/C
ID AAH75307 standard; DNA; 20 BP.
XX
XX AAH75307;
XX
XX 02-OCT-2001 (first entry)
XX
XX Mouse inducible NOS antisense oligonucleotide SEQ ID NO 151.
DE
XX
XX Antisense oligonucleotide; inducible nitric oxide synthase; NOS;
KW modulate expression; immunomodulator; antidiabetic; cardiovascular;
KW cardiant; neuroprotective; vasotropic; ischaemia; reperfusion injury;
KW 2'-O-methoxyethyl; phosphorothioate; mouse; ss.
XX
XX Mus sp.
OS
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /notes= "phosphorothioate backbone, 5' and 3' five
FT nucleotide 2'-MOE (2'-O-methoxyethyl) wings, all cytidine
FT residues are 5-methylcytidines and a deoxy gap"
XX
XX WO200152902-A1.
PN
XX
XX 26-JUL-2001.
PD
XX
XX
XX

```

```

PF 15-JAN-2001; 2001WO-US001381.
XX
XX
PR 24-JAN-2000; 2000US-00490208.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Dean NM, Cowsert LM;
XX
XX WPI; 2001-465340/50.
XX
XX New antisense oligonucleotides for modulating the expression of inducible
XX nitric oxide synthase in cells or tissues, particularly useful for
XX treating e.g. immunological, cardiovascular or neurological disorders, or
XX ischemia.
XX
XX Example 17; Page 87; 144pp; English.
XX
XX The invention relates to antisense compounds, especially
XX oligonucleotides, which are targeted to a nucleic acid encoding inducible
XX nitric oxide synthase and which specifically hybridize to and modulate
XX expression of inducible nitric oxide synthase. The antisense compounds
XX have immunomodulator, antidiabetic, cardiovascular, cardiant,
XX neuroprotective, disorder and vasotropic activity. The antisense
XX oligonucleotides are useful for inhibiting the expression of inducible
XX nitric oxide synthase in cells or tissues. In particular, the antisense
XX oligonucleotides are useful for treating diseases or disorders associated
XX with inducible nitric oxide synthase, e.g. diabetes, immunological
XX disorder, cardiovascular disorder, neurological disorder or
XX ischaemia/reperfusion injury. The antisense oligonucleotides are also
XX useful for research and diagnostics. The present sequence is that of an
XX antisense 2'-O-methoxyethyl gapper oligonucleotide with a
XX phosphorothioate backbone, a central "gap" region of ten nucleotides
XX flanked by five nucleotide 2'-MOE (2'-methoxyethyl) wings and 5-
XX methylcytidine residues throughout the oligonucleotide. The antisense
XX oligonucleotide is targeted to mouse inducible nitric oxide synthase (NOS)
XX mRNA (AAH47974)
XX
XX Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 385 ACAGATGGCTGGAGAA 404
Db 20 ACCAAGATGGCTGGAGAA 1
RESULT 117
AAF99116/c
ID AAF99116 standard; DNA; 20 BP.
XX
XX AAF99116;
XX
XX 12-JUN-2001 (first entry)
XX
XX Immunostimulatory nucleic acid #232.
XX
XX Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
XX immunostimulatory; tumour; viral infection; bacterial infection;
XX fungal infection; parasitic infection; cancer; asthma;
XX infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
XX Synthetic.
XX
XX WO200122972-A2.
XX
XX 05-APR-2001.
XX
XX 25-SEP-2000; 2000WO-US026393.
XX
XX 25-SEP-1999; 99US-0156113P.
XX
XX 27-SEP-1999; 99US-0156135P.
XX
PR 23-AUG-2000; 2000US-0227436P.
XX
XX (IOWA ) UNIV IOWA RES FOUND.
XX (COLE-) COLEY PHARM GMEH.
XX
XX Krieg AM, Schetter C, Vollmer J;
XX
XX WPI; 2001-273485/28.
XX
XX Vaccinating against tumors, infectious diseases, allergies and asthma
XX using immunostimulatory Py-rich and TG nucleic acids.
XX
XX Claim 101; Page 43; 338pp; English.
XX
XX The present invention relates to a method for stimulating an immune
XX response. The method comprises administering an immunostimulatory nucleic
XX acid to a non-rodent subject in sufficient quantity to stimulate an
XX immune response. The present sequence is one such immunostimulatory
XX nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
XX (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
XX against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
XX and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
XX haemophilus, campylobacter, clostridium, Escherichia coli and/or
XX staphylococcus), fungal antigens and/or parasitic antigens. The method is
XX also useful for preventing cancer, asthma, infectious disease, allergy or
XX immune deficiency. The present sequence can also be used to redirect a
XX Th2 to a Th1 immune response and to activate immune cells. Note: the
XX present sequence may have a phosphorothioate backbone
XX
XX Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy 29 CCGCTCCGTCGCGCGTC 48
Db 20 CCGCGCGCGCGCGCGCC 1
RESULT 118
AAS08746
ID AAS08746 standard; DNA; 20 BP.
XX
XX AAS08746;
XX
XX 26-SEP-2001 (first entry)
XX
XX Human PD-ABC form 1 DNA exon 14 3' splice site.
XX
XX PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
XX peripheral blood leukocyte; bone marrow; lymph node; dyslipidaemia;
XX cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
XX epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
XX familial high-density lipoprotein deficiency; fatty liver disease;
XX atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
XX alcoholism; retinal degeneration; hypertension; vascular disease.
XX
XX Homo sapiens.
XX
XX WO200153490-A1.
XX
XX 26-JUL-2001.
XX
XX 23-JAN-2001; 2001WO-US002191.
XX
XX 24-JAN-2000; 2000US-0177889P.
XX 30-JUN-2000; 2000US-0215405P.
XX
XX (WARN ) WARNER LAMBERT CO.
XX
XX Johns MA, Tafuri SR, Wang M;
XX

```

```

DR WPI; 2001-442259/47.
XX
PT New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
PT of dyalipidemia, epilepsy and diseases related to abnormal calcium flux.
XX
PS Disclosure; Page 37; 77pp; English.
XX
CC The sequence represents a splice site within a DNA molecule encoding
CC human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
CC 19p13.3 and is expressed in various tissues including spleen, thymus,
CC peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA
CC molecules and proteins are used to diagnose and treat cardiovascular
CC disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases
CC related to abnormal calcium flux, coronary artery disease, Tangier's
CC disease, familial high-density lipoprotein deficiency, atherosclerosis,
CC diabetes, fatty liver disease, insulin resistance, obesity, alcoholism,
CC retinal degeneration, hypertension and vascular disease. The sequences
CC are also used in drug screening assays
XX
SQ Sequence 20 BP; 2 A; 6 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 36 CGTGGCGCGCGTCAGAGCCG 55
Db 1 CGTGGCGCGCGTCAGAGCCG 20

RESULT 119
AAS08837
ID AAS08837 standard; DNA; 20 BP.
XX
AC AAS08837;
XX
DT 26-SEP-2001 (first entry)
XX
DE Human PD-ABC form 2 DNA exon 14 3' splice site.
XX
KW PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
KW peripheral blood leukocyte; bone marrow; lymph node; dyslipidaemia;
KW cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
KW epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
KW familial high-density lipoprotein deficiency; fatty liver disease;
KW atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
KW alcoholism; retinal degeneration; hypertension; vascular disease.
XX
OS Homo sapiens.
XX
PN W0200153490-A1.
XX
PD 26-JUL-2001.
XX
PF 23-JAN-2001; 2001WO-US002191.
XX
PR 24-JAN-2000; 2000US-0177889P.
XX
PR 30-JUN-2000; 2000US-0215405P.
XX
PA (WARN ) WARNER LAMBERT CO.
XX
PI Johns MA, Tafuri SR, Wang M;
XX
WPI; 2001-442259/47.
XX
DR New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
DR of dyalipidemia, epilepsy and diseases related to abnormal calcium flux.
XX
PS Disclosure; Page 39; 77pp; English.
XX
CC The sequence represents a splice site within a DNA molecule encoding
CC human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
CC 19p13.3 and is expressed in various tissues including spleen, thymus,
XX
SQ Sequence 20 BP; 2 A; 6 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 36 CGTGGCGCGCGTCAGAGCCG 55
Db 1 CGTGGCGCGCGTCAGAGCCG 20

RESULT 120
AAF23716/c
ID AAF23716 standard; DNA; 20 BP.
XX
AC AAF23716;
XX
DT 27-MAR-2001 (first entry)
XX
DE Human PPARGamma antisense oligonucleotide ISIS# 106034.
XX
KW Cytostatic; antiinflammatory; antisense oligonucleotide; PPARGamma;
KW peroxisome proliferator-activated receptor gamma; transcription factor;
KW nuclear hormone receptor; human; infection; inflammation; tumour;
KW phosphorothioate; 2-methoxyethyl wing; ss.
XX
OS Homo sapiens.
XX
PN US6159734-A.
XX
PD 12-DEC-2000.
XX
PF 18-JAN-2000; 2000US-00484345.
XX
PR 18-JAN-2000; 2000US-00484345.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI McKay R, Baker BF, Borchers AH;
XX
WPI; 2001-070112/08.
XX
PT Novel antisense compounds capable of modulating expression of peroxisome
PT proliferator-activated receptor gamma useful for diagnosis, prophylaxis
PT and treatment of diseases associated with expression of the receptor.
XX
PS Example 15; Col 43-44; 40pp; English.
XX
CC Peroxisome proliferator-activated receptors (PPARs) are members of the
CC nuclear hormone receptor subfamily of transcription factors. The present
CC invention relates to antisense oligonucleotides, targeted to a nucleic
CC acid molecule encoding human PPARGamma, which specifically hybridises
CC with and inhibits the expression of human PPARGamma. The present sequence
CC is one such antisense oligonucleotide. The oligonucleotides of the
CC present invention can be used in the diagnosis and treatment of diseases
CC associated with the expression of PPARGamma, e.g. to prevent or delay
CC infection, inflammation or tumour formation. Note: the present sequence
CC may have a phosphorothioate backbone and 2'-O-(2-methoxyethyl) (2-MOE)
CC wings
XX
SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;

```

CC peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA molecules and proteins are used to diagnose and treat cardiovascular disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases related to abnormal calcium flux, coronary artery disease, Tangier's disease, familial high-density lipoprotein deficiency, atherosclerosis, diabetes, fatty liver disease, insulin resistance, obesity, alcoholism, retinal degeneration, hypertension and vascular disease. The sequences are also used in drug screening assays

Query Match 0.8%; Score 15.2; DB 1; Length 20; Best Local Similarity 85.0%; Pred. No. 1.2e+02; Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 36 CGTGGCGCGCGTCAGAGCCG 55
 ||| ||||| ||| |||||
 Db 1 CGTGGCGCGCGTCAGAGCCG 20

RESULT 120
 AAF23716/c
 ID AAF23716 standard; DNA; 20 BP.
 XX
 AC AAF23716;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Human PPARGamma antisense oligonucleotide ISIS# 106034.
 XX
 KW Cytostatic; antiinflammatory; antisense oligonucleotide; PPARGamma;
 KW peroxisome proliferator-activated receptor gamma; transcription factor;
 KW nuclear hormone receptor; human; infection; inflammation; tumour;
 KW phosphorothioate; 2-methoxyethyl wing; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6159734-A.
 XX
 PD 12-DEC-2000.
 XX
 PF 18-JAN-2000; 2000US-00484345.
 XX
 PR 18-JAN-2000; 2000US-00484345.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI McKay R, Baker BF, Borchers AH;
 XX
 WPI; 2001-070112/08.
 XX
 PT Novel antisense compounds capable of modulating expression of peroxisome
 PT proliferator-activated receptor gamma useful for diagnosis, prophylaxis
 PT and treatment of diseases associated with expression of the receptor.
 XX
 PS Example 15; Col 43-44; 40pp; English.
 XX
 CC Peroxisome proliferator-activated receptors (PPARs) are members of the
 CC nuclear hormone receptor subfamily of transcription factors. The present
 CC invention relates to antisense oligonucleotides, targeted to a nucleic
 CC acid molecule encoding human PPARGamma, which specifically hybridises
 CC with and inhibits the expression of human PPARGamma. The present sequence
 CC is one such antisense oligonucleotide. The oligonucleotides of the
 CC present invention can be used in the diagnosis and treatment of diseases
 CC associated with the expression of PPARGamma, e.g. to prevent or delay
 CC infection, inflammation or tumour formation. Note: the present sequence
 CC may have a phosphorothioate backbone and 2'-O-(2-methoxyethyl) (2-MOE)
 CC wings
 XX
 SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;

ABL39008/C
ID: ABL39008 standard: DNA: 20 BP.

XX WPI; 2002-144136/19.
 XX Arraying genome clones.
 XX Claim 4; Page 15; 528pp; Japanese.
 XX The present invention describes a method of arraying genome clones. The
 CC method comprises: (a) clones of the genomic libraries contained in
 CC multiwell plates numbered for discrimination are mixed in each of the
 CC multiwell plates; (b) a primer designed based on the chromosome marker
 CC sequence is added to the mixture to carry out an amplification reaction;
 CC (c) a signal corresponding to the marker is detected from the resultant
 CC amplified product to specify the discrimination Nos. of the multiwell
 CC plates containing the clones having said marker sequence; (d) the order
 CC of the markers is changed so that the same discrimination Nos. succeed to
 CC the maximum in the specified discrimination Nos. to array the multiwell
 CC plates; (e) the clones in the multiwell plates of the specified
 CC discrimination Nos. are mixed respectively in each wells of longitudinal
 CC and lateral directions; (f) the mixed clones are cultured and the
 CC resultant cultures are amplified by using the above primer; (g) signals
 CC are detected from the amplified products; (h) the clones in the multiwell
 CC plates are specified from the detected result; and (i) the clones are
 CC reconstituted as the positions on the chromosome and arrayed. The
 CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
 CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
 CC represent PCR primers for human chromosome 21q22.1, which are
 CC specifically claimed for use in the present invention
 XX
 XX Sequence 20 BP; 7 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1789 TTCGACTTTAAAGTAACA 1808
 DB 1 TTCGACTTTGCAAGCAACA 20
 RESULT 126
 ABL13053
 ID ABL13053 standard; DNA; 20 BP.
 XX
 XX ABL13053;
 AC
 XX
 DT 30-JAN-2003 (first entry)
 XX
 XX Human apolipoprotein A-IV PCR primer (SNP specific) #19.
 DE
 XX
 XX Human; PCR; primer; ss; gene therapy; single nucleotide polymorphism;
 KW cytochrome C oxidase subunit VIB; COX6B; high serum cholesterol; GPI-1;
 KW N-acetylglucosaminyl transferase component; cardiovascular disease; HDL;
 KW glycosylphosphatidylinositol-1; SNP; low serum high density lipoprotein.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200272604-A2.
 PN
 XX
 PD 19-SEP-2002.
 XX
 XX 05-MAR-2002; 2002WO-US006728.
 XX
 XX 09-MAR-2001; 2001US-00802640.
 XX
 XX (SEQU-) SEQUENOM INC.
 XX
 XX Braun A, Bansal A, Kleya PW;
 XX
 XX WPI; 2002-750478/81.
 XX
 XX Detecting the presence or absence of an allelic variant of a polymorphic
 PT region of COX6B and/or GPI-1 gene, useful for detecting a predisposition

PT to high serum cholesterol, low serum HDL and cardiovascular disease.
 XX
 XX Disclosure; Page 32; 199pp; English.
 XX
 CC The invention comprises methods of detecting the presence or absence of
 CC at least one allelic variant of a polymorphic region of a gene associated
 CC with cardiovascular disease. The invention specifically relates to
 CC detecting the region of a cytochrome C oxidase subunit VIB (COX6B) gene
 CC that is associated with high serum cholesterol, or the region of the N-
 CC acetylglucosaminyl transferase component glycosylphosphatidylinositol-1
 CC (GPI-1) gene that is associated with low serum high density lipoprotein
 CC (HDL). The methods of the invention are useful for detecting a
 CC predisposition to high serum cholesterol, low serum HDL and
 CC cardiovascular disease. The methods are also useful for elucidating
 CC pathological pathways, developing diagnostic assays and new drug
 CC therapies for such disorders. The present DNA sequence represents a PCR
 CC primer used to amplify a human gene that is associated with high serum
 CC cholesterol, low serum HDL and/or cardiovascular disease
 XX
 XX Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1265 GAGCCTGCTGCAGCCCTCA 1284
 DB 1 GTGACTTCTGCAGCCCTCA 20
 RESULT 127
 ABL80988
 ID ABL80988 standard; DNA; 20 BP.
 XX
 XX ABL80988;
 AC
 XX
 DT 15-JUL-2002 (first entry)
 XX
 XX Mouse caspase 7 phosphorothioate oligonucleotide SEQ ID NO:166.
 DE
 XX
 KW Caspase 7; antisense modulation; antiinflammatory; cytostatic;
 KW antisense therapy; caspase 7 inhibitor; inflammatory condition;
 KW hyperproliferative disorder; cancer; bone metabolism; infection;
 KW cholesterol disorder; inflammation; tumour; phosphorothioate; ss.
 XX
 XX Mus musculus.
 OS
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) wing"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) wing"
 FT
 XX
 XX WO200222640-A1.
 PN
 XX
 XX 21-MAR-2002.
 PD
 XX
 XX 10-SEP-2001; 2001WO-US028232.
 XX
 XX 11-SEP-2000; 2000US-00659860.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Zhang H, Watt AT;
 XX

DR WPI; 2002-404806/43.

XX Novel antisense compounds targeted to nucleic acids encoding caspase 7,

PT for modulating gene expression and treating diseases associated with

PT expression of caspase 7 in humans.

XX

PS Example 16; Page 89; 138pp; English.

XX

CC The present invention describes a compound (I) 8-50 nucleobases in length

CC targeted to a nucleic acid molecule encoding caspase 7, which

CC specifically hybridises with and inhibits the expression of caspase 7.

CC (I) has antiinflammatory and cytostatic activities, and can be used in

CC antisense therapy and as an inhibitor of caspase 7 expression. (I) is

CC useful for inhibiting the expression of caspase 7 in human cells or

CC tissues, and for treating a human having a disease or condition

CC associated with caspase 7 including inflammatory condition,

CC hyperproliferative disorder (cancer), or bone metabolism or cholesterol

CC disorder. (I) is useful for diagnostics, therapeutics, prophylaxis and as

CC research reagent and kits. (I) is useful prophylactically to prevent or

CC delay infection, inflammation or tumour formation. The present sequence

CC represent a mouse caspase 7 inhibiting chimeric phosphorothioate

CC oligonucleotide having 2'-MOE wings and a deoxy gap, which is used in an

CC example from the present invention

XX

SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1528 AAGGAACGTTTCATGCTT 1547

Db 1 AAGGAACCTTTTCATGCTT 20

RESULT 128

ABK47992

ID ABK47992 standard; DNA; 20 BP.

XX

AC ABK47992;

DT 02-JUL-2002 (first entry)

XX

DE Human MIP-3 beta RT-PCR primer +25/MIP-3 beta.

XX

Human; chemokine; MCP-4; hMCP-4; ss; 6CKine; dendritic cell; renal;

KW autoimmune disease; tissue rejection; allergy; cancer; hepatocellular;

KW melanoma; breast; pancreas; colon; glioma; endometrium; intestine; lung;

KW prostate; thyroid; ovary; testis; liver; head; neck; colorectal; bladder;

KW oesophagus; stomach; eye; glioblastoma; gastric; metastatic carcinoma;

KW immunosuppressive; antiallergic; cytostatic; rectum; RT-PCR; primer;

KW reverse transcriptase; macrophage inflammatory protein 3 beta;

KW MIP-3 beta.

XX

OS Homo sapiens.

XX

PN US2002034494-A1.

XX

PD 21-MAR-2002.

XX

PF 24-JAN-2001; 2001US-00768917.

XX

PR 24-JAN-2001; 2001US-00768917.

XX

PA (VICA/) VICARI A P.

PA (CAUX/) CAUX C.

PA (LAFA/) LAFA D.

XX

PI Vicari AP, Caux C, Laface D;

XX

DR WPI; 2002-351086/38.

XX

PT Using chemokine MCP-4 or 6CKine to attract dendritic cells to the site of

PT an antigen is useful to treat disease states, particularly autoimmune

PT disease, tissue rejection, allergy and cancer.

XX

PS Example; Page 7; 29pp; English.

XX

CC The invention relates to a method for enhancing an immune response in a

CC mammal, comprising administering chemokine MCP-4 or 6CKine or their

CC biologically active fragments. The chemokines are capable of directing

CC the migration of dendritic cells to manufacture a medicament for a

CC disease state. The invention is used to treat disease states, including

CC an autoimmune disease, tissue rejection or an allergy, or a cancer,

CC particularly melanoma, breast, pancreatic, colon, lung, glioma,

CC hepatocellular, endometrial, gastric, intestinal, renal, prostate,

CC thyroid, ovarian, testicular, liver, head and neck, colorectal,

CC oesophagus, stomach, eye or bladder cancer, glioblastoma or metastatic

CC carcinoma. This sequence represents an RT-PCR primer for macrophage

CC inflammatory protein 3 beta (MIP-3 beta), used in analysis of

CC responsiveness to chemokines

XX

SQ Sequence 20 BP; 1 A; 6 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1083 CGGCTGGTCTCTGGACTGC 1102

Db 1 CTGCTGGTCTCTGGACTTC 20

RESULT 129

ACD99549/c

ID ACD99549 standard; DNA; 20 BP.

XX

AC ACD99549;

DT 25-SEP-2003 (first entry)

XX

DE Immunostimulatory nucleic acid #235.

XX

KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;

KW antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;

KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;

KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.

XX

XX Synthetic.

XX OS

XX US2003050268-A1.

PN

XX

PD 13-MAR-2003.

XX

PF 29-MAR-2002; 2002US-00112653.

XX

PR 29-MAR-2001; 2001US-0279642P.

XX

XX (KRIE/) KRIEG A M.

PA (BERG/) BERG D J.

XX

PI Krieg AM, Berg DJ;

XX

DR WPI; 2003-521815/49.

XX

PT Treating non-allergic inflammatory diseases, such as psoriasis, eczema,

PT allergic contact dermatitis, latex dermatitis or inflammatory bowel

PT disease by administering an immunostimulatory nucleic acid.

XX

PS Disclosure; Page 15; 229pp; English.

XX

CC The invention describes a method of treating non-allergic inflammatory

CC disease comprising administering to a subject having or at risk of

CC developing a non-allergic inflammatory disease an immunostimulatory

CC nucleic acid for prevention or treatment of the disease. The method is

CC useful for treating non-allergic inflammatory diseases, such as

CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
 CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
 CC This sequence represents an immunostimulatory nucleic acid
 XX
 SQ Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 29 CCGCCTCGTCGCCCGTC 48
 ||||| ||||| ||||| |||||
 Db 20 CCGCCCGCCGCCCGCCG 1

RESULT 130
 ADB36618/c
 ID ADB36618 standard; DNA; 20 BP.

AC ADB36618;

DT 04-DEC-2003 (first entry)

DE Immunostimulatory nucleic acid #232.

ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
 KW hypo-responsive subject; immunostimulatory.

OS Synthetic.

XX US2003087848-A1.

XX 08-MAY-2003.

XX 02-FEB-2001; 2001US-00776479.

XX 03-FEB-2000; 2000US-0179991P.

XX (BRAT/) BRATZLER R L.

XX (PETE/) PETERSEN D M.

XX (FOUR/) FOURON Y.

XX Bratzler RL, Petersen DM, Fouron Y;

XX WPI; 2003-657977/62.

PT Treating and/or preventing allergy or asthma using an immunostimulatory
 PT nucleic acid alone or in combination with an asthma/allergy medicament.

XX Disclosure; Page 8; 221pp; English.

XX The invention relates to a method of treating or preventing allergy or
 CC asthma which comprises administering to a subject a poly-G nucleic acid
 CC in an aerosol formulation. The methods and compositions of the present
 CC invention are useful for diagnosing and/or treating asthma and allergy
 CC especially in a hypo-responsive subject. The present sequence represents
 CC an immunostimulatory nucleic acid of the invention.

XX Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 29 CCGCCTCGTCGCCCGTC 48
 ||||| ||||| ||||| |||||
 Db 20 CCGCCCGCCGCCCGCCG 1

RESULT 131
 ADD24338
 ID ADD24338 standard; DNA; 20 BP.

XX

AC

ADD24338;

DT 15-JAN-2004 (first entry)

DE CD2 binding protein 1 (CD2BP1) primer #7.

XX human; CD2 binding protein; CD2BP1; genetic marker; autoimmune disorder;
 KW PAPA syndrome; familial recurrent arthritis; FRA syndrome; ss; PCR;
 KW primer.

OS Homo sapiens.

XX US2003104404-A1.

XX 05-JUN-2003.

XX 04-FEB-2002; 2002US-00067076.

XX 08-NOV-2000; 2000US-00710693.

XX 01-MAY-2001; 2001US-0287893P.

XX (WISE/) WISE C A.

XX Wise CA;

XX WPI; 2003-801229/75.

XX Novel isolated nucleic acid molecule useful as genetic markers for
 PT autoimmune disorder such as PAPA syndrome.

XX Example 2; SEQ ID NO 10; 22pp; English.

XX The invention relates to an isolated nucleic acid molecule where the
 CC molecule encodes CD2 binding protein (CD2BP1). The nucleic acid is useful
 CC as genetic markers for autoimmune disorder such as PAPA syndrome which is
 CC a combination of familial recurrent arthritis (FRA) syndrome and PAPA
 CC syndrome. The present sequence is used in the exemplification of the
 CC present invention.

XX Sequence 20 BP; 5 A; 2 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 989 GCAGGTGTCATGATGATG 1008

Db 1 GCAGTGTGTCAGGATGATG 20

RESULT 132

AAD63540

ID AAD63540 standard; DNA; 20 BP.

XX AAD63540;

XX 12-FEB-2004 (first entry)

XX Human CD2BP1 cDNA amplifying PCR primer, CD2BP1-4F.

XX Human; CD2 binding protein; CD2BP1; familial recurrent arthritis; FRA;
 KW CD2BP1 mediated disorder; PCR; primer; ss.

OS Homo sapiens.

XX US6642370-B1.

XX 04-NOV-2003.

XX 08-NOV-2000; 2000US-00710693.

XX 08-NOV-2000; 2000US-00710693.

XX

```
PA (TEXA-) TEXAS SCOTTISH RITE HOSPITAL.
XX
XX
PI Wise CA;
XX
XX
DR WPI; 2003-851363/79.
XX
XX
PT New nucleic acid encoding CD2 binding protein CD2BP1, useful for
PT producing antibodies, in diagnostic assays or identifying cellular or
PT extracellular gene products involved in the regulation of a CD2BP1
PT mediated disorder.
XX
XX
PT Example 2; Col 22; Opp; English.
PS
XX
XX
CC The present invention relates to the identification of a gene encoding
CC CD2 binding protein, CD2BP1 as the inherited factor associated with
CC familial recurrent arthritis (FRA). Particularly mutant alleles of CD2BP1
CC are identified as a causative factor in FRA. Nucleic acid molecules of
CC the invention are used for the production of antibodies, in diagnostic
CC assays or for the identification of other cellular or extracellular gene
CC products involved in the regulation of CD2BP1 mediated disorders
CC including FRA. The present sequence is a PCR primer used to amplify human
CC CD2BP1 cDNA
XX
XX
SQ Sequence 20 BP; 5 A; 2 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 989 GCAGGGTGCCATGATGATG 1008
DB 1 GCAGTGTCAGATGATG 20
|||||
|||||

RESULT 133
ABZ90044
ID ABZ90044 standard; DNA; 20 BP.
XX
XX
AC ABZ90044;
XX
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX
PN WO200285308-A2.
XX
XX
PD 31-OCT-2002.
XX
XX
PF 23-APR-2002; 2002WO-US013135.
XX
XX
PR 24-APR-2001; 2001US-0286137P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX
DR WPI; 2003-229219/22.
XX
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
```

```
PS Disclosure; SEQ ID NO 5286; 872pp; English.
XX
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of ubiquinone or
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 20 BP; 8 A; 1 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1672 AAATTCCTGATTCATAGAAA 1691
DB 1 AAATTTTGATTCATATAA 20
|||||
|||||

RESULT 134
ABZ89607/c
ID ABZ89607 standard; DNA; 20 BP.
XX
XX
AC ABZ89607;
XX
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX
PN WO200285308-A2.
XX
XX
PD 31-OCT-2002.
XX
XX
PF 23-APR-2002; 2002WO-US013135.
XX
XX
PR 24-APR-2001; 2001US-0286137P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX
DR WPI; 2003-229219/22.
XX
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
```

PS Disclosure; SEQ ID NO 4849; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a first active agent comprising an oligonucleotide antisense to the initiation codon, coding region, 5' or 3' end genomic flanking regions, 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of junctions of genes encoding a polypeptide associated with lung and/or nasal airway dysfunction and a second active agent comprising an antiinflammatory steroid and ubiquinone. A composition of the invention has antiinflammatory, antiallergic, antiasthmatic, hypotensive, immunosuppressive, and cytostatic activity. The composition may have a use in antisense gene therapy. The composition is useful for treating or preventing a respiratory, lung or malignant disease or condition, also for enhancing the prophylactic or therapeutic respiratory effect of an antiinflammatory steroid in a subject, for reducing or depleting levels of, or reducing sensitivity to adenosine, reducing levels of adenosine receptor, producing bronchodilation, increasing levels of ubiquinone or lung surfactant in a subject's tissue, or treating bronchoconstriction, lung inflammation, lung allergies, or a respiratory disease or condition. Note: The sequence data for this patent is not represented in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 7 A; 2 C; 5 G; 6 T; 0 U; 0 Other;

XX Query Match 0.8%; Score 15.2; DB 1; Length 20;

XX Best Local Similarity 85.0%; Pred.No. 1.2e+02;

XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 888 CCAGTACTGATTCCTTCAA 907

Db 20 CCAATATGTTGCTTCAA 1

RESULT 135

ABZ90469/C

ID ABZ90469 standard; DNA; 20 BP.

AC ABZ90469;

XX 17-OCT-2003 (first entry)

XX Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction; antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic; antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy; antisense gene therapy; respiratory; lung; adenosine sensitivity; adenosine receptor; bronchodilation; bronchoconstriction; lung allergy; lung inflammation; respiratory disease; ds.

XX Homo sapiens.

OS

XX WO200285308-A2.

PN

XX 31-OCT-2002.

PD

XX 23-APR-2002; 2002WO-US013135.

PF

XX 24-APR-2001; 2001US-0286137P.

PR

XX (EPIG-) EPIGENESIS PHARM INC.

PA

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

PI

XX WPI; 2003-229219/22.

DR

XX Pharmaceutical composition for treating ailments associated with impaired respiration, has oligo(s) antisense to specific gene(s) or its corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or ubiquinone.

XX

PS Disclosure; SEQ ID NO 5711; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a first active agent comprising an oligonucleotide antisense to the initiation codon, coding region, 5' or 3' end genomic flanking regions, 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of junctions of genes encoding a polypeptide associated with lung and/or nasal airway dysfunction and a second active agent comprising an antiinflammatory steroid and ubiquinone. A composition of the invention has antiinflammatory, antiallergic, antiasthmatic, hypotensive, immunosuppressive, and cytostatic activity. The composition may have a use in antisense gene therapy. The composition is useful for treating or preventing a respiratory, lung or malignant disease or condition, also for enhancing the prophylactic or therapeutic respiratory effect of an antiinflammatory steroid in a subject, for reducing or depleting levels of, or reducing sensitivity to adenosine, reducing levels of adenosine receptor, producing bronchodilation, increasing levels of ubiquinone or lung surfactant in a subject's tissue, or treating bronchoconstriction, lung inflammation, lung allergies, or a respiratory disease or condition. Note: The sequence data for this patent is not represented in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 2 A; 1 C; 4 G; 13 T; 0 U; 0 Other;

XX Query Match 0.8%; Score 15.2; DB 1; Length 20;

XX Best Local Similarity 85.0%; Pred.No. 1.2e+02;

XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1518 AAACAGTAAAGAAACGT 1537

Db 20 AAACACTAAGAAACAAACAT 1

RESULT 136

ABZ82795

ID ABZ82795 standard; DNA; 20 BP.

AC ABZ82795;

XX 14-MAY-2003 (first entry)

XX Mouse HSL chimeric phosphorothioate oligonucleotide SEQ ID NO:184.

XX Hormone-sensitive lipase; antisense oligonucleotide; inhibitor; obesity; phosphorothioate; antidiabetic; anorectic; cytostatic; antisense therapy; abnormal metabolic condition; hyperlipidaemia; type 2 diabetes; cancer; hyperproliferative disorder; mouse; ss.

XX Mus musculus.

OS

XX Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "phosphorothioate linkages"

FT modified_base 1..5

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyl (2'-MOE) wing"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyl (2'-MOE) wing"

XX

XX WO2003010139-A2.

PN

XX 06-FEB-2003.

PD

XX 15-JUL-2002; 2002WO-US022672.

PF

XX 26-JUL-2001; 2001US-00915814.

PR

```

XX (ISIS-) ISIS PHARM INC.
XX Butler MM, Watt AT, Freier SM, Wyatt JR;
XX WPI; 2003-239411/23.
XX
XX New antisense oligonucleotides targeted against nucleic acids encoding
XX hormone-sensitive lipase, useful for treating abnormal metabolic
XX condition, e.g. hyperlipidemia and obesity, or a hyperproliferative
XX disorder, e.g. cancer.
XX
XX Example 17; Page 93; 167pp; English.
XX
XX The present invention describes a compound (I) 8-50 nucleobases in length
XX targeted to a nucleic acid molecule encoding a hormone-sensitive lipase
XX (HSL) or a splice variant of HSL. The compound specifically hybridizes
XX with and inhibits the expression of HSL or a splice variant of HSL, or
XX specifically hybridizes with at least an 8-nucleobase portion of an
XX active site on a nucleic acid molecule encoding HSL. (I) have anorectic,
XX anti-diabetic and cytostatic activities, and can be used in antisense
XX therapy. (I) is useful for treating an animal, particularly human,
XX suspected of having an abnormal metabolic condition such as obesity,
XX hyperlipidaemia, type 2 diabetes, a hyperproliferative disorder such as
XX cancer (e.g. pituitary, colorectal, breast, testicular, pulmonary or
XX epithelial cancer). (I) is also useful in modulating blood glucose
XX levels, particularly plasma or serum glucose levels, in a diabetic
XX animal. The present sequence represents a mouse hormone-sensitive lipase
XX chimeric phosphorothioate antisense oligonucleotide, which is used in an
XX example from the present invention
XX
XX Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 524 TCCAGAGGCGATTACAGCAG 543
DB 1 TCCAGAGGCGTTTCCAGAG 20
XX
RESULT 137
ABD26699/C
XX ABD26699 standard; DNA; 20 BP.
XX
AC ABD26699;
XX
XX 29-JUL-2004 (first entry)
XX
XX N35316-derived oligonucleotide SEQ ID 5711.
XX
Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX

```

```

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 5711; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory
XX distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX transplantation rejection, pulmonary infections, bronchitis or cancer.
XX The reduced adenosine content of the anti-sense oligos corresponding to
XX thymidines present in the target RNA serves to prevent the breakdown of
XX the oligonucleotides into products that free adenosine into the system
XX e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 2 A; 1 C; 4 G; 13 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 1518 AAACACTAAGAAAGAACGT 1537
DB 20 AAACACTAAGAAACAACAT 1
XX
RESULT 138
ABD26274
XX ABD26274 standard; DNA; 20 BP.
XX
AC ABD26274;
XX
XX 29-JUL-2004 (first entry)
XX
XX AA398883-derived oligonucleotide SEQ ID 5286.
XX
Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX

```

OS Homo sapiens.
 XX WO200285309-A2.
 PN 31-OCT-2002.
 PD 23-APR-2002; 2002WO-US013143.
 XX 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR Pharmaceutical composition for treating asthma, has antisense
 XX oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 5286; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 8 A; 1 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1672 AAATTCTCTGATTCTAGAAA 1691
 DB 1 AAATTTTGATTCTATAAA 20
 RESULT 139
 ABD25837/c
 ID ABD25837 standard; DNA; 20 BP.
 XX
 AC ABD25837;
 XX 29-JUL-2004 (first entry)
 DT

XX DE
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS
 XX WO200285309-A2.
 PN 31-OCT-2002.
 PD 23-APR-2002; 2002WO-US013143.
 XX 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR Pharmaceutical composition for treating asthma, has antisense
 XX oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 4849; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 7 A; 2 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

Qy      888 CCAGATACCTGATTCCTTCAA 907
Db      ||||| ||||| ||||| ||||| |||||
        20 CCAATATTGCTGCTTCAA 1

RESULT 140
ADH1329/c
ID      ADH1329 standard; DNA; 20 BP.
XX
AC      ADH1329;
XX
DT      11-MAR-2004 (first entry)
XX
DE      Human ovarian specific gene (OSG) PCR primer #2.
XX
KW      human; ovarian specific gene; OSG; gynaecologic cancer; PCR; ss; primer.
XX
OS      Homo sapiens.
XX
PN      US2003096238-A1.
XX
PD      22-MAY-2003.
XX
PF      17-AUG-2001; 2001US-00932419.
XX
PR      17-AUG-2000; 2000US-0225857P.
XX
PA      (SALC/) SALCEDA S.
PA      (CAFF/) CAFFERKEY R.
XX
PI      Salceda S, Cafferkey R;
XX
XX      WPI; 2004-096548/10.
XX
PT      New ovarian specific gene, useful for diagnosing metastasis, staging and
PT      for treating gynecologic cancer in a patient, and for identifying
PT      potential therapeutic agents for use in imaging and treating gynecologic
PT      cancers.
XX
PS      Example; SEQ ID NO 5; 35pp; English.
XX
CC      The invention comprises a human the DNA sequence of an ovarian specific
CC      gene (OSG) and the encoded protein. The DNA and protein sequences of the
CC      invention are useful for diagnosing, monitoring and treating gynaecologic
CC      cancer. The DNA and protein sequences are also useful for imaging a
CC      gynaecologic cancer. The present DNA sequence represents a PCR primer
CC      that was used in an example of the invention.
XX
XX      Sequence 20 BP; 9 A; 6 C; 4 G; 1 T; 0 U; 0 Other;

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1445 TGTTGCTGCTGCTTTGGG 1464
Db      ||||| ||||| ||||| ||||| |||||
        20 TCTTGATGCTGCTGTTTCGG 1

RESULT 141
ADH18272/c
ID      ADH18272 standard; DNA; 20 BP.
XX
AC      ADH18272;
XX
DT      11-MAR-2004 (first entry)
XX
DE      2'-MOE gapmer antisense oligo targeted to human Apob DNA 1 - SEQ ID 261.
XX
KW      apolipoprotein B; Apob; antiarteriosclerotic; cardiant; antidiabetic;
KW      anorectic; lipid; cholesterol metabolism; atherosclerosis;
KW      diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
KW      antisense; 2'-O-methoxyethyl gapmer; phosphorothioate backbone; 2'-MOE;
KW      human; ss.
XX
XX      Oryctolagus cuniculus.
XX
OS      OS
XX
PN      WO2003097662-A1.
XX
XX      27-NOV-2003.
XX
PD      15-MAY-2003; 2003WO-US015493.
XX
PF      15-MAY-2003; 2003WO-US015493.
XX

```

```

KW      human; ss.
XX
OS      Homo sapiens.
XX
PN      WO2003097662-A1.
XX
PD      27-NOV-2003.
XX
PF      15-MAY-2003; 2003WO-US015493.
XX
PR      15-MAY-2002; 2002US-00147196.
PR      13-NOV-2002; 2002US-0426324P.
XX
PA      (ISIS-) ISIS PHARM INC.
XX
PI      Crooke RM, Graham MJ;
XX
XX      WPI; 2004-022840/02.
XX
PT      New antisense compound, useful for preparing a composition for treating
PT      abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT      2, obesity, hyperlipidemia or cardiovascular disease.
XX
PS      Claim 1; SEQ ID NO 261; 405pp; English.
XX
CC      The invention relates to a novel antisense compound targeted to a nucleic
CC      acid molecule encoding human apolipoprotein B (Apob) which specifically
CC      hybridises with and inhibits the expression of human apolipoprotein B.
CC      The compound of the invention demonstrates antiarteriosclerotic,
CC      cardiant, antidiabetic and anorectic activities and may be useful for
CC      preparing a composition for treating abnormal lipid or cholesterol
CC      metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC      cardiovascular disease. Furthermore, the compound has gene therapy
CC      applications. The current sequence is that of the 2'-O-methoxyethyl (2'-
CC      MOE) gapmer antisense oligo of the invention which has 2'-MOE 'wings', a
CC      phosphorothioate backbone throughout and in which all cytidine residues
CC      are 5-methylcytidines.
XX
XX      Sequence 20 BP; 6 A; 1 C; 4 G; 9 T; 0 U; 0 Other;

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      780 AAAATTCACACGCTGTAT 799
Db      ||||| ||||| ||||| ||||| |||||
        20 AAAATTCAAACTGCCTATAT 1

RESULT 142
ADH18846
ID      ADH18846 standard; DNA; 20 BP.
XX
AC      ADH18846;
XX
DT      11-MAR-2004 (first entry)
XX
DE      2'-MOE gapmer antisense oligo targeted to rabbit Apob DNA - SEQ ID 835.
XX
KW      apolipoprotein B; Apob; antiarteriosclerotic; cardiant; antidiabetic;
KW      anorectic; lipid; cholesterol metabolism; atherosclerosis;
KW      diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
KW      antisense; 2'-O-methoxyethyl gapmer; phosphorothioate backbone; 2'-MOE;
KW      human; ss.
XX
XX      Oryctolagus cuniculus.
XX
OS      OS
XX
PN      WO2003097662-A1.
XX
XX      27-NOV-2003.
XX
PD      15-MAY-2003; 2003WO-US015493.
XX
PF      15-MAY-2003; 2003WO-US015493.
XX

```

```

PR 15-MAY-2002; 2002US-00147196.
PR 13-NOV-2002; 2002US-0426324P.
XX (ISIS-) ISIS PHARM INC.
XX Crooke RM, Graham MJ;
PI WPI; 2004-022840/02.
XX New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT 2, obesity, hyperlipidaemia or cardiovascular disease.
XX Claim 1; SEQ ID NO 835; 405pp; English.
XX The invention relates to a novel antisense compound targeted to a nucleic
CC acid molecule encoding human apolipoprotein B (ApoB) which specifically
CC hybridises with and inhibits the expression of human apolipoprotein B.
CC The compound of the invention demonstrates antiarteriosclerotic,
CC cardiant, antidiabetic and anorectic activities and may be useful for
CC preparing a composition for treating abnormal lipid or cholesterol
CC metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC cardiovascular disease. Furthermore, the compound has gene therapy
CC applications. The current sequence is that of the 2'-O-methoxyethyl (2'-
CC MOE) gapmer antisense oligo of the invention which has 2'-MOE "wings", a
CC phosphorothioate backbone throughout and in which all cytidine residues
XX are 5-methylcytidines.
XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. NO. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 167 ATGCAAGATCGCATCTCTA 186
Db 1 ATGGAAGACTGCAGCTCTA 20
RESULT 143
ADH18638
ID ADH18638 standard; DNA; 20 BP.
XX ADH18638;
AC ADH18638;
XX 11-MAR-2004 (first entry)
DE Human apolipoprotein B antisense inhibition target DNA - SEQ ID 627.
XX apolipoprotein B; ApoB; antiarteriosclerotic; cardiant; antidiabetic;
XX anorectic; lipid; cholesterol metabolism; atherosclerosis;
XX diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
XX antisense inhibition target; human; ds.
XX Homo sapiens.
XX WO2003097662-A1.
XX 27-NOV-2003.
XX 15-MAY-2003; 2003WO-US015493.
XX 15-MAY-2002; 2002US-00147196.
XX 13-NOV-2002; 2002US-0426324P.
XX (ISIS-) ISIS PHARM INC.
XX Crooke RM, Graham MJ;
PI WPI; 2004-022840/02.
XX New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT 2, obesity, hyperlipidaemia or cardiovascular disease.
XX Claim 1; SEQ ID NO 835; 405pp; English.
XX The invention relates to a novel antisense compound targeted to a nucleic
CC acid molecule encoding human apolipoprotein B (ApoB) which specifically
CC hybridises with and inhibits the expression of human apolipoprotein B.
CC The compound of the invention demonstrates antiarteriosclerotic,
CC cardiant, antidiabetic and anorectic activities and may be useful for
CC preparing a composition for treating abnormal lipid or cholesterol
CC metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC cardiovascular disease. Furthermore, the compound has gene therapy
CC applications. The current sequence is that of the 2'-O-methoxyethyl (2'-
CC MOE) gapmer antisense oligo of the invention which has 2'-MOE "wings", a
CC phosphorothioate backbone throughout and in which all cytidine residues
XX are 5-methylcytidines.
XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. NO. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 167 ATGCAAGATCGCATCTCTA 186
Db 1 ATGGAAGACTGCAGCTCTA 20
RESULT 143
ADH18638
ID ADH18638 standard; DNA; 20 BP.
XX ADH18638;
AC ADH18638;
XX 11-MAR-2004 (first entry)
DE Human apolipoprotein B antisense inhibition target DNA - SEQ ID 627.
XX apolipoprotein B; ApoB; antiarteriosclerotic; cardiant; antidiabetic;
XX anorectic; lipid; cholesterol metabolism; atherosclerosis;
XX diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
XX antisense inhibition target; human; ds.
XX Homo sapiens.
XX WO2003097662-A1.
XX 27-NOV-2003.
XX 15-MAY-2003; 2003WO-US015493.
XX 15-MAY-2002; 2002US-00147196.
XX 13-NOV-2002; 2002US-0426324P.
XX (ISIS-) ISIS PHARM INC.
XX Crooke RM, Graham MJ;
PI WPI; 2004-022840/02.
XX New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT 2, obesity, hyperlipidaemia or cardiovascular disease.
XX Claim 1; SEQ ID NO 627; 405pp; English.
XX The invention relates to a novel antisense compound targeted to a nucleic
CC acid molecule encoding human apolipoprotein B (ApoB) which specifically
CC hybridises with and inhibits the expression of human apolipoprotein B.
CC The compound of the invention demonstrates antiarteriosclerotic,
CC cardiant, antidiabetic and anorectic activities and may be useful for
CC preparing a composition for treating abnormal lipid or cholesterol
CC metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC cardiovascular disease. Furthermore, the compound has gene therapy
CC applications. The current sequence is that of the human ApoB antisense
CC inhibition target DNA of the invention.
XX Sequence 20 BP; 9 A; 4 C; 1 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. NO. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 780 AAAATTCACACGCTGTAT 799
Db 1 AAAATTCACACGCTGTAT 20
RESULT 144
ADJ31845/C
ID ADJ31845 standard; DNA; 20 BP.
XX ADJ31845;
AC ADJ31845;
XX 22-APR-2004 (first entry)
DE Human splicing factor R/S-rich 10 antisense oligonucleotide ISIS #156237.
XX Splicing factor R/S-rich 10; hyperproliferative disorder; infection;
XX inflammation; tumour formation; therapy; human; antisense; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone: All cytidines are 5'-
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'- methoxyethyl (2'- MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'- methoxyethyl (2'- MOE) nucleotides"
XX US2003232977-A1.
XX 18-DEC-2003.
XX 17-JUN-2002; 2002US-00175499.
XX 17-JUN-2002; 2002US-00175499.
XX (ISIS-) ISIS PHARM INC.
XX Bennett CF, Dobie KW, Myers SJ;
PI WPI; 2004-081292/08.
XX New compound targeted to a nucleic acid molecule encoding splicing factor
PT R/S-rich 10, useful in treating hyperproliferative disorder or disease

```

PT involving cellular development and in preventing infection, inflammation
 PT or tumor formation.

XX Example 15; SEQ ID NO 39; 46pp; English.

XX The present invention is directed to antisense compounds which are
 CC targeted to nucleic acid encoding splicing factor R/S-rich 10 and which
 CC modulate the expression of splicing factor R/S-rich 10. The invention is
 CC useful for treating a disease or condition associated with splicing
 CC factor R/S-rich 10 such as hyperproliferative disorder and which involves
 CC cellular development and in preventing infection, inflammation and tumour
 CC formation. The present sequence is human splicing factor R/S-rich 10
 CC antisense oligonucleotide.

XX Sequence 20 BP; 6 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1411 ACACATGATGTCATGGAT 1430
 Db 20 ACACATACCTGTCATGGAT 1

RESULT 145
 ADK43211/c
 ID ADK43211 standard; DNA; 20 BP.

XX AC ADK43211;

DT 06-MAY-2004 (first entry)

XX Antisense 2'-MOE gapmer oligo targeted to human PTPRA - SEQ ID 35.

XX PTPRA; protein tyrosine phosphatase, receptor type alpha;
 KW LCA-related phosphatase; LRP; HLP; HPTPA; PTPRL2; RPTPA; cytosolic;
 KW hyperproliferative disorder; metabolic; antisense; ss; human;
 KW 2'-MOE wing; 2'-methoxyethyl gapmer; phosphorothioate backbone.

XX Homo sapiens.

XX Key Location/Qualifiers
 XX modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = Bases 1-5 and 16-20 comprise 2'-
 FT methoxyethyl (2'-MOE) wings. Phosphorothioate backbone
 FT throughout. All cytidines are 5-methylcytidines"

XX WO2004011623-A2.

XX 05-FEB-2004.

XX 31-JUL-2003; 2003WO-US023972.

XX 31-JUL-2002; 2002US-00210556.

XX (ISIS-) ISIS PHARM INC.

XX Cowser LM, Freier SM, Dobie KW;

XX WPI; 2004-143851/14.

XX New compounds, particularly antisense oligonucleotides targeted to a
 PT nucleic acid encoding protein tyrosine phosphatase receptor type alpha
 PT (PTPRA), useful for treating hyperproliferative or metabolic disorder.

XX Example 15; SEQ ID NO 35; 289pp; English.

XX The invention relates to a novel compound 8-80 nucleobases in length
 CC which is targeted to and specifically hybridises with a nucleic acid
 CC molecule encoding PTPRA (protein tyrosine phosphatase, receptor type

CC alpha, LCA-related phosphatase; LRP; HLP; HPTPA; PTPRL2; RPTPA) and
 CC inhibits the expression of PTPRA. The compound of the invention
 CC demonstrates cytostatic activities and may be useful for treating a
 CC disease or condition associated with PTPRA, such as a hyperproliferative
 CC disorder or metabolic disorder, as well as in research and diagnostics
 CC for modulating the expression of PTPRA. The current sequence is that of
 CC an antisense 2'-MOE (2'-methoxyethyl) gapmer oligonucleotide which was
 CC targeted to human PTPRA of the invention.

XX Sequence 20 BP; 6 A; 2 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 888 CCAGATCTGATTCCTCA 907
 Db 20 CCAGATCTGATTCATCA 1

RESULT 146
 ADK43334
 ID ADK43334 standard; DNA; 20 BP.

XX AC ADK43334;

DT 06-MAY-2004 (first entry)

XX Human PTPRA DNA targeted for antisense therapy - SEQ ID 158.

XX PTPRA; protein tyrosine phosphatase, receptor type alpha;
 KW LCA-related phosphatase; LRP; HLP; HPTPA; PTPRL2; RPTPA; cytosolic;
 KW hyperproliferative disorder; metabolic; antisense target; human; ds.

XX Homo sapiens.

XX WO2004011623-A2.

XX 05-FEB-2004.

XX 31-JUL-2003; 2003WO-US023972.

XX 31-JUL-2002; 2002US-00210556.

XX (ISIS-) ISIS PHARM INC.

XX Cowser LM, Freier SM, Dobie KW;

XX WPI; 2004-143851/14.

XX New compounds, particularly antisense oligonucleotides targeted to a
 PT nucleic acid encoding protein tyrosine phosphatase receptor type alpha
 PT (PTPRA), useful for treating hyperproliferative or metabolic disorder.

XX Example 16; SEQ ID NO 158; 289pp; English.

XX The invention relates to a novel compound 8-80 nucleobases in length
 CC which is targeted to and specifically hybridises with a nucleic acid
 CC molecule encoding PTPRA (protein tyrosine phosphatase, receptor type
 CC alpha, LCA-related phosphatase; LRP; HLP; HPTPA; PTPRL2; RPTPA) and
 CC inhibits the expression of PTPRA. The compound of the invention
 CC demonstrates cytostatic activities and may be useful for treating a
 CC disease or condition associated with PTPRA, such as a hyperproliferative
 CC disorder or metabolic disorder, as well as in research and diagnostics
 CC for modulating the expression of PTPRA. The current sequence is that of a
 CC human PTPRA DNA of the invention which was targeted for antisense
 CC therapy.

XX Sequence 20 BP; 7 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;


```

QY 888 CCAGATCTGATTCCTTCAA 907
DB 1 CCAGATCTGATTCATCAA 20

RESULT 147
ADJ24885
ID ADJ24885 standard; DNA; 20 BP.
XX
AC ADJ24885;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human endothelial lipase antisense oligonucleotide, SEQ ID 3283.
XX
KW Antilipemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
KW Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW cardiovascular disorder; metabolic syndrome X; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 4 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX
PN WO2004009541-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022410.
XX
PR 19-JUL-2002; 2002US-0397106P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Bhat BG;
XX
WPI; 2004-132912/13.
XX
PT New antisense oligonucleotide for modulating endothelial lipase
PT expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT high density lipoprotein or cardiovascular disorders.
XX
PS Claim 3; SEQ ID NO 3283; 1007pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADJ21603-
CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC with and inhibits the expression of EL. The antisense oligonucleotides
CC are useful for modulating the expression of endothelial lipase in cells
CC or tissues to treat diseases associated with EL expression, such as
CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX
SQ Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 319 TTGGACCCAGACTGAGTGGC 338
DB 1 TTGTACCAAGACTGAGGAGC 20

RESULT 149
ADK79679
ID ADK79679 standard; DNA; 20 BP.
XX
XX ADK79679;
XX
XX
```

DT 20-MAY-2004 (first entry)
 XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #7013.
 DE
 XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
 KW diabetic neuropathy; arthritic pain; migraine headache;
 KW infantile epilepsy; ataxia; ss.
 XX
 OS Synthetic.
 XX
 XX WO2004016754-A2.
 XX
 XX 26-FEB-2004.
 XX
 XX 14-AUG-2003; 2003WO-US025465.
 XX
 XX 14-AUG-2002; 2002US-0403416P.
 XX
 XX (PHAA) PHARMACIA CORP.
 XX
 XX Roberds SL;
 XX
 XX WPI; 2004-203785/19.
 DR
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT Nav1.3, useful for treating a disease or condition associated
 PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
 PT disorder, or ataxia.
 XX
 XX Claim 4; SEQ ID NO 7013; 417pp; English.
 XX
 CC The present invention relates to an antisense compound targeted to a
 CC nucleic acid molecule encoding Nav1.3, where the antisense compound
 CC specifically hybridizes with and inhibits the expression of Nav1.3. The
 CC compound and composition are useful for treating a disease or condition
 CC associated with Nav1.3, e.g. pain including but not limited to
 CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
 CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
 CC pain from burns, migraine headache, cluster headache, mild-to-moderate
 CC headache; seizure disorder such as childhood seizure disorder, including
 CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
 CC sequence represents a chimeric phosphorothioate oligonucleotide with
 CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
 CC human Nav1.3 expression, the oligonucleotides are designed to target
 CC different regions of the human Nav1.3 RNA.
 XX
 XX Sequence 20 BP; 12 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 XX
 Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 91 AAAAAAAAAATGAAATTCCTT 110
 |||||
 Db 1 AATAAAAAATGAAATTATT 20
 RESULT 150
 ADK75648
 ID ADK75648 standard; DNA; 20 BP.
 XX
 XX ADK75648;
 AC
 XX 20-MAY-2004 (first entry)
 DT
 XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #2982.
 DE
 XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
 KW diabetic neuropathy; arthritic pain; migraine headache;
 KW infantile epilepsy; ataxia; ss.
 XX
 OS Synthetic.

PN WO2004016754-A2.
 XX
 PD 26-FEB-2004.
 XX
 XX 14-AUG-2003; 2003WO-US025465.
 XX
 PR 14-AUG-2002; 2002US-0403416P.
 XX
 XX (PHAA) PHARMACIA CORP.
 XX
 XX Roberds SL;
 XX
 XX WPI; 2004-203785/19.
 DR
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT Nav1.3, useful for treating a disease or condition associated
 PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
 PT disorder, or ataxia.
 XX
 XX Claim 4; SEQ ID NO 2982; 417pp; English.
 XX
 CC The present invention relates to an antisense compound targeted to a
 CC nucleic acid molecule encoding Nav1.3, where the antisense compound
 CC specifically hybridizes with and inhibits the expression of Nav1.3. The
 CC compound and composition are useful for treating a disease or condition
 CC associated with Nav1.3, e.g. pain including but not limited to
 CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
 CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
 CC pain from burns, migraine headache, cluster headache, mild-to-moderate
 CC headache; seizure disorder such as childhood seizure disorder, including
 CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
 CC sequence represents a chimeric phosphorothioate oligonucleotide with
 CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
 CC human Nav1.3 expression, the oligonucleotides are designed to target
 CC different regions of the human Nav1.3 RNA.
 XX
 XX Sequence 20 BP; 13 A; 1 C; 2 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 86 ACTGGAAGAAAAAATGAAAT 105
 |||||
 Db 1 AATGCATAAAAAATGAAAT 20
 RESULT 151
 ADK75704
 ID ADK75704 standard; DNA; 20 BP.
 XX
 XX ADK75704;
 AC
 XX 20-MAY-2004 (first entry)
 DT
 XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #3038.
 DE
 XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
 KW diabetic neuropathy; arthritic pain; migraine headache;
 KW infantile epilepsy; ataxia; ss.
 XX
 OS Synthetic.
 XX
 XX WO2004016754-A2.
 PN
 XX 26-FEB-2004.
 PD
 XX 14-AUG-2003; 2003WO-US025465.
 PF
 XX 14-AUG-2002; 2002US-0403416P.
 PR
 XX (PHAA) PHARMACIA CORP.
 XX
 XX Roberds SL;
 XX
 XX WPI; 2004-203785/19.
 DR
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT Nav1.3, useful for treating a disease or condition associated
 PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
 PT disorder, or ataxia.
 XX
 XX Claim 4; SEQ ID NO 2982; 417pp; English.
 XX
 CC The present invention relates to an antisense compound targeted to a
 CC nucleic acid molecule encoding Nav1.3, where the antisense compound
 CC specifically hybridizes with and inhibits the expression of Nav1.3. The
 CC compound and composition are useful for treating a disease or condition
 CC associated with Nav1.3, e.g. pain including but not limited to
 CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
 CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
 CC pain from burns, migraine headache, cluster headache, mild-to-moderate
 CC headache; seizure disorder such as childhood seizure disorder, including
 CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
 CC sequence represents a chimeric phosphorothioate oligonucleotide with
 CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
 CC human Nav1.3 expression, the oligonucleotides are designed to target
 CC different regions of the human Nav1.3 RNA.
 XX
 XX Sequence 20 BP; 13 A; 1 C; 2 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 86 ACTGGAAGAAAAAATGAAAT 105
 |||||
 Db 1 AATGCATAAAAAATGAAAT 20

PI Roberds SL;
 XX WPI; 2004-203785/19.
 XX
 XX New antisense compound targeted to a nucleic acid molecule encoding
 PT Navi1.3, useful for treating a disease or condition associated
 PT with Navi1.3, e.g. pain, seizure disorder such as childhood seizure
 PT disorder, or ataxia.
 XX
 XX Claim 4; SEQ ID NO 3038; 417pp; English.
 PS
 XX
 XX The present invention relates to an antisense compound targeted to a
 CC nucleic acid molecule encoding Navi1.3, where the antisense compound
 CC specifically hybridizes with and inhibits the expression of Navi1.3. The
 CC compound and composition are useful for treating a disease or condition
 CC associated with Navi1.3, e.g. pain including but not limited to
 CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
 CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
 CC pain from burns, migraine headache, cluster headache, mild-to-moderate
 CC headache; seizure disorder such as childhood seizure disorder, including
 CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
 CC sequence represents a chimeric phosphorothioate oligonucleotide with
 CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
 CC human Navi1.3 expression, the oligonucleotides are designed to target
 CC different regions of the human Navi1.3 RNA.
 XX
 SQ Sequence 20 BP; 14 A; 1 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 85 AACTGCAATATAAATGAAA 104
 |||||
 DB 1 AAATGCAATATAAATGAAA 20
 |||||
 RESULT 152
 ADM70098/c
 ID ADM70098 standard; DNA; 20 BP.
 XX
 AC ADM70098;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 XX Plant gene polymorphism marker related primer, SEQ ID 977.
 DE
 XX
 KW Primer; variation mapping; mutation mapping; plant;
 KW gene polymorphism marker; ss.
 XX
 OS Synthetic.
 XX
 XX JP2003289885-A.
 XX
 XX 14-OCT-2003.
 XX
 XX 31-JAN-2003; 2003JP-00024620.
 XX
 XX 01-FEB-2002; 2002JP-00025338.
 XX
 XX (RIKA) RIKAGAKU KENKYUSHO.
 PA (SAIM-) SAI MEDIA KK.
 PA (MATSU) MATSUI M.
 PA (NAKA) NAKAZAWA M.
 XX
 XX WPI; 2004-126231/13.
 DR
 XX
 XX A primer set and method useful for mapping at least the
 PT variation/mutation part of a plant gene using a gene polymorphism marker.
 PT
 XX
 XX Claim 7; SEQ ID NO 977; 120pp; Japanese.
 PS
 XX
 XX The present invention relates to a primer set and method for mapping at

CC least the variation/mutation part of a plant gene using a gene
 CC polymorphism marker. A mutation site of the plant gene is mapped by
 CC utilizing a genetic polymorphism marker as follows: (a) genomic DNA is
 CC prepared from a plant homozygously having a mutation to be an object of
 CC the mapping; (b) A forward primer 1 containing a base corresponding to
 CC the gene polymorphic maker of one ecotype plant, a forward primer 2
 CC containing a base corresponding to the genetic polymorphism of the other
 CC ecotype plant and a reverse primer 3 based on the base sequence common
 CC with both the ecotype plants are prepared; (c) two kinds of
 CC oligonucleotides emitting fluorescence of different colors when the
 CC genetic polymorphism marker is detected are prepared; (d) an
 CC amplification reaction of the genomic DNA is carried out in the presence
 CC of the primers 1, 2 and 3 and the two kinds of the oligonucleotides; (e)
 CC the fluorescence intensity emitted from the resultant reaction product
 CC is detected and (f) the position on the genome of the mutation site is
 CC determined from the results of detection. The present sequence is a
 CC primer, used to illustrate the invention.
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 784 TTCCAACAGCCTGTATTACG 803
 |||||
 DB 20 TTGGAACAGCCTGTATTATG 1
 |||||
 RESULT 153
 ADL91774
 ID ADL91774 standard; DNA; 20 BP.
 XX
 AC ADL91774;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 XX Sequencing primer SEQ ID NO:175 for sequencing FZD10 constructs.
 DE
 XX
 KW Synovial sarcoma; SYX; sarcoma-associated gene; drug screening;
 KW Frizzled homologue 10; FZD10-associated disease; colorectal cancer;
 KW gastric cancer; chronic myeloid leukaemia; acute myeloid leukaemia;
 KW FZD10 antibody; diagnosis; prognosis; prevention; cytostatic;
 KW gene therapy; sequencing; primer; ss.
 XX
 OS Unidentified.
 XX
 XX WO2004020668-A2.
 XX
 XX 11-MAR-2004.
 XX
 XX 21-AUG-2003; 2003WO-JP010591.
 XX
 XX 30-AUG-2002; 2002US-0407506P.
 XX
 XX 11-JUL-2003; 2003US-0486195P.
 XX
 XX (ONCO-) ONCOTHERAPY SCI INC.
 XX (UYTY) UNIV TOKYO.
 XX
 XX Nakamura Y, Katagiri T;
 XX WPI; 2004-239208/22.
 XX
 XX Use of a compound or composition for diagnosing, treating or preventing
 PT synovial sarcoma or a disease associated with Frizzled homologue 10, e.g.
 PT colorectal cancer, gastric cancer, chronic myeloid leukemia or acute
 -PT myeloid leukemia.
 XX
 XX Example 8; SEQ ID NO 175; 143pp; English.
 PS
 XX
 XX The invention relates to the use of a compound or composition for
 CC diagnosing, prognosing, treating or preventing synovial sarcoma or a
 CC Frizzled homologue 10 (FZD10)-associated disease in a patient. The

CC invention encompasses the use of sarcoma-associated genes designated SYX
 CC 1-26 or their encoded proteins in diagnosing of synovial sarcoma and in
 CC screening for compounds for treating or preventing this condition; and
 CC the use of antibodies specific for FZD10 (FZD10 is also referred to as
 CC SYX 1 in the specification) for diagnosing, treating or preventing FZD10-
 CC associated diseases. The compound, composition and methods of the
 CC invention are useful for diagnosing, treating or preventing synovial
 CC sarcoma or FZD10-associated diseases, such as colorectal cancer, gastric
 CC cancer, chronic myeloid leukaemia or acute myeloid leukaemia. The present
 CC sequence represents a primer used in sequencing FZD10 constructs in an
 CC example of the invention.

SQ Sequence 20 BP; 2 A; 10 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 720 GCTCTCTTCTCCATCTACAG 739

Db 1 GTCCCTTCTCCATCTCCAG 20

RESULT 154

ADM41705/C
 ID ADM41705 standard; DNA; 20 BP.

XX AC ADM41705;

XX DT 17-JUN-2004 (first entry)

XX DE Cephalosporin C biosynthetic protein cefD1 and cefD2 gene PCR primer.

XX KW Cephalosporin C; antibiotic; cefD1; cefD2; PCR; primer; ss.

XX OS Acromonium chrysogenum.

XX PN W02004026902-A1.

XX PD 01-APR-2004.

XX PF 16-SEP-2003; 2003WO-EP010289.

XX PR 17-SEP-2002; 2002AT-00001397.

XX PA (SANO) SANDOZ GMBH.

XX PI Kuernsteiner H, Friedlin E;

XX DR WPI; 2004-295383/27.

XX PT Novel Acromonium chrysogenum protein useful in synthetic or semi-
 PT synthetic production of cephalosporin C or its derivatives with
 PT antibiotic properties.

XX PS Example 7; SEQ ID NO 21; 43pp; English.

XX CC The present sequence is that of primer PCR7r. This was used, with primer
 CC PCR7f ADM41704, in an example from the invention to confirm
 CC transformation of Acromonium chrysogenum strain CEF-67605 with a plasmid
 CC carrying the A. chrysogenum cefD1 and cefD2 genes ADM41690. The primers
 CC amplify a 9001 bp DNA fragment. It is an object of the present invention
 CC to provide a nucleic acid ADM41686-ADM41688 and vectors which code for a
 CC new protein ADM41685 of A. chrysogenum, and which can be used for
 CC transformation of an A. chrysogenum host cell such that the host cell is
 CC capable of producing cephalosporin C in good yield. The vector may
 CC additionally include the cefD1 and cefD2 genes.

SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 381 CTGCACCAAGATGGGCTGGA 400
 Db 20 CTGGAGCAAGGTGAGCTGGA 1

RESULT 155

ADM15799/C

ID ADM15799 standard; DNA; 20 BP.

XX AC ADM15799;

XX DT 15-JUL-2004 (first entry)

XX DE Murine SAC1 DNA PCR primer #64.

XX KW Mouse; SAC1; PCR; ss; carbohydrate; sweetener; ethanol; obesity;
 KW diabetes; alcoholism; antidiabetic; alcohol; anorectic; antialcoholic;
 KW primer.

XX OS Mus musculus.

XX PN US2004081964-A1.

XX PD 29-APR-2004.

XX PF 25-OCT-2002; 2002US-00280183.

XX PR 25-OCT-2002; 2002US-00280183.

XX PA (BACH/) BACHMANOV A A.

XX PA (BEAU/) BEAUCHAMP G K.

XX PA (LISS/) LI S.

XX PA (LIXX/) LI X.

XX PA (REED/) REED D R.

XX PA (TORD/) TORDOFF M G.

XX PA (ROSS/) ROSS D A.

XX PA (OHMA/) OHMAN J D.

XX PA (CHAI/) CHATTERJEE A.

XX PA (DJON/) DE JONG P J.

XX PI Bachmanov AA, Beauchamp GK, Li S, Li X, Reed DR, Tordoff MG;

XX PI Ross DA, Ohman JD, Chatterjee A, De Jong PJ;

XX XX WPI; 2004-340133/31.

XX PT New isolated polynucleotides for sensing carbohydrates, other sweeteners,
 PT or ethanol, useful for screening drugs for inhibition or restoration of
 PT gene function as antidiabetic, antioesity or antialcohol consumption
 PT therapies.

XX PS Example 12; SEQ ID NO 69; 148pp; English.

XX CC The invention relates to SAC1 polypeptides and the polynucleotides
 CC encoding them. The polynucleotides contain a variation associated with
 CC sensing carbohydrates, other sweeteners or ethanol. The invention also
 CC relates to a method for analysing a biomolecule in a biological sample,
 CC comprising altering SAC1 activity in the sample and measuring the
 CC activity, a method for analysing a polynucleotide in a biological sample,
 CC comprising contacting a polynucleotide in a biological sample with a
 CC probe where the probe hybridises to a SAC1 polynucleotide to form a
 CC hybridisation complex and detecting the hybridisation complex, a method
 CC of identifying susceptibility to obesity or diabetes comprising comparing
 CC the nucleotide sequence of the suspected SAC1 allele with a wild type
 CC nucleotide sequence, where the difference between the suspected allele
 CC and the wild-type sequence identifies a sequence variation of the SAC1
 CC nucleotide sequence, and a method of treating or preventing obesity,
 CC diabetes or alcoholism associated with expression of SAC1, comprising
 CC administering to a subject a pharmaceutical composition and a transgenic
 CC animal that carries an altered SAC1 allele. The methods and compositions
 CC of the invention are useful for screening drugs for inhibition or
 CC restoration of gene function as antidiabetic, antioesity or antialcohol
 CC consumption therapies and for identifying sweeteners and alcohols. This

CC sequence represents a PCR primer used to amplify murine SAC1 DNA of the
 CC invention.

SQ Sequence 20 BP; 8 A; 8 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 685 AGGTGGGGCTTTGGCATCT 704

Db 20 AGGTGAGGGTTTGGCTTCT 1

RESULT 156

ADO01532/c

ID ADO01532 standard; DNA; 20 BP.

XX ADO01532;

DT 29-JUL-2004 (first entry)

DE Human IGFBP-1 reverse transcription PCR primer.

KW liver regeneration; quinazolinone derivative; hepatotropic;
 KW antiinflammatory; insulin like growth factor binding protein;
 KW IGFBP-1 gene expression modulator; IGFBP-3 gene expression modulator;
 KW liver fibrosis; cirrhotic liver; partial hepatectomy;
 KW signal transduction pathway; hepatocyte growth factor;
 KW reverse transcription; PCR; RT-PCR; primer; human; IGFBP-1; ss.

OS Homo sapiens.

OS Synthetic.

XX WO2004039308-A2.

XX 13-MAY-2004.

PF 30-OCT-2003; 2003WO-IL000900.

PR 31-OCT-2002; 2002US-0422487P.

XX (ISRA) ISRAEL MIN AGRIC.

PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.

XX (COLL-) COLLAGARD BIOPHARMACEUTICALS LTD.

PI Pines M, Nagler A, Yarkoni S;

DR WPI; 2004-390189/36.

PT Use of a composition comprising quinazolinone derivatives for the
 improvement of liver regeneration e.g. cirrhosis.

XX Example; Page 27; 49pp; English.

CC The present invention describes a method for the improvement of liver
 regeneration. The method comprises administration of a composition (I)
 comprising quinazolinone derivatives (A) and their salts. (I) has
 CC hepatotropic and antiinflammatory activities, and can be used in insulin
 CC like growth factor binding protein 1 (IGFBP-1) gene expression modulators
 CC and IGFBP-3 gene expression modulators. (I) is useful for treating or
 CC preventing pathological processes, related to toxin (particularly
 CC thioacetamide (TAA)) induced alterations in gene expression and
 CC alterations in gene expression of at least one of IGFBP-1, IGFBP-3,
 CC protein related lamda-1 (PRL-1) protein tyrosine phosphatase 411
 CC (PTP411), apolipoprotein A IV precursor, phosphatidylinositol 3-kinase
 CC p85-alpha subunit, mitogen activated protein kinase p38, Proteasome
 CC component C8, epidermal fatty acid-binding protein, peripheral myelin
 CC protein (PMP) (PMP-22/SR13), proliferation cell nuclear antigen,
 CC Proteasome activator RPA28 subunit alpha, c-K-ras 2b proto-oncogene,
 CC alcohol sulfoltransferase (ST2) A (ST2A2) (Probable alcohol
 CC sulfoltransferase), tissue inhibitor of metalloproteinase (MMP) 2 (TIMP-2)
 CC metalloproteinase inhibitor 2 (Precursor), MMP-3 or MMP-13 (preferably

CC IGFBP-1 or IGFBP-3)) during fibrotic processes (particularly liver
 CC fibrosis). (I) is also useful for improving the capacity of a cirrhotic
 CC liver to regenerate following partial hepatectomy, by inducing gene
 CC expression (of at least one gene of IGFBP-1, PRL-1, MMP-3 or MMP-13) or
 CC by affecting the molecules in the signal transduction pathway of
 CC hepatocyte growth factor. (I) is also useful for increasing the amount of
 CC biologically active IGF-1. The present sequence represents a reverse
 CC transcription PCR (RT-PCR) primer for human IGFBP-1, which is used in an
 CC example from the present invention.

SQ Sequence 20 BP; 7 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 219 GCCAGCTGTGGAGATGTTC 238

Db 20 GCTACCTGTGGTGTGATGTC 1

RESULT 157

ADP79070

ID ADP79070 standard; DNA; 20 BP.

XX ADP79070;

DT 12-AUG-2004 (first entry)

DE Chimeric phosphorothioate oligonucleotide #2869.

XX GFAT; Antidiabetic; Cardiant;

KW Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
 KW reperfusion; ss.

OS Synthetic.

Key modified_base 1. .4 Location/Qualifiers
 FT /tag= a
 FT /mod_base= other
 FT /note= "2-methoxyethyl wing"

FT modified_base 17. .20

FT /tag= b

FT /mod_base= other

FT /note= "2-methoxyethyl wing"

XX WO2004035763-A2.

XX 29-APR-2004.

XX 02-OCT-2003; 2003WO-US033332.

XX 17-OCT-2002; 2002US-0419268P.

XX (PHAA) PHARMACIA CORP.

XX Broschat KO, Crosby SD;

XX WPI; 2004-348453/32.

XX New compounds, particularly antisense oligonucleotides targeted to a
 CC nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
 CC (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,
 CC ischemia/reperfusion injury.

XX Claim 4; SEQ ID NO 2869; 175pp; English.

XX The present invention relates to a compound which specifically hybridizes
 CC with a nucleic acid molecule encoding GFAT, and inhibits the expression
 CC of GFAT. Specifically claimed are antisense oligonucleotides capable of
 CC modulating the expression of GFAT, and which comprise any of the 3063
 CC sequences of 20 base pairs, given in the specification. The compound,

QY 37 GTGCGCGCGTCAGAGCCGC 56
|||
Db 1 GTGCGCGCGCATCAAGCCGC 20

RESULT 160

ADN30177/c
ID ADN30177 standard; DNA; 20 BP.

XX AC ADN30177;

XX DT 12-AUG-2004 (first entry)

XX DE Hepatocyte growth factor receptor antisense oligonucleotide #9.

XX KW cytosatic; hepatocyte growth factor receptor;
XX KW hyperproliferative disorder; antisense technology; human;
XX KW antisense oligonucleotide; ss.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

XX FT modified_base 1..20

XX FT /*tag= b

XX FT /mod_base= OTHER

XX FT /note= "OTHER= Phosphorothioate backbone. All cytidines
XX FT are 5-methylcytidines"

XX FT modified_base 1..5

XX FT /*tag= a

XX FT /mod_base= OTHER

XX FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX FT modified_base 15..20

XX FT /*tag= c

XX FT /mod_base= OTHER

XX FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX PN US2004102622-A1.

XX PD 27-MAY-2004.

XX PF 23-NOV-2002; 2002US-00304019.

XX PP 23-NOV-2002; 2002US-00304019.

XX PR (ISIS-) ISIS PHARM INC.

XX PA Dean NM, Bennett CF, Dobie KW;

XX PI WPI; 2004-399741/37.

XX DR New compound targeted to a nucleic acid molecule encoding hepatocyte

XX PT growth factor receptor, useful in diagnosing and treating

XX FT hyperproliferative disorder.

XX PS Example 15; SEQ ID NO 23; 116pp; English.

XX CC The invention describes a new compound 8-80 nucleobases in length
XX CC targeted to a nucleic acid molecule encoding hepatocyte growth factor
XX CC receptor, where the compound specifically hybridises with the nucleic
XX CC acid molecule encoding hepatocyte growth factor receptor comprising a
XX CC sequence of 4586 bp (SEQ ID NO: 4) and inhibits the expression of
XX CC hepatocyte growth factor receptor. Also described are: a method of
XX CC inhibiting the expression of hepatocyte growth factor receptor in cells
XX CC or tissues; screening for a modulator of hepatocyte growth factor
XX CC receptor; a diagnostic method for identifying a disease state; a kit or
XX CC assay device comprising the compound; and treating an animal having a
XX CC disease or condition associated with hepatocyte growth factor receptor.
XX CC The compound and methods are useful in diagnosing and treating
XX CC hyperproliferative disorder. This sequence represents a human hepatocyte
XX CC growth factor receptor antisense oligonucleotide.

SQ Sequence 20 BP; 9 A; 1 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No: 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1664 TACTTCCAAATCTCTGAT 1693

Db 20 TCCTTCCAAATCTTTGAT 1

RESULT 161

ADN30248

ID ADN30248 standard; DNA; 20 BP.

XX AC ADN30248;

XX DT 12-AUG-2004 (first entry)

XX DE Hepatocyte growth factor receptor antisense oligonucleotide #80.

XX KW cytosatic; hepatocyte growth factor receptor;
XX KW hyperproliferative disorder; antisense technology; human;
XX KW antisense oligonucleotide; ss.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

XX FT modified_base 1..20

XX FT /*tag= b

XX FT /mod_base= OTHER

XX FT /note= "OTHER= Phosphorothioate backbone. All cytidines
XX FT are 5-methylcytidines"

XX FT modified_base 1..5

XX FT /*tag= a

XX FT /mod_base= OTHER

XX FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX FT modified_base 15..20

XX FT /*tag= c

XX FT /mod_base= OTHER

XX FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX PN US2004102622-A1.

XX PD 27-MAY-2004.

XX PF 23-NOV-2002; 2002US-00304019.

XX PP 23-NOV-2002; 2002US-00304019.

XX PR (ISIS-) ISIS PHARM INC.

XX PA Dean NM, Bennett CF, Dobie KW;

XX PI WPI; 2004-399741/37.

XX PT New compound targeted to a nucleic acid molecule encoding hepatocyte
XX PT growth factor receptor, useful in diagnosing and treating

XX FT hyperproliferative disorder.

XX PS Example 15; SEQ ID NO 94; 116pp; English.

XX CC The invention describes a new compound 8-80 nucleobases in length
XX CC targeted to a nucleic acid molecule encoding hepatocyte growth factor
XX CC receptor, where the compound specifically hybridises with the nucleic
XX CC acid molecule encoding hepatocyte growth factor receptor comprising a
XX CC sequence of 4586 bp (SEQ ID NO: 4) and inhibits the expression of
XX CC hepatocyte growth factor receptor. Also described are: a method of
XX CC inhibiting the expression of hepatocyte growth factor receptor in cells
XX CC or tissues; screening for a modulator of hepatocyte growth factor
XX CC receptor; a diagnostic method for identifying a disease state; a kit or
XX CC assay device comprising the compound; and treating an animal having a
XX CC disease or condition associated with hepatocyte growth factor receptor.
XX CC The compound and methods are useful in diagnosing and treating

CC lipid or cholesterol metabolism. The compound may be useful for
 CC decreasing circulating lipoprotein levels, triglyceride levels,
 CC cholesterol levels, lipid levels, fatty acid levels, acute phase
 CC reactants and chylomicrons and thus may be utilised during treatment of
 CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
 CC cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's
 CC syndrome, sexual ateliotic dwarfism, hepatoma, multiple myeloma, uraemia,
 CC anorexia nervosa, Werner's syndrome, hyperthyroidism, hypertension,
 CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
 CC diabetes, obesity and atherosclerosis. The current sequence is that of a
 CC human apolipoprotein B (ApoB) antisense therapy target DNA of the
 CC invention. The human ApoB gene is located at chromosome 2p23-2p24.
 XX
 XX Sequence 20 BP; 9 A; 4 C; 1 G; 6 T; 0 U; 0 Other;
 Qy Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Db 780 AAAATTCCACAGCTGTAT 799
 1 AAAATTCAAAGCTGCTATAT 20
 RESULT 164
 ADO33387
 ID ADO33387 standard; DNA; 20 BP.
 AC ADO33387;
 XX ADO33387;
 XX
 XX 12-AUG-2004 (first entry)
 DE Antisense 2'-MOE gapmer oligo targeted to rabbit ApoB - SEQ 835.
 XX
 KW apolipoprotein B; ApoB; cardiovascular; antiarteriosclerotic;
 KW antilipaeamic; antidiabetic; anorectic; cardiac; vasotropic; hypotensive;
 KW anabolic; eating disorder; cytostatic; endocrine; vasotropic;
 KW neuroprotective; nontropic; lipid; cholesterol metabolism;
 KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
 KW Von Gierke's disease; lipodystrophy; Cushing's syndrome;
 KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;
 KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
 KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
 KW obesity; atherosclerosis; antisense; 2'-MOE gapmer; 2'-methoxyethyl wing;
 KW phosphorothioate backbone; rabbit; ss.
 XX
 OS Oryctolagus cuniculus.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = Phosphorothioate backbone, bases 1-5 and
 FT 16-20, 2'-MOE wing bases, all cytidine residues are 5-
 FT methylcytidines"
 XX
 XX WO2004044181-A2.
 XX 27-MAY-2004.
 XX
 XX 13-NOV-2003; 2003WO-US036411.
 XX
 XX 13-NOV-2002; 2002US-0426234P.
 XX 15-MAY-2003; 2003WO-US015493.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Crooke R, Graham M, Lemonidis-Tarbet K, Dobie KW;
 XX WPI; 2004-420321/39.
 XX
 XX Antisense oligonucleotide compound that inhibits expression of mRNA
 XX encoding human apolipoprotein B, useful for treating hyperlipidemia,
 FT

PT diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
 XX syndrome.
 PS Example 42; SEQ ID NO 835; 483pp; English.
 XX
 CC The invention relates to a novel antisense compound where the compound
 CC hybridises to and inhibits expression of mRNA encoding human
 CC apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%
 CC confluent HepG2 cells in culture at a concentration of 150 nM. The
 CC compound of the invention demonstrates cardiovascular,
 CC antiarteriosclerotic, antilipaeamic, antidiabetic, anorectic, cardiac,
 CC endocrine, hypotensive, anabolic, eating disorder-related, cytostatic,
 CC anorectic, vasotropic, neuroprotective and nontropic activities and may
 CC be useful for inhibiting the expression of apolipoprotein B in cells or
 CC tissues in vivo in order to address a condition associated with abnormal
 CC lipid or cholesterol metabolism. The compound may be useful for
 CC decreasing circulating lipoprotein levels, triglyceride levels,
 CC cholesterol levels, lipid levels, fatty acid levels, acute phase
 CC reactants and chylomicrons and thus may be utilised during treatment of
 CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
 CC cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's
 CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
 CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
 CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
 CC diabetes, obesity and atherosclerosis. The current sequence is that of an
 CC antisense 2'-MOE (2'-methoxyethyl) gapmer oligo of the invention which is
 CC targeted to rabbit ApoB.
 XX
 XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 Qy Query Match 0.8%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Db 167 ATGCACGAATGGCATCTCTA 186
 1 ATGCAGAGACTGGCAGCTCTA 20
 RESULT 165
 ADO33432/C
 ID ADO33432 standard; RNA; 20 BP.
 XX ADO33432;
 AC ADO33432;
 XX
 XX 12-AUG-2004 (first entry)
 DE Phosphodiester double-stranded RNA targeted to human ApoB - SEQ ID 880.
 XX
 KW apolipoprotein B; ApoB; cardiovascular; antiarteriosclerotic;
 KW antilipaeamic; antidiabetic; anorectic; cardiac; vasotropic; hypotensive;
 KW anabolic; eating disorder; cytostatic; endocrine; vasotropic;
 KW neuroprotective; nontropic; lipid; cholesterol metabolism;
 KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
 KW Von Gierke's disease; lipodystrophy; Cushing's syndrome;
 KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;
 KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
 KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
 KW obesity; atherosclerosis; human; chromosome 2p23-2p24; ds;
 KW phosphodiester backbone.
 XX
 XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = Phosphodiester backbone"
 XX
 XX WO2004044181-A2.
 XX 27-MAY-2004.
 XX

```

PF 13-NOV-2003; 2003WO-US036411.
XX
XX
PR 13-NOV-2002; 2002US-0426234P.
PR 15-MAY-2003; 2003WO-US015493.
XX
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX
PI Crooke R, Graham M, Lemonidis-Tarbet K, Dobie KW;
XX
XX WPI; 2004-420321/39.
XX
XX
PT Antisense oligonucleotide compound that inhibits expression of mRNA
PT encoding human apolipoprotein B, useful for treating hyperlipidemia,
PT diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
PT syndrome.
XX
XX
PS Example 60; SEQ ID NO 880; 483pp; English.
XX
XX
PS The invention relates to a novel antisense compound where the compound
CC hybridises to and inhibits expression of mRNA encoding human
CC apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%
CC confluent HepG2 cells in culture at a concentration of 150 nM. The
CC compound of the invention demonstrates cardiovascular,
CC antiarteriosclerotic, antilipemic, antidiabetic, anorectic, cardiact,
CC endocrine, vasotropic, neuroprotective and nootropic activities and may
CC be useful for inhibiting the expression of apolipoprotein B in cells or
CC tissues in vivo in order to address a condition associated with abnormal
CC lipid or cholesterol metabolism. The compound may be useful for
CC decreasing circulating lipoprotein levels, triglyceride levels,
CC cholesterol levels, lipid levels, fatty acid levels, acute phase
CC reactants and chylomicrons and thus may be utilised during treatment of
CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
CC cardiovascular disorders, von Gierke's disease, lipodystrophy, Cushing's
CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
CC diabetes, obesity and atherosclerosis. The current sequence is that of a
CC phosphodiester double-stranded RNA of the invention which is targeted to
CC human ApoB RNA.
XX
XX
SQ Sequence 20 BP; 3 A; 6 C; 5 G; 0 T; 6 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 941 AGAACAGGTTGTACTGGTCA 960
DB 20 AGAACAGGCGAGTCTGGTCA 1
RESULT 166
AD032813/C
ID AD032813 standard; DNA; 20 BP.
XX
XX
AC AD032813;
XX
XX
DT 12-AUG-2004 (first entry)
XX
XX
DE Antisense 2'-MOE gapmer oligo targeted to human ApoB RNA - SEQ 261.
XX
XX
KW apolipoprotein B; ApoB; cardiovascular; antiarteriosclerotic;
KW antilipemic; antidiabetic; anorectic; cardiact; vasotropic; hypotensive;
KW anabolic; eating disorder; cytostatic; endocrine; vasotropic;
KW neuroprotective; nootropic; lipid; cholesterol metabolism;
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW von Gierke's disease; lipodystrophy; Cushing's syndrome;
KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;
KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
KW obesity; atherosclerosis; antisense; 2'-MOE gapmer; 2'-methoxyethyl wing;
KW phosphorothioate backbone; human; chromosome 2p23-2p24; ss.

```

```

XX OS Homo sapiens.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER = Phosphorothioate backbone, bases 1-5 and
FT 16-20 2'-MOE wing bases, all cytidine residues are 5-
FT methylcytidines"
XX
XX
PN WO2004044181-A2.
XX
XX
PD 27-MAY-2004.
XX
XX
PF 13-NOV-2003; 2003WO-US036411.
XX
XX
PR 13-NOV-2002; 2002US-0426234P.
PR 15-MAY-2003; 2003WO-US015493.
XX
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX
PI Crooke R, Graham M, Lemonidis-Tarbet K, Dobie KW;
XX
XX WPI; 2004-420321/39.
XX
XX
PT Antisense oligonucleotide compound that inhibits expression of mRNA
PT encoding human apolipoprotein B, useful for treating hyperlipidemia,
PT diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
PT syndrome.
XX
XX
PS Example 29; SEQ ID NO 261; 483pp; English.
XX
XX
PS The invention relates to a novel antisense compound where the compound
CC hybridises to and inhibits expression of mRNA encoding human
CC apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%
CC confluent HepG2 cells in culture at a concentration of 150 nM. The
CC compound of the invention demonstrates cardiovascular,
CC antiarteriosclerotic, antilipemic, antidiabetic, anorectic, cardiact,
CC vasotropic, hypotensive, anabolic, eating disorder-related, cytostatic,
CC endocrine, vasotropic, neuroprotective and nootropic activities and may
CC be useful for inhibiting the expression of apolipoprotein B in cells or
CC tissues in vivo in order to address a condition associated with abnormal
CC lipid or cholesterol metabolism. The compound may be useful for
CC decreasing circulating lipoprotein levels, triglyceride levels,
CC cholesterol levels, lipid levels, fatty acid levels, acute phase
CC reactants and chylomicrons and thus may be utilised during treatment of
CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
CC cardiovascular disorders, von Gierke's disease, lipodystrophy, Cushing's
CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
CC diabetes, obesity and atherosclerosis. The current sequence is that of an
CC antisense 2'-MOE (2'-methoxyethyl) gapmer oligo of the invention which is
CC targeted to human ApoB RNA.
XX
XX
SQ Sequence 20 BP; 6 A; 1 C; 4 G; 9 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 780 AAAATTCACAGCGCTGTAT 799
DB 20 AAAATTCACAGCGCTGTAT 1
RESULT 167
ADP68918/C
ID ADP68918 standard; DNA; 20 BP.
XX
XX
AC ADP68918;
XX

```

```
DT 09-SEP-2004 (first entry)
DE Human DRAX2 antisense oligonucleotide ISIS224163.
XX
XX Human; ss; antisense; DRAX2;
KW death-associated protein kinase-rel. apoptosis-inducing protein kinase;
KW serine/threonine kinase 17B; STK17B; apoptosis; degenerative disorder;
KW neurological disorder; Alzheimer's disease; Parkinson's disease;
KW Amyotrophic lateral sclerosis; ALS; retinitis pigmentosa;
KW blood cell disorder; cancer; autoimmune disorder; viral infection;
KW gene therapy; hyperproliferative disorder; chromosome 2.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone and all cytidines are 5
FT -methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residue"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residue"
XX
XX US2004115645-A1.
XX
XX 17-JUN-2004.
XX
XX 12-DEC-2002; 2002US-00318819.
XX
XX 12-DEC-2002; 2002US-00318819.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Dobie KW;
XX WPI; 2004-449384/42.
XX
XX New oligonucleotide compound that inhibits expression of DRAX2, useful
XX for preparing a composition for treating hyperproliferative disorder,
XX e.g., cancer.
XX
XX Example 15; SEQ ID NO 64; 87pp; English.
XX
XX The invention relates to a new compound (e.g. an antisense
XX oligonucleotide), having a sequence comprising 8-80 bp targeted to a
XX nucleic acid encoding DRAX2 (death-associated protein kinase-related
XX apoptosis-inducing protein kinase 2, also known as serine/threonine
XX kinase 17B, STK17B), specifically hybridizes with the nucleic acid
XX encoding DRAX2 (appearing as ADP68859 and representing bases 58695-149492
XX of human chromosome 2) and inhibits expression of DRAX2. Also included
XX are inhibiting the expression of DRAX2 in cells or tissues, screening for
XX a modulator of DRAX2, a diagnostic method for identifying a disease
XX state, a kit or assay device comprising the compound and treating an
XX animal having a disease or condition associated with DRAX2. The
XX oligonucleotide compound is useful for preparing a composition for
XX treating hyperproliferative disorders, degenerative disorders,
XX neurological disorders, Alzheimer's disease, Parkinson's disease,
XX Amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, blood cell
XX disorders, cancer, autoimmune disorders and viral infection. The present
XX sequence represents an antisense oligonucleotide targeting DRAX2.
XX
XX Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 1.2e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 501 CTTGGCAGCAGCATTTGGAC 520
Db ||||| ||||| |||||
20 CTTGGCTACAGCAGTGGAC 1

RESULT 168
ADP68974
ID ADP68974 standard; DNA; 20 BP.
AC ADP68974;
XX
XX 09-SEP-2004 (first entry)
XX
XX Human DRAX2 antisense target region #36.
XX
XX Human; ds; antisense; DRAX2;
KW death-associated protein kinase-rel. apoptosis-inducing protein kinase;
KW serine/threonine kinase 17B; STK17B; apoptosis; degenerative disorder;
KW neurological disorder; Alzheimer's disease; Parkinson's disease;
KW Amyotrophic lateral sclerosis; ALS; retinitis pigmentosa;
KW blood cell disorder; cancer; autoimmune disorder; viral infection;
KW gene therapy; hyperproliferative disorder; chromosome 2.
XX
XX Homo sapiens.
XX
XX US2004115645-A1.
XX
XX 17-JUN-2004.
XX
XX 12-DEC-2002; 2002US-00318819.
XX
XX 12-DEC-2002; 2002US-00318819.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Dobie KW;
XX WPI; 2004-449384/42.
XX
XX New oligonucleotide compound that inhibits expression of DRAX2, useful
XX for preparing a composition for treating hyperproliferative disorder,
XX e.g., cancer.
XX
XX Example 15; SEQ ID NO 120; 87pp; English.
XX
XX The invention relates to a new compound (e.g. an antisense
XX oligonucleotide), having a sequence comprising 8-80 bp targeted to a
XX nucleic acid encoding DRAX2 (death-associated protein kinase-related
XX apoptosis-inducing protein kinase 2, also known as serine/threonine
XX kinase 17B, STK17B), specifically hybridizes with the nucleic acid
XX encoding DRAX2 (appearing as ADP68859 and representing bases 58695-149492
XX of human chromosome 2) and inhibits expression of DRAX2. Also included
XX are inhibiting the expression of DRAX2 in cells or tissues, screening for
XX a modulator of DRAX2, a diagnostic method for identifying a disease
XX state, a kit or assay device comprising the compound and treating an
XX animal having a disease or condition associated with DRAX2. The
XX oligonucleotide compound is useful for preparing a composition for
XX treating hyperproliferative disorders, degenerative disorders,
XX neurological disorders, Alzheimer's disease, Parkinson's disease,
XX Amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, blood cell
XX disorders, cancer, autoimmune disorders and viral infection. The present
XX sequence represents a target region for the antisense oligonucleotides,
XX from the DRAX2 genomic DNA.
XX
XX Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 1.2e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 501 CTTGGCAGCAGCATTTGGAC 520
Db ||||| ||||| |||||
1 CTTGGCTACAGCAGTGGAC 20
```

```
RESULT 169
ADQ13711
ID ADQ13711 standard; DNA; 20 BP.
XX
XX
AC ADQ13711;
XX
XX
DT 07-OCT-2004 (first entry)
DE
DE DMD region PCR primer, SEQ ID 106.
XX
XX Human; SCAIP; dystrophin; Duchenne Muscular Dystrophy; DMD;
KW Becker Muscular Dystrophy; BMD; PCR; primer; ss;
KW Single Condition Amplification/ Internal Primer.
XX
XX Homo sapiens.
XX
XX WO2004058985-A2.
XX
XX 15-JUL-2004.
XX
XX 17-DEC-2003; 2003WO-US040278.
XX
XX 17-DEC-2002; 2002US-0433774P.
XX
XX (UTAH ) UNIV UTAH RES FOUND.
XX
XX Flanigan KM, Weiss RB, Dunn DM, Von Niederhausern A;
XX WPI; 2004-525893/50.
XX
XX Characterizing a nucleic acid region, useful for detecting genetic
PT mutations in any large multi-exon gene e.g., those indicating
PT dystrophinopathy, comprises using a Single Condition
PT Amplification/Internal Primer (SCAIP) sequencing method.
XX
XX Example 1; Page 31; 174pp; English.
XX
XX The present invention relates to a Single Condition Amplification/
CC Internal Primer (SCAIP) sequencing method for direct sequence analysis of
CC large multi-exon genes from genomic DNA samples and identifying mutations
CC in multi-exon genes e.g. the dystrophin gene, CAPN3 gene and DYSF gene.
CC Mutations in the dystrophin gene result in both Duchenne Muscular
CC Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). Mutations in the
CC CAPN3 gene, encoding calpain (calcium-activated neutral protease) result
CC in limb-girdle muscular dystrophy type 2A (LGMD2A) and mutations in the
CC DYSF gene, encoding dysferlin, result in limb-girdle muscular dystrophy
CC type 2B (LGMD2B). The method comprises bringing into contact in each of
CC the reaction chambers an amplicon from a different one of the
CC amplification reactions and one or more internal sequencing primers
CC corresponding to the amplicon and analysing the sequences of the
CC amplicons. The method allows for the rapid, accurate, and economical
CC analysis of any large multi-exon gene. The method is useful in detecting
CC genetic mutations in any large multi-exon gene. It is also useful for the
CC identification and analysis of specific individual genomic mutations
CC including deletions, point mutations, or its combinations, gene complexes
CC with multiple exons/introns spanning large genomic regions. The present
CC sequence is a PCR primer, used in the method of the invention.
XX
XX Sequence 20 BP; 6 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 445 GAGAGAAGTACGCTGTGATG 464
DB 1 GAGAAGAATGAGCTGGGCTG 20
RESULT 170
ADR32216
```

```
ID
XX
AC ADR32216;
XX
XX 18-NOV-2004 (first entry)
XX
XX Human nestin reverse RT-PCR primer, SEQ ID NO:8.
XX
XX Human; salivary gland; stem cell; hSGSC; CD49f-positive; differentiation;
KW liver; pancreas; nestin-positive cell; albumin-positive cell;
KW insulin-positive cell; glucagon-positive cell; organ regeneration;
KW organ transplant; hepatotropic; nestin; reverse transcription-PCR;
KW expression analysis; RT-PCR; primer; ss.
XX
XX Homo sapiens.
XX
XX WO2004074465-A1.
XX
XX 02-SEP-2004.
XX
XX 20-FEB-2004; 2004WO-JP002002.
XX
XX 20-FEB-2003; 2003JP-00043339.
XX
XX (BIOS-) BIOS RES INST INC.
PA (ENDO/) ENDO F.
PA
XX
XX Endo F, Okumura K, Nakamura K;
PI WPI; 2004-642513/62.
XX
XX New isolated human stem cell from a salivary gland, capable of
PT differentiating into a nestin-positive and albumin-positive cell, insulin
PT -positive and glucagon-positive cell, for use in the regeneration of
PT liver.
XX
XX Example 3; SEQ ID NO 8; 28pp; Japanese.
XX
XX The invention relates to an isolated CD49f-positive adult human salivary
CC gland stem cell (hSGSC) which is capable of differentiating into cells
CC characteristic of various organs such as the liver or pancreas when
CC cultured in vitro. Specifically, the hSGSCs are capable of
CC differentiating into nestin-positive and albumin-positive cells, insulin-
CC positive cells or glucagon-positive cells. The invention also relates to
CC the differentiated cells produced from hSGSCs; methods of inducing
CC differentiation of hSGSCs into nestin-positive/albumin positive, insulin-
CC positive or glucagon-positive cells by in vitro culture in the presence
CC of a fibroblast growth factor, epithelial cell growth factor and
CC leukaemia inhibitory factor; and a method of isolating hSGSCs from human
CC salivary gland and culturing them in the presence of epithelial cell
CC growth factor. The hSGSCs can be used to regenerate human liver and
CC pancreas. The regenerated organs eliminate transplant rejection, as the
CC stem cells used to produce the organs are taken from the patient.
CC Sequences ADR32209-ADR32230 represent reverse transcription-PCR (RT-PCR)
CC primers used to analyse gene expression in hSGSCs in an example of the
CC invention.
XX
XX Sequence 20 BP; 8 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 926 TGGGAGCAAAATATCCAGAAC 945
DB 1 TGGGAGCAAAAGATCCAAGAC 20
RESULT 171
ADT79911/c
ID ADT79911 standard; cDNA; 20 BP.
XX
XX ADT79911;
AC
```

XX 16-DEC-2004 (first entry)
XX Human squalene synthase antisense target region #15.
XX
DE Human squalene synthase; squalene synthase;
XX farnesyl diphosphate farnesyl transferase 1; cholesterol;
KW atherosclerosis; coronary heart disease; hypercholesterolaemia.
XX
XX Homo sapiens.
OS
XX US2004102405-A1.
XX
XX 27-MAY-2004.
XX
XX 23-NOV-2002; 2002US-00304125.
XX
XX 23-NOV-2002; 2002US-00304125.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Freier SM, Bennett CF, Dean NM, Dobie KW;
XX
XX WPI; 2004-399735/37.
XX
XX New oligonucleotide targeted to a nucleic acid molecule encoding squalene
PT synthase, useful in diagnosing and treating atherosclerosis.
XX
XX Example 15; SEQ ID NO 100; 67pp; English.
XX
XX The invention relates to a new compound 8-80 nucleobases in length (an
CC antisense oligonucleotide) targeted to a nucleic acid molecule encoding
CC squalene synthase (also known as farnesyl diphosphate farnesyl
CC transferase 1), where the compound specifically hybridises with the
CC nucleic acid molecule encoding human squalene synthase appearing as
CC AD79815 and inhibits the expression of squalene synthase. Also included
CC are inhibiting the expression of squalene synthase in cells or tissues,
CC screening for a modulator of squalene synthase, a diagnostic method for
CC identifying a disease state, a kit or assay device comprising the
CC compound and treating an animal having a disease or condition associated
CC with squalene synthase. The compound and methods are useful in diagnosing
CC and treating disorders related to cholesterol biosynthesis e.g.
CC atherosclerosis, coronary heart disease and hypercholesterolaemia. The
CC present sequence is a squalene synthase DNA sequence target region for
CC the antisense oligonucleotides.
XX
XX Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e-02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 973 ACAGCTGGGATGTGGGCGAG 992
Db 20 ACATCTGGGATGTGGTGCAG 1
RESULT 172
AAZ59263
ID AAZ59263 standard; DNA; 15 BP.
XX
XX AC AAZ59263;
XX
XX 24-MAY-2000 (first entry)
XX
XX Human NR8 gene probe #6.
XX
XX Haemopoietin receptor family; NR8; antibody; diagnosis;
KW blood formation disorder; fusion protein; probe; ss.
XX
XX Homo sapiens.
OS
XX WO9967290-A1.
XX
XX

XX 29-DEC-1999.
XX
XX 23-JUN-1999; 99WO-JP003351.
XX
XX 24-JUN-1998; 98JP-00214720.
PR 19-OCT-1998; 98JP-00297409.
XX
XX (CHUS) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
XX Nomura H, Maeda M;
XX
XX WPI; 2000-116933/10.
XX
XX Hemopoietin receptor protein family NR8 used for diagnosis of blood
PT formation disorders.
XX
XX Example 1; Page 38; 176pp; Japanese.
XX
XX The invention relates to the isolation of sequences encoding human
CC haemopoietin receptor protein family NR8 genes. The NR8 family sequences
CC were initially searched for comparison on a nucleic acid database with
CC the nucleic acid probe sequence TGGAGYNNYTGAGY encoding the amino acid
CC sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-Z59300 and AAZ90816-
CC Z90925 represent specific examples of probe sequences used in the search.
CC Antibodies to the NR8 family proteins are used for the diagnosis of blood
CC formation disorders. Compounds identified as binding to the proteins are
CC used for the treatment of such disorders
XX
XX Sequence 15 BP; 2 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 98;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1343 TGGAGTCCCTGGAGC 1357
Db 1 TGGAGTCCCTGGAGC 15
RESULT 173
ADQ81798/c
ID ADQ81798 standard; DNA; 15 BP.
XX
XX AC ADQ81798;
XX
XX 07-OCT-2004 (first entry)
XX
XX Oligonucleotide synthesis method polynucleotide #2.
DE
XX ss; primer; DNA synthesis; nucleotide chemistry.
XX
XX Synthetic.
OS
XX WO2004058794-A1.
XX
XX 15-JUL-2004.
XX
XX 31-DEC-2002; 2002WO-EF014905.
PF
XX 31-DEC-2002; 2002WO-EF014905.
XX
XX (PROJ-) PROLIGO LLC.
XX
XX Arar K;
XX
XX WPI; 2004-553145/53.
XX
XX Synthesis of oligonucleotides in nucleotide chemistry involves providing
PT solid support of anchor group protected by orthogonal protective group,
PT removing the protective group, synthesizing an oligonucleotide followed
PT by capping and cleaving.
XX
XX

```

PS Example 9; SEQ ID NO 13; 77pp; English.
XX
CC The present invention relates to a method for the synthesis of at least
CC two different oligonucleotides, which involves providing a solid support
CC comprising anchor groups that are protected by at least two orthogonal
CC protective groups, removing one of the protective groups from the anchor
CC groups, synthesizing an oligonucleotide on the deprotected anchor groups,
CC capping the synthesized oligonucleotide, repeating these steps until all
CC of anchor groups are deprotected, and cleaving the synthesized
CC oligonucleotides. The method can be used for the synthesis of at least
CC two different oligonucleotides, in the field of nucleotide chemistry, in
CC applying the required pairs of oligonucleotide primers, several probes at
CC a time, duplexed nuclei acid fragments (including PCR, sequencing,
CC multiplexed genotyping, cloning and RNA interference), for applying to
CC any known methods for the solid phase synthesis of oligonucleotides
CC (including phosphoramidite chemistry, H-phosphonate chemistry,
CC phosphotriester chemistry, or any other synthetic chemistry used to
CC prepare oligonucleotides on solid supports). The present sequence is a
CC polynucleotide used to demonstrate the method of the invention.
XX
SQ Sequence 15 BP; 0 A; 0 C; 0 G; 15 T; 0 U; 0 Other;
    Query Match      0.8%; Score 15; DB 1; Length 15;
    Best Local Similarity 100.0%; Pred. No. 98;
    Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 174
ABZ61173/c
ID ABZ61173 standard; RNA; 17 BP.
XX
AC ABZ61173;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human K-Ras DNase substrate #1285.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016940.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI McSwiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
XX Claim 58; Page 109; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic

```

```

CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ5989 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66595 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 0 T; 3 U; 0 Other;
    Query Match      0.8%; Score 15; DB 1; Length 17;
    Best Local Similarity 100.0%; Pred. No. 1.1e+02;
    Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 AATGTTGCTGCTGCT 1457
Db 16 AATGTTGCTGCTGCT 2

RESULT 175
ADF13436
ID ADF13436 standard; DNA; 18 BP.
XX
AC ADF13436;
XX
DT 12-FEB-2004 (first entry)
XX
DE Cdc42-interacting protein 4 (CIP4), BaySNP 5002, PCR primer #2.
XX
KW Cardiant; antiarteriosclerotic; vasotropic; cerebroprotective;
KW hypotensive; gene therapy; human; Cdc42-interacting protein 4; CIP4; PCR;
KW primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003072813-A2.
XX
PD 04-SEP-2003.
XX
PF 14-FEB-2003; 2003WO-EP001514.
XX
PR 27-FEB-2002; 2002EP-00004258.
XX
PA (PARE ) BAYER AG.
XX
PI Stropp U, Schwes S, Kallabis H;
XX
DR WPI; 2003-712738/67.
XX
PT New isolated polynucleotide encoded by a phenotype-associated gene,
PT useful for prognosticating statin therapy response, and diagnosing or
PT treating cardiovascular diseases, such as hypertension, myocardial
PT infarction and stroke.
XX
PS Example 1; Page 68; 182pp; English.
XX
CC The present invention relates to human phenotype-associated (PA) genes (I
CC ; ADF1307-ADF13386) which contain a Single Nucleotide Polymorphism
CC (SNP). The SNP is given in the sequence as a variant nucleotide. Also
CC claimed are methods for screening for agents which regulate the activity
CC of a PA gene and reagents that modulate the activity of a PA polypeptide
CC or a polynucleotide where the reagent is identified by the screening
CC methods. The methods and compositions of the present invention are useful
CC for prognosticating, diagnosing and treating cardiovascular diseases,
CC such as atherosclerosis, hypertension, restenosis, arterial inflammation,
CC myocardial infarction and stroke. The present sequence is a PCR primer,
CC used in the examples from the invention.
XX
SQ Sequence 18 BP; 8 A; 2 C; 7 G; 1 T; 0 U; 0 Other;
    Query Match      0.8%; Score 15; DB 1; Length 18;
    Best Local Similarity 100.0%; Pred. No. 1.2e+02;

```

Matches 15; _Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1103 AGAAGAACAAAGTGG 1117
 |||||
 Db 4 AGAAGAACAAAGTGG 18

RESULT 176
 AAH58054/c
 ID AAH58054 standard; DNA; 19 BP.
 AC AAH58054;
 XX
 XX
 DT 04-DEC-2000 (first entry)
 DE
 DE cdk4 ribozyme binding site #73.
 KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
 KW Mammalia.
 OS
 XX WO200032765-A2.
 XX
 XX PD 08-JUN-2000.
 XX
 XX PF 06-DEC-1999; 99WO-US028772.
 XX
 XX PR 04-DEC-1998; 98US-0110954P.
 XX
 XX PA (IMMU-) IMMUSOL INC.
 XX
 XX PI Tritz R, Welch PJ, Barber JR, Robbins JM;
 XX
 XX DR WPI; 2000-412314/35.
 XX
 XX PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
 PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
 PT PCNA and Cyclin B1.
 XX
 XX PS Disclosure; Page 53; 109pp; English.
 XX
 XX CC The present invention relates to a hairpin or hammerhead ribozyme,
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
 CC Representative examples of ribozyme recognition sites are given in
 CC AAH58054 to AAH58057. The ribozyme of the invention is useful for
 CC inhibiting restenosis by introduction of the ribozyme into cells. The
 CC ribozyme is resistant to endonuclease activity and hence is efficient in
 CC restenosis treatment
 XX
 XX SQ Sequence 19 BP; 3 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1096 GGACTGCAGAGAAC 1110
 |||||
 Db 19 GGACTGCAGAGAAC 5

RESULT 177
 AAH58054/c
 ID AAH58054 standard; DNA; 19 BP.
 AC AAH58054;
 XX
 XX
 DT 10-SEP-2001 (first entry)
 DE
 DE Cell-cycle dependent kinase cdk4 ribozyme binding site SEQ ID NO:478.
 XX
 XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
 KW recognition site; target; ribozyme binding site; eye disease; vulnary;

KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
 KW antiproliferative; dermatological; antiseborrheic; antidiabetic; virucide;
 KW antiscarring; ophthalmological; keratolytic; gene therapy; viral wart;
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
 KW sickle cell retinopathy; ss.
 XX
 XX OS Homo sapiens.
 XX Synthetic.
 XX
 XX PN WO200130362-A2.
 XX
 XX PD 03-MAY-2001.
 XX
 XX PF 26-OCT-2000; 2000WO-US029500.
 XX
 XX PR 26-OCT-1999; 99US-0161532P.
 XX
 XX PA (IMMU-) IMMUSOL INC.
 XX
 XX PI Robbins JM, Tritz R;
 XX
 XX DR WPI; 2001-300427/31.
 XX
 XX PT Treating proliferative skin or eye diseases and scarring, using ribozymes
 PT that cleave RNA encoding cytokines involved in inflammation, matrix
 PT metalloproteinases, growth factors and cell-cycle dependent kinases.
 XX
 XX PS Example 1; Page 106; 408pp; English.
 XX
 XX CC The present invention describes a method for treating a proliferative
 CC skin or eye disease and scarring. The method involves administering a
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
 CC dependent kinase, growth factor or a reductase, or administering a
 CC nucleic acid molecule (II) comprising a promoter operably linked to a
 CC nucleic acid segment encoding (I). (I) can have antiproliferative,
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antiscarring,
 CC ophthalmological, vulnary, keratolytic and virucide activities, and
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
 CC also be used for treating proliferative eye diseases such as diabetic
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
 CC prematurity and retinal detachment, and for treating and preventing
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
 CC scar. AAH57577 to AAH62099 represent sequences used in the
 CC exemplification of the present invention
 XX
 XX SQ Sequence 19 BP; 3 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1096 GGACTGCAGAGAAC 1110
 |||||
 Db 19 GGACTGCAGAGAAC 5

RESULT 178
 AAH58054/c
 ID AAH58054 standard; DNA; 20 BP.
 AC AAH58054;
 XX
 XX
 DT 09-JAN-2001 (first entry)
 DE
 DE Antisense oligonucleotide #20946 targeted to human G-alpha-S1.
 KW


```

AC AAA94503;
XX 09-JAN-2001 (first entry)
XX
XX Antisense oligonucleotide #20942 targeted to human G-alpha-S1.
XX
XX G-alpha-S1; infection; inflammation; tumour; antisense; human;
KW phosphorothioate; 2'-methoxyethyl; MOE; 5-methylcytidine;
KW Gs-alpha short form; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /mod_base= OTHER
XX /note= "Optionally the internucleotide linkages are
XX phosphorothioate"
XX modified_base 1..5
XX /mod_base= OTHER
XX /note= "Optionally the nucleotides are 2'-methoxyethyl
XX and cytidine residues are 5-methylcytidines"
XX modified_base 16..20
XX /mod_base= OTHER
XX /note= "Optionally the nucleotides are 2'-methoxyethyl
XX and cytidine residues are 5-methylcytidines"
XX
XX US6110664-A.
XX
XX 29-AUG-2000.
XX
XX 25-JUN-1999; 99US-00344914.
XX
XX 25-JUN-1999; 99US-00344914.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cowser LM;
XX
XX WPI; 2000-586346/55.
XX
XX New antisense compounds for modulating the expression of G-alpha-S1,
XX especially useful for diagnostics, therapeutics and prophylaxis, e.g. to
XX prevent or delay infection, inflammation or tumor formation.
XX
XX Claim 3; Col 39; 37pp; English.
XX
XX The present invention relates to antisense compounds 8-30 bases long
XX targeted to a coding region, a stop codon, or a 3' untranslated region of
XX human G-alpha-S1 (see AAA9451). The antisense compounds specifically
XX hybridize with and inhibit the expression of human G-alpha-S1. The
XX antisense compounds are useful for diagnostics, therapeutics and
XX prophylaxis, e.g. to prevent or delay infection, inflammation or tumour
XX formation. Particularly, the antisense oligonucleotides are useful for
XX treating humans prone to a disease or condition associated with
XX expression of G-alpha-S1. The present sequence an antisense
XX oligonucleotide targeted to the 3' untranslated region of human G-alpha-
XX S1
XX
XX Sequence 20 BP; 1 A; 3 C; 4 G; 12 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 15; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.3e+02;
XX Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1447 TTGCTGCTGCTGTTT 1461
XX 1 TTGCTGCTGCTGTTT 15
XX
XX RESULT 181

```

```

RESULT 182
AAA94506
ID AAA94506 standard; DNA; 20 BP.
XX
AC AAA94506;
XX
DT 09-JAN-2001 (first entry)
XX
DE Antisense oligonucleotide #20945 targeted to human G-alpha-S1.
XX
KW G-alpha-S1; infection; inflammation; tumour; antisense; human;
KW phosphorothioate; 2'-methoxyethyl; MOE; 5-methylcytidine;
XX Gs-alpha short form; ss.
XX
OS Homo sapiens.
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Optionally the internucleotide linkages are
FT phosphorothioate"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
XX
PN US6110664-A.
XX
PD 29-AUG-2000.
XX
PF 25-JUN-1999; 99US-00344914.
XX
PR 25-JUN-1999; 99US-00344914.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowser LM;
XX
PI WPI; 2000-586346/55.
XX
PT New antisense compounds for modulating the expression of G-alpha-S1,
PT especially useful for diagnostics, therapeutics and prophylaxis, e.g. to
PT prevent or delay infection, inflammation or tumor formation.
XX
PS Claim 3; Col 39; 37pp; English.
XX
CC The present invention relates to antisense compounds 8-30 bases long
CC targeted to a coding region, a stop codon, or a 3' untranslated region of
CC human G-alpha-S1 (see AAA94451). The antisense compounds specifically
CC hybridize with and inhibit the expression of human G-alpha-S1. The
CC antisense compounds are useful for diagnostics, therapeutics and
CC prophylaxis, e.g. to prevent or delay infection, inflammation or tumor
CC formation. Particularly, the antisense oligonucleotides are useful for
CC treating humans prone to a disease or condition associated with
CC expression of G-alpha-S1. The present sequence an antisense
CC oligonucleotide targeted to the 3' untranslated region of human G-alpha-
XX S1
XX Sequence 20 BP; 1 A; 3 C; 5 G; 11 T; 0 U; 0 Other;
XX Query Match 0.8%; Score 15; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.3e+02;
XX Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1447 TTGCTGCTGCTGTTT 1461
DB 4 TTGCTGCTGCTGTTT 18
XX
RESULT 183
AAA94508
ID AAA94508 standard; DNA; 20 BP.
XX
AC AAA94508;
XX
DT 09-JAN-2001 (first entry)
XX
DE Antisense oligonucleotide #20947 targeted to human G-alpha-S1.
XX
KW G-alpha-S1; infection; inflammation; tumour; antisense; human;
KW phosphorothioate; 2'-methoxyethyl; MOE; 5-methylcytidine;
XX Gs-alpha short form; ss.
XX
OS Homo sapiens.
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Optionally the internucleotide linkages are
FT phosphorothioate"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
XX
PN US6110664-A.
XX
PD 29-AUG-2000.
XX
PF 25-JUN-1999; 99US-00344914.
XX
PR 25-JUN-1999; 99US-00344914.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowser LM;
XX
PI WPI; 2000-586346/55.
XX
PT New antisense compounds for modulating the expression of G-alpha-S1,
PT especially useful for diagnostics, therapeutics and prophylaxis, e.g. to
PT prevent or delay infection, inflammation or tumor formation.
XX
PS Claim 3; Col 39; 37pp; English.
XX
CC The present invention relates to antisense compounds 8-30 bases long
CC targeted to a coding region, a stop codon, or a 3' untranslated region of
CC human G-alpha-S1 (see AAA94451). The antisense compounds specifically
CC hybridize with and inhibit the expression of human G-alpha-S1. The
CC antisense compounds are useful for diagnostics, therapeutics and
CC prophylaxis, e.g. to prevent or delay infection, inflammation or tumor
CC formation. Particularly, the antisense oligonucleotides are useful for
CC treating humans prone to a disease or condition associated with
CC expression of G-alpha-S1. The present sequence an antisense
CC oligonucleotide targeted to the 3' untranslated region of human G-alpha-
XX S1
XX Sequence 20 BP; 0 A; 3 C; 5 G; 12 T; 0 U; 0 Other;
XX Query Match 0.8%; Score 15; DB 1; Length 20;

```

```

Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGCTTT 1461
Db 6 TTGCTGCTGCTGCTTT 20

RESULT 184
ABZ85199
ID ABZ85199 standard; DNA; 20 BP.
XX
AC ABZ85199;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosstatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 441; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytosstatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 8 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 775 TGCCCAAAATTCCAA 789
Db 4 TGCCCAAAATTCCAA 18

RESULT 185
ABZ85565/C
ID ABZ85565 standard; DNA; 20 BP.
XX
AC ABZ85565;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosstatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 807; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytosstatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 0 C; 13 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 20;

```

```
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1704 TCCCTCCCTCCAC 1718
Db 20 TCCCTCCCTCCAC 6

RESULT 186
ABD21429
ID ABD21429 standard; DNA; 20 BP.
AC ABD21429;
XX
XX 29-JUL-2004 (first entry)
DT
DE
XX
XX Human transglutaminase-derived oligo SEQ ID 441.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 441; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers. (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory
```

CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 5 A; 0 C; 13 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1704 TCCCTCTCCCTCCAC 1718
 |||||
 Db 20 TCCCTCTCCCTCCAC 6

RESULT 188
 ADP11714
 ID ADP11714 standard; DNA; 20 BP.
 XX
 AC ADP11714;
 XX
 DT 12-AUG-2004 (first entry)
 XX
 DE Set 2 left PCR primer for marker probe #66.
 XX
 KW transplant rejection; immune system; rheumatoid arthritis; lupus;
 KW inflammatory bowel disease; multiple sclerosis; HIV; AIDS; ss; primer.
 XX
 OS Homo sapiens.
 XX
 FN WO2004042346-A2.
 XX
 PD 21-MAY-2004.
 XX
 PF 24-APR-2003; 2003WO-US012946.
 XX
 PR 24-APR-2002; 2002US-00131831.
 PR 20-DEC-2002; 2002US-00325899.
 XX
 PA (EXPR-) EXPRESSION DIAGNOSTICS INC.
 XX
 PI Wohlgenuth J, Fry K, Woodward R, Ly N, Prentice J, Morris M;
 PI Rosenberg S;
 XX
 DR WPI; 2004-400724/37.
 XX
 PT Diagnosing or monitoring transplant rejection, e.g. heart, kidney, liver,
 PT pancreas, pancreatic islet, lung, bone marrow or stem cell transplant
 PT rejection, in an individual, comprises detecting the expression level of
 PT the genes.
 XX
 PS Claim 58; SEQ ID NO 1723; 1762pp; English.
 XX
 CC The present invention relates to diagnosing or monitoring transplant
 CC rejection, e.g. cardiac or kidney transplant rejection, in an individual
 CC comprises detecting the expression level of one or more genes. The

CC methods, system and kits are useful in diagnosing or monitoring
 CC transplant rejection, e.g. heart, kidney, liver, pancreas, pancreatic
 CC islet, lung, bone marrow or stem cell transplant rejection,
 CC xenotransplant rejection or mechanical organ replacement rejection, in an
 CC individual. The method is also useful in assessing the immune status of
 CC a disease that involve the immune system, e.g. rheumatoid arthritis,
 CC lupus, inflammatory bowel diseases, multiple sclerosis, HIV/AIDS or
 CC viral, bacterial or fungal infection. The present sequence represents a
 CC primer for a 50 mer oligonucleotide marker for diagnosis and monitoring
 CC of allograft rejection and other disorders.

Qy Sequence 20 BP; 2 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1448 TGCTGCTGCTGTTTG 1462
 |||||
 Db 6 TGCTGCTGCTGTTTG 20

RESULT 189
 AAF85699/c
 ID AAF85699 standard; DNA; 18 BP.
 XX
 AC AAF85699;
 XX
 DT 13-JUL-2001 (first entry)
 XX
 DE Multiple repeated heat process PCR related oligonucleotide #3.
 XX
 KW Multiple repeated heat circulation; polymerase chain reaction; PCR;
 KW target DNA production; DNA synthesis; ds.
 XX
 OS Unidentified.
 XX
 FN CN1278558-A.
 XX
 PD 03-JAN-2001.
 XX
 PF 22-JUN-1999; 99CN-00114949.
 XX
 PR 22-JUN-1999; 99CN-00114949.
 XX
 PA (XIAQ/) XIA Q.
 XX
 PI Xia Q;
 XX
 DR WPI; 2001-245741/26.
 XX
 PT Asynchronous chain-extending polymerase chain reaction for producing lots
 PT of target DNA fragments, comprises a multiple repeated heat circulation
 PT process.
 XX
 PS Disclosure; Page 3; 4pp; Chinese.
 XX
 CC The present invention relates to a kind of two chains asynchronously-
 CC elongated DNA amplification technology in vitro, which is characterized
 CC by that firstly, a pair of specific primers is synthesized according to
 CC the target DNA sequence to be amplified, then a repetitive sequence
 CC complementary oligo-repetitive sequence of 3' target DNA chain whose tail
 CC end is modified and elongation vitality is lost, then the oligo-
 CC repetitive sequence, chain primer, heat-resisting DNA polymerase, dNTP
 CC substrate, template DNA, magnesium ion, polymerase chain reaction (PCR)
 CC buffer solution and ultra-pure water are mixed uniformly and made into a
 CC reaction system. The reaction system then undergoes the processes of high
 CC -temp., low-temp., medium-low temp., medium-temp. and repeated heat
 CC circulation treatment in the heat-circulating instrument to obtain
 CC million copies of specific target DNA fragments. The invention adopts a
 CC multiple repeated heat circulation process, so that it can produce lots
 CC of target DNA fragments. The present sequence was used in the

```

CC exemplification of the invention
XX
SQ Sequence 18 BP; 0 A; 6 C; 12 G; 0 T; 0 U; 0 Other;

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 29 CGCGCTCCGTCGCGCGCG 46
Db 18 CGCGCGCGCGCGCGCG 1

RESULT 190
ADO26654/c
ID ADO26654 standard; DNA; 18 BP.
XX
AC ADO26654;
XX
DT 12-AUG-2004 (first entry)
XX
DE Synthetic leader sequence encoding DNA SEQ ID NO:47.
XX
KW phenotype; phenotypic preference; phenotype modulation; leader; ds.
XX
OS Synthetic.
XX
FN WO2004042059-A1.
XX
PD 21-MAY-2004.
XX
PF 10-NOV-2003; 2003WO-AU001487.
XX
PR 08-NOV-2002; 2002US-0425163P.
XX
PA (UYQU ) UNIV QUEENSLAND.
XX
PI Frazer IH;
XX
DR WPI; 2004-411519/38.
DR P-PSDB; ADO26655.
XX
Constructing synthetic polynucleotide for modulating the quality of a
selected phenotype displayed by an organism comprises replacing a first
codon with a synonymous codon to construct the synthetic polynucleotide.

Example 1; SEQ ID NO 47; 86pp; English.

The present invention describes a method for constructing a synthetic
polynucleotide from which a polypeptide is producible to confer a
selected phenotype to an organism of interest or part in a different
quality than that conferred by a parent polynucleotide that encodes the
same polypeptide. The method comprises: (a) selecting a first codon of
the parent polynucleotide for replacement with a synonymous codon, where
the synonymous codon is selected on the basis that it exhibits a
different phenotypic preference than the first codon in a comparison of
phenotypic preferences in test organisms or parts, where the test
organism are selected from organisms of the same species as the organism
of interest and organisms that are related to the organisms of interest;
and (b) replacing the first codon with the synonymous codon to construct
the synthetic polynucleotide. Also described: (1) a method for
determining the phenotypic preference of a first codon in an organism of
interest or its parts; (2) a synthetic polynucleotide constructed from
the method above; (3) an organism of interest or part containing a
synthetic polynucleotide constructed from the method above; (4) an
organism of interest or part containing a synthetic construct that
comprises a regulatory polynucleotide operably linked to a tandem repeat
of a first codon fused in frame with a reporter polynucleotide that
encodes a reporter protein, which produces, or is predicted to produce a
selected phenotype or a phenotype of the same class as the selected
phenotype in the organism or part; (5) a method of modulating the quality
of a selected phenotype that is displayed by an organism of interest or
part and that results from the expression of a parent polynucleotide that
encodes the polypeptide; (6) a method of enhancing the quality of a
selected phenotype that is displayed by an organism of interest or part
and that results from the expression of a parent polynucleotide that
encodes the polypeptide; and (7) a method of reducing the quality of a
selected phenotype that is displayed by an organism of interest or part
and that results from the expression of a parent polynucleotide that
encodes the polypeptide. The method is useful for constructing a
synthetic polynucleotide from which a polypeptide is producible to confer
a selected phenotype to an organism of interest or part in a different
quality than that conferred by a parent polynucleotide that encodes the
same polypeptide. It is useful for modulating the quality of a selected
phenotype displayed by an organism or part. The present sequence encodes
a synthetic leader sequence, which is used in an example from the present
invention.

Sequence 18 BP; 0 A; 6 C; 12 G; 0 T; 0 U; 0 Other;

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCTCTCCGTCGCGCGCC 45
Db 18 GCCTCTCCGTCGCGCGCC 1

RESULT 191
ADO26616
ID ADO26616 standard; DNA; 18 BP.
XX
AC ADO26616;
XX
DT 12-AUG-2004 (first entry)
XX
DE Synthetic leader sequence encoding DNA SEQ ID NO:9.
XX
KW phenotype; phenotypic preference; phenotype modulation; leader; ds.
XX
OS Synthetic.
XX
FN WO2004042059-A1.
XX
PD 21-MAY-2004.
XX
PF 10-NOV-2003; 2003WO-AU001487.
XX
PR 08-NOV-2002; 2002US-0425163P.
XX
PA (UYQU ) UNIV QUEENSLAND.
XX
PI Frazer IH;
XX
DR WPI; 2004-411519/38.
DR P-PSDB; ADO26617.
XX
Constructing synthetic polynucleotide for modulating the quality of a
selected phenotype displayed by an organism comprises replacing a first
codon with a synonymous codon to construct the synthetic polynucleotide.

Example 1; SEQ ID NO 9; 86pp; English.

The present invention describes a method for constructing a synthetic
polynucleotide from which a polypeptide is producible to confer a
selected phenotype to an organism of interest or part in a different
quality than that conferred by a parent polynucleotide that encodes the
same polypeptide. The method comprises: (a) selecting a first codon of
the parent polynucleotide for replacement with a synonymous codon, where
the synonymous codon is selected on the basis that it exhibits a
different phenotypic preference than the first codon in a comparison of
phenotypic preferences in test organisms or parts, where the test
organism are selected from organisms of the same species as the organism
of interest and organisms that are related to the organisms of interest;
and (b) replacing the first codon with the synonymous codon to construct
the synthetic polynucleotide. Also described: (1) a method for
determining the phenotypic preference of a first codon in an organism of
interest or its parts; (2) a synthetic polynucleotide constructed from
the method above; (3) an organism of interest or part containing a
synthetic polynucleotide constructed from the method above; (4) an
organism of interest or part containing a synthetic construct that
comprises a regulatory polynucleotide operably linked to a tandem repeat
of a first codon fused in frame with a reporter polynucleotide that
encodes a reporter protein, which produces, or is predicted to produce a
selected phenotype or a phenotype of the same class as the selected
phenotype in the organism or part; (5) a method of modulating the quality
of a selected phenotype that is displayed by an organism of interest or
part and that results from the expression of a parent polynucleotide that

```

CC the synthetic polynucleotide. Also described: (1) a method for
 CC determining the phenotypic preference of a first codon in an organism of
 CC interest or its parts; (2) a synthetic polynucleotide constructed from
 CC the method above; (3) an organism of interest or part containing a
 CC synthetic polynucleotide constructed from the method above; (4) an
 CC organism of interest or part containing a synthetic construct that
 CC comprises a regulatory polynucleotide operably linked to a tandem repeat
 CC of a first codon fused in frame with a reporter polynucleotide that
 CC encodes a reporter protein, which produces, or is predicted to produce a
 CC selected phenotype or a phenotype of the same class as the selected
 CC phenotype in the organism or part; (5) a method of modulating the quality
 CC of a selected phenotype that is displayed by an organism of interest or
 CC part and that results from the expression of a parent polynucleotide that
 CC encodes the polypeptide; (6) a method of enhancing the quality of a
 CC and that results from the expression of a parent polynucleotide that
 CC encodes the polypeptide; and (7) a method of reducing the quality of a
 CC selected phenotype that is displayed by an organism of interest or part
 CC and that results from the expression of a parent polynucleotide that
 CC encodes the polypeptide. The method is useful for constructing a
 CC synthetic polynucleotide from which a polypeptide is producible to confer
 CC a selected phenotype to an organism of interest or part in a different
 CC quality than that conferred by a parent polynucleotide that encodes the
 CC same polypeptide. It is useful for modulating the quality of a selected
 CC phenotype displayed by an organism or part. The present sequence encodes
 CC a synthetic leader sequence, which is used in an example from the present
 CC invention.

XX Sequence 18 BP; 0 A; 12 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. NO. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCTCCGTCGCCGC 45

Db 1 GCCGCGCGCGCGCGCC 18

RESULT 192

ID ADO26622/c

AD026622 standard; DNA; 18 BP.

XX ADO26622;

XX 12-AUG-2004 (first entry)

DE Synthetic leader sequence encoding DNA SEQ ID NO:15.

XX phenotype; phenotypic preference; phenotype modulation; leader; ds.

OS Synthetic.

FN WO2004042059-A1.

XX 21-MAY-2004.

XX 10-NOV-2003; 2003WO-AU001487.

XX 08-NOV-2002; 2002US-0425163P.

XX (UYQU) UNIV QUEENSLAND.

XX Frazer IH;

XX WPI; 2004-411519/38.

XX P-ESDB; ADO26623.

XX Constructing synthetic polynucleotide for modulating the quality of a
 XX selected phenotype displayed by an organism comprises replacing a first
 XX codon with a synonymous codon to construct the synthetic polynucleotide.

XX Example 1; SEQ ID NO 15; 86pp; English.

PS

xx

CC The present invention describes a method for constructing a synthetic
 CC polynucleotide from which a polypeptide is producible to confer a
 CC selected phenotype to an organism of interest or part in a different
 CC quality than that conferred by a parent polynucleotide that encodes the
 CC same polypeptide. The method comprises: (a) selecting a first codon of
 CC the parent polynucleotide for replacement with a synonymous codon, where
 CC the synonymous codon is selected on the basis that it exhibits a
 CC different phenotypic preference than the first codon in a comparison of
 CC phenotypic preferences in test organisms or parts, where the test
 CC organism are selected from organisms of the same species as the organism
 CC of interest and organisms that are related to the organisms of interest;
 CC and (b) replacing the first codon with the synonymous codon to construct
 CC the synthetic polynucleotide. Also described: (1) a method for
 CC determining the phenotypic preference of a first codon in an organism of
 CC interest or its parts; (2) a synthetic polynucleotide constructed from
 CC the method above; (3) an organism of interest or part containing a
 CC synthetic polynucleotide constructed from the method above; (4) an
 CC organism of interest or part containing a synthetic construct that
 CC comprises a regulatory polynucleotide operably linked to a tandem repeat
 CC of a first codon fused in frame with a reporter polynucleotide that
 CC encodes a reporter protein, which produces, or is predicted to produce a
 CC selected phenotype or a phenotype of the same class as the selected
 CC phenotype in the organism or part; (5) a method of modulating the quality
 CC of a selected phenotype that is displayed by an organism of interest or
 CC part and that results from the expression of a parent polynucleotide that
 CC encodes the polypeptide; (6) a method of enhancing the quality of a
 CC selected phenotype that is displayed by an organism of interest or part
 CC and that results from the expression of a parent polynucleotide that
 CC encodes the polypeptide. The method is useful for constructing a
 CC synthetic polynucleotide from which a polypeptide is producible to confer
 CC a selected phenotype to an organism of interest or part in a different
 CC quality than that conferred by a parent polynucleotide that encodes the
 CC same polypeptide. It is useful for modulating the quality of a selected
 CC phenotype displayed by an organism or part. The present sequence encodes
 CC a synthetic leader sequence, which is used in an example from the present
 CC invention.

XX Sequence 18 BP; 0 A; 6 C; 12 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 29 CCGCCCTCCGTCGCCGC 46

Db 18 CCGCCCGCGCGCGCGC 1

RESULT 193

AD026692

ID ADO26692 standard; DNA; 18 BP.

XX ADO26692;

XX 12-AUG-2004 (first entry)

XX Synthetic leader sequence encoding DNA SEQ ID NO:85.

XX phenotype; phenotypic preference; phenotype modulation; leader; ds.

XX Synthetic.

XX WO2004042059-A1.

XX 21-MAY-2004.

XX 10-NOV-2003; 2003WO-AU001487.

XX 08-NOV-2002; 2002US-0425163P.

```

XX PA (UYQU ) UNIV QUEENSLAND.
XX PI
XX P-PSDB; ADO26693.
XX DR
XX DR
XX PT Constructing synthetic polynucleotide for modulating the quality of a
XX PT selected phenotype displayed by an organism comprises replacing a first
XX PT codon with a synonymous codon to construct the synthetic polynucleotide.
XX PS
XX PS Example 1; SEQ ID NO 85; 86pp; English.
XX CC
XX CC The present invention describes a method for constructing a synthetic
XX CC polynucleotide from which a polypeptide is producible to confer a
XX CC selected phenotype to an organism of interest or part in a different
XX CC quality than that conferred by a parent polynucleotide that encodes the
XX CC same polypeptide. The method comprises: (a) selecting a first codon of
XX CC the parent polynucleotide for replacement with a synonymous codon, where
XX CC the synonymous codon is selected on the basis that it exhibits a
XX CC different phenotypic preference than the first codon in a comparison of
XX CC phenotypic preferences in test organisms or parts, where the test
XX CC organism are selected from organisms of the same species as the organism
XX CC of interest and organisms that are related to the organisms of interest;
XX CC and (b) replacing the first codon with the synonymous codon to construct
XX CC the synthetic polynucleotide. Also described: (1) a method for
XX CC determining the phenotypic preference of a first codon in an organism of
XX CC interest or its parts; (2) a synthetic polynucleotide constructed from
XX CC the method above; (3) an organism or interest or part containing a
XX CC synthetic polynucleotide constructed from the method above; (4) an
XX CC organism or interest or part containing a synthetic construct that
XX CC comprises a regulatory polynucleotide operably linked to a tandem repeat
XX CC of a first codon fused in frame with a reporter polynucleotide that
XX CC encodes a reporter protein, which produces, or is predicted to produce a
XX CC selected phenotype or a phenotype of the same class as the selected
XX CC phenotype in the organism or part; (5) a method of modulating the quality
XX CC of a selected phenotype that is displayed by an organism of interest or
XX CC part and that results from the expression of a parent polynucleotide that
XX CC encodes the polypeptide; (6) a method of enhancing the quality of a
XX CC selected phenotype that is displayed by an organism of interest or part
XX CC and that results from the expression of a parent polynucleotide that
XX CC encodes the polypeptide; and (7) a method of reducing the quality of a
XX CC selected phenotype that is displayed by an organism of interest or part
XX CC and that results from the expression of a parent polynucleotide that
XX CC encodes the polypeptide. The method is useful for constructing a
XX CC synthetic polynucleotide from which a polypeptide is producible to confer
XX CC a selected phenotype to an organism of interest or part in a different
XX CC quality than that conferred by a parent polynucleotide that encodes the
XX CC same polypeptide. It is useful for modulating the quality of a selected
XX CC phenotype displayed by an organism or part. The present sequence encodes
XX CC a synthetic leader sequence, which is used in an example from the present
XX CC invention.
XX SQ Sequence 18 BP; 0 A; 12 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 29 CCGCCTCCGTCGCGCGG 46
DB 1 CCGCCCGCCGCGCGCGG 18
RESULT 194
AAA85973/c
ID AAA85973 standard; DNA; 19 BP.
XX AC
XX AC AAA85973;
XX DT
XX DT 04-DEC-2000 (first entry)
Tritz R, Welch PJ, Barber JR, Robbins JM;
WPI; 2000-412314/35.
Cdc 25 hs ribozyme binding site #81.
Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
Mammalia.
WO200032765-A2.
08-JUN-2000.
06-DEC-1999; 99WO-US028772.
04-DEC-1998; 98US-0110954P.
(IMMU-) IMMUSOL INC.
Tritz R, Welch PJ, Barber JR, Robbins JM;
WPI; 2000-412314/35.
New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PCNA and Cyclin B1.
Disclosure; Page 100; 109pp; English.
The present invention relates to a hairpin or hammerhead ribozyme,
designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
Representative examples of ribozyme recognition sites are given in
AAA82415 to AAA86787. The ribozyme of the invention is useful for
inhibiting restenosis by introduction of the ribozyme into cells. The
ribozyme is resistant to endonuclease activity and hence is efficient in
restenosis treatment
SQ Sequence 19 BP; 3 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 963 GGACATCTGGACAGCTGG 980
DB 19 GGACATCTGGACAGCGG 2
RESULT 195
AAA85142/c
ID AAA85142 standard; DNA; 19 BP.
XX AC
XX AC AAA85142;
XX DT
XX DT 04-DEC-2000 (first entry)
Cyclin G1 ribozyme binding site #167.
Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
Mammalia.
WO200032765-A2.
08-JUN-2000.
06-DEC-1999; 99WO-US028772.
04-DEC-1998; 98US-0110954P.
(IMMU-) IMMUSOL INC.
Tritz R, Welch PJ, Barber JR, Robbins JM;
WPI; 2000-412314/35.

```


XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Disclosure; Page 88; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AA82415 to AA86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 19 BP; 5 A; 3 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1326 AACTTTTGGATCCAGCT 1343
DB 18 AACATTGGATACAGCT 1
RESULT 196
AAZ72532/C
ID AAZ72532 standard; DNA; 19 BP.
XX
AC AAZ72532;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker upstream amplification primer SEQ ID NO:6888.
XX
XX Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
XX Cohen D, Blumenfeld M, Chumakov I;
XX WPI; 2000-013267/01.
XX
XX Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome.
XX
XX Claim 9; Page 1699; 2745pp; English.
XX
XX AA265654 to AA269578 represent human biallelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AA269579 to AA277440 represent amplification
XX primers for the biallelic markers. The biallelic markers of the invention
XX have a variety of uses: they can be used for high density mapping of the
XX human genome, and in complex association studies and haplotyping studies
XX which are useful in determining the genetic basis for disease states.
XX Compositions and methods of the invention can also be useful for the
XX identification of the targets for the development of pharmaceutical
XX agents and diagnostic methods, as well as the characterisation of the
XX differential efficacious responses to and side effects from
XX pharmaceutical agents acting on a disease as well as other treatment.
XX N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
XX 3367, are not actually given a sequence in the Sequence Listing from the
XX present invention

CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 19 BP; 11 A; 3 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1467 GTTCTTCTTATGTGTT 1484
DB 19 GTTCTTCTTATGTGTT 2
RESULT 197
AAZ72783/C
ID AAZ72783 standard; DNA; 19 BP.
XX
AC AAZ72783;
XX
DT 10-SEP-2001 (first entry)
XX
DE Human biallelic marker upstream amplification primer SEQ ID NO:7139.
XX
XX Human genome; biallelic marker; high density disequilibrium map;
KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW haplotyping; hybridisation; identification; characterisation;
KW amplification; single nucleotide polymorphism; SNP; PCR primer;
KW diagnosis; ss.
XX
OS Homo sapiens.
XX
PN WO9954500-A2.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1999; 99WO-IB000822.
XX
PR 21-APR-1998; 98US-0082614P.
PR 23-NOV-1998; 98US-0109732P.
XX
PA (GEST) GENSET.
XX
XX Cohen D, Blumenfeld M, Chumakov I;
XX WPI; 2000-013267/01.
XX
XX Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome.
XX
XX Claim 9; Page 1753; 2745pp; English.
XX
XX AA265654 to AA269578 represent human biallelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AA269579 to AA277440 represent amplification
XX primers for the biallelic markers. The biallelic markers of the invention
XX have a variety of uses: they can be used for high density mapping of the
XX human genome, and in complex association studies and haplotyping studies
XX which are useful in determining the genetic basis for disease states.
XX Compositions and methods of the invention can also be useful for the

SQ Sequence 19 BP; 11 A; 1 C; 7 G; 0 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1629 CTCATTTCATGCTTCT 1646
DB 19 CTCCTTCTGCTTCT 2

RESULT 198
AAH56723/C
ID AAH56723 standard; DNA; 19 BP.
XX AC AAH56723;
DT 06-SEP-2001 (first entry)
DE S. aureus groE operon antisense oligonucleotide SEQ ID NO:371.
XX Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;
KW Microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;
KW Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;
KW antibacterial; antiviral; antiproliferative; antisense therapy;
KW microbial infection; ss.
XX Staphylococcus aureus.
XX WO200136625-A2.
XX 25-MAY-2001.
XX 20-NOV-2000; 2000WO-CA001347.
XX 18-NOV-1999; 99US-0166249P.
XX (GENE-) GENESENSE TECHNOLOGIES INC.
XX Wright JA, Young AH, Dugourd D;
XX WPI; 2001-355633/37.
XX Novel antisense compounds targeting nucleic acid encoding groEL or groES
PT Gene of microorganism, which hybridize with and inhibit expression of the
PT genes, useful to inhibit growth of microorganism having the genes.
XX Claim 3; Page 51; 110pp; English.
XX The present invention specifically claims AAH56368 to AAH56832 which are
CC antisense oligonucleotides to nucleotide sequences encoding groE. More
CC generally, antisense compounds (I) comprising antisense oligonucleotides
CC of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat
CC shock protein (HSP)60) (GL) and groES (HSP10) (GS) gene from a
CC microorganism, where the antisense compound is complementary to GL or GS
CC of a microorganism and specifically hybridizes with and inhibits the
CC expression of GL or GS, is claimed. (I) have antibacterial, antiviral and
CC antiproliferative activities, and can be used in antisense therapy and
CC for inhibition of expression of groE or groEL. (II) are useful for
CC inhibiting expression of GL or GS in cells or tissues in vitro. (I) are
CC also useful for inhibiting the growth of a microorganism, or inhibiting
CC the expression of GL or GS gene in a microorganism (a bacterial cell or a
CC virus) having a GL or GS gene which involves administering to the
CC microorganism or to a cell infected with the microorganism, (I). (I) are
CC also useful for treating a mammalian pathological condition mediated by
CC the microorganisms which involves identifying a eukaryotic organism
CC having a pathological condition mediated by microorganisms having a GL or
CC GS gene and administering (I) such that the growth of microorganism is
CC inhibited. The antisense compounds are utilised for diagnostics,
CC therapeutics, prophylaxis and as research reagents and kits, e.g., to
CC prevent or delay microbial infections in humans. They are also useful as
CC molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854
CC represent PCR primers for groE sequences which are used in the

CC exemplification of the present invention. AAH56855 to AAH56870 represent
CC groE nucleotide sequence given in the present invention
XX SQ Sequence 19 BP; 5 A; 2 C; 0 G; 12 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 88 TCGAAAAAAATGAAAT 105
DB 18 TGAATAAAAAATGAAAT 1

RESULT 199
AAH60304/C
ID AAH60304 standard; DNA; 19 BP.
XX AC AAH60304;
DT 10-SEP-2001 (first entry)
DE Cyclin G1 ribozyme binding site SEQ ID NO:2728.
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnery;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytoskeletal;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antiskinning; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
XX sickle cell retinopathy; ss.
XX Homo sapiens.
OS Synthetic.
XX WO200130362-A2.
XX 03-MAY-2001.
XX 26-OCT-2000; 2000WO-US029500.
XX 26-OCT-1999; 99US-0161532P.
XX (IMMU-) IMMUSOL INC.
XX Robbins JM, Tritz R;
XX WPI; 2001-300427/31.
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX Example 1; Page 270; 408pp; English.
XX The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antiskinning,
CC ophthalmological, vulnery, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of

CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 5 A; 3 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1326 AACTTTTGGATCAAGCT 1343
Db 18 AACATTGGATCAAGCT 1

RESULT 200
AAH61135/c
ID AAH61135 standard; DNA; 19 BP.

XX AC AAH61135;

XX DT 10-SEP-2001 (first entry)

XX DE Cdc25 hs ribozyme binding site SEQ ID NO:3559.

XX KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200130362-A2.

XX PD 03-MAY-2001.

XX PF 26-OCT-2000; 2000WO-US029500.

XX PR 26-OCT-1999; 99US-0161532P.

XX PA (IMMU-) IMMUSOL INC.

XX PI Robbins JM, Tritz R;

XX DR WPI; 2001-300427/31.

XX PT Treating proliferative skin or eye diseases and scarring, using ribozymes
XX that cleave RNA encoding cytokines involved in inflammation, matrix
XX metalloproteinases, growth factors and cell-cycle dependent kinases.

XX PS Example 1; Page 330; 408pp; English.

XX CC The present invention describes a method for treating a proliferative
XX skin or eye disease and scarring. The method involves administering a
XX ribozyme (I) which cleaves RNA encoding a cytokine involved in
XX inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
XX dependent kinase, growth factor or a reductase, or administering a
XX nucleic acid molecule (II) comprising a promoter operably linked to a
XX nucleic acid segment encoding (I). (I) can have antipsoriatic,
XX dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
XX ophthalmological, vulnary, keratolytic and virucide activities, and
XX cleaves RNA encoding cytokine involved in inflammation. (I) can be used
XX in gene therapy. (I) and (II) are useful for treating proliferative skin
XX diseases such as psoriasis, atopic dermatitis, actinic keratosis,
XX squamous or basal cell carcinoma and viral or seborrheic wart. They can

CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX

SQ Sequence 19 BP; 3 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 963 GGACATCTGGACAGCTGG 980
Db 19 GGACATCTGGACAGCG 2

RESULT 201
ADJ94210/c
ID ADJ94210 standard; DNA; 19 BP.

XX AC ADJ94210;

XX DT 06-MAY-2004 (first entry)

XX DE Human MYOC gene mutation detection primer M-SR13.

XX KW glaucoma; detection; mutation; MYOC; primer; ss.

XX OS Homo sapiens.

XX PN WO2003083108-A1.

XX PD 09-OCT-2003.

XX PF 19-MAR-2003; 2003WO-JP003307.

XX PR 29-MAR-2002; 2002JP-00093443.

XX PA (SYSM-) SYSMEX CORP.

XX PI Asano K, Takahata T, Numada S, Masago A, Kouchi Y;

XX DR WPI; 2003-804059/75.

XX PT Examining genes to assess the risk of the onset of glaucoma by detecting
XX mutations in the MYOC gene or the region upstream from it.

XX PS Example 1; SEQ ID NO 24; 42pp; Japanese.

XX CC The invention relates to a method of examining genes to assess the risk
XX of the onset of glaucoma comprising detection of at least two mutations
XX in the glaucoma related gene encoding region and/or a region upstream
XX from it. The glaucoma related gene is preferably the MYOC gene. The
XX method is useful for the prevention or early detection of glaucoma. This
XX sequence corresponds to a PCR primer used to detect mutations in the
XX human MYOC gene (ADJ94187).

SQ Sequence 19 BP; 8 A; 4 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1017 GCCTTTATATCATCGGAA 1034
Db 19 GCCTTTATTTAATGGAA 2

RESULT 202
ADM70255/c
ID ADM70255 standard; DNA; 19 BP.

```

KW AC ADM70255;
XX
XX DT 03-JUN-2004 (first entry)
XX
XX DE Plant gene polymorphism marker related primer, SEQ ID 1134.
XX
XX KW Primer; variation mapping; mutation mapping; plant;
XX gene polymorphism marker; ss.
XX
XX OS Synthetic.
XX
XX PN JP2003289885-A.
XX
XX PD 14-OCT-2003.
XX
XX 31-JAN-2003; 2003JP-00024620.
XX
XX 01-FEB-2002; 2002JP-00025338.
XX
XX (RIKA ) RIKAGAKU KENKYUSHO.
XX (SAIM-) SAI MEDIA KK.
XX (MATS/) MATSUI M.
XX (NAKA/) NAKAZAWA M.
XX
XX WPI; 2004-126231/13.
XX
XX A primer set and method useful for mapping at least the
XX variation/mutation part of a plant gene using a gene polymorphism marker.
XX
XX Claim 7; SEQ ID NO 1134; 120pp; Japanese.
XX
XX The present invention relates to a primer set and method for mapping at
XX least the variation/mutation part of a plant gene using a gene
XX polymorphism marker. A mutation site of the plant gene is mapped by
XX utilizing a genetic polymorphism marker as follows: (a) genomic DNA is
XX prepared from a plant homozygously having a mutation to be an object of
XX the mapping; (b) A forward primer 1 containing a base corresponding to
XX the gene polymorphic maker of one ecotype plant, a forward primer 2
XX containing a base corresponding to the genetic polymorphism of the other
XX ecotype plant and a reverse primer 3 based on the base sequence common
XX with both the ecotype plants are prepared; (c) two kinds of
XX oligonucleotides emitting fluorescence of different colors when the
XX genetic polymorphism marker is detected are prepared; (d) an
XX amplification reaction of the genomic DNA is carried out in the presence
XX of the primers 1, 2 and 3 and the two kinds of the oligonucleotides; (e)
XX the fluorescence intensity emitted from the resultant reactional product
XX is detected and (f) the position on the genome of the mutation site is
XX determined from the results of detection. The present sequence is a
XX primer, used to illustrate the invention.
XX
XX Sequence 19 BP; 3 A; 7 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 88.9%; Pred. No. 1.4e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 595 CAAGAGGGGAAGATTGTTG 612
XX
XX DB 18 CAAGAGGGGAACATTGGTG 1
XX
XX RESULT 203
XX ADM88693/c
XX ID ADM88693 standard; DNA; 19 BP.
XX
XX AC ADM88693;
XX
XX DT 15-JUL-2004 (first entry)
XX
XX DE Example nucleotide sequence #14 used in nucleic acid synthesis method.
XX
XX KW Nucleic acid synthesis; continuous nucleotide sequence; exon;
XX
XX gene expression; protein synthesis; gene function; ss.
XX
XX Synthetic.
XX
XX US6730500-B1.
XX
XX 04-MAY-2004.
XX
XX 23-AUG-2001; 2001US-00938077.
XX
XX 30-AUG-2000; 2000US-0229109P.
XX 20-DEC-2000; 2000US-0257079P.
XX
XX (ZYMO ) ZYMOGENETICS INC.
XX
XX Lok S;
XX
XX WPI; 2004-354680/33.
XX
XX Producing nucleic acid that comprises continuous nucleotide sequence to
XX produce protein, by amplifying nucleotide sequences using primer pairs,
XX cleaving amplified products with restriction endonuclease, and ligating
XX cleaved fragments.
XX
XX Disclosure; SEQ ID NO 19; 17pp; English.
XX
XX The present invention relates to a method for producing nucleic acid
XX molecules that comprise continuous nucleotide sequences capable of being
XX transcribed and translated to produce a protein of interest. The method
XX comprises amplifying two nucleotide sequences from a single nucleic acid
XX template using primer pairs, cleaving amplified products with a class IIS
XX restriction endonuclease to produce nucleic acid fragments, and ligating
XX cleaved nucleic acid fragments to produce a nucleic acid comprising a
XX continuous nucleotide sequence. The nucleic acid molecule template is
XX chosen from genomic DNA, cDNA, vector DNA and chemically-synthesized
XX nucleic acid molecule. In the method, each of the amplified products
XX comprises at least a portion of an exon. One or more of the amplified
XX products comprises at least a portion of an exon, and at least one of the
XX amplified products comprises a nucleotide sequence capable of controlling
XX gene expression. In the method, one primer of each primer pair is
XX partially complementary to the antisense strand of the 5' end of an exon,
XX where the other primer of each primer pair is partially complementary to
XX the sense strand of the 3'-end of the exon. One of the amplified products
XX comprises at least one mutation of the nucleotide sequence, which resides
XX in the corresponding nucleic acid molecule template, where at least one
XX mutation resides in an amino acid encoding sequence. The act of
XX amplification is performed using PCR. The method of the invention is
XX useful for producing a nucleic acid molecule that comprises a continuous
XX nucleotide sequence capable of being transcribed and transplanted to
XX produce a protein of interest. The method is useful for restoring gene
XX function rendered inactive by naturally occurring mutations to produce
XX proteins with useful functions, or for producing polypeptides having
XX value in industry, therapeutics, diagnostics or research. The method is
XX an improved method for producing nucleic acid molecules that encode a
XX protein of interest. The present DNA sequence is used in the
XX exemplification of the method of the invention.
XX
XX Sequence 19 BP; 5 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 88.9%; Pred. No. 1.4e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1065 CGTCCAAAGAGGACTCTG 1082
XX
XX DB 19 CTTCCATAGAGGACTCTG 2
XX
XX RESULT 204
XX ADR80686/c
XX ID ADR80686 standard; DNA; 19 BP.
XX
XX AC ADR80686;

```

XX 16-DEC-2004 (first entry)
 XX Human apolipoprotein B (ApoB) oligonucleotide seqid 5183.
 XX
 XX antilipemic; cardiatic; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cystostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
 XX
 XX Homo sapiens.
 XX
 XX W02004080406-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 08-MAR-2004; 2004WO-US007070.
 XX
 XX 07-MAR-2003; 2003US-0452682P.
 XX 12-MAR-2003; 2003US-0454285P.
 XX 13-MAR-2003; 2003US-0454962P.
 XX 13-MAR-2003; 2003US-0455050P.
 XX 14-APR-2003; 2003US-0462894P.
 XX 17-APR-2003; 2003US-0463772P.
 XX 25-APR-2003; 2003US-0465665P.
 XX 25-APR-2003; 2003US-0465802P.
 XX 09-MAY-2003; 2003US-0469612P.
 XX 08-AUG-2003; 2003US-0493986P.
 XX 11-AUG-2003; 2003US-0494597P.
 XX 26-SEP-2003; 2003US-0506341P.
 XX 09-OCT-2003; 2003US-0510246P.
 XX 10-OCT-2003; 2003US-0510318P.
 XX 07-NOV-2003; 2003US-0518453P.
 XX
 XX (ALNY-) ALNYLAM PHARM.
 XX
 XX Manoharan M, Bumcrot D;
 XX WPI; 2004-677362/66.
 XX
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX
 XX Example 5; SEQ ID NO 5183; 378pp; English.
 XX
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-

CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.

XX Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 1.4e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 400 AGAAAGTTCACCTCGAGC 417

Db 19 AGTAAAGTTCTCTCGAGC 2

RESULT 205

ADR81197

ID ADR81197 standard; DNA; 19 BP.

XX AC ADR81197;

XX DT 16-DEC-2004 (first entry)

XX DE Hepatitis C virus (HCV) oligonucleotide seqid 5696.

XX antilipemic; cardiatic; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cystostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.

XX Hepatitis C virus.

XX W02004080406-A2.

XX PD 23-SEP-2004.

XX PF 08-MAR-2004; 2004WO-US007070.

XX PR 07-MAR-2003; 2003US-0452682P.

XX PR 12-MAR-2003; 2003US-0454285P.

XX PR 13-MAR-2003; 2003US-0454962P.

XX PR 13-MAR-2003; 2003US-0455050P.

XX PR 14-APR-2003; 2003US-0462894P.

XX PR 17-APR-2003; 2003US-0463772P.

XX PR 25-APR-2003; 2003US-0465665P.

XX PR 25-APR-2003; 2003US-0465802P.

XX PR 09-MAY-2003; 2003US-0469612P.

XX PR 08-AUG-2003; 2003US-0493986P.

XX PR 11-AUG-2003; 2003US-0494597P.

XX PR 26-SEP-2003; 2003US-0506341P.

XX PR 09-OCT-2003; 2003US-0510246P.

XX PR 10-OCT-2003; 2003US-0510318P.

XX PR 07-NOV-2003; 2003US-0518453P.

XX PA (ALNY-) ALNYLAM PHARM.

XX FI Manoharan M, Bumcrot D;

XX WPI; 2004-677362/66.

XX Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.

XX Example 5; SEQ ID NO 5696; 378pp; English.

XX The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
CC be used to control HCV gene expression.
XX Sequence 19 BP; 8 A; 7 C; 3 G; 1 T; 0 U; 0 Other;
SQ

Query Match 0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.4e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
SQ Sequence 19 BP; 8 A; 7 C; 3 G; 1 T; 0 U; 0 Other;

Qy 374 CCAAAACCTGCAGCAAGA 391
Db 2 CGAAACCTGCAGCAACA 19

RESULT	206	
ADNR78028/c		
ID	ADNR78028	standard; DNA; 19 BP.
XX		
XX	ADNR78028;	
XX		
XX	16-DEC-2004	(first entry)
DT		
DT		
XX		
DE	Human apolipoprotein B (ApoB)	oligonucleotide seqid 2513.
XX		
KW	antilipemic;	cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW	cytostatic;	anticonvulsant; nootropic; muscula; anti-HIV;
KW	RNA interference;	IRNA; antisense technology; lipid metabolism;
KW	cholesterol imbalance;	dyslipidaemia hypercholesterolaemia;
KW	coronary artery disease;	CAD; coronary heart disease; CHD;
KW	atherosclerosis;	hepatic glucose production;
KW	glucose-metabolism-related disorder;	diabetes; cancer; breast cancer;
KW	colon cancer;	lung cancer; neurological disease; Huntington disease;
KW	spinocerebellar ataxia;	viral disease; AIDS; apolipoprotein B; apoB; s.
XX		
OS	Homo sapiens.	

PN WO2004080406-A2.

23-SEP-2004.

08-MAR-2004; 2004WO-US007070.

XX
PR 07-MAR-2003: 2003US-0452682P.

PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.

PR 13-MAR-2003; 2003US-0455050P.

PR	14-APR-2003	2003US-04628944
PR	17-APR-2003	2003US-04637722
PR	21-APR-2003	2003US-04637659
PR	23-APR-2003	2003US-04658659
PR	25-APR-2003	2003US-04658022
PR	9-MAY-2003	2003US-04696122
PR	08-AUG-2003	2003US-04939866
PR	11-AUG-2003	2003US-04945977
PR	18-AUG-2003	2003US-05063412
PR	26-SEP-2003	2003US-05102466
PR	03-OCT-2003	2003US-05103182
PR	10-OCT-2003	2003US-05103182
PR	07-NOV-2003	2003US-05184539

PA (ALNY-) ALNYLAM PHARM.

PI Manoharan M, Bumcrot D;

WPI: 2004-677362/66.

Interference RNA agent useful for treating dyslipidemias, coronary artery disease, diabetes, cancer or neurological disease, comprises sense sequence and antisense sequence which has specific modifications.

XX
PS
Example 5: SEQ ID NO 2513: 378pp: English:

The invention describes a RNA interference (iRNA) agent (I) comprising a sense sequence and an antisense sequence, where the sense sequences have one or more asymmetrical 2'-O alkyl modifications, the antisense sequences have one or more asymmetrical phosphorothioate modifications and the antisense sequence targets a human gene sequence. Also described are: a pharmaceutical preparation comprising (I); reducing (MI) apob-100 levels or glucose-6-phosphatase levels in a subject; producing (I); stabilising (I), involves selecting a sequence with activity and introducing one or more asymmetrical modification in the sequence, where the modification decreases nuclease sensitivity while not decreasing its activity; a kit comprising (I) and instruction for its use; and a device that can be dispense or administer a composition comprising (I). (I) is useful for reducing apob-100 levels or glucose-6-phosphatase levels. (MI) is useful for reducing apob-100 levels or glucose-6-phosphatase levels. The subject is suffering from a disorder characterised by elevated or otherwise unwanted expression of apob-100, elevated or otherwise unwanted levels of cholesterol, and/or dysregulation of lipid metabolism. The disorder is chosen from the HDL/LDL cholesterol imbalance, dyslipidaemias, hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary artery disease (CAD), coronary heart disease (CHD) and atherosclerosis. (I) is administered to a subject to inhibit hepatic glucose production or for treating glucose-metabolism-related disorder e.g. diabetes or type-2 diabetes. (I) is useful for treating the diseases as mentioned above, cancer (e.g. breast, colon or lung cancer), neurological disease (e.g., Huntington disease or spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence represents a human apolipoprotein B (ApoB) antisense oligonucleotide that can be used to control ApoB gene expression.

Sequence 19 BP: 5 A: 5 C: 4 G: 5 T: 0 U: 0 Other: 0

Query Match	0.8%;	Score 14.8;	DB 1;	Length 19;
Best Local Similarity	88.9%;	Pred. No. 1.4e+02;		
Matches	16:	Conservative	2:	Indels
		Mismatches	0:	Gaps

Qy 400 AGAAAGTTACCTGGAGC 417
 |||||
 pb 19 AGTAAGTTCTCCTGGAGC 2

RESULT 207

ABL57076
ID ABL

XX
DD DD/DD/DD, DDMM, YY ZZAC
XX
ABJ37076;XX
DT 22-JUL-2002 (FIRST ENTRY)

DE MOLECULAR BEACON TARGET SEQUENCE (SINGLE MISMATCH):

XX Molecular beacon; fluorophore; nanoparticle; nucleic acid detection; ss.
 XX Synthetic.
 XX Key Location/Qualifiers
 FT misc_feature 9 /*tag= a
 FT /note= "mismatch site"
 XX WO200218951-A2.
 XX 07-MAR-2002.
 XX 29-AUG-2001; 2001WO-US041941.
 XX 29-AUG-2000; 2000US-0228728P.
 XX 30-MAR-2001; 2001US-0280350P.
 XX (UVRQ) UNIV ROCKEFELLER.
 XX Dubertret B, Calame M, Libchaber A;
 XX WPI; 2002-404569/43.
 XX Sensitive detecting proximity changes in a system that utilizes an
 PT interacting fluorophore and quencher, for high sensitivity applications,
 PT involves utilizing a metal surface as quencher.
 XX Example 3; Page 30; 62pp; English.
 XX The present sequence is that of a single mismatch target sequence for a
 CC molecular beacon comprising an oligonucleotide probe (see ABL57069)
 CC covalently attached at the 3' end to fluorescent dye and at the 5' end to
 CC a nanoparticle. In the native state, the probe forms a hairpin
 CC conformation with hybridised termini. The proximity of the fluorophore
 CC and quencher (gold nanoparticle) in the molecular beacon results in
 CC little or no detectable fluorescence. Upon hybridisation of the central
 CC complementary stretch of the probe to a target sequence, such as the
 CC present sequence, the hairpin undergoes a conformational change resulting
 CC in an increase in fluorescence, the extent of which is proportional to
 CC the amount of target sequence present. Experiments with the present
 CC sequence and a perfectly-matched target (see ABL57071) showed that
 CC hybridisation was very specific to the matched target. The invention
 CC relates generally to the use of metal surface quenchers such as particles
 CC or films for high sensitivity applications in, for example, detection and
 CC diagnostic systems
 XX Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 14.4; DB 1; Length 16;
 Best Local Similarity 93.8%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1834 GAAAAA AAAAAA 1849
 Db 1 GAAAAA AAAAAA 16
 RESULT 208
 AAD57846
 ID AAD57846 standard; DNA; 16 BP.
 XX AC AAD57846;
 XX 20-NOV-2003 (first entry)
 XX Target oligonucleotide #3 used in nonlinear optical technique.
 DE Nonlinear optical technique; screening; ss.
 KW Unidentified.
 XX

PN WO2003064991-A2.
 PD 07-AUG-2003.
 XX 17-JUL-2002; 2002WO-US022681.
 XX 17-JUL-2001; 2001US-0306040P.
 PR 23-OCT-2001; 2001US-0347821P.
 PR 06-FEB-2002; 2002US-0354668P.
 XX (SALA/) SALAFSKY J S.
 XX Salafsky JS;
 XX WPI; 2003-646172/61.
 XX Screening candidate binding partner(s) for binding to test molecule by
 PT applying external force field to sample in homogeneous phase,
 PT illuminating sample with light beam(s) at fundamental frequencies, and
 PT measuring physical properties.
 XX Disclosure; Fig 20-B; 146pp; English.
 XX The present invention relates to a method for detecting interactions
 CC between biological components using a nonlinear optical technique. The
 CC invention is used for screening candidate binding partner(s) for binding
 CC to test molecule. It can also be used to detect changes in orientation or
 CC conformation of the probe and/or target. The present sequence is a target
 CC oligonucleotide used in nonlinear optical technique
 XX Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 14.4; DB 1; Length 16;
 Best Local Similarity 93.8%; Pred. No. 1.3e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1834 GAAAAA AAAAAA 1849
 Db 1 GAAAAA AAAAAA 16
 RESULT 209
 ADF23332
 ID ADF23332 standard; DNA; 16 BP.
 XX AC ADF23332;
 XX 12-FEB-2004 (first entry)
 XX Binding partner screening method molecular beacon analogue #3.
 DE binding partner screening; light beam; nonlinear optical light beam; ss;
 KW molecular beacon analogue.
 XX Synthetic.
 XX US2003148391-A1.
 XX 07-AUG-2003.
 XX 06-JUN-2002; 2002US-00164915.
 XX 24-JAN-2002; 2002US-0351879P.
 PR 06-FEB-2002; 2002US-0354668P.
 PR 06-FEB-2002; 2002US-0354679P.
 PR 05-MAR-2002; 2002US-0362003P.
 XX (SALA/) SALAFSKY J S.
 XX Salafsky JS;
 XX WPI; 2003-897567/82.
 XX

PT Screening of candidate binding partners for binding to test molecule
PT comprises illuminating sample with light beams and measuring physical
PT properties of nonlinear optical light beam emanating from sample.
XX
PS Disclosure; SEQ ID NO 3; 58pp; English.
XX
CC The invention describes screening a candidate binding partner by
CC illuminating the sample with light beams at fundamental frequencies to
CC binding partners, and measuring physical properties of a nonlinear
CC optical light beam emanating from sample. On binding to the test molecule
CC the properties change relative to that in absence of exposure of the test
CC molecule. The invention is used in the screening of candidate binding
CC partners for binding to test molecule. This sequence represents a
CC molecular beacon analogue, an exemplary test molecule of the invention.
XX
SQ Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1834 GAAAAAAAAAAAAA 1849
DB 1 GAAAAAAAAAAAAA 16
RESULT 210
ADSI5827
ID ADSI5827 standard; DNA; 16 BP. .
XX
AC ADSI5827;
XX
DT 02-DEC-2004 (first entry)
XX
DE Control probe targeted to labelled/bound oligo in binding analysis.
XX
KW binding; sequence detection; reaction kinetics; ss; probe.
XX
OS Synthetic.
XX
PN DEI0307801-A1.
XX
PD 09-SEP-2004.
XX
PF 24-FEB-2003; 2003DE-01007801.
XX
PR 24-FEB-2003; 2003DE-01007801.
XX
PA (ADVA-) ADVALYTIX AG.
XX
PI Kirchner R, Gauer C;
XX
DR WPI; 2004-654186/64.
XX
PT Analyzing binding between macromolecules, useful for detecting nucleic
PT acids by hybridization, where a labeled detector molecule is immobilized
PT and becomes fluorescent only after specific binding.
XX
PS Example; Page 6; 11pp; German.
XX
CC The invention relates to a novel analytical method for examining binding
CC events between first and second macromolecules. The method comprises
CC preparing a surface on which a fluorescently-labelled first macromolecule
CC is bound and which is at least partly fitted with a fluorescence-
CC suppressing layer. A sample liquid containing the second macromolecule is
CC applied and fluorescence is measured. The first macromolecule has a
CC secondary structure such that its fluorescence is suppressed by the
CC suppressing layer when it is not specifically bound to the second
CC macromolecule, but fluorescence is not suppressed when the two
CC macromolecules are specifically bound. The method of the invention may be
CC used to detect hybridisation of RNA or, particularly DNA, especially for
CC detecting the presence of particular sequences in samples, but also for
CC studying reaction kinetics. The method allows the use of molecular

CC beacons that are simple to prepare or synthesize, particularly because
CC they do not require incorporation of a quencher. The current sequence is
CC that of the control probe of the invention which is targeted to the
CC fluorescent-labelled and bound DNA oligonucleotide in the binding
CC analysis method.
XX
SQ Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1834 GAAAAAAAAAAAAA 1849
DB 1 GAAAAAAAAAAAAA 16
RESULT 211
AAA25490
ID AAA25490 standard; DNA; 17 BP.
XX
AC AAA25490;
XX
DT 19-JUL-2000 (first entry)
XX
DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1988.
XX
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
XX
OS Homo sapiens.
XX
PN WO954459-A2.
XX
PD 28-OCT-1999.
XX
PF 19-APR-1999; 99WO-US008547.
XX
PR 20-APR-1998; 98US-0082404P.
XX
PR 23-JUN-1998; 98US-00103636.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerli P;
PI Matulic-Adamic J;
XX
DR WPI; 2000-013248/01.
XX
PT New nucleic acids that interact, and optionally cleave, target sequences,
PT used to treat cancer.
XX
PS Claim 77; Page 81; 148pp; English.
XX
CC The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphorodithioate
CC link, having endonuclease activity. (A), and more generally any catalytic
CC nucleic acid (A') that modulates expression of the oestrogen receptor
CC gene, are used to treat cancer (particularly of breast or endometrium),
CC in vivo or by transforming cells ex vivo and implanting treated cells, or
CC for other conditions associated with levels of oestrogen receptor.
CC Because of the high selectivity for targeted RNA, (A) can also be used to
CC correlate inhibition of gene expression with alterations in phenotype,
CC particularly for identification of therapeutic targets, and as research
CC reagents (for RNA, in the same way that restriction endonucleases are
CC used with DNA). The combination of modifications in (A) improves
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC AAA24748 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA24748 to AAA25992 represent their corresponding target sequences.
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC sequences, and AAA26107 to AAA26218 represent their corresponding target

CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present
CC invention

XX SQ Sequence 17 BP; 4 A; 5 C; 1 G; 7 T; 0 U; 0 Other;
SQ Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1324 TCAACTTTTGGATCCA 1339
Db 1 TCAACTTTTGGATCCA 16

RESULT 212
AAA25488
ID AAA25488 standard; DNA; 17 BP.
XX AC
XX AAA25488;
XX DT
XX 19-JUL-2000 (first entry)
XX DE
XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1986.
XX KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
XX OS Homo sapiens.
XX PN WO9954459-A2.
XX FN
XX PD 28-OCT-1999.
XX PF 19-APR-1999; 99WO-US008547.
XX PR 20-APR-1998; 98US-0082404P.
XX PR 23-JUN-1998; 98US-00103636.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;
PI Matulic-Adamic J;
XX DR WPI; 2000-013248/01.
XX PT New nucleic acids that interact, and optionally cleave, target sequences,
XX used to treat cancer.
XX PS
XX Claim 77; Page 81; 148pp; English.

XX The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphorodithioate
CC link, having endonuclease activity. (A), and more generally any catalytic
CC nucleic acid (A') that modulates expression of the oestrogen receptor
CC gene, are used to treat cancer (particularly of breast or endometrium),
CC in vivo or by transforming cells ex vivo and implanting treated cells, or
CC for other conditions associated with levels of oestrogen receptor.
CC Because of the high selectivity for targeted RNA, (A) can also be used to
CC correlate inhibition of gene expression with alterations in phenotype,
CC particularly for identification of therapeutic targets, and as research
CC reagents (for RNA, in the same way that restriction endonucleases are
CC used with DNA). The combination of modifications in (A) improves
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC AAA24748 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA25993 to AAA25992 represent their corresponding target sequences.
CC AAA26219 to AAA26271 represent oestrogen receptor hairpin ribozyme
CC sequences, and AAA26107 to AAA26218 represent their corresponding target
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present

CC invention
XX SQ Sequence 17 BP; 4 A; 4 C; 1 G; 8 T; 0 U; 0 Other;
SQ Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1323 ATCAACTTTTGGATCC 1338
Db 2 ATCAACTTTTGGATCC 17

RESULT 213
AAA25596
ID AAA25596 standard; DNA; 17 BP.
XX AC
XX AAA25596;
XX DT
XX 19-JUL-2000 (first entry)
XX DE
XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:2094.
XX KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
XX OS Homo sapiens.
XX PN WO9954459-A2.
XX FN
XX PD 28-OCT-1999.
XX PF 19-APR-1999; 99WO-US008547.
XX PR 20-APR-1998; 98US-0082404P.
XX PR 23-JUN-1998; 98US-00103636.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;
PI Matulic-Adamic J;
XX DR WPI; 2000-013248/01.
XX PT New nucleic acids that interact, and optionally cleave, target sequences,
XX used to treat cancer.
XX PS
XX Claim 77; Page 84; 148pp; English.

XX The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphorodithioate
CC link, having endonuclease activity. (A), and more generally any catalytic
CC nucleic acid (A') that modulates expression of the oestrogen receptor
CC gene, are used to treat cancer (particularly of breast or endometrium),
CC in vivo or by transforming cells ex vivo and implanting treated cells, or
CC for other conditions associated with levels of oestrogen receptor.
CC Because of the high selectivity for targeted RNA, (A) can also be used to
CC correlate inhibition of gene expression with alterations in phenotype,
CC particularly for identification of therapeutic targets, and as research
CC reagents (for RNA, in the same way that restriction endonucleases are
CC used with DNA). The combination of modifications in (A) improves
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC AAA24748 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA25993 to AAA25992 represent their corresponding target sequences.
CC AAA26219 to AAA26271 represent oestrogen receptor hairpin ribozyme
CC sequences, and AAA26107 to AAA26218 represent their corresponding target
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present
XX invention

SQ Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1569 GCAACTTGGAAACT 1584
|||||
Db 2 GCAACTTGGAAACT 17
RESULT 214
ABK03734
ID ABK03734 standard; RNA; 17 BP.
AC ABK03734;
DT 12-MAR-2002 (first entry)
XX Human CD20 Antibody #83.
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hamsterhead ribozyme;
KW DNazyme; inozyme; G-cleaver; ambzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX Homo sapiens.
OS Synthetic.
OS
XX
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B W.
XX
XX Blatt L, Mcswiggen J, Chowrira BM;
PI WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
XX Claim 30; Page 168; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
CC an ambzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of

CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapeutics. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapeutics. In particular, the NOGO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an ambzyme molecule of the invention
XX

SQ Sequence 17 BP; 11 A; 0 C; 4 G; 0 T; 2 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.4e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 202 AAATRAAAGAGAAAT 217
|||||
Db 1 AAATRAAAGAGAGAU 16

RESULT 215
ABN10039/C
ID ABN10039 standard; DNA; 17 BP.
XX
XX AC ABN10039;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10031.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234587P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
PA
XX

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 10031; 214pp; English.
 PS
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1065 CGTCCAGAGGAGCTC 1080
 Db 16 CGTCCAGAGGAGCTC 1
 RESULT 216
 ABN08373
 ID AEN08373 standard; DNA; 17 BP.
 AC AEN08373;
 XX
 DT 29-MAY-2002 (first entry)
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8365.
 XX
 XX Human; genome-derived myosin-like protein 1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 OS
 XX WO200192524-A2.
 PN
 XX
 PD 06-DEC-2001.
 XX
 XX 25-MAY-2001; 2001WO-US0016981.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 8365; 214pp; English.
 PS
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 395 GCTGGAGAAAGTTCAC 410
 Db 1 GCTGGAGAAAGTTCAC 16
 RESULT 217
 ABN10038/c
 ID AEN10038 standard; DNA; 17 BP.
 AC AEN10038;
 XX
 XX 29-MAY-2002 (first entry)
 DT
 XX
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10030.
 DE
 XX
 XX Human; genome-derived myosin-like protein 1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 OS Homo sapiens.
 XX
 XX WO200192524-A2.
 PN
 XX

PD 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 10030; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX Sequence 17 BP; 2 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1065 CGTCCAAAGAGGACTC 1080
 ||||| |||||
 Db 17 CGTCCACAGAGGACTC 2
 RESULT 218
 ABN08372
 ID ABN08372 standard; DNA; 17 BP.
 XX AC ABN08372;
 XX 29-MAY-2002 (first entry)

Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8364.
 Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 skeletal muscle disorder; amplicon; screening; ss.
 Homo sapiens.
 WO200192524-A2.
 06-DEC-2001.
 25-MAY-2001; 2001WO-US016981.
 26-MAY-2000; 2000US-0207456P.
 21-SEP-2000; 2000US-0234687P.
 27-SEP-2000; 2000US-0236359P.
 04-OCT-2000; 2000GB-00024263.
 30-JAN-2001; 2001WO-US000661.
 30-JAN-2001; 2001WO-US000662.
 30-JAN-2001; 2001WO-US000663.
 30-JAN-2001; 2001WO-US000664.
 30-JAN-2001; 2001WO-US000665.
 30-JAN-2001; 2001WO-US000666.
 30-JAN-2001; 2001WO-US000667.
 30-JAN-2001; 2001WO-US000668.
 30-JAN-2001; 2001WO-US000669.
 05-FEB-2001; 2001US-0266860P.
 (AEOM-) AEOMICA INC.
 Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 WPI; 2002-179446/23.
 New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 or as specific biomolecule capture probes for surface-enhanced laser
 desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 Disclosure; SEQ ID NO 8364; 214pp; English.
 The present invention describes a human genome-derived myosin-like
 protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 nucleic acids can be used as probes to detect, characterise and quantify
 hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 provide initial substrates for the recombinant engineering of hGDMPLP-1
 protein variants having desired phenotypic improvements, and for
 expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 used as immunogens to raise antibodies that specifically recognise hGDMPLP
 -1 proteins, as standards in assays used to determine the concentration
 and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 capture probes for surface-enhanced laser desorption/ionisation, as
 therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 production, and in vaccines or for replacement therapy. The
 polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 disorder associated with the expression of hGDMPLP-1, in particular heart
 and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 The present sequence represents an oligomer used in the screening of the
 hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 The sequence data for this patent did not form part of the printed
 specification, but was obtained in electronic format directly from WIPO
 at ftp.wipo.int/pub/published_pct_sequence
 Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 395 GCTGGAGAAAGTTTCC 410


```

DT 22-APR-2004 (first entry)
XX WNV minus strand DNazyme substrate SEQ ID NO 13702.
DE
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
XX WO200268637-A2.
PN
XX
XX 06-SEP-2002.
PD
XX
XX 19-OCT-2001; 2001WO-US048350.
PF
XX
XX 20-OCT-2000; 2000US-0242411P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX
XX WPI; 2002-706994/76.
DR
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
PT
XX
XX Claim 23; SEQ ID NO 13702; 495pp; English.
PS
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1241 CAGGGCCATCATGGAG 1256
DB |||||
17 CAGGGCCATCATTTGAG 2

RESULT 222
ACN12456/c
ID ACN12456 standard; RNA; 17 BP.
XX
XX ACN12456;
AC
XX
XX 22-APR-2004 (first entry)
DT
XX
XX WNV minus strand Zinzyme substrate SEQ ID NO 12459.
DE
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX
XX WO200268637-A2.
PN
XX
XX 06-SEP-2002.
PD
XX
XX 19-OCT-2001; 2001WO-US048350.
PF
XX
XX 20-OCT-2000; 2000US-0242411P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX
XX WPI; 2002-706994/76.
DR
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
PT
XX
XX Claim 23; SEQ ID NO 13702; 495pp; English.
PS
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1239 GCCAGGGCCATCATGG 1254
DB |||||
16 GCCAGGGCCATCATTTG 1

RESULT 223
ACN01677/c
ID ACN01677 standard; RNA; 17 BP.
XX
XX ACN01677;
AC
XX
XX 22-APR-2004 (first entry)
DT
XX
XX WNV Inozyme substrate SEQ ID NO 1667.
DE
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX
XX WO200268637-A2.
PN
XX
XX

```

KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.

OS West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (WNV), useful for treating a condition related to WNV infection e.g.

XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 12459; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
 of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 treating a condition related to WNV infection e.g. pancreatitis,
 encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 molecule is selected from the group of ribozymes consisting of
 Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 nucleic acid molecules further comprise at least five ribose residues, at
 least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 least three of the 5' terminal nucleotides and a 3' end modification of a
 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 in the specification. The present sequence is that of a nucleic acid
 molecule of the invention

XX Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;

XX Query Match 0.8%; Score 14.4; DB 1; Length 17;

XX Best Local Similarity 93.8%; Pred. No. 1.4e+02;

XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1239 GCCAGGGCCATCATGG 1254

DB |||||

ACN01677/c

ID ACN01677 standard; RNA; 17 BP.

XX ACN01677;

XX 22-APR-2004 (first entry)

XX WNV Inozyme substrate SEQ ID NO 1667.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX

PD 06-SEP-2002.
 XX 19-OCT-2001; 2001WO-US048350.
 XX 20-OCT-2000; 2000US-0242411P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 XX Claim 23; SEQ ID NO 1667; 495pp; English.
 XX WPI; 2002-706994/76.
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention.
 XX Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
 SQ Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 328 GACTGAGTGGCTCCAA 343
 Db 16 GCCTGAGTGGCTCCAA 1
 RESULT 224
 ACN15154
 ID ACN15154 standard; RNA; 17 BP.
 AC ACN15154;
 XX 22-APR-2004 (first entry)
 DT WNV minus strand Amberzyme substrate SEQ ID NO 15157.
 XX
 DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX West Nile Virus.
 OS WO200268637-A2.
 XX 06-SEP-2002.
 PD 19-OCT-2001; 2001WO-US048350.
 XX 20-OCT-2000; 2000US-0242411P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 XX Claim 23; SEQ ID NO 15157; 495pp; English.
 XX WPI; 2002-706994/76.
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention.
 XX Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
 SQ Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 328 GACTGAGTGGCTCCAA 343
 Db 16 GCCTGAGTGGCTCCAA 1
 RESULT 224
 ACN15154
 ID ACN15154 standard; RNA; 17 BP.
 AC ACN15154;
 XX 22-APR-2004 (first entry)
 DT WNV minus strand Amberzyme substrate SEQ ID NO 15157.
 XX
 DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX West Nile Virus.
 OS WO200268637-A2.
 XX 06-SEP-2002.
 PD 19-OCT-2001; 2001WO-US048350.
 XX 20-OCT-2000; 2000US-0242411P.
 XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 PI Blatt L, Mcswiggen JA;
 XX WPI; 2002-706994/76.
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX Claim 23; SEQ ID NO 15157; 495pp; English.
 XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention.
 XX Sequence 17 BP; 3 A; 6 C; 5 G; 0 T; 3 U; 0 Other;
 SQ Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 1.4e+02;
 Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 Qy 328 GACTGAGTGGCTCCAA 343
 Db 1 GCCUGAGUGGCUCCAA 16
 RESULT 225
 ABZ61174/c
 ID ABZ61174 standard; RNA; 17 BP.
 XX ABZ61174;
 AC ABZ61174;
 XX 21-MAR-2003 (first entry)
 DT Human K-Ras DNazyme substrate #1286.
 XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.
 XX Homo sapiens.
 OS WO200297114-A2.
 XX 05-DEC-2002.
 PD 29-MAY-2002; 2002WO-US016940.
 XX 29-MAY-2001; 2001US-0294140P.
 PR 06-JUN-2001; 2001US-0296249P.
 PR 10-SEP-2001; 2001US-0318471P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Mcswiggen J;
 PI WPI; 2003-140484/13.
 XX Novel short interfering RNA and enzymatic nucleic acid useful for treating cancer, modulates the expression of a nucleic acid encoding

PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
 XX
 PS Claim 58; Page 109; 185pp; English.
 XX
 CC The invention relates to a novel short interfering RNA (siRNA) nucleic acid molecule or an enzymatic nucleic acid molecule, that modulates expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras, human immunodeficiency virus (HIV) or a component of HIV. The nucleic acid molecule of the invention has cytostatic, anti-HIV, and anti-rheumatic activity. The nucleic acid molecules are useful for reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are also useful for treating breast, ovarian, colorectal, lung, prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences shown in AB259889 - AB262216, AB264544 - AB265531, AB266520 - AB266524, AB266530 - AB266585 represent substrate/target sequences for the human CC ribozymes of the invention
 XX
 SQ Sequence 17 BP; 8 A; 4 C; 2 G; 0 T; 3 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1440 ATGAATGTTGCTGCTG 1455
 Db 16 ATTAATGTTGCTGCTG 1
 RESULT 226
 ACDS0766/c
 ID ACDS0766 standard; RNA; 17 BP.
 XX
 AC ACDS0766;
 XX
 DT 23-SEP-2003 (first entry)
 XX
 DE HBV hammerhead ribozyme substrate sequence #232.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis B virus.
 XX
 XX WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 XX 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (NACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey J, Morrissey D, Lee P;
 PI Draper K, Roberts E;

XX
 DR WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus infection.
 XX
 PS Example 1; Page 140; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of Hepatitis C virus (HCV) or Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes, inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed are nucleic acid/decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences, as well as oligonucleotides that specifically bind the Enhancer I region of HBV DNA. The nucleic acids may be used to modulate the expression of HBV genes and HBV viral replication. Also disclosed is a method for screening compounds and/or potential therapies directed against HBV, and compounds that modulate the expression and/or replication of HCV. The compounds and methods of the invention are useful for the treatment of degenerative and disease states related to HBV and HCV infection, replication and gene expression such as cirrhosis, liver failure, and hepatocellular carcinoma. The present sequence represents a substrate for one of the HBV ribozyme, inozyme, G-cleaver, zinzyme, DNzyme or amberyne sequences disclosed in the present invention
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 2 G; 0 T; 8 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 530 AGGCATTACAGCAGAA 545
 Db 17 AGGCATTAAAGCAGAA 2
 RESULT 227
 ACDB63373
 ID ACDB63373 standard; RNA; 17 BP.
 XX
 AC ACDB63373;
 XX
 DT 30-SEP-2003 (first entry)
 XX
 DE HCV minus strand DNzyme substrate sequence #1012.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 XX
 XX WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 XX 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 XX Claim 1; Page 293; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinczymes, amberyzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 1.4e+02;
 Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 QY 1005 GATGGCGGTGGAGCCT 1020
 DB ||:||||:||||:
 2 GAUGGGGUGGAGCCU 17
 RESULT 228
 ACD59296/C
 ID ACD59296 standard; RNA; 17 BP.
 XX
 AC ACD59296;
 XX
 DT 24-SEP-2003 (first entry)
 XX
 DE HCV DNazyme substrate sequence #1266.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinczyme;
 KW amberyzyme; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO200281494-A1.
 XX

PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX WPI; 2003-229207/22.
 XX
 PT Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 XX Claim 1; Page 256; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinczymes, amberyzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP; 3 A; 10 C; 2 G; 0 T; 2 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1005 GATGGCGGTGGAGCCT 1020
 DB |||||:|||||||
 17 GATGGGGGTGGAGCCT 2
 RESULT 229
 ACD59612/C
 ID ACD59612 standard; RNA; 17 BP.
 XX
 AC ACD59612;
 XX
 DT 24-SEP-2003 (first entry)
 XX
 DE HCV DNazyme substrate sequence #1414.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;

KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; HCV infection; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis C virus.
XX
XX WO200281494-A1.
XX
XX 17-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
XX
XX 08-JUN-2001; 2001US-00877478.
XX
XX 08-JUN-2001; 2001US-0296876P.
XX
XX 24-OCT-2001; 2001US-0335059P.
XX
XX 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX (BLAT/) BLATT L.
XX
XX (NACE/) MACEJAK D.
XX
XX (MCSW/) MCSWIGGEN J.
XX
XX (MORR/) MORRISSEY D.
XX
XX (PAVC/) PAVCO P.
XX
XX (LEEP/) LEE P.
XX
XX (DRAP/) DRAPER K.
XX
XX (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX Draper K, Roberts E;
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
XX hepatocellular carcinoma, or condition associated with hepatitis C virus
XX infection.
XX
XX Claim 1; Page 259; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
XX Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
XX inozymes, zinzymes, amberzymes, and G-cleaver ribozymes, DNazymes,
XX are nucleic acid decoy molecules and aptamers that bind to HBV reverse
XX transcriptase and/or HBV reverse transcriptase primer sequences, as well
XX as oligonucleotides that specifically bind the Enhancer I region of HBV
XX DNA. The nucleic acids may be used to modulate the expression of HBV
XX genes and HBV viral replication. Also disclosed is a method for screening
XX compounds and/or potential therapies directed against HBV, and compounds
XX that modulate the expression and/or replication of HCV. The compounds and
XX methods of the invention are useful for the treatment of degenerative and
XX disease states related to HBV and HCV infection, replication and gene
XX expression such as cirrhosis, liver failure, and hepatocellular
XX carcinoma. The present sequence represents a substrate for one of the HCV
XX DNazyme or minus strand DNazyme sequences disclosed in the present
XX invention
XX
XX Sequence 17 BP; 4 A; 9 C; 2 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 0.8%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 1.4e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1173 CTGGTGATGAGGCTG 1188
XX Db 16 CTGGTGATGAGGCTG 1
XX
XX RESULT 230

ACD50768/c
ID ACD50768 standard; RNA; 17 BP.
XX
XX ACD50768;
AC
XX
XX 23-SEP-2003 (first entry)
DT
XX
XX HBV hammerhead ribozyme substrate sequence #234.
DE
XX
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
XX Hepatitis B virus.
OS
XX
XX WO200281494-A1.
XX
XX 17-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-US009187.
XX
XX 26-MAR-2001; 2001US-00817879.
XX
XX 08-JUN-2001; 2001US-00877478.
XX
XX 08-JUN-2001; 2001US-0296876P.
XX
XX 24-OCT-2001; 2001US-0335059P.
XX
XX 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX (BLAT/) BLATT L.
XX
XX (NACE/) MACEJAK D.
XX
XX (MCSW/) MCSWIGGEN J.
XX
XX (MORR/) MORRISSEY D.
XX
XX (PAVC/) PAVCO P.
XX
XX (LEEP/) LEE P.
XX
XX (DRAP/) DRAPER K.
XX
XX (ROBE/) ROBERTS E.
XX
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX Draper K, Roberts E;
XX WPI; 2003-229207/22.
XX
XX Novel compound useful for treating cirrhosis, liver failure,
XX hepatocellular carcinoma, or condition associated with hepatitis C virus
XX infection.
XX
XX Example 1; Page 140; 387pp; English.
XX
XX The present invention relates to nucleic acid molecules which modulate
XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
XX Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
XX inozymes, zinzymes, amberzymes, and G-cleaver ribozymes, DNazymes,
XX are nucleic acid decoy molecules and aptamers that bind to HBV reverse
XX transcriptase and/or HBV reverse transcriptase primer sequences, as well
XX as oligonucleotides that specifically bind the Enhancer I region of HBV
XX DNA. The nucleic acids may be used to modulate the expression of HBV
XX genes and HBV viral replication. Also disclosed is a method for screening
XX compounds and/or potential therapies directed against HBV, and compounds
XX that modulate the expression and/or replication of HCV. The compounds and
XX methods of the invention are useful for the treatment of degenerative and
XX disease states related to HBV and HCV infection, replication and gene
XX expression such as cirrhosis, liver failure, and hepatocellular
XX carcinoma. The present sequence represents a substrate for one of the HBV
XX ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberzyme sequences
XX disclosed in the present invention
XX
XX Sequence 17 BP; 2 A; 4 C; 2 G; 0 T; 9 U; 0 Other;

```

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 529 AAGCATTACAGCAGA 544
DB 16 AAGCATTAAAGCAGA 1

RESULT 231
ACC65059
ID ACC65059 standard; DNA; 17 BP.
XX
AC ACC65059;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2306.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrania; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 300; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC6806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrania
XX
SQ Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 492 ATCTGGCTCTTGCA 507
DB 2 ATCTGGCTCTTGCA 17

RESULT 232
ACC63426/c
ID ACC63426 standard; DNA; 17 BP.
XX

```

```

ACC63426;
01-JUL-2003 (first entry)
Murine oligonucleotide associated with tumour suppression, SEQ ID 673.
Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
tumour suppression; tumour reversion; apoptosis; virus resistance;
viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
schizophrania; ss.
Mus musculus.
WO2003025176-A2.
27-MAR-2003.
17-SEP-2002; 2002WO-IB004210.
17-SEP-2001; 2001FR-00011979.
(MOLE-) MOLECULAR ENGINES LAB.
Telerman A, Amson R, Tuijnder M;
WPI; 2003-333167/31.
New isolated nucleic acid, useful for treating viral diseases associated
with tumors and cell degeneration, also related polypeptides, antibodies
and transfected cells.
Disclosure; Page 109; 738pp; French.
The present invention relates to murine oligonucleotides (ACC62754-
ACC6806), which are associated with tumour suppression, tumour
reversion, apoptosis and virus resistance. The oligonucleotides are
useful as (1) as probes and primers for detecting, identifying,
quantifying and/or amplifying nucleic acid, e.g. as one component of a
gene chip; in vitro as (anti)sense reagents; and (2) for production of a
recombinant polypeptides. The oligonucleotides are useful for preparation
of pharmaceuticals for prevention and/or treatment of viral diseases that
are characterised by development of tumours or cell degeneration,
specifically cancer but also Alzheimer's disease and schizophrania
SQ Sequence 17 BP; 5 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 968 TCTGGACAGCTGGGAT 983
DB 17 TCTGGATAGCTGGGAT 2

RESULT 233
ACC64367
ID ACC64367 standard; DNA; 17 BP.
XX
AC ACC64367;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 1614.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrania; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.

```

```

XX PD 27-MAR-2003.
XX PF
XX PR 17-SEP-2002; 2002WO-IB004210.
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX PR WPI; 2003-333167/31.
XX PT New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 219; 738pp; French.
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX CC ACC68806), which are associated with tumour suppression, tumour
XX CC reversion, apoptosis and virus resistance. The oligonucleotides are
XX CC useful as (1) as probes and primers for detecting, identifying,
XX CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX CC recombinant polypeptides. The oligonucleotides are useful for preparation
XX CC of pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia.
XX SQ Sequence 17 BP; 3 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1558 ATCTGGGTCTGCAAC 1573
Db 2 ATCTGGGTCTGCAAC 17

RESULT 234
ACC65664/c
ID ACC65664 standard; DNA; 17 BP.
XX AC ACC65664;
XX DT 01-JUL-2003 (first entry)
XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2911.
XX KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; murine;
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; ss.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX PR WPI; 2003-333167/31.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX PR WPI; 2003-333167/31.
XX PT New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 538; 738pp; French.
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX CC ACC68806), which are associated with tumour suppression, tumour
XX CC reversion, apoptosis and virus resistance. The oligonucleotides are
XX CC useful as (1) as probes and primers for detecting, identifying,
XX CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX CC recombinant polypeptides. The oligonucleotides are useful for preparation
XX CC of pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia.
XX SQ Sequence 17 BP; 6 A; 1 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TCACATTATTAAAGATC 1056
Db 16 TCACATTATTACAGATC 1

RESULT 235
ACC67091/c
ID ACC67091 standard; DNA; 17 BP.
XX AC ACC67091;
XX DT 01-JUL-2003 (first entry)
XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 4338.
XX KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; murine;
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; ss.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX PR WPI; 2003-333167/31.
XX OS New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 538; 738pp; French.
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX CC ACC68806), which are associated with tumour suppression, tumour
XX CC reversion, apoptosis and virus resistance. The oligonucleotides are
XX CC useful as (1) as probes and primers for detecting, identifying,
XX CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX CC recombinant polypeptides. The oligonucleotides are useful for preparation
XX CC of pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia.

```

CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 CTTCTGGCCAGGAATC 1560
DB 16 CTTCTGGCCAGGATC 1

RESULT 236
ADI48639
ID ADI48639 standard; DNA; 17 BP.
XX
AC ADI48639;
XX
DT 15-APR-2004 (first entry)
XX
DE Human tumour suppression/reversion-related DNA sequence SeqID1142.
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytosstatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
FN WO2003025177-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004523.
XX
PR 17-SEP-2001; 2001FR-00011980.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
WPI; 2003-313354/30.
XX
DR New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
PS Disclosure; SEQ ID NO 1142; 30pp; French.
XX
CC This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX neurotropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ Sequence 17 BP; 8 A; 2 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1376 ATCAAGTATTCTTC 1391
DB 2 ATCAAGTATTCTTC 17

RESULT 238
ADM58131/c
ID ADM58131 standard; RNA; 17 BP.

QY 920 GATCACTGGGAGCAAA 935
DB 1 GATCACTGGGAGAAA 16

RESULT 237
ADI49463
ID ADI49463 standard; DNA; 17 BP.
XX
AC ADI49463;
XX
DT 15-APR-2004 (first entry)
XX
DE Human tumour suppression/reversion-related DNA sequence SeqID1366.
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytosstatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
FN WO2003025177-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004523.
XX
PR 17-SEP-2001; 2001FR-00011980.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
WPI; 2003-313354/30.
XX
DR New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
PS Disclosure; SEQ ID NO 1966; 30pp; French.
XX
CC This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX neurotropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ Sequence 17 BP; 4 A; 4 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1376 ATCAAGTATTCTTC 1391
DB 2 ATCAAGTATTCTTC 17

RESULT 238
ADM58131/c
ID ADM58131 standard; RNA; 17 BP.

```
XX AC ADM58131;
XX DT 03-JUN-2004 (first entry)
XX DE Hepatitis B virus (HBV) RNA target sequence #265.
XX KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
XX KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
XX KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
XX KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX OS Hepatitis B virus.
XX PN US2004054156-A1.
XX PD 18-MAR-2004.
XX PF 15-JAN-2003; 2003US-00342902.
XX PR 14-MAY-1992; 92US-00882712.
XX PR 07-FEB-1994; 94US-00193627.
XX PR 08-NOV-1999; 99US-00436430.
XX PR 20-MAR-2000; 2000US-00531025.
XX PR 09-AUG-2000; 2000US-00636385.
XX PR 24-OCT-2000; 2000US-00696347.
XX PR 08-JUN-2001; 2001US-00877478.
XX PA (DRAP/) DRAPER K.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX PA (MORR/) MORRISSEY D.
XX PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX DR WPI; 2004-247781/23.
XX PT Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
XX PT specifically cleaving RNA derived from hepatitis B virus and comprising
XX PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX PS Disclosure; SEQ ID NO 265; 122pp; English.
XX CC The invention relates to an enzymatic nucleic acid molecule that
XX CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX CC comprising one or more binding arms, without requiring the presence of a
XX CC 2'-OH group within the molecule for activity. The nucleic acids are
XX CC useful for treating hepatitis B virus infection, hepatitis,
XX CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX CC combination with other therapies such as lamivudine and interferons. The
XX CC nucleic acids are useful as diagnostic tools to examine genetic drift and
XX CC mutations within diseased cells, for detecting the presence of HBV RNA in
XX CC a cell, for the study of RNA and for down-regulating gene expression of
XX CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX CC sequence represents an HBV RNA target sequence, used in the scope of the
XX CC invention. Note: The sequence data for this patent is also available in
XX CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 17 BP; 3 A; 4 C; 2 G; 0 T; 8 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 530 AGGCATTACAGCAA 545
DB 17 AGGCATTAAAGCAGAA 2
RESULT 239
ADMS8133/c
ID ADM58133 standard; RNA; 17 BP.
XX
```

```
AC ADM58133;
XX DT 03-JUN-2004 (first entry)
XX DE Hepatitis B virus (HBV) RNA target sequence #267.
XX KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
XX KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
XX KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
XX KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX OS Hepatitis B virus.
XX PN US2004054156-A1.
XX PD 18-MAR-2004.
XX PF 15-JAN-2003; 2003US-00342902.
XX PR 14-MAY-1992; 92US-00882712.
XX PR 07-FEB-1994; 94US-00193627.
XX PR 08-NOV-1999; 99US-00436430.
XX PR 20-MAR-2000; 2000US-00531025.
XX PR 09-AUG-2000; 2000US-00636385.
XX PR 24-OCT-2000; 2000US-00696347.
XX PR 08-JUN-2001; 2001US-00877478.
XX PA (DRAP/) DRAPER K.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX PA (MORR/) MORRISSEY D.
XX PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX DR WPI; 2004-247781/23.
XX PT Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
XX PT specifically cleaving RNA derived from hepatitis B virus and comprising
XX PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX PS Disclosure; SEQ ID NO 267; 122pp; English.
XX CC The invention relates to an enzymatic nucleic acid molecule that
XX CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX CC comprising one or more binding arms, without requiring the presence of a
XX CC 2'-OH group within the molecule for activity. The nucleic acids are
XX CC useful for treating hepatitis B virus infection, hepatitis,
XX CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX CC combination with other therapies such as lamivudine and interferons. The
XX CC nucleic acids are useful as diagnostic tools to examine genetic drift and
XX CC mutations within diseased cells, for detecting the presence of HBV RNA in
XX CC a cell, for the study of RNA and for down-regulating gene expression of
XX CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX CC sequence represents an HBV RNA target sequence, used in the scope of the
XX CC invention. Note: The sequence data for this patent is also available in
XX CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 17 BP; 2 A; 4 C; 2 G; 0 T; 9 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 529 AGGCATTACAGCAGA 544
DB 16 AGGCATTAAAGCAGA 1
RESULT 240
AD184168/c
ID AD184168 standard; RNA; 17 BP.
XX
AC AD184168;
```

```

XX 03-JUN-2004 (first entry)
DT
XX HCV DNazyme substrate sequence #1414.
DE
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNazyme.
XX
XX Hepatitis C virus.
OS
XX US2003125270-A1.
PN
XX
XX 03-JUL-2003.
PD
XX
XX 18-DEC-2000; 2000US-00740332.
PF
XX 18-DEC-2000; 2000US-00740332.
PR
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
DR
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 1414; 198pp; English.
PS
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNazyme substrate
CC sequence.
XX
XX Sequence 17 BP; 4 A; 9 C; 2 G; 0 T; 2 U; 0 Other;
SQ
    Query Match      0.8%; Score 14.4; DB 1; Length 17;
    Best Local Similarity 93.8%; Pred. No. 1.4e+02;
    Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1173 CTGGTGATGGAGTCTG 1188
Db 16 CTGGTGATGGAGGCTG 1

RESULT 241
AD186043
ID AD186043 standard; RNA; 17 BP.
XX
XX AD186043;
AC
XX
XX 03-JUN-2004 (first entry)
DT
XX
XX HCV DNazyme substrate sequence #3289.
DE
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNazyme.
XX
XX Hepatitis C virus.
OS
XX US2003125270-A1.
PN
XX
XX 03-JUL-2003.
PD
XX

```

```

PF 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
PR
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
DR
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 3289; 198pp; English.
PS
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNazyme substrate
CC sequence.
XX
XX Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;
SQ
    Query Match      0.8%; Score 14.4; DB 1; Length 17;
    Best Local Similarity 75.0%; Pred. No. 1.4e+02;
    Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Oy 1005 GATGCGGTGGAGCCT 1020
Db 2 GAUGGGGGUGAGCCU 17

RESULT 242
ADR27062
ID ADR27062 standard; DNA; 17 BP.
XX
XX ADR27062;
AC
XX
XX 04-NOV-2004 (first entry)
DT
XX
XX Human single nucleotide polymorphism detection primer #152.
DE
XX
XX ss; primer; single nucleotide polymorphism; SNP; diagnosis;
KW disease association; linkage analysis; autoimmune disease;
KW rheumatoid arthritis; diabetes; multiple sclerosis;
KW systemic lupus erythematosus; inflammatory bowel disease; psoriasis;
KW thyroiditis; celiac disease; pernicious anaemia; asthma; vitiligo;
KW glomerulonephritis; Graves' disease; myocarditis; Sjogren disease;
KW primary systemic vasculitis; genotyping; gene therapy; PCR primer.
XX
XX Homo sapiens.
OS
XX
XX WO2004067779-A2.
PN
XX
XX 12-AUG-2004.
PD
XX
XX 30-JAN-2004; 2004WO-US002652.
PF
XX
XX 30-JAN-2003; 2003US-0443566P.
PR
XX 18-MAR-2003; 2003US-0455444P.
PR
XX 25-APR-2003; 2003US-0465241P.
PR
XX 15-AUG-2003; 2003US-0495115P.
PR
XX 13-NOV-2003; 2003US-0519270P.
XX
XX (APPL-) APPLERA CORP.
XX

```


KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX Homo sapiens.
 XX US2004137589-A1.
 XX 15-JUL-2004.
 XX 26-NOV-2003; 2003US-00723361.
 XX 26-MAY-2000; 2000US-0207456P.
 XX 21-SEP-2000; 2000US-0234687P.
 XX 27-SEP-2000; 2000US-0236359P.
 XX 04-OCT-2000; 2000GB-00024263.
 XX 30-JAN-2001; 2001WO-US000661.
 XX 30-JAN-2001; 2001WO-US000662.
 XX 30-JAN-2001; 2001WO-US000663.
 XX 30-JAN-2001; 2001WO-US000664.
 XX 30-JAN-2001; 2001WO-US000665.
 XX 30-JAN-2001; 2001WO-US000666.
 XX 30-JAN-2001; 2001WO-US000667.
 XX 30-JAN-2001; 2001WO-US000668.
 XX 30-JAN-2001; 2001WO-US000669.
 XX 30-JAN-2001; 2001WO-US000670.
 XX 05-FEB-2001; 2001US-0266860P.
 XX 25-MAY-2001; 2001US-00866108.
 XX (GUY)/ GU Y.
 XX (JIY)/ JI Y.
 XX (PENN)/ PENN S G.
 XX (HANZ)/ HANZEL D K.
 XX (RANK)/ RANK D.
 XX (CHEN)/ CHEN W.
 XX (SHAN)/ SHANNON M E.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 XX associated with decreased expression or activity of human genome-derived
 XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 XX function.
 XX Disclosure; SEQ ID NO 8365; Opp; English.
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 XX defined in the specification, a fragment of at least 8 amino acids of
 XX (S1), 95% deviation from (S1) which are conservative substitutions, and
 XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 XX pharmaceutical composition of the invention is useful for treating or
 XX preventing a disorder associated with decreased expression or activity of
 XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 XX The present sequence represents a 17-mer nucleotide, used in the
 XX invention for scanning the sequence represented in ACN63103
 XX
 XX SQ Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
 XX
 XX Query Match 0.8%; Score 14.4; DB 1; Length 17;
 XX Best Local Similarity 93.8%; Pred. No. 1.4e+02;
 XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 395 GCTGGAGAAAGTTCCAC 410
 DB 1 GCTGGAGAAAGTGCAC 16
 RESULT 245
 ACN73129/C
 ID ACN73129 standard; DNA; 17 BP.

XX ACN73129;
 XX 02-DEC-2004 (first entry)
 XX Human GDMPLP-1 probe SEQ ID NO:10031.
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX Homo sapiens.
 XX US2004137589-A1.
 XX 15-JUL-2004.
 XX 26-NOV-2003; 2003US-00723361.
 XX 26-MAY-2000; 2000US-0207456P.
 XX 21-SEP-2000; 2000US-0234687P.
 XX 27-SEP-2000; 2000US-0236359P.
 XX 04-OCT-2000; 2000GB-00024263.
 XX 30-JAN-2001; 2001WO-US000661.
 XX 30-JAN-2001; 2001WO-US000662.
 XX 30-JAN-2001; 2001WO-US000663.
 XX 30-JAN-2001; 2001WO-US000664.
 XX 30-JAN-2001; 2001WO-US000665.
 XX 30-JAN-2001; 2001WO-US000666.
 XX 30-JAN-2001; 2001WO-US000667.
 XX 30-JAN-2001; 2001WO-US000668.
 XX 30-JAN-2001; 2001WO-US000669.
 XX 05-FEB-2001; 2001US-0266860P.
 XX 25-MAY-2001; 2001US-00866108.
 XX (GUY)/ GU Y.
 XX (JIY)/ JI Y.
 XX (PENN)/ PENN S G.
 XX (HANZ)/ HANZEL D K.
 XX (RANK)/ RANK D.
 XX (CHEN)/ CHEN W.
 XX (SHAN)/ SHANNON M E.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 XX associated with decreased expression or activity of human genome-derived
 XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 XX function.
 XX Disclosure; SEQ ID NO 10031; Opp; English.
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 XX defined in the specification, a fragment of at least 8 amino acids of
 XX (S1), 95% deviation from (S1) which are conservative substitutions, and
 XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 XX pharmaceutical composition of the invention is useful for treating or
 XX preventing a disorder associated with decreased expression or activity of
 XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 XX The present sequence represents a 17-mer nucleotide, used in the
 XX invention for scanning the sequence represented in ACN63103
 XX
 XX SQ Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 XX
 XX Query Match 0.8%; Score 14.4; DB 1; Length 17;
 XX Best Local Similarity 93.8%; Pred. No. 1.4e+02;
 XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
QY 1065 CGTCCAAAGAGGACTC 1080
Db 16 CGTCCACAGAGGACTC 1

RESULT 246
ACN71462
ID ACN71462 standard; DNA; 17 BP.
AC ACN71462;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMLP-1 probe SEQ ID NO:8364.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 05-FEB-2001; 2001WO-US000670.
XX
XX 05-FEB-2001; 2001US-0266860P.
XX
XX 25-MAY-2001; 2001US-00866108.
XX
XX (GUIY/) GU Y.
XX
XX (JIY/) JI Y.
XX
XX (PEN/) PENN S G.
XX
XX (HANZ/) HANZEL D K.
XX
XX (RANK/) RANK D.
XX
XX (CHEV/) CHEN W.
XX
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 8364; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 68% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX
XX The present sequence represents a 17-mer nucleotide, used in the
```

```
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 395 GCTGGAGAAAGTTTCAC 410
Db 2 GCTGGAGAAAGTGCAC 17

RESULT 247
AAZ25403
ID AAZ25403 standard; DNA; 18 BP.
XX
XX AAZ25403;
XX
DT 16-DEC-1999 (first entry)
XX
XX Infectious pancreatic necrosis virus PCR primer #5.
XX
XX Infectious pancreatic necrosis virus; IPNV; strain West Buxton;
XX strain SP; segment A; segment B; nonpathogenic; Birnaviridae family;
XX infection; live attenuated vaccine; aquaculture industry; Rainbow trout;
XX Brook trout; Atlantic salmon; PCR primer; ss.
XX
XX Synthetic.
XX
XX Infectious pancreatic necrosis virus.
XX
XX WO9950419-A2.
XX
XX 07-OCT-1999.
XX
XX 31-MAR-1999; 99WO-US004285.
XX
XX 31-MAR-1998; 98US-0080178P.
XX
XX (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.
XX
XX Vakharia VN, Yao K;
XX WPI; 1999-591321/50.
XX
XX Preparing nonpathogenic infectious pancreatic necrosis virus, IPNV,
XX useful for producing attenuated virus for vaccines useful in the
XX aquaculture industry.
XX
XX Example 1; Page 35; 63pp; English.
XX
XX A method has been developed for preparing nonpathogenic, infectious
XX pancreatic necrosis virus (IPNV). The method comprises: 1) preparing cDNA
XX containing the IPNV genome segments A and B where A is modified to
XX prevent expression of an arginine-rich non-structural (NS) protein; 2)
XX transcribing the cDNA to produce RNA; 3) incubating the host cells in a
XX culture medium; and 4) isolating live IPNV from the culture medium. The
XX method is useful to produce live nonpathogenic IPNV, useful to study
XX viral pathogenesis and for the production of live, nonpathogenic IPNV
XX vaccines, since it was demonstrated that the NS protein-deficient virus
XX could replicate but did not invoke a pathological response in hosts.
XX
XX Combination vaccines may also be produced by combining the IPNV with
XX bacteriophage antigens (especially from gram negative bacteria e.g. Aeromonas
XX salmonicida) and/or antigens from aquatic viruses other than Birnaviruses
XX (the family to which IPNV belongs) e.g. Infectious haematopoietic
XX necrosis virus. The method may also be used to generate a nonpathogenic
XX chimeric virus when the cDNA of segment A encodes epitopic determinants
XX from at least two different IPNV strains. IPNV causes a highly contagious
XX and destructive disease of juvenile Rainbow and Brook trout and Atlantic
XX salmon (e.g. highly virulent strains can cause more than 90 % mortality
XX in hatchery stocks less than 4 months old and survivors can remain
XX lifelong carriers and reservoirs of infection); IPNV is therefore a
XX pathogen of major economic importance to the aquaculture industry. The
```

CC present sequence represents an IPNV PCR primer used in an example from
CC the present invention
XX
SQ Sequence 18 BP; 4 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 450 GAATCAGCTGTGATGC 465
||||| |||||
Db 3 GAATCAGCTGTGATGC 18
RESULT 248
AAA10847/C
ID AAA10847 standard; DNA; 18 BP.
XX
AC AAA10847;
XX
DT 14-JUL-2000 (first entry)
XX
DE G-alpha-i1 antisense oligonucleotide ISIS# 25748.
XX
KW G-alpha-i1; G protein; adenyl cyclase hormonal inhibition; tumour;
KW plasma membrane regulation; antisense composition; treatment; prevent;
KW delay; infection; inflammation; tumour formation; research; diagnose; ss.
XX
OS Synthetic.
XX
XX US6046321-A.
XX
XX 04-APR-2000.
XX
XX 09-APR-1999; 99US-00289377.
XX
XX 09-APR-1999; 99US-00289377.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cowseert LM;
XX
XX WPI; 2000-292434/25.
XX
XX New antisense compounds targeting nucleic acids encoding human G-alpha-i1
XX useful for modulating G-alpha-i1 expression and for treating diseases
XX associated with G-alpha-i1 expression.
XX
XX Example 15; Col 38; 31pp; English.
XX
XX Human G-alpha-i1 is a member of the Gi subfamily of G proteins which is
XX involved in hormonal inhibition of adenylyl cyclase and in the regulation
XX of plasma membrane enzymes. The expression of G-alpha-i1 is altered in
XX some tumours. The present sequence is a G-alpha-i1 antisense
XX oligonucleotide, which can be used to inhibit the expression of human G-
XX alpha-i1. The invention relates to antisense oligonucleotides represented
XX in AAA10814-A10853, which can be used in the treatment of diseases or
XX condition associated with the expression of G-alpha-i1 by modulating the
XX expression of G-alpha-i1 in cells or tissues. The antisense compositions
XX may also be used prophylactically, e.g. to prevent or delay infection,
XX inflammation, or tumour formation. Furthermore, the antisense
XX oligonucleotides may also be useful in research and diagnostics, e.g. in
XX detecting nucleic acids encoding G-alpha-i1 by conjugation of an enzyme
XX to the oligonucleotide, or radiolabelling the oligonucleotide. Kits using
XX may also be prepared. Antisense oligonucleotides, which are able to
XX inhibit specific gene expression, are often used to elucidate the
XX function of particular genes. These antisense compounds are also used to
XX distinguish between functions of various members of a biological pathway
XX
SQ Sequence 18 BP; 3 A; 5 C; 1 G; 9 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 807 GAAGATCGAGAAATGA 822
||||| |||||
Db 16 GAAGATCGAGAAATGA 1
RESULT 249
AAA86639/C
ID AAA86639 standard; DNA; 18 BP.
XX
AC AAA86639;
XX
DT 04-DEC-2000 (first entry)
XX
DE Cdc 2 kinase hammerhead ribozyme recogniton site #70.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
XX WO200032765-A2.
XX
XX 08-JUN-2000.
XX
XX 06-DEC-1999; 99WO-US028772.
XX
XX 04-DEC-1998; 98US-0110954P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
XX WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PCNA and Cyclin B1.
XX
XX Example 1; Page 19; 109pp; English.
XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
XX designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX Representative examples of ribozyme recognition sites are given in
XX AAA82415 to AAA86787. The ribozyme of the invention is useful for
XX inhibiting restenosis by introduction of the ribozyme into cells. The
XX ribozyme is resistant to endonuclease activity and hence is efficient in
XX restenosis treatment
XX
XX Sequence 18 BP; 7 A; 2 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 1376 ATACAGTATTCTTC 1391
||||| |||||
Db 16 ATACAGTATTCTTC 1
RESULT 250
AAA58514/C
ID AAA58514 standard; DNA; 18 BP.
XX
AC AAA58514;
XX
XX 20-OCT-2000 (first entry)
XX
DE PCR primer used to amplify bleomycin (BLM) gene cluster ORF28.
XX
KW BLM gene cluster; bleomycin gene cluster; polyketide metabolite;

```
KW bleomycin; bleomycin analogue; holo-carrier protein; thiazolidine;
KW thiazoline; bithiazoline; microbial metabolite; sugar; PCR primer; ss.
XX Streptomyces verticillus.
XX WO200040704-A1.
XX 13-JUL-2000.
XX
XX 06-JAN-2000; 2000WO-US000445.
XX
XX 06-JAN-1999; 99US-0115435P.
XX 05-FEB-1999; 99US-0118848P.
XX 05-JAN-2000; 2000US-00477962.
XX
XX (REGC ) UNIV CALIFORNIA.
XX
XX PI Shen B, Du L, Sanchez C, Chen M, Edwards DJ;
XX WPI; 2000-465974/40.
XX
XX New bleomycin gene cluster components useful for peptide and/or
XX polyketide metabolites, especially bleomycin, production and for
XX chemically modifying biological molecules.
XX
XX Disclosure; Page 22; 162pp; English.
XX
XX PCR primers AA58474-A58541 were used to amplify open reading frames
XX (ORFs) 8 to 41 of the BLM (Bleomycin) gene cluster. The proteins encoded
XX by the gene cluster are useful for producing peptides and/or polyketide
XX metabolites, especially bleomycin or bleomycin analogues. They are also
XX useful for chemically modifying biological molecules to produce branched
XX methyl groups, and for coupling amino acids and fatty acids. They may be
XX reacted with an apo-carrier protein and coenzyme A to produce a holo-
XX carrier protein. The BLM gene cluster or catalytic domains can be used
XX individually or collectively to produce thiazolidine, thiazoline,
XX bithiazoline and bithiazoline-containing microbial metabolites. The BLM
XX gene cluster may also be used to produce sugars
XX
XX Sequence 18 BP; 6 A; 5 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 14.4; DB 1; Length 18;
XX Best Local Similarity 93.8%; Pred. No. 1.5e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1292 TCAGTCTCTGAGCCAT 1307
XX ||||| |||||
XX Db 16 TCAGTCTCTGAGCCAT 1
XX
XX RESULT 251
XX AAH61805/c
XX ID AAH61805 standard; DNA; 18 BP.
XX
XX AC AAH61805;
XX
XX DT 10-SEP-2001 (first entry)
XX
XX Cdc 2 kinase hammerhead ribozyme recognition site SEQ ID NO:4229.
XX
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
XX recognition site; target; ribozyme binding site; eye disease; vulnery;
XX proliferative disease; skin disease; psoriasis; diabetic retinopathy;
XX cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
XX matrix metalloproteinase; growth factor; reductase; scarring; cytosolic;
XX antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
XX antisking; ophthalmological; keratolytic; gene therapy; viral wart;
XX atopic dermatitis; actinic keratosis; squamous cell carcinoma;
XX basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
XX sickle cell retinopathy; ss.
XX
XX Homo sapiens.
XX Synthetic.
OS
```

```
XX WO200130362-A2.
XX 03-MAY-2001.
XX
XX 26-OCT-2000; 2000WO-US029500.
XX
XX 26-OCT-1999; 99US-0161532P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Robbins JM, Tritz R;
XX WPI; 2001-300427/31.
XX
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
XX that cleave RNA encoding cytokines involved in inflammation, matrix
XX metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Disclosure; Page 381; 408pp; English.
XX
XX The present invention describes a method for treating a proliferative
XX skin or eye disease and scarring. The method involves administering a
XX ribozyme (I) which cleaves RNA encoding a cytokine involved in
XX inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
XX dependent kinase, growth factor or a reductase, or administering a
XX nucleic acid molecule (II) comprising a promoter operably linked to a
XX nucleic acid segment encoding (I). (I) can have antipsoriatic,
XX dermatological, cytostatic, antiseborrheic, antidiabetic, antisking,
XX ophthalmological, vulnery, keratolytic and virucide activities, and
XX cleaves RNA encoding cytokine involved in inflammation. (I) can be used
XX in gene therapy. (I) and (II) are useful for treating proliferative skin
XX diseases such as psoriasis, atopic dermatitis, actinic keratosis,
XX squamous or basal cell carcinoma and viral or seborrheic wart. They can
XX also be used for treating proliferative eye diseases such as diabetic
XX retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
XX prematurity and retinal detachment, and for treating and preventing
XX scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
XX scar. AAH57577 to AAH62099 represent sequences used in the
XX exemplification of the present invention
XX
XX Sequence 18 BP; 7 A; 2 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 14.4; DB 1; Length 18;
XX Best Local Similarity 93.8%; Pred. No. 1.5e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1376 ATACAAGTATTCTTC 1391
XX ||||| |||||
XX Db 16 ATCCAAGTATTCTTC 1
XX
XX RESULT 252
XX ABZ72355
XX ID ABZ72355 standard; DNA; 18 BP.
XX
XX AC ABZ72355;
XX
XX DT 03-APR-2003 (first entry)
XX
XX Gene 216 polymorphism genotyping A50 primer SEQ ID NO 327.
XX
XX Human; Gene 216; chromosome 20p13-p12; antiasthmatic; anorectic;
XX antiinflammatory; gastrointestinal; gene therapy; vaccine; asthma;
XX obesity; inflammatory bowel disease; primer; ss.
XX
XX Synthetic.
XX
XX WO200178894-A2.
XX
XX 25-OCT-2001.
XX
XX 13-APR-2001; 2001WO-US012245.
```

XX PR 13-APR-2000; 2000US-00548797.
 XX PA (GENO-) GENOME THERAPEUTICS CORP.
 XX PI Keith T;
 XX DR WPI; 2001-639428/73.
 XX PT Isolated genes (Gene 216) from human chromosome 20p13-p12 and the
 PT proteins they encode, useful for the prevention, diagnosis and treatment
 PT of asthma, obesity and inflammatory bowel disease.
 XX PS Example 11; Page 156; 520pp; English.
 XX CC The invention relates to isolated genes (Gene 216) from human chromosome
 CC 20p13-p12 and the proteins they encode. The nucleic acids and proteins
 CC may be used in the prevention, diagnosis and treatment of diseases
 CC associated with inappropriate Gene 216 expression. For example, the
 CC nucleic acids (or vectors) and proteins may be used to treat disorders
 CC associated with decreased expression by rectifying mutations or deletions
 CC in a patient's genome that affect the activity of gene 216 by expressing
 CC inactive proteins or to supplement the patients own production of Gene
 CC 216 proteins. Additionally, the nucleic acids may be used to produce the
 CC secreted Gene 216 protein, by inserting the nucleic acids into a host
 CC cell and culturing the cell to express the protein. The nucleic acids and
 CC complementary sequences may also be used as DNA probes in diagnostic
 CC assays to detect and quantitate the presence of similar nucleic acid
 CC sequences in samples and therefore which patients may be in need of
 CC restorative therapy. The Gene 216 protein may also be used as antigens in
 CC the production of antibodies against Gene 216 and in assays to identify
 CC modulators of Gene 216 expression and activity. The anti-Gene 216
 CC antibodies and antagonists may also be used to down regulate expression
 CC and activity. The anti-Gene 216 antibodies may also be used as diagnostic
 CC agents for detecting the presence of Gene 216 proteins in samples (e.g.
 CC by enzyme linked immunosorbant assay or ELISA). Disorders that may be
 CC prevented, diagnosed and/or treated by the above methods include, for
 CC example asthma, obesity and inflammatory bowel disease. The present
 CC sequence is that of a Gene 216 related primer used in examples of the
 CC invention. The primers are used in the physical mapping of the gene
 CC (ABZ72067-ABZ72088), polymorphism identification using single strand
 CC conformational polymorphism (SSCP) analysis (ABZ72091-ABZ72184),
 CC sequencing (ABZ72185-ABZ72268) and genotyping (ABZ72317-ABZ72362).
 XX SQ Sequence 18 BP; 1 A; 3 C; 9 G; 5 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. NO. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 453 TCAGCTGTGGTGGTGG 468
 Db 3 TCAGCTGTGGTGGTGG 18
 RESULT 253
 AAD40167/c
 ID AAD40167 standard; DNA; 18 BP.
 XX AC AAD40167;
 XX DT 22-OCT-2002 (first entry)
 XX DE Cauliflower mosaic virus 35S promoter target DNA.
 XX KW Identification; production; DNA binding protein; gene construct;
 KW target gene regulator; therapeutic; gene; ds.
 XX OS Cauliflower mosaic virus.
 XX FN WO200240632-A2.
 XX PD 23-MAY-2002.

XX 16-NOV-2001; 2001WO-US043107.
 XX PR 17-NOV-2000; 2000US-0249546P.
 XX PA (WISE/) WISE J C.
 XX PA (FROM/) FROMKNECHT K.
 XX PI Wise JG, Fromknecht K;
 XX DR WPI; 2002-500212/53.
 XX PT Deriving DNA binding protein sequence binding to target regulatory
 PT sequence comprises selecting sequence for protein, mutating it, and
 PT providing to cell having reporter/separator gene and screening for gene
 PT expression.
 XX PS Example 2; Fig 4; 90pp; English.
 XX CC The invention relates to methods for identification and production of new
 CC DNA binding proteins that up or down regulate the expression of pre-
 CC determined target genes. Such genes include DNA sequences that encode
 CC proteins that regulate such target genes as well as gene constructs and
 CC biological materials that contain such DNA binding proteins and/or their
 CC DNA sequences. The method is useful for deriving a gene sequence of a new
 CC DNA binding protein that can bind to a target regulatory sequence where
 CC the gene sequence derived is useful as a tool for controlling gene
 CC expression and as therapeutics. The present sequence is Cauliflower
 CC mosaic virus 35S promoter target DNA used to illustrate the method of the
 CC invention
 XX SQ Sequence 18 BP; 7 A; 2 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. NO. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 97 AAATGAATTCCTTAT 112
 Db 16 AAATGAATTCCTTAT 1
 RESULT 254
 AAD40589/c
 ID AAD40589 standard; DNA; 18 BP.
 XX AC AAD40589;
 XX DT 30-OCT-2002 (first entry)
 XX DE HIV-1 LTR luciferase reporter gene mutant fragment, A7.
 XX KW Human immunodeficiency virus; HIV; infection; transcriptional repressor;
 KW OTK18; brain; polymorphonuclear blood mononucleocyte; neuronal injury;
 KW CD4+ T cell; antiretroviral; mononuclear phagocyte; MP; macrophage;
 KW gene therapy; anti-HIV; mutant; ds.
 XX OS Human immunodeficiency virus 1.
 XX OS Synthetic.
 XX FN WO200235981-A2.
 XX PD 10-MAY-2002.
 XX PF 06-NOV-2001; 2001WO-US044336.
 XX PR 06-NOV-2000; 2000US-0246331P.
 XX PR 06-APR-2001; 2001US-00828648.
 XX PA (IYNE-) UNIV NEBRASKA.
 XX PI Ikezu T, Leisman G, Carlson KA, Gendelman HE;
 XX

DR WPI; 2002-519218/55.
XX
PT New truncated OTK18 transcriptional repressor protein, useful for
PT treating human immunodeficiency virus infection and for identifying OTK18
PT expression in a biological sample.
XX
XX Example 2; Fig 11A; 96pp; English.
PS
XX
XX The invention relates to methods and compositions for the treatment of
CC human immunodeficiency virus (HIV) infection. The invention also relates
CC to OTK18 transcriptional repressor protein and its corresponding nucleic
CC acid. An antibody to OTK18 is useful for identifying OTK18 expression in
CC a biological sample (e.g. polymorphonuclear blood mononuclear cells, brain
CC tissue, macrophages and CD4+ T cells). OTK18 is used for treating HIV
CC infection. It is useful for screening molecules that modulate or affect
CC its activity. Its antibody is useful for identifying multinuclear giant
CC cells in HIV encephalitic brains or immune activated mononuclear
CC phagocytes (MP) in the brains, for fluorescent activated cell sorting
CC (FACS) analysis of peripheral blood cells to evaluate the antiretroviral
CC reaction of MP and for immunoprecipitating proteins from a sample
CC containing a mixture of proteins and other biological molecules. OTK18
CC molecules are useful in the treatment and diagnosis of HIV infection, as
CC research tools to identify the control of gene expression in response to
CC HIV infection and subsequent neuronal injury. OTK18 DNA is useful in gene
CC therapy. The present sequence is HIV-1 LTR luciferase reporter gene
CC derived mutant DNA fragment used to illustrate the method of the
CC invention
XX
SQ Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 956 GGTCAGTGGACATCTG 971
Db 16 GGTCAGTGGATATCTG 1
RESULT 255
ABX75208
ID ABX75208 standard; DNA; 18 BP.
XX
XX
AC ABX75208;
XX
XX 25-MAR-2003 (first entry)
DT
DE Human 216 gene allele specific oligonucleotide probe #39.
XX
XX Human; mouse; ss; probe; gene 216; antiasthmatic; antiinflammatory;
KW anorectic; chromosome 20p13-p12; single nucleotide polymorphism; SNP;
KW gene therapy; respiratory disease; asthma; obesity;
KW bronchial hyper-responsiveness; chronic obstructive pulmonary disease;
KW adult respiratory distress syndrome; inflammatory bowel syndrome.
XX
XX Homo sapiens.
OS
XX WO200283077-A2.
PN
XX 24-OCT-2002.
XX
XX 15-APR-2002; 2002WO-US012063.
PF
XX 13-APR-2001; 2001US-00834597.
PR
XX 13-APR-2001; 2001WO-US012245.
PR
XX (SCHE) SCHERING CORP.
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
XX Keith T, Little RD, Van Eerdewegh P, Dupuis J, Del Mastro RG;
PI Simon J, Allen K, Pandit S;
XX WPI; 2003-092960/08.
PT
PT

XX
PT New isolated gene 216 nucleic acids, useful for diagnosing, preventing or
PT treating a disorder, such as asthma, bronchial hyper-responsiveness,
PT chronic obstructive pulmonary disease, obesity or inflammatory bowel
PT syndrome.
XX
XX Example 10; Page 166; 650pp; English.
PS
XX
XX This invention relates to a novel isolated nucleic acid, gene 216,
CC identified from human chromosome 20p13-p12. The invention also discloses
CC regions of the 216 gene that contain single nucleotide polymorphisms
CC (SNP's) which may be used as markers for disease susceptibility or
CC severity. The nucleotides of the invention may have antiasthmatic,
CC antiinflammatory or anorectic activities and may be used in gene therapy.
CC The nucleic acids, antibodies or its fragments are useful for diagnosing,
CC preventing or treating a disorder, such as respiratory diseases (e.g.
CC asthma, bronchial hyper-responsiveness, chronic obstructive pulmonary
CC disease or adult respiratory distress syndrome), obesity, or inflammatory
CC bowel syndrome. The nucleic acids are also useful for identifying
CC increased susceptibility of a subject to the disorders mentioned. The
CC nucleic acids can also be used as primers and templates for the
CC recombinant production of disorder-associated peptides or polypeptides,
CC for chromosome and gene mapping, or for tissue distribution studies. The
CC present sequence represents a gene 216 specific oligonucleotide probe
CC used in the scope of the invention
XX
SQ Sequence 18 BP; 1 A; 3 C; 9 G; 5 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 453 TCAGCTGTGATCTGG 468
Db 3 TCAGCTGTGCTGTGG 18
RESULT 256
ABZ81757/C
ID ABZ81757 standard; DNA; 18 BP.
XX
XX
AC ABZ81757;
XX
XX 11-JUN-2003 (first entry)
DT
DE Huntington's disease exon 1 triplet repeat sequence.
XX
XX Huntington's disease; nootropic; anticonvulsant; huntingtin; human;
KW gene therapy; ss.
XX
XX Homo sapiens.
OS
XX WO2003013437-A2.
PN
XX 20-FEB-2003.
PD
XX 07-AUG-2002; 2002WO-US025352.
PF
XX 07-AUG-2001; 2001US-0310757P.
PR
XX 08-AUG-2001; 2001US-0310770P.
PR
XX 08-AUG-2001; 2001US-0310889P.
PR
XX 04-DEC-2001; 2001US-0337219P.
PR
XX (UYDE) UNIV DELAWARE.
PA
XX Kmiec EB, Parekh-Olmedo H;
PI WPI; 2003-256478/25.
XX
XX New single stranded oligonucleotides comprising a DNA domain having at
PT least one mismatch with respect to the genetic sequence of the
PT Huntington's disease gene to be altered, useful for treating or
PT preventing Huntington's disease.
PT

XX PS Example 1; Page 57; 133pp; English.

CC The present sequence is an example of a poly-glutamine triplet repeat

CC region found in exon 1 of the Huntington's disease (HD) gene. The

CC invention is based on the discovery that oligonucleotides can be designed

CC to target sequence alterations to the triplet repeat region of the HD

CC gene. Preferred oligonucleotides are single-stranded, have at least one

CC mismatch with respect to the HD gene region to be altered, and have

CC chemical modifications, or are chimeric RNA/DNA oligonucleotides. They

CC can be used for the treatment or prevention of HD

XX SQ Sequence 18 BP; 9 A; 6 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1445 TGTGCTGCTGCTGTT 1460

Db 17 TGTGCTGCTGCTGTT 2

RESULT 257

ACC70479/c

ID ACC70479 standard; DNA; 18 BP.

AC ACC70479;

XX 12-AUG-2003 (first entry)

XX HIV DNA Sp41 sequencing primer SEQ ID 29.

XX HIV; treatment; therapy; PCR; primer; ss.

XX Human immunodeficiency virus.

XX EP1283272-A2.

XX 12-FEB-2003.

XX 08-AUG-2002; 2002EP-00078298.

XX 08-AUG-2001; 2001EP-00203011.

XX 08-AUG-2001; 2001US-0310497P.

XX (TIBO-) TIBOTEC PHARM LTD.

XX Kemp S, Vingerhoets JHJ, Michiels LEJ;

XX WPI; 2003-364991/35.

XX Determining the susceptibility of the HIV virus to a drug by monitoring

XX molecular events at the HIV envelope protein, useful for the diagnosis,

XX evaluation of treatment and drug screening and/or drug development in HIV

XX disease.

XX Claim 11; Page 6; 54pp; English.

XX The present invention relates to a method for determining the

XX susceptibility of HIV to a drug. The method comprises obtaining a sample

XX comprising HIV RNA or DNA, reverse-transcribing and amplifying the RNA or

XX DNA, homologously recombining or ligating at least one amplicon with to

XX prepare a recombinant virus, and monitoring the recombinant virus in the

XX presence of the drug to determine the phenotypic susceptibility. The

XX methods and compositions of the present invention are useful for the

XX evaluation of HIV treatment, in particular for the determination of

XX molecular events at the HIV envelope protein and their effect on

XX therapeutic efficacy of drugs. The methods may find use in multiple

XX fields including diagnostics, drug screening, pharmacogenetics and drug

XX development in HIV disease. The present sequence is a PCR primer, used in

XX the method of the invention

SQ Sequence 18 BP; 1 A; 9 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1104 GAAGAACAAAGGTGGAG 1119

Db 18 GAAGAACAAAGGTGGAG 3

RESULT 258

ADD94304

ID ADD94304 standard; DNA; 18 BP.

AC ADD94304;

XX 29-JAN-2004 (first entry)

XX Mouse HUI77/HUIV26 antibody related PCR primer SeqID189.

XX grafted antibody; complementarity determining region; CDR; light CDR;

XX heavy CDR; cryptic collagen epitope; solid tumour;

XX new blood vessel growth; angiogenesis; tumour growth; cytostatic;

XX collagen agonist; collagen antagonist; cancer metastasis;

XX anti-cryptic collagen; HUI77; HUIV26; mouse; murine; PCR; primer; ss;

XX heavy chain.

XX Mus musculus.

XX WO2003046204-A2.

XX 05-JUN-2003.

XX 26-NOV-2002; 2002WO-US038147.

XX 26-NOV-2001; 2001US-00995529.

XX 06-DEC-2001; 2001US-00011250.

XX (CELL-) CELL MATRIX INC.

XX Watking JD, Huse WD, Tang Y, Broek D, Brooks PC;

XX WPI; 2003-513649/48.

XX New cryptic collagen antibody with one or more complementarity

XX determining regions, useful for diagnosing and treating disorders

XX associated with angiogenesis, tumor growth and/or cancer metastasis.

XX Example 1; SEQ ID NO 189; 232pp; English.

XX This invention relates to a novel grafted antibody or its functional

XX fragment comprising one or more complementarity determining regions

XX (CDRs) of a defined light CDR and a heavy CDR with at least one amino

XX acid (aa) substitution where the antibody has specific binding activity

XX for a cryptic collagen epitope. The growth of all solid tumours requires

XX new blood vessel growth, angiogenesis, inhibition of which is an approach

XX to limiting tumour growth. The invention may allow development of

XX therapeutics with a cytostatic activity as a collagen agonist or

XX antagonist. The invention is useful for diagnosing and treating disorders

XX associated with angiogenesis, tumour growth and/or cancer metastasis. The

XX present sequence is that of a mutagenic PCR primer for amplification of

XX the sequence encoding the light chain of mouse HUI77 or HUIV26 antibodies

XX and used in the exemplification of the invention.

XX SQ Sequence 18 BP; 0 A; 3 C; 4 G; 7 T; 0 U; 4 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;

Best Local Similarity 75.0%; Pred. No. 1.5e+02;

Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1444 ATGTTGCTGCTGCTGT 1459

Db 1444 ATGTTGCTGCTGCTGT 1459

Db 1 RTRTCTGCTGCTRT 16

RESULT 259
ADH71082/c
ID ADH71082 standard; DNA, 18 BP.
XX
XX
AC ADH71082;
XX
XX
XX 25-MAR-2004 (first entry)
XX Human Vbeta microsatellite primer #25.
XX human; T-cell associated disease; Vbeta; autoimmune disease;
XX degenerative nervous system disease; graft versus host disease;
XX hypersensitivity disease; infectious disease; neoplastic disease;
XX Addison's disease; atrophic gastritis;
XX degenerative nervous system disease; multiple sclerosis;
XX Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
XX allergy; type II hypersensitivity; Goodpasture's syndrome;
XX type IV hypersensitivity; leprosy; infectious disease; viral infection;
XX HIV; fungal infection; Candida; parasitic infection; schistosoma;
XX filaria; bacterial infection; Mycobacterium; neoplastic disease;
XX lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
XX breast cancer; ss; primer; microsatellite.
XX Homo sapiens.
XX
XX US2002150891-A1.
XX
XX 17-OCT-2002.
XX
XX 05-MAR-1999; 99US-00263959.
XX
XX 19-SEP-1994; 94US-00309335.
XX 19-SEP-1995; 95US-00531241.
XX
XX (HOOD/) HOOD L E.
XX (ROWE/) ROWEN L.
XX
XX Hood LE, Rowen L;
XX
XX WPI; 2004-059052/06.
XX
XX Kit for diagnosing and treating T-cell associated diseases e.g.
XX autoimmune, degenerative nervous system and infectious disease, comprises
XX nucleic acid primers specifically priming and allowing amplification of a
XX Vbeta gene.
XX
XX Disclosure; SEQ ID NO 1276; 164pp; English.
XX
XX The invention relates to a kit for diagnosing and treating T-cell
XX associated diseases which comprises a panel of nucleic acid primers
XX specifically priming and allowing amplification of each Vbeta gene,
XX VbetapNA or cDNA. The kit is useful for diagnosing organ transplant
XX rejection and diagnosing and treating T-cell associated diseases
XX including autoimmune diseases, degenerative nervous system diseases,
XX graft versus host disease, hypersensitivity diseases, infectious diseases
XX and neoplastic diseases. Autoimmune diseases include Addison's disease,
XX atrophic gastritis. Degenerative nervous system diseases include multiple
XX sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
XX I hypersensitivities such as contact with allergens that lead to
XX allergies, type II hypersensitivities such as those present in
XX Goodpasture's syndrome and Type IV hypersensitivities such as those
XX manifested in leprosy. Infectious diseases include viral infections
XX caused by viruses such as HIV, fungal infections such as those caused by
XX the yeast genus Candida, parasitic infections such as those caused by
XX schistosomes, filaria and bacterial infections such as those caused by
XX Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
XX such as leukaemias, lymphomas and cancers such as cancer of the brain,
XX breast. The present sequence represents a Vbeta microsatellite primer.
XX
XX Sequence 18 BP; 3 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1335 ATCCAGCTGGAGTGC 1350
||||| |||||||
Db 17 ATCCAGCTGGAGTGC 2

RESULT 260
ADJ36936
ID ADJ36936 standard; DNA; 18 BP.
XX
XX ADJ36936;
XX
XX 22-APR-2004 (first entry)
XX
XX Gene 216 related allele specific oligonucleotide seq id 327.
XX
XX antiasthmatic; respiratory; gene therapy; asthma;
XX bronchial hyperresponsiveness; atopy; chronic obstructive lung disease;
XX adult respiratory distress syndrome; obesity; inflammatory bowel disease;
XX human; gene 216; single nucleotide polymorphism; SNP;
XX allele specific oligonucleotide; ASO; ss.
XX
XX Homo sapiens.
XX
XX US2004002470-A1.
XX
XX 01-JAN-2004.
XX
XX 17-OCT-2002; 2002US-00277216.
XX
XX 13-APR-2000; 2000US-00548797.
XX 13-APR-2001; 2001US-00834597.
XX 19-APR-2002; 2002US-00126022.
XX
XX (KEIT/) KEITH T.
XX (LITT/) LITTLE R D.
XX (VEER/) VAN EERDEWEGH P.
XX (DUPU/) DUPUIS J.
XX (DMAS/) DEL MASTRO R G.
XX (SIMO/) SIMON J.
XX (ALLE/) ALLEN K.
XX (PAND/) PANDIT S.
XX
XX Keith T, Little RD, Eerdewegh PV, Dupuis J, Del Mastro RG;
XX Simon J, Allen K, Pandit S;
XX
XX WPI; 2004-061675/06.
XX
XX Gene 216 nucleic acid, useful for preparing a composition for treating
XX disorders e.g., asthma, bronchial hyperresponsiveness, atopy, chronic
XX obstructive lung disease and adult respiratory distress syndrome.
XX
XX Example 11A; SEQ ID NO 327; 441pp; English.
XX
XX The invention describes a new isolated nucleic acid comprising a fully
XX defined sequence having 23574 bp or at least its 50 or 15 contiguous
XX nucleotides and includes: allele G of single nucleotide polymorphism
XX (SNP) AB+2; allele G of SNP BC+1; and allele C of SNP BC+2. The invention
XX describes identifying increased susceptibility to a disorder comprising
XX asthma, bronchial hyperresponsiveness, atopy, chronic obstructive lung
XX disease and adult respiratory distress syndrome in a subject comprising
XX testing a biological sample obtained from a subject for the presence of
XX at least one allele or haplotype given in the specification, where the
XX presence identifies an increased susceptibility to the disorder. The
XX nucleic acid is useful for preparing a composition for treating disorders
XX comprising asthma, bronchial hyperresponsiveness, atopy, chronic
XX obstructive lung disease and adult respiratory distress syndrome. This
XX sequence represents an allele specific oligonucleotide used in the
XX polymorphism genotyping of human gene 216 single nucleotide


```
CC polymorphisms.
SQ Sequence 18 BP; 1 A; 3 C; 9 G; 5 T; 0 U; 0 Other;

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 453 TCAGCTGTGATGCTGG 468
Db 3 TCAGCTGTGATGCTGG 18

RESULT 261
ADL81514
ID ADL81514 standard; DNA; 18 BP.
AC ADL81514;
XX
XX
XX 20-MAY-2004 (first entry)
XX
XX Gene 216 ASO primer #39.
XX
XX asthma; bronchial hyperresponsiveness; obesity;
KW inflammatory bowel disease; human; Gene 216; ss; primer.
XX
XX Homo sapiens.
XX
XX OS
XX US2004023215-A1.
XX
XX 05-FEB-2004.
XX
XX 19-APR-2002; 2002US-00126022.
XX
XX 13-APR-1999; 99US-0129391P.
PR 13-APR-2000; 2000US-00548797.
PR 13-APR-2001; 2001US-00834597.
XX
XX (KEIT/) KEITH T.
PA (LITT/) LITTLE R D.
PA (EERD/) EERDEWEGH P V.
PA (DUPU/) DUPUIS J.
PA (DMAS/) DEL MASTRO R G.
PA (SIMO/) SIMON J.
PA (ALLE/) ALLEN K.
PA (PAND/) PANDIT S.
XX
XX Keith T, Little RD, Berdewegh PV, Dupuis J, Del Mastro RG;
PI Simon J, Allen K, Pandit S;
XX
XX WPI; 2004-142647/14.
XX
XX New isolated nucleic acid molecules useful for diagnosing or treating
PT asthma or bronchial hyperresponsiveness, or other diseases such as
PT obesity or inflammatory bowel disease.
XX
XX Example 11; SEQ ID NO 327; 485pp; English.
XX
XX The invention relates to an isolated nucleic acid molecule, or a set of
CC nucleic acid molecules each given in the specification. The composition
CC and methods are useful in diagnosing or treating asthma or bronchial
CC hyperresponsiveness, and other diseases such as obesity or inflammatory
CC bowel disease. The present sequence is used in the exemplification of the
CC present invention.
XX
XX Sequence 18 BP; 1 A; 3 C; 9 G; 5 T; 0 U; 0 Other;

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 453 TCAGCTGTGATGCTGG 468
|||||
```

```
Db 3 TCAGCTGTGATGCTGG 18

RESULT 262
AAH5466/C
ID AAH5466 standard; DNA; 19 BP.
XX
XX AAH5466;
AC
XX
XX 04-DEC-2000 (first entry)
DT
XX
XX Cyclin A1 ribozyme binding site #88.
DE
XX
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
KW
XX
XX Mammalia.
OS
XX
XX WO200032765-A2.
FN
XX
XX 08-JUN-2000.
PD
XX
XX 06-DEC-1999; 99WO-US028772.
PF
XX
XX 04-DEC-1998; 98US-0110954P.
PR
XX
XX (IMMU-) IMMUSOL INC.
PA
XX
XX Tritz R, Welch PJ, Barber JR, Robbins JW;
PI
XX
XX WPI; 2000-412314/35.
DR
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
XX Disclosure; Page 92; 109pp; English.
XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAH2415 to AAH6787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
XX Sequence 19 BP; 2 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

Query Match      0.8%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 433 ACTGGGAGAGGGGAGA 448
Db 17 ACTGGGAGAGGGGAGA 2

RESULT 263
AAH60628/C
ID AAH60628 standard; DNA; 19 BP.
XX
XX AAH60628;
AC
XX
XX 10-SEP-2001 (first entry)
DT
XX
XX Cyclin A1 ribozyme binding site SEQ ID NO:3052.
DE
XX
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
```

KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX W0200130362-A2.
PN
XX 03-MAY-2001.
XX
XX 26-OCT-2000; 2000WO-US029500.
XX
XX 26-OCT-1999; 99US-0161532P.
XX (IMMU-) IMMUSOL INC.
XX PA Robbins JM, Tritz R;
XX PI
XX WPI; 2001-300427/31.
DR
XX
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 294; 408pp; English.
XX
XX The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antiproliferative,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 2 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 433 ACTGGGAGAGGGGAGA 448
Db |||||
17 ACTGGGAGAGGGGAGA 2

RESULT 264
ADF54045/C
ID ADF54045 standard; RNA; 19 BP.
XX
AC ADF54045;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human GAB2 short interfering nucleic acid upper sequence SEQ ID NO:118.
XX
XX RNA interference; short interfering nucleic acid; siRNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;

KW pharmacogenomics; gene function analysis; gene mapping; human;
KW GRB2-associated binding protein; GAB2; cancer; inflammation; allergy;
KW chromosome 11; cytosolic; antinflammatory; antiallergic;
KW target sequence; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX W02003070903-A2.
PN
XX 28-AUG-2003.
XX
XX 18-FEB-2003; 2003WO-US004909.
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX PA
XX Mcswiggen J, Beigelman L, Usman N;
PI
XX WPI; 2003-697611/66.
DR
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of the GRB2-associated
PT binding protein gene.
XX
XX Example 3; SEQ ID NO 118; 140pp; English.
XX
XX The present invention relates to short interfering nucleic acids (siNA)
CC which downregulate expression of the human GRB2-associated binding
CC protein (GAB2) gene by RNA interference. The siNAs may or may not
CC comprise ribonucleotides and may be double or single stranded. They
CC further comprise sense and antisense regions, or alternatively are
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.
CC Specifically, the siNAs include short interfering RNA (siRNA), double-
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs
CC can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC of siNA; and vectors that express siNA. The siNAs are used to modulate
CC expression of the GAB2 gene in cells, tissue explants or organisms (e.g.,
CC by ex vivo gene therapy), or in grafts and transplants for the treatment
CC of a variety of conditions. They may be used for treating cancer.
CC inflammation and allergies. The siNAs are also useful for drug screening,
CC diagnosis, therapeutic target identification and validation, genetic
CC engineering, pharmacogenomics, studying gene function, and gene mapping
CC (e.g., of single nucleotide polymorphisms). The human GAB2 gene is
CC located on chromosome 11, more specifically to region 11q13.4. The human
CC GAB2 siNAs have cytostatic, antinflammatory and antiallergic activities.
CC The present sequence represents the upper strand of a human GAB2-targeted
CC double-stranded siNA, which is identical to the GAB2 transcript target
CC sequence.
XX
SQ Sequence 19 BP; 3 A; 8 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 219 GCCAGCTGTGGAGATG 234
Db |||||
16 GCCAGCTGTGGAGATG 1

RESULT 265
ADF54381


```

PF 21-JUN-2000; 2000WO-US017103.
XX
XX
PR 21-JUN-1999; 99US-00334512.
XX
XX
PA (GEMY ) GENETICS INST INC.
XX
PA (UYXO ) UNIV JOHNS HOPKINS.
XX
XX
PI Collins M, Donaldson D, Fitz L, Neben T, Whitters MJ, Wood C;
PI Wills-Karp M;
XX
DR WPI; 2001-080753/09.
XX
XX
PT Treating tissue fibrosis and/or inhibiting formation of tissue fibrosis
PT in a mammalian subject, involves administering a pharmaceutical
PT composition comprising IL-13 antagonist.
XX
XX
PS Example 1; Page 20; 72pp; English.
XX
XX
CC The invention relates to a method of treating, or inhibiting the
CC formation of tissue fibrosis in mammals, which involves administering a
CC pharmaceutical composition comprising interleukin (IL)-13 antagonist. The
CC protein of the invention is useful for treating tissue fibrosis resulting
CC from infection with Schistosoma or from healing of a wound which is a
CC surgical incision, or inhibiting formation of tissue fibrosis which
CC affects tissues such as liver, skin epidermis and endodermis, muscle,
CC tendon, cartilage, cardiac tissue, pancreas, lung, uterine tissue, neural
CC tissue, testis, ovary, adrenal gland, artery, vein, colon, small
CC intestine, biliary tract and gut. It is also used in the treatment or
CC modulation of various IL-13 related conditions such as allergic
CC conditions, nephrotic syndrome, thyroiditis, Grave's disease and cancer.
CC The present sequence is degenerate 17mer oligonucleotide probe used for
CC isolating murine interleukin (IL)-13 binding chain of IL-13 receptor (IL-
CC 13bc) cDNA library. IL-13bc protein is used to potentiate the effects of
CC IL-13. This protein is also used to enhance macrophage activation and
CC hence can be used in vaccination or treatment of mycobacterial or
CC parasitic infections
XX
XX
SQ Sequence 17 BP; 2 A; 7 C; 0 G; 2 T; 0 U; 6 Other;
Query Match 0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.5e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGCCA 1359
Db 17 TGGAGYGMVTCGAGYSM 1

RESULT 270
AAC81417/c
ID AAC81417 standard; cDNA; 17 BP.
XX
XX
AC AAC81417;
XX
XX
DT 23-FEB-2001 (first entry)
XX
XX
DE Degenerate hybridisation probe used to isolate mouse IL-13bc cDNA.
XX
XX
KW Mouse; murine; IL-13 receptor; interleukin-13; IL-13 binding chain;
KW IL-13bc; IL-13 antagonist; fibrosis inhibition; scarring; vulnerability;
KW wound healing; schistosoma infection; liver; skin; muscle; cartilage;
KW cardiac tissue; lung tissue; uterine tissue; intestinal tissue;
KW vascular tissue; neural tissue; degenerate; hybridisation probe; ss.
XX
XX
OS Synthetic.
XX
XX
PN WO200064944-A1.
XX
XX
PD 02-NOV-2000.
XX
XX
PF 28-APR-2000; 2000WO-US011612.
XX
XX
PR 28-APR-1999; 99US-00301808.

(GEMY ) GENETICS INST INC.
Wynn TA, Chiaramonte MG, Collins M, Donaldson D, Fitz L, Neben T;
Whitters MJ, Wood C;
WPI; 2001-024676/03.
Treating or inhibiting tissue fibrosis resulting from infection with
schistosoma and wound healing involves administering interleukin-13 or
interleukin-4 antagonist.
Example 1; Page 22; 82pp; English.
The invention relates to a method of treating fibrosis in a mammal by
administering an interleukin-13 (IL-13) antagonist or an IL-4 antagonist.
In particular, the IL-13 antagonist is the IL-13 binding chain (IL-13bc;
AA29747, AA29748) of the IL-13 receptor (IL-13R), or soluble fragments
thereof. The method is useful for treating or inhibiting the formation of
tissue fibrosis resulting from the healing of a wound, including a
surgical incision wound, or from infection with schistosoma. The method
may be used to treat fibrosis in a variety of tissues, particularly liver
tissue, but also skin epidermis, skin endodermis, muscle, tendon,
cartilage, cardiac tissue, pancreatic tissue, lung tissue, uterine
tissue, neural tissue, testis, ovary, adrenal gland, artery, vein, colon,
small intestine, biliary tract or gut tissue. The present sequence
represents a degenerate hybridisation probe used in an exemplification to
isolate cDNA encoding mouse IL-13bc
SQ Sequence 17 BP; 2 A; 7 C; 0 G; 2 T; 0 U; 6 Other;
Query Match 0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.5e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGCCA 1359
Db 17 TGGAGYGMVTCGAGYSM 1

RESULT 271
AAT76210
ID AAT76210 standard; DNA; 14 BP.
XX
XX
AC AAT76210;
XX
XX
DT 12-SEP-1997 (first entry)
XX
XX
DE Human IL4 receptor antisense oligonucleotide.
XX
XX
KW Asthma; airway epithelium; adenosine free; cystic fibrosis;
KW chronic obstructive pulmonary disease; bronchitis; interleukin; ss.
XX
XX
OS Synthetic.
XX
XX
PN WO9640162-A1.
XX
XX
PD 19-DEC-1996.
XX
XX
PF 06-JUN-1996; 96WO-US009306.
XX
XX
PR 07-JUN-1995; 95US-00474497.
XX
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
XX
PI Nyce JW, Metzger WJ;
XX
XX
DR WPI; 1997-051871/05.
XX
XX
PT Treatment of airway diseases such as asthma - by topically applying
PT adenosine-free antisense oligo:nucleotide to airway epithelium of
PT subject.
XX

```

```

PS Example 5; Page 30; 71pp; English.
XX
CC A method for treating airway disease in a subject has been produced,
CC which involves the topical administration of an essentially adenosine
CC free antisense oligonucleotide (ON) to the airway epithelium of the
CC subject. The present sequence is an antisense oligonucleotide specific
CC for the human IL4 receptor. The method can be used to treat airway
CC diseases such as cystic fibrosis, asthma, chronic obstructive pulmonary
CC disease, bronchitis and other airway diseases characterised by an
CC inflammatory response. By eliminating adenosine from the antisense ON,
CC its liberation upon antisense degradation is prevented, thereby
CC preventing adenosine-induced bronchoconstriction in patients with hyper-
CC reactive airways
XX
SQ Sequence 14 BP; 0 A; 2 C; 8 G; 4 T; 0 U; 0 Other;
      Query Match      0.8%; Score 14; DB 1; Length 14;
      Best Local Similarity 100.0%; Pred. No. 1.4e+02;
      Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 687 GTGGGGGCTTTGGC 700
Db 1 GTGGGGGCTTTGGC 14

RESULT 272
AA54005
ID AAX54005 standard; DNA; 14 BP.
XX
AC AAX54005;
XX
DT 05-JUL-1999 (first entry)
XX
DE Human IL-4 receptor antisense oligonucleotide fragment.
XX
KW Antisense oligonucleotide; multiple target; antisense treatment;
KW impaired respiration; inflammation; lung disease;
KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
KW acute asthma; allergy; asthma; impeded respiration;
KW respiratory distress syndrome; pain; cystic fibrosis;
KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
KW prostate cancer; ss.
XX
OS Synthetic.
XX
PN WO9913886-A1.
XX
PD 25-MAR-1999.
XX
PF 17-SEP-1998; 98WO-US019419.
XX
PR 17-SEP-1997; 97US-0059160P.
PR 09-JUN-1998; 98US-00093972.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW;
XX
DR WPI; 1999-229400/19.
XX
PT New antisense oligonucleotides used in treatment of, e.g. pulmonary
PT vasoconstriction.
PS Disclosure; Page 49; 120pp; English.
XX
CC The specification describes antisense oligonucleotides (AAX52869-X55271)
CC directed against at least 2 mRNAs selected from target genes, coding and
CC non-coding regions of RNAs corresponding to target genes, gene initiation
CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-
CC end and the juxta-section between coding and non-coding regions and all

```

```

CC segments of RNAs encoding proteins associated with one or more diseases,
CC conditions or mixtures. The antisense oligonucleotides may be derived
CC from sequences AAX5272-74. These multiple target oligonucleotides
CC (specifically AAX55180-271) can be used for the antisense treatment of
CC diseases and conditions. Typical diseases and conditions are those
CC associated with impaired respiration and inflammation, including lung
CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC acute asthma, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
CC well as all types of cancers which may metastasize or have metastasized
XX to the lungs, including breast and prostate cancer
XX
SQ Sequence 14 BP; 0 A; 2 C; 8 G; 4 T; 0 U; 0 Other;
      Query Match      0.8%; Score 14; DB 1; Length 14;
      Best Local Similarity 100.0%; Pred. No. 1.4e+02;
      Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 687 GTGGGGGCTTTGGC 700
Db 1 GTGGGGGCTTTGGC 14

RESULT 273
AA54005
ID AAA33449 standard; DNA; 14 BP.
XX
AC AAA33449;
XX
DT 28-JUL-2000 (first entry)
XX
DE Low adenosine antisense oligonucleotide SEQ ID NO:1138.
XX
KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW phosphothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
OS Homo sapiens.
XX
PN WO200009525-A2.
XX
PD 24-FEB-2000.
XX
PF 03-AUG-1999; 99WO-US017712.
XX
PR 03-AUG-1998; 98US-0095212P.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW;
XX
DR WPI; 2000-205971/18.
XX
PT New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers.
PS Claim 18; Page 407; 1343pp; English.
XX
CC The present invention describes a new composition comprising an antisense
CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,

```

CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, leukaemias, lymphomas,
 CC pulmonary disease (COPD), and cancers such as metastasise to the lungs, including
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA33313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
 CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
 CC AAA33992) are specifically claimed ONs from the present invention. N.B.
 CC Sequences given in the disclosure of the present invention do not match
 CC up with their corresponding SEQ ID NO: sequences given in the sequence
 CC listing
 XX
 SQ Sequence 14 BP; 0 A; 2 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 687 GTGGGGGCTTTGGC 700
 Db 1 GTGGGGGCTTTGGC 14

RESULT 274

AAF19571
 ID AAF19571 standard; DNA; 14 BP.

XX AAF19571;

AC AAF19571;

DT 14-MAR-2001 (first entry)

XX Human IL4 receptor polynucleotide fragment #1138.

DE Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 XX human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.

XX Homo sapiens.

XX WO2000062736-A2.

XX 26-OCT-2000.

XX 24-MAR-2000; 2000WO-US008020.

XX 06-APR-1999; 99US-0127958P.

XX (UYEC-) UNIV EAST CAROLINA.

PA (NYCE/) NYCE J W.

XX Nyce JW;

XX WPI; 2000-679539/66.

DR Low adenosine (A) content antisense oligonucleotides which do not trigger
 XX adenosine receptors during metabolism, useful e.g. for treating cancers
 PT

PT and respiratory obstructions.
 XX Claim 14; Page 208; 1592pp; English.

XX The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergies (ies) and/or
 CC surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention
 XX

SQ Sequence 14 BP; 0 A; 2 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 687 GTGGGGGCTTTGGC 700

Db 1 GTGGGGGCTTTGGC 14

RESULT 275

ABZ95265
 ID ABZ95265 standard; DNA; 14 BP.

XX ABZ95265;

AC ABZ95265;

DT 17-OCT-2003 (first entry)

XX Human IL-4 receptor antisense fragment no.1129.

DE Human; antisense; lung dysfunction; nasal airway dysfunction;
 XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX WO200285308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (SPIG-) EPIGENESIS PHARM INC.

```

XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 10507; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 14 BP; 0 A; 2 C; 8 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 687 GTGGGGCGCTTTGGC 700
Db 1 GTGGGGCGCTTTGGC 14
RESULT 276
ABD19234
ID ABD19234 standard; DNA; 14 BP.
AC ABD19234;
XX
XX 29-JUL-2004 (first entry)
XX
XX Human IL4 receptor DNA fragment 1129.
XX
XX Human; antisense: bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; db.
XX
XX Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX

```

```

XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 10507; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating or
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 14 BP; 0 A; 2 C; 8 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 687 GTGGGGCGCTTTGGC 700
Db 1 GTGGGGCGCTTTGGC 14
RESULT 277
AAZ90832
ID AAZ90832 standard; DNA; 15 BP.
XX
XX AAZ90832;
XX
XX 24-MAY-2000 (first entry)
XX
XX Human NR8 gene probe #60.
XX
XX Haemopoietin receptor family; NR8; antibody; diagnosis;
XX blood formation disorder; fusion protein; probe; ss.
XX
XX Homo sapiens.
XX
XX WO967290-A1.
XX

```


XX PD 29-DEC-1999.
XX PF 23-JUN-1999; 99WO-JP003351.
XX PR 24-JUN-1998; 98JP-00214720.
XX PR 19-OCT-1998; 98JP-00297409.
XX PA (CHUS) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX PI Nomura H, Maeda M;
XX DR WPI; 2000-116933/10.
XX PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX PT formation disorders.
XX PS Example 1; Page 40; 176pp; Japanese.
XX CC The invention relates to the isolation of sequences encoding human
CC haemopoietin receptor protein family NR8 genes. The NR8 family sequences
CC were initially searched for comparison on a nucleic acid database with
CC the nucleic acid probe sequence TGGAGYNNNTGGAGY encoding the amino acid
CC sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-Z59300 and AAZ90816-
CC Z90925 represent specific examples of probe sequences used in the search.
CC Antibodies to the NR8 family proteins are used for the diagnosis of blood
CC formation disorders. Compounds identified as binding to the proteins are
CC used for the treatment of such disorders
XX SQ Sequence 15 BP; 2 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1343 TGGAGTGCCTGGAG 1356
Db 1 TGGAGTGCCTGGAG 14
RESULT 278
AAZ59267
ID AAZ59267 standard; DNA; 15 BP.
XX AC AAZ59267;
XX DT 24-MAY-2000 (first entry)
XX DE Human NR8 gene probe #10.
XX KW Haemopoietin receptor family; NR8; antibody; diagnosis;
XX KW blood formation disorder; fusion protein; probe; ss.
XX OS Homo sapiens.
XX PN WO9967290-A1.
XX PD 29-DEC-1999.
XX PF 23-JUN-1999; 99WO-JP003351.
XX PR 24-JUN-1998; 98JP-00214720.
XX PR 19-OCT-1998; 98JP-00297409.
XX PA (CHUS) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX PI Nomura H, Maeda M;
XX DR WPI; 2000-116933/10.
XX PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX PT formation disorders.

PS Example 1; Page 38; 176pp; Japanese.
XX CC The invention relates to the isolation of sequences encoding human
CC haemopoietin receptor protein family NR8 genes. The NR8 family sequences
CC were initially searched for comparison on a nucleic acid database with
CC the nucleic acid probe sequence TGGAGYNNNTGGAGY encoding the amino acid
CC sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-Z59300 and AAZ90816-
CC Z90925 represent specific examples of probe sequences used in the search.
CC Antibodies to the NR8 family proteins are used for the diagnosis of blood
CC formation disorders. Compounds identified as binding to the proteins are
CC used for the treatment of such disorders
XX SQ Sequence 15 BP; 2 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1343 TGGAGTGCCTGGAG 1356
Db 1 TGGAGTGCCTGGAG 14
RESULT 279
AAZ90877
ID AAZ90877 standard; DNA; 15 BP.
XX AC AAZ90877;
XX DT 24-MAY-2000 (first entry)
XX DE Human NR8 gene probe #105.
XX KW Haemopoietin receptor family; NR8; antibody; diagnosis;
XX KW blood formation disorder; fusion protein; probe; ss.
XX OS Homo sapiens.
XX PN WO9967290-A1.
XX PD 29-DEC-1999.
XX PF 23-JUN-1999; 99WO-JP003351.
XX PR 24-JUN-1998; 98JP-00214720.
XX PR 19-OCT-1998; 98JP-00297409.
XX PA (CHUS) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX PI Nomura H, Maeda M;
XX DR WPI; 2000-116933/10.
XX PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX PT formation disorders.
XX PS Example 1; Page 43; 176pp; Japanese.
XX CC The invention relates to the isolation of sequences encoding human
CC haemopoietin receptor protein family NR8 genes. The NR8 family sequences
CC were initially searched for comparison on a nucleic acid database with
CC the nucleic acid probe sequence TGGAGYNNNTGGAGY encoding the amino acid
CC sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-Z59300 and AAZ90816-
CC Z90925 represent specific examples of probe sequences used in the search.
CC Antibodies to the NR8 family proteins are used for the diagnosis of blood
CC formation disorders. Compounds identified as binding to the proteins are
CC used for the treatment of such disorders
XX SQ Sequence 15 BP; 2 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY      1343 TGGAGTGCCTGGAG 1356
Db      1 TGGAGTGCCTGGAG 14

RESULT 280
AAZ90872
ID      AAZ90872 standard; DNA; 15 BP.
XX
XX      AC      AAZ90872;
XX      AC      24-MAY-2000 (first entry)
XX      AC      Human NR8 gene probe #100.
XX      AC      Haemopoietin receptor family; NR8; antibody; diagnosis;
XX      AC      blood formation disorder; fusion protein; probe; ss.
XX      AC      Homo sapiens.
XX      AC      WO9967290-A1.
XX      AC      29-DEC-1999.
XX      AC      23-JUN-1999; 99WO-JP003351.
XX      AC      24-JUN-1998; 98JP-00214720.
XX      AC      19-OCT-1998; 98JP-00297409.
XX      AC      (CHUS ) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX      AC      Nomura H, Maeda M;
XX      AC      WPI; 2000-116933/10.
XX      AC      Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX      AC      formation disorders.
XX      AC      Example 1; Page 42; 176pp; Japanese.
XX      AC      The invention relates to the isolation of sequences encoding human
XX      AC      haemopoietin receptor protein family NR8 genes. The NR8 family sequences
XX      AC      were initially searched for comparison on a nucleic acid database with
XX      AC      the nucleic acid probe sequence TGGAGYNNNTGGAGY encoding the amino acid
XX      AC      sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-Z59300 and AAZ90816-
XX      AC      Z90925 represent specific examples of probe sequences used in the search.
XX      AC      Antibodies to the NR8 family proteins are used for the diagnosis of blood
XX      AC      formation disorders. Compounds identified as binding to the proteins are
XX      AC      used for the treatment of such disorders
XX      AC      Sequence 15 BP; 2 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
XX      AC      Query Match      0.8%; Score 14; DB 1; Length 15;
XX      AC      Best Local Similarity 100.0%; Pred. No. 1.5e+02;
XX      AC      Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1343 TGGAGTGCCTGGAG 1356
Db      1 TGGAGTGCCTGGAG 14

RESULT 281
ABK98169/c
ID      ABK98169 standard; DNA; 15 BP.
XX
XX      AC      ABK98169;
XX      AC      07-OCT-2002 (first entry)
XX      AC      Triple helix forming associated oligonucleotide #39.
XX      AC      Triple-helix formation; purine-rich target sequence; double-helix DNA;

QY      1835 AAAAAAAAAAAAAA 1849
Db      15 AAAAAAAAAAAAAA 1

RESULT 282
ABK98187/c
ID      ABK98187 standard; DNA; 15 BP.
XX
XX      AC      ABK98187;
XX      AC      07-OCT-2002 (first entry)
XX      AC      Triple helix forming associated oligonucleotide #51.

KW      gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW      pathogenic bacteria; virus; replication; virulence; cancer;
KW      oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX      Synthetic.
XX      US6403302-B1.
XX      11-JUN-2002.
XX      16-DEC-1993; 93US-00168920.
XX      17-SEP-1992; 92US-00946976.
XX      (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX      Dervan PB, Beal PA;
XX      WPI; 2002-536030/57.
XX      A triple-helix comprising a double helical nucleic acid (DHNA) and an
XX      oligonucleotide which binds in parallel and antiparallel orientation,
XX      respectively, for targeting sequences on alternate strands of DHNA to
XX      control gene expression.
XX      Example 6; Fig 20A; 108pp; English.
XX      The present invention relates to methods and oligonucleotides for forming
XX      a triple-helix comprising a double helical nucleic acid comprising first
XX      and second substantially complementary strands, and an oligonucleotide
XX      bound to a purine-rich target sequence within the double helical nucleic
XX      acid, where the oligonucleotide binds in a parallel and antiparallel
XX      orientation, respectively, to target sequences on alternate strands of
XX      the double helical nucleic acid. The method has therapeutic applications,
XX      where gene expression is controlled by selective triple-helix formation,
XX      within expression regulatory sequences of a target gene. The
XX      oligonucleotides can be used to form triple-helices, and are useful to
XX      detect the presence or absence of specific sequences within genomic DNA
XX      for diagnostic and therapeutic purposes. The oligonucleotides can be
XX      selected to specifically bind to pathogenic bacteria or viruses for
XX      specific sequences required by pathogenic bacteria or viruses for
XX      replication or virulence, reducing their pathogenicity. Alternatively,
XX      the oligonucleotide can be chosen to target a unique sequence of the
XX      pathogen which is not found in the genome of pathogen's host. The
XX      oligonucleotides can be used in cancer treatment by way of triple-helix
XX      suppression of specific oncogenes including those of endogenous or viral
XX      origin. Such therapeutic oligonucleotides are capable of forming triple-
XX      helices with such sequences in cancerous cells containing the activated
XX      oncogene, so preferentially killing or repressing the cancer causing
XX      cell. The present sequence represents an oligonucleotide used in the
XX      methods of the present invention
XX      Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;
XX      Query Match      0.8%; Score 14; DB 1; Length 15;
XX      Best Local Similarity 93.3%; Pred. No. 1.5e+02;
XX      Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

KW Triple-helix formation; purine-rich target sequence; double-helix DNA;
 gene expression; regulatory sequence; pathogenic double-stranded DNA;
 KW pathogenic bacteria; virus; replication; virulence; cancer;
 KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
 XX
 OS Synthetic.
 PN US6403302-B1.
 XX
 PD 11-JUN-2002.
 XX
 PF 16-DEC-1993; 93US-00168920.
 XX
 PR 17-SEP-1992; 92US-00946976.
 XX
 XX (CALY) CALIFORNIA INST OF TECHNOLOGY.
 XX
 XX Dervan PB, Beal PA;
 XX
 DR WPI; 2002-536030/57.
 XX
 XX A triple-helix comprising a double helical nucleic acid (DHNA) and an
 PT oligonucleotide which binds in parallel and antiparallel orientation,
 PT respectively, for targeting sequences on alternate strands of DHNA to
 PT control gene expression.
 XX
 PS Example 7; Fig 24A; 108pp; English.
 XX
 CC The present invention relates to methods and oligonucleotides for forming
 CC a triple-helix comprising a double helical nucleic acid comprising first
 CC and second substantially complementary strands, and an oligonucleotide
 CC bound to a purine-rich target sequence within the double helical nucleic
 CC acid, where the oligonucleotide binds in a parallel and antiparallel
 CC orientation, respectively, to target sequences on alternate strands of
 CC the double helical nucleic acid. The method has therapeutic applications,
 CC where gene expression is controlled by selective triple-helix formation
 CC within expression regulatory sequences of a target gene. The
 CC oligonucleotides can be used to form triple-helices, and are useful to
 CC detect the presence or absence of specific sequences within genomic DNA
 CC for diagnostic and therapeutic purposes. The oligonucleotides can be
 CC selected to specifically bind to pathogenic double-stranded DNA including
 CC specific sequences required by pathogenic bacteria or viruses for
 CC replication or virulence, reducing their pathogenicity. Alternatively,
 CC the oligonucleotide can be chosen to target a unique sequence of the
 CC pathogen which is not found in the genome of pathogen's host. The
 CC oligonucleotides can be used in cancer treatment by way of triple-helix
 CC suppression of specific oncogenes including those of endogenous or viral
 CC origin. Such therapeutic oligonucleotides are capable of forming triple-
 CC helices with such sequences in cancerous cells containing the activated
 CC oncogene, so preferentially killing or repressing the cancer causing
 CC cell. The present sequence represents an oligonucleotide used in the
 CC methods of the present invention
 XX
 SQ Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;
 Query Match 0.8%; Score 14; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1835 AAAAAAAAAAAAAA 1849
 Db 15 AAAAAAAAAAAAAA 1
 RESULT 283
 ABK98168/C
 ID ABK98168 standard; DNA; 15 BP.
 XX
 XX AC ABK98168;
 XX
 DT 07-OCT-2002 (first entry)
 XX
 DE Triple helix forming associated oligonucleotide #38.

XX Triple-helix formation; purine-rich target sequence; double-helix DNA;
 KW gene expression; regulatory sequence; pathogenic double-stranded DNA;
 KW pathogenic bacteria; virus; replication; virulence; cancer;
 KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
 XX
 OS Synthetic.
 PN US6403302-B1.
 XX
 PD 11-JUN-2002.
 XX
 PF 16-DEC-1993; 93US-00168920.
 XX
 PR 17-SEP-1992; 92US-00946976.
 XX
 XX (CALY) CALIFORNIA INST OF TECHNOLOGY.
 XX
 XX Dervan PB, Beal PA;
 XX
 DR WPI; 2002-536030/57.
 XX
 XX A triple-helix comprising a double helical nucleic acid (DHNA) and an
 PT oligonucleotide which binds in parallel and antiparallel orientation,
 PT respectively, for targeting sequences on alternate strands of DHNA to
 PT control gene expression.
 XX
 PS Example 6; Fig 20A; 108pp; English.
 XX
 CC The present invention relates to methods and oligonucleotides for forming
 CC a triple-helix comprising a double helical nucleic acid comprising first
 CC and second substantially complementary strands, and an oligonucleotide
 CC bound to a purine-rich target sequence within the double helical nucleic
 CC acid, where the oligonucleotide binds in a parallel and antiparallel
 CC orientation, respectively, to target sequences on alternate strands of
 CC the double helical nucleic acid. The method has therapeutic applications,
 CC where gene expression is controlled by selective triple-helix formation
 CC within expression regulatory sequences of a target gene. The
 CC oligonucleotides can be used to form triple-helices, and are useful to
 CC detect the presence or absence of specific sequences within genomic DNA
 CC for diagnostic and therapeutic purposes. The oligonucleotides can be
 CC selected to specifically bind to pathogenic double-stranded DNA including
 CC specific sequences required by pathogenic bacteria or viruses for
 CC replication or virulence, reducing their pathogenicity. Alternatively,
 CC the oligonucleotide can be chosen to target a unique sequence of the
 CC pathogen which is not found in the genome of pathogen's host. The
 CC oligonucleotides can be used in cancer treatment by way of triple-helix
 CC suppression of specific oncogenes including those of endogenous or viral
 CC origin. Such therapeutic oligonucleotides are capable of forming triple-
 CC helices with such sequences in cancerous cells containing the activated
 CC oncogene, so preferentially killing or repressing the cancer causing
 CC cell. The present sequence represents an oligonucleotide used in the
 CC methods of the present invention
 XX
 SQ Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;
 Query Match 0.8%; Score 14; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1835 AAAAAAAAAAAAAA 1849
 Db 15 AAAAAAAAAAAAAA 1
 RESULT 284
 ABK98167/C
 ID ABK98167 standard; DNA; 15 BP.
 XX
 XX AC ABK98167;
 XX
 DT 07-OCT-2002 (first entry)
 XX

```
DE Triple helix forming associated oligonucleotide #37.
XX
XX Triple-helix formation; purine-rich target sequence; double-helix DNA;
KW gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW pathogenic bacteria; virus; replication; virulence; cancer;
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX
OS Synthetic.
XX
XX US6403302-B1.
XX
XX 11-JUN-2002.
XX
XX 16-DEC-1993; 93US-00168920.
XX
XX 17-SEP-1992; 92US-00946976.
XX
XX (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX
XX Dervan PB, Beal PA;
XX
XX WPI; 2002-536030/57.
XX
XX A triple-helix comprising a double helical nucleic acid (DHNA) and an
PT oligonucleotide which binds in parallel and antiparallel orientation,
PT respectively, for targetting sequences on alternate strands of DHNA to
PT control gene expression.
XX
XX Example 6; Fig 20A; 108pp; English.
XX
XX The present invention relates to methods and oligonucleotides for forming
CC a triple-helix comprising a double helical nucleic acid comprising first
CC and second substantially complementary strands, and an oligonucleotide
CC bound to a purine-rich target sequence within the double helical nucleic
CC acid, where the oligonucleotide binds in a parallel and antiparallel
CC orientation, respectively, to target sequences on alternate strands of
CC the double helical nucleic acid. The method has therapeutic applications,
CC where gene expression is controlled by selective triple-helix formation
CC within expression regulatory sequences of a target gene. The
CC oligonucleotides can be used to form triple-helices, and are useful to
CC detect the presence or absence of specific sequences within genomic DNA
CC for diagnostic and therapeutic purposes. The oligonucleotides can be
CC selected to specifically bind to pathogenic double-stranded DNA including
CC specific sequences required by pathogenic bacteria or viruses for
CC replication or virulence, reducing their pathogenicity. Alternatively,
CC the oligonucleotide can be chosen to target a unique sequence of the
CC pathogen which is not found in the genome of pathogen's host. The
CC oligonucleotides can be used in cancer treatment by way of triple-helix
CC suppression of specific oncogenes including those of endogenous or viral
CC origin. Such therapeutic oligonucleotides are capable of forming triple-
CC helices with such sequences in cancerous cells containing the activated
CC oncogene, so preferentially killing or repressing the cancer causing
CC cell. The present sequence represents an oligonucleotide used in the
CC methods of the present invention
XX
XX Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1
RESULT 285
ABK98186/c
ID ABK98186 standard; DNA; 15 BP.
XX
AC ABK98186;
XX
XX 07-OCT-2002 (first entry)
DT
```

```
XX
DE Triple helix forming associated oligonucleotide #50.
XX
XX Triple-helix formation; purine-rich target sequence; double-helix DNA;
KW gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW pathogenic bacteria; virus; replication; virulence; cancer;
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX
OS Synthetic.
XX
XX US6403302-B1.
XX
XX 11-JUN-2002.
XX
XX 16-DEC-1993; 93US-00168920.
XX
XX 17-SEP-1992; 92US-00946976.
XX
XX (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX
XX Dervan PB, Beal PA;
XX
XX WPI; 2002-536030/57.
XX
XX A triple-helix comprising a double helical nucleic acid (DHNA) and an
PT oligonucleotide which binds in parallel and antiparallel orientation,
PT respectively, for targetting sequences on alternate strands of DHNA to
PT control gene expression.
XX
XX Example 7; Fig 24A; 108pp; English.
XX
XX The present invention relates to methods and oligonucleotides for forming
CC a triple-helix comprising a double helical nucleic acid comprising first
CC and second substantially complementary strands, and an oligonucleotide
CC bound to a purine-rich target sequence within the double helical nucleic
CC acid, where the oligonucleotide binds in a parallel and antiparallel
CC orientation, respectively, to target sequences on alternate strands of
CC the double helical nucleic acid. The method has therapeutic applications,
CC where gene expression is controlled by selective triple-helix formation
CC within expression regulatory sequences of a target gene. The
CC oligonucleotides can be used to form triple-helices, and are useful to
CC detect the presence or absence of specific sequences within genomic DNA
CC for diagnostic and therapeutic purposes. The oligonucleotides can be
CC selected to specifically bind to pathogenic double-stranded DNA including
CC specific sequences required by pathogenic bacteria or viruses for
CC replication or virulence, reducing their pathogenicity. Alternatively,
CC the oligonucleotide can be chosen to target a unique sequence of the
CC pathogen which is not found in the genome of pathogen's host. The
CC oligonucleotides can be used in cancer treatment by way of triple-helix
CC suppression of specific oncogenes including those of endogenous or viral
CC origin. Such therapeutic oligonucleotides are capable of forming triple-
CC helices with such sequences in cancerous cells containing the activated
CC oncogene, so preferentially killing or repressing the cancer causing
CC cell. The present sequence represents an oligonucleotide used in the
CC methods of the present invention
XX
XX Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1
RESULT 286
ADR36131
ID ADR36131 standard; DNA; 16 BP.
XX
AC ADR36131;
XX
```

```

DT 04-NOV-2004 (first entry)
DE Human nicking agent DNA containing BstNBI restriction site #2551.
XX
XX
XX ss; nicking agent; assay panel; diagnosis; expression pattern;
KW DNA fingerprinting; nosocomial infection; microbiological assay;
KW bacterial contamination; genome mapping; bioremediation.
XX
XX Homo sapiens.
XX WO2004067765-A2.
XX
XX 12-AUG-2004.
XX
XX 29-JAN-2004; 2004WO-US002720.
XX
XX 29-JAN-2003; 2003US-0443811P.
XX
XX (KECK-) KECK GRADUATE INST.
XX
XX Van Ness J, Galas DJ, Van Ness LK;
XX WPI; 2004-581010/56.
XX
XX Identifying nucleic acid sample source, useful for identifying bacterial
PT strains involved in nosocomial infections, comprises treating the nucleic
PT acid sample with components comprising a nicking agent under nicking
PT conditions.
XX
XX Example 3; Page 105-219; 238pp; English.
XX
XX The invention relates to a method of treating a nucleic acid sample with
CC components under nicking conditions, where the components comprise a
CC nicking agent, and the conditions cause the nicking agent to nick the
CC nucleic acid sample to thus produce a family of initiating
CC oligonucleotide fragments, and subjecting one or more members of the
CC family of initiating oligonucleotide fragments to a characterization
CC assay panel of diagnostic oligonucleotides that can identify any organism
CC or individual. The method is useful for characterizing other DNA
CC molecules e.g., cDNA, and for characterizing cDNA expression patterns.
CC The method, kit or composition is useful for identifying the source
CC organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,
CC non-human animal or human. The method is particularly useful for rapidly
CC fingerprinting DNA to identifying prokaryotic and eukaryotic species,
CC subspecies, and especially strains or individuals of the subspecies. It
CC is especially useful for identifying different bacterial strains involved
CC in e.g., nosocomial infections. Furthermore, the method is useful for
CC diagnosing bacterial disease in plants and humans, monitoring for
CC bacterial content and/or contamination in the environment, monitoring
CC food for bacterial contamination, monitoring quality assurance/quality control of
CC bacterial contamination, monitoring quality assurance/quality control of
CC laboratory tests involving microbiological assays, tracing bacterial
CC contamination and/or outbreaks of bacterial infections, genome mapping,
CC monitoring bioremediation sites, and for monitoring agricultural sites
CC for test crops, bacteria and recombinant molecules. Sequences ADR33581-
CC ADR37496 correspond to target nucleic acids containing an NbsrNBI
XX restriction site and used in the method of the invention.
XX
XX Sequence 16 BP; 5 A; 3 C; 5 G; 2 T; 0 U; 1 Other;
XX
XX Query Match 0.8%; Score 14; DB 1; Length 16;
XX Best Local Similarity 87.5%; Pred. No. 1.6e+02;
XX Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 381 CTCGACCAAGATGGGC 396
XX :| |||||
XX 1 STACAGCAAGATGGGC 16
XX
XX Db
XX
XX RESULT 287
XX ADR36132
XX ID ADR36132 standard; DNA; 16 BP.

```

```

XX
XX ADR36132;
XX
XX 04-NOV-2004 (first entry)
XX
XX Human nicking agent DNA containing BstNBI restriction site #2552.
XX
XX ss; nicking agent; assay panel; diagnosis; expression pattern;
KW DNA fingerprinting; nosocomial infection; microbiological assay;
KW bacterial contamination; genome mapping; bioremediation.
XX
XX Homo sapiens.
XX WO2004067765-A2.
XX
XX 12-AUG-2004.
XX
XX 29-JAN-2004; 2004WO-US002720.
XX
XX 29-JAN-2003; 2003US-0443811P.
XX
XX (KECK-) KECK GRADUATE INST.
XX
XX Van Ness J, Galas DJ, Van Ness LK;
XX WPI; 2004-581010/56.
XX
XX Identifying nucleic acid sample source, useful for identifying bacterial
PT strains involved in nosocomial infections, comprises treating the nucleic
PT acid sample with components comprising a nicking agent under nicking
PT conditions.
XX
XX Example 3; Page 105-219; 238pp; English.
XX
XX The invention relates to a method of treating a nucleic acid sample with
CC components under nicking conditions, where the components comprise a
CC nicking agent, and the conditions cause the nicking agent to nick the
CC nucleic acid sample to thus produce a family of initiating
CC oligonucleotide fragments, and subjecting one or more members of the
CC family of initiating oligonucleotide fragments to a characterization
CC process to thus provide results. The method is useful for creating an
CC assay panel of diagnostic oligonucleotides that can identify any organism
CC or individual. The method is useful for characterizing other DNA
CC molecules e.g., cDNA, and for characterizing cDNA expression patterns.
CC The method, kit or composition is useful for identifying the source
CC organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,
CC non-human animal or human. The method is particularly useful for rapidly
CC fingerprinting DNA to identifying prokaryotic and eukaryotic species,
CC subspecies, and especially strains or individuals of the subspecies. It
CC is especially useful for identifying different bacterial strains involved
CC in e.g., nosocomial infections. Furthermore, the method is useful for
CC diagnosing bacterial disease in plants and humans, monitoring for
CC bacterial content and/or contamination in the environment, monitoring
CC food for bacterial contamination, monitoring quality assurance/quality control of
CC bacterial contamination, monitoring quality assurance/quality control of
CC laboratory tests involving microbiological assays, tracing bacterial
CC contamination and/or outbreaks of bacterial infections, genome mapping,
CC monitoring bioremediation sites, and for monitoring agricultural sites
CC for test crops, bacteria and recombinant molecules. Sequences ADR33581-
CC ADR37496 correspond to target nucleic acids containing an NbsrNBI
XX restriction site and used in the method of the invention.
XX
XX Sequence 16 BP; 5 A; 3 C; 5 G; 2 T; 0 U; 1 Other;
XX
XX Query Match 0.8%; Score 14; DB 1; Length 16;
XX Best Local Similarity 87.5%; Pred. No. 1.6e+02;
XX Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 381 CTCGACCAAGATGGGC 396
XX :| |||||
XX 1 STACAGCAAGATGGGC 16
XX
XX Db

```

```

RESULT 288
ADR36130
ID  ADR36130 standard; DNA; 16 BP.
XX
AC  ADR36130;
XX
DT  04-NOV-2004 (first entry)
XX
DE  Human nicking agent DNA containing BstNBI restriction site #2550.
XX
KW  ss; nicking agent; assay panel; diagnosis; expression pattern;
KW  DNA fingerprinting; nosocomial infection; microbiological assay;
KW  bacterial contamination; genome mapping; bioremediation.
XX
OS  Homo sapiens.
XX
PN  WO2004067765-A2.
XX
PD  12-AUG-2004.
XX
PF  29-JAN-2004; 2004WO-US002720.
XX
PR  29-JAN-2003; 2003US-0443811P.
XX
PA  (KECK-) KECK GRADUATE INST.
XX
PI  Van Ness J, Galas DJ, Van Ness LK;
XX  WPI; 2004-581010/56.
XX
PT  Identifying nucleic acid sample source, useful for identifying bacterial
PT  strains involved in nosocomial infections, comprises treating the nucleic
PT  acid sample with components comprising a nicking agent under nicking
PT  conditions.
XX
PS  Example 3; Page 105-219; 238pp; English.
XX
CC  The invention relates to a method of treating a nucleic acid sample with
CC  components under nicking conditions, where the components comprise a
CC  nicking agent, and the conditions cause the nicking agent to nick the
CC  nucleic acid sample to thus produce a family of initiating
CC  oligonucleotide fragments, and subjecting one or more members of the
CC  family of initiating oligonucleotide fragments to a characterization
CC  process to thus provide results. The method is useful for creating an
CC  assay panel of diagnostic oligonucleotides that can identify any organism
CC  or individual. The method is useful for characterizing other DNA
CC  molecules e.g., cDNA, and for characterizing cDNA expression patterns.
CC  The method, kit or composition is useful for identifying the source
CC  organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,
CC  non-human animal or human. The method is particularly useful for rapidly
CC  fingerprinting DNA to identifying prokaryotic and eukaryotic species,
CC  subspecies, and especially strains or individuals of the subspecies. It
CC  is especially useful for identifying different bacterial strains involved
CC  in e.g., nosocomial infections. Furthermore, the method is useful for
CC  diagnosing bacterial disease in plants and humans, monitoring for
CC  bacterial content and/or contamination in the environment, monitoring
CC  food for bacterial contamination, monitoring manufacturing processes for
CC  bacterial contamination, monitoring quality assurance/quality control of
CC  laboratory tests involving microbiological assays, tracing bacterial
CC  contamination and/or outbreaks of bacterial infections, genome mapping,
CC  monitoring bioremediation sites, and for monitoring agricultural sites
CC  for test crops, bacteria and recombinant molecules. Sequences ADR33581-
CC  ADR37496 correspond to target nucleic acids containing an NBstNBI
CC  restriction site and used in the method of the invention.
XX
SQ  Sequence 16 BP; 5 A; 3 C; 5 G; 2 T; 0 U; 1 Other;

Query Match      0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. NO. 1.6e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY  381 CTGCAGCAAGATGGGC 396
    : |||||||

```

```

Db 1 STACAGCAAGATGGGC 16

RESULT 289
ADR36129
ID  ADR36129 standard; DNA; 16 BP.
XX
AC  ADR36129;
XX
DT  04-NOV-2004 (first entry)
XX
DE  Human nicking agent DNA containing BstNBI restriction site #2549.
XX
KW  ss; nicking agent; assay panel; diagnosis; expression pattern;
KW  DNA fingerprinting; nosocomial infection; microbiological assay;
KW  bacterial contamination; genome mapping; bioremediation.
XX
OS  Homo sapiens.
XX
PN  WO2004067765-A2.
XX
PD  12-AUG-2004.
XX
PF  29-JAN-2004; 2004WO-US002720.
XX
PR  29-JAN-2003; 2003US-0443811P.
XX
PA  (KECK-) KECK GRADUATE INST.
XX
PI  Van Ness J, Galas DJ, Van Ness LK;
XX  WPI; 2004-581010/56.
XX
PT  Identifying nucleic acid sample source, useful for identifying bacterial
PT  strains involved in nosocomial infections, comprises treating the nucleic
PT  acid sample with components comprising a nicking agent under nicking
PT  conditions.
XX
PS  Example 3; Page 105-219; 238pp; English.
XX
CC  The invention relates to a method of treating a nucleic acid sample with
CC  components under nicking conditions, where the components comprise a
CC  nicking agent, and the conditions cause the nicking agent to nick the
CC  nucleic acid sample to thus produce a family of initiating
CC  oligonucleotide fragments, and subjecting one or more members of the
CC  family of initiating oligonucleotide fragments to a characterization
CC  process to thus provide results. The method is useful for creating an
CC  assay panel of diagnostic oligonucleotides that can identify any organism
CC  or individual. The method is useful for characterizing other DNA
CC  molecules e.g., cDNA, and for characterizing cDNA expression patterns.
CC  The method, kit or composition is useful for identifying the source
CC  organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,
CC  non-human animal or human. The method is particularly useful for rapidly
CC  fingerprinting DNA to identifying prokaryotic and eukaryotic species,
CC  subspecies, and especially strains or individuals of the subspecies. It
CC  is especially useful for identifying different bacterial strains involved
CC  in e.g., nosocomial infections. Furthermore, the method is useful for
CC  diagnosing bacterial disease in plants and humans, monitoring for
CC  bacterial content and/or contamination in the environment, monitoring
CC  food for bacterial contamination, monitoring manufacturing processes for
CC  bacterial contamination, monitoring quality assurance/quality control of
CC  laboratory tests involving microbiological assays, tracing bacterial
CC  contamination and/or outbreaks of bacterial infections, genome mapping,
CC  monitoring bioremediation sites, and for monitoring agricultural sites
CC  for test crops, bacteria and recombinant molecules. Sequences ADR33581-
CC  ADR37496 correspond to target nucleic acids containing an NBstNBI
CC  restriction site and used in the method of the invention.
XX
SQ  Sequence 16 BP; 5 A; 3 C; 5 G; 2 T; 0 U; 1 Other;

Query Match      0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. NO. 1.6e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```

Qy 381 CTGACGCAAGATGGGC 396
 Db 1 STACAGCAAGATGGGC 16

RESULT 290
 ABK02857
 ID ABK02857 standard; RNA; 17 BP.
 XX
 AC ABK02857;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human CD20 Hammerhead ribozyme #156.
 XX
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200159103-A2.
 XX
 XX 16-AUG-2001.
 XX
 XX 09-FEB-2001; 2001WO-US004273.
 XX
 XX 11-FEB-2000; 2000US-0181797P.
 XX
 XX 28-FEB-2000; 2000US-0185516P.
 XX
 XX 06-MAR-2000; 2000US-0187128P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC..
 XX (BLATT) BLATT L.
 XX (MCSW/) MCSWIGGEN J.
 XX (CHOW/) CHOWRIRA B M.
 XX
 XX Blatt L, Mcswiggen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 XX
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 XX constructs, which down regulate expression of a CD20 gene or neurite
 XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 XX central nervous system injury.
 XX
 XX Claim 30; Page 142; 200pp; English.
 XX
 XX The invention relates to a nucleic acid molecule which down regulates
 XX expression of a CD20 gene and a nucleic acid molecule which down
 XX regulates expression of a neurite growth inhibitor gene (NOGO). The
 XX nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 XX DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 XX an amberzyme (cleaving RNA with an MGN triplet), a zinczyme (cleaving RNA
 XX with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 XX of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 XX Furthermore, it may be contacted with a cell to reduce CD20 activity of
 XX the cell and treat a patient having a condition associated with the level
 XX of CD20. The treatment may further comprise the use of one or more
 XX therapies. In particular, the CD20 targeting nucleic acid may be used to
 XX treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 XX Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic

CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention
 XX
 SQ Sequence 17 BP; 11 A; 0 C; 3 G; 0 T; 3 U; 0 Other;
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 1.7e+02;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 Qy 201 GAAATATAAAGAAGA 214
 Db 4 GAAATATAAAGAAGA 17
 ||||:|||||
 ||||:|||||

RESULT 291
 ABN02598
 ID ABN02598 standard; DNA; 17 BP.
 XX
 AC ABN02598;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2590.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 OS
 XX WO200192524-A2.
 XX
 XX 06-DEC-2001.
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 XX
 XX 21-SEP-2000; 2000US-0234687P.
 XX
 XX 27-SEP-2000; 2000US-0236359P.
 XX
 XX 04-OCT-2000; 2000GB-00024263.
 XX
 XX 30-JAN-2001; 2001WO-US000661.
 XX
 XX 30-JAN-2001; 2001WO-US000662.
 XX
 XX 30-JAN-2001; 2001WO-US000663.
 XX
 XX 30-JAN-2001; 2001WO-US000664.
 XX
 XX 30-JAN-2001; 2001WO-US000665.
 XX
 XX 30-JAN-2001; 2001WO-US000666.
 XX
 XX 30-JAN-2001; 2001WO-US000667.
 XX
 XX 30-JAN-2001; 2001WO-US000668.
 XX
 XX 30-JAN-2001; 2001WO-US000669.
 XX
 XX 30-JAN-2001; 2001WO-US000670.
 XX
 XX 03-FEB-2001; 2001US-0266860P.
 XX
 XX (AEOM-) AEOMICA INC.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,

PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 2590; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 990 CAGGGTGCCATGGA 1003
Db |||||
4 CAGGGTGCCATGGA 17
RESULT 292
ABN02601
ID ABN02601 standard; DNA; 17 BP.
XX
XX AC ABN02601;
XX
XX DT 29-MAY-2002 (first entry)
XX
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2593.
XX
XX KW Human; genome-derived myosin-like protein 1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200192524-A2.
XX
XX PD 06-DEC-2001.
XX
XX PF 25-MAY-2001; 2001WO-US016981.
XX
XX PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0268660P.
XX
XX PA (AEOM-) AEOMICA INC.
XX
XX GU Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
XX
XX WPI; 2002-179446/23.
DR
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 2593; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 990 CAGGGTGCCATGGA 1003
Db |||||
1 CAGGGTGCCATGGA 14
RESULT 293
ABN02599
ID ABN02599 standard; DNA; 17 BP.
XX
XX AC ABN02599;
XX
XX DT 29-MAY-2002 (first entry)
XX
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2591.
XX
XX KW Human; genome-derived myosin-like protein 1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200192524-A2.
XX
XX PD 06-DEC-2001.
XX
XX PF 25-MAY-2001; 2001WO-US016981.
XX
XX PR 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 2591; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 14; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 1.7e+02;
XX Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 990 CAGGGTGCCATGGA 1003
XX
XX Db 3 CAGGGTGCCATGGA 16
XX
XX RESULT 294
XX ABN02600
XX ID ABN02600 standard; DNA; 17 BP.
XX
XX AC ABN02600;
XX
XX XX
XX DT 29-MAY-2002 (first entry)
XX
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2592.
XX
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX
XX PD 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 2592; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterise and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 14; DB 1; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 1.7e+02;
XX Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 990 CAGGGTGCCATGGA 1003
XX
XX Db 2 CAGGGTGCCATGGA 15
XX
XX RESULT 295

Query Match	0.8%;	Score 14;	DB 1;	Length 17;
Best Local Similarity	85.7%;	Pred. No. 1.7e+02;		
Matches 12;	Conservative 2;	Mismatches 0;	Indels 0;	Gaps 0;
Qy	1239	GCCAGGGCCATCAT	1252	
Db	4	GCCAGGGCCAUCAU	17	
RESULT 296				
ACN13433				
ID	ACN13433	standard; RNA; 17 BP.		
XX				
AC	ACN13433;			
XX				
XX				
DT	22-APR-2004	(first entry)		
XX				
XX				
DE	WNV Zinzyme substrate SEQ ID NO 3637.			
XX				
XX				
KW	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;			
KW	virucide; neuroprotective; antibacterial; replication; pancreatitis;			
KW	encephalitis; myocarditis; meningitis; infection; hepatitis;			
KW	liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;			
KW	Amberzyme; Zinzyme; ss.			

```

XX OS      West Nile Virus.
XX PN      WO200268637-A2.
XX PD      06-SEP-2002.
XX PF      19-OCT-2001; 2001WO-US048350.
XX PR      20-OCT-2000; 2000US-0242411P.
XX PA      (RIBO-) RIBOZYME PHARM INC.
XX PA      (BLAT/) BLATT L.
XX PA      (MCSW/) MCSWIGGEN J A.
XX PI      Blatt L, Mcswiggen JA;
XX XX      WPI; 2002-706994/76.
XX DR      New nucleic acid molecule that modulates replication of West Nile Virus
XX PT      (WNV), useful for treating a condition related to WNV infection e.g.
XX PT      pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX PS      Claim 23; SEQ ID NO 3637; 495pp; English.
XX CC      The invention relates to nucleic acid molecules that modulate replication
XX CC      of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX CC      treating a condition related to WNV infection e.g. pancreatitis,
XX CC      encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX CC      liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX CC      molecule is selected from the group of ribozymes consisting of
XX CC      Hammerhead, inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyme. The
XX CC      nucleic acid molecules further comprise at least five ribose residues, at
XX CC      least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX CC      least three of the 5' terminal nucleotides and a 3' end modification of a
XX CC      3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX CC      are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX CC      in the specification. The present sequence is that of a nucleic acid
XX CC      molecule of the invention
XX SQ      Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      330 CTGAGTGGCTCCAA 343
Db      17 CTGAGTGGCTCCAA 4

RESULT 298
ACN04524
ID      ACN04524 standard; RNA; 17 BP.
XX AC      ACN04524;
XX XX      22-APR-2004 (first entry)
XX DT      WNV Zinzyme substrate SEQ ID NO 4527.
XX DE      WNV; West Nile Virus; antiinflammatory; cytosstatic; hepatotropic;
XX KW      virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX KW      encephalitis; myocarditis; meningitis; infection; hepatitis;
XX KW      liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
XX KW      Amberzyme; Zinzyme; ss.
XX OS      West Nile Virus.
XX OS      WO200268637-A2.
XX PN      06-SEP-2002.
XX PD      19-OCT-2001; 2001WO-US048350.
XX PR      20-OCT-2000; 2000US-0242411P.
XX PA      (RIBO-) RIBOZYME PHARM INC.
XX PA      (BLAT/) BLATT L.
XX PA      (MCSW/) MCSWIGGEN J A.
XX PI      Blatt L, Mcswiggen JA;
XX XX      WPI; 2002-706994/76.
XX DR      New nucleic acid molecule that modulates replication of West Nile Virus
XX PT      (WNV), useful for treating a condition related to WNV infection e.g.
XX PT      pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX PS      Claim 23; SEQ ID NO 3637; 495pp; English.
XX CC      The invention relates to nucleic acid molecules that modulate replication
XX CC      of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX CC      treating a condition related to WNV infection e.g. pancreatitis,
XX CC      encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX CC      liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX CC      molecule is selected from the group of ribozymes consisting of
XX CC      Hammerhead, inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyme. The
XX CC      nucleic acid molecules further comprise at least five ribose residues, at
XX CC      least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX CC      least three of the 5' terminal nucleotides and a 3' end modification of a
XX CC      3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX CC      are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX CC      in the specification. The present sequence is that of a nucleic acid
XX CC      molecule of the invention
XX SQ      Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      330 CTGAGTGGCTCCAA 343
Db      17 CTGAGTGGCTCCAA 4

RESULT 298
ACN04524
ID      ACN04524 standard; RNA; 17 BP.
XX AC      ACN04524;
XX XX      22-APR-2004 (first entry)
XX DT      WNV Zinzyme substrate SEQ ID NO 4527.
XX DE      WNV; West Nile Virus; antiinflammatory; cytosstatic; hepatotropic;
XX KW      virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX KW      encephalitis; myocarditis; meningitis; infection; hepatitis;
XX KW      liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
XX KW      Amberzyme; Zinzyme; ss.
XX OS      West Nile Virus.
XX OS      WO200268637-A2.
XX PN      06-SEP-2002.
XX PD      19-OCT-2001; 2001WO-US048350.
XX PR      20-OCT-2000; 2000US-0242411P.
XX PA      (RIBO-) RIBOZYME PHARM INC.
XX PA      (BLAT/) BLATT L.
XX PA      (MCSW/) MCSWIGGEN J A.

```

```

PF      19-OCT-2001; 2001WO-US048350.
XX PR      20-OCT-2000; 2000US-0242411P.
XX PA      (RIBO-) RIBOZYME PHARM INC.
XX PA      (BLAT/) BLATT L.
XX PA      (MCSW/) MCSWIGGEN J A.
XX PI      Blatt L, Mcswiggen JA;
XX XX      WPI; 2002-706994/76.
XX DR      New nucleic acid molecule that modulates replication of West Nile Virus
XX PT      (WNV), useful for treating a condition related to WNV infection e.g.
XX PT      pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX PS      Claim 23; SEQ ID NO 4527; 495pp; English.
XX CC      The invention relates to nucleic acid molecules that modulate replication
XX CC      of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX CC      treating a condition related to WNV infection e.g. pancreatitis,
XX CC      encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX CC      liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX CC      molecule is selected from the group of ribozymes consisting of
XX CC      Hammerhead, inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyme. The
XX CC      nucleic acid molecules further comprise at least five ribose residues, at
XX CC      least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX CC      least three of the 5' terminal nucleotides and a 3' end modification of a
XX CC      3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX CC      are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX CC      in the specification. The present sequence is that of a nucleic acid
XX CC      molecule of the invention
XX SQ      Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.7e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1239 GCCAGGGCCATCAT 1252
Db      3 GCCAGGGCCCAUCAU 16

RESULT 299
ACN0921/c
ID      ACN0921 standard; RNA; 17 BP.
XX AC      ACN0921;
XX XX      22-APR-2004 (first entry)
XX DT      WNV minus strand Inozyme substrate SEQ ID NO 9924.
XX DE      WNV; West Nile Virus; antiinflammatory; cytosstatic; hepatotropic;
XX KW      virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX KW      encephalitis; myocarditis; meningitis; infection; hepatitis;
XX KW      liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
XX KW      Amberzyme; Zinzyme; ss.
XX OS      West Nile Virus.
XX OS      WO200268637-A2.
XX PN      06-SEP-2002.
XX PD      19-OCT-2001; 2001WO-US048350.
XX PR      20-OCT-2000; 2000US-0242411P.
XX PA      (RIBO-) RIBOZYME PHARM INC.
XX PA      (BLAT/) BLATT L.
XX PA      (MCSW/) MCSWIGGEN J A.

```

XX PI Blatt L, Mcswiggen JA;
 XX DR WPI; 2002-706994/76.
 XX PT New nucleic acid molecule that modulates replication of West Nile Virus
 XX PT (WNV), useful for treating a condition related to WNV infection e.g.
 XX PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX PS Claim 23; SEQ ID NO 9924; 495pp; English.
 XX CC The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. NO. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1239 GCCAGGGCCATCAT 1252
 DB 14 GCCAGGGCCATCAT 1
 RESULT 300
 ABT39396/C
 ID ABT39396 standard; DNA; 17 BP.
 XX AC ABT39396;
 XX DT 12-JUN-2003 (first entry)
 XX DE Tumour suppression related human fukutin oligo SEQ ID No 5033.
 XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX OS Homo sapiens.
 XX PN WO2003025175-A2.
 XX PD 27-MAR-2003.
 XX PF 17-SEP-2002; 2002WO-IB004208.
 XX PR 17-SEP-2001; 2001FR-00011978.
 XX PA (MOLE-) MOLECULAR ENGINES LAB.
 XX PI Telerman A, Amson R, Tuijnder M;
 XX WPI; 2003-313353/30.
 XX PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX PS Disclosure; Page 622; 720pp; French.

XX CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (antisense) reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX SQ Sequence 17 BP; 5 A; 4 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. NO. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 189 AGGACTTTTGAAGA 202
 DB 16 AGGACTTTTGAAGA 3
 RESULT 301
 ADA99846/C
 ID ADA99846 standard; DNA; 17 BP.
 XX AC ADA99846;
 XX DT 20-NOV-2003 (first entry)
 XX DE Human MDZ3 scanning oligonucleotide SEQ ID 835.
 XX KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MDZ3; MDZ7; MDZ12; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX OS Homo sapiens.
 XX PN EP1281758-A2.
 XX PD 05-FEB-2003.
 XX PF 30-JUL-2002; 2002EP-00016874.
 XX PR 02-AUG-2001; 2001US-00922181.
 XX PA (AEOM-) AEOMICA INC.
 XX PI Shannon M, Gu Y, Nguyen C;
 XX WPI; 2003-423107/40.
 XX PT New zinc finger-containing proteins and nucleic acids, useful in
 PT manufacturing a medicament for treating or preventing a disorder
 PT associated with decreased or increased expression or activity of MDZ3,
 PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
 XX PS Example 8; SEQ ID NO 835; 103pp; English.

CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MD23,
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
 CC acids and proteins are also useful for diagnosing or monitoring a disease
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
 CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 AAGGCCAGGGCCAT 1249
 Db 16 AAGGCCAGGGCCAT 3

RESULT 302
 ADA99847/C
 ID ADA99847 standard; DNA; 17 BP.
 XX
 AC ADA99847;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human MD23 scanning oligonucleotide SEQ ID 836.
 XX
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1281758-A2.
 XX
 PD 05-FEB-2003.
 XX
 PF 30-JUL-2002; 2002EP-00016874.
 XX
 PR 02-AUG-2001; 2001US-00922181.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Shannon M, Gu Y, Nguyen C;
 XX
 DR WPI; 2003-423107/40.
 XX

PT New zinc finger-containing proteins and nucleic acids, useful in
 PT manufacturing a medicament for treating or preventing a disorder
 PT associated with decreased or increased expression or activity of MD23,
 PT MD24, MD27 or MD212, e.g. cancer.
 XX
 PS Example 8; SEQ ID NO 836; 103pp; English.

XX The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MD23,
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic

CC acids and proteins are also useful for diagnosing or monitoring a disease
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
 CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.
 XX

SQ Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 AAGGCCAGGGCCAT 1249
 Db 15 AAGGCCAGGGCCAT 2

RESULT 303
 ADA99845/C
 ID ADA99845 standard; DNA; 17 BP.
 XX
 AC ADA99845;
 XX

DT 20-NOV-2003 (first entry)
 XX
 DE Human MD23 scanning oligonucleotide SEQ ID 834.
 XX

KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX
 OS Homo sapiens.
 XX

PN EP1281758-A2.
 XX
 PD 05-FEB-2003.
 XX
 PF 30-JUL-2002; 2002EP-00016874.
 XX
 PR 02-AUG-2001; 2001US-00922181.
 XX
 PA (AEOM-) AEOMICA INC.
 XX

PI Shannon M, Gu Y, Nguyen C;
 XX
 DR WPI; 2003-423107/40.
 XX

PT New zinc finger-containing proteins and nucleic acids, useful in
 PT manufacturing a medicament for treating or preventing a disorder
 PT associated with decreased or increased expression or activity of MD23,
 PT MD24, MD27 or MD212, e.g. cancer.
 XX
 PS Example 8; SEQ ID NO 834; 103pp; English.

XX The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MD23,
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
 CC acids and proteins are also useful for diagnosing or monitoring a disease
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
 CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.
 XX

SQ Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1236 AAGGCCAGGGCCAT 1249
|||||
DB 17 AAGGCCAGGGCCAT 4
RESULT 304
ADA9848/c
ID ADA9848 standard; DNA; 17 BP.
XX AC ADA9848;
XX XX
DT 20-NOV-2003 (first entry)
XX
DE Human MD23 scanning oligonucleotide SEQ ID 837.
XX
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX
OS Homo sapiens.
XX
PN EP1281758-A2.
XX
PD 05-FEB-2003.
XX
PF 30-JUL-2002; 2002EP-00016874.
XX
PR 02-AUG-2001; 2001US-00922181.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M, Gu Y, Nguyen C;
XX
DR WPI; 2003-423107/40.
XX
PT New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX
PS Example 8; SEQ ID NO 837; 103pp; English.
XX
CC The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX
SQ Sequence 17 BP; 1 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1236 AAGGCCAGGGCCAT 1249
|||||

DB 14 AAGGCCAGGGCCAT 1
RESULT 305
ADC37816/c
ID ADC37816 standard; DNA; 17 BP.
XX ADC37816;
AC ADC37816;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:165.
XX
KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1a; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003037931-A2.
XX
PD 08-MAY-2003.
XX
PF 01-NOV-2002; 2002WO-US035129.
XX
PR 01-NOV-2001; 2001US-0334773P.
XX
PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Shannon M, Phan T;
XX
DR WPI; 2003-430501/40.
XX
PT New isolated nucleic acid molecule encoding a human angiominotin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
PS Example 2; SEQ ID NO 165; 172pp; English.
XX
CC The present invention describes the human angiominotin-like protein 1
CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLP1. The present sequence represents a scanning
CC oligonucleotide for human AMLP1a, which is used in an example from the
CC present invention.
XX
SQ Sequence 17 BP; 6 A; 5 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1445 TGTGTCTGCTGCTG 1458
|||||
DB 17 TGTGTCTGCTGCTG 4
RESULT 306
ADC37833
ID ADC37833 standard; DNA; 17 BP.
XX ADC37833;
AC ADC37833;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:182.
XX
KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1a; ss.
XX
OS Synthetic.

Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458
Db 15 TGTGCTGCTGCTG 2

RESULT 309
ADC37817/c
ID ADC37817 standard; DNA; 17 BP.
XX AC ADC37817;
XX DT 18-DEC-2003 (first entry)
XX DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:166.
XX KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
XX KW AMLP1a; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO2003037931-A2.
XX PD 08-MAY-2003.
XX PF 01-NOV-2002; 2002WO-US035129.
XX PR 01-NOV-2001; 2001US-0334773P.
XX DT 18-DEC-2003 (first entry)
XX DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:166.
XX KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
XX KW AMLP1a; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO2003037931-A2.
XX PD 08-MAY-2003.
XX PF 01-NOV-2002; 2002WO-US035129.
XX PR 01-NOV-2001; 2001US-0334773P.
XX PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX PI Shannon M, Phan T;
XX PI WPI; 2003-430501/40.
XX DR New isolated nucleic acid molecule encoding a human angiominotin-like
XX PT protein, useful for treating or preventing a disorder associated with
XX PT decreased or increased expression or activity of AMLP1.
XX PS Example 2; SEQ ID NO 166; 172pp; English.
XX CC The present invention describes the human angiominotin-like protein 1
XX CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
XX CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
XX CC compositions of the present invention can be used for treating or
XX CC preventing a disorder associated with decreased or increased expression
XX CC or activity of AMLP1. The present sequence represents a scanning
XX CC oligonucleotide for human AMLP1a, which is used in an example from the
XX CC present invention.
XX SQ Sequence 17 BP; 6 A; 5 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458
Db 16 TGTGCTGCTGCTG 3

RESULT 310
ADC37819/c
ID ADC37819 standard; DNA; 17 BP.
XX AC ADC37819;
XX DT 18-DEC-2003 (first entry)
XX DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:168.

XX KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
XX KW AMLP1a; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO2003037931-A2.
XX PD 08-MAY-2003.
XX PF 01-NOV-2002; 2002WO-US035129.
XX PR 01-NOV-2001; 2001US-0334773P.
XX PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX PI Shannon M, Phan T;
XX PI WPI; 2003-430501/40.
XX DR New isolated nucleic acid molecule encoding a human angiominotin-like
XX PT protein, useful for treating or preventing a disorder associated with
XX PT decreased or increased expression or activity of AMLP1.
XX PS Example 2; SEQ ID NO 168; 172pp; English.
XX CC The present invention describes the human angiominotin-like protein 1
XX CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
XX CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
XX CC compositions of the present invention can be used for treating or
XX CC preventing a disorder associated with decreased or increased expression
XX CC or activity of AMLP1. The present sequence represents a scanning
XX CC oligonucleotide for human AMLP1a, which is used in an example from the
XX CC present invention.
XX SQ Sequence 17 BP; 7 A; 6 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458
Db 14 TGTGCTGCTGCTG 1

RESULT 311
ADC37834
ID ADC37834 standard; DNA; 17 BP.
XX AC ADC37834;
XX DT 18-DEC-2003 (first entry)
XX DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:183.
XX KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
XX KW AMLP1a; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO2003037931-A2.
XX PD 08-MAY-2003.
XX PF 01-NOV-2002; 2002WO-US035129.
XX PR 01-NOV-2001; 2001US-0334773P.
XX PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.

PI Shannon M, Phan T;
XX WPI; 2003-430501/40.
XX
XX New isolated nucleic acid molecule encoding a human angiominin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLP1.
XX
XX Example 2; SEQ ID NO 183; 172pp; English.
XX
XX The present invention describes the human angiominin-like protein 1
CC (AMLPI). human AMLPI has cytostatic activity, and can be used in gene
CC therapy. The AMLPI protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLPI. The present sequence represents a scanning
CC oligonucleotide for human AMLPI, which is used in an example from the
CC present invention.
XX
XX Sequence 17 BP; 2 A; 3 C; 11 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 662 GCAGGGGCGGTGG 675
Db 3 GCAGGGGCGGTGG 16
RESULT 312
ADC37836
ID ADC37836 standard; DNA; 17 BP.
XX
XX ADC37836;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human AMLPI scanning 17-mer oligonucleotide SEQ ID NO:185.
XX
XX human; angiominin-like protein 1; AMLPI; cytostatic; gene therapy;
KW AMLPI; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO2003037931-A2.
XX
XX 08-MAY-2003.
XX
XX 01-NOV-2002; 2002WO-US035129.
XX
XX 01-NOV-2001; 2001US-0334773P.
XX
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX
XX Shannon M, Phan T;
XX
XX WPI; 2003-430501/40.
XX
XX New isolated nucleic acid molecule encoding a human angiominin-like
PT protein, useful for treating or preventing a disorder associated with
PT decreased or increased expression or activity of AMLPI.
XX
XX Example 2; SEQ ID NO 185; 172pp; English.
XX
XX The present invention describes the human angiominin-like protein 1
CC (AMLPI). human AMLPI has cytostatic activity, and can be used in gene
CC therapy. The AMLPI protein, nucleic acid molecules, antibodies, and
CC compositions of the present invention can be used for treating or
CC preventing a disorder associated with decreased or increased expression
CC or activity of AMLPI. The present sequence represents a scanning
CC oligonucleotide for human AMLPI, which is used in an example from the

CC present invention.
XX
XX Sequence 17 BP; 1 A; 4 C; 11 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 662 GCAGGGGCGGTGG 675
Db 1 GCAGGGGCGGTGG 14
RESULT 313
ADL49810
ID ADL49810 standard; RNA; 17 BP.
XX
XX ADL49810;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PKR substrate sequence #924.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-029412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 3343; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR

```

CC  substrate sequence.
XX  Sequence 17 BP; 7 A; 4 C; 4 G; 0 T; 2 U; 0 Other;
SQ  Query Match      0.8%; Score 14; DB 1; Length 17;
    Best Local Similarity 92.9%; Pred. No. 1.7e+02;
    Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy  272 AGCCGAGAACAGAT 285
Db  4 AGCCGAGAACAGAU 17
    |||||
    |||||

RESULT 314
ADL50678
ID  ADL50678 standard; RNA; 17 BP.
XX
AC  ADL50678;
XX
DT  20-MAY-2004 (first entry)
XX
DE  Human PKR substrate sequence #1792.
XX
KW  antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW  prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW  protein kinase PKR; cerebrovascular accident;
KW  central nervous system injury; CNS injury; spinal cord injury; cancer;
KW  melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW  restenosis; asthma; Crohn's disease; diabetes; obesity;
KW  autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW  graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW  allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW  substrate; ds.
XX
OS  Unidentified.
XX
PN  WO200281628-A2.
XX
PD  17-OCT-2002.
XX
PF  03-APR-2002; 2002WO-US010512.
XX
PR  05-APR-2001; 2001US-00827395.
XX
PR  29-MAY-2001; 2001US-0294412P.
XX
PR  28-AUG-2001; 2001US-0315315P.
XX
PA  (RIBO-) RIBOZYME PHARM INC.
XX
PI  Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX  WPI; 2003-058513/05.
XX
PT  Novel enzymatic nucleic acid that down-regulates expression of neurite
PT  growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT  protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS  Claim 59; SEQ ID NO 4211; 317pp; English.
XX
XX  The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX  that down regulate the expression or inhibit the function of a receptor
XX  for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX  IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX  invention are useful for treating: cerebrovascular accident, central
XX  nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX  lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX  restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX  disease, lupus, multiple sclerosis, transplant/graft rejection,
XX  ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX  conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX  nucleic acids of the invention are also useful for down-regulating the
XX  expression of a target gene and as a diagnostic tool to examine genetic
XX  drifts and mutations within diseased cells or to detect the presence of a
XX  target RNA in a cell. The present RNA sequence represents a human PKR

```

CC substrate sequence.
 XX Sequence 17 BP; 6 A; 5 C; 3 G; 0 T; 3 U; 0 Other;
 SQ

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 1.7e+02;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 272 AGCCGAGACAGAT 285
 |||||
 Db 1 AGCCGAGACAGAU 14

RESULT 316
 ACN65689
 ID ACN65689 standard; DNA; 17 BP.
 XX
 XX ACN65689;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:2591.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX
 PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 2591; Opp; English.
 XX
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (SI) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of
 CC (SI), 95% deviation from (SI) which are conservative substitutions, and
 CC 65% identity to (SI). A polypeptide of the invention acts as a agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 990 CAGGTCGCATGGA 1003
 |||||
 Db 3 CAGGTCGCATGGA 16

RESULT 317
 ACN65688
 ID ACN65688 standard; DNA; 17 BP.
 XX
 XX ACN65688;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:2590.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 XX
 PT Novel myosin-like protein-1, useful for treating or preventing disorder

PT	associated with decreased expression or activity of human genome-derived	PA	(CHEN/) CHEN W.
PT	myosin-like protein-1 such as disorder of heart and/or skeletal muscle	PA	(SHAN/) SHANNON M E.
PT	function.	PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX		XX	WPI; 2004-533378/51.
PS	Disclosure; SEQ ID NO 2590; Opp; English.	XX	
XX		XX	Novel myosin-like protein-1, useful for treating or preventing disorder
CC	The invention relates to a novel polypeptide (I) comprising a sequence	PT	associated with decreased expression or activity of human genome-derived
CC	(S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully	PT	myosin-like protein-1 such as disorder of heart and/or skeletal muscle
CC	defined in the specification, a fragment of at least 8 amino acids of	PT	function.
CC	(S1), 95% deviation from (S1) which are conservative substitutions, and	XX	
CC	65% identity to (S1). A polypeptide of the invention acts as an agonist or	XX	Disclosure; SEQ ID NO 2592; Opp; English.
CC	antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A	XX	
CC	pharmaceutical composition of the invention is useful for treating or	CC	The invention relates to a novel polypeptide (I) comprising a sequence
CC	preventing a disorder associated with decreased expression or activity of	CC	(S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC	hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.	CC	defined in the specification, a fragment of at least 8 amino acids of
CC	The present sequence represents a 17-mer nucleotide, used in the	CC	(S1), 95% deviation from (S1) which are conservative substitutions, and
CC	invention for scanning the sequence represented in ACN63102	CC	65% identity to (S1). A polypeptide of the invention acts as a agonist or
XX		CC	antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
SQ	Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;	CC	pharmaceutical composition of the invention is useful for treating or
		CC	preventing a disorder associated with decreased expression or activity of
		CC	hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
		CC	The present sequence represents a 17-mer nucleotide, used in the
		CC	invention for scanning the sequence represented in ACN63102
		XX	
		SQ	Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
		Query Match	0.8%; Score 14; DB 1; Length 17;
		Best Local Similarity	100.0%; Pred. No. 1.7e+02;
		Matches 14; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	990 CAGGGTGCCATGGA 1003		
Db			
	4 CAGGGTGCCATGGA 17		
RESULT 318			
ACN65690			
ID	ACN65690 standard; DNA; 17 BP.		
XX			
AC	ACN65690;		
XX			
DT	02-DEC-2004 (first entry)		
XX			
DE	Human GDMLP-1 probe SEQ ID NO:2592.		
XX			
KW	Human; ss; probe; myosin-like protein-1; hGDMLP-1;		
KW	hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;		
KW	skeletal muscle function.		
XX			
OS	Homo sapiens.		
XX			
PN	US2004137589-A1.		
XX			
PD	15-JUL-2004.		
XX			
PF	26-NOV-2003; 2003US-00723361.		
XX			
PR	26-MAY-2000; 2000US-0207456P.		
PR	21-SEP-2000; 2000US-0234687P.		
PR	27-SEP-2000; 2000US-0236359P.		
PR	04-OCT-2000; 2000GB-00024263.		
PR	30-JAN-2001; 2001WO-US000661.		
PR	30-JAN-2001; 2001WO-US000662.		
PR	30-JAN-2001; 2001WO-US000663.		
PR	30-JAN-2001; 2001WO-US000664.		
PR	30-JAN-2001; 2001WO-US000665.		
PR	30-JAN-2001; 2001WO-US000666.		
PR	30-JAN-2001; 2001WO-US000667.		
PR	30-JAN-2001; 2001WO-US000668.		
PR	05-FEB-2001; 2001US-0266860P.		
PR	25-MAY-2001; 2001US-00866108.		
XX			
PA	(GUY/) GU Y.		
PA	(JIY/) JI Y.		
PA	(PENN/) PENN S G.		
PA	(HANZ/) HANZEL D K.		
PA	(RANK/) RANK D.		

PA	(CHEN/) CHEN W.
PA	(SHAN/) SHANNON M E.
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX	WPI; 2004-533378/51.
XX	
XX	Novel myosin-like protein-1, useful for treating or preventing disorder
PT	associated with decreased expression or activity of human genome-derived
PT	myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT	function.
XX	
PS	Disclosure; SEQ ID NO 2592; Opp; English.
XX	
CC	The invention relates to a novel polypeptide (I) comprising a sequence
CC	(S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC	defined in the specification, a fragment of at least 8 amino acids of
CC	(S1), 95% deviation from (S1) which are conservative substitutions, and
CC	65% identity to (S1). A polypeptide of the invention acts as a agonist or
CC	antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC	pharmaceutical composition of the invention is useful for treating or
CC	preventing a disorder associated with decreased expression or activity of
CC	hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC	The present sequence represents a 17-mer nucleotide, used in the
CC	invention for scanning the sequence represented in ACN63102
XX	
SQ	Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
	Query Match
	Best Local Similarity
	Matches 14; Conservative
	0.8%; Score 14; DB 1; Length 17;
	100.0%; Pred. No. 1.7e+02;
	0; Mismatches 0; Indels 0; Gaps 0;
QY	990 CAGGGTGCCATGGA 1003
Db	
	2 CAGGGTGCCATGGA 15
RESULT 319	
ACN65691	
ID	ACN65691 standard; DNA; 17 BP.
XX	
AC	ACN65691;
XX	
DT	02-DEC-2004 (first entry)
XX	
DE	Human GDMLP-1 probe SEQ ID NO:2593.
XX	
KW	Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW	hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW	skeletal muscle function.
XX	
OS	Homo sapiens.
XX	
PN	US2004137589-A1.
XX	
PD	15-JUL-2004.
XX	
PF	26-NOV-2003; 2003US-00723361.
XX	
PR	26-MAY-2000; 2000US-0207456P.
PR	21-SEP-2000; 2000US-0234687P.
PR	27-SEP-2000; 2000US-0236359P.
PR	04-OCT-2000; 2000GB-00024263.
PR	30-JAN-2001; 2001WO-US000661.
PR	30-JAN-2001; 2001WO-US000662.
PR	30-JAN-2001; 2001WO-US000663.
PR	30-JAN-2001; 2001WO-US000664.
PR	30-JAN-2001; 2001WO-US000665.
PR	30-JAN-2001; 2001WO-US000666.
PR	30-JAN-2001; 2001WO-US000667.
PR	30-JAN-2001; 2001WO-US000668.
PR	05-FEB-2001; 2001US-0266860P.
PR	25-MAY-2001; 2001US-00866108.
XX	
PA	(GUY/) GU Y.
PA	(JIY/) JI Y.
PA	(PENN/) PENN S G.
PA	(HANZ/) HANZEL D K.
PA	(RANK/) RANK D.

```

PR 05-FEB-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 2593; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGMLP-1, or as an inhibitor of hGMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
XX Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 990 CAGGTCGCATGGA 1003
DB 1 CAGGTCGCATGGA 14
RESULT 320
AAV01069
ID AAV01069 standard; DNA; 18 BP.
XX
XX AAV01069;
XX
XX 30-MAR-1998 (first entry)
XX
XX Primer R8 for human PKR gene.
XX
XX Human; PKR; double stranded RNA-activated protein kinase; neoplasm;
XX cell growth; differentiation; tumour suppressor; tumorigenesis; primer;
XX PCR; amplification; ss.
XX
XX Synthetic.
XX OS Homo sapiens.
XX
XX US5670330-A.
XX
XX 23-SEP-1997.
XX
XX 25-OCT-1993; 93US-00143219.
XX
XX 29-SEP-1992; 92US-00953681.
XX
XX 22-OCT-1993; 93US-00141244.
XX
XX (UYMC-) UNIV MCGILL.
XX (UNIW) UNIV WASHINGTON.
XX

```

```

XX Roy S, Barber GH, Koromillas AE, Sonenberg N, Katze MG;
XX WPI; 1997-479453/44.
XX
XX Screening method for identifying anti-tumour agents.- based on an
PT increase in the activity of a double stranded RNA-activated protein
PT kinase.
XX
XX Disclosure; Col 37; 41pp; English.
XX
XX The primers AAV01061-V01071 were used to PCR amplify the gene encoding
CC the human PKR protein (AAV01060), a double stranded RNA-activated protein
CC kinase. The protein can be used in a screening method for identifying
CC anti-tumour agents by measuring PKR activity in a system before and after
CC adding a test agent, where an increase in PKR activity indicates that the
CC agent is an anti-tumour agent, especially useful for the prevention
CC and/or treatment of neoplasms. PKR is an interferon-inducible cytoplasmic
CC Ser-Thr specific protein kinase which can also be activated by double
CC stranded RNA. PKR is active in cell growth and differentiation by
CC regulating protein synthesis, and thus has been suggested to function as
CC a tumour suppressor. The screening system may also include a further
CC protein which inhibits PKR activity thereby inducing tumourigenesis. An
CC example of such a protein is the P58 protein, a cellular 58 kD protein
CC purified from influenza-infected cells (see AAW36140)
XX
XX Sequence 18 BP; 6 A; 5 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 272 AGCCGAGAACAGAT 285
DB 1 AGCCGAGAACAGAT 14
RESULT 321
ADQ25637
ID ADQ25637 standard; DNA; 18 BP.
XX
XX ADQ25637;
XX
XX 23-SEP-2004 (first entry)
XX
XX L primer used to detect SSR profiles of inbred maize line PH87H #1.
XX
XX PH87H; maize inbred line; herbicide resistance; transgenic; food;
XX livestock feed; primer; plant; SSR; simple sequence repeat; maize; ss.
XX
XX Zea mays.
XX
XX US6759580-B1.
XX
XX 06-JUL-2004.
XX
XX 15-OCT-2002; 2002US-00271065.
XX
XX 28-JAN-2002; 2002US-0352291P.
XX
XX (PION-) PIONEER HI-BRED INT INC.
XX
XX Cunnyngham CT;
XX
XX WPI; 2004-497138/47.
XX
XX New seed of maize inbred line designated PH87H, useful for producing
XX first generation F1 maize hybrids with superior characteristics (e.g.,
XX herbicide resistance) and as human food, livestock feed or as raw
XX material in industry.
XX
XX Disclosure; SEQ ID NO 1; 28pp; English.
XX

```

CC The present invention provides a seed of maize inbred line, designated
 CC PH87H. The invention is useful for producing first generation F1 maize
 CC hybrids with superior characteristics (e.g., herbicide resistance). The
 CC seed of inbred maize line PH87H, the plant produced from it, hybrid seed
 CC and various parts of the hybrid maize plant and transgenic versions are
 CC used as human food, livestock feed and as a raw material in industry. The
 CC present sequence is a primer used to detect unique simple sequence repeat
 CC (SSR) profiles for PH1279122 locus of inbred maize line PH87H. This
 CC sequence is used in the invention.

XX Sequence 18 BP; 2 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 1.8e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1084 GGCTGGTGTCTGG 1097

Db 4 GGCTGGTGTCTGG 17

RESULT 322

ADR74179/c

ID ADR74179 standard; DNA; 18 BP.

XX ADR74179;

DT 16-DEC-2004 (first entry)

DE Allele specific primer A for human MI-associated marker hCV25627205.

KW Human; ss; PCR; primer; SNP; single nucleotide polymorphism;

KW myocardial infarction; allele specific primer.

XX Homo sapiens.

XX WO2004081187-A2.

XX 23-SEP-2004.

XX 10-MAR-2004; 2004WO-US007141.

XX 10-MAR-2003; 2003US-0453135P.

PR 30-APR-2003; 2003US-0466412P.

XX (APPL-) APPLERA CORP.

XX Cargill M, Devlin JJ, Iakoubova O, Shiffman D;

XX WPI; 2004-677537/66.

PT Identifying an individual who has altered risk for developing myocardial
 PT infarction comprises detecting single nucleotide polymorphism (SNP), in
 PT the individual's nucleic acids.

XX Claim 19; SEQ ID NO 44004; 139pp; English.

XX The invention relates to identifying an individual who has altered risk
 CC for developing myocardial infarction comprises detecting single
 CC nucleotide polymorphism (SNP) in any one of the 4336 nucleotide
 CC sequences (not given in the specification), in the individual's nucleic
 CC acids, where the presence of the SNP is correlated with an altered risk
 CC for myocardial infarction in the individual. Also included are an
 CC isolated nucleic acid molecule (comprising at least 8 contiguous
 CC nucleotides where one of the nucleotides is an SNP as cited above, or
 CC their complement), an isolated polypeptide comprising an amino acid
 CC sequence selected from any of the 696 amino acid sequences not defined in
 CC the specification, an antibody that specifically binds to the polypeptide
 CC (or its antigen-binding fragment), an amplified polynucleotide containing
 CC the SNP as cited (where the amplified polynucleotide is between about 16
 CC and about 1,000 nucleotides in length), an isolated polynucleotide which
 CC specifically hybridises to a nucleic acid molecule containing the SNP, a
 CC kit for detecting SNP in a nucleic acid, detecting SNP in a nucleic acid

CC molecule, detecting a variant polypeptide and identifying an agent useful
 CC in therapeutically or prophylactically treating myocardial infarction.
 CC The detection step of the method is carried out by a process selected
 CC from allele-specific probe hybridisation, allele-specific primer
 CC extension, allele-specific amplification, sequencing, 5' nuclease
 CC digestion, molecular beacon assay, oligonucleotide ligation assay, size
 CC analysis, and single-stranded conformation polymorphism. The method is
 CC useful for identifying an individual who has altered risk for developing
 CC myocardial infarction. The present sequence is an allele specific PCR
 CC primer used to amplify an SNP-containing region from a myocardial
 CC infarction-associated marker gene. NOTE: SEQ IDs 1-43787 are not shown in
 CC the specification and are not available from WIPO. These sequence are
 CC contained on a CD-R named CL001509CDR which has not been supplied with
 CC the specification.

SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 1.8e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1221 TTCACCTGGCAGTGA 1234

Db 16 TTCACCTGGCAGTGA 3

RESULT 323

AAQ20006/c

ID AAQ20006 standard; DNA; 17 BP.

XX AAQ20006;

DT 01-APR-1992 (first entry)

XX Oligonucleotide #2 able to covalently cross-link to target DNA.

XX deoxyribonucleic acid; major groove; ethanoamino group;

XX aziridinylcytosine; cross-linking group; ss.

XX Synthetic.

XX Key Location/Qualifiers

FH modified_base 8 /tag= b

FT /mod_base= m5c

FT modified_base 14 /tag= c

FT /mod_base= m5c

FT modified_base 17 /tag= a

FT /mod_base= OTHER

FT /note= "N4N4-ethanocytosine"

XX WO9118997-A.

XX 12-DEC-1991.

XX 25-MAY-1990; 90US-00529346.

XX 25-MAY-1990; 90US-00529346.

PR 14-JAN-1991; 91US-00640654.

XX (GILB-) GILEAD SCIE INC.

XX Matteucci MD, Krawczyk S;

XX WPI; 1992-007480/01.

XX New sequence-specific non-photo-activated crosslinking agents - bind to

XX the major groove of duplex DNA and are esp. useful for treating latent

XX infections e.g. HIV.

XX Example 2; Page 20; 42pp; English.

XX The 3' end of this oligonucleotide carries 1,3-propanediol. The oligo is
 CC one of four oligonucleotides which were designed to specifically bind and
 CC cross-link to the duplex target sequence AAQ20004. Oligo #2 has the
 CC covalent cross-linking group, i.e. N4N4-ethanocytosine, at its 3' end. An
 CC assay for crosslinked triple helix showed considerable reaction with
 CC Oligo #2 and with Oligo #1 (see AAQ20005) which has the crosslinking
 CC group at the 5' end. The most complete reaction was seen with Oligo #3
 CC (see AAQ20007) having N4N4-ethanocytosine at both the 5' and 3' termini.
 CC A control oligo with no cross-linking group showed no reaction. The half-
 CC life of the cross-linking reaction for Oligo #2 was ca. 1 hr (1 microm);
 CC Oligo #1 showed a rate four times slower. See also AAQ20008
 XX Sequence 17 BP; 0 A; 3 C; 0 G; 14 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1834 GAAAGAAAAAAGAAAAA 1850
 Db 17 GAAGAAAAAAGAAAAA 1

RESULT 324
 AAQ79246/c
 ID AAQ79246 standard; DNA; 17 BP.

AC AAQ79246;

XX 25-MAR-2003 (revised)

DT 18-JUL-1995 (first entry)

XX Guanosine rich oligonucleotide used to treat viral infection.

XX Guanosine; tetrad; inhibition; replication; virus; treatment; therapy;
 KW infection; herpes simplex virus; human papilloma virus;
 KW Epstein-Barr virus; HIV, adenovirus; respiratory syncytial virus;
 KW hepatitis B virus; human cytomegalovirus; ss.

OS Synthetic.

XX Key Location/Qualifiers

FH misc_feature 17

FT /*tag= a

FT /mod base

FT /note= "Propanolamine group attached to this base."

XX WO9425037-A1.

XX 10-NOV-1994.

XX 25-APR-1994; 94WO-US004529.

XX 23-APR-1993; 93US-00053027.

XX 28-OCT-1993; 93US-00145704.

XX (TRIP-) TRIPLEX PHARM CORP.

XX (BAYU) BAYLOR COLLEGE MEDICINE.

XX Rando RF, Fennewald S, Zengdegi JG, Ojwang JO, Hogan ME;

XX WPI; 1994-357890/44.

XX Oligo-nucleotide(s) rich in guanosine which form guanosine tetrads - used
 PT to treat viral infections, e.g. herpes-virus and HIV.

XX Claim 41; Page 68; 101pp; English.

XX The oligonucleotides (see AAQ79201-52) can be used to treat viral
 CC infections. The oligonucleotides inhibit viral replication by forming
 CC guanosine tetrads which form a stabilised 3D structure. Preferred
 CC oligonucleotides contain at least 2 runs of at least 2 guanosine bases

CC and may be capped at the 3' terminus with a modifier selected from
 CC polyamine, poly-L-lysine, cholesterol and propanolamine. They may also
 CC have a modified phosphodiester linkage or be modified to contain a
 CC phosphorothioate linkage. They are used to treat infections with viruses
 CC such as herpes simplex virus, human papilloma virus, Epstein-Barr virus,
 CC HIV, adenovirus, respiratory syncytial virus, hepatitis B virus or human
 CC cytomegalovirus. (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 17 BP; 0 A; 0 C; 13 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1705 CCCCTCCCTCCACAC 1721

Db 17 CCCACCCACCCACAC 1

RESULT 325

AAT51663/c

ID AAT51663 standard; DNA; 17 BP.

XX AAT51663;

AC AAT51663;

DT 12-NOV-1997 (first entry)

XX Viral integrase inhibiting oligonucleotide.

XX Human immunodeficiency virus; HIV; Epstein Barr virus; EBV;
 KW herpes simplex virus; HSV; human papilloma virus; HPV; adenovirus;
 KW respiratory syncytial virus; RSV; cytomegalovirus; CMV; hepatitis B;
 KW integrase inhibition; guanosine tetrad; ss.

OS Synthetic.

XX WO9703997-A1.

XX 06-FEB-1997.

XX 17-JUL-1996; 96WO-US011786.

XX 19-JUL-1995; 95US-0001505P.

XX 23-OCT-1995; 95US-00535168.

XX 19-MAR-1996; 96US-0013688P.

XX 25-MAR-1996; 96US-0014007P.

XX 17-APR-1996; 96US-0015714P.

XX 23-APR-1996; 96US-0016271P.

XX (ARON-) ARONEX PHARM INC.

XX Rando RF, Fennewald S, Zengdegi JG, Ojwang JO, Hogan ME;

XX Pommer Y, Mazumder A;

XX WPI; 1997-132569/12.

XX Oligo-nucleotide(s) capable of forming guanosine tetrads - inhibit viral
 PT enzyme responsible for integrating viral nucleic acid into the host
 FT genome.

XX Claim 3; Page 166; 245pp; English.

XX AAT51619-T51698 are oligonucleotides used to inhibit the production of
 CC viruses within a host cell. The oligonucleotides may form guanosine
 CC tetrads (structures formed of eight hydrogen bonds by coordination of the
 CC four oxygen atoms of guanine with alkali cations believed to bind to the
 CC centre of a quadruplex, and by strong stacking interactions) and are used
 CC to prevent the integration of viral nucleic acid into a host genome. The
 CC oligonucleotides inhibit functioning of the integrase enzyme and hence
 CC prevent viral infection. Viral infections that may be treated include
 CC human immunodeficiency virus (HIV), Epstein Barr virus (EBV), herpes
 CC simplex virus (HSV), human papilloma virus (HPV), adenovirus, respiratory
 CC syncytial virus (RSV), cytomegalovirus (CMV) and hepatitis B virus (HBV),

```
CC especially HIV-1 infection
XX
SQ Sequence 17 BP; 0 A; 0 C; 13 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1705 CCCCTCCCTCCACAC 1721
Db 17 CCCACCCACCCACAC 1

RESULT 326
AAAX71500/c
ID AAX71500 standard; RNA; 17 BP.
XX
AC AAX71500;
XX
XX 28-JUL-1999 (first entry)
DT
DE Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #596.
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; Kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Mus sp.
XX
XX WO9715662-A2.
PN
XX
XX 01-MAY-1997.
PD
XX
XX 25-OCT-1996; 96WO-US017480.
PF
XX
XX 26-OCT-1995; 95US-0005974P.
PR
XX 11-JAN-1996; 96US-00584040.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX (CHIR ) CHIRON CORP.
XX
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 173; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
XX Sequence 17 BP; 0 A; 0 C; 2 G; 0 T; 15 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAA AAAAAA AAAAAA 1851
Db 17 AAACAAAAAACA AAAAAA 1

RESULT 328
AAAX71415
ID AAX71415 standard; RNA; 17 BP.
XX
AC AAX71415;
XX
XX 28-JUL-1999 (first entry)
DT
XX Human KDR VEGF receptor hammerhead ribozyme substrate #427.
DE
```


XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX OS Homo sapiens.
 XX PN WO9715662-A2.
 XX PD 01-MAY-1997.
 XX PF 25-OCT-1996; 96WO-US017480.
 XX PR 26-OCT-1995; 95US-0005974P.
 XX PR 11-JAN-1996; 96US-00584040.
 XX XX (RIBO-) RIBOZYME PHARM INC.
 XX PA (CHIR) CHIRON CORP.
 XX PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 XX XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 XX rheumatoid arthritis, etc., in a human patient.
 XX Claim 4; Page 110; 218pp; English.
 XX XX The present invention describes nucleic acid molecules which modulate the
 XX synthesis, expression and/or stability of a mRNA encoding 1 or more
 XX receptors of vascular endothelial growth factor (VEGF). A patient
 XX (preferably human) having a condition associated with the level of the
 XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 XX angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 XX treated by administering the nucleic acid molecule or the expression
 XX vector to the patient. AAX67275 to AAX75752 represent specific examples
 XX of nucleic acid molecules from the present invention
 XX SQ Sequence 17 BP; 6 A; 3 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 58.8%; Pred. No. 1.8e+02;
 Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
 Qy 1568 TGCAACTTTGGAAACT 1584
 Db 1 UGCAAAUUGGAACCU 17
 RESULT 329
 AAX72984
 ID AAX72984 standard; RNA; 17 BP.
 XX AC AAX72984;
 XX XX 28-JUL-1999 (first entry)
 XX DE Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #417.
 XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX OS Mus sp.
 XX PN WO9715662-A2.
 XX PD 01-MAY-1997.
 XX PF 25-OCT-1996; 96WO-US017480.
 XX PR 26-OCT-1995; 95US-0005974P.
 XX PR 11-JAN-1996; 96US-00584040.
 XX XX (RIBO-) RIBOZYME PHARM INC.
 XX PA (CHIR) CHIRON CORP.
 XX PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 XX XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 XX rheumatoid arthritis, etc., in a human patient.
 XX Claim 4; Page 110; 218pp; English.
 XX XX The present invention describes nucleic acid molecules which modulate the
 XX synthesis, expression and/or stability of a mRNA encoding 1 or more
 XX receptors of vascular endothelial growth factor (VEGF). A patient
 XX (preferably human) having a condition associated with the level of the
 XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 XX angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 XX treated by administering the nucleic acid molecule or the expression
 XX vector to the patient. AAX67275 to AAX75752 represent specific examples
 XX of nucleic acid molecules from the present invention
 XX SQ Sequence 17 BP; 6 A; 3 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 58.8%; Pred. No. 1.8e+02;
 Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
 Qy 1568 TGCAACTTTGGAAACT 1584
 Db 1 UGCAAAUUGGAACCU 17
 RESULT 329
 AAX72984
 ID AAX72984 standard; RNA; 17 BP.
 XX AC AAX72984;
 XX XX 28-JUL-1999 (first entry)
 XX DE Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #417.
 XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX OS Mus sp.
 XX PN WO9715662-A2.
 XX PD 01-MAY-1997.
 XX PF 25-OCT-1996; 96WO-US017480.
 XX PR 26-OCT-1995; 95US-0005974P.
 XX PR 11-JAN-1996; 96US-00584040.
 XX XX (RIBO-) RIBOZYME PHARM INC.
 XX PA (CHIR) CHIRON CORP.
 XX PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;

PD 01-MAY-1997.
 XX 25-OCT-1996; 96WO-US017480.
 XX 26-OCT-1995; 95US-0005974P.
 XX 11-JAN-1996; 96US-00584040.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (CHIR) CHIRON CORP.
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 XX rheumatoid arthritis, etc., in a human patient.
 XX Claim 4; Page 136; 218pp; English.
 XX The present invention describes nucleic acid molecules which modulate the
 XX synthesis, expression and/or stability of a mRNA encoding 1 or more
 XX receptors of vascular endothelial growth factor (VEGF). A patient
 XX (preferably human) having a condition associated with the level of the
 XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 XX angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 XX treated by administering the nucleic acid molecule or the expression
 XX vector to the patient. AAX67275 to AAX75752 represent specific examples
 XX of nucleic acid molecules from the present invention
 XX SQ Sequence 17 BP; 5 A; 4 C; 4 G; 0 T; 4 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 Qy 1567 CTGCAACTTTGGAAAC 1583
 Db 1 CUGCAAGUUGGAAC 17
 RESULT 330
 AAX73070/C
 ID AAX73070 standard; RNA; 17 BP.
 XX AC AAX73070;
 XX XX 28-JUL-1999 (first entry)
 XX DE Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #503.
 XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX OS Mus sp.
 XX PN WO9715662-A2.
 XX PD 01-MAY-1997.
 XX PF 25-OCT-1996; 96WO-US017480.
 XX PR 26-OCT-1995; 95US-0005974P.
 XX PR 11-JAN-1996; 96US-00584040.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (CHIR) CHIRON CORP.
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;

```

XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 138; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 4 A; 2 C; 3 G; 0 T; 8 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1149 AAGGTAAATATTTCCAA 1165
DB 17 AAGGAAAATATTTCCCA 1
RESULT 331
AAX72985
ID AAX72985 standard; RNA; 17 BP.
XX
XX AAX72985;
XX
XX 28-JUL-1999 (first entry)
XX
XX Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #418.
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
XX KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
XX fms-like tyrosine kinase 1; kinase insert domain containing receptor;
XX foetal liver kinase 1; ss.
XX
XX Mus sp.
XX
XX WO9715662-A2.
XX
XX 01-MAY-1997.
XX
XX 25-OCT-1996; 96WO-US017480.
XX
XX 26-OCT-1995; 95US-0005974P.
XX
XX 11-JAN-1996; 96US-00584040.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (CHIR ) CHIRON CORP.
XX
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 136; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 5 A; 3 C; 4 G; 0 T; 5 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.8e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 1568 TGCACACTTGGAAACT 1584
DB 1 UGCAAGUUGGAAACCU 17
RESULT 332
AAX75069/C
ID AAX75069 standard; RNA; 17 BP.
XX
XX AAX75069;
XX
XX 28-JUL-1999 (first entry)
XX
XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #597.
XX
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
XX KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
XX fms-like tyrosine kinase 1; kinase insert domain containing receptor;
XX foetal liver kinase 1; ss.
XX
XX Mus sp.
XX
XX WO9715662-A2.
XX
XX 01-MAY-1997.
XX
XX 25-OCT-1996; 96WO-US017480.
XX
XX 26-OCT-1995; 95US-0005974P.
XX
XX 11-JAN-1996; 96US-00584040.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (CHIR ) CHIRON CORP.
XX
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 173; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 0 A; 0 C; 2 G; 0 T; 15 U; 0 Other;

```

```

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
    ||||| ||||| |||||
Db 17 AAAAAAAAAACAAAAA 1

RESULT 333
AAX71414
ID AAX71414 standard; RNA; 17 BP.
XX
AC AAX71414;
XX
DT 28-JUL-1999 (first entry)
XX
DE Human KDR VEGF receptor hammerhead ribozyme substrate #426.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
XX
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PA (CHIR ) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
XX WPI, 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 110; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 6 A; 4 C; 3 G; 0 T; 4 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTCGAAAC 1583
    ||||| :|||
Db 1 CUGCAAAUUGGAAAC 17

RESULT 334
AAX97651
ID AAX97651 standard; RNA; 17 BP.
XX
AC AAX97651;
XX
DT 17-MAR-1999 (first entry)
XX
DE Human EGF-R target sequence nucleotide position 3744.
XX
KW Human epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW cancer; genetic drift; detection; mutation; ss.
XX
OS Homo sapiens.
XX
PN WO9833893-A2.
XX
PD 06-AUG-1998.
XX
PF 14-JAN-1998; 98WO-US000730.
XX
PR 31-JAN-1997; 97US-0036476P.
XX
PR 04-DEC-1997; 97US-00985162.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PA (UYAS-) UNIV ASTON.
XX
PI Akhtar S, Pell P, Mcswiggen JA;
XX
XX WPI, 1998-437449/37.
XX
PT Enzymatic nucleic acids - which cleave RNA derived from an epidermal
PT growth factor receptor, useful for inhibiting cell proliferation and for
PT treating cancers.
XX
PS Claim 5; Page 77; 109pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules (NAMS)
CC which specifically cleave RNA derived from an epidermal growth factor
CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC represent specifically claimed target sequence from human EGF-R. AAV98044
CC to AAV98866 and AAV98867 to 9878 represent hammerhead ribozymes and
CC hairpin ribozymes respectively for human EGF-R. The NAMS are useful for
CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC expression levels e.g. to inhibit cell proliferation in the prevention or
CC treatment of cancers. The NAMS can also be used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of EGF-R RNA in a cell
XX
SQ Sequence 17 BP; 5 A; 2 C; 5 G; 0 T; 5 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 174 AATGGCATCTCTAAGAG 190
    ||||| :|||
Db 1 AAUGCAUUCUUAAGGG 17

RESULT 335
AAX79245/C
ID AAX79245 standard; DNA; 17 BP.
XX
AC AAX79245;
XX
DT 21-OCT-2004 (revised)
DT 31-AUG-1999 (first entry)
XX
DE Oligonucleotide #38 forms an intramolecular stacked tetrad structure.
XX
KW Column; box; stacked tetrad; inhibition; replication; pathophysiological;
KW herpes simplex virus; HSV; human papilloma virus; Epstein Barr Virus;
KW HPV; EBV; HIV; human immunodeficiency virus; adenovirus; RSV; HBV; HCMV;

```

KW respiratory syncytial virus; hepatitis B virus; human cytomegalovirus;
 KW human T-cell leukaemia virus; HTLV; ss.
 XX Synthetic.
 XX Key Location/Qualifiers
 XX misc_structure 1. .17
 FT /tag= a
 FT /note= "forms intramolecular stacked tetrad or 3D
 FT columnar box structure"
 FT modified_base 1. .17
 FT /tag= b
 FT /mod_base= optionally contains phosphodiester
 FT internucleotide linkages
 XX WO9833807-A1.
 XX 06-AUG-1998.
 XX 03-FEB-1998; 98WO-US001974.
 XX 04-FEB-1997; 97US-0037374P.
 PR 09-DEC-1997; 97US-00987574.
 XX (ARON-) ARONEX PHARM INC.
 PA Rando RF, Ojwang JO, Hogan ME, Wallace TL, Cossum PA;
 PI WPI; 1998-446809/38.
 XX New guanosine-rich tetrad forming oligonucleotide(s) - used for
 PT inhibiting virus replication for treating e.g. herpes simplex, papilloma,
 PT HIV, adenovirus or hepatitis B virus infection.
 XX Disclosure; Page 147; 140pp; English.
 XX Sequences AAX79210-X79275 represent oligonucleotides (ON) which are able
 CC to form a columnar box or "stacked tetrad" structure by intramolecular
 CC internucleotide binding. The ONs are used to inhibit the replication of
 CC viruses. They are able to suppress virus production for prolonged periods
 CC after an initial short treatment regimen. They can be used for treating
 CC pathophysiological states caused by viruses such as herpes simplex virus,
 CC human papilloma virus, Epstein Barr Virus, HIV, adenovirus, respiratory
 CC syncytial virus, hepatitis B virus, human cytomegalovirus and HTLV I and
 CC II
 CC Revised record issued on 21-OCT-2004 : Correction to feature table key
 XX Sequence 17 BP; 0 A; 0 C; 13 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1705 CCCCTCCCTCCACCCAC 1721
 Db ||||| ||||| ||||| |||||
 17 CCCACCCACCCACCCAC 1
 RESULT 336
 AAA21122/c
 ID AAA21122 standard; RNA; 17 BP.
 XX AAA21122;
 AC
 XX 19-JUN-2000 (first entry)
 XX Integrin alpha 6 subunit substrate sequence SEQ ID NO:4348.
 DE
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;

KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX Homo sapiens.
 OS
 XX WO9950403-A2.
 PN 07-OCT-1999.
 XX 24-MAR-1999; 99WO-US006507.
 PF 27-MAR-1998; 98US-0079678P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 PI WPI; 1999-591315/50.
 DR Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 XX Claim 55; Page 188; 305pp; English.
 XX The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequences
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT.
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX Sequence 17 BP; 1 A; 2 C; 0 G; 0 T; 14 U; 0 Other;
 SQ
 Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 202 AAATAAAGAGAAATA 218
 Db ||||| ||||| ||||| |||||
 17 AAAGAAAGAGAAATA 1
 RESULT 337
 AAA18738/c
 ID AAA18738 standard; RNA; 17 BP.
 XX AAA18738;
 AC
 XX 19-JUN-2000 (first entry)
 XX Human TIE-2 substrate sequence SEQ ID NO:1964.
 DE

XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytotstatic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX Homo sapiens.
 OS
 XX
 XX WO9950403-A2.
 PN
 XX
 XX 07-OCT-1999.
 PD
 XX
 XX 24-MAR-1999; 99WO-US006507.
 PF
 XX
 XX 27-MAR-1998; 98US-0079678P.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 PI WPI; 1999-591315/50.
 DR
 XX
 XX Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 PT
 XX
 XX Claim 56; Page 114; 305pp; English.
 FS
 XX
 XX The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 XX Sequence 17 BP; 3 A; 4 C; 0 G; 0 T; 10 U; 0 Other;
 SQ
 Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 203 AATAAAGCAAGAAATAG 219
 DB 17 AGTAATAGCAAGAAATAG 1
 RESULT 338
 AAA25595
 ID AAA25595 standard; DNA; 17 BP.
 XX

AC
 XX
 XX 19-JUL-2000 (first entry)
 DT
 XX
 XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:2093.
 DE
 XX
 XX Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
 KW gene expression modification; cancer; phosphorothioate; endonuclease;
 KW anticancer; breast cancer; endometrium cancer; ss.
 KW
 XX Homo sapiens.
 OS
 XX
 XX WO9954459-A2.
 PN
 XX
 XX 28-OCT-1999.
 PD
 XX
 XX 19-APR-1999; 99WO-US008547.
 PF
 XX
 XX 20-APR-1998; 98US-0082404P.
 PR
 XX
 XX 23-JUN-1998; 98US-00103636.
 PA
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PI
 XX
 XX Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
 PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;
 PI Matulic-Adamic J;
 DR WPI; 2000-013248/01.
 XX
 XX New nucleic acids that interact, and optionally cleave, target sequences,
 PT used to treat cancer.
 PT
 XX
 XX Claim 77; Page 84; 148pp; English.
 PS
 XX
 XX The present invention describes nucleic acids (A) that interact stably
 CC with a target sequence and contain at least one phosphorodithioate
 CC link, having endonuclease activity. (A), and more generally any catalytic
 CC nucleic acid (A') that modulates expression of the oestrogen receptor
 CC gene, are used to treat cancer (particularly of breast or endometrium),
 CC in vivo or by transforming cells ex vivo and implanting treated cells, or
 CC for other conditions associated with levels of oestrogen receptor.
 CC Because of the high selectivity for targeted RNA, (A) can also be used to
 CC correlate inhibition of gene expression with alterations in phenotype,
 CC particularly for identification of therapeutic targets, and as research
 CC reagents (for RNA, in the same way that restriction endonucleases are
 CC used with DNA). The combination of modifications in (A) improves
 CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
 CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
 CC AAA24748 to AAA25992 represent their corresponding target sequences.
 CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
 CC sequences, and AAA26107 to AAA26218 represent their corresponding target
 CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
 CC antisense oligonucleotides used in the exemplification of the present
 CC invention
 XX
 XX Sequence 17 BP; 6 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1567 CTGCAACTTTGGAAAC 1583
 DB 1 CAGCAACTTTGGAATC 17
 RESULT 339
 AAA25180/c
 ID AAA25180 standard; DNA; 17 BP.
 XX
 XX AAA25180;
 AC
 XX

DT 19-JUL-2000 (first entry)
DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1678.
XX
XX
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
XX
XX Homo sapiens.
XX
XX WO9954459-A2.
XX
XX 28-OCT-1999.
XX
XX 19-APR-1999; 99WO-US008547.
XX
XX 20-APR-1998; 98US-0082404P.
XX
XX 23-JUN-1998; 98US-00103636.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeberli P;
PI Matulic-Adamic J;
XX
XX WPI; 2000-013248/01.
XX
XX New nucleic acids that interact, and optionally cleave, target sequences,
XX used to treat cancer.
XX
XX Claim 77; Page 71; 149pp; English.
XX
XX The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphorodi(thioate
CC link, having endonuclease activity. (A), and more generally any catalytic
CC nucleic acid (A') that modulates expression of the oestrogen receptor
CC gene, are used to treat cancer (particularly of breast or endometrium),
CC in vivo or by transforming cells ex vivo and implanting treated cells, or
CC for other conditions associated with levels of oestrogen receptor.
CC Because of the high selectivity for targeted RNA, (A) can also be used to
CC correlate inhibition of gene expression with alterations in phenotype,
CC particularly for identification of therapeutic targets, and as research
CC reagents (for RNA, in the same way that restriction endonucleases are
CC used with DNA). The combination of modifications in (A) improves
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA24748 to AAA25992 represent their corresponding target sequences.
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC sequences, and AAA26107 to AAA26218 represent their corresponding target
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present
CC invention
XX
XX Sequence 17 BP; 1 A; 0 C; 1 G; 15 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1835 AAAAAAAAAAAAAA 1851
DB 17 AAAAAAAAAACAAAA 1
RESULT 340
AAH94595/c
ID AAH94595 standard; RNA; 17 BP.
AC AAH94595;
XX
XX 09-OCT-2001 (first entry)
DT XX

DE Human Chk1 ribozyme substrate SEQ ID NO: 20.
XX
KW Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;
KW RNA cleavage; cancer; ss.
XX
OS Homo sapiens.
XX
XX WO200157206-A2.
XX
XX 09-AUG-2001.
XX
XX 02-FEB-2001; 2001WO-US003504.
XX
XX 03-FEB-2000; 2000US-0179983P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX (FATT/) FATTAEY A R.
XX
XX Fattaey AR, Jarvis T, Mcswiggen J, Boohar RN, Holman PS;
XX
XX WPI; 2001-496922/54.
XX
XX Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid
PT molecules, which downregulates expression of a checkpoint kinase-1 gene,
PT useful for treating colorectal, lung, breast or prostate cancers.
XX
XX Claim 4; Page 52; 115pp; English.
XX
XX The present invention provides nucleic acid molecules capable of
CC downregulating the expression of the human checkpoint kinase-1 (Chk1)
CC gene. These may be antisense or ribozyme sequences, and are useful in the
CC treatment of diseases associated with conditions affected by Chk1 levels,
CC including cancer. The present sequence is an oligonucleotide described in
CC the exemplification of the invention
XX
XX Sequence 17 BP; 11 A; 0 C; 3 G; 0 T; 3 U; 0 Other;
SQ
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1654 TCTTCTTGATCTTTC 1670
DB 17 TCTTCTTAATTTTC 1
RESULT 341
ABK02550
ID ABK02550 standard; RNA; 17 BP.
XX
XX ABK02550;
AC
XX
XX 12-MAR-2002 (first entry)
DT XX
XX
XX Human NOGO Amberzyme #222.
XX
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX WO200159103-A2.
PN

```
XX PD 16-AUG-2001.
XX PF
XX PP
XX PR 09-FEB-2001; 2001WO-US004273.
XX PR 11-FEB-2000; 2000US-0181797P.
XX PR 28-FEB-2000; 2000US-0185516P.
XX PR 06-MAR-2000; 2000US-0187128P.
XX PR (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (CHOW/) CHOWRIRA B M.
XX PI
XX PI Blatt L, Mcswiggen J, Chowrira BM;
XX DR WPI; 2001-607195/69.
XX DR
XX PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX PT constructs, which down regulate expression of a CD20 gene or neurite
XX PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX PT central nervous system injury.
XX PS Claim 88; Page 135; 200pp; English.
XX CC The invention relates to a nucleic acid molecule which down regulates
XX CC expression of a CD20 gene and a nucleic acid molecule which down
XX CC regulates expression of a neurite growth inhibitor gene (NOGO). The
XX CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX CC DNzyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
XX CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
XX CC an amberyzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
XX CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
XX CC of CD20 in the presence of a divalent cation that is preferably Mg2+.
XX CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX CC the cell and treat a patient having a condition associated with the level
XX CC of CD20. The treatment may further comprise the use of one or more
XX CC therapies. In particular, the CD20 targetting nucleic acid may be used to
XX CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
XX CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
XX CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
XX CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
XX CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
XX CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
XX CC presence of a divalent cation that is preferably Mg2+. Furthermore, the
XX CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
XX CC cell and treat a patient having a condition associated with the level of
XX CC NOGO. The treatment may further comprise the use of one or more
XX CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
XX CC treat central nervous system (CNS) injury and cerebrovascular accident
XX CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX CC disease, muscular dystrophy, and/or other neurodegenerative disease
XX CC states which respond to the modulation of NOGO expression. The present
XX CC sequence is an amberyzyme molecule of the invention
XX SQ Sequence 17 BP; 10 A; 0 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.8e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAGGAAGAAAT 217
Db 1 GGAUUAAGGAGAAAU 17

RESULT 342
AAS56748/C
ID AAS56748 standard; RNA; 17 BP.
XX
AC AAS56748;

XX PD 16-AUG-2001.
XX PF
XX PP
XX PR 09-FEB-2001; 2001WO-US004273.
XX PR 11-FEB-2000; 2000US-0181797P.
XX PR 28-FEB-2000; 2000US-0185516P.
XX PR 06-MAR-2000; 2000US-0187128P.
XX PR (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (CHOW/) CHOWRIRA B M.
XX PI
XX PI Blatt L, Mcswiggen J, Chowrira BM;
XX DR WPI; 2001-607195/69.
XX DR
XX PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX PT constructs, which down regulate expression of a CD20 gene or neurite
XX PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX PT central nervous system injury.
XX PS Claim 88; Page 135; 200pp; English.
XX CC The invention relates to a nucleic acid molecule which down regulates
XX CC expression of a CD20 gene and a nucleic acid molecule which down
XX CC regulates expression of a neurite growth inhibitor gene (NOGO). The
XX CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX CC DNzyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
XX CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
XX CC an amberyzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
XX CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
XX CC of CD20 in the presence of a divalent cation that is preferably Mg2+.
XX CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX CC the cell and treat a patient having a condition associated with the level
XX CC of CD20. The treatment may further comprise the use of one or more
XX CC therapies. In particular, the CD20 targetting nucleic acid may be used to
XX CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
XX CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
XX CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
XX CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
XX CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
XX CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
XX CC presence of a divalent cation that is preferably Mg2+. Furthermore, the
XX CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
XX CC cell and treat a patient having a condition associated with the level of
XX CC NOGO. The treatment may further comprise the use of one or more
XX CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
XX CC treat central nervous system (CNS) injury and cerebrovascular accident
XX CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX CC disease, muscular dystrophy, and/or other neurodegenerative disease
XX CC states which respond to the modulation of NOGO expression. The present
XX CC sequence is an amberyzyme molecule of the invention
XX SQ Sequence 17 BP; 10 A; 0 C; 5 G; 0 T; 2 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.8e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAGGAAGAAAT 217
Db 1 GGAUUAAGGAGAAAU 17

RESULT 342
AAS56748/C
ID AAS56748 standard; RNA; 17 BP.
XX
AC AAS56748;

XX DT 16-JAN-2002 (first entry)
XX DE BR1 ribozyme sequence tag RNA #17.
XX DE
XX KW Human; BRCA-1 regulator; ribozyme; BR1; RNA target recognition; probe;
XX KW cytosolic; RNA cleavage; tumour suppressor; PCR primer; CHLR2; AF6; BR2;
XX KW inhibitor dominant negative 4; breast basic conserved protein 1; BRC1;
XX KW BR3; ID4; cancer; proliferative disorder; tumour proliferation; ss.
XX KW
XX OS Homo sapiens.
XX XX WO200170982-A2.
XX XX PD 27-SEP-2001.
XX XX
XX PF 23-MAR-2001; 2001WO-US009559.
XX PR 23-MAR-2000; 2000US-00536058.
XX PR (IMMU-) IMMUSOL INC.
XX PA (BEGE/) BEGER C.
XX XX
XX PI Bege C, Barber J, Wong-Staal F;
XX XX WPI; 2001-611503/70.
XX XX
XX PT Novel polypeptides that are the regulators of BRCA-1, useful for treating
XX PT cancer and diagnosing the presence of neoplastic cells in biological
XX PT sample.
XX PS Disclosure; Page 20; 97pp; English.
XX CC Sequences AAS56729-AAS56968 represent DNA encoding BRCA-1 regulators, RNA
XX CC ribozyme target recognition RNA sequences, DNA fragments encoding the RNA
XX CC and primers used in the methods of the invention. Hybridisation of
XX CC ribozymes to their targets results in cleavage of the RNA target. The
XX CC ribozymes can be used to cleave regulators of the tumour suppressor BRCA-
XX CC 1, resulting in upregulation or downregulation of BRCA-1 in a cell. The
XX CC mRNA targets include those encoding the BRCA-1 regulator BR1, inhibitor
XX CC dominant negative 4 (ID4), breast basic conserved protein 1 (BBC1),
XX CC CHLR2, AF6, BR2 and BR3. Regulation of BRCA-1 is useful for treating and
XX CC diagnosing cancer and other proliferative disorders. The severity of an
XX CC incidence of cancer can be lessened by regulating tumour proliferation
XX CC through modulation of BRCA-1 expression. The sequences of the invention
XX CC are useful in the development of anti-cancer drugs
XX SQ Sequence 17 BP; 10 A; 3 C; 1 G; 0 T; 3 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1468 TTGTTTCTTATGTTGTT 1484
Db 17 TTGATTCTAATGTTGTT 1

RESULT 343
AAF83171
ID AAF83171 standard; DNA; 17 BP.
XX
AC AAF83171;
XX
DT 09-JUL-2001 (first entry)
XX DE
XX KW Probe PN(n)T used in detection by allele specific extension.
XX KW Immobilisation; chemical; biological; polynucleotide amplification;
XX KW nucleic acid detection; probe; hybridisation; PCR primer; ss.
XX OS Synthetic.
XX XX
```

```
PN WO200127327-A2.
XX
PD 19-APR-2001.
XX
XX 06-OCT-2000; 2000WO-US027872.
XX
XX 08-OCT-1999; 99US-0158315P.
XX
XX (PROT-) PROTOGENE LAB INC.
XX
XX Brennan TM, Chatelain F, Berninger M;
XX
XX WPI; 2001-290733/30.
XX
XX Apparatus and method for performing a large number of chemical and
PT biological reactions by bringing two arrays into close apposition and
PT allowing reactants on the surfaces of the two arrays to come into
PT contact.
XX
XX Example 11; Fig 18B; 112pp; English.
XX
XX The invention provides a novel system for performing reactions, that
CC comprises a first solid support with a reactant of each reaction
CC immobilized on to it, and a second solid support either providing a
CC second reactant confined to a specific area on the surface, or a chemical
CC /mechanical separation of the reactions, where the first and second solid
CC supports are assembled to provide an environment for performing the
CC reactions in parallel. The methods and apparatus are useful for
CC performing a large number of chemical and biological reactions,
CC especially polynucleotide amplification reactions and the detection of
CC sequence variations, expression levels and their functions. The method is
CC capable of generating large amounts of data or products per unit time by
CC carrying out large numbers of reactions in parallel. The process is also
CC amenable to full automation. Sequences AAF83164-179 represent probes used
CC in detecting amplified products by allele specific extension, thep
CC products amplified by performing large numbers of PCR reactions using
CC array-immobilised and releasable primers
XX
XX Sequence 17 BP; 5 A; 9 C; 2 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1709 TCCCTCCACACATAG 1725
Db ||||| ||||| |||
1 TCCACCCACACACAG 17
RESULT 344
ABN01544
ID ABN01544 standard; DNA; 17 BP.
XX
XX AC ABN01544;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1536.
DE
XX
XX Human; genome-derived myosin-like protein 1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
OS
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
PR
PR 04-OCT-2000; 2000GB-00024263.
PR
PR 30-JAN-2001; 2001WO-US000661.
PR
PR 30-JAN-2001; 2001WO-US000662.
PR
PR 30-JAN-2001; 2001WO-US000663.
PR
PR 30-JAN-2001; 2001WO-US000664.
PR
PR 30-JAN-2001; 2001WO-US000665.
PR
PR 30-JAN-2001; 2001WO-US000666.
PR
PR 30-JAN-2001; 2001WO-US000667.
PR
PR 30-JAN-2001; 2001WO-US000668.
PR
PR 30-JAN-2001; 2001WO-US000669.
PR
PR 05-FEB-2001; 2001WO-US000670.
PR
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 1536; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 0 A; 4 C; 9 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1081 TGGGGCTGGTCTCTCG 1097
Db ||||| ||||| |||||
1 TGGGGCTGGTGGCCCTCG 17
RESULT 345
ABN09580/C
ID ABN09580 standard; DNA; 17 BP.
XX
XX AC ABN09580;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9572.
DE
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
```


XX OS Homo sapiens.
XX PN WO200192524-A2.
XX XX
XX PD 06-DEC-2001.
XX XX
XX PF 25-MAY-2001; 2001WO-US016981.
XX XX
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024283.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AEOM-) AEOMICA INC.
XX XX
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX XX
XX XX WPI; 2002-179446/23.
XX XX
XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX XX
XX PS Disclosure; SEQ ID NO 9572; 214pp; English.
XX XX
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX CC nucleic acids can be used as probes to detect, characterise and quantify
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX CC production, and in vaccines or for replacement therapy. The
XX CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX CC disorder associated with the expression of hGDMPLP-1, in particular heart
XX CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX CC The present sequence represents an oligomer used in the screening of the
XX CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX CC The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

XX SQ Query Match 0.7%; Score 13.8; DB 1; Length 17;
XX SQ Best Local Similarity 88.2%; Pred. No. 1.8e+02;
XX SQ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX Qy 969 CTGCACAGCTGGGATGT 985
XX Db 17 CTCGACAGCGGGGATGT 1

XX RESULT 346
XX ABN08368

ID XX ABN08368 standard; DNA; 17 BP.
XX AC ABN08368;
XX DT
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8360.
XX DE
XX KW Human; genome-derived myosin-like protein 1; hGDMPLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX XX
XX PD 06-DEC-2001.
XX XX
XX PF 25-MAY-2001; 2001WO-US016981.
XX XX
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024283.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AEOM-) AEOMICA INC.
XX XX
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX XX
XX XX WPI; 2002-179446/23.
XX XX
XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX XX
XX PS Disclosure; SEQ ID NO 8360; 214pp; English.
XX XX
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX CC nucleic acids can be used as probes to detect, characterise and quantify
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX CC production, and in vaccines or for replacement therapy. The
XX CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX CC disorder associated with the expression of hGDMPLP-1, in particular heart
XX CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX CC The present sequence represents an oligomer used in the screening of the
XX CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX CC The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 6 A; 1 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 390 GATGGCTGGAGAAAGT 406
 |||||
 Db 1 GAGGAGCTGGAGAAAGT 17

RESULT 347
 ABN08371
 ID ABN08371 standard; DNA; 17 BP.
 AC ABN08371;
 XX
 XX 29-MAY-2002 (first entry)
 XX
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8363.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO200192524-A2.
 XX
 XX 06-DEC-2001.
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 XX (AEOM-) AEOMICA INC.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 XX or as specific biomolecule capture probes for surface-enhanced laser
 XX desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 8363; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 XX nucleic acids can be used as probes to detect, characterize and quantify
 XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 XX provide initial substrates for the recombinant engineering of hGDMPLP-1
 XX protein variants having desired phenotypic improvements, and for
 XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
 XX -1 proteins, as standards in assays used to determine the concentration
 XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 XX capture probes for surface-enhanced laser desorption/ionisation, as
 XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 XX production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 XX Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 393 GGGCTGGAGAAAGTCA 409
 |||||
 Db 1 GAGCTGGAGAAAGTCA 17

RESULT 348
 ABN01545
 ID ABN01545 standard; DNA; 17 BP.
 AC ABN01545;
 XX
 XX 29-MAY-2002 (first entry)
 XX
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1537.
 XX
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO200192524-A2.
 XX
 XX 06-DEC-2001.
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 XX (AEOM-) AEOMICA INC.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 XX or as specific biomolecule capture probes for surface-enhanced laser
 XX desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 XX Disclosure; SEQ ID NO 1537; 214pp; English.
 XX
 XX The present invention describes a human genome-derived myosin-like
 XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 1 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1082 GCGGCTGGTGTCTCTGGA 1098
Db 1 GGGGCTGGTGTCTCTGGA 17
|||||

RESULT 349
ABQ63943
ID ABQ63943 standard; DNA; 17 BP.
XX
AC ABQ63943;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 656.
XX
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
OS Homo sapiens.
XX
FN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 23-MAY-2001; 2001US-00864761.
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (ABOM-) ABOMICA INC.
XX
PI Zhang J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.

DR WPI; 2002-479509/51.
XX
PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
XX Example 2; Page 243; 418pp; English.
XX
CC The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostatic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1414 CCATGACTGTCATGGAT 1430
Db 1 CCAGGACTGTCAGGGAT 17
|||||

RESULT 350
ABV83005/C
ID ABV83005 standard; DNA; 17 BP.
XX
AC ABV83005;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 4251.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
FN EPI229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-00001167.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 23-MAY-2001; 2001WO-US000669.
PR 09-OCT-2001; 2001US-00864761.
XX
PA (ABOM-) ABOMICA INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.

XX Example 2; Page 621; 718pp; English.

XX The present invention relates to human testis expressed Patched like protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL has two isoforms, with a few single base pair differences between the two. One of the single base pair changes introduces a premature stop codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL shares an overall structure organisation with the Patched protein. The shared structural features strongly imply that HTPL plays a role similar to that of Patched, and is a potential tumour suppressor. HTPL is important in regulating male germ cell development, and the HTPL gene was mapped to human chromosome 10p12.1. HTPL and its coding sequence are useful for diagnosing a disorder caused by mutation in HTPL, and in therapy and manufacture of a medicament for treatment or prevention of such disorder associated with decreased expression or activity of human HTPL. Such disorders include disorders of testis, or adrenal, adult and foetal liver, bone marrow, brain, kidney, lung, placenta, prostate, skeletal muscle or colon function. HTPL proteins and nucleic acids are clinically useful diagnostic markers and potential therapeutic agents for male infertility and cancer. The present oligonucleotide was used in an example from the invention

XX Sequence 17 BP; 3 A; 1 C; 2 G; 11 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 ATTATCTTAACAAGAAA 81
DB 17 AATATCATACAGAAA 1
||||| |||||||

RESULT 351
ABK17547/c
ID ABK17547 standard; RNA; 17 BP.
XX ABK17547;
XX 09-APR-2002 (first entry)
XX Human ERG hammerhead ribozyme target sequence, Seq ID No 194.
XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
amberzyme.
XX Homo sapiens.
XX WO200188124-A2.
XX 22-NOV-2001.
XX 16-MAY-2001; 2001WO-US015866.
XX 16-MAY-2000; 2000US-00572021.
XX (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.
XX Jarvis T, Von Carlowitz I, Mcswiggen-JA, McLaughlin F, Randi AM;
XX WPT; 2002-082995/11.
XX Novel polynucleotide which down regulates expression of Ets-related gene,
PT useful for treating cancer, diabetic retinopathy, macular degeneration,

PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
XX Claim 4; Page 62; 149pp; English.
XX The invention relates to a nucleic acid molecule (I) which down regulates expression of an Ets-related gene (ERG). (I) is useful for treating conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma, tumour angiogenesis, diabetic retinopathy, macular degeneration, neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for treating a patient having a condition associated with the level of ERG, by contacting cells of the patient with (I) under conditions suitable for the treatment. The method comprises the use of one or more therapies under conditions suitable for the treatment. Leukaemia or tumour angiogenesis is treated by administering (I) to the patient in conjunction with one or more of other therapies such as radiation or chemotherapy treatment. (I) is useful for reducing ERG activity in a cell, by contacting the cell with (I). (I) is useful for cleaving RNA of ERG gene, by contacting (I) with RNA, in the presence of a divalent cation such as Mg²⁺. (I) is useful for diagnosis of conditions and diseases related to the expression of ERG, and as diagnostic tool to examine genetic drift and mutations within diseased cells or to detect the presence of ERG RNA in a cell. (I) is useful for specifically targeting genes that share homology with ERG gene or ERG fusion genes. ABK17354-ABK22719 represent nucleic acids, including antisense and enzymatic nucleic acid molecules which regulate expression of ERG, and related PCR primers of the invention

XX Sequence 17 BP; 6 A; 5 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1118 AGTTGGTGCTTCCAGT 1134
DB 17 AGTTGGTGATTCAGT 1
||||| |||||||

RESULT 352
ABK19008/c
ID ABK19008 standard; RNA; 17 BP.
XX ABK19008;
XX 09-APR-2002 (first entry)
XX Human ERG DNAzyme target sequence Seq ID No 1655.
XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
amberzyme.
XX Homo sapiens.
XX WO200188124-A2.
XX 22-NOV-2001.
XX 16-MAY-2001; 2001WO-US015866.
XX 16-MAY-2000; 2000US-00572021.
XX (RIBO-) RIBOZYME PHARM INC.
PA (GLAX) GLAXO GROUP LTD.

XX PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 XX WI; 2002-082995/11.
 XX DR Novel polynucleotide which down regulates expression of Ets-related gene,
 XX PT useful for treating cancer, diabetic retinopathy, macular degeneration,
 XX PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 XX PS Claim 4; Page 106; 149pp; English.
 XX CC The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules, which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX SQ Sequence 17 BP; 7 A; 4 C; 2 G; 0 T; 4 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1120 TTGGTGCTTCCAGTAT 1136
 Db 17 TTGGTGAATTCAGTAT 1
 RESULT 353
 ID ABK18911/c
 XX ABK18911 standard; RNA; 17 BP.
 XX AC ABK18911;
 XX 09-APR-2002 (first entry)
 XX Human ERG DNazyme target sequence Seq ID No 1558.
 XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritis; antipsoriatic; virucide; osteopathic;
 KW lymphoma; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNazyme; inozyme;
 KW amberyze.
 XX Homo sapiens.
 XX WO200188124-A2.
 XX 22-NOV-2001.

XX 16-MAY-2001; 2001WO-US015866.
 XX 16-MAY-2000; 2000US-00572021.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (GLAX) GLAXO GROUP LTD.
 XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 XX WI; 2002-082995/11.
 XX Novel polynucleotide which down regulates expression of Ets-related gene,
 XX PT useful for treating cancer, diabetic retinopathy, macular degeneration,
 XX PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 XX PS Claim 4; Page 105; 149pp; English.
 XX CC The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration, verruca
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX SQ Sequence 17 BP; 1 A; 7 C; 9 G; 0 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 30 CGCCTCGTCGCGCGCG 46
 Db 17 CGCGCGCGTCGCGCGCG 1
 RESULT 354
 ID AAD41868/c
 XX AAD41868 standard; RNA; 17 BP.
 XX AC AAD41868;
 XX 30-OCT-2002 (first entry)
 XX ON-21 oligonucleotide used in the exemplification of the invention.
 XX Antisense therapy; infection; cardiovascular disorder; immune reaction;
 KW gene therapy; virucide; cytostatic; antibacterial; antiinflammatory;
 KW cancer; cardiant; ss.
 XX Unidentified.
 XX Key Location/Qualifiers
 XX modified_base 2. .5

```
FT FT /*tag= a
FT FT /mod_base= OTHER
FT FT /note= "5-(1-propynyl)-2'-deoxyuridine; This base is
FT FT given as N in the sequence shown as SEQ ID NO: 15 in the
FT FT sequence listing"
FT FT 6
FT FT modified_base
FT FT
FT FT /*tag= b
FT FT /mod_base= OTHER
FT FT /note= "5-methyl-2'-deoxycytidine; This base is given as
FT FT N in the sequence shown as SEQ ID NO: 15 in the sequence
FT FT listing"
FT FT 7. .8
FT FT modified_base
FT FT
FT FT /*tag= c
FT FT /mod_base= OTHER
FT FT /note= "5-(1-propynyl)-2'-deoxyuridine; This base is
FT FT given as N in the sequence shown as SEQ ID NO: 15 in the
FT FT sequence listing"
FT FT 9
FT FT modified_base
FT FT
FT FT /*tag= d
FT FT /mod_base= OTHER
FT FT /note= "5-methyl-2'-deoxycytidine; This base is given as
FT FT N in the sequence shown as SEQ ID NO: 15 in the sequence
FT FT listing"
FT FT 11. .16
FT FT modified_base
FT FT
FT FT /*tag= e
FT FT /mod_base= OTHER
FT FT /note= "5-(1-propynyl)-2'-deoxyuridine; This base is
FT FT given as N in the sequence shown as SEQ ID NO: 15 in the
FT FT sequence listing"
FT FT 17
FT FT modified_base
FT FT
FT FT /*tag= f
FT FT /mod_base= OTHER
FT FT /note= "5-methyl-2'-deoxycytidine; This base is given as
FT FT N in the sequence shown as SEQ ID NO: 15 in the sequence
FT FT listing"
FT FT 18. .19
FT FT modified_base
FT FT
FT FT /*tag= g
FT FT /mod_base= OTHER
FT FT /note= "5-(1-propynyl)-2'-deoxyuridine; This base is
FT FT given as N in the sequence shown as SEQ ID NO: 15 in the
FT FT sequence listing"
FT FT 20
FT FT modified_base
FT FT
FT FT /*tag= h
FT FT /mod_base= OTHER
FT FT /note= "5-methyl-2'-deoxycytidine; This base is given as
FT FT N in the sequence shown as SEQ ID NO: 15 in the sequence
FT FT listing"
FT FT
FT FT US6380368-B1.
FT FT
FT FT 30-APR-2002.
FT FT
FT FT 12-FEB-1996; 96US-00599738.
FT FT
FT FT 26-NOV-1991; 91US-00799824.
FT FT 25-AUG-1992; 92US-00935444.
FT FT 23-OCT-1992; 92US-00965941.
FT FT 25-NOV-1992; 92US-00976103.
FT FT 14-NOV-1994; 94US-00338352.
FT FT
FT FT (ISIS-) ISIS PHARM INC.
FT FT
FT FT Froehler B, Wagner R, Mattencio M, Jones RJ, Gutierrez AJ;
FT FT Pudlo J;
FT FT
FT FT WPI; 2002-535437/57.
FT FT
FT FT New oligomers useful for binding to DNA duplex target sequence and for
FT FT treating e.g. diseases caused by viruses and inflammatory conditions
FT FT comprise at least three 3'-5' linked nucleosides.
FT FT
FT FT Example 6; Col 41-42; 106pp; English.
FT FT
XX XX
```

```
CC The present invention relates to novel oligomers which have enhanced
CC ability with respect to forming duplexes or triplexes. The oligomers
CC comprise at least three 3'-5' linked nucleosides or their salts. At least
CC one internucleoside linkage is not a phosphodiester linkage and at least
CC one nucleoside comprises a base. Sequences of the invention are useful
CC for binding to a DNA duplex target sequence via either CT or GT triplex
CC helix binding motif and in antisense therapies. They are also used for
CC treating diseases caused by viruses and for diagnostic applications to
CC detect viral infections, bacterial infections and diseases such as
CC cancers. The oligomers are also used as primers, in the treatment of
CC pathological conditions associated with inflammatory conditions,
CC cardiovascular disorders, immune reactions and bacterial infections and
CC for modulating target gene expression. They are also useful in gene
CC therapy. The present sequence is an oligonucleotide used in the
CC exemplification of the invention
XX XX
SQ Sequence 17 BP; 2 A; 3 C; 0 G; 0 T; 12 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 90 GAAAAAAATGAAATT 106
Db 17 GAAGAAAAATGAAAT 1
RESULT 355
ABK55893
ID ABK55893 standard; RNA; 17 BP.
XX ABK55893;
AC ABK55893;
XX 02-JUL-2002 (first entry)
DT Human CLC1 gene enzymatic nucleic acid #264.
XX
DE Human; chloride channel calcium activated 1; CLC1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
XX Homo sapiens.
XX
XX WO200211674-A2.
XX
XX 14-FEB-2002.
XX
XX 09-AUG-2001; 2001WO-US024970.
XX
XX 09-AUG-2000; 2000US-0224383P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (SYNT ) SYNTEX USA LLC.
XX (THOM/) THOMPSON J.
XX
XX Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
XX Grupe A;
XX WPI; 2002-217145/27.
XX
XX Enzymatic polynucleotide that down regulates expression of chloride
XX channel calcium activated gene, useful for treating Chronic obstructive
XX pulmonary disease (COPD), chronic bronchitis and asthma.
XX
XX Claim 4; Page 57; 152pp; English.
XX
XX The invention relates to enzymatic nucleic acid molecules that down
XX regulate expression of chloride channel calcium activated 1 (CLC1) genes
XX by cleaving RNA derived from the genes. The nucleic acid sequences are
XX useful as pharmaceutical agents for treating conditions such as chronic
XX obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
XX obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
XX obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
```

CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention

XX
 SQ Sequence 17 BP; 8 A; 3 C; 3 G; 0 T; 3 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 1.8e+02;
 Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 210 GAAGAAATAGCCAGCTG 226
 |||||:|||||:
 Db 1 GAAGAAAUUCCACUG 17

RESULT 356
 ABK55827/c
 ID ABK55827 standard; RNA; 17 BP.

AC AC

XX ABK55827;

DT 02-JUL-2002 (first entry)

DE Human CLCA1 gene enzymatic nucleic acid #198.

XX Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KW acetylcysteine.

XX Homo sapiens.

XX WO200211674-A2.

XX 14-FEB-2002.

XX 09-AUG-2001; 2001WO-US024970.

XX 09-AUG-2000; 2000US-0224383P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (SYNT) SYNTEX USA LLC.

XX (THOM/) THOMPSON J.

XX Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
 PI Grupe A;

XX WPI; 2002-217145/27.

XX Enzymatic polynucleotide that down regulates expression of chloride
 PT channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma.

XX Claim 4; Page 56; 152pp; English.

XX The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,

CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention

XX Sequence 17 BP; 5 A; 3 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1722 ATAGAAATCAACATATGG 1738
 |||||:|||||:
 Db 17 ATAGAAATCAACATGTTG 1

RESULT 357

ACN01678/c

ID ACN01678 standard; RNA; 17 BP.

XX ACN01678;

XX 22-APR-2004 (first entry)

XX MNV Inozyme substrate SEQ ID NO 1668.

DE MNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
 KW Amberzyme; Zinzyme; ss.

XX West Nile Virus.

XX WO200268637-A2.

XX 06-SEP-2002.

XX 19-OCT-2001; 2001WO-US048350.

XX 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (MNV), useful for treating a condition related to MNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 1668; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (MNV). The nucleic acid molecules are useful for
 CC treating a condition related to MNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
SQ Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 325 CCAGACTGAGTGCTCC 341
DB 17 CCTGCTGAGTGCTCC 1
RESULT 358
ACN13432
ID ACN13432 standard; RNA; 17 BP.
XX ACN13432;
XX ACN13432;
DT 22-APR-2004 (first entry)
XX WNV minus strand Zinzyme substrate SEQ ID NO 13435.
DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX West Nile Virus.
OS West Nile Virus.
XX WO200268637-A2.
PN WO200268637-A2.
XX 06-SEP-2002.
PD 06-SEP-2002.
XX 19-OCT-2001; 2001WO-US048350.
PF 19-OCT-2001; 2001WO-US048350.
XX 20-OCT-2000; 2000US-0242411P.
PR 20-OCT-2000; 2000US-0242411P.
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX Blatt L, Mcswiggen JA;
PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
DR WPI; 2002-706994/76.
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX Claim 23; SEQ ID NO 13435; 495pp; English.
PS Claim 23; SEQ ID NO 13435; 495pp; English.
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
SQ Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 326 CAGACTGAGTGCTCCA 342
DB 1 CUGCCGAGUGGCUCCA 17
RESULT 359
ACN03066
ID ACN03066 standard; RNA; 17 BP.
XX ACN03066;
XX ACN03066;
DT 22-APR-2004 (first entry)
XX WNV Inozyme substrate SEQ ID NO 3069.
DE WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX West Nile Virus.
OS West Nile Virus.
XX WO200268637-A2.
PN WO200268637-A2.
XX 06-SEP-2002.
PD 06-SEP-2002.
XX 19-OCT-2001; 2001WO-US048350.
PF 19-OCT-2001; 2001WO-US048350.
XX 20-OCT-2000; 2000US-0242411P.
PR 20-OCT-2000; 2000US-0242411P.
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX Blatt L, Mcswiggen JA;
PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
DR WPI; 2002-706994/76.
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX Claim 23; SEQ ID NO 3069; 495pp; English.
PS Claim 23; SEQ ID NO 3069; 495pp; English.
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX Sequence 17 BP; 9 A; 1 C; 4 G; 0 T; 3 U; 0 Other;
SQ Sequence 17 BP; 9 A; 1 C; 4 G; 0 T; 3 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.8e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 473 AGGAATTCATAGTAG 489
DB 1 AGGAATTCATAGTAG 17


```

RESULT 360
ACN04090/c
ID ACN04090 standard; RNA; 17 BP.
XX
AC ACN04090;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV Zinzyme substrate SEQ ID NO 4093.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
FN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 4093; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 4 A; 4 C; 3 G; 0 T; 6 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 937 ATCCAGACAGGTTGTA 953
Db 17 ATCCAGACAGGTTGTA 1
RESULT 361
ACN03719
ID ACN03719 standard; RNA; 17 BP.
XX
AC ACN03719;
XX
DT 22-APR-2004 (first entry)

```

```

XX WNV Zinzyme substrate SEQ ID NO 3722.
DE
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
FN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 3722; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.8e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
Oy 503 TGGCAGCAGCATTGGGA 519
Db 1 UGGAAGCAGCAUUGGCA 17
RESULT 362
ACN15153
ID ACN15153 standard; RNA; 17 BP.
XX
AC ACN15153;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Amberzyme substrate SEQ ID NO 15156.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;

```

```

KW  Amberzyme; Zinzyne; ss.
XX  West Nile Virus.
OS  WO200268637-A2.
XX  06-SEP-2002.
XX  19-OCT-2001; 2001WO-US048350.
XX  20-OCT-2000; 2000US-0242411P.
XX  (RIBO-) RIBOZYME PHARM INC.
XX  (BLAT/) BLATT L.
XX  (MCSW/) MCSWIGGEN J A.
XX  Blatt L, Mcswiggen JA;
XX  WPI; 2002-706994/76.
XX  New nucleic acid molecule that modulates replication of West Nile Virus
XX  (WNV), useful for treating a condition related to WNV infection e.g.
XX  pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX  Claim 23; SEQ ID NO 15156; 495pp; English.
XX  The invention relates to nucleic acid molecules that modulate replication
XX  of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX  treating a condition related to WNV infection e.g. pancreatitis,
XX  encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX  liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX  molecule is selected from the group of ribozymes consisting of
XX  Hammerhead, Inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyne. The
XX  nucleic acid molecules further comprise at least five ribose residues, at
XX  least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX  least three of the 5' terminal nucleotides and a 3' end modification of a
XX  3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX  are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX  in the specification. The present sequence is that of a nucleic acid
XX  molecule of the invention
XX  Sequence 17 BP; 1 A; 7 C; 5 G; 0 T; 4 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.8e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY  324 CCCAGACTGAGTGGCTC 340
DB  1 CCCUGCCUGAGUGGCUC 17

RESULT 363
ACN00195/c
ID  ACN00195 standard; RNA; 17 BP.
AC  ACN00195;
XX  22-APR-2004 (first entry)
XX  WNV Hammerhead Ribozyme substrate SEQ ID NO 185.
XX  WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX  virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX  encephalitis; myocarditis; meningitis; infection; hepatitis;
XX  liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
XX  Amberzyme; zinzyne; ss.
XX  West Nile Virus.
XX  WO200268637-A2.
XX  06-SEP-2002.

Amberzyme; Zinzyne; ss.
West Nile Virus.
WO200268637-A2.
06-SEP-2002.
19-OCT-2001; 2001WO-US048350.
20-OCT-2000; 2000US-0242411P.
(RIBO-) RIBOZYME PHARM INC.
(BLAT/) BLATT L.
(MCSW/) MCSWIGGEN J A.
Blatt L, Mcswiggen JA;
WPI; 2002-706994/76.
New nucleic acid molecule that modulates replication of West Nile Virus
(WNV), useful for treating a condition related to WNV infection e.g.
pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
Claim 23; SEQ ID NO 15156; 495pp; English.
The invention relates to nucleic acid molecules that modulate replication
of the West Nile Virus (WNV). The nucleic acid molecules are useful for
treating a condition related to WNV infection e.g. pancreatitis,
encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
molecule is selected from the group of ribozymes consisting of
Hammerhead, Inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyne. The
nucleic acid molecules further comprise at least five ribose residues, at
least ten 2'-O-methyl modifications, phosphorothioate linkages on at
least three of the 5' terminal nucleotides and a 3' end modification of a
3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
in the specification. The present sequence is that of a nucleic acid
molecule of the invention
Sequence 17 BP; 1 A; 7 C; 5 G; 0 T; 4 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.8e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY  324 CCCAGACTGAGTGGCTC 340
DB  1 CCCUGCCUGAGUGGCUC 17

RESULT 363
ACN00195/c
ID  ACN00195 standard; RNA; 17 BP.
AC  ACN00195;
XX  22-APR-2004 (first entry)
XX  WNV Hammerhead Ribozyme substrate SEQ ID NO 185.
XX  WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX  virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX  encephalitis; myocarditis; meningitis; infection; hepatitis;
XX  liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNzyme;
XX  Amberzyme; zinzyne; ss.
XX  West Nile Virus.
XX  WO200268637-A2.
XX  06-SEP-2002.

Amberzyme; Zinzyne; ss.
West Nile Virus.
WO200268637-A2.
06-SEP-2002.
19-OCT-2001; 2001WO-US048350.
20-OCT-2000; 2000US-0242411P.
(RIBO-) RIBOZYME PHARM INC.
(BLAT/) BLATT L.
(MCSW/) MCSWIGGEN J A.
Blatt L, Mcswiggen JA;
WPI; 2002-706994/76.
New nucleic acid molecule that modulates replication of West Nile Virus
(WNV), useful for treating a condition related to WNV infection e.g.
pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
Claim 23; SEQ ID NO 185; 495pp; English.
The invention relates to nucleic acid molecules that modulate replication
of the West Nile Virus (WNV). The nucleic acid molecules are useful for
treating a condition related to WNV infection e.g. pancreatitis,
encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
molecule is selected from the group of ribozymes consisting of
Hammerhead, Inozyme, G-cleaver, DNzyme, Amberzyme and Zinzyne. The
nucleic acid molecules further comprise at least five ribose residues, at
least ten 2'-O-methyl modifications, phosphorothioate linkages on at
least three of the 5' terminal nucleotides and a 3' end modification of a
3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
in the specification. The present sequence is that of a nucleic acid
molecule of the invention
Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  324 CCCAGACTGAGTGGCTC 340
DB  17 CCCTGCTGAGTGGCTC 1

RESULT 364
ABT36759
ID  ABT36759 standard; DNA; 17 BP.
XX  ABT36759;
XX  12-JUN-2003 (first entry)
XX  Tumour suppression related human fukutin oligo SEQ ID No 2396.
XX  Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; gene chip;
XX  antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX  schizophrenia; protein chip; gene therapy; tumour suppression;
XX  human fukutin; ds.
XX  Homo sapiens.
XX  WO2003025175-A2.
XX  27-MAR-2003.
XX  17-SEP-2002; 2002WO-IB004208.
XX  17-SEP-2001; 2001FR-00011978.
XX  (MOLE-) MOLECULAR ENGINES LAB.
XX  Telerman A, Amson R, Tuijnder M;

```

XX WPI; 2003-313353/30.

XX New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX Disclosure; Page 313; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,

CC given in the specification, a sequence containing at least 15 consecutive

CC nucleotides from the 17 mer sequence, a sequence with, after optimal

CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that

CC hybridizes to them under highly stringent conditions, or the complement

CC of any of them, or the corresponding RNA. The novel isolated nucleic

CC acids of the invention are useful as probes and primers for detecting,

CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one

CC component of a gene chip, in vitro as (anti)sense reagents, and for

CC production of recombinant polypeptides. Any of the nucleic acids,

CC polypeptides, vectors containing the nucleic acids, cells containing the

CC vector or antibodies directed against the polypeptides are useful for

CC preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterized by development of tumours or cell

CC degeneration, specifically cancer but also Alzheimer's disease and

CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in

CC patient samples is useful for diagnosis and/or prognosis of these

CC diseases. The polypeptides can also be used to generate antibodies, and

CC both the polypeptide and antibodies are useful as components of protein

CC chips. The nucleic acid sequences of the invention can be used in gene

CC therapy. This polynucleotide sequence represents a tumour suppression

CC related human fukutin oligonucleotide of the invention

XX

XX Sequence 17 BP; 9 A; 1 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1827 GATCTCTGAAAAAATAA 1843

Db 1 GATCTGTGAAAAAATAA 17

|||||

RESULT 365

ADB04829

ID ADB04829 standard; DNA; 17 BP.

AC ADB04829;

XX 20-NOV-2003 (first entry)

XX Human MD212 scanning oligonucleotide SEQ ID 5815.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;

KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;

KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;

KW developmental disorder; ss.

XX Homo sapiens.

XX EPI281758-A2.

XX 05-FEB-2003.

XX 30-JUL-2002; 2002EP-00016874.

XX 02-AUG-2001; 2001US-00922181.

XX (AEOM-) AEOMICA INC.

XX Shannon M, Gu Y, Nguyen C;

XX WPI; 2003-423107/40.

XX New zinc finger-containing proteins and nucleic acids, useful in

PT manufacturing a medicament for treating or preventing a disorder

PT associated with decreased or increased expression or activity of MD23,

PT MD24, MD27 or MD212, e.g. cancer.

XX Example 8; SEQ ID NO 5815; 103pp; English.

XX The present invention relates to novel human zinc finger-containing

CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is

CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,

CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome

CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,

CC or in manufacturing a medicament for treating or preventing a disorder

CC associated with decreased or increased expression or activity of MD23

CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic

CC acids and proteins are also useful for diagnosing or monitoring a disease

CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic

CC acids can also be used as probes to detect and characterize gross

CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are

CC useful in constructing microarrays for measuring gene expression. The

CC proteins are useful as therapeutic agents for gene therapy or as

CC vaccines. The present sequence was used to illustrate the invention.

XX

XX Sequence 17 BP; 7 A; 3 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1102 CAGAGAACCAAGGTGGA 1118

Db 1 CAGCAGAACCAATGTGGA 17

|||||

RESULT 366

ABZ61368/C

ID ABZ61368 standard; RNA; 17 BP.

XX ABZ61368;

XX 21-MAR-2003 (first entry)

XX Human H-Ras DNase target #159.

XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;

KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;

KW anti-rheumatic; cancer; AIDS; ss.

XX Homo sapiens.

XX WO200297114-A2.

XX 05-DEC-2002.

XX 29-MAY-2002; 2002WO-US016840.

XX 29-MAY-2001; 2001US-0294140P.

PR 06-JUN-2001; 2001US-0296249P.

PR 10-SEP-2001; 2001US-0318471P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J;

XX WPI; 2003-140484/13.

XX Novel short interfering RNA and enzymatic nucleic acid useful for

PT treating cancer, modulates the expression of a nucleic acid encoding

PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.

XX Claim 58; Page 114; 185pp; English.

CC The invention relates to a novel short interfering RNA (siRNA) nucleic acid molecule or an enzymatic nucleic acid molecule, that modulates expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras, human immunodeficiency virus (HIV) or a component of HIV. The nucleic acid molecule of the invention has cytostatic, anti-HIV, and anti-rheumatic activity. The nucleic acid molecules are useful for reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are also useful for treating breast, ovarian, colorectal, lung, prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target sequences for the human CC ribozymes of the invention

XX
SQ Sequence 17 BP; 0 A; 6 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 98.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 CGCCTCGTCCGCCGCG 46
Db 17 CGCGCGCGCGCGCGCG 1

RESULT 367
ACD63057
ID ACD63057 standard; RNA; 17 BP.

XX AC ACD63057;

XX 24-SEP-2003 (first entry)

DE HCV minus strand DNzyme substrate sequence #864.

XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.

XX Hepatitis C virus.

XX WO200281494-A1.

XX 17-OCT-2002.

XX 26-MAR-2002; 2002WO-US009187.

XX 26-MAR-2001; 2001US-00817879.

XX 08-JUN-2001; 2001US-00877478.

XX 08-JUN-2001; 2001US-0296876P.

XX 24-OCT-2001; 2001US-0335059P.

XX 05-DEC-2001; 2001US-0337055P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MACE/) MACEJAK D.

PA (MCSW/) MCSWIGGEN J.

PA (MORR/) MORRISSEY D.

PA (PAVC/) PAVCO P.

PA (LEEP/) LEE P.

PA (DRAP/) DRAPER K.

PA (ROBE/) ROBERTS E.

PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;

PI Draper K, Roberts E;

XX WPI; 2003-229207/22.

XX Novel compound useful for treating cirrhosis, liver failure,

PT hepatocellular carcinoma, or condition associated with hepatitis C virus infection.

XX Claim 1; Page 290; 387pp; English.

XX The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of Hepatitis C virus (HCV) or Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes, inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed are nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences, as well as oligonucleotides that specifically bind the Enhancer I region of HBV DNA. The nucleic acids may be used to modulate the expression of HBV genes and HBV viral replication. Also disclosed is a method for screenings compounds and/or potential therapies directed against HBV, and compounds that modulate the expression and/or replication of HCV. The compounds and methods of the invention are useful for the treatment of degenerative and disease states related to HBV and HCV infection, replication and gene expression such as cirrhosis, liver failure, and hepatocellular carcinoma. The present sequence represents a substrate for one of the HCV DNzyme or minus strand DNzyme sequences disclosed in the present invention

XX Sequence 17 BP; 2 A; 2 C; 9 G; 0 T; 4 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 64.7%; Pred. No. 1.8e+02;

Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1171 GTCCTGGTGGAGTCT 1187

Db 1 GGCUGGUGAUGAGGCGU 17

RESULT 368

ACD59841

ID ACD59841 standard; RNA; 17 BP.

XX AC ACD59841;

XX 24-SEP-2003 (first entry)

DE HCV DNzyme substrate sequence #1531.

XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.

OS Hepatitis C virus.

XX WO200281494-A1.

XX 17-OCT-2002.

XX 26-MAR-2002; 2002WO-US009187.

XX 26-MAR-2001; 2001US-00817879.

XX 08-JUN-2001; 2001US-00877478.

XX 08-JUN-2001; 2001US-0296876P.

XX 24-OCT-2001; 2001US-0335059P.

XX 05-DEC-2001; 2001US-0337055P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MACE/) MACEJAK D.

PA (MCSW/) MCSWIGGEN J.

PA (MORR/) MORRISSEY D.

CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip; in vitro as (antisense reagents; and (2) for production of
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia
 XX
 SQ Sequence 17 BP; 8 A; 1 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1040 CTCACCTATTAAAGATC 1056
 ||| ||||| ||||| |||||
 Db 17 CTCCTTTTATTAAAGATC 1

RESULT 371
 ADC04228/c
 ID ADC04228 standard; DNA; 17 BP.
 XX AC ADC04228;
 XX AC
 DT 18-DEC-2003 (first entry)
 DE Human Na/H exchanger-like protein 1 gene oligonucleotide #675.
 XX ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
 KW NHELP1; passive replacement therapy; vaccine; diagnosis.
 XX Homo sapiens.
 XX EP1273660-A2.
 XX 08-JAN-2003.
 XX 25-JAN-2002; 2002EP-00001160.
 XX 30-JAN-2001; 2001WO-US000666.
 PR 23-MAY-2001; 2001US-00864761.
 PR 21-DEC-2001; 2001US-0343331P.
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y;
 XX WPI; 2003-302724/30.
 XX New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
 PT passive replacement therapy or as a vaccine for treating or preventing
 PT disorders associated with aberrant expression or activity of human
 PT NHELP1.
 XX Example 2; SEQ ID NO 715; 468pp; English.

XX The invention relates to a nucleic acid molecule which encodes a Na+/H+
 CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
 CC polypeptide, an antibody against the protein or its antigen-binding
 CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
 CC polypeptide and an agonist are particularly useful for manufacturing a
 CC medicament for treating or preventing a disorder associated with
 CC decreased expression or activity of human NHELP1. The antibody or its
 CC antigen-binding fragment, and an antagonist, are useful for manufacturing
 CC a medicament for treating or preventing a disorder associated with
 CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid
 CC or protein is useful as passive replacement therapy, as a vaccine, or in
 CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
 CC spanning the sequence of the human NHELP1 gene (ADC03514).
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 911 TGTAGCAGAGATCACTG 927
 ||||| ||||| ||||| |||||
 Db 17 TGTAGCAGAGATCACTG 1

RESULT 372
 ADC04229/c
 ID ADC04229 standard; DNA; 17 BP.
 XX AC ADC04229;
 XX AC
 DT 18-DEC-2003 (first entry)
 DE Human Na/H exchanger-like protein 1 gene oligonucleotide #676.
 XX ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
 KW NHELP1; passive replacement therapy; vaccine; diagnosis.
 XX Homo sapiens.
 XX EP1273660-A2.
 XX 08-JAN-2003.
 XX 25-JAN-2002; 2002EP-00001160.
 XX 30-JAN-2001; 2001WO-US000666.
 PR 23-MAY-2001; 2001US-00864761.
 PR 21-DEC-2001; 2001US-0343331P.
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y;
 XX WPI; 2003-302724/30.
 XX New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
 PT passive replacement therapy or as a vaccine for treating or preventing
 PT disorders associated with aberrant expression or activity of human
 PT NHELP1.
 XX Example 2; SEQ ID NO 716; 468pp; English.

XX The invention relates to a nucleic acid molecule which encodes a Na+/H+
 CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
 CC polypeptide, an antibody against the protein or its antigen-binding
 CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
 CC polypeptide and an agonist are particularly useful for manufacturing a
 CC medicament for treating or preventing a disorder associated with
 CC decreased expression or activity of human NHELP1. The antibody or its
 CC antigen-binding fragment, and an antagonist, are useful for manufacturing
 CC a medicament for treating or preventing a disorder associated with
 CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid
 CC or protein is useful as passive replacement therapy, as a vaccine, or in
 CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
 CC spanning the sequence of the human NHELP1 gene (ADC03514).
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 910 CTGTAGCAGAGATCACT 926
 ||||| ||||| ||||| |||||
 Db 17 CTGTAGCAGAGATCACT 1

RESULT 373
 ADF64149/c

```

ID ADF64149 standard; DNA; 17 BP.
XX AC
XX ADF64149;
XX DT
XX 12-FEB-2004 (first entry)
XX DE
XX Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2053.
XX KW
XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
XX KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
XX KW human; ss; probe.
XX OS
XX Homo sapiens.
XX PN
XX WO2003050284-A1.
XX PD
XX 19-JUN-2003.
XX PF
XX 22-NOV-2002; 2002WO-US037506.
XX PR
XX 10-DEC-2001; 2001US-0339764P.
XX PA
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX PI
XX Guo J;
XX DR
XX WPI; 2003-532916/50.
XX KW
XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
XX PT composition for treating or preventing a disorder associated with
XX PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX XX
XX Example 2; SEQ ID NO 2053; 164pp; English.
XX CC
XX The invention relates to a novel isolated nucleic acid that encodes a
XX CC protein with a chromatin organisation modifier (CHROMO) domain. The
XX CC polynucleotide of the invention demonstrates cytostatic activity and may
XX CC be useful for preparing a composition for treating or preventing a
XX CC disorder associated with decreased or increased expression or activity of
XX CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
XX CC during gene therapy and vaccine production procedures. The current
XX CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
XX CC directed probe of the invention. Note: The current sequence is not shown
XX CC within the specification per se but was retrieved from the Wipoweb
XX CC database.
XX SQ
XX Sequence 17 BP; 6 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 511 GCATTGGGACTCTCCCA 527
Db ||||| ||||| ||||| ||||| |||||
17 GCATTGGGACTCTCTTA 1

RESULT 374
ADG38381/C
ID ADG38381 standard; DNA; 17 BP.
XX AC
XX ADG38381;
XX DT
XX 26-FEB-2004 (first entry)
XX DE
XX Anti-HIV L-DNA #48.
XX KW
XX L-DNA; ss; anti-HIV; antiviral; AIDS; acquired immunodeficiency syndrome;
XX KW guanine tetrad; viral disease.
XX OS
XX Synthetic.
XX PN
XX JP2003204793-A.

XX 22-JUL-2003.
XX PF
XX 15-JAN-2002; 2002JP-00006108.
XX PR
XX 15-JAN-2002; 2002JP-00006108.
XX PA
XX (TAKE ) TAKEDA CHEM IND LTD.
XX DR
XX WPI; 2003-807784/76.
XX PT
XX Novel L-DNA or its salt forming guanine tetrad(s), useful as prophylactic
XX PT or therapeutic agent for viral disease e.g., human immunodeficiency
XX PT virus.
XX PS
XX Disclosure; SEQ ID NO 48; 22pp; Japanese.
XX CC
XX The invention relates to L-DNA or its salt forming guanine tetrad(s). L-
XX CC DNA means DNA whose sugar moiety in L-deoxyribose rather than the normal
XX CC D-deoxyribose. Also included are an antiviral agent containing L-DNA, and
XX CC a prophylactic or therapeutic agent for the viral disease, containing L-
XX CC DNA. The L-DNA is useful as a prophylactic or therapeutic agent of viral
XX CC disease (e.g. AIDS, acquired immunodeficiency syndrome) caused by e.g.,
XX CC human immunodeficiency virus. L-DNA has an excellent antiviral activity,
XX CC is less toxic and chemically stable. The present sequence is an L-DNA
XX CC oligonucleotide of the invention.
XX SQ
XX Sequence 17 BP; 0 A; 0 C; 13 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1705 CCCCTCCCTCCACCAC 1721
Db ||||| ||||| ||||| ||||| |||||
17 CCCACCACCCACCAC 1

RESULT 375
AD148002
ID AD148002 standard; DNA; 17 BP.
XX AC
XX AD148002;
XX DT
XX 15-APR-2004 (first entry)
XX DE
XX Human tumour suppression/reversion-related DNA sequence SeqID505.
XX KW
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW cytostatic; viricide; neuroprotective; neurotropic; neuroleptic; probe;
XX KW primer; PCR; gene chip; antisense; viral disease; tumour;
XX KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX OS
XX Homo sapiens.
XX PN
XX WO2003025177-A2.
XX PD
XX 27-MAR-2003.
XX PF
XX 17-SEP-2002; 2002WO-IB004523.
XX PR
XX 17-SEP-2001; 2001FR-00011980.
XX PA
XX (MOLE-) MOLECULAR ENGINES LAB.
XX PI
XX Telerman A, Amson R, Tuijnder M;
XX DR
XX WPI; 2003-313354/30.
XX KW
XX New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX XX
```

PS Disclosure; SEQ ID NO 505; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved

CC in the phenomena of tumour suppression, tumour reversion, apoptosis

CC and/or resistance to viruses. The invention may be useful for the

CC development of compounds with a cytostatic, virucide, neuroprotective,

CC neurotropic or neuroleptic activity. The DNA sequences may be useful as

CC probes and primers for detecting, identifying, quantifying and/or

CC amplifying nucleic acid, for example as one component of a gene chip, in

CC vitro as antisense reagents and for production of recombinant

CC polypeptides. The invention may therefore be useful for preparation of

CC pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration. The

CC specifically cancer but also Alzheimer's disease and schizophrenia. The

CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/publishedpct_sequences

XX

SQ Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 231 GATGTTGCTAAGCAAT 247

DB 1 GATCTTGCTACAGCAAT 17

|||||

RESULT 376

AD149572/c

ID AD149572 standard; DNA; 17 BP.

XX

AC AD149572;

DT 15-APR-2004 (first entry)

XX

DE Human tumour suppression/reversion-related DNA sequence SeqID2075.

XX

KW tumour suppression; tumour reversion; apoptosis; virus resistance;

KW cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;

KW primer; PCR; gene chip; antisense; viral disease; tumour;

KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX

OS Homo sapiens.

XX

PN WO2003025177-A2.

XX

PD 27-MAR-2003.

XX

PF 17-SEP-2002; 2002WO-IB004523.

XX

PR 17-SEP-2001; 2001FR-00011980.

XX

PA (MOLE-) MOLECULAR ENGINES LAB.

XX

PI Telerman A, Amson R, Tuijnder M;

XX

WPI; 2003-313354/30.

XX

PT New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX

PS Disclosure; SEQ ID NO 2075; 30pp; French.

XX

CC This invention relates to novel isolated nucleic acid sequences involved

CC in the phenomena of tumour suppression, tumour reversion, apoptosis

CC and/or resistance to viruses. The invention may be useful for the

CC development of compounds with a cytostatic, virucide, neuroprotective,

CC neurotropic or neuroleptic activity. The DNA sequences may be useful as

CC probes and primers for detecting, identifying, quantifying and/or

CC amplifying nucleic acid, for example as one component of a gene chip, in

CC vitro as antisense reagents and for production of recombinant

CC polypeptides. The invention may therefore be useful for preparation of

CC pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration. The

CC specifically cancer but also Alzheimer's disease and schizophrenia. The

CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/publishedpct_sequences

XX

SQ Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 231 GATGTTGCTAAGCAAT 247

DB 1 GATCTTGCTACAGCAAT 17

|||||

RESULT 377

AD149244

ID AD149244 standard; DNA; 17 BP.

XX

AC AD149244;

DT 15-APR-2004 (first entry)

XX

DE Human tumour suppression/reversion-related DNA sequence SeqID1747.

XX

KW tumour suppression; tumour reversion; apoptosis; virus resistance;

KW cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;

KW primer; PCR; gene chip; antisense; viral disease; tumour;

KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX

OS Homo sapiens.

XX

PN WO2003025177-A2.

XX

PD 27-MAR-2003.

XX

PF 17-SEP-2002; 2002WO-IB004523.

XX

PR 17-SEP-2001; 2001FR-00011980.

XX

PA (MOLE-) MOLECULAR ENGINES LAB.

XX

PI Telerman A, Amson R, Tuijnder M;

XX

WPI; 2003-313354/30.

XX

PT New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX

PS Disclosure; SEQ ID NO 1747; 30pp; French.

XX

CC This invention relates to novel isolated nucleic acid sequences involved

CC in the phenomena of tumour suppression, tumour reversion, apoptosis

CC and/or resistance to viruses. The invention may be useful for the

CC development of compounds with a cytostatic, virucide, neuroprotective,

CC neurotropic or neuroleptic activity. The DNA sequences may be useful as

CC probes and primers for detecting, identifying, quantifying and/or

CC amplifying nucleic acid, for example as one component of a gene chip, in

CC vitro as antisense reagents and for production of recombinant

CC polypeptides. The invention may therefore be useful for preparation of

CC pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration. The

CC specifically cancer but also Alzheimer's disease and schizophrenia. The

CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/publishedpct_sequences

XX

SQ Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 129 GGTGTTCACTTTTATC 145

DB 17 GGTGTTCACTTTTGATC 1

|||||

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences

SQ Sequence 17 BP; 9 A; 2 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1827 GATCTCTGAAAAA 1843

DB 1 GATCTCTTAAATAAAA 17

RESULT 378

ADIS0952

ID ADIS0952 standard; DNA; 17 BP.

XX

AC ADIS0952;

XX

DT 15-APR-2004 (first entry)

XX

DE Human tumour suppression/reversion-related DNA sequence SeqID3455.

XX

KW tumour suppression; tumour reversion; apoptosis; virus resistance;

KW cytosstatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;

KW primer; PCR; gene chip; antisense; viral disease; tumour;

KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX

OS Homo sapiens.

XX

PN WO2003025177-A2.

XX

PD 27-MAR-2003.

XX

PF 17-SEP-2002; 2002WO-IB004523.

XX

PR 17-SEP-2001; 2001FR-00011980.

XX

PA (MOLE-) MOLECULAR ENGINES LAB.

XX

PI Telerman A, Amson R, Tuijnder M;

XX

DR WPI; 2003-313354/30.

XX

PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.

XX

PS Disclosure; SEQ ID NO 3455; 30pp; French.

XX

CC This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC neurotropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, identifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of
CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences

XX

SQ Sequence 17 BP; 5 A; 3 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 GATCAAAATGTCATTC 861

DB 1 GATCAAAATGTCCTGC 17

RESULT 379

ABZ97381/C

ID ABZ97381 standard; DNA; 17 BP.

XX

AC ABZ97381;

XX

DT 17-OCT-2003 (first entry)

XX

DE Human IL4-R oligonucleotide sequence.

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX

OS Homo sapiens.

XX

PN WO200285308-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013135.

XX

PR 24-APR-2001; 2001US-0286137P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasegna A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX

DR WPI; 2003-229219/22.

XX

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX

PS Disclosure; SEQ ID NO 12623; 872pp; English.

XX

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1342 CTGGAGTGCCTGGAGCC 1358
 |||||
 DB 17 CTGGAGTGCCTGGAGCC 1

RESULT 380

ADL49803
 ID ADL49803 standard; RNA; 17 BP.

XX AC ADL49803;

XX DT 20-MAY-2004 (first entry)

XX DE Human PKR substrate sequence #917.

XX antisenase oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;

KW substrate; ds.

XX Unidentified.

OS Unidentified.

XX WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 3336; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human PKR

CC substrate sequence.

XX Sequence 17 BP; 8 A; 3 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 70.6%; Pred. No. 1.8e+02;

Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1823 GGAAGATCTCTGAAAA 1839
 |||||
 DB 1 GUAACAUCUCUGAAAAA 17

RESULT 381

ADL46473/C
 ID ADL46473 standard; RNA; 17 BP.

XX AC ADL46473;

XX DT 20-MAY-2004 (first entry)

XX DE Human NOGO receptor hammerhead ribozyme substrate sequence #6.

XX antisenase oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis;

KW NOGO receptor hammerhead ribozyme; substrate; ds.

XX Unidentified.

OS Unidentified.

XX WO200281628-A2.

PN 17-OCT-2002.

XX 03-APR-2002; 2002WO-US010512.

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 9; SEQ ID NO 6; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)

CC that down regulate the expression or inhibit the function of a receptor

CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),

CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the

CC invention are useful for treating: cerebrovascular accident, central

CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,

CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,

CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune

CC disease, lupus, multiple sclerosis, transplant/graft rejection,

CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic

CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The

CC nucleic acids of the invention are also useful for down-regulating the

CC expression of a target gene and as a diagnostic tool to examine genetic

CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human NOGO

CC receptor hammerhead ribozyme substrate sequence.

XX Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 382 TGCAGCAAGATGGGCTG 398
|||:||||:|||||
Db 17 TGCAGGAAGATGCGCTG 1

RESULT 382
ADL47007
ID ADL47007 standard; RNA; 17 BP.
XX
AC ADL47007;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human NOGO receptor inozyme substrate sequence #440.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor inozyme; substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 9; SEQ ID NO 540; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor inozyme substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 3 C; 8 G; 0 T; 4 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1085 GCTGTCCTCTGGACTG 1101
|||:||||:|||||
Db 1 GCUGGUGCUGGACAG 17

RESULT 383
ADL49254
ID ADL49254 standard; RNA; 17 BP.
XX
AC ADL49254;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #368.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2787; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 7 A; 3 C; 2 G; 0 T; 5 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```

```
QY 1822 TGAAGATCTCTGAAA 1938
Db 1 UGUACAUCUCUGAAA 17

RESULT 384
ABD30412/C
ID ABD30412 standard; DNA; 17 BP.
XX AC ABD30412;
DT 29-JUL-2004 (first entry)
XX DE Human IL4-R derived oligonucleotide SEQ ID 12623.
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX OS Homo sapiens.
XX PN WO200285309-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013143.
XX PR 24-APR-2001; 2001US-0286036P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
DR WPI; 2003-093058/08.
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX Claim 15; SEQ ID NO 12623; 763pp; English.
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
```

```
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1342 CTGGAGTGCCTGGAGCC 1358
Db 17 CTGGAGTGCCTGGAGCC 1

RESULT 385
ADJ59200/C
ID ADJ59200 standard; DNA; 17 BP.
XX AC ADJ59200;
XX DT 06-MAY-2004 (first entry)
XX DE Oligonucleotide associated to IL 4R #55.
XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX OS Homo sapiens.
XX PN WO2004011613-A2.
XX PD 05-FEB-2004.
XX PF 25-JUL-2003; 2003WO-US023509.
XX PR 29-JUL-2002; 2002US-0399076P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
DR WPI; 2004-203534/19.
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX Claim 2; SEQ ID NO 56; 85pp; English.
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
```

```

CC invention.
XX SQ Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;
    Query Match      0.7%; Score 13.8; DB 1; Length 17;
    Best Local Similarity 88.2%; Pred. No. 1.8e+02;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1342 CTGGAGTCCTGGAGCC 1358
Db 17 CTGGAGTCAGTGGAGCC 1

RESULT 386
ADI84285
ID ADI84285 standard; RNA; 17 BP.
XX AC ADI84285;
XX DT 03-JUN-2004 (first entry)
XX DE HCV DNazyme substrate sequence #1531.
XX KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
XX KW HCV infection; type I interferon; DNazyme.
XX OS Hepatitis C virus.
XX PN US2003125270-A1.
XX PD 03-JUL-2003.
XX PF 18-DEC-2000; 2000US-00740332.
XX PR 18-DEC-2000; 2000US-00740332.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (ROBE/) ROBERTS E.
XX PA (PAVC/) PAVCO P A.
XX PA (MACE/) MACEJACK D.
XX PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX DR WPI; 2004-031273/03.
XX PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX PS especially in combination with type I interferon therapy.
XX SQ Claim 1; SEQ ID NO 1531; 198pp; English.
XX CC The invention relates to an enzymatic nucleic acid molecule which
XX CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX CC the binding arms of the enzymatic nucleic acid molecule comprises
XX CC sequences complementary to any of the defined substrate sequences given
XX CC in the specification. The nucleic acid molecule may be administered for
XX CC the treatment of HCV infections, especially in combination with type I
XX CC interferons. The present sequence represents a HCV DNazyme substrate
XX CC sequence.
XX SQ Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;
    Query Match      0.7%; Score 13.8; DB 1; Length 17;
    Best Local Similarity 64.7%; Pred. No. 1.8e+02;
    Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1287 ATCACTCAGGTCCTGAG 1303
Db 1 AUCACUCAGCUGCUGAG 17

RESULT 387
ADI84285
ID ADI84285 standard; RNA; 17 BP.
XX AC ADI84285;
XX DT 03-JUN-2004 (first entry)
XX DE HCV DNazyme substrate sequence #1531.
XX KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
XX KW HCV infection; type I interferon; DNazyme.
XX OS Hepatitis C virus.
XX PN US2003125270-A1.
XX PD 03-JUL-2003.
XX PF 18-DEC-2000; 2000US-00740332.
XX PR 18-DEC-2000; 2000US-00740332.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (ROBE/) ROBERTS E.
XX PA (PAVC/) PAVCO P A.
XX PA (MACE/) MACEJACK D.
XX PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX DR WPI; 2004-031273/03.
XX PT Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX PS especially in combination with type I interferon therapy.
XX SQ Claim 1; SEQ ID NO 1531; 198pp; English.
XX CC The invention relates to an enzymatic nucleic acid molecule which
XX CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX CC the binding arms of the enzymatic nucleic acid molecule comprises
XX CC sequences complementary to any of the defined substrate sequences given
XX CC in the specification. The nucleic acid molecule may be administered for
XX CC the treatment of HCV infections, especially in combination with type I
XX CC interferons. The present sequence represents a HCV DNazyme substrate
XX CC sequence.
XX SQ Sequence 17 BP; 4 A; 5 C; 4 G; 0 T; 4 U; 0 Other;
    Query Match      0.7%; Score 13.8; DB 1; Length 17;
    Best Local Similarity 64.7%; Pred. No. 1.8e+02;
    Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1287 ATCACTCAGGTCCTGAG 1303
Db 1 AUCACUCAGCUGCUGAG 17

RESULT 388
ADO44690/c
ID ADO44690 standard; DNA; 17 BP.
XX AC ADO44690;
XX DT 15-JUL-2004 (first entry)
XX DE Human oligonucleotide #56.
XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
XX KW CCR1; CCR3; Botaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
XX KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
XX KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
XX KW asthma; lung allergy; inflammation; inflammatory disease;

```

KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 56; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1342 CTGGAGTGCTGGAGCC 1358

|||||

17 CTGGAGTGAGTGGAGCC 1

RESULT 389
 ACN64635
 ID ACN64635 standard; DNA; 17 BP.
 XX
 AC ACN64635;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:1537.

XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

PN 15-JUL-2004.

PD 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

PR 21-SEP-2000; 2000US-0234687P.

PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000SB-00024263.

PR 30-JAN-2001; 2001WO-US000661.

PR 30-JAN-2001; 2001WO-US000662.

PR 30-JAN-2001; 2001WO-US000663.

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 05-FEB-2001; 2001WO-US000670.

PR 25-MAY-2001; 2001US-0266860P.

PR 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.

PA (JIYY/) JI Y.

PA (PENNY/) PENN S G.

PA (HANS/) HANZEL D K.

PA (RANK/) RANK D.

PA (CHEN/) CHEN W.

PA (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder
 associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.

XX Disclosure; SEQ ID NO 1537; Opp; English.

XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1); 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102

XX Sequence 17 BP; 1 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;


```

PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 8360; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 6 A; 1 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 390 GATGGCTGGAGAAAGT 406
Db 1 GAGGAGCTGGAGAAAGT 17
RESULT 394
AAQ20007/c
ID AAQ20007 standard; DNA; 18 BP.
XX
XX AAQ20007;
XX
XX 01-APR-1992 (first entry)
XX
XX Oligonucleotide #3 able to covalently cross-link to target DNA.
XX
XX deoxyribonucleic acid; major groove; ethanamine group;
XX aziridinylcytosine; cross-linking group; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1
FT /*tag= a
FT /mod_base= OTHER
FT /note= "N4N4-ethanocytosine"
FT modified_base 9
FT /*tag= b
FT /mod_base= m5c
FT modified_base 15
FT /*tag= c
FT /mod_base= m5c
FT modified_base 18
FT /*tag= da
FT /mod_base= OTHER
FT /note= "N4N4-ethanocytosine"
XX
XX W09118997-A.
XX
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 8360; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 6 A; 1 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 390 GATGGCTGGAGAAAGT 406
Db 1 GAGGAGCTGGAGAAAGT 17
RESULT 394
AAQ20007/c
ID AAQ20007 standard; DNA; 18 BP.
XX
XX AAQ20007;
XX
XX 01-APR-1992 (first entry)
XX
XX Oligonucleotide #3 able to covalently cross-link to target DNA.
XX
XX deoxyribonucleic acid; major groove; ethanamine group;
XX aziridinylcytosine; cross-linking group; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1
FT /*tag= a
FT /mod_base= OTHER
FT /note= "N4N4-ethanocytosine"
FT modified_base 9
FT /*tag= b
FT /mod_base= m5c
FT modified_base 15
FT /*tag= c
FT /mod_base= m5c
FT modified_base 18
FT /*tag= da
FT /mod_base= OTHER
FT /note= "N4N4-ethanocytosine"
XX
XX W09118997-A.
XX
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 8360; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 6 A; 1 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1834 GAAAAAAGAAAAA 1850
Db 18 GAGAAAAAGAAAAA 2
RESULT 395
AAQ24901
ID AAQ24901 standard; DNA; 18 BP.
XX
XX AAQ24901;
XX
XX 25-MAR-2003 (revised)
XX 19-NOV-1992 (first entry)
XX
XX Human leukocyte antigen probe.
XX
XX HLA; polymerase chain reaction; inflammatory arthropathy; susceptibility;
XX arthritis; arthritis related diseases; ss.
XX
XX Synthetic.
XX
XX WO9207956-A1.
XX
XX 14-MAY-1992.
XX
XX 05-NOV-1991; 91WO-GB001935.
XX
XX 05-NOV-1990; 90GB-00024005.
XX
XX (BRBI-) BRITISH BIO-TECHNOLOGY LTD.
XX
XX Hill AV;
XX
XX WPI; 1992-183691/22.
XX
XX PCR amplification of nucleic acids using buffer soln. and chelating agent
XX - for detecting HLA class I alleles for determining susceptibility to

```

```
PT arthritis etc.
XX
PS Disclosure; Page 14; 52pp; English.
XX
CC The sequence is that of a probe which hybridises to one of the human
CC leukocyte antigen (HLA) sequences in the primer extension products (or
CC strands) produced during PCR amplification of the HLA class I alleles. It
CC is specific for the sequence encoding amino acids 56-61 of the alpha 1
CC domain of HLA-B. It can be used in the detection and/or identification of
CC an HLA sequence that may be indicative of a patients susceptibility to
CC inflammatory arthropathy such as arthritis and arthritis related
CC diseases. Such diseases include reactive arthritis, rheumatoid arthritis,
CC Reiter's syndrome, uveitis, viral arthritis, psoriatic arthropathy, gouty
CC arthritis, septic arthritis, erythema nodosum, Henoch-Schloelein purpura
CC and esp. ankylosing spondylitis. See also AAQ24895-Q24902. (Updated on 25
CC -MAR-2003 to correct PN field.)
XX
SQ Sequence 18 BP; 3 A; 4 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 504 GGCAGCAGCATTTGGGAC 520
Db 2 GGCAGCAGCATTTGGGAC 18
RESULT 396
AAQ42926
ID AAQ42926 standard; DNA; 18 BP.
XX
AC AAQ42926;
XX
DT 25-MAR-2003 (revised)
DT 11-OCT-1993 (first entry)
XX
DE Primer CDRBACK.
XX
KW Polymerase chain reaction; PCR; amplify; primer; D-segment; variable;
KW heavy; domain; VH; region; J-segment; human; germline; back primers;
KW cloning; vector; PHEN1-V3; Vlamda3; light; chain; scFv; BSA; CDR3;
KW thyroglobulin; ss.
XX
OS Synthetic.
XX
PN WO9311236-A1.
XX
PD 10-JUN-1993.
XX
PF 02-DEC-1992; 92WO-GB002240.
XX
PR 02-DEC-1991; 91GB-00025579.
PR 02-DEC-1991; 91GB-00025582.
PR 24-MAR-1992; 92GB-00006318.
PR 24-MAR-1992; 92GB-00006372.
PR 23-SEP-1992; 92WO-GB001755.
XX
(MEDI-) MEDICAL RES COUNCIL.
PA (CAMB-) CAMBRIDGE ANTIBODY TECHNOLOGY.
XX
Griffiths AD, Hoogenboom HRJM, Marks JD, McCafferty J, Winter GP;
PI Gri99 GW;
XX
WPI; 1993-197055/24.
XX
Prodn. of anti-self antibodies - using replicating genetic display
PT packages, i.e. AB repertoires displayed on phage.
XX
Disclosure; Page 80; 95pp; English.
XX
The sequences given in AAQ42925-26 are primers which were used in to
CC analyse the CDR3 length of thyroglobulin binding clones (see also
```

```
CC AAQ42923-24). In thyroglobulin binding clones a CDR3 length of 10
CC residues was found. (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ Sequence 18 BP; 5 A; 2 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 795 TGTATTACGTTGGAGA 811
Db 2 TGTATTACTGTGCAAGA 18
RESULT 397
AAQ70349/c
ID AAQ70349 standard; DNA; 18 BP.
XX
AC AAQ70349;
XX
DT 25-MAR-2003 (revised)
DT 15-FEB-1995 (first entry)
XX
DE Antisense oligonucleotide for mouse FGF.
XX
KW Fibroblast growth factor; hybridisation; laser procedures;
KW vascular smooth muscle cell; proliferation; SMC; vascular stenosis;
KW post angioplasty restenosis; atherosclerosis; cardiac hypertrophy;
KW organ transplant; ss.
XX
OS Synthetic.
XX
PN WO9415945-A1.
XX
PD 21-JUL-1994.
XX
PF 28-DEC-1993; 93WO-US012600.
XX
PR 31-DEC-1992; 92US-00999706.
XX
(TEXA-) TEXAS BIOTECHNOLOGY CORP.
XX
Denner LA, Rege AA, Dixon RA;
PI
XX
WPI; 1994-249123/30.
XX
New anti-sense polynucleotide(s) to fibroblast growth factor receptor -
PT used for inhibiting vascular smooth muscle cell proliferation, partic.
PT for treating restenosis.
XX
Claim 3; Page 9; 53pp; English.
XX
The sequence is an antisense molecule directed against position -6 to
CC +12, relative to the start codon of the gene for mouse fibroblast growth
CC factor 1. The polynucleotide can be used for inhibiting vascular smooth
CC muscle cell proliferation and for treating a disease e.g. vascular
CC stenosis, post angioplasty restenosis, atherectomy, atherosclerosis,
CC atrial venous shunt failure, cardiac hypertrophy, vascular surgery and
CC organ transplant. See also AAQ70333-60. (Updated on 25-MAR-2003 to
CC correct PN field.)
XX
SQ Sequence 18 BP; 4 A; 10 C; 2 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 977 CTGGGATGTTGGGCGG 993
Db 17 CTGGGATGTTGGGCTGG 1
RESULT 398
```

```

AA15196/c
ID  AA15196 standard; DNA; 18 BP.
XX
AC  AA15196;
XX
DT  25-MAR-2003 (revised)
DT  28-APR-1999 (first entry)
XX
DE  XX
XX  Triple helix forming oligonucleotide.
XX
XX  Double-stranded DNA; triple helix; quinoline;
KW  quinazoline-based structure; hydrogen bonding; ss.
XX
OS  Synthetic.
XX
PN  WO9623777-A1.
XX
XX  08-AUG-1996.
XX
PF  29-JAN-1996; 96WO-US001473.
XX
PR  01-FEB-1995; 95US-00384324.
XX
XX  (UYNE-) UNIV NEBRASKA.
XX
PI  Gold BI;
XX
XX  WPI; 1996-371338/37.
XX
XX  New subst. quinoline and quinazoline cpds. - are monomers for triple
PT  helix-forming oligonucleotide analogues useful e.g. for treating tumours
PT  or viral infection.
XX
XX  Disclosure; Fig 1; 102pp; English.
XX
XX  The present sequence represents a triple helix forming oligonucleotide
CC  that form a triple helix with the double-stranded DNA sequence described
CC  in AA15195. The specification describes novel monomeric compositions
CC  which are substituted quinoline or quinazoline-based structures capable
CC  of hydrogen bonding specifically with interstrand purine-pyrimidine pairs
CC  in a double stranded Watson-Crick DNA molecule to form a triple-helix.
CC  (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ  Sequence 18 BP; 0 A; 3 C; 0 G; 15 T; 0 U; 0 Other;
    Query Match 0.7%; Score 13.8; DB 1; Length 18;
    Best Local Similarity 88.2%; Pred. No. 1.9e+02;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  1834 GAAAAAAAAAAAAA 1850
DB  ||||| ||||| |||||
    17 GAAAAAGAAAAAGAAAA 1

RESULT 399
AA177597
ID  AA177597 standard; DNA; 18 BP.
XX
AC  AA177597;
XX
DT  11-SEP-1997 (first entry)
XX
XX  Wheat microsatellite WMS155 left primer.
XX
XX  Microsatellite marker; hypervariable genomic fragment; Triticum aestivum;
KW  wheat; Triticaceae; sequence tagged site; STS; primer; PCR; amplify;
KW  polymorphism; genetic analysis; hexaploid; tetraploid; mapping; ss.
XX
OS  Synthetic.
XX
PN  DE19525284-A1.
XX
PD  02-JAN-1997.

XX  28-JUN-1995; 95DE-01025284.
XX
XX  28-JUN-1995; 95DE-01025284.
XX
PA  (PFLA-) INST PFLANZENGENETIK & KULTURPFLANZENFOR.
XX
PI  Roeder M, Plaschke J, Ganai M;
XX
XX  WPI; 1997-053731/06.
XX
XX  Primers for STS microsatellite markers for wheat and related species -
PT  useful for genetic mapping, analysis and labelling etc. of wheat.
XX
XX  Claim 5; Page 7; 8pp; German.
XX
XX  Microsatellite markers based on hypervariable genomic fragments, from
CC  Triticum aestivum (wheat) or the tribe Triticaceae, consist of a sequence
CC  tagged site (STS), defined by 2 specific primers (of mean size 17-23
CC  bases) that flank a microsatellite sequence at both ends, which can be
CC  amplified to polymorphisms (PCR products of different sizes). The
CC  microsatellites are n-fold tandem repeats (n = 10 or more) of di-, tri-
CC  or tetra-nucleotide sequences, combination microsatellite sequences or an
CC  imperfect sequence in which individual bases are mutated. The
CC  microsatellite markers can be used for genetic analysis of hexaploid and
CC  tetraploid forms of wheat and for genetic mapping or labelling of
CC  monogenic and polygenic properties, and for their selection; for
CC  analysing relationships and identifying varieties; and for evaluating
CC  varietal purity, hybrid identification and plant growth. The markers can
CC  differentiate between almost all European wheat lines and show a higher
CC  degree of DNA polymorphism than known probes for the wheat genome. They
CC  can be detected by PCR, so large numbers of samples can be analysed
CC  easily (e.g. several hundred per day). Microsatellite marker-related
CC  polymorphisms are stably inherited so can also serve as genetic markers.
CC  AAT77003-22 and AAT77335-716 are primer pairs that define the
CC  microsatellite markers. WMS155 has a CT type repeat
XX
SQ  Sequence 18 BP; 3 A; 10 C; 0 G; 5 T; 0 U; 0 Other;
    Query Match 0.7%; Score 13.8; DB 1; Length 18;
    Best Local Similarity 88.2%; Pred. No. 1.9e+02;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  1696 AATCATTTCCCTCC 1712
DB  ||||| ||||| |||||
    2 AATCATTTCCCTCC 18

RESULT 400
AAV30476/c
ID  AAV30476 standard; DNA; 18 BP.
XX
XX  AAV30476;
XX
XX  14-OCT-1998 (first entry)
XX
XX  Canine beta-3 adrenergic receptor antisense primer 1263.
XX
XX  Canine; beta-adrenergic receptor; brown adipose tissue; probe; human;
KW  hybridisation; ligand; primer; ss.
XX
OS  Synthetic.
OS  Canis familiaris.
XX
XX  WO9735973-A2.
XX
PD  02-OCT-1997.
XX
XX  26-MAR-1997; 97WO-FR000537.
XX
XX  26-MAR-1996; 96FR-00003730.
XX
XX  (VETI-) VETIGEN.

```

XX Lenzen G, Pietri-Rouxel P, Drumare M, Strosberg AD;
 XX WPI; 1998-032136/03.
 XX Canine beta 2 and beta 3 adrenergic receptors and coding sequences -
 XX useful for identifying specific ligands and (ant)agonists to develop
 XX specific treatments for obesity in dogs.
 XX Claim 17; Page 49; 79pp; French.
 XX Primers AAV30470-V30490 were used for sequencing the coding region of the
 XX canine beta 3-adrenergic receptor (RA-Ca-b3) gene (AAV30469). RA-Ca-b3
 XX has been implicated in obesity and obesity-related metabolic disorders
 XX e.g. diabetes. The canine version of RA-Ca-b3 can be used to develop
 XX treatments specific for dogs. The sequence can also be used in
 XX differential screening for ligands for RA-Ca-b3 as compared to the beta-2
 XX adrenergic receptor (AAW44932)
 XX Sequence 18 BP; 6 A; 1 C; 10 G; 1 T; 0 U; 0 Other;
 XX Query Match 0.7%; Score 13.8; DB 1; Length 18;
 XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX 721 CCTCCTTCTCCATCTAC 737
 XX 18 CCTCCTTCTCCATCTAC 2
 XX
 XX RESULT 401
 XX AAV16014/C
 XX ID AAV16014 standard; DNA; 18 BP.
 XX AC AAV16014;
 XX 21-MAY-1998 (first entry)
 XX PCR primer G-R used to identify Sox-3 gene mutations in mice.
 XX Mutation; Sox-3; ENU mutagenesis; mutational screening; recessive;
 XX single strand conformation polymorphism; SSCP; phenotypic alteration;
 XX PCR primer; amplify; ss.
 XX Synthetic.
 XX Mus sp.
 XX WO9744485-A1.
 XX 27-NOV-1997.
 XX 16-MAY-1997; 97WO-GB001354.
 XX 17-MAY-1996; 96GB-00010355.
 XX (HEXA-) HEXAGEN TECHNOLOGY LTD.
 XX Goodfellow PN;
 XX WPI; 1998-018536/02.
 XX Identification of mutation(s) in genes of interest - without prior
 XX observation of phenotypic alteration in the mutated organism or cell.
 XX Example 4; Page 41; 66pp; English.
 XX PCR primers AAV16001-18 were used to identify mutations in Sox-3 using
 XX the method of the invention. The primers are located throughout the gene
 XX and are unique to Sox-3. The method comprises testing a nucleic acid
 XX sample from a mutated organism for a mutation in a gene of interest
 XX without the prior observation of a phenotypic alteration in the mutated
 XX organism resulting from the mutation. Sox-3 is a member of the Sox gene
 XX family, a family of about 20 genes which all encode a "HMG" box, which is

CC a DNA-binding domain. Mice were mutagenised using ENU mutagenesis. The
 CC mutagenised mice were tested by PCR with each primer set and fluorescent
 CC single strand conformation polymorphism (SSCP), which identifies mice
 CC carrying mutations in Sox-3. The method provides mutational screening
 CC based on genomic and genetic techniques rather than on phenotypic
 CC observation. The method identifies and characterises genes via
 CC mutagenesis to identify genes encoding products which may have
 CC therapeutic benefit. The method also identifies the presence of mutations
 CC in a gene which do not rely solely upon prior matching of a gene with a
 CC disease. Heterozygotic organisms can also be screened to identify those
 CC carrying a mutation in a copy of a gene of interest even though the gene
 CC may be recessive and therefore causes no phenotypic alteration
 XX
 XX Sequence 18 BP; 0 A; 7 C; 11 G; 0 T; 0 U; 0 Other;
 XX Query Match 0.7%; Score 13.8; DB 1; Length 18;
 XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX 28 GCGGCTCGTCGCGC 44
 XX 17 GCGGCTCGTCGCGC 1
 XX
 XX RESULT 402
 XX AAV3800/C
 XX ID AAV3800 standard; DNA; 18 BP.
 XX AC AAV3800;
 XX 30-DEC-1998 (first entry)
 XX Human growth hormone receptor exon 2 DNA primer 101.
 XX Growth hormone receptor; GHR; idiopathic short stature; ISS; GH;
 XX partial growth hormone insensitivity syndrome; GHIS; growth hormone;
 XX insulin-like growth factor I; IGF-I; growth hormone binding protein;
 XX laron syndrome; PCR; primer; amplification; ss.
 XX Synthetic.
 XX Homo sapiens.
 XX US5824642-A.
 XX 20-OCT-1998.
 XX 06-JUN-1995; 95US-00468580.
 XX 07-APR-1994; 94US-00224982.
 XX 24-MAR-1995; 95US-00410452.
 XX (GETH) GENENTECH INC.
 XX Gesundheit N, Goddard A, Attie K, Carlsson LMS;
 XX WPI; 1998-582593/49.
 XX Treatment of non growth hormone dependent short stature - comprises
 XX administration of growth factor and/or insulin-like growth factor I.
 XX Example 4; Col 27-28; 57pp; English.
 XX Primers 101 and 102 (AAV3801) were used to amplify the human growth
 XX hormone receptor exon 2 coding region and its flanking splice sites. The
 XX PCR product was used in the method of the invention. The invention
 XX provides a method for increasing the growth rate of a patient having
 XX partial growth hormone insensitivity syndrome (GHIS) comprising of
 XX administering growth hormone (GH) and/or insulin-like growth factor I
 XX (IGF-I). The patients chosen had a height of less than -2 standard
 XX deviations below normal for age and sex, had a serum level of high-
 XX affinity GH-binding protein of at least 2 standard deviations below
 XX normal levels, had a mean or maximum stimulated serum GH level that was
 XX at least normal, and did not have Laron syndrome

XX SQ Sequence 18 BP; 2 A; 5 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 264 TATGGTAAAGCCAGAA 280
 |||||
 Db 17 TAAGGTAAGCCAGCA 1

RESULT 403
 AAZ31824
 ID AAZ31824 standard; DNA; 18 BP.
 XX
 AC AAZ31824;
 XX
 DT 24-JAN-2000 (first entry)
 XX
 DE Human G-alpha-13 antisense inhibitor ISIS# 20773.
 XX
 KW G-alpha-13; human; inhibitor; cancer; antisense compound; therapy; ss.
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN US981732-A.
 XX
 PD 09-NOV-1999.
 PF
 PP 04-DEC-1998; 98US-00205860.
 XX
 PR 04-DEC-1998; 98US-00205860.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cowseert LM;
 XX
 DR WPI; 1999-633376/54.
 XX
 PT Antisense compound inhibiting expression of human G-alpha-13.
 PS Claim 11; Col 39; 38pp; English.
 XX
 CC This sequence represents an antisense inhibitor of the invention, and
 CC inhibits the expression of the human G-alpha-13 protein. The antisense
 CC compounds of the invention are of 8 to 30 nucleobases in length, that
 CC inhibits the expression of the human G-alpha-13. The antisense compound
 CC is useful for treating an animal, particularly humans, having or being
 CC prone to a disease or condition associated with the expression of G-alpha
 CC -13, such as cancer
 XX
 SQ Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1778 AAAACATTTGTTCCAC 1794
 |||||
 Db 2 AAACCCCTGTTCCAC 18

RESULT 404
 AAZ39664/C
 ID AAZ39664 standard; DNA; 18 BP.
 XX
 AC AAZ39664;
 XX
 DT 28-FEB-2000 (first entry)
 XX
 DE Human vth aggregation factor gene specific FPCR-SSCP primer.

XX Gene polymorphism; human; vth aggregation factor; genetic diagnosis;
 KW diabetes; FPCR; SSCP; fluorescence-based polymerase chain reaction;
 KW single strand conformation polymorphism; PCR primer; ss.
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN JP11313676-A.
 XX
 PD 16-NOV-1999.
 XX
 PF 30-APR-1998; 98JP-00120217.
 XX
 PR 30-APR-1998; 98JP-00120217.
 XX
 PA (SAKA) OTSUKA PHARM CO LTD.
 XX
 DR WPI; 2000-057352/05.
 XX
 DE Discrimination of human V aggregation factor gene polymorphism.
 XX
 PS Disclosure; Page 10; 34pp; Japanese.
 XX
 CC The invention provides a method for the discrimination of the gene
 CC polymorphism of human vth aggregation factor, where one of the following
 CC (1) to (6)) residues/nucleotides in the aggregation gene is discriminated
 CC in the patient to be tested: (1) residue 495: guanine (G) or adenine (A),
 CC (2) residue 642: (G) or thymine (T), (3) residue 2663: (G) or (A), (4)
 CC residue 2763: (G) or (A), (5) residue 2863: (A) or (G), (6) residue 5112:
 CC (A) or (G). The method is useful in the genetic diagnosis of a diabetes
 CC patient. The method uses FPCR-SSCP (fluorescence-based polymerase chain
 CC reaction-single strand conformation polymorphism) for analyzing DNA
 CC samples for polymorphisms. Sequences AAZ39632-717 represent primers used
 CC for the FPCR-SSCP analysis of the human vth aggregation factor gene
 XX
 SQ Sequence 18 BP; 3 A; 5 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1685 CTAGAAAAGGATCAT 1701
 |||||
 Db 18 CTAGAAAAGGATCAT 2

RESULT 405
 AAZ43273/C
 ID AAZ43273 standard; DNA; 18 BP.
 XX
 AC AAZ43273;
 XX
 DT 11-FEB-2000 (first entry)
 XX
 DE Murine Sox3 gene PCR primer 14.
 XX
 KW Screening; mutation; treatment; disease; drug discovery; PCR primer; ss.
 XX
 OS Mus musculus.
 OS
 PN US5994075-A.
 XX
 PD 30-NOV-1999.
 XX
 PF 16-MAY-1997; 97US-00857946.
 XX
 PR 17-MAY-1996; 96US-0017824P.
 XX
 PA (HEXA-) HEXAGEN TECHNOLOGY LTD.
 XX
 PI Goodfellow PN;
 XX

DR WPI; 2000-038255/03.
XX Identifying a mutation in a gene of interest in an organism useful for
PT identifying genes encoding products which may have therapeutic benefits.
PS Example 5; Col 65-66; 70pp; English.
XX
XX This invention describes a novel mutational screening method based on
CC genomic and genetic techniques to identify and characterize a mutation in
CC a gene of interest without first selecting a phenotypic characteristic.
CC The screening methods are useful for identifying genes encoding products
CC which may have therapeutic benefit for treating human or animal diseases.
CC The method can be used for the DNA mutation screening of a class or a
CC family of genes providing a rapid assay for identifying mutant genes. The
CC methods produce organisms which can be used for drug discovery e.g.
CC providing a model for the study and treatment of a disease state, allow
CC in vitro assessment of drug activity and interbreeding of mutants which
CC allow investigation of gene interactions in the overall phenotype. A
CC range of phenotypes associated with different mutations, and specified
CC mutations in a gene of interest can be determined. The method can be
CC adapted to screen for a mutation in two or more genes of interest in an
CC organism. The methods allow mutations in a gene of interest to be
CC identified without having to rely on matching a gene with a disease.
CC AA243260-Z43421 represent PCR primers used in the method of the invention
XX
SQ Sequence 18 BP; 0 A; 7 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCCGTCGCCGC 44
Db 17 GCCGCGCGCGCGCGC 1

RESULT 406
AA05258/C
ID AAA05258 standard; DNA; 18 BP.
AC AAA05258;
XX 19-MAY-2000 (first entry)
XX PCR primer G-R used in Sox-3 amplicon generation.
XX
XX PCR primer; Sox-2; Sox-3; T gene; Tyrosinase; MGF; Sry; c-kit; Tryp-1;
KW Pax-6; mutation detection; therapeutic target identification; mouse;
KW mast cell growth factor; ss.
XX Mus sp.
OS
XX US6015670-A.
PN
XX 18-JAN-2000.
XX
XX 14-NOV-1997; 97US-00970740.
PF
XX 17-MAY-1996; 96US-0017824P.
PR
XX 16-MAY-1997; 97US-00857946.
XX
XX (HEXA-) HEXAGEN TECHNOLOGY LTD.
XX
XX Goodfellow PN;
PI
XX WPI; 2000-181139/16.
XX
XX Detecting mutations in selected genes, useful e.g. for identifying
PT therapeutic targets or products, by analysing DNA in mutated embryonic
PT stem cells without phenotypic characterization.
XX
XX Example 5; Col 31; 66pp; English.
XX

CC PCR primers AAA05245-A05406 are used to generate amplicons from the mouse
CC Sox-3 gene, Sox-2 gene, T gene, tyrosinase gene, Tryp-1 gene, Sry gene,
CC MGF (mast cell growth factor) gene, c-kit gene, and the Pax-6 gene. The
CC primers are used in a method for the identification of a mutation in a
CC selected gene in a tissue without the prior observation of a phenotypic
CC alteration in the mutated organism or cell. The method is used to
CC identify mutations in a selected gene that encode products of potential
CC therapeutic activity or that are potential targets, particularly where
CC the gene of interest has been identified as a candidate gene by
CC positional cloning. Other applications are determining functions of genes
CC detecting the range of phenotypes associated with different mutations
CC in a particular gene and identification of particular mutations. Animals
CC containing an identified mutation are used as models for studying
CC diseases or their treatment, and cells from them for in vitro assessment
CC of drug action. Interbreeding of mutant mice is used to investigate
CC genetic interaction in the overall phenotype
XX
SQ Sequence 18 BP; 0 A; 7 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCCGTCGCCGC 44
Db 17 GCCGCGCGCGCGCGC 1

RESULT 407
AAF26702
ID AAF26702 standard; DNA; 18 BP.
XX
AC AAF26702;
XX
DT 09-SEP-2004 (revised)
DT 02-APR-2001 (first entry)
XX
XX Human Smad7 phosphorothioate antisense oligonucleotide SEQ ID NO:45.
XX
XX Human; Smad7; antisense oligonucleotide; phosphorothioate; inhibition;
KW antiinflammatory; cytostatic; infection; inflammation; tumour formation;
KW ss.
XX Homo sapiens.
OS Unidentified.
XX
XX Key Location/Qualifiers
FH modified_base 1..18
FT /tag= a
FT /mod_base
FT /note= "phosphorothioate linkages"
XX
XX US6159697-A.
PN
XX 12-DEC-2000.
XX
XX 09-JAN-2000; 2000US-00487444.
PF
XX 09-JAN-2000; 2000US-00487444.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Monia BP, Cowser LM;
PI
XX WPI; 2001-070108/08.
XX
XX Antisense compound capable of inhibiting the expression of human Smad7,
PT useful for preventing or delaying infection, inflammation or tumor
PT formation.
XX
XX Example 15; Col 41; 33pp; English.
XX
XX The present invention describes an antisense compound (I) of up to 30

CC nucleobases in length capable of inhibiting the expression of human
CC Smad7. (I) has antiinflammatory and cytostatic, and is a modulator of
CC Smad7 expression. (I) can be useful for inhibiting the expression of
CC human Smad7 in human cells or tissues, in vitro. (I) is commonly used as
CC a research reagent and in diagnostics for example, to elucidate the
CC function of particular genes. (I) is also useful for distinguishing
CC between functions of various members of a biological pathway and for
CC research use. (I) is also utilised for diagnostics, therapeutics,
CC prophylaxis and in kits. (I) is also useful prophylactically, e.g. to
CC prevent or delay infection, inflammation or tumour formation. AAF26667 to
CC AAF26706 represent human Smad7 antisense oligonucleotides from the
CC present invention

CC Revised record issued on 09-SEP-2004 : Correction to feature table key

XX ABZ72129
SQ Sequence 18 BP; 11 A; 0 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 196 TTGAAGAATAAAGAA 212
DB 2 TAGAAGAATAAAGAA 18
|||||

RESULT 408
AAF92967/c
ID AAF92967 standard; DNA; 18 BP.

XX AAF92967;

XX 17-MAY-2001 (first entry)

XX Wild type sequence for ABC1 polymorphic site #28.

XX High density lipoprotein-cholesterol; HDL-C; cardiovascular; ABC1; ds.

XX Homo sapiens.

XX WO200115676-A2.

XX 08-MAR-2001.

XX 01-SEP-2000; 2000WO-IB001492.

XX 01-SEP-1999; 98US-0151977P.

XX 15-MAR-2000; 2000US-00526193.

XX 23-JUN-2000; 2000US-0213958P.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX (XENO-) XENON GENETICS INC.

XX Hayden MR, Brooks-Wilson AR, Pimstone SN, Clee SM;
XX WPI; 2001-244356/25.

XX Treating a lower than normal high density lipoprotein-cholesterol (HDL-C)
XX level, a higher than normal triglyceride level, or a cardiovascular
XX disease, by administering a compound that modulates LXR- or RXR-mediated
XX transcriptional activity.

XX Disclosure; Fig 4; 317pp; English.

XX The present invention relates to a method for treating a patient
XX diagnosed as having a lower than normal high density lipoprotein-
XX cholesterol (HDL-C) level, a higher than normal triglyceride level, or a
XX cardiovascular disease, involving administering a compound that modulates
XX LXR- or RXR-mediated transcriptional activity or ABC1 expression or
XX activity. The LXR gene product may be used in an assay to identify
XX compounds useful for the treatment of a disease or condition selected a
XX lower than normal HDL cholesterol level, a higher than normal
XX triglyceride level, and a cardiovascular disease

XX

SQ Sequence 18 BP; 10 A; 1 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1641 CTTTCTGTATTATCTT 1657
|||||

DB 18 CTTTCTGTATTATCTT 2
|||||

RESULT 409

ABZ72129

ID ABZ72129 standard; DNA; 18 BP.

XX ABZ72129;

XX 03-APR-2003 (first entry)

XX Gene 216 SSCP detection primer SEQ ID NO 101.

XX Human; Gene 216; chromosome 20p13-p12; antiasthmatic; anorectic;
XX antiinflammatory; gastrointestinal; gene therapy; vaccine; asthma;
XX obesity; inflammatory bowel disease; primer; ss.

XX Synthetic.

XX WO200178894-A2.

XX 25-OCT-2001.

XX 13-APR-2001; 2001WO-US012245.

XX 13-APR-2000; 2000US-00548797.

XX (GENO-) GENOME THERAPEUTICS CORP.

XX Keith T;

XX WPI; 2001-639428/73.

XX Isolated genes (Gene 216) from human chromosome 20p13-p12 and the
XX proteins they encode, useful for the prevention, diagnosis and treatment
XX of asthma, obesity and inflammatory bowel disease.

XX Example 10; Page 149; 520pp; English.

XX The invention relates to isolated genes (Gene 216) from human chromosome
XX 20p13-p12 and the proteins they encode. The nucleic acids and proteins
XX may be used in the prevention, diagnosis and treatment of diseases
XX associated with inappropriate Gene 216 expression. For example, the
XX nucleic acids (or vectors) and proteins may be used to treat disorders
XX associated with decreased expression by rectifying mutations or deletions
XX in a patient's genome that affect the activity of gene 216 by expressing
XX inactive proteins or to supplement the patients own production of Gene
XX 216 proteins. Additionally, the nucleic acids may be used to produce the
XX secreted Gene 216 protein, by inserting the nucleic acids into a host
XX cell and culturing the cell to express the protein. The nucleic acids and
XX complementary sequences may also be used as DNA probes in diagnostic
XX assays to detect and quantitate the presence of similar nucleic acid
XX sequences in samples and therefore which patients may be in need of
XX restorative therapy. The Gene 216 protein may also be used as antigens in
XX the production of antibodies against Gene 216 and in assays to identify
XX modulators of Gene 216 expression and activity. The anti-Gene 216
XX antibodies and antagonists may also be used to down regulate expression
XX and activity. The anti-Gene 216 antibodies may also be used as diagnostic
XX agents for detecting the presence of Gene 216 proteins in samples (e.g.
XX by enzyme linked immunosorbent assay or ELISA). Disorders that may be
XX prevented, diagnosed and/or treated by the above methods include, for
XX example asthma, obesity and inflammatory bowel disease. The present
XX sequence is that of a Gene 216 related primer used in examples of the
XX invention. The primers are used in the physical mapping of the gene

CC	(ABZ72067-ABZ72088), polymorphism identification using single strand
CC	conformational polymorphism (SSCP) analysis (ABZ72091-ABZ72184),
CC	sequencing (ABZ72185-ABZ72268) and genotyping (ABZ72317-ABZ72362)
XX	
SQ	Sequence 18 BP; 5 A; 2 C; 10 G; 1 T; 0 U; 0 Other;
	Query Match 0.7%; Score 13.8; DB 1; Length 18;
	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy	1101 GCAGAGACCAAGGTGG 1117
Db	2 GCAGAGGACCAAGGTGG 18
RESULT 410	
ID	ABK41013/C
XX	ABK41013 standard; DNA; 18 BP.
AC	ABK41013;
XX	
DT	21-MAY-2002 (first entry)
XX	
DE	Human obesity-associated biallelic marker upstream PCR primer #90.
XX	
KW	Human; obesity associated-biallelic marker; chromosome 10; obesity; ss;
KW	drug response; hyperuricaemia; digestive pathology; hypertension; cancer;
KW	hepatic function disorder; cardiovascular disease; hyperlipidaemia; PCR;
KW	insulin disorder; atheromatous disease; cardiac insufficiency; primer.
XX	
OS	Homo sapiens.
XX	
PN	WO200206525-A2.
XX	
PD	24-JAN-2002.
XX	
PF	28-JUN-2001; 2001WO-IB001477.
XX	
PR	18-JUL-2000; 2000US-0219704P.
XX	
PA	(GEST) GENSET.
XX	
PI	Cohen D, Blumenfeld M, Chumakov I, Abderrahim H, Bihain B;
XX	
DR	WPI; 2002-155043/20.
XX	
PT	Set of novel map-related biallelic markers, preferably located on obesity
PT	disorder-associated chromosomal regions on chromosomes 3, 10 and 19,
PT	useful, for e.g. detecting statistical correlations between marker allele
PT	and a phenotype.
XX	
PS	Example 2; Page 246; 31pp; English.
XX	
CC	The invention relates to a set of novel map-related biallelic markers,
CC	preferably located on obesity disorder-associated chromosomal regions on
CC	chromosomes 3, 10 and 19. The markers are useful for genotyping or
CC	estimating the frequency of an allele in a population, for detecting an
CC	association between a genotype or haplotype and a phenotype, e.g. a
CC	disease involving drug responses, obesity or disorders related to
CC	obesity, such as hyperuricaemia, digestive pathology, hepatic function
CC	disorders, cancer, cardiovascular disease, hypertension, hyperlipidaemia,
CC	insulin disorders, atheromatous disease and cardiac insufficiency. The
CC	markers are useful for detecting a statistical correlation between a
CC	biallelic marker allele and a phenotype and/or between a biallelic marker
CC	haplotype and a phenotype. This sequence represents a PCR primer used to
CC	amplify a human obesity-associated biallelic marker
XX	
SQ	Sequence 18 BP; 5 A; 5 C; 3 G; 5 T; 0 U; 0 Other;
	Query Match 0.7%; Score 13.8; DB 1; Length 18;
	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY	224 CTGTGGAGATGTTGCTA 240
Db	17 CTGTGAAGATGATGCTA 1
RESULT 411	
ABSN97456	
ID	ABSN97456 standard; DNA; 18 BP.
XX	
AC	ABSN97456;
XX	
DT	23-DEC-2002 (first entry)
XX	
DE	Human diazepam binding inhibitor (DBI) gene PCR Primer #6.
XX	
KW	Human; ss; primer; cytochrome P450 A1; CYP450A1; UGT2B4; MDR1; PCR;
KW	cytochrome P450 A2; CYP450A2; cytochrome P450 02E; CYP45002E1; LTF;
KW	adrenergic receptor beta1; ADBR1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW	aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW	cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW	epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW	glutathione-S-transferase 12; GSTI2; histamine-N-methyl transferase;
KW	HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
KW	NADPH quinone oxidoreductase 2; NQO2; sulfoxidoreductase thermolabile; STM;
KW	UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW	UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW	multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW	multidrug resistance associated protein 3; cancer; prostate;
KW	acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW	altered drug metabolism; cardiovascular function; colorectal tumour;
KW	central nervous system; pulmonary; immunological.
XX	
OS	Homo sapiens.
XX	
PN	WO200257410-A2.
XX	
PD	25-JUL-2002.
XX	
PF	28-NOV-2001; 2001WO-US044838.
XX	
PR	28-NOV-2000; 2000US-00724389.
XX	
PA	(DNAS-) DNA SCI LAB INC.
XX	
PI	Guida M, Hall J;
XX	
DR	WPI; 2002-698522/75.
XX	
PT	Isolated nucleic acid molecules having polymorphisms in known human genes
PT	e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
PT	for locating, identifying and characterizing the genes responsible for
PT	disorder-related traits.
XX	
PS	Example 9; Page 115; 714pp; English.
XX	
CC	This invention relates to the sequence of an isolated nucleic acid
CC	molecule comprising at least one base variation from that of a known
CC	human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),
CC	cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),
CC	aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
CC	(ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
CC	inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating
CC	protein (FLAP), glutathione-S-transferase 12 (GSTI2), histamine-N-methyl
CC	transferase (HNMT), kallikrein 2 (KLK2), nicotinamide -N-methyl
CC	sulfoxidoreductase thermolabile (STM), UDP-glucuronosyl transferase 2B4
CC	(UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
CC	transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
CC	(MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
CC	(MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
CC	receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
CC	The polymorphisms in the human genes cited in the invention are useful as
CC	genetic linkage markers for locating and characterising the genes that

CC are responsible for specific traits within the genome and eventually
 CC identifying the genes responsible for a variety of disorder-related
 CC traits as a result of their e.g., overexpression, constitutive
 CC expression, mutation or underexpression, which may be used in diagnosing
 CC and/or treating the disorders. The nucleic acid molecules comprising the
 CC polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502E1,
 CC ARNT, EPHX2, GSTI2, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B15, AHR,
 CC MDR1 and/or MDR3 are useful for screening individuals for altered drug
 CC metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,
 CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for
 CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
 CC used to screen for altered cardiovascular function, in COX2 for altered
 CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
 CC nervous system function, in FLAP and HNMT for altered pulmonary,
 CC immunological or haematological function, in KLK2 for altered serine
 CC protease activity in the prostate, in LTF for altered immunological or
 CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
 CC peripheral nervous system function. The present sequence represents a PCR
 CC primer used to amplify the sequences of the invention
 XX

SQ Sequence 18 BP; 6 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 411 CTGGAGCCAGTCAGAAAT 427
 |||||
 Db 1 CTGGAGACACTGAGAAAT 17

RESULT 412
 ABS66015
 ID ABS66015 standard; DNA; 18 BP.
 AC ABS66015;
 XX
 DT 15-NOV-2002 (first entry)
 XX
 DE Mycobacterium intracellulare primer #2.
 XX
 KW Microbe detection; Legionella; Pseudomonas aeruginosa; Mycobacterium;
 KW Burkholderia cepacia; Escherichia coli; Acinetobacter; Acanthamoeba;
 KW Cryptosporidium parvum; PCR; primer; ss.
 XX
 OS Mycobacterium.
 XX
 PN JP2002223766-A.
 XX
 PD 13-AUG-2002.
 XX
 PF 31-JAN-2001; 2001JP-00023742.
 XX
 PR 31-JAN-2001; 2001JP-00023742.
 XX
 PA (RAKA-) RAKAN KK.
 PA (GIFU-) GIFU DAIGAKUCHO.
 XX
 DR WPI; 2002-649521/70.
 XX
 PT Detection of a microbe and a primer set for the detection.
 XX
 PS Claim 4; Page 5; 25pp; Japanese.
 XX
 CC The invention relates to a method for detection of a microbe by
 CC amplifying the gene of the microbe belonging to a specified range of
 CC classification by polymerase chain reaction (PCR) using a primer
 CC targeting the gene of the microbe. A primer set for the detection of a
 CC microbe is included for the detection of Legionella spp, Pseudomonas
 CC aeruginosa, Burkholderia cepacia, Escherichia coli, Acinetobacter.
 CC Mycobacterium, Acanthamoeba, Cryptosporidium parvum groups. ABS66002-
 CC ABS66053 represent primers used to detect the microbes of the invention
 XX

SQ Sequence 18 BP; 2 A; 9 C; 1 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 725 CTTCTCCATCTACAGTC 741
 |||||
 Db 2 CTTCTCCATCTACAGTC 18

RESULT 413
 ABS66019
 ID ABS66019 standard; DNA; 18 BP.
 AC ABS66019;
 XX
 DT 15-NOV-2002 (first entry)
 XX
 DE Mycobacterium intracellulare detection primer #2.
 XX
 KW Microbe detection; Legionella; Pseudomonas aeruginosa; Mycobacterium;
 KW Burkholderia cepacia; Escherichia coli; Acinetobacter; Acanthamoeba;
 KW Cryptosporidium parvum; PCR; primer; ss.
 XX
 OS Mycobacterium intracellulare.
 XX
 PN JP2002223766-A.
 XX
 PD 13-AUG-2002.
 XX
 PF 31-JAN-2001; 2001JP-00023742.
 XX
 PR 31-JAN-2001; 2001JP-00023742.
 XX
 PA (RAKA-) RAKAN KK.
 PA (GIFU-) GIFU DAIGAKUCHO.
 XX
 DR WPI; 2002-649521/70.
 XX
 PT Detection of a microbe and a primer set for the detection.
 XX
 PS Claim 4; Page 5; 25pp; Japanese.
 XX
 CC The invention relates to a method for detection of a microbe by
 CC amplifying the gene of the microbe belonging to a specified range of
 CC classification by polymerase chain reaction (PCR) using a primer
 CC targeting the gene of the microbe. A primer set for the detection of a
 CC microbe is included for the detection of Legionella spp, Pseudomonas
 CC aeruginosa, Burkholderia cepacia, Escherichia coli, Acinetobacter,
 CC Mycobacterium, Acanthamoeba, Cryptosporidium parvum groups. ABS66002-
 CC ABS66053 represent primers used to detect the microbes of the invention
 XX

SQ Sequence 18 BP; 2 A; 9 C; 1 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 725 CTTCTCCATCTACAGTC 741
 |||||
 Db 2 CTTCTCCATCTACAGTC 18

RESULT 414
 AAD34959
 ID AAD34959 standard; DNA; 18 BP.
 XX
 AC AAD34959;
 XX
 DT 16-JUL-2002 (first entry)
 XX
 DE Human SDF1 gene amplifying forward PCR primer.

```
XX Human; CCR2; SDF1; Factor V; MTHFR; Factor XIII; CCR5; detection; PCR;
KW primer; ss.
XX
XX Homo sapiens.
OS
XX US2002037507-A1.
PN
XX 28-MAR-2002.
XX
XX 14-DEC-2000; 2000US-00736863.
XX
XX 16-DEC-1999; 99US-0171126P.
XX
XX (WALK/) WALKERPEACH C R.
PA (HUX/) HU X.
PA
XX Walkerpeach CR, Hu X;
XX
XX WPI; 2002-329124/36.
DR
XX Polynucleotide primers and probes useful for single base substitutions in
PT the human CCR2, SDF1, Factor V, MTHFR, Factor XIII genes, and a 32-bp
PT deletion in the human CCR5 gene by polymerase chain reaction.
PT
XX Claim 1; Page 12; 41pp; English.
PS
XX The invention relates to sequence-specific polynucleotide probes, pairs
XX of probes, the design of pairs of probes in relation to the strands of
XX target nucleic acid and coordinate sequence-specific pairs of primers,
XX for the detection of four single base substitutions in the human CCR2,
XX SDF1, Factor V, MTHFR, Factor XIII genes, and a 32-bp deletion in the
XX human CCR5 gene. The polynucleotides of the invention are used for the
XX detection of four single base substitutions in the human CCR2, SDF1,
XX Factor V, MTHFR, Factor XIII genes, and a 32-bp deletion in the human
XX CCR5 gene. The present sequence is a PCR primer used for target
XX amplification and detection of human SDF1 gene
XX
XX Sequence 18 BP; 3 A; 10 C; 0 G; 5 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 722 CTCCTTCTCCATCACA 738
Db 1 CCCCTTCTCCATCACA 17
RESULT 415
ABK98126/c
ID ABK98126 standard; DNA; 18 BP.
XX
XX AC ABK98126;
XX
XX 07-OCT-2002 (first entry)
XX
XX Triple helix forming associated oligonucleotide #15.
DE
XX Triple-helix formation; purine-rich target sequence; double-helix DNA;
KW gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW pathogenic bacteria; virus; replication; virulence; cancer;
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX
XX Synthetic.
XX
XX US6403302-B1.
XX
XX 11-JUN-2002.
XX
XX 16-DEC-1993; 93US-00168920.
XX
XX 17-SEP-1992; 92US-00946976.
XX
```

```
XX (CALY ) CALIFORNIA INST OF TECHNOLOGY.
PA
XX Dervan PB, Beal PA;
XX
XX WPI; 2002-536030/57.
XX
XX A triple-helix comprising a double helical nucleic acid (DHNA) and an
PT oligonucleotide which binds in parallel and antiparallel orientation,
PT respectively, for targeting sequences on alternate strands of DHNA to
PT control gene expression.
XX
XX Example 7; Col 41; 108pp; English.
XX
XX The present invention relates to methods and oligonucleotides for forming
XX a triple-helix comprising a double helical nucleic acid comprising first
XX and second substantially complementary strands, and an oligonucleotide
XX bound to a purine-rich target sequence within the double helical nucleic
XX acid, where the oligonucleotide binds in a parallel and antiparallel
XX orientation, respectively, to target sequences on alternate strands of
XX the double helical nucleic acid. The method has therapeutic applications,
XX where gene expression is controlled by selective triple-helix formation
XX within expression regulatory sequences of a target gene. The
XX oligonucleotides can be used to form triple-helices, and are useful to
XX detect the presence or absence of specific sequences within genomic DNA
XX for diagnostic and therapeutic purposes. The oligonucleotides can be
XX selected to specifically bind to pathogenic double-stranded DNA including
XX specific sequences required by pathogenic bacteria or viruses for
XX replication or virulence, reducing their pathogenicity. Alternatively,
XX the oligonucleotide can be chosen to target a unique sequence of the
XX pathogen which is not found in the genome of pathogen's host. The
XX oligonucleotides can be used in cancer treatment by way of triple-helix
XX suppression of specific oncogenes including those of endogenous or viral
XX origin. Such therapeutic oligonucleotides are capable of forming triple-
XX helices with such sequences in cancerous cells containing the activated
XX oncogene, so preferentially killing or repressing the cancer causing
XX cell. The present sequence represents an oligonucleotide used in the
XX methods of the present invention
XX
XX Sequence 18 BP; 0 A; 2 C; 0 G; 14 T; 0 U; 2 Other;
SQ Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.9e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1834 GAAAAAAGAAAAA 1850
Db 17 GAAAAAAGAAAAA 1
RESULT 416
ABX74982
ID ABX74982 standard; DNA; 18 BP.
XX
XX AC ABX74982;
XX
XX 25-MAR-2003 (first entry)
XX
XX Human gene 216 polymorphism detection PCR primer #39.
DE
XX Human; mouse; ss; primer; Gene 216; antiasthmatic; antiinflammatory;
KW anorectic; chromosome 20p13-p12; single nucleotide polymorphism; SNP;
KW gene therapy; respiratory disease; asthma; obesity; PCR;
KW bronchial hyper-responsiveness; chronic obstructive pulmonary disease;
KW adult respiratory distress syndrome; inflammatory bowel syndrome.
XX
XX Homo sapiens.
XX
XX WO200283077-A2.
XX
XX 24-OCT-2002.
XX
XX 15-APR-2002; 2002WO-US012063.
XX
```

XX 13-APR-2001; 2001US-00834597.
 PR 13-APR-2001; 2001WO-US012245.
 XX (SCHE) SCHERING CORP.
 PA (GENO-) GENOME THERAPEUTICS CORP.
 XX Keith T, Little RD, Van Berdewegh P, Dupuis J, Del Mastro RG;
 PI Simon J, Allen K, Pandit S;
 XX WPI; 2003-092960/08.
 DR
 XX New isolated gene 216 nucleic acids, useful for diagnosing, preventing or
 PT treating a disorder, such as asthma, bronchial hyper-responsiveness,
 PT chronic obstructive pulmonary disease, obesity or inflammatory bowel
 PT syndrome.
 XX
 PS Example 10; Page 155; 650pp; English.
 XX This invention relates to a novel isolated nucleic acid, gene 216,
 CC identified from human chromosome 20p13-p12. The invention also discloses
 CC regions of the 216 gene that contain single nucleotide polymorphisms
 CC (SNP's) which may be used as markers for disease susceptibility or
 CC severity. The nucleotides of the invention may have antiasthmatic,
 CC antiinflammatory or anorectic activities and may be used in gene therapy.
 CC The nucleic acids, antibodies or its fragments are useful for diagnosing,
 CC preventing or treating a disorder, such as respiratory diseases (e.g.
 CC asthma, bronchial hyper-responsiveness, chronic obstructive pulmonary
 CC disease or adult respiratory distress syndrome), obesity, or inflammatory
 CC bowel syndrome. The nucleic acids are also useful for identifying
 CC increased susceptibility of a subject to the disorders mentioned. The
 CC nucleic acids can also be used as primers and templates for the
 CC recombinant production of disorder-associated peptides or polypeptides,
 CC for chromosome and gene mapping, or for tissue distribution studies. The
 CC present sequence represents a gene 216 specific PCR primer used in the
 CC scope of the invention
 XX
 SQ Sequence 18 BP; 5 A; 2 C; 10 G; 1 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Oy 1101 GCAGAAGAACAAAGGTGG 1117
 ||||| |||||
 Db 2 GCAGAGGAGCAAGGTGG 18
 RESULT 417
 ADA27361/c
 ID ADA27361 standard; DNA; 18 BP.
 XX
 AC ADA27361;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human microsatellite repeat M2_3_8.
 XX
 KW ds; HLA-related research; HLA class II-associated disease;
 KW transplantation matching; recombination hot spot identification;
 KW linkage disequilibrium study; human; microsatellite.
 XX
 OS Homo sapiens.
 XX
 PN US2003108940-A1.
 XX
 PD 12-JUN-2003.
 XX
 PF 06-DEC-2002; 2002US-00314405.
 XX
 PR 15-NOV-2000; 2000US-00713616.
 XX
 PA (INOK/) INOKO H.

XX Inoko H, Tamiya G, Matsuzaka Y;
 PI WPI; 2003-616782/58.
 DR
 XX New oligonucleotide primer capable of specifically hybridizing to a DNA
 PT having the sequence of the flanking regions of a microsatellite (e.g.
 PT M249), useful for HLA-related research, e.g. transplantation matching.
 XX
 PS Example 2; Page 5; 20pp; English.
 XX
 CC The invention relates to an oligonucleotide primer capable of
 CC specifically hybridizing to a DNA having the sequence of the flanking
 CC regions of a microsatellite selected from M2-4-9, M2-2-9, M2-2-12, M2-3-
 CC 11, M2-2-20, M2-2-21, M2-2-22, M2-2-23, M2-2-24, M2-4-25, M2-4-26, M2-2-
 CC 29, M2-2-32, M2-4-32, M2-4-33, M2-4-37, M2-3-22, M2-3-36, M2-5-11, M2-2-
 CC 46, and M2-2-48. The primer is useful for determining the number of
 CC repeat units of the microsatellite cited above. The primer is useful in
 CC HLA-related research, such as genetic mapping of HLA class II-associated
 CC diseases, transplantation matching, population genetics, and
 CC identification of recombination hot spots as well as linkage
 CC disequilibrium studies. The present sequence represents the human
 CC microsatellite repeat M2_3_8.
 XX
 SQ Sequence 18 BP; 0 A; 6 C; 12 G; 0 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Oy 30 CGCTCTCGTCGCGCGCG 46
 ||||| |||||
 Db 18 CGCGCGCGCGCGCGCGCG 2
 RESULT 418
 AAL60043/c
 ID AAL60043 standard; DNA; 18 BP.
 XX
 AC AAL60043;
 XX
 DT 27-AUG-2003 (first entry)
 XX
 DE Human GH-1 gene amplifying PCR primer, CRV156.5a1.
 XX
 KW Human; growth hormone 1; GH-1; single nucleotide polymorphism; SNP;
 KW gene therapy; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003042226-A2.
 XX
 PD 22-MAY-2003.
 XX
 PF 07-NOV-2002; 2002WO-US035719.
 XX
 PR 09-NOV-2001; 2001US-0347448P.
 XX
 PA (PHAA) PHARMACIA & UPJOHN CO.
 XX
 PI Wood LS, Wagner S, Parodi LA;
 XX
 DR WPI; 2003-449555/42.
 XX
 PT New growth hormone 1 (GH-1) diagnostic polynucleotide, useful as markers
 PT for the analysis of a disease, or of susceptibility to drug treatment for
 PT GH-1 dysfunction or other diseases.
 XX
 PS Example 2; Page 30; 74pp; English.
 XX
 CC The invention relates to growth hormone 1 (GH-1) gene including single
 CC nucleotide polymorphisms (SNP). The GH-1 diagnostic polynucleotide is
 CC useful as markers for the analysis of a disease, of susceptibility to

CC drug treatment for GH-1 dysfunction or other diseases, or may be included
CC in any complete or partial genetic map of the human genome. GH-1 mutant
CC polypeptides are useful as antagonists of GH-1 hormone action.
CC Polynucleotides encoding these polypeptides are useful in gene therapy.
CC The present sequence is a PCR primer used for amplifying human GH-1 gene
XX
SQ Sequence 18 BP; 3 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1554 AGGAATCCTGGTCTGC 1570
||| ||||| |||
Db 17 AGGACTCTGGTCTGC 1

RESULT 419
AAL60014/C
ID AAL60014 standard; DNA; 18 BP.
XX
AC AAL60014;
XX
DT 27-AUG-2003 (first entry)
XX
DE Human GH-1 gene amplifying PCR primer, CRV156.2d1.
XX
KW Human; growth hormone 1; GH-1; single nucleotide polymorphism; SNP;
KW gene therapy; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003042226-A2.
XX
PD 22-MAY-2003.
XX
PF 07-NOV-2002; 2002WO-US035719.
XX
PR 09-NOV-2001; 2001US-0347448P.
XX
PA (PHAA) PHARMACIA & UPJOHN CO.
XX
PI Wood LS, Wagner S, Parodi LA;
XX
XX WPT: 2003-449555/42.
XX
XX New growth hormone 1 (GH-1) diagnostic polynucleotide, useful as markers
PT for the analysis of a disease, or of susceptibility to drug treatment for
PT GH-1 dysfunction or other diseases.
XX
XX Example 2; Page 30; 74pp; English.
XX
XX The invention relates to growth hormone 1 (GH-1) gene including single
CC nucleotide polymorphisms (SNP). The GH-1 diagnostic polynucleotide is
CC useful as markers for the analysis of a disease, of susceptibility to
CC drug treatment for GH-1 dysfunction or other diseases, or may be included
CC in any complete or partial genetic map of the human genome. GH-1 mutant
CC polypeptides are useful as antagonists of GH-1 hormone action.
CC Polynucleotides encoding these polypeptides are useful in gene therapy.
CC The present sequence is a PCR primer used for amplifying human GH-1 gene
XX
SQ Sequence 18 BP; 3 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1554 AGGAATCCTGGTCTGC 1570
||| ||||| |||
Db 17 AGGACTCTGGTCTGC 1

RESULT 420.

ADRI3507/c
ID ADEI3507 standard; DNA; 18 BP.
XX
AC ADEI3507;
XX
DT 29-JAN-2004 (first entry)
XX
DE HLA class I allele specific primer #123.
XX
KW ss; primer; PCR; human; Human Leukocyte Antigen; HLA; genotype.
XX
OS Homo sapiens.
XX
PN US2003165884-A1.
XX
PD 04-SEP-2003.
XX
PF 25-APR-2002; 2002US-00133779.
XX
PR 20-DEC-1999; 99US-0172768P.
PR 20-DEC-2000; 2000US-00747391.
XX
XX (STEM-) STEMCYTE INC.
XX
XX Chow R, Tonai R;
XX WPI; 2003-874916/81.
XX
XX Identifying class I or II Human Leukocyte Antigen genotypes using
PT hybridization and amplification assays.
XX
XX Claim 7; SEQ ID NO 125; 66pp; English.
XX
XX The invention relates to a method of identifying a class I or II Human
CC Leukocyte Antigen (HLA) genotype of a subject using hybridisation and
CC amplification assay. The method is used for determining the HLA genotype
CC of a subject. The present sequence represents a HLA class I allele
CC specific primer.
XX
SQ Sequence 18 BP; 2 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 382 TGCAGCAAGTCGGCTG 398
||| ||||| |||
Db 17 TGCAGCAGCAGGGGCTG 1

RESULT 421
ADEI3393/c
ID ADEI3393 standard; DNA; 18 BP.
XX
AC ADEI3393;
XX
DT 29-JAN-2004 (first entry)
XX
DE HLA class I allele specific primer #9.
XX
KW ss; primer; PCR; human; Human Leukocyte Antigen; HLA; genotype.
XX
OS Homo sapiens.
XX
PN US2003165884-A1.
XX
PD 04-SEP-2003.
XX
PF 25-APR-2002; 2002US-00133779.
XX
PR 20-DEC-1999; 99US-0172768P.
PR 20-DEC-2000; 2000US-00747391.
XX

PA (STEM-) STEM-CYTE INC.
 XX Chow R, Tonai R;
 XX WPI; 2003-874916/81.
 XX Identifying class I or II Human Leukocyte Antigen genotypes using
 PT hybridization and amplification assays.
 XX Claim 7; SEQ ID NO 9; 66pp; English.
 XX The invention relates to a method of identifying a class I or II Human
 CC Leukocyte Antigen (HLA) genotype of a subject using hybridisation and
 CC amplification assay. The method is used for determining the HLA genotype
 CC of a subject. The present sequence represents a HLA class I allele
 XX specific primer.
 XX
 SQ Sequence 18 BP; 2 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 382 TGCAGCAAGATGGGCTG 398
 Db 17 TGCAGCACGAGGGGCTG 1
 RESULT 422
 ADF13036
 ID ADF13036 standard; DNA; 18 BP.
 XX AC ADF13036;
 XX DT 12-FEB-2004 (first entry)
 XX DE Human PCMI exon 33 splice donor fragment.
 XX KW schizophrenia; chromosome 8p21-22; pericentriolar material 1; PCMI;
 KW marker; microsatellite repeat; NT 000501 contig; polymorphic marker;
 KW linkage disequilibrium; D8S261; D8S2615; D8S2616;
 KW single nucleotide polymorphism; SNP; ds.
 XX OS Homo sapiens.
 XX PN WO2003050301-A2.
 XX PD 19-JUN-2003.
 XX PF 12-DEC-2002; 2002WO-GB005630.
 XX PR 12-DEC-2001; 2001GB-00029758.
 XX PA (GURL/) GURLING H M D.
 XX PI Gurling HMD;
 XX WPI; 2003-532919/50.
 XX Determining the susceptibility of an individual to a neuropsychiatric
 PT disorder (e.g. schizophrenia) or diagnosing or prognosing the disorder
 PT comprises using a pericentriolar material 1 marker in the chromosomal
 PT region 8p21-22.
 XX Claim 9; Fig 6; 108pp; English.
 XX This invention describes a novel method of determining the susceptibility
 CC to or diagnosis of schizophrenia comprising using a marker located in the
 CC chromosomal region 8p21-22. The method involves determining the presence
 CC or absence in a test sample of a pericentriolar material 1 (PCMI) marker
 CC which is selected from any of the microsatellite repeats present in the
 CC NT 000501 contig on chromosome 8p21-22 or a polymorphic marker which is
 CC in linkage disequilibrium with the chromosome. The PCMI marker is

CC preferably D8S261, D8S2615 or D8S2616 and lies within the PCMI gene. The
 CC novel method involves assessing two or more of the PCMI markers single
 CC nucleotide polymorphisms (SNPs). The PCMI gene is amplified, particularly
 CC within the intronic sequence 3' to exon 4, in exon 4, or in the intronic
 CC sequence 5' of exon 5. The PCMI marker is assessed by strand conformation
 CC polymorphic marker analysis, heteroduplex analysis or restriction
 CC fragment length polymorphism (RFLP) analysis. Schizophrenia therapy
 CC comprises screening an individual for a genetic predisposition to
 CC schizophrenia, where the predisposition is correlated with the PCMI
 CC marker and if a predisposition is identified, providing therapeutic
 CC treatment for the individual. Alternatively, the method comprises
 CC administering to a patient a substance that modulates the expression from
 CC the PCMI gene or a gene located within 1000 base of the PCMI locus. This
 CC sequence represents the human PCMI exon 33 splice donor region.
 SQ Sequence 18 BP; 10 A; 1 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 1514 CTAGAAACAGTAAGAA 1530
 Db 1 CTAGTAAAGTAAGAA 17
 RESULT 423
 ADF78408
 ID ADF78408 standard; DNA; 18 BP.
 XX AC ADF78408;
 XX DT 26-FEB-2004 (first entry)
 XX DE Chromosomal abnormality detection-related APC small deletion DNA 154.
 XX KW chromosomal abnormality; maternal locus; genetic disorder; foetus;
 KW mutation; translocation; transversion; monosomy; trisomy; trisomy 21;
 KW chromosome 21; Down's Syndrome; aneuploidies; chromosome deletion;
 KW chromosome addition; chromosome amplification; chromosome translocation;
 KW chromosome rearrangement; single nucleotide polymorphism detection;
 KW SNP detection; pregnant female; APC; adenomatous polyposis coli; ds.
 XX OS Homo sapiens.
 XX PN WO2003074723-A2.
 XX PD 12-SEP-2003.
 XX PF 28-FEB-2003; 2003WO-US0006198.
 XX PR 01-MAR-2002; 2002US-0360232P.
 XX PR 11-MAR-2002; 2002US-00093618.
 XX PR 08-MAY-2002; 2002US-0378354P.
 XX PA (DHALL/) DHALLAN R.
 XX PI Dhallan R;
 XX WPI; 2003-845073/78.
 XX Detection of chromosomal abnormalities e.g. Down's Syndrome, non-
 PT invasively in a fetus, comprises forming a ratio of amounts of alleles at
 PT a locus of interest and a different heterozygous locus.
 XX Example 7; Page 163; 164pp; English.
 XX This invention relates to a novel method of detecting chromosomal
 CC abnormalities by determining the sequence of alleles of a locus of
 CC interest from template DNA, determining which alleles are present and
 CC comparing to amounts of alleles at a different, selected heterozygous
 CC locus (for example on another chromosome or a maternal locus); relative
 CC amounts are expressed as a ratio indicating presence or absence of the

CC abnormality. The method is useful for the detection of genetic disorders,
 CC especially in a foetus, including chromosomal abnormalities and
 CC mutations, for example translocations, transversions, monosomies,
 CC trisomies (for example trisomy 21 in which an additional copy of
 CC chromosome 21 results in Down's Syndrome) and other aneuploidies,
 CC deletions, additions, amplifications, translocations and rearrangements.
 CC It can be used to detect any alterations in a gene sequence, especially
 CC single nucleotide polymorphisms (SNPs), and may be used to detect
 CC numerous abnormalities simultaneously, for example if several SNPs are
 CC associated with a particular disease. The method provides a rapid, non-
 CC invasive method for determining the sequence of DNA from a foetus using a
 CC sample from a pregnant female, for example to detect genetic disorders as
 CC above or to determine if a foetus is a carrier of a disease or
 CC predisposed to a disease.

SQ Sequence 18 BP; 12 A; 0 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAAATAAAGAGAAAT 217
 Db 1 GAAATAAAGAGAAAT 17
 |||||

RESULT 424
 ADG70285
 ID ADG70285 standard; DNA; 18 BP.
 XX
 AC ADG70285;
 XX
 DT 11-MAR-2004 (first entry)
 DE
 DE CLLD8 exon 12 and ANGE exon 3 SNP identification primer #101.
 XX
 XX ANGE; CLLD8; CLLD7; ANGE-CLLD8; ANGE-CLLD7; CLLD7-CLLD8;
 KW ANGE-CLLD8-CLLD7; anti-allergic; antiasthmatic; dermatological;
 KW antipyretic; antiinflammatory; gene therapy; IGE-mediated disease;
 KW primer; ss.
 XX
 OS Unidentified.

XX
 XX W0203000727-A2.
 XX 03-JAN-2003.
 XX 21-JUN-2002; 2002WO-GB002859.
 XX 21-JUN-2001; 2001GB-00015211.
 PR 21-JUN-2001; 2001GB-00015212.
 PR 21-JUN-2001; 2001GB-00015213.
 XX (ISIS-) ISIS INNOVATIONS LTD.
 XX
 XX Zhang Y, Moffatt M, Cookson W, Tinsley J;
 XX WPI; 2003-201405/19.
 XX
 XX New nucleic acid sequence comprising an ANGE, CLLD8 or CLLD7 mRNA, or
 PT their hybrid, useful for screening agents for treating IGE-mediated
 PT diseases, e.g. asthma, atopy, hay fever, eczema, atopic dermatitis, or
 PT allergic rhinitis.

XX Disclosure; Page 408; 429pp; English.
 PS
 PS The invention relates to a novel isolated or recombinant nucleic acid
 CC sequence comprising an ANGE, CLLD8 or CLLD7 mRNA, or ANGE-CLLD8, ANGE-
 CC CLLD7, CLLD7-CLLD8, or ANGE-CLLD8-CLLD7 hybrid mRNA sequence, its
 CC complement, homologue or fragment. The novel nucleic acid sequences have
 CC the following activities: anti-allergic, antiasthmatic, dermatological,
 CC antipyretic, and antiinflammatory. The nucleic acids of the invention may
 CC be used in gene therapy to treat disorders. The nucleic acid sequences

CC are useful for screening agents that inhibit or enhance activity of an
 CC ANGE, CLLD8 or CLLD7 gene. The agent or antibody is useful for treating
 CC IGE-mediated diseases, such as asthma, atopy, hay fever, eczema, atopic
 CC dermatitis, allergic rhinitis or non-atopic asthma. The antibody is
 CC useful in an assay detecting or measuring the polypeptide in the sample.
 CC The host cell is useful for producing, regulating and analyzing the
 CC polypeptide. The splice variant of ANGE, CLLD8, or CLLD7 is useful for
 CC diagnosing an IGE-mediated disease, atopy, a form of atopic disease or
 CC non-atopic asthma, or predicting the severity, or predisposition to a
 CC disease. This polynucleotide sequence represents a primer used in the
 CC exemplification of the invention.

SQ Sequence 18 BP; 4 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 939 CCAGAACAGGTGTACT 955
 Db 1 CCTGAACAGGCTGTACT 17
 |||||

RESULT 425
 ADG73179/c
 ID ADG73179 standard; DNA; 18 BP.
 XX
 AC ADG73179;
 XX
 DT 11-MAR-2004 (first entry)
 DE
 DE Pseudomonas syringae pv. tomato DC3000 Avr gene PCR primer #14.
 XX
 XX Avr; Hop; transgenic plant; disease resistance; cancer; bacteria;
 KW metabolic pathway; eukaryotic cell death; programmed cell death;
 KW cytosstatic; PCR; primer; ss.
 XX
 OS Pseudomonas syringae; pv. tomato str. DC3000.
 XX
 XX US2003204868-A1.
 XX 30-OCT-2003.
 XX 12-FEB-2003; 2003US-00365742.
 PF 12-FEB-2002; 2002US-0356408P.
 PR 10-MAY-2002; 2002US-0380185P.
 XX (COLL/) COLLIER A.
 PA (ALFA/) ALFANO J R.
 PA (CART/) CARTINHOOR S W.
 PA (SCHN/) SCHNEIDER D J.
 PA (TANG/) TANG X.

XX Collmer A, Alfano JR, Cartinhour SW, Schneider DJ, Tang X;
 XX WPI; 2003-875735/81.
 XX
 XX New nucleic acid, useful in imparting disease resistance to a plant or in
 PT preparing a composition for treating cancer.
 XX
 XX Example; SEQ ID NO 173; 209pp; English.
 PS
 XX The present invention relates to the isolation of Pseudomonas syringae
 CC pv. tomato DC3000 Avr/Hop proteins, and the polynucleotide sequences
 CC encoding them. Also disclosed are expression vectors, host cells, and
 CC transgenic plants comprising polynucleotide sequences of the invention.
 CC The polynucleotide and polypeptide sequences are useful in imparting
 CC disease resistance to a plant or in preparing a composition for treating
 CC cancer. The sequences may also be used to make a plant hypersusceptible
 CC to colonisation by nonpathogenic bacteria, modify a metabolic pathway in
 CC a cell, cause eukaryotic cell death, and inhibit programmed cell death.
 CC The present sequence represents a PCR primer used in the examples of the

CC present invention.

XX Sequence 18 BP; 5 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 13.8; DB 1; Length 18;

XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;

XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1416 ATGACTGTCATGGATCC 1432

Db ||| ||||| ||||| |||||

18 ACGATTGTCATGGATCC 2

RESULT 426

ADH42989

ID ADH42989 standard; DNA; 18 BP.

XX

AC ADH42989;

XX

DT 25-MAR-2004 (first entry)

XX

DE Lower PCR primer used for RT-PCR analysis of human PC 5/6.

XX

XX Primer; ss; RT-PCR; reverse transcriptase; proprotein convertase 5/6;

KW PC 5/6; uterus; serine proteinase; implantation; fertilised egg; embryo;

KW pregnancy; fertile period; early pregnancy; inhibiting fertility;

KW fertility; contraceptive; antisense gene therapy; uterine receptivity;

KW fertility-related condition; infertility; luteal phase defect; abortion;

KW parturition; isoform.

XX

OS Synthetic.

XX

XX WO2003011328-A1.

XX

XX 13-FEB-2003.

XX

XX 31-JUL-2002; 2002WO-AU001020.

XX

XX 31-JUL-2001; 2001AU-00006730.

XX

XX (PRIN-) PRINCE HENRY'S INST MEDICAL RES.

XX

XX Nie G, Salomonsen LA, Findlay JK;

XX

XX WPI; 2003-248116/24.

XX

XX Promoting fertility of a female mammal comprises stimulating the activity

XX of proprotein convertase 5/6 enzyme in the uterus of the female mammal.

XX

XX Example 13; SEQ ID NO 51; 99pp; English.

XX

XX The invention discloses a method for promoting the fertility of a female

XX mammal comprising stimulating the activity of proprotein convertase 5/6

XX (PC 5/6) in the uterus of a female mammal. PC 5/6 (a serine proteinase)

XX is believed to be useful in promoting the implantation of the fertilised

XX egg in the uterus, development of the embryo and maintenance of

XX pregnancy. Also claimed are methods for detecting a fertile period in a

XX female mammal by measuring the activity of or detecting the presence of

XX PC 5/6 in a biological sample from the mammal; detecting whether the

XX uterus of a female mammal is in a receptive state by detecting the

XX presence or absence of PC 5/6 in a biological sample from the mammal, or

XX its presence in increased amounts at a particular stage of the cycle

XX compared with another stage; detecting an early pregnancy by detecting

XX the presence of PC 5/6 activity or an increase of PC 5/6 above the level

XX in the non-pregnant state in a biological sample from the mammal;

XX inhibiting fertility in a female mammal by administering a PC 5/6

XX antagonist to a female mammal; screening for compounds which can modulate

XX PC 5/6 activity, by assessing the ability of a candidate compound to

XX increase or decrease PC 5/6 activity; identifying molecules necessary for

XX implantation by testing a candidate molecule for the ability to promote

XX the conversion of protein precursors cleavable by PC 5/6 into mature

XX proteins; a nucleic acid molecule encoding an isoform of PC 5/6 and a

XX protein having PC 5/6 activity encoded by a nucleic acid molecule. The

XX

CC method is used for promoting fertility of a female mammal. The PC 5/6

CC enzyme is a useful in controlling fertility (e.g. as a contraceptive and

CC antisense gene therapy), monitoring early pregnancy, for detecting

CC uterine receptivity, promoting the implantation of the fertilised egg in

CC the uterus, development of embryo and maintenance of pregnancy, and in

CC diagnosing fertility-related conditions (e.g. infertility due to luteal

CC phase defect, early abortion or early parturition). The sequence

CC presented is a reverse transcriptase PCR (RT-PCR) primer which was used

CC for semi-quantitative detection of human PC 5/6 cDNA expression in the

CC edometrium with ADH42973.

XX

XX Sequence 18 BP; 3 A; 9 C; 2 G; 4 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 13.8; DB 1; Length 18;

XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;

XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 509 CAGCATTGGGACTCTC 525

Db ||||| ||||| |||||

2 CAGCATTGGGACTCTC 18

RESULT 427

ADH53213

ID ADH53213 standard; DNA; 18 BP.

XX

AC ADH53213;

XX

DT 25-MAR-2004 (first entry)

XX

DE Human APC (adenomatous polyposis coli) DNA fragment 150.

XX

XX sequence determination; recognition site; restriction endonuclease;

KW human; APC; adenomatous polyposis coli; chromosome 5q21-22;

KW colorectal cancer; ds.

XX

XX Homo sapiens.

XX

XX WO2003074740-A1.

XX

XX 12-SEP-2003.

XX

XX 28-FEB-2003; 2003WO-US006376.

XX

XX 01-MAR-2002; 2002US-0360232P.

XX

XX 11-MAR-2002; 2002US-00093618.

XX

XX 08-MAY-2002; 2002US-0378354P.

XX

XX (DHAL/) DHALLAN R.

XX

XX Dhallan R;

XX

XX WPI; 2003-756772/71.

XX

XX Determining a sequence of a locus of interest comprises replicating a

XX region of DNA comprising a locus of interest from a template

XX polynucleotide by using a first and a second primer.

XX

XX Example 5; Page 140; 190pp; English.

XX

XX The invention relates to a novel method for determining the sequence of a

XX locus of interest which comprises replicating a region of DNA comprising

XX a locus of interest from a template polynucleotide by using a first and a

XX second primer where the second primer contains a sequence that generates

XX a recognition site for a restriction enzyme such that digestion with the

XX restriction enzyme generates a 5' overhang containing the locus of

XX interest. The method may be useful for determining the sequences of

XX multiple loci of interest concurrently and for determining the sequence

XX of a mutant allele in the presence of a normal allele. The current

XX sequence is that of the human APC (adenomatous polyposis coli) DNA

XX fragment of the invention which is located on chromosome 5q21-22 and in

XX which mutations are associated with colorectal cancer.

XX

```
SQ Sequence 18 BP; 12 A; 0 C; 3 G; 3 T; 0 U; 0 Other;
Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 201 GAAATAAAGAGAAAT 217
DB 1 GAAATAAAGAGAAAGAT 17

RESULT 428
ADL12235/c
ID ADL12235 standard; DNA; 18 BP.
XX
AC ADL12235;
DT 06-MAY-2004 (first entry)
XX
DE Pseudomonas syringae anti-cancer gene primer #46.
XX
KW cytostatic; gene therapy; Avr; Hop; cancer; primer; ss.
XX
OS Pseudomonas syringae; pv tomato DC3000.
XX
PN WO2003068930-A2.
XX
PD 21-AUG-2003.
XX
PF 12-FEB-2003; 2003WO-US004450.
XX
PR 12-FEB-2002; 2002US-0356408P.
PR 10-MAY-2002; 2002US-0380185P.
XX
PA (CORR ) CORNELL RES FOUND INC.
PA (USDA ) US SEC OF AGRIC.
PA (UYNE-) UNIV NEBRASKA.
PA (UNIV ) UNIV KANSAS STATE RES FOUND.
XX
PI Collmer A, Alfano JR, Cartinhour SW, Schneider DU, Tang X;
XX
XX WPI; 2003-679632/64.
XX
PT New nucleic acid molecule, useful for preparing a composition for
PT treating cancer.
XX
PS Disclosure; SEQ ID NO 173; 284pp; English.
XX
CC The invention relates to novel Pseudomonas Avr and Hop genes, a sequence
CC that hybridizes with these sequences under stringency conditions
CC comprising a hybridization medium that includes 0.9 x saline sodium
CC citrate (SSC) buffer at a temperature of 42 deg C. The nucleic acid
CC molecule is useful for preparing a composition for treating cancer. This
CC sequence corresponds to a PCR to isolate and amplify one of the genes of
CC the invention.
XX
DE
XX
SQ Sequence 18 BP; 5 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1416 ATGACTGTCATGGATCC 1432
DB 18 ACGATTGTCATGGATCC 2

RESULT 429
ADM07244
ID ADM07244 standard; DNA; 18 BP.
XX
AC ADM07244;
XX
```

```
DT 20-MAY-2004 (first entry)
XX
XX PCR primer 2 used to graft murine 15A2 DNA into canine gp 2 light chain.
XX
KW canine; dog; heavy; immunoglobulin; antibody light chain variable domain;
KW antiallergic; allergy; IgE; gene therapy; PCR; primer; ss; group 2;
KW murine; mouse; 15A2; CDR grafting; complementarity determining region.
XX
OS Canis familiaris.
OS Mus sp.
XX
PN WO2003060080-A2.
XX
PD 24-JUL-2003.
XX
PF 20-DEC-2002; 2002WO-US041362.
XX
PR 21-DEC-2001; 2001US-0344874P.
XX
XX (IDEX-) IDEXX LAB INC.
XX
PI Krah ER, Guo H, Aiyappa A, Lawton R;
XX
XX WPI; 2003-598521/56.
XX
PT New canine heavy and light chain variable domain polypeptides, useful for
PT treating canine allergy.
XX
PS Example 5; Page 46; 130pp; English.
XX
CC The invention relates to a novel canine heavy or light chain variable
CC domain polypeptide. The protein of the invention demonstrates
CC antiallergic activity and may be useful for treating canine allergy.
CC possibly via gene therapy. The current sequence is that of an PCR primer
CC which was used in the exemplification of the invention.
XX
SQ Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1069 CAAAGAGGACTCTGCGG 1085
DB 1 CTAAGAGCACTCTGCGG 17

RESULT 430
ADM07236
ID ADM07236 standard; DNA; 18 BP.
XX
AC ADM07236;
XX
DT 20-MAY-2004 (first entry)
XX
DE PCR primer 2 used to amplify canine lambda constant domain DNA.
XX
KW canine; dog; heavy; immunoglobulin; antibody light chain variable domain;
KW antiallergic; allergy; IgG; gene therapy; PCR; primer; ss;
KW lambda constant domain.
XX
OS Canis familiaris.
XX
PN WO2003060080-A2.
XX
PD 24-JUL-2003.
XX
PF 20-DEC-2002; 2002WO-US041362.
XX
PR 21-DEC-2001; 2001US-0344874P.
XX
XX (IDEX-) IDEXX LAB INC.
XX
```



```
Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 382 TGCAGCAAGATGGGCTG 398
Db 17 TGCAGCAGGAGGGGCTG 1

RESULT 433
ADL09357/c
ID ADL09357 standard; DNA; 18 BP.
XX
AC ADL09357;
XX
DT 06-MAY-2004 (first entry)
XX
DE HLA locus-specific capture oligonucleotide #123.
XX
KW ss; primer; human leukocyte antigen; HLA; HLA genotyping; human; PCR.
XX
OS Homo sapiens.
XX
PN US6670124-B1.
XX
PD 30-DEC-2003.
XX
PF 20-DEC-2000; 2000US-00747391.
XX
PR 20-DEC-1999; 99US-0172768P.
XX
PA (STEM-) STEMCYTE INC.
XX
PI Chow R, Tonai R;
XX
DR WPI; 2004-068584/07.
XX
PT Identifying an HLA genotype of a subject by hybridizing the amplification
PT products with an HLA locus-specific capture oligonucleotide and detecting
PT the detectable complexes to identify the HLA genotype of the subject.
XX
PS Example 1; SEQ ID NO 125; 68pp; English.
XX
CC The invention describes a method of identifying a human leukocyte antigen
CC (HLA) genotype of a subject comprising: obtaining a sample comprising a
CC template nucleic acid from the subject; amplifying the template nucleic
CC acid with HLA allele-specific forward primers and HLA allele-specific
CC reverse primers to form amplification products; hybridising the
CC amplification products with an HLA locus-specific capture oligonucleotide
CC ; and detecting the detectable complexes to identify the HLA genotype of
CC the subject. The present sequence represents one of 276 HLA locus-
CC specific capture oligonucleotides of the invention.
XX
SQ Sequence 18 BP; 2 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 382 TGCAGCAAGATGGGCTG 398
Db 17 TGCAGCAGGAGGGGCTG 1

RESULT 434
ADL81289
ID ADL81289 standard; DNA; 18 BP.
XX
AC ADL81289;
XX
DT 20-MAY-2004 (first entry)
XX
DE Gene 216 SSCP primer #39.

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 382 TGCAGCAAGATGGGCTG 398
Db 17 TGCAGCAGGAGGGGCTG 1

RESULT 435
ADM76352
ID ADM76352 standard; DNA; 18 BP.
XX
AC ADM76352;
XX
DT 03-JUN-2004 (first entry)
XX
DE NEPHA gene transcriptional control region Pax-8 binding site.
XX
KW Human; NEPHA; ephrin receptor; brain; chromosome 1; apoptosis;
KW drug screening; antisense therapy; gene therapy; cancer; tumour;
KW lung cancer; ovarian cancer; breast cancer; cervical cancer;
KW prostate cancer; bladder cancer; stomach cancer; colorectal cancer;
KW cyostatic; transcriptional control region; promoter;
KW transcription factor binding site; ds.
XX
OS Homo sapiens.
XX
```

```
XX
KW asthma; bronchial hyperresponsiveness; obesity;
KW inflammatory bowel disease; human; gene 216; ss; primer.
XX
OS Homo sapiens.
XX
PN US2004023215-A1.
XX
PD 05-FEB-2004.
XX
PF 19-APR-2002; 2002US-00126022.
XX
PR 13-APR-1999; 99US-0129391P.
PR 13-APR-2000; 2000US-00548797.
PR 13-APR-2001; 2001US-00834597.
XX
PA (KEIT/) KEITH T.
PA (LITT/) LITTLE R D.
PA (EERD/) EERDEWEGH P V.
PA (DUPU/) DUPUIS J.
PA (DMAS/) DEL MASTRO R G.
PA (SIMO/) SIMON J.
PA (ALLE/) ALLEN K.
PA (PAND/) PANDIT S.
XX
PI Keith T, Little RD, Eerdewegh PV, Dupuis J, Del Mastro RG;
PI Simon J, Allen K, Pandit S;
XX
DR WPI; 2004-142647/14.
XX
PT New isolated nucleic acid molecules useful for diagnosing or treating
PT asthma or bronchial hyperresponsiveness, or other diseases such as
PT obesity or inflammatory bowel disease.
XX
PS Example 10; SEQ ID NO 101; 485pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule, or a set of
CC nucleic acid molecules each given in the specification. The composition
CC and methods are useful in diagnosing or treating asthma or bronchial
CC hyperresponsiveness, and other diseases such as obesity or inflammatory
CC bowel disease. The present sequence is used in the exemplification of the
CC present invention.
XX
SQ Sequence 18 BP; 5 A; 2 C; 10 G; 1 T; 0 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1101 GCAGAGACACAGGTGG 1117
Db 2 GCAGAGGACAGGTGG 18

RESULT 436
ADM76352
ID ADM76352 standard; DNA; 18 BP.
XX
AC ADM76352;
XX
DT 03-JUN-2004 (first entry)
XX
DE NEPHA gene transcriptional control region Pax-8 binding site.
XX
KW Human; NEPHA; ephrin receptor; brain; chromosome 1; apoptosis;
KW drug screening; antisense therapy; gene therapy; cancer; tumour;
KW lung cancer; ovarian cancer; breast cancer; cervical cancer;
KW prostate cancer; bladder cancer; stomach cancer; colorectal cancer;
KW cyostatic; transcriptional control region; promoter;
KW transcription factor binding site; ds.
XX
OS Homo sapiens.
XX
```

```

PN JP2003289876-A.
XX 14-OCT-2003.
XX
XX 05-APR-2002; 2002JP-00103497.
XX
XX 05-APR-2002; 2002JP-00103497.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX WPI; 2004-038434/04.
XX
XX Novel antisense oligonucleotide useful as anticancer agent for preventing
XX cancer e.g. lung cancer, stomach cancer, breast cancer.
XX
XX Example 2; Page 28; 38pp; Japanese.
XX
XX The invention relates to antisense oligonucleotides (ADM76030 and
XX ADM76031) targeted to the human NEPHA gene (ADM76029), which encodes a
XX novel brain-derived ephrin receptor (ADM76028). The NEPHA protein has
XX 50.7% homology to the human EphA7 ephrin receptor and its gene is located
XX on chromosome 1. Ephrin receptors are overexpressed in various cancers
XX and it has been found that inhibition of NEPHA expression promotes
XX apoptosis. The invention also relates to the NEPHA transcriptional
XX control (promoter) region (ADM76037); recombinant vectors and host cells
XX comprising the NEPHA promoter operably linked to a reporter gene; a
XX method of screening for compounds which inhibit or activate transcription
XX of the NEPHA gene; and pharmaceutical compositions comprising an
XX antisense oligonucleotide or a transcriptional inhibitor or activator.
XX The antisense oligonucleotides and modulators of NEPHA transcription are
XX useful for inducing apoptosis for the treatment and/or prevention of
XX cancers in which NEPHA is overexpressed such as lung cancer, ovarian
XX cancer, breast cancer, cervical cancer, prostate cancer, bladder cancer,
XX stomach cancer and colorectal cancer. Sequences ADM76038-ADM76371
XX represent transcription factor binding sites within the transcriptional
XX control region of the NEPHA gene.
XX
XX Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 13.8; DB 1; Length 18;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 993 GGTGCCATGGATGG 1009
XX DB 1 GTTCCCATGGATGG 17
XX
XX RESULT 436
XX ADM76353
XX ID ADM76353 standard; DNA; 18 BP.
XX
XX AC ADM76353;
XX
XX 03-JUN-2004 (first entry)
XX
XX NEPHA gene transcriptional control region Pax-8 binding site.
XX
XX Human; NEPHA; ephrin receptor; brain; chromosome 1; apoptosis;
XX drug screening; antisense therapy; gene therapy; cancer; tumour;
XX lung cancer; ovarian cancer; breast cancer; cervical cancer;
XX prostate cancer; bladder cancer; stomach cancer; colorectal cancer;
XX cytostatic; transcriptional control region; promoter;
XX transcription factor binding site; ds.
XX
XX Homo sapiens.
XX
XX JP2003289876-A.
XX
XX 14-OCT-2003.
XX
XX 05-APR-2002; 2002JP-00103497.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX WPI; 2004-038434/04.
XX
XX Novel antisense oligonucleotide useful as anticancer agent for preventing
XX cancer e.g. lung cancer, stomach cancer, breast cancer.
XX
XX Example 2; Page 28; 38pp; Japanese.
XX
XX The invention relates to antisense oligonucleotides (ADM76030 and
XX ADM76031) targeted to the human NEPHA gene (ADM76029), which encodes a
XX novel brain-derived ephrin receptor (ADM76028). The NEPHA protein has
XX 50.7% homology to the human EphA7 ephrin receptor and its gene is located
XX on chromosome 1. Ephrin receptors are overexpressed in various cancers
XX and it has been found that inhibition of NEPHA expression promotes
XX apoptosis. The invention also relates to the NEPHA transcriptional
XX control (promoter) region (ADM76037); recombinant vectors and host cells
XX comprising the NEPHA promoter operably linked to a reporter gene; a
XX method of screening for compounds which inhibit or activate transcription
XX of the NEPHA gene; and pharmaceutical compositions comprising an
XX antisense oligonucleotide or a transcriptional inhibitor or activator.
XX The antisense oligonucleotides and modulators of NEPHA transcription are
XX useful for inducing apoptosis for the treatment and/or prevention of
XX cancers in which NEPHA is overexpressed such as lung cancer, ovarian
XX cancer, breast cancer, cervical cancer, prostate cancer, bladder cancer,
XX stomach cancer and colorectal cancer. Sequences ADM76038-ADM76371
XX represent transcription factor binding sites within the transcriptional
XX control region of the NEPHA gene.
XX
XX Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 13.8; DB 1; Length 18;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 993 GGTGCCATGGATGG 1009
XX DB 1 GTTCCCATGGATGG 17
XX
XX RESULT 437
XX ADM06884/C
XX ID ADM06884 standard; DNA; 18 BP.
XX
XX AC ADM06884;
XX
XX 17-JUN-2004 (first entry)
XX
XX Mouse Hnf4 exon 8/10 reverse RT-PCR primer.
XX
XX Glycosylated PNA monomer; peptide nucleic acid; PNA; antisense;
XX targeting; uptake; cell-specific; tissue-specific;
XX pharmacokinetic behaviour; infection; bacterial; viral; protozoal;
XX fungal; cancer; metabolic disease; cardiovascular disease;
XX autoimmune disorder; immunological disorder; disinfectant; antibacterial;
XX virucide; protozoacide; fungicide; cytostatic; immunosuppressive; mouse;
XX murine; hepatocyte nuclear factor 4alpha; Hnf4; splice pattern;
XX exon skipping; reverse transcription-PCR; RT-PCR; primer; ss.
XX
XX Mus sp.
XX
XX W02004024757-A2.
XX
XX 25-MAR-2004.
XX
XX 11-SEP-2003; 2003WO-DK000588.
XX
XX 11-SEP-2002; 2002DK-00001334.
XX
XX 19-NOV-2002; 2002DK-00001786.
XX
XX 20-DEC-2002; 2002DK-00001956.
XX
XX 16-APR-2003; 2003DK-00000600.

```

```

PR 05-APR-2002; 2002JP-00103497.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX WPI; 2004-038434/04.
XX
XX Novel antisense oligonucleotide useful as anticancer agent for preventing
XX cancer e.g. lung cancer, stomach cancer, breast cancer.
XX
XX Example 2; Page 28; 38pp; Japanese.
XX
XX The invention relates to antisense oligonucleotides (ADM76030 and
XX ADM76031) targeted to the human NEPHA gene (ADM76029), which encodes a
XX novel brain-derived ephrin receptor (ADM76028). The NEPHA protein has
XX 50.7% homology to the human EphA7 ephrin receptor and its gene is located
XX on chromosome 1. Ephrin receptors are overexpressed in various cancers
XX and it has been found that inhibition of NEPHA expression promotes
XX apoptosis. The invention also relates to the NEPHA transcriptional
XX control (promoter) region (ADM76037); recombinant vectors and host cells
XX comprising the NEPHA promoter operably linked to a reporter gene; a
XX method of screening for compounds which inhibit or activate transcription
XX of the NEPHA gene; and pharmaceutical compositions comprising an
XX antisense oligonucleotide or a transcriptional inhibitor or activator.
XX The antisense oligonucleotides and modulators of NEPHA transcription are
XX useful for inducing apoptosis for the treatment and/or prevention of
XX cancers in which NEPHA is overexpressed such as lung cancer, ovarian
XX cancer, breast cancer, cervical cancer, prostate cancer, bladder cancer,
XX stomach cancer and colorectal cancer. Sequences ADM76038-ADM76371
XX represent transcription factor binding sites within the transcriptional
XX control region of the NEPHA gene.
XX
XX Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 13.8; DB 1; Length 18;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 993 GGTGCCATGGATGG 1009
XX DB 1 GTTCCCATGGATGG 17
XX
XX RESULT 437
XX ADM06884/C
XX ID ADM06884 standard; DNA; 18 BP.
XX
XX AC ADM06884;
XX
XX 17-JUN-2004 (first entry)
XX
XX Mouse Hnf4 exon 8/10 reverse RT-PCR primer.
XX
XX Glycosylated PNA monomer; peptide nucleic acid; PNA; antisense;
XX targeting; uptake; cell-specific; tissue-specific;
XX pharmacokinetic behaviour; infection; bacterial; viral; protozoal;
XX fungal; cancer; metabolic disease; cardiovascular disease;
XX autoimmune disorder; immunological disorder; disinfectant; antibacterial;
XX virucide; protozoacide; fungicide; cytostatic; immunosuppressive; mouse;
XX murine; hepatocyte nuclear factor 4alpha; Hnf4; splice pattern;
XX exon skipping; reverse transcription-PCR; RT-PCR; primer; ss.
XX
XX Mus sp.
XX
XX W02004024757-A2.
XX
XX 25-MAR-2004.
XX
XX 11-SEP-2003; 2003WO-DK000588.
XX
XX 11-SEP-2002; 2002DK-00001334.
XX
XX 19-NOV-2002; 2002DK-00001786.
XX
XX 20-DEC-2002; 2002DK-00001956.
XX
XX 16-APR-2003; 2003DK-00000600.

```

```

XX PA (SANT-) SANTARIS PHARMA AS.
XX PI Rasmussen P, Frandsen NM, Nyborg M, Rasmussen FW, Hamzavi R;
XX PI Nielsen PE, Kjaerulff S;
XX DR WPI; 2004-329446/30.
XX PT Novel modified peptide nucleic acid monomer, useful for treating
XX PT bacterial, viral, and fungal infections, cancer and cardiovascular
XX PT disease.
XX PS Example 65; Page 84; 112pp; English.
XX CC The invention relates to glycosylated peptide nucleic acid (PNA)
XX CC monomers. The glycosylated PNA monomers may be incorporated into
XX CC antisense PNA oligomers to improve the cell and/or organ-specific uptake
XX CC of PNAs and hence their pharmacokinetic behaviour. The PNA monomers and
XX CC PNA oligomers constructed using them are useful in the treatment or
XX CC prevention of bacterial, viral, protozoal and fungal infections, cancer,
XX CC metabolic diseases, cardiovascular diseases, autoimmune and immunological
XX CC disorders. They are also useful for disinfecting non-living objects, such
XX CC as tools used in surgery and dentistry and equipment used in
XX CC slaughterhouses, in the dairy industry, and in the hair and beauty
XX CC industries. In an example of the invention, mice were treated with
XX CC glycosylated PNA oligomers (ADM06878-ADM06879) which alter the splice
XX CC pattern of Hnf4 (hepatocyte nuclear factor 4alpha) pre-mRNA. Sequences
XX CC ADM06880-ADM06884 represent reverse transcription-PCR (RT-PCR) primers
XX CC used to analyse Hnf4 mRNA from tissue samples from the mice to determine
XX CC whether exons had been skipped.
XX SQ Sequence 18 BP; 2 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 332 GAGTGCTCCAGAAC 348
Db 18 GAGTGCTCCGAGAAC 2

RESULT 438
ADO26612/C
XX AC ADO26612;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic leader sequence encoding DNA SEQ ID NO:5.
XX KW phenotype; phenotypic preference; phenotype modulation; leader; ds.
XX OS Synthetic.
XX PN WO2004042059-A1.
XX PD 21-MAY-2004.
XX PF 10-NOV-2003; 2003WO-AU001487.
XX PR 08-NOV-2002; 2002US-0425163P.
XX PA (UYQU ) UNIV QUEENSLAND.
XX PI Frazer IH;
XX DR WPI; 2004-411519/38.
XX DR P-PSDB; ADO26613.
XX PT Constructing synthetic polynucleotide for modulating the quality of a
XX PT selected phenotype displayed by an organism comprises replacing a first
codon with a synonymous codon to construct the synthetic polynucleotide.
Example 1; SEQ ID NO 5; 86pp; English.
The present invention describes a method for constructing a synthetic
polynucleotide from which a polypeptide is producible to confer a
selected phenotype to an organism of interest or part in a different
quality than that conferred by a parent polynucleotide that encodes the
same polypeptide. The method comprises: (a) selecting a first codon of
the parent polynucleotide for replacement with a synonymous codon, where
the synonymous codon is selected on the basis that it exhibits a
different phenotypic preference than the first codon in a comparison of
phenotypic preferences in test organisms or parts, where the test
organism are selected from organisms of the same species as the organism
of interest and organisms that are related to the organisms of interest;
and (b) replacing the first codon with the synonymous codon to construct
the synthetic polynucleotide. Also described: (1) a method for
determining the phenotypic preference of a first codon in an organism of
interest or its parts; (2) a synthetic polynucleotide constructed from
the method above; (3) an organism of interest or part containing a
synthetic polynucleotide constructed from the method above; (4) an
organism of interest or part containing a synthetic construct that
comprises a regulatory polynucleotide operably linked to a tandem repeat
of a first codon fused in frame with a reporter polynucleotide that
encodes a reporter protein, which produces, or is predicted to produce a
selected phenotype or a phenotype of the same class as the selected
phenotype in the organism or part; (5) a method of modulating the quality
of a selected phenotype that is displayed by an organism of interest or
part and that results from the expression of a parent polynucleotide that
encodes the polypeptide; (6) a method of enhancing the quality of a
selected phenotype that is displayed by an organism of interest or part
and that results from the expression of a parent polynucleotide that
encodes the polypeptide; and (7) a method of reducing the quality of a
selected phenotype that is displayed by an organism of interest or part
and that results from the expression of a parent polynucleotide that
encodes the polypeptide. The method is useful for constructing a
synthetic polynucleotide from which a polypeptide is producible to confer
a selected phenotype to an organism of interest or part in a different
quality than that conferred by a parent polynucleotide that encodes the
same polypeptide. It is useful for modulating the quality of a selected
phenotype displayed by an organism or part. The present sequence encodes
a synthetic leader sequence, which is used in an example from the present
invention.
XX SQ Sequence 18 BP; 0 A; 6 C; 12 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 CGCTCCGTCGCGCG 46
Db 18 CGCGCGCGCGCGCG 2

RESULT 439
ADO26628
XX ID ADO26628 standard; DNA; 18 BP.
XX AC ADO26628;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic leader sequence encoding DNA SEQ ID NO:21.
XX KW phenotype; phenotypic preference; phenotype modulation; leader; ds.
XX OS Synthetic.
XX PN WO2004042059-A1.
XX PD 21-MAY-2004.
XX PT Constructing synthetic polynucleotide for modulating the quality of a
XX PT selected phenotype displayed by an organism comprises replacing a first

```

```

PF 10-NOV-2003; 2003WO-AU001487.
XX
XX
PR 08-NOV-2002; 2002US-0425163P.
XX
XX
PA (UYQU ) UNIV QUEENSLAND.
XX
XX
PI Frazer IH;
XX
XX
DR WPI; 2004-411519/38.
XX
XX
DR P-PSDB; ADO26629.
XX
XX
PT Constructing synthetic polynucleotide for modulating the quality of a
PT selected phenotype displayed by an organism comprises replacing a first
PT codon with a synonymous codon to construct the synthetic polynucleotide.
XX
XX
PS Example 1; SEQ ID NO 21; 86pp; English.
XX
XX
CC The present invention describes a method for constructing a synthetic
CC polynucleotide from which a polypeptide is producible to confer a
CC selected phenotype to an organism of interest or part in a different
CC quality than that conferred by a parent polynucleotide that encodes the
CC same polypeptide. The method comprises: (a) selecting a first codon of
CC the parent polynucleotide for replacement with a synonymous codon, where
CC the synonymous codon is selected on the basis that it exhibits a
CC different phenotypic preference than the first codon in a comparison of
CC phenotypic preferences in test organisms or parts, where the test
CC organism are selected from organisms of the same species as the organism
CC of interest and organisms that are related to the organisms of interest;
CC and (b) replacing the first codon with the synonymous codon to construct
CC the synthetic polynucleotide. Also described: (1) a method for
CC determining the phenotypic preference of a first codon in an organism of
CC interest or its parts; (2) a synthetic polynucleotide constructed from
CC the method above; (3) an organism of interest or part containing a
CC synthetic polynucleotide constructed from the method above; (4) an
CC organism of interest or part containing a synthetic construct that
CC comprises a regulatory polynucleotide operably linked to a tandem repeat
CC of a first codon fused in frame with a reporter polynucleotide that
CC encodes a reporter protein, which produces, or is predicted to produce a
CC selected phenotype or a phenotype of the same class as the selected
CC phenotype in the organism or part; (5) a method of modulating the quality
CC of a selected phenotype that is displayed by an organism of interest or
CC part and that results from the expression of a parent polynucleotide that
CC encodes the polypeptide; (6) a method of enhancing the quality of a
CC selected phenotype that is displayed by an organism of interest or part
CC and that results from the expression of a parent polynucleotide that
CC encodes the polypeptide; and (7) a method of reducing the quality of a
CC selected phenotype that is displayed by an organism of interest or part
CC and that results from the expression of a parent polynucleotide that
CC encodes the polypeptide. The method is useful for constructing a
CC synthetic polynucleotide from which a polypeptide is producible to confer
CC a selected phenotype to an organism of interest or part in a different
CC quality than that conferred by a parent polynucleotide that encodes the
CC same polypeptide. It is useful for modulating the quality of a selected
CC phenotype displayed by an organism or part. The present sequence encodes
CC a synthetic leader sequence, which is used in an example from the present
XX invention.
XX
SQ Sequence 18 BP; 0 A; 12 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 CGCCTCCGTCGCCGCCG 46
DB 1 CGCCGCCGCCGCCGCCG 17

RESULT 440
ADP27776/C
ID ADP27776 standard; DNA; 18 BP.
XX
XX AC ADP27776;

10-NOV-2003; 2003WO-AU001487.
XX
XX
DE 26-AUG-2004 (first entry)
XX
XX
DE PCR primer to amplify a human cancer prognostic marker DNA SeqID 213.
XX
XX
KW human; primer; PCR; prognostic marker; EGFR;
KW epidermal growth factor receptor; cancer; gene expression profiling;
KW microarray; head and neck cancer; colon cancer; metastatic spread;
KW neoplastic disease; ss.
XX
XX
OS Homo sapiens.
XX
XX
PN W02004046386-A1.
XX
XX
PD 03-JUN-2004.
XX
XX
PF 14-NOV-2003; 2003WO-US036777.
XX
XX
PR 15-NOV-2002; 2002US-0427090P.
XX
XX
PA (GENO-) GENOMIC HEALTH INC.
PA (VALL-) VALL HEBRON UNIV HOSPITAL.
XX
XX
PI Baker JB, Cronin MT, Shak S, Baselga J;
XX WPI; 2004-420643/39.
XX
XX
PT Prognosing a patient with EGFR-expressing colon cancer comprises
PT subjecting a sample comprising EGFR-expressing cancer cells to
PT quantitative analysis of the expression level of the RNA transcript of at
PT least one gene e.g., CD44v3.
XX
XX
PS Claim 54; SEQ ID NO 213; 113pp; English.
XX
XX
CC This invention relates to a novel method concerning prognostic markers
CC associated with EGFR (epidermal growth factor receptor) positive cancer.
CC Specifically, it refers to a gene expression profiling method that can
CC provide a prediction as to whether a patient is likely to respond well to
CC treatment with an EGFR inhibitor. The present invention describes the
CC quantitative analysis of the expression level of the RNA transcript of at
CC least one gene selected from the group of CD44v3, CD44v6, DR5, GR01,
CC KRT17, LAMC2 or their products thereof. It further provides a cDNA
CC microarray containing named genes that represent prognostic transcripts
CC which are useful for determining whether a patient diagnosed with an EGFR
CC -expressing head or neck cancer or colon cancer exhibits elevated or
CC decreased expression levels of these genes compared to normal. As such,
CC these methods are also useful for prognosing or predicting the likelihood
CC of cancer-attributable death or progression, including recurrence and
CC metastatic spread of a neoplastic disease, as well as drug resistance.
CC This oligonucleotide sequence is a PCR primer used to amplify a human PCR
CC amplicon DNA sequence used as a prognostic cancer marker, given in an
CC exemplification of the invention.
XX
SQ Sequence 18 BP; 4 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 673 TGAAGCTGCCAAGGTG 689
DB 17 TGGCAGCTGCCCAGGTG 1

RESULT 441
ADP08680/C
ID ADP08680 standard; DNA; 18 BP.
XX
XX AC ADP08680;
XX
XX DT 26-AUG-2004 (first entry)
XX
XX DE Extend primer 17 used to genotype human glycoprotein VI polymorphism.

```

```

XX breast cancer; cytostatic; gene therapy; human; platelet glycoprotein VI;
KW GP6; GPIV; GPIV; chromosome 19q13.4; ss; PCR; primer; SNP;
KW single nucleotide polymorphism.
OS Homo sapiens.
XX WO2004047767-A2.
XX 10-JUN-2004.
XX .25-NOV-2003; 2003WO-US037966.
XX 25-NOV-2002; 2002US-0429136P.
XX 24-JUL-2003; 2003US-0490234P.
XX (SEQU-) SEQUENOM INC.
XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX WPI; 2004-441082/41.
XX Identifying a subject at risk of breast cancer by detecting the presence
XX or absence of one or more nucleotide polymorphic variations, useful for
XX diagnosing, preventing and/or treating breast cancer.
XX Example 3; Page 82; 286pp; English.
XX The invention relates to a novel method for identifying a subject at risk
XX of breast cancer which comprises detecting the presence or absence of one
XX or more polymorphic variations associated with breast cancer in a nucleic
XX acid sample from a subject. The method of the invention has cytostatic
XX applications and may be useful for identifying a risk of breast cancer,
XX as well as therapeutic and prophylactic treatments that specifically
XX target breast cancer, such as gene therapy. The current sequence is that
XX of an extend primer of the invention which was used to genotype single
XX nucleotide polymorphisms within human glycoprotein VI (platelet) (GP6;
XX GPIV/GPVI) DNA which is located at chromosomal position 19q13.4.
XX Sequence 18 BP; 3 A; 3 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 910 CTGTAGCAGATCACT 926
Db ||| ||||| |||||
18 CTGAAGCAGACATCACT 2

RESULT 442
ADQ78196/c
ID ADQ78196 standard; DNA; 18 BP.
XX AC ADQ78196;
XX 09-SEP-2004 (first entry)
XX PCR primer used to amplify cancer related genes for biochip Seqid 878.
XX mini-sequencing; CpG island; methylation specific PCR; MSP;
XX multiplex MSP PCR; cancer; PCR; primer; ss; microarray chip.
XX Unidentified.
XX KR2003069752-A.
XX 27-AUG-2003.
XX 07-MAY-2002; 2002KR-00025108.
XX 20-FEB-2002; 2002KR-00009132.
XX

```

```

PA (GOOD-) GOODGENE INC.
XX Choi HI, Bom TH, Jun BI, Kim OH, Mun UC, Oh MY, Song MG;
XX WPI; 2004-095256/10.
XX Minisequencing type oligonucleotide chip for detecting methylation of
XX promoter CpG islands of multiple genes, useful for detecting cancer.
XX Claim 13; SEQ ID NO 878; 248pp; Korean.
XX This invention relates to a novel mini-sequencing type DNA
XX oligonucleotide chip. Specifically, it refers to a chip that is useful
XX for detecting methylation of promoter CpG islands occurring in multiple
XX genes. The present invention describes using oligonucleotide primers to
XX determine the position of a target gene and promoter CpG islands, this
XX constitutes treating DNA of the target gene with sodium bisulfite in
XX order to carry out methylation specific (MSP) PCR or multiplex MSP PCR to
XX amplify the sodium bisulfite treated DNA and sequencing the PCR product
XX to confirm the hypomethylation site of the promoter CpG islands of
XX multiple genes. Accordingly, the chip comprises primer sequences designed
XX from these PCR products that have amine linkers of 12 carbons attached to
XX the 5'-terminal, which are spotted onto the glass slide coated with 3-
XX aminopropyltrimethoxylan and 1,4-diisothiocyanate using an array robot.
XX The resulting minisequencing chip is useful for detecting cancer, thereby
XX accurately and rapidly detecting methylation of CpG islands of multiple
XX genes. This oligonucleotide sequence is a PCR primer given in an
XX exemplification of the invention.
XX Sequence 18 BP; 1 A; 0 C; 1 G; 16 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db ||||| ||||| |||||
18 AAAAAACAAATATAAAAA 2

RESULT 443
ADP84638
ID ADP84638 standard; DNA; 18 BP.
XX AC ADP84638;
XX 09-SEP-2004 (first entry)
XX Human breast-specific gene-related PCR primer #4.
XX human; breast-specific protein; breast cancer; PCR; primer; ss.
XX Homo sapiens.
XX WO2004053077-A2.
XX 24-JUN-2004.
XX 05-DEC-2003; 2003WO-US038815.
XX 05-DEC-2002; 2002US-0431123P.
XX (DIAD-) DIADEXUS INC.
XX Macina RA, Turner LR, Sun Y, Chen H, Rodriguez M;
XX WPI; 2004-468848/44.
XX New breast specific nucleic acid molecules and polypeptides useful for
XX diagnosing, preventing or treating breast cancer, for producing
XX transgenic animals or cells, or for research purposes.
XX Example 2b; SEQ ID NO 237; 521pp; English.

```

XX The invention comprises the amino acid and coding sequences of human
CC breast-specific proteins. The DNA and protein sequences of the invention
CC are useful for the diagnosis, treatment and prevention of breast cancer.
CC The present DNA sequence represents a PCR primer that was used in an
CC example of the invention.
XX
SQ Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 680 TGCCAAGGTGGGGCTT 696
Db 2 TGCCAAGGTGGGAGCTT 18
RESULT 444
ADNR00170/C
ID ADR00170 standard; DNA; 18 BP.
XX
AC ADR00170;
XX
XX 21-OCT-2004 (first entry)
DE EGFR PCR reverse primer, SEQ ID 208.
XX
XX Breast cancer; human; ss; PCR; primer; EGFR.
XX
XX Homo sapiens.
XX
XX WO2004065583-A2.
XX
XX 05-AUG-2004.
XX
XX 14-JAN-2004; 2004WO-US000985.
XX
XX 15-JAN-2003; 2003US-0440861P.
XX
XX (GENO-) GENOMIC HEALTH INC.
XX (UTRU-) UNIV RUSH MEDICAL CENT.
XX
XX Cobleigh MA, Shak S, Baker JB, Cronin MT;
XX
XX WPI; 2004-593480/57.
XX
XX Predicting likelihood of long-term survival of a breast cancer patient
PT without the recurrence of breast cancer by determining the expression
PT level of prognostic RNA transcripts or their expression products in a
PT breast cancer tissue sample.
XX
XX Claim 33; SEQ ID NO 208; 125pp; English.
XX
XX The present invention relates to a method for predicting the likelihood
CC of long-term survival of a breast cancer patient without the recurrence
CC of breast cancer. The method comprises determining the expression level
CC of one or more prognostic RNA transcripts or their expression products in
CC a breast cancer tissue sample obtained from the patient. The prognostic
CC RNA transcript is the transcript of one or more genes, e.g. TP53BP2,
CC GRB7, PR, CD68, Bcl2, KRT14, IRS1, CTSL, Estr1, Chk1, IGFBP2, BAG1,
CC CEGP1, STK15, GSTM1, FHIT, RIZ1, AIB1, SURV, BBC3, IGFBP2, p27, GATA3,
CC ZNF217, EGFR, CD9, MYBL2, HIF1alpha, pS2, ErbB3, TOP2B, MDM2, RAD51C,
CC KRT19, TS, Her2, KLK10, beta-Catenin, gamma-Catenin, MCM2, PI3KC2A, IGFL,
CC TBP, CNB1, FBX05, or DR5, where expression of one or more of GRB7, CD68,
CC CTSL, Chk1, AIB1, CNB1, MCM2, FBX05, Her2, STK15, SURV, EGFR, MYBL2,
CC HIF1alpha, or TS indicates a decreased likelihood of long-term survival
CC without breast cancer recurrence, and where the expression of one or more
CC of TP53BP2, PR, Bcl2, KRT14, Estr1, IGFBP2, BAG1, CEGP1, KLK10, beta-
CC Catenin, gamma-Catenin, DR5, PI3KCA2, RAD51C, GSTM1, FHIT, RIZ1, BBC3,
CC TBP, p27, IRS1, IGFBP2, GATA3, ZNF217, CD9, pS2, ErbB3, TOP2B, MDM2, IGFL,
CC or KRT19 indicates an increased likelihood of long-term survival without
CC breast cancer recurrence. The present sequence is a PCR primer used to

CC amplify one such prognostic gene of the invention.
XX
SQ Sequence 18 BP; 4 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 673 TGGGAAGCTGCCAAGGTG 689
Db 17 TGGCAGCTGCCCAGGTG 1
RESULT 445
ADS90224/C
ID ADS90224 standard; DNA; 18 BP.
XX
AC ADS90224;
XX
XX 18-NOV-2004 (first entry)
DE Oligonucleotide of the invention SEQ ID NO:1240.
XX
XX ss; cell proliferative disorder; breast; methylation; cytostatic;
KW gene therapy; single nucleotide polymorphism; SNP.
XX
XX Unidentified.
XX
XX WO2004035803-A2.
XX
XX 29-APR-2004.
XX
XX 01-OCT-2003; 2003WO-EP010881..
XX
XX 01-OCT-2002; 2002DE-01045779.
XX
XX 07-JAN-2003; 2003DE-01000096.
XX
XX 17-APR-2003; 2003DE-01017955.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Foekens J, Harbeck N, Koenig T, Maier S, Martens J, Model P;
XX Nimmrich I, Rujan T, Schmitt A, Schmitt M, Look MP, Marx A;
XX
XX WPI; 2004-348468/32.
XX
XX Predicting responsiveness of a subject with breast cell proliferative
PT disorder, useful for treating or differentiating breast cell
PT proliferative disorders comprises analyzing methylation pattern of a
PT genomic DNA from the subject.
XX
XX Disclosure; SEQ ID NO 1240; 104pp; English.
XX
XX The invention relates to a novel method for predicting the responsiveness
CC of a subject with a cell proliferative disorder of the breast tissues to
CC a therapy comprising analyzing the methylation pattern of a target
CC nucleic acid by contacting at least one of the target nucleic acids in a
CC biological sample obtained from the subject prior to or during treatment.
CC The method of the invention has cytostatic activity, and may have a use
CC in gene therapy. The set of oligonucleotides comprising at least two of
CC the oligomers are useful for detecting the cytosine methylation state
CC and/or single nucleotide polymorphisms (SNPs) within the sequences. The
CC methods, nucleic acid, oligonucleotide, and kit are useful for the
CC treatment, characterization, classification and/or differentiation, of
CC breast cell proliferative disorders. The method is also useful for
CC predicting the responsiveness of a subject with a cell proliferative
CC disorder of the breast tissues to a therapy. The present sequence is used
CC in the exemplification of the invention.
XX
SQ Sequence 18 BP; 5 A; 0 C; 5 G; 8 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1617 TTCACAGCACAACCTCTA 1633
Db 18 TTCAAAACACATCTCTA 2

RESULT 446
ADR97984
ID ADR97984 standard; DNA; 18 BP.
XX ADR97984;
DT 02-DEC-2004 (first entry)
XX Human APC DNA fragment containing deletion at codon 1306.
XX db; chromosomal abnormality; detection; foetus; translocation;
KW transversion; monosomy; trisomy; aneuploidy; deletion; addition;
KW amplification; prenatal diagnosis; SNP; single nucleotide polymorphism;
KW human; chromosome 5q21-22; adenomatous polyposis coli; mutation.
XX

OS Homo sapiens.
OS Synthetic.
XX WO2004079011-A1.
XX PN WO2004079011-A1.
XX PD 16-SEP-2004.
XX 29-AUG-2003; 2003WO-US027308.
XX PF 28-FEB-2003; 2003WO-US006198.
XX PR (RAVG-) RAVGEN INC.
XX PA
XX PI
XX Dhallan R;
XX WPI; 2004-677127/66.
XX DR
XX PT Detecting a chromosomal abnormality, e.g. translocations, transversions,
PT monosomes, trisomes, aneuploidies, deletions, or arrangements, comprises
PT determining the sequence of alleles of a locus of interest in the sample
PT from template DNA.
XX
XX Example 7; Page 155; 429pp; English.

CC This invention describes a novel method for detecting a chromosomal
CC abnormality in a sample which comprises determining the sequence of
CC alleles of a locus of interest in a sample from template DNA where
CC determining the sequence of the alleles comprises amplifying the locus of
CC interest, hybridising the amplified loci to GeneChip array, washing
CC GeneChip array, staining the GeneChip array with detectable reagents, and
CC scanning GeneChip array. The amplification method is self-sustained
CC sequence reaction, ligase chain reaction, rapid amplification of cDNA
CC ends, PCR and ligase chain reaction, Q-beta phage amplification, strand
CC displacement amplification, or splice overlap extension PCR, preferably
CC PCR. The determination of the sequence of the alleles comprises
CC amplifying the locus of interest, fragmenting the amplicon, hybridising
CC fragmented amplicons to CodeLink Arrays, extension reaction to
CC incorporate a nucleotide and detecting incorporated nucleotides. The
CC amplicon fragmentation is by exonuclease digestion. Detecting a
CC chromosomal abnormality in a sample comprises determining the sequence of
CC alleles of a locus of interest from template DNA, where determining the
CC determination of the sequence of the alleles may also be done by
CC amplifying the locus of interest, dephosphorylation of the unused
CC reagents, in vitro transcription reaction of the products, Rhase A
CC cleavage of the products, mixing the products with CleanResin.
CC transferring products to SpectroCHIP, and analysing the SpectroCHIP. The
CC dephosphorylation reaction is with shrimp alkaline phosphatase.
CC Alternatively, the determination of the sequence of the alleles comprises
CC amplifying the locus of interest, dephosphorylation of the unused
CC reagents, hybridising a primer to the locus of interest, incorporating a
CC nucleotide, mixing the products with CleanResin, transferring products to

CC SpectroCHIP, and analysing the SpectroCHIP. The hybridisation of primer
CC is adjacent to the locus of interest. The determination of the sequence
CC of the alleles may also comprise amplifying the locus of interest,
CC treating the products with exonuclease, single stranded DNA is annealed
CC to an oligonucleotide, incorporating a nucleotide using the annealed
CC template and primer, and detecting the incorporated nucleotide. The
CC method is useful for detecting a chromosomal abnormality in a sample.
CC Specifically, the method is useful for detecting chromosomal
CC abnormalities in a fetus including translocations, transversions,
CC monosomes, trisomes, and other aneuploidies, deletions, additions,
CC amplifications, and arrangements. The method of the invention can also be
CC used for prenatal diagnosis. This sequence represents a fragment of the
CC human adenomatous polyposis coli (APC) gene which contains a nucleotide
CC deletion.
XX

SQ Sequence 18 BP; 12 A; 0 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 201 GAAATAAAAGAGAAAT 217
Db 1 GAAATAAAAGAGAAAGAT 17

RESULT 447
ADS08668
ID ADS08668 standard; DNA; 18 BP.
XX ADS08668;
XX 02-DEC-2004 (first entry)
XX Human DNA oligonucleotide #157.
XX Human; nucleic acid detection; cell lysis; chromosomal abnormality;
KW cancer; carcinoma; bladder; breast; bronchus; colon; kidney; liver; lung;
KW oesophagus; gall bladder; ovary; pancreas; stomach; cervix; thyroid;
KW prostate; skin; small cell lung cancer; squamous cell carcinoma;
KW leukaemia; lymphoma; myelodysplastic syndrome; fibrosarcoma;
KW rhabdomyosarcoma; astrocytoma; neuroblastoma; glioma; schwannoma;
KW melanoma; seminoma; teratocarcinoma; osteosarcoma; ds.
XX
XX Homo sapiens.
XX Synthetic.
XX WO2004078994-A2.
XX PD 16-SEP-2004.
XX PF 01-MAR-2004; 2004WO-US006337.
XX PR 28-FEB-2003; 2003WO-US006198.
XX (RAVG-) RAVGEN INC.
XX Dhallan R;
XX WPI; 2004-662434/64.
XX Detecting presence or absence of nucleic acid, containing mutation,
PT involves isolating nucleic acid from sample containing cell lysis
PT inhibitor, and detecting presence or absence of nucleic acid.
XX
XX Example 7; Page 164; 440pp; English.
XX The invention relates to a method for detecting a nucleic acid, involving
CC isolating a nucleic acid from a sample, where an agent that impedes cell
CC lysis was added to the sample, and detecting the presence or absence of
CC the nucleic acid. The invention also relates to a method for detecting
CC chromosomal abnormalities in a DNA sample and determining the sequence of
CC foetal DNA from a sample of a pregnant female. The nucleic acid contains

at least one mutation chosen from a single point mutation, multiple point mutations, an insertion, a frameshift, a truncation, a deletion, a duplication and a transversion. The method is useful for detecting a nucleic acid in a sample obtained from a source chosen from bacteria, viruses, fungi, mycobacteria, protozoa, molds, yeasts, plants, humans, non-humans, multi-cellular parasites, animals and archaeobacteria. The method is useful for detecting, diagnosing or monitoring a disease such as cancer chosen from carcinoma of the bladder, breast, bronchus, colon, cervix, thyroid, prostate and skin, small cell lung cancer, squamous cell carcinoma, haematopoietic tumours of lymphoid lineage, leukaemia, acute lymphocytic leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, Burkett's lymphoma, haematopoietic tumours of myeloid lineage, acute and chronic myelogenous leukaemias, myelodysplastic syndrome and promyelocytic leukaemia, tumours of mesenchymal origin, fibrosarcoma and rhabdomyosarcoma, tumours of the central and peripheral nervous system, astrocytoma, neuroblastoma, glioma and schwannomas, melanoma, seminoma, teratocarcinoma and osteosarcoma. The method is also useful for monitoring response to treatment chosen from surgery, radiation, lifestyle change, dietary protocol and supplementary agents, anti-bacterial agents, anti-viral agents, anti-fungal agents, targeted-cancer drugs, cytotoxic agents, cytostatic agents and anti-proliferative agents. This sequence represents a DNA oligonucleotide used in the scope of the invention.

Sequence 18 BP; 12 A; 0 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAAATAAAGAGAAAT 217
|||||
Db 1 GAAATAAAGAGAAAT 17

RESULT 448

AA595939

ID AA595939 standard; DNA; 15 BP.

AC AA595939;

DT 26-FEB-2002 (first entry)

DE Human CALM1 gene allele-specific oligonucleotide #48.

XX Calmodulin 1; CALM1; human; single nucleotide polymorphism; SNP;

KW haplotyping; SCYA3; Alzheimer's disease; drug screening;

KW calcium-dependent signal transduction; PCR primer; ss.

XX Homo sapiens.

XX WO200179218-A2.

XX 25-OCT-2001.

XX 09-APR-2001; 2001WO-US011509.

XX 12-APR-2000; 2000US-0196340P.

XX (GENA-) GENAISSANCE PHARM INC.

XX Bentivegna SC, Chew A, Choi JY, Koshy B, Stephens JC;

XX WPI; 2002-049190/06.

XX New calmodulin-1 (CALM-1) isogene polymorphic variants, useful in
PT expressing CALM1 protein for use in screening for candidate drugs to
PT treat diseases related to CALM1 activity such as Alzheimer's disease.

PS Claim 15; Page 13; 82pp; English.

XX The invention relates to an isolated polynucleotide comprising a sequence
CC selected from a polymorphic variant of calmodulin 1 (CALM1). The
CC polymorphic variant comprises an CALM1 isogene defined by a haplotype
CC selected from haplotypes 1-21 given in the specification. The
CC polymorphisms are useful for studying the biological function of CALM1 as
CC well as in identifying drugs targeting this protein for the treatment of
CC a disorder related to its abnormal expression or function. The
CC polymorphic variants may also be used in screening for compounds
CC targeting CALM1 to treat a specific condition or disease predicted to be
CC associated with CALM1 activity. Establishing CALM1 haplotype or haplotype
CC pair of an individual is useful for improving the efficiency and
CC reliability of several steps in the discovery and development of drugs
CC for treating diseases associated with SCYA3 activity, e.g. Alzheimer's
CC disease and diseases involving defects in calcium-dependent signal
CC transduction. Haplotyping the CALM1 gene in an individual is also useful
CC in the design of clinical trials of candidate drugs for treating a
CC specific condition or disease predicted to be associated with CALM1
CC activity. AA595892-AA596018 represent human CALM1 allele-specific
CC oligonucleotides and PCR primers of the invention
XX

Sequence 15 BP; 1 A; 3 C; 10 G; 0 T; 0 U; 1 Other;

Query Match 0.7%; Score 13.6; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.7e+02;

Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 661 CGCAGGGGGCGGTG 674

Db 2 CGCAGGGGGCGGTG 15

Search completed: July 12, 2005, 10:40:15

Job time : 11 secs

THIS PAGE BLANK (USPTO)